<SEC-DOCUMENT>0001178913-25-000679.txt : 20250304
<SEC-HEADER>0001178913-25-000679.hdr.sgml : 20250304
<ACCEPTANCE-DATETIME>20250304073038
ACCESSION NUMBER:		0001178913-25-000679
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250304
DATE AS OF CHANGE:		20250304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		25701560

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>zk2532769.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cgen="http://cgen.com/20241231" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:cyd-af="http://xbrl.sec.gov/cyd-af/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>COMPUGEN LTD - 1119774 - 2025</title></head><body style="font-size:10pt;font-family:Times New Roman, Times, serif;"><div style="font-size: 10pt;"><div style="font-size: 10pt;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20240101to20241231" id="FFact_0000000000684">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20240101to20241231" id="FFact_0000000000685">0001119774</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20240101to20241231" id="FFact_0000000000686">FY</ix:nonNumeric><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember" id="Fxbrl_20240730211801692_20250224141027740_2" unitRef="usd" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" contextRef="C_20231231" id="Fxbrl_20240730224938615_20250224141027741_9" unitRef="usd" xsi:nil="true"></ix:nonFraction><ix:footnote id="FN20250224141027743_19" xml:lang="en-US">Represents an amount lower than $1</ix:footnote>
<ix:footnote id="FN20250224141027743_20" xml:lang="en-US">Represents an amount lower than $1.</ix:footnote>
<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20250224182302928" unitRef="usd" xsi:nil="true"></ix:nonFraction><ix:footnote id="FN20250225105352845" xml:lang="en-US">Representing amount lower than $ 1</ix:footnote>
</ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cgen-20241231.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20240101to20241231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-11-02</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandTenShareOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandTenShareOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-10-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-10-10</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230131_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LeerinkPartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LeerinkPartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20130801to20130805"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2013-08-01</xbrli:startDate>
        <xbrli:endDate>2013-08-05</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20130805"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2013-08-05</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211130"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231218"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-18</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231218"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-18</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240131"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenGileadAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:GileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:AntibodiesDiscoveryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:AntibodiesDiscoveryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:AntibodiesDiscoveryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240131_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgen:OrdinarySharesIssuedAndSoldThroughAtmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221101to20221111"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-11</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210901to20210929"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-29</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231201to20231227"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-12-01</xbrli:startDate>
        <xbrli:endDate>2023-12-27</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231210to20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LicenseAgreementWithGileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-12-10</xbrli:startDate>
        <xbrli:endDate>2023-12-18</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LicenseAgreementWithGileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-18</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201201to20201218"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-18</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240501to20240530"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-05-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapSubsidiaryOfCommonParentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:SubsidiaryOfCommonParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_cgenSegmentReportingGeographicAreaAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_cgenSegmentReportingGeographicAreaAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_cgenSegmentReportingGeographicAreaAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cgen:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cgen:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cgen:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:unit id="NIS_Per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Segment"><xbrli:measure>cgen:Segment</xbrli:measure></xbrli:unit>
<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<ix:relationship fromRefs="Fxbrl_20240730211801692_20250224141027740_2" toRefs="FN20250224141027743_19"/><ix:relationship fromRefs="Fxbrl_20240730224938615_20250224141027741_9" toRefs="FN20250224141027743_20"/><ix:relationship fromRefs="Fxbrl_20250224182302928" toRefs="FN20250225105352845"/></ix:resources></ix:header></div><div>
  <div>
    <div>
      <div>
        <div>
          <div>
            <div>
              <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/>
              <div>
                <div style="line-height:1.25">&#160;<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><strong><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif">UNITED STATES</span></span></strong></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><strong><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif">SECURITIES AND EXCHANGE COMMISSION</span></span></strong></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">WASHINGTON, D.C. 20549</span></span></div>
                  <div style="line-height:1.25;text-align:center">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif">FORM <ix:nonNumeric id="F20241016070140805_0" name="dei:DocumentType" contextRef="C_20240101to20241231">20-F</ix:nonNumeric></span></span></div>
                  <div style="line-height:1.25;text-align:center">&#160;</div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241016070140806_1" name="dei:DocumentRegistrationStatement" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></td>
                        <td style="width:auto;vertical-align:top">
                          <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></div>
                        </td>
                      </tr>

                  </table>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">OR</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241016070140806_2" name="dei:DocumentAnnualReport" contextRef="C_20240101to20241231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></td>
                        <td style="width:auto;vertical-align:top">
                          <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></div>
                        </td>
                      </tr>

                  </table>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the fiscal year ended <ix:nonNumeric id="F20241016070140807_3" name="dei:DocumentPeriodEndDate" contextRef="C_20240101to20241231" format="ixt:date-monthname-day-year-en"><ix:nonNumeric id="F20241016070140807_4" name="dei:CurrentFiscalYearEndDate" contextRef="C_20240101to20241231" format="ixt:date-monthname-day-en">December 31</ix:nonNumeric>, <ix:nonNumeric id="F20241016070140807_5" name="dei:DocumentFiscalYearFocus" contextRef="C_20240101to20241231">2024</ix:nonNumeric></ix:nonNumeric></span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">OR</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241016070140808_6" name="dei:DocumentTransitionReport" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></td>
                        <td style="width:auto;vertical-align:top">
                          <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></div>
                        </td>
                      </tr>

                  </table>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">OR</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241016070140808_7" name="dei:DocumentShellCompanyReport" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></td>
                        <td style="width:auto;vertical-align:top">
                          <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></div>
                        </td>
                      </tr>

                  </table>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date of event requiring this shell company report <span style="font-weight:bold">-----------------------------</span></span></span></div>
                  <div style="line-height:1.25;text-align:center">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">For the transition period from </span>____________ <span style="font-weight:bold">to </span>____________</span></span></div>
                  <div style="line-height:1.25;text-align:center">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commission file number: <span style="font-weight:bold"><ix:nonNumeric id="F20241016070140808_8" name="dei:EntityFileNumber" contextRef="C_20240101to20241231">000-30902</ix:nonNumeric></span></span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">____________________________________________________</span></span></div>
                  <div style="line-height:1.25;text-align:center">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:16pt;font-weight:bold"><span style="font-size:16pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241016070140808_9" name="dei:EntityRegistrantName" contextRef="C_20240101to20241231">Compugen Ltd</ix:nonNumeric>.</span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Exact name of Registrant as specified in its charter)</span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">____________________________________</span></span></div>
                  <div style="line-height:1.25;text-align:center">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;(Translation of Registrant&#8217;s name into English)</span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">___________________________________________________________________</span></span></div>
                  <div style="line-height:1.25;text-align:center">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241016070140817_36" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20240101to20241231" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Jurisdiction of incorporation or organization)</span></span></div>
                  <div style="line-height:1.25;text-align:center">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241016070140809_10" name="dei:EntityAddressAddressLine1" contextRef="C_20240101to20241231">Azrieli Center</ix:nonNumeric>, <ix:nonNumeric id="F20241016070140809_11" name="dei:EntityAddressAddressLine2" contextRef="C_20240101to20241231">26 Harokmim Street</ix:nonNumeric>, <ix:nonNumeric id="F20241016070140809_12" name="dei:EntityAddressAddressLine3" contextRef="C_20240101to20241231">Building D</ix:nonNumeric>, <ix:nonNumeric id="F20241016070140810_13" name="dei:EntityAddressCityOrTown" contextRef="C_20240101to20241231">Holon</ix:nonNumeric>&#160;<ix:nonNumeric id="F20241016070140810_14" name="dei:EntityAddressPostalZipCode" contextRef="C_20240101to20241231">5885849</ix:nonNumeric>&#160;<ix:nonNumeric id="F20241016070140810_15" name="dei:EntityAddressCountry" contextRef="C_20240101to20241231" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Address of principal executive offices)</span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">________________________________________________</span></span></div>
                  <div style="line-height:1.25;text-align:center">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241016070140810_16" name="dei:ContactPersonnelName" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">David Silberman</ix:nonNumeric>, Chief Financial Officer</span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Phone: +<ix:nonNumeric id="F20241016070140811_17" name="dei:CityAreaCode" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">972</ix:nonNumeric>-<ix:nonNumeric id="F20241016070140818_39" name="dei:LocalPhoneNumber" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">3-765-8585</ix:nonNumeric>, Fax: +<ix:nonNumeric id="F20241016070140811_18" name="dei:ContactPersonnelFaxNumber" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">972-3-765-8555</ix:nonNumeric></span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241016070140811_19" name="dei:EntityAddressAddressLine1" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Azrieli Center</ix:nonNumeric>, <ix:nonNumeric id="F20241016070140811_20" name="dei:EntityAddressAddressLine2" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">26 Harokmim Street</ix:nonNumeric>, <ix:nonNumeric id="F20241016070140812_21" name="dei:EntityAddressAddressLine3" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Building D</ix:nonNumeric>, <ix:nonNumeric id="F20241016070140812_22" name="dei:EntityAddressCityOrTown" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Holon</ix:nonNumeric>&#160;<ix:nonNumeric id="F20241016070140812_23" name="dei:EntityAddressPostalZipCode" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">5885849</ix:nonNumeric>&#160;<ix:nonNumeric id="F20241016070140812_24" name="dei:EntityAddressCountry" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">________________________________________________</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
                    <div style="page-break-after:always">
                      <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
                    </div>
                  </div>
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Securities registered or to be registered pursuant to Section 12(b) of the Act.</span></span></div>
                    <div style="line-height:1.25">&#160;</div>
                  </div>
                  <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:33%;vertical-align:top">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title&#160;of&#160;each&#160;class</span></span></div>
                        </td>
                        <td style="width:33%;vertical-align:top">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trading Symbol(s)</span></span></div>
                        </td>
                        <td style="width:33%;vertical-align:top">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width:33%;vertical-align:top">
                          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241016070140813_25" name="dei:Security12bTitle" contextRef="C_20240101to20241231">Ordinary shares, par value NIS 0.01 per share</ix:nonNumeric></span></span></div>
                        </td>
                        <td style="width:33%;vertical-align:top">
                          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241016070140813_26" name="dei:TradingSymbol" contextRef="C_20240101to20241231">CGEN</ix:nonNumeric></span></span></div>
                        </td>
                        <td style="width:33%;vertical-align:top">
                          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The <ix:nonNumeric id="F20241016070140813_27" name="dei:SecurityExchangeName" contextRef="C_20240101to20241231" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Stock Market LLC</span></span></div>
                          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;(The Nasdaq Capital Market)</span></span></div>
                        </td>
                      </tr>

                  </table>
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">&#160;</div>
                  </div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Securities registered or to be registered pursuant to Section 12(g) of the Act.</span></span></div>
                  <div style="line-height:1.25;text-align:center">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None</span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Title of Class)</span></span></div>
                  <div style="line-height:1.25;text-align:center">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.</span></span></div>
                  <div style="line-height:1.25;text-align:center">&#160;</div>
                  <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None</span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Title of Class)</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report: <span style="font-weight:bold"><ix:nonFraction id="F20241016070140813_28" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_20241231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,541,246</ix:nonFraction></span>&#160;<span style="font-weight:bold">Ordinary Shares</span></span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate by check mark <span style="font-weight:bold">if <span style="font-weight:normal">the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></span></span></span></div>
                  <div style="line-height:1.25;font-weight:normal">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744; Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9746; <ix:nonNumeric id="F20241016070140814_29" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_20240101to20241231">No</ix:nonNumeric></span></span></div>
                  <div style="line-height:1.25;font-weight:normal">&#160;</div>
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to</span><span style="font-weight:normal"> Section 13 or 15(d) of the Securities Exchange Act of 1934</span></span></span></div>
                  <div style="line-height:1.25;font-weight:normal">&#160;</div>
                  <div style="text-align:center;line-height:1.25">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744; Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9746; <ix:nonNumeric id="F20241016070140814_30" name="dei:EntityVoluntaryFilers" contextRef="C_20240101to20241231">No</ix:nonNumeric></span></span></div>
                  </div>
                  <div style="line-height:1.25;font-weight:normal">&#160;</div>
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act</span><span style="font-weight:normal"> of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></span></span></div>
                  <div style="line-height:1.25;font-weight:normal">&#160;</div>
                  <div style="text-align:center;line-height:1.25">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#9746;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"> <ix:nonNumeric id="Fxbrl_20250304022141436" name="dei:EntityCurrentReportingStatus" contextRef="C_20240101to20241231">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#9744;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;No</span></span></div>
                  </div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:center;line-height:1.25">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#9746;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<ix:nonNumeric id="Fxbrl_20250304022146953" name="dei:EntityInteractiveDataCurrent" contextRef="C_20240101to20241231">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#9744;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;No</span></span></div>
                  </div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See definition of &#8220;accelerated filer&#8221; &#8220;large accelerated filer&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></span></div>
                  <div style="line-height:1.25;font-weight:normal">&#160;</div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Large accelerated filer &#9744; <ix:nonNumeric id="F20241016070140818_40" name="dei:EntityFilerCategory" contextRef="C_20240101to20241231" format="ixt-sec:entityfilercategoryen">Accelerated filer</ix:nonNumeric>&#160;<span>&#9746; </span>Non-accelerated filer &#9744;&#160;Emerging growth company <ix:nonNumeric id="Fxbrl_20250228181502329" name="dei:EntityEmergingGrowthCompany" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></div>
                  <div style="line-height:1.25;font-weight:normal">&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards</span>&#8224;<span> provided pursuant to Section 13(a) of the Exchange Act </span>&#9744;</span></span></div>
                  <div style="line-height:1.25;font-weight:normal">&#160;</div>
                  <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
                    <div style="page-break-after:always">
                      <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
                    </div>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</span></span></div>
                  <div style="line-height:1.25;font-weight:normal">&#160;</div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric id="F20241016070140815_33" name="dei:IcfrAuditorAttestationFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If securities are registered pursuant to Section 12(b) of the Act indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statement. <ix:nonNumeric id="F20241016070140818_38" name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:33%;vertical-align:top">
                          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241016070140815_34" name="dei:DocumentAccountingStandard" contextRef="C_20240101to20241231">U.S. GAAP</ix:nonNumeric> &#9746;</span></span></div>
                        </td>
                        <td style="width:33%;vertical-align:top">
                          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">International Financial Reporting Standards as issued</span></span></div>
                        </td>
                        <td style="width:33%;vertical-align:top">
                          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other &#9744;</span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width:33%;vertical-align:top">&#160;</td>
                        <td style="width:33%;vertical-align:top">
                          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">by the International Accounting Standards Board &#9744;</span></span></div>
                        </td>
                        <td style="width:33%;vertical-align:top">&#160;</td>
                      </tr>

                  </table>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Item 17 &#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Item 18 &#9744;</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25">
                      <div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744; Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric id="F20241016070140815_35" name="dei:EntityShellCompany" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9746;</ix:nonNumeric> No</span></span></div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
            <div style="text-align:center">
              <div style="line-height:1.25">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;text-align:left">&#160;</div>
                </div>
              </div>
            </div>
            <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
              <div style="page-break-after:always">
                <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-bottom:10pt"/>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>

<!-- Field: Include-Text; File: pf\body.htm; Date: 2025%2D03%2D04T10:21:22; Size: 0x000F628C; Options: XMLPreprocess -->
<br/>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span style="text-decoration: underline">TABLE OF CONTENTS</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: -72pt; margin-left: 72pt; line-height: 1.25"><a href="#CAUTIONARY">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</a></div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" id="z969f58b19c21450fbb5708fd4c43dbbb" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#PARTI.">PART I.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">&#160;</td>
    <td style="width: 4.4%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM1.">ITEM 1.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM1.">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1</div> </td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM2.">ITEM 2.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM2.">OFFER STATISTICS AND EXPECTED TIMETABLE</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1</div> </td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM3.">ITEM 3.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM3.">KEY INFORMATION</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1</div> </td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM4.">ITEM 4.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM4.">INFORMATION ON THE COMPANY</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">48<br/> </td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM4A.">ITEM 4A.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM4A.">UNRESOLVED STAFF COMMENTS</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">65</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM5.">ITEM 5.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM5.">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">65</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM6.">ITEM 6.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM6.">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">78</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM7.">ITEM 7.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM7.">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">100</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM8.">ITEM 8.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM8.">FINANCIAL INFORMATION</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">100</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM9.">ITEM 9.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM9.">THE OFFER AND LISTING</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">100</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM10.">ITEM 10.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM10.">ADDITIONAL INFORMATION</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">101</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM11.">ITEM 11.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM11.">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">109</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM12.">ITEM 12.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM12.">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">110</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#PARTII">PART II.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">&#160;</td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM13.">ITEM 13.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM13.">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">110</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM14.">ITEM 14.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM14.">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</a></div>
        </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">110</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM15.">ITEM 15.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM15.">CONTROLS AND PROCEDURES</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">110</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16.">ITEM 16.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16.">RESERVED</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">111</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16A.">ITEM 16A.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16A.">AUDIT COMMITTEE FINANCIAL EXPERT</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">111</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16B.">ITEM 16B </a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16B.">CODE OF ETHICS</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">111</div> </td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16C.">ITEM 16C.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16C.">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">111</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16D.">ITEM 16D.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16D.">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">112</div> </td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16E.">ITEM 16E.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16E.">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">112</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16F.">ITEM 16F.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16F.">CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">112</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16G.">ITEM 16G.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16G.">CORPORATE GOVERNANCE</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">112</div> </td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16H.">ITEM 16H.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16H.">MINE SAFETY DISCLOSURE</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">112</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16I.">ITEM 16I. </a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16I.">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">112</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16J">ITEM 16J</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16J">INSIDER TRADING POLICIES</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">113</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16K">ITEM 16K.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16K">CYBERSECURITY</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">113</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#PARTIII">PART III</a> </div> </td>
    <td style="width: 85.52%; vertical-align: top">&#160;</td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM17">ITEM 17.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM17">FINANCIAL STATEMENTS</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">114</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM18">ITEM 18.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM18">FINANCIAL STATEMENTS</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">114</td> </tr>
  <tr>
    <td style="width: 10.09%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM19">ITEM 19.</a></div> </td>
    <td style="width: 85.52%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM19">EXHIBITS</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">115</td> </tr>
  </table> &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">(i)</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">CERTAIN DEFINED TERMS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All references in this Annual Report on Form 20-F to &#8220;Compugen,&#8221; the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or similar references refer to Compugen Ltd. and our wholly owned subsidiary Compugen
USA, Inc., except where the context otherwise requires or as otherwise indicated.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25">&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have prepared our consolidated financial statements in United States dollars and
in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. All references herein to &#8220;dollars&#8221;
or &#8220;$&#8221; or &#8220;USD&#8221; are to United States dollars, and all references to &#8220;Shekels&#8221; or &#8220;NIS&#8221;
are to New Israeli Shekels.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">(ii)</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="CAUTIONARY"><!--Anchor--></span>CAUTIONARY STATEMENT REGARDING</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">FORWARD-LOOKING STATEMENTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">This Annual Report on Form 20-F, or the Annual Report, includes &#8220;forward-looking statements&#8221;
within the meaning of the Securities Act of 1933, as amended, or the Securities Act, the Securities Exchange Act of 1934, as amended,
or the Exchange Act, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements
are based on our current beliefs, expectations and assumptions. Forward-looking statements can be identified by the use of terminology
such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;assume,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221;
&#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;believe,&#8221; &#8220;suggest,&#8221;
&#8220;plan,&#8221; and &#8220;intend,&#8221; and similar expressions that are intended to identify forward-looking statements, although
not all forward-looking statements contain these identifying words. These forward-looking statements involve known and unknown risks and
uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially
from those projected in the forward-looking statements include, without limitation, the risk factors set forth under &#8220;Item 3. Key
Information - D. Risk Factors,&#8221; the information about us set forth under &#8220;Item 4. Information on the Company&#8221; and information
related to our financial condition under &#8220;Item 5. Operating and Financial Review and Prospects.&#8221; Any forward-looking statements
represent our views only as of the date hereof and should not be relied upon as representing our views as of any subsequent date. We do
not assume any obligation to update any forward-looking statements unless required by law.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">(iii)</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>
<!--PROfilePageNumberReset%Num%1%%%-->

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="PARTI."><!--Anchor--></span>PART I.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold">ITEM 1.</span><span id="ITEM1."><!--Anchor--></span> <span style="font-weight: bold">IDENTITY
OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold">ITEM 2.<span id="ITEM2."><!--Anchor--></span></span> <span style="font-weight: bold">OFFER
STATISTICS AND EXPECTED TIMETABLE</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold">ITEM 3.<span id="ITEM3."><!--Anchor--></span></span> <span style="font-weight: bold">KEY
INFORMATION</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">A. [RESERVED]</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">B. CAPITALIZATION AND INDEBTEDNESS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. REASONS FOR THE OFFER AND USE OF PROCEEDS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">D. RISK FACTORS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">An investment in our ordinary shares involves a high
degree of risk and many factors could affect our results, financial condition, cash flows and results of operations. You should carefully
consider the following risk factors, as well as the other information in this Annual Report. If we do not, or cannot, successfully address
the risks to which we are subject, we could experience a material adverse effect on our business, results of operations and financial
condition, which could include the need to limit or even discontinue our business operations, and accordingly our share price may decline,
and you could lose all or part of your investment. We can give no assurance that we will successfully address any of these risks. The
principal risks we face are described below</span>.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Summary Risk Factors</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Our business is subject to a number of risks of which you should
be aware of before making an investment decision. These risks are discussed more fully under the caption &#8220;Item 3. Key Information
- D. Risk Factors&#8221; section of this Annual Report. These risks include, but are not limited to, the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z25fb0760331248428523ce0074fc5762" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We have a history of losses and we expect to incur future losses and may never achieve or sustain profitability.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8967ab8bae7141d89f6db0c21e4f2141" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We expect to raise additional funds in the future, and if we are unable to raise such additional funds, we may need to limit, curtail
        or cease operations. To the extent any such funding is based on the sale of equity, our existing shareholders would experience dilution
        of their shareholdings.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf53b9b623aeb4dd288a0a4f610a2a369" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We cannot provide assurance that our business model will succeed in generating substantial revenues.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z29b11909c24a42dc997c08f1d6264f22" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>In the near term, we are highly dependent on the success of COM701, COM902, GS-0321 (previously COM503) and rilvegostomig.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z39371d9940194761be05934a8b89ed00" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Clinical trials of any product candidates that we, or any current or future collaborators may conduct, may fail to satisfactorily
        demonstrate safety and/or efficacy, and we, or any collaborator, may incur additional costs or experience delays in completing, or ultimately
        be unable to complete the development and commercialization of these product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd9258d29eef6431b80410d32e5839613" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Clinical development involves a lengthy and expensive process, with an uncertain outcome. We may encounter substantial delays or
        even an inability to begin clinical trials for any specific product or may not be able to conduct or complete our trials on the timelines
        we expect.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb82000ead8b341e98a3bc3a64fdc541d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>From time to time, we publicly disclose preliminary data from our ongoing clinical trials. As more patient data become available,
        the data and the interpretation of the data may change.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z61d06082295340f4b80deabf8527ad6a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We rely and expect to continue to rely on third parties to conduct our clinical trials. These third parties may not successfully
        or professionally carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, and we may experience
        significant delays in the conduct of our clinical trials as well as significant increased expenditures.</div> </td> </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman,Times,serif; font-weight: normal; font-style: normal">1</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbbf7c2ea5a2549aa974bb6a98efd5904" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Serious adverse events or undesirable side effects or lack of efficacy, may emerge in clinical trials conducted by other companies
        running clinical trials investigating the same target as us, which could adversely affect our development programs or our capability to
        enroll patients or partner the program for further development and commercialization.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7dcfc2b339754c45b1c23f2d703230f6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We are subject to certain manufacturing risks, any of which could either result in additional costs or delays in completing, or ultimately
        make us unable to complete, the development and commercialization of our product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze31af4d745984798ad07172c1534b85f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>There are risks that are inherent in the development and commercialization of novel therapeutic products.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z22220b1a95bb41128d8243a63dfdf600" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our approach to the discovery of therapeutic products is based on our AI/ML powered predictive computational discovery platform,
        recently branded as Unigen&#8482; that is not yet fully proven clinically, and we do not know whether we will be able to discover and
        develop additional potential product candidates or products of commercial value.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8b383e20e2044c6e8d49f672d519d657" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We are focusing our discovery and therapeutic development activities on therapeutic product candidates for uses in immuno-oncology.
        Our current candidates may fail, and we may fail to continue to discover and develop therapeutic product candidates of industry interest
        in this field.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7f77f92626ef48d9837d77a543a71900" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We depend significantly on third parties (including partners) to carry out the research, development and commercialization of our
        therapeutic product candidates. If we are unable to maintain our existing agreements or to enter into additional agreements with such
        third parties, mainly collaborators, in the future, our business will likely be materially harmed.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zeb7772d110914b2c9f37a6c40c9477fb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We rely and expect to continue to rely on third parties to conduct our clinical trials. These third parties may not successfully
        or professionally carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, and we may experience
        significant delays in the conduct of our clinical trials as well as significant increased expenditures.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze5ff5f0331004e4b8313d864d680d548" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our dependence on collaboration agreements with third parties presents number of risks.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za9aaa1715f3d4ef9a7e91b0e963f6c32" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We operate in a highly competitive and rapidly changing industry which may result in others discovering, developing or commercializing
        competing products ahead of us or more successfully than we do.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2d982c6867534802928390ede5458617" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our information technology systems, or those of the third parties upon whom we rely, including our cloud and SaaS providers, CROs
        or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption to our business,
        as well as to regulatory investigations or actions; litigation; fines and penalties; reputational harm; loss of revenue and other adverse
        consequences.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z01e7ecf17c934e6e8d95218ec7462acf" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We are subject to stringent and changing obligations related to data privacy and security. Failure or perceived failure to comply
        with current or future obligations could lead to government enforcement actions (which could include civil or criminal penalties), private
        litigation, and/or adverse publicity and could negatively affect our operating results and business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z86a4964d586547e69a7425b23bd51016" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability
        to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z874fb8e20e8f491783f100a2be4f657b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We may need to obtain additional licenses of third-party technology or other rights that may not be available to us or are available
        only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that
        was not anticipated.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z23028802cde54ae7a9f46ad8aa699549" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We, or potential collaborators and licensees, may infringe third-party rights and may become involved in litigation, which may materially
        harm our business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf6b3cfa7904646509c53051d5062fa3b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time
        consuming and unsuccessful.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8b36bf10e379493cadd2b839d1fe727e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Conditions in Israel and in the Middle East may adversely affect our operations.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfbc3f74006ea4a47bf01dc972bae8fcc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our results of operations may be adversely affected by the exchange rate fluctuations between the dollar and the New Israeli Shekel.</div>
        </td> </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman,Times,serif; font-weight: normal; font-style: normal">2</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zec34904415774cfa9c69accfa3b06b07" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Future sales of our ordinary shares or securities convertible or exchangeable for our ordinary shares may depress our share price.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1cf4d40ac1014d238e6b95238f6e6e6f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>If we sell ordinary shares in future financings, shareholders may experience immediate dilution and, as a result, our share price
        may decline.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5f978813267b4564ba1f6422ec9e5291" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our share price and trading volume have been volatile and may be volatile in the future and that could limit investors&#8217; ability
        to sell our shares at a profit and could limit our ability to successfully raise funds.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Risks Related to our Business, Financial Results and Financing Needs</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We have a history of losses and we expect to
incur future losses and may never achieve or sustain profitability.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2024, we had an accumulated deficit of approximately $488.8 million
and have incurred net losses of approximately $14.2 million in 2024, approximately $18.8 million in 2023 and approximately $33.7 million
in 2022, in large part due to the expenditures associated with our ongoing research and development and limited revenues received to date.
In addition, we expect to continue to incur net losses in the future due to our anticipated costs and expenses, primarily associated with
our research, preclinical and clinical activities. We currently have two therapeutic pipeline program-based partnership agreements in
effect, one with AstraZeneca plc, or AstraZeneca, and the second with Gilead Sciences, Inc., or Gilead. In 2024, we received $76.5 million
as an upfront and milestone payments from Gilead (after $13.5 million tax withheld at source) and $15 million as milestone payments from
AstraZeneca. We cannot be certain that we will receive additional revenues under any of these partnership agreements or that we will enter
into additional arrangements for any of our therapeutic pipeline programs or with respect to our AI/ML powered predictive computational
discovery platform, recently branded as Unigen<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>,
or that such additional arrangements, if any, will provide sufficient revenues to achieve profitability.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We expect to raise additional funds in the
future, and if we are unable to raise such additional funds, we may need to limit, curtail or cease operations. To the extent any such
funding is based on the sale of equity, our existing shareholders would experience dilution of their shareholdings.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We believe that our current existing cash and cash equivalents, short-term bank deposits,
investment in marketable securities will be sufficient to fund operations into 2027, without considering the possible receipt of any additional
funds, such as proceeds from existing or additional licensing and/or collaborative agreements, or from financings. However, if our plans
change or if our burn-rate increases, our cash balances may only be sufficient for a shorter period of time. We cannot predict with any
degree of certainty when, or even if, we will generate significant revenues or achieve profitability, and therefore we expect to need
additional funds in the future to continue financing our operations. We may seek additional capital for various reasons, including for
our ongoing operations or strategic considerations, even if we believe we have sufficient funds for our current and future operating plans.
Additional funds, including proceeds from license or collaborative agreements, or from other financings, may not be available to us on
acceptable terms, or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our existing shareholders.
For example, if we raise additional funds by issuing equity securities, our existing shareholders will experience dilution of their shareholdings.
Debt financing, if available, may involve restrictive covenants that could limit our flexibility in conducting future business activities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any failure to raise funds as and when needed would materially harm our business,
financial condition and results of operations, and result in us having to significantly curtail one or more of our research or development
programs or otherwise reduce our operations and thereby not having the ability to have some or all of such therapeutic product candidates
developed and have a negative impact on our ability to pursue our business strategy.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman,Times,serif; font-weight: normal; font-style: normal">3</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We cannot provide assurance that our business
model will succeed in generating substantial revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business model is primarily based on expected future revenues in various forms,
including upfront fees, research funding, in-kind funding, milestone payments, license fees, royalties on product sales and other revenue
sharing payments from development and commercialization of products by third parties, pursuant to various forms of collaborations for
our novel targets and related drug product candidates at various stages of research and development. Our primary focus in immuno-oncology
utilizes our Unigen<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>
platform to identify novel drug targets and develop potentially first-in-class therapeutics in the field of cancer immunotherapy. Drug
target candidates discovered by our Unigen<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>
platform undergo initial target validation studies and, in selected cases, are advanced to the discovery and development of the therapeutic
product candidate. Such drug target candidates and their related therapeutic product candidates may serve as the basis for licensing and
other forms of third-party collaborations, though there can be no guarantee that our Unigen<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>
platform will yield any additional drug target candidates or therapeutic product candidates. While we currently have two collaborations
in effect, one with AstraZeneca and the second with Gilead, the termination of either or both existing or any future collaboration agreements
may have varying impacts on our financial position and, specifically, our ability to generate revenue. For example, the termination of
our agreement with Bristol Myers Squibb in 2022 had different effects on our operations and caused us to lose free access to PD-1 immune
checkpoint inhibitor, which has an adverse impact on our expenditure thereby requiring us to purchase PD-1 inhibitor for our clinical
studies. The main effect of the termination of the collaboration agreement with Bayer in 2023 was extinguishing our potential to achieve
future revenues from such collaboration.&#160;The inability to derive adequate revenues, or at all, from our business model would materially
harm our business, financial condition and results of operations and could result in the need to limit or even discontinue our business
operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We have a limited operating
history with respect to the partnering and commercialization aspects of our business model upon which investors can base an investment
decision or upon which to predict future revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ability to generate revenues from partnerships for our novel drug targets and
related therapeutic product candidates at various stages of research and development has been limited. To date, we have entered into four
partnership agreements with respect to our therapeutic pipeline programs (of which we currently have two collaborations in effect) under
which we have received a total amount of $182.2 million (after $13.5 million withholding taxes), of which $32.0 million was in the form
of an equity investment. We recognized revenue of approximately $27.9 million in 2024, approximately $33.5 million in 2023 and approximately
$7.5 million in 2022 from our partnerships. There can be no guarantee that we will achieve the same level of revenue in the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We cannot be certain that our focus on discovery, research and drug development in
the field of immuno-oncology, along with advancing selected programs to preclinical and clinical development partially or fully at our
own expense, will generate a stable or significant revenue stream. Additionally, financial terms for agreements by other companies, to
the degree disclosed, vary greatly and therefore financial terms that may be available for our candidates at the various R&amp;D stages
may vary greatly. The inability to derive adequate revenues within our field of focus and for our specific drug targets or product candidates
would materially harm our business, financial condition and results of operations and could result in the need to limit or even discontinue
our business operations. Moreover, our operating history with respect to the partnering and commercialization aspects of our model provides
a limited basis to assess our ability to generate significant fees, research revenues, milestone payments, royalties or other revenue
sharing payments from the licensing, development and anticipated future commercialization of our programs based on our existing and future
novel drug targets and related therapeutic products and any future product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Our failure to establish
and maintain effective internal control over financial reporting could result in material misstatements in our financial statements or
a failure to meet our reporting obligations. This may cause investors to lose confidence in our reported financial information, which
could result in the trading price of our shares to decline.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our management is responsible for establishing and maintaining adequate internal control
over financial reporting, as such term is defined in Rule&#160;13a-15(f) of the Exchange Act. Under the supervision and with the participation
of our management, including the Chief Executive Officer and the Chief Financial Officer, we carried out an evaluation of the effectiveness
of our internal control over financial reporting as of December&#160;31, 2024, using the criteria established in &#8220;Internal Control
- Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO
criteria). Based on our assessment under that framework and the criteria established therein, our management concluded that the Company&#8217;s
internal control over financial reporting was effective as of December 31, 2024, in providing reasonable assurance regarding the reliability
of the Company&#8217;s financial reporting.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman,Times,serif; font-weight: normal; font-style: normal">4</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">However, if we conclude in the future that our internal controls over financial reporting
are not effective, we may fail to meet our future reporting obligations on a timely basis, our financial statements may contain material
misstatements, our operating results may be negatively impacted, and we may be subject to litigation and regulatory actions, causing investor
perceptions to be adversely affected and potentially resulting in a decline in the market price of our shares. Even if we conclude that
our internal controls over financial reporting are adequate, any internal control or procedure, no matter how well designed and operated,
can only provide reasonable assurance of achieving desired control objectives and cannot prevent all mistakes or intentional misconduct
or fraud.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Risks Related to Development, Manufacturing, Clinical Trials and Government Regulation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">In the near term, we are
highly dependent on the success of COM701, COM902, GS-0321 (previously COM503) and rilvegostomig.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently have no products approved for commercialization and are investing a significant
portion of our efforts and financial resources into the clinical development of COM701, COM902 and GS-0321 (previously COM503) (which
was licensed to Gilead). Our prospects are substantially dependent on our ability, or that of any existing and future partners, as applicable,
to manufacture, develop, obtain marketing approval for and successfully commercialize any of COM701, COM902, rilvegostomig and GS-0321
(previously COM503) as a stand alone drug product or in combination with other drugs. We have reported favorable safety and toxicity profile
and preliminary signals of antitumor activity in our ongoing Phase 1 clinical trial with COM701 monotherapy, COM701 combination with nivolumab,
and in the triplet combination of COM701, nivolumab and BMS-986207 (anti-TIGIT antibody) and with triple combination of COM701, COM902
and pembrolizumab. We have reported preliminary signals of antitumor activity from our Phase 1 dose escalation monotherapy trial of COM902
with a best response of stable disease. These preliminary clinical results may not predict the final results of the on-going clinical
trials or future clinical trials or otherwise be sufficient to attract a partner or support a future path to registration or drug approval.
Many companies in the pharmaceutical, biopharmaceutical and biotechnology industries have suffered significant setbacks or failures in
clinical trials after achieving positive results, and we cannot be certain that we will not face similar setbacks or failures.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our pipeline currently consists of four clinical stage programs, which are at various
stages of clinical development. Two, COM701 and COM902 are being developed internally in Phase 1 trials. The third, rilvegostomig, is
being developed by our collaborator, AstraZeneca across various development stages, including multiple Phase 3 trials. The fourth, GS-0321
(previously COM503), is licensed to Gilead, and is being developed by us in a Phase 1 clinical trial with first patient dosed on January
7, 2025.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">While we completed enrollment of our clinical trials with COM902 as combination and we continue monitoring
a few of the patients still on treatment as of the middle of February 2025, our newly planned adaptive platform trial in patients with
relapsed platinum sensitive ovarian cancer in the maintenance setting is expected to first evaluate single agent COM701 and only then
may cover future combinations, which may include COM902. Therefore, in the near future we do not expect to have new meaningful data from
our COM902 program, however we do expect data of other companies that develop their own anti-TIGIT antibodies and from our partner AstraZeneca
for rilvegostomig (a PD-1/TIGIT bi-specific antibody with a TIGIT component that is derived from our COM902).</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">Recently, several clinical trials with TIGIT inhibitors have faced setbacks due to
mixed or disappointing efficacy results. For instance, Roche&#8217;s tiragolumab and Merck&#8217;s vibostolimab have encountered challenges
in late-stage trials. These results and any future results from other companies in the space could impact the potential success and market
acceptance of TIGIT inhibitors, including as it relates to our COM902 program and rilvegostomig.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we advance our programs throughout the different clinical development phases (where
with respect to GS-0321 (previously COM503), we are only responsible for Phase 1 development), we will need to expand our personnel and
operational capabilities to support these activities. We expect to need to raise additional capital in such event. In part because of
our limited infrastructure, limited experience in conducting clinical trials and limited experience in interacting with regulatory authorities,
we cannot be certain that our planned clinical trials will be initiated on time, that our clinical trials will be completed on time, if
at all, that our planned development programs and development path forward will be designed well or would be acceptable to the U.S. Food
and Drug Administration, or FDA, or other comparable foreign regulatory authorities, or that, even if approval is obtained, such investigational
products can be successfully commercialized.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The success of COM701, COM902 and GS-0321 (previously COM503) (for which we are only
responsible for the Phase 1 development) and rilvegostomig which is developed by AstraZeneca is dependent upon several factors, including
the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z040c84661bac40e4aeab363b286978f3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the successful clinical trial design (and implementation thereof) and results;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman,Times,serif; font-weight: normal; font-style: normal">5</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="zfa982bf3e98a494e9c594c8f904922cf" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to fund clinical trials designed to obtain regulatory approval and to become commercially successful;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z03f535f68cc54dfdb9c593cff6339b97" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to design trials required to allow for a path for registration or obtain regulatory approval;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z35f1405907e74751add34a339177079b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the success of trials designed to allow for a path for registration/approval by regulatory authorities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc718fabd098747a5bfad2f0f5bf89aa8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our selected regulatory strategy;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc26bdcac68994efd91b2f0219d177b39" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our timely initiation, enrollment and completion of clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd5d572909623478fade7cfb3b3a6290c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the enrolled patient population&#8217;s demographics, prior therapy/ies and other patients characteristics, even if they meet the
        inclusion/exclusion enrollment criteria;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za17a51f352194f87a0917c5266d0df35" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the availability of the patient population selected for enrollment;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z45420365face488daa9f834061a7b537" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the safety, tolerability and efficacy profile, alone or in combination with other approved or investigational products, that is satisfactory
        to the FDA or comparable foreign regulatory authorities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zec2563e060d143c7b49e475ffcd91467" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the safety, tolerability and efficacy profile, alone or in combination with other approved or investigational products, that fits
        the competitive treatment landscape/ unmet patients&#8217; need;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z86045783b1eb4613960fc2e9256019b3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>selection of drug dosing;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf436e76093f14e1187c9652c1c871d42" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>selection of indications;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9377ced29f3142c08dba376007f9cc85" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>selection of patient populations;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z67ce1fa33690425ea1eb8f1583bb6d5c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>selection of comparator trial arm(s);</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z387c4dbe499c43378e0c904a24163d91" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>selection of drug(s) for combinations;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z32edad8e69004230888443065858e30f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>access to drugs required for combination studies or approval;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc60efc953ebe40ba8a52ed2e80a33a0a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>successful identification of biomarkers, including for patient selection;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze8d3836d39fa4a899ca8a12786c074ce" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>timely receipt of marketing approvals from applicable regulatory authorities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7d4c6d37a77d4eb4ae52d09c97176cfe" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the performance of our current and future collaborators, if any;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf0d2a67a366c45b9a139fa28139da510" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the extent of any required post-marketing approval commitments to applicable regulatory authorities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8e7e9bd0373d4d45a38ac7beece0c05a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>establishment, management and monitoring of CRO arrangements and processes with third-party service providers for conducting the
        clinical trial;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf5319eac163f40db9a848e78b66913da" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>ability to convince clinical investigators in the potential of our clinical drug candidates and their interest in enrolling patients
        to our studies;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc5012f4e9d6643fa921e5a8a16859e66" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>establishment and monitoring of manufacturing arrangements and processes with third-party service providers and clinical manufacturing
        organizations for manufacturing drug substance and drug product;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z530c37f77847427e9210af533f21412e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>establishment and monitoring of arrangements with third-party suppliers of raw materials and service for fill-finish, packaging and
        labeling;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za66f2b975f1d4e24b6b8fae7ca8bb1fe" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>stability of our drug substance and drug products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb8cef01b99cd481d919f13c53da209df" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>supply of our drugs in sufficient quantities and quality for our clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7b29b3ae4c404085b066a248d4956e95" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>establishment of arrangements with third-party manufacturers and processes monitoring to obtain commercial quality drug product that
        is appropriately packaged for sale;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1fd454b038a14ae88501cc7384dd47eb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>adequate ongoing availability of raw materials and drug product for clinical development and any commercial sales;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1790b6570988485abbea0411a2858191" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>protection of our rights in our intellectual property portfolio;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z60305fab9a0845a1ab12a560a69b6054" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>successful launch of commercial sales following any marketing approval and the size of the potential patient population;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z766f0b5b3b9742cc9576c84adceaa49b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>a continued acceptable safety profile following any marketing approval;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman,Times,serif; font-weight: normal; font-style: normal">6</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6fd503e924214d8e8067f199cf35e90a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>commercial acceptance by patients, the medical community and third-party payors; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6c6ceae6b1b14908875fdf834a7968af" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the success of other anti-PVRIG, anti-TIGIT and anti-IL-18 binding protein pathway molecules.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Many of these factors are beyond our or our partners&#8217; control, including clinical
development by us, our partners and our competitors, the regulatory submission and review process, potential threats to intellectual property
rights and the manufacturing, marketing and sales efforts of any current and future third party. If we are unable to develop, receive
marketing approval for and successfully commercialize COM701, COM902 and GS-0321 (previously COM503), on our own or with any collaborator,
or AstraZeneca is unable to do so with respect to rilvegostomig, or experience delays as a result of any of these factors or otherwise,
without developing new programs that can potentially generate value, our business could be substantially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We depend on enrollment
of patients in our clinical trials in order to continue development of our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">We are currently enrolling patients for our Phase 1 clinical trial to assess the safety and tolerability
of GS-0321 (previously COM503) as monotherapy and in combination with zimberelimab in participants with advanced solid tumors. We plan
to start enrolling patients to our adaptive platform trial in relapsed platinum sensitive ovarian cancer, evaluating COM701 in sub-trial
1 as a monotherapy, in the second quarter of 2025 and we expect to share interim analysis data from this sub-trial in the second half
of 2026. Our anticipated time to data in these trials is subject to our ability to enroll a sufficient number of patients that meet our
inclusions and exclusion criteria, our ability to monitor these patients as required and that such number of eligible patients is sufficient
for observing clinical activity, if at all. There can be no assurance that we will complete enrollment or have data from the trials when
we anticipate or at all or that our data will support the further development of our potential product candidates. </div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may experience difficulties in patient enrollment in our clinical trials for a
variety of reasons. Patient enrollment is affected by many factors including the size and nature of the patient population, the eligibility
criteria for the trial, the design of the clinical trial, the size of the patient population required for analysis of the trial&#8217;s
primary endpoints, the proximity of patients to clinical trial sites, our ability to recruit clinical trial investigators with the appropriate
competencies and experience, the number of enrolling clinical sites, our ability to obtain and maintain patient consents, the risk that
patients enrolled in clinical trials will drop out of the trials before completion or even before any/sufficient imaging assessment, the
willingness of patients to participate in our study or attend clinic visits for various reasons, including epidemic and pandemic concerns,
and competing clinical trials (including other clinical trials that we are conducting or will conduct in the future) and clinicians&#8217;
and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, or
competing drugs against the same target as well as a changing treatment landscape, including any new drugs that may be approved for the
indications we are investigating. For example, several pharmaceutical companies are conducting clinical trials in the same patient population
as in our clinical studies and their molecules might have better clinical efficacy. Examples of such studies are Abbvie&#8217;s Phase
3 clinical trial with mirvetuximab + bevacizumab (GLORIOSA) and OSE Immunotherapeutics&#8217;s Phase 2 clinical trial with OSE2101 in
combination with Keytruda (TEDOVA) in the maintenance setting in platinum sensitive ovarian cancer patients. Also, after the successful
results of Antibody-Drug Conjugates (ADCs), in the platinum resistant ovarian patient population, some of the companies with these agents
might also start clinical studies in the maintenance setting in platinum sensitive ovarian patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Many pharmaceutical companies are conducting clinical trials in
patients with the disease indications that COM701, COM902, GS-0321 (previously COM503) and our future potential drug products may target.
Additionally, other pharmaceutical companies are already clinically investigating their own therapeutic candidates against PVRIG, the
target of COM701, or against TIGIT, the target of COM902, and the IL-18 pathway, which GS-0321 (previously COM503) is targeting, which
may hamper the enrollment of patients in our trials for COM701, COM902, or GS-0321 (previously COM503) and may present a higher bar for
success. For example, in the case of COM701, there are currently several PVRIG antibodies in clinical studies, such as GSK&#8217;s GSK4381562
(previously SRF813) anti-PVRIG in Phase 2, and several in Phase 1 clinical trials, such as Biotheus&#8217;s (now BioNTech) PM-1009, a
PVRIG/TIGIT bi-specific, Simcere&#8217;s SIM0348 a TIGIT/PVRIG bispecific antibody, and Hefei TG ImmunoPharma&#8217;s NM1F anti PVRIG.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman,Times,serif; font-weight: normal; font-style: normal">7</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">In the case of COM902, the landscape includes a significant number of anti-TIGIT antibodies at various
stages of development, with the leading ones currently in Phase 3 clinical trials, such as tiragolumab by Roche (despite some disappointing
results), rilvegostomig by AstraZeneca, ociperlimab by Beigene, domvanalimab by Arcus and belrestotug by GSK/ITeos, as well as others
at earlier stages in development. In the IL-18 pathway field, the programs that are more advanced than GS-0321 (previously COM503) and
are in clinical stage are Simcha Therapeutics&#8217; ST-067 (DR18), a mutated IL18, BrightPeak&#8217;s BPT-567, an IL18/PD-1, and additional
four IL-18 related CAR-T therapies TmCD19-IL18 by Kite/University of Pennsylvania, EU-307, a GPC3 + IL-18 CART by Eutilex, 19-28z/IL-18
CAR T cells and CD371-YSNVZ-IL18 by Memorial Sloan Kettering Cancer Center.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">As a result, we must compete with these competitors for clinical sites, clinicians&#8217;
interest and the limited number of patients who fulfill the stringent requirements for participation in clinical trials in general as
well as on the clinical value of our data. Also, patient enrollment may be limited due to changes in the regulatory landscape in the indications
of interest to us. Our clinical trials may be delayed or terminated due to the inability to enroll enough patients or lack of successful
drug performance. The delay or inability to meet planned patient enrollment or successful results may result in increased costs and delay
or termination of our trials, which could have a harmful effect on our ability to develop products and continue our operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Clinical trials of any product
candidates that we, or any current or future collaborators may conduct, may fail to satisfactorily demonstrate safety and/or efficacy,
and we, or any collaborator, may incur additional costs or experience delays in completing, or ultimately be unable to complete the development
and commercialization of these product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We, and any current or future collaborators, are not permitted to commercialize, market,
promote or sell any therapeutic product candidate in any jurisdiction without obtaining marketing approval from the relevant regulatory
authority, such as the FDA in case of the United States. We, and any collaborators, must complete clinical trials to demonstrate the safety
and efficacy of our therapeutic product candidates in humans before we will be able to obtain these approvals.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Clinical testing is expensive, difficult to design and implement, can take many years
to complete and is inherently uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed
on schedule, if at all. The clinical development of our therapeutic product candidates is susceptible to the risk of failure inherent
at any stage of product development, including failure to demonstrate efficacy in a clinical trial or across population of patients, choosing
the incorrect patient population or indication, the occurrence of adverse events that are severe or medically or commercially unacceptable,
failure to comply with protocols or applicable regulatory requirements and determination by the FDA that a therapeutic product candidate
may not continue development or is not approvable. The outcome of preclinical studies and early clinical trials may not predict the success
of later clinical trials and interim results of a clinical trial do not necessarily predict final results. A number of companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or
unacceptable safety profiles, notwithstanding promising results in earlier trials. Despite the preliminary safety and anti-tumor activity
results reported to date from our ongoing Phase 1 clinical trials for COM701 and COM902, we do not know whether the clinical trials we
or our partners may conduct will demonstrate adequate efficacy and safety to result in the further advancement of clinical development
or regulatory approval to market COM701 and/or COM902, or any other of our product candidates when they reach the clinic, in any particular
jurisdiction or jurisdictions. The same applies to GS-0321 (previously COM503) which recently entered the clinic. It is also possible
that, even if one or more of our therapeutic product candidates has a beneficial effect, that effect will not be detected during clinical
evaluation as a result of one or more of a variety of factors, including the size, patient population, duration, design, measurements,
conduct or analysis of our clinical trials, patient monitoring, the dosing we choose and other factors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any inability to successfully complete clinical development could result in additional
costs to us, or any collaborators, and impair our ability to generate revenues from product sales, development, regulatory and commercialization
milestones and royalties. Moreover, if we, or any collaborators, are required to conduct additional clinical trials or repeat clinical
trials or other testing of our product candidates beyond the trials and testing that we or they contemplate, if we, or they, are unable
to successfully complete clinical trials of our product candidates or other testing, or the results of these trials or tests are unfavorable,
uncertain or are only modestly favorable, or there are unacceptable safety concerns associated with our product candidates, we, or any
collaborators, may, among others:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd863c2e752a548a6973f43e47a809f79" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>cease the development of the product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z96d7df4bc1f946d4a51fcd4b0a8f6250" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>incur additional unplanned costs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd2d3ceba6ddf449390b93bdb76fd7145" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>terminate or amend the respective collaboration, if applicable;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman,Times,serif; font-weight: normal; font-style: normal">8</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z41a4b6e1cd014d5dae4328802bac0df0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>not obtain approval to proceed to next development phase;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6fb286a764a24a479ccd62a2e1fec1b4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>be delayed in obtaining marketing approval for our product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z49a0776687714b8e98963bb54fda2183" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>not obtain marketing approval at all;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z76d2f52674f5416f809ae0bd43fb53bc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>obtain approval for indications or patient populations that are not as broad as intended or desired;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z02f274f4053e4cb0b2b84be1ff18fbec" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including
        boxed warnings;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z76b63a73f6ef422a925fb1eacdd12676" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>be subject to additional post-marketing testing or other requirements; or</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5bf88094d5f943c09a8862a71d175e1a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>be required to remove the product from the market after obtaining marketing approval.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our failure or failure of any of our collaborators, to successfully initiate and complete
clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market
any of our product candidates or those of our collaborators, and to successfully market these products, if approved, would significantly
harm our business, could further result in significant harm to our financial position and results of operations and could result in the
need to limit or even discontinue our business operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Clinical development involves a lengthy and
expensive process, with an uncertain outcome. We may encounter substantial delays or even an inability to begin clinical trials for any
specific product or may not be able to conduct or complete our trials on the timelines we expect.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Obtaining marketing approval from regulatory authorities for the
sale of any therapeutic product requires substantial preclinical development and then extensive human clinical trials to demonstrate the
safety and efficacy of such product candidates. It is impossible to predict when or if any of our programs or those of our collaborators
based on our target discoveries will yield products that will be approved for human testing, or, if such testing is proven sufficiently
safe and effective for further development or to receive regulatory approval for marketing. Preclinical and clinical testing are expensive,
time consuming, and subject to uncertainty and will require significant additional financial and management resources. As a company, we
have limited experience in conducting clinical trials and have never progressed a product candidate through to regulatory approval. In
part because of this lack of experience, our clinical trials may require more time and incur greater costs than we anticipate. We cannot
guarantee that any of our therapeutic drug candidates from our pipeline will be advanced into clinical trials or that our clinical trials
will be conducted as planned or completed on schedule, if at all. The outcome of preclinical testing and early clinical trials may not
be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed
their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to continue to achieve
such successes at later stages of the clinical studies or to obtain marketing approval for such products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">There can be no assurance that our clinical trials will begin at
any predicted date or will be completed on schedule, if at all. We are also conducting or planning to conduct clinical trials in additional
jurisdictions outside the United States. The FDA or other regulatory authorities could require us to conduct additional preclinical studies
or added clinical evaluation under any IND, clinical trial agreement or similar regulatory filing, which may lead to delays and increase
the costs of our preclinical and clinical development programs. There may be unforeseen cultural, legal, and operational issues that could
arise in clinical trials outside of the United States impacting the timely and successful completion of our clinical trials in such new
territories. These factors could lead to increased costs or delays, or even the inability to complete our clinical trials as planned,
which could adversely affect our development timelines and could cause us material harm. Moreover, even if these clinical trials begin
on time, issues may arise that could result in the suspension of or termination of such clinical trials. A failure of one or more clinical
trials can occur at any stage of testing. Events that may prevent successful or timely commencement and completion of clinical development
include:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd90bd5e3db734c2d9300da9bb7072d4c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>inability to generate sufficient preclinical, toxicology, or other data to support the initiation of clinical trials;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z768ddae083e44b1d9431da8dac023a0f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>lack of authorization from regulators or institutional review boards, or IRBs, or ethics committees to allow us or our investigators
        to amend a clinical trial or commence a clinical trial or conduct a clinical trial at a prospective trial site or continue such clinical
        trial;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">9</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc3e400cc378d43f7b9f8a8b21d0ee8f8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays in sufficiently developing, characterizing, or controlling a manufacturing process suitable for clinical trials;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z22de4da7d7874c908f522d250dc87556" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>inability to generate sufficient quantities or quality of our drug substance or drug product to support the initiation or continuation
        of clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb606a8756dfa4e128ff3ac57e45730c1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays in reaching a consensus with collaborators or regulatory agencies on trial design or trial amendment;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z348dd9c48ba240909900d50e3908df2f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays in reaching agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject
        to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3720a6c3f8654a2b8d61db23e323be10" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>significantly increased spendings required by our CROs as compared to our forecasts/projected spendings;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7f30d97f3b8943f7a9ac24d48d5929e1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>imposition of a temporary or permanent clinical hold by the FDA, or a similar delay imposed by foreign regulatory agencies for a
        number of reasons, including after review of an IND, other application or amendment; (i) as a result of a new safety finding that presents
        unreasonable risk to clinical trial participants; (ii) a negative finding from an inspection of our clinical trial operations or trial
        sites; (iii) developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of
        the technology broadly; or (iv) if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze2c96128bb7047aabe05d0baa7696266" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>failure of clinical trials of any product candidates to show safety or efficacy, which may result in additional preclinical studies
        or clinical trials or abandonment of product candidates development programs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfcd10da7c85a4d35be366be7ba2e3e5a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>difficulty collaborating with patient groups and investigators;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd7df21a642594996b854e2a90885439e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>failure by our CROs, other third parties, or us to adhere to clinical trial and related regulatory requirements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z709e3159ba7a4b82baef0077ac385067" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>failure to perform in accordance with the FDA&#8217;s Good Clinical Practice, or GCP, requirements, or similar applicable regulatory
        guidelines in other countries;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4332dbf2cd834f97a64f527195599d82" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>failure to perform in accordance with the FDA&#8217;s Good Manufacturing Practice, or GMP, requirements, or similar applicable regulatory
        guidelines in other countries;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za880d31c9b2a415f8584e11e43d58a11" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the number of patients required for clinical trials of any product candidates may be larger than we anticipate or can financially
        support, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or
        fail to return for post-treatment follow-up at a higher rate than we anticipate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2770a657f1b34f2a99929de01c077582" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays in having patients complete their participation in a trial or return for post-treatment follow-up;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7a07d3e4d31c4995bce40a88e9be808b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaa4b896beda94cda9f771fb8da48221b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3bcc5db733364ab0a8f51a22aadd0c89" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in the standard of care or in the regulatory landscape on which a clinical development plan was based, which may require
        new or additional trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf6fec7cb252148e28c606039be1866bc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the cost of clinical trials of our product candidates being greater than we anticipate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5eb00c33e0324cff911603e6bd3a7833" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>clinical trials of our product candidates producing negative or inconclusive results, or early results that will not be repeated
        in larger or future cohorts or randomized studies, which may result in our decision, or regulators requiring us, to conduct additional
        clinical trials or abandon product development programs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9c82ddf9e58944cb8d2837511355e9d6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>choosing the wrong dosing regimen and/or wrong drug combination and/or wrong patient population;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za06bfe9aac9843cd821ef0a6c9216e88" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays or failure to secure supply agreements with suitable reagent suppliers, or any failures by suppliers to meet our quantity
        or quality requirements for necessary reagents; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z92715a47f45648539d5339fe46f0482c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates
        for use in clinical trials or the inability to do any of the foregoing.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any delays in our preclinical or clinical development programs may harm our business,
financial condition and prospects significantly.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">10</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">From time to time, we publicly disclose preliminary
data from our ongoing clinical trials. As more patient data become available, the data and the interpretation of the data may change.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">From time to time, we publish preliminary or interim investigator assessed data from
our ongoing clinical trials. Preliminary data remain subject to audit confirmation and verification procedures that may result in the
final data being materially different from the preliminary data we previously published. Preliminary data are also subject to the risk
that one or more of the clinical outcomes may materially change as time goes by and cutoff date changes, patient enrollment continues
and with further patient monitoring where more patient data become available. As a result, preliminary data should be viewed with caution
until clinical trial completion where the final data are available. Also, data may also change upon further assessment in additional studies.
Material adverse changes in the data along the clinical development process could significantly harm our business prospects, financial
condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Serious adverse events or undesirable side
effects or lack of efficacy, may emerge in clinical trials conducted by other companies running clinical trials investigating the same
drug target as us, which could adversely affect our development programs or our capability to enroll patients or partner the program for
further development and commercialization.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We initiated a Phase 1 clinical trial for COM902, which targets TIGIT, in March 2020.
There are additional companies that have a program targeting TIGIT in advanced clinical trials, such as Roche, Gilead/Arcus, AstraZeneca,
and BeiGene. We have no control over their clinical trials or development programs, and lack of or insufficient efficacy such as recently
reported for Roche&#8217;s TIGIT targeting antibody tiragolumab in small cell lung cancer, or SCLC and non-small cell lung cancer, or
NSCLC or Merck&#8217;s, adverse events or undesirable side effects experienced by participants in their clinical trials could affect our
development plans and trials execution and regulatory path of COM902 or the enthusiasm of clinicians recruiting patients for our clinical
trials for COM902 or any other service provider or harm its potential to be partnered for further development and commercialization and
generate revenues for the Company.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Furthermore, any negative results that may be reported in clinical
trials of other programs targeting TIGIT may make it difficult or impossible to recruit and retain participants in our clinical trials
of COM902. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials,
which could prevent completion of these trials and adversely affect our ability to advance the development of COM902. Failures in planned
participant enrollment or retention may result in increased costs or program delays and could render further development impossible.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The same risk applies to COM701 and GS-0321 (previously COM503),
both of which are in the clinic. For a list of companies that have programs targeting PVRIG and IL-18/IL-18BP see &#8220;Item 3. Key Information
- D. Risk Factors &#8211; Risks Related to Development, Manufacturing, Clinical Trials and Government Regulation - We depend on enrollment
of patients in our clinical trials in order to continue development of our product candidates.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are subject to certain manufacturing risks,
any of which could either result in additional costs or delays in completing, or ultimately make us unable to complete, the development
and commercialization of our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The process of manufacturing biologics, in addition to the shipment and storage thereof,
is susceptible to product loss or unavailability due to contamination, degradation, instability, equipment failure, lack of critical reagents
or disposables, improper installation or operation of equipment, vendor or operator error leading to process deviations or any other factor.
Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply
disruptions up to supply termination. If microbial, viral or other contaminations are discovered in our products or in the manufacturing
facilities in which our products are made, the products may need to be manufactured again and/or such manufacturing facilities may need
to be closed for an extended time to investigate and remediate the contamination. In addition, the product manufactured may be determined
at a later stage to be insufficiently stable or qualified as a therapeutic agent, even following treatment.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">11</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">We have not contracted with alternate suppliers to support us in the event we experience
any problems with our current manufacturers and we believe that even if we purchase an insurance to cover financial loss, such insurance
may not suffice and even if such insurance would cover the financial loss, the result of such events may have an adverse effect which
is beyond our financial loss. If we are unable to arrange for alternative third-party manufacturing sources or are unable to reserve another
manufacturing slot with our current manufacturers or are unable to do so on commercially reasonable terms or in a timely manner, or are
unable to provide backup drug, we may incur additional costs or be delayed in the development or delivery of our current and future product
candidates, and even fail to supply drug to patients on trial treatment on time or at all, or meet other obligations, each event of which
can cause us material harm.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">It may be difficult to manufacture therapeutic products addressing
our drug target candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Our clinical stage pipeline is focused mainly on therapeutic antibodies,
generated against our discovered targets. These types of therapeutics can be difficult to manufacture in the quantity and quality needed
for preclinical, clinical and commercial use. The production of therapeutic antibodies must be conducted pursuant to a well-controlled
and reproducible process and the resulting product testing must conform to defined quality standards. Should it prove to be difficult
to manufacture or repeat manufacturing, of any therapeutics addressing our drug candidates in sufficient quantities or commercial scale,
meeting the required quality standards or in an economical manner to conduct clinical trials and to commercialize any approved therapeutic
candidate, our business, financial condition and results of operations would be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We or any of our collaborators, or third-party
manufacturers, may fail to comply with regulatory and legal requirements, and we or they could be subject to enforcement or other regulatory
actions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">If we or any of our collaborators or third-party manufacturers
with whom we work or with whom we may enter into agreements in the future fail to comply with applicable federal, state or foreign laws
or regulations, or other legal obligations we or they could be subject to enforcement or other regulatory actions. These actions may include:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze9185085b00644c091334c8313aef7c2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>warning letters;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf560ed735f0e499d830457b1a45dfbab" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>clinical trial holds;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z63f6bca1099a4c009476c5ea9320ef03" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>recalls, product seizures or medical product safety alerts;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z853bafe7e042438c8c334a8f4562e1fc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>data lock or order to destroy or not use personal data;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd0532ea0da19479382839558fcb19182" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>restrictions on, or prohibitions against, marketing such products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc56630e17a58474da3c5fcea444b751b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>restrictions on importation of such products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb990d841ea4740e4a28b48b974484c68" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>suspension of review or refusal to accept or approve new or pending applications;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7058d2add1ac408daaedc424f92e0d49" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>withdrawal of product approvals;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5151f310e5074b289f8a1005f4cd15e0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>injunctions;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc511dc1d39c0472bbb7010e19a141265" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>civil and criminal penalties and fines; or</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3486e9abd47044d099da43467f333240" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>debarment or other exclusions from government programs.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we or our collaborators become subject to such enforcement actions, these enforcement
actions could affect the ability to successfully develop, market and sell therapeutic products based on our discoveries and could significantly
harm our financial status and/or reputation and lead to reduced acceptance of such products by the market.&#160;In addition, we may be
subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement or imprisonment.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">12</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may require companion or complementary diagnostics
and/or biomarkers for our clinical trials, or a portion of our clinical trials, and may be required to have such in order to obtain marketing
approval or commercialization of our therapeutic programs. Failure to successfully discover, develop, validate and obtain regulatory clearance
or approval for such tests could harm our patients&#8217; selection strategy and may harm our clinical outcome.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Companion or complementary diagnostics are subject to regulation by the FDA and comparable
foreign regulatory authorities and may require separate regulatory authorization prior to commercialization. We may require for our clinical
trials or for certain portions of our clinical programs, companion diagnostics and/or biomarkers to correctly identify the right patients
for treatment. We rely on access to patient clinical and demographics data, tumor, blood samples for analysis of protein, DNA, and RNA
biomarkers. We may rely on third parties for the tumor and blood samples&#8217; handling, processing, and analysis, discovery, development,
and validation of these potential biomarker candidates, biomarkers and/or companion diagnostics, as well as the application for and receipt
of any required regulatory authorization. If we, or the third parties we engage for this purpose, are unable to successfully discover,
validate and/or develop the required companion diagnostics and/or biomarkers for our clinical programs, or develop with altered specifications,
or experience delays in doing so, the development of our clinical candidates may be adversely affected and this can harm our patient selection
and our clinical outcome, as well as obtaining marketing authorization for these product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">From time to time, we may also publish preliminary
biomarker data from our ongoing clinical trials. As more patient data become available, the data and the interpretation of the data may
change.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Preliminary biomarker data are subject to the risk that it may materially change as
patient enrollment continues, as assay or reagents conditions change, as selected signal cutoff changes and it remains subject to audit
confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously
published. As a result, preliminary data should be viewed with caution. Material adverse changes in the biomarker data along the clinical
development process could modify or harm our patient selection strategies, the success of our studies and could cause other damages and
could eventually significantly harm our business prospects, financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to our Discovery and Development Activities</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">There are risks that are inherent in the development
and commercialization of novel therapeutic products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We and our collaborators face a number of risks of failure that are inherent in the
lengthy and costly process of developing and commercializing novel therapeutic products. These risks, which typically result in very high
failure rates even for successful biopharmaceutical companies, include, among others, the possibility that:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb23ee767fd744096bc06860e7aea2dcc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not be able to discover additional drug targets;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc89b6b91b38142178c227c9c80a3945b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our novel target candidates will prove to be inappropriate for treatment of cancer;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc72e4d6966d24d20bd6f48b98a339e4b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our novel target candidates will prove to be inappropriate for therapeutic product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z861b6eb50d9f410389632032efb8db46" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our novel target candidates will prove to be inappropriate for immunotherapy;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc229bcf168b841fc8c625884046d27b3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not succeed in selecting the appropriate tumor type, indication or patient population for the therapeutic product candidate;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7f60d308d8ef4d349fc2245115dd2c81" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not succeed in developing or choosing the appropriate monoclonal antibody, or mAb, for these targets, or the appropriate
        mAb isotype, or the appropriate therapeutic lead;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6af2a58944394bbcac9365273220a3e9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not succeed in identifying, validating or developing a biomarker or companion diagnostic for our therapeutic product candidates;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3f0a6c6ed24a4f46a7a1dd2fd0a7107e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not succeed in choosing or developing the appropriate drug modality for these targets or we will not have the expertise to
        do so;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbd320bf4a6ff45219499f29b7e29ffc4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our therapeutic product candidates will fail to progress to preclinical studies or clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z53fa40ae2b9b4c5a8b81bb3f30797a98" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our therapeutic product candidates will be found to be therapeutically ineffective;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z030d4ce1b6144574a5cc2e413dab0a21" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not choose or have access to the right drug combination for our therapeutic product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z273eeabfee17420391199d66f1d8d4d3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not select or find the appropriate dosing regimen;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf4413eb373754dc0a19652dcf808158c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our therapeutic product candidates will be found to be toxic or to have other unacceptable side effects or negative consequences;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze7c6af7b67c1410f9e0c3bc8b06ac2d7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our therapeutic product candidates will be inferior, or not show added value, compared to competing products or the standard of care;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfd5ee94757e84975868488d3f3881f3a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our products covered by our collaborations may face internal competition from our partners&#8217; internal pipeline;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3a88e0c567ea4b12a99108559bb8bf78" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we or our collaborators will fail to receive required regulatory approvals;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">13</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z688f43730ab446efa849cdbab5f90ba1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the discovery of drug targets and the discovery, development or commercialization of our therapeutic product candidates will infringe
        third-party intellectual property rights;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z22327d8a9efd44169e1c8a4cd3652e2a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the development, marketing or sale of our therapeutic product candidates will fail because of our inability or failure to protect
        or maintain our own intellectual property rights;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcd93bdb6605044f4b9283cb2a8460d3c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>once a product is commercially available, there will be little or no demand for it for a number of possible reasons, including lack
        of acceptance by the medical community or by patients, a very small patient population size, lack of or insufficient coverage and payment
        by third-party payors, inefficient or insufficient marketing and sales activities or as a result of there being more attractive, less
        risky or less expensive, products available for the same use; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcd0796d9695a46329782554e2f4a4aac" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the product will be withdrawn from the market, or sales limited due to side effects observed in clinical practice.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If one or more of these risks or any similar risks should materialize, our business,
financial condition and results of operations may be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our computational target discovery activities
are primarily focused on the discovery of novel drug target candidates and our therapeutic pipeline is based on our discovered targets.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While we believe that our drug target programs represent a compelling and unique opportunity
to generate potentially first-in-class therapeutics in the field of cancer immunotherapy, they require significant investment in the research
and validation of the drug target candidate and in the discovery and development of the respective therapeutic product candidate and bear
high risk. Our Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup> platform is a source for the development
of potential first-in-class therapeutics in the field of cancer immunotherapy, but the inherent lack of sufficient published scientific
and clinical data to support the potential of these novel drug targets candidates to serve as therapeutic opportunities, increases the
risk of failure. Although we have built AI/ML powered predictive computational discovery platform, recently branded as Unigen&#8482;,
that we believe is required to scientifically validate our novel drug targets and to later translate them into therapeutic antibody development
programs, we cannot be assured that our investment in such novel discoveries will result in validated drug targets that will enable the
development of effective cancer immunotherapies, nor that we will realize success in product development or our ability to partner and
commercialize such opportunities and generate revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our approach to the discovery of therapeutic
products is based on our AI/ML powered predictive computational discovery platform, recently branded as Unigen&#8482; that is not yet
fully proven clinically, and we do not know whether we will be able to discover and develop additional potential product candidates or
products of commercial value.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our method of identifying novel drug targets is based on our AI/ML powered predictive
computational discovery platform, recently branded as Unigen&#8482;. It involves first identifying unmet needs in the field of cancer
immunotherapy, where we believe its capabilities would be relevant or could be developed to be relevant. We focus on the discovery of
drug targets that could serve as the basis for the development of possible treatments for patients non-responsive, refractory or relapsing
to existing cancer immunotherapies. In this field, we apply our predictive computational target discovery capabilities, or develop new
capabilities, to identify novel drug targets for addressing such unmet patient need.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While we believe that using Unigen&#8482; to identify novel drug targets may potentially
enable the development of potentially first-in-class therapeutics in the field of cancer immunotherapy, Unigen&#8482; is not yet fully
proven clinically and our efforts may not result in the discovery and development of therapeutic products, or commercially viable or successful
therapeutic products. Moreover, AI/ML powered models may provide biased decisions, errors, or security weaknesses and could negatively
affect Unigen&#8482; (and perspective by potential collaborators). Although our approach has resulted in the discovery of several novel
drug targets and their related potential first-in-class or best-in-class therapeutic product candidates in the field of cancer immunotherapy,
they are in early stages of research and development or in clinical stage. Our approach may not result in time savings, higher success
rates or reduced costs, or clinically meaningful programs and if not, we may not attract collaborators or develop new drugs as quickly
or cost effectively or at all and therefore we may not be able to partner and commercialize our products as expected.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">14</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are focusing our discovery and therapeutic
development activities on therapeutic product candidates for uses in immuno-oncology. Our current candidates may fail, and we may fail
to continue to discover and develop therapeutic product candidates of industry interest in this field.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The focus of our discovery and therapeutic development activities is on therapeutics
antibodies in the field of immuno-oncology for treatment of cancer. As a result, we are not undertaking internal discovery and development
activities in other therapeutic areas, and presently we only pursue activities in our area of focus. If our current candidates fail, or
if the interest for naked mAb therapeutics in this field continue to decrease, or if the pharma interest in immuno-oncology shifts, or
if the pharma interest in drug modalities that we are not developing increases, or if we fail to continue to discover and develop therapeutic
product candidates of clinical value and medical interest in this field, or if we fail to discover therapeutic product candidates to feed
our clinical stage pipeline in a timely manner and generate a sustainable clinical stage pipeline, or if we are unable to discover drug
targets, our business will likely be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">There can be no assurance that our therapeutic product candidates or our earlier stage
immuno-oncology target candidates in our pipeline, will provide clinical advantages or interest, that no long-term adverse effects will
be seen, or that other classes of targets or other products or modalities will not be discovered and developed with comparable or superior
attributes or clinical activity. In the event of any of these occurrences, the actual and/or perceived value of a substantial portion
of our pipeline would likely be reduced in which case our business may be materially harmed. To date, we have signed four partnership
agreements involving our therapeutic product candidates, two of which, one with AstraZeneca and one with Gilead, are in effect. There
is no assurance that we will be able to enter into additional collaborations or agreements on reasonable terms, if at all. In addition,
if we fail to continue to discover and validate drug targets or develop product candidates of industry interest in our field of focus,
our business will likely be materially harmed. There are many risks associated with our decision to focus on immuno-oncology that include,
among others:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z07a90bf861af4f93b7afba3e28f600a5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>industry interest in this area or in specific classes/families of drug targets within this area of focus would decrease over time;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z871e06b7cde14103bae2a29a44c1f424" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the continued fatigue impacting the checkpoint inhibitors field;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd9d67d61723543208cb4a5c8711bac8b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>other modalities, such as ADC, will continue to show beneficial clinical results in indications in which checkpoint inhibitors have
        failed;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z958dd933febb473eae9f719fb42702cb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>not being able to discover novel drug targets in this field;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z87867bd93cb340d18e52a741757a8e48" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our full scope of target discovery capabilities may not be adequate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za3719c69c45246908d5dfee6a77572c4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>having chosen a therapeutic area with a very high degree of competition;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb90120225e004100a08e41929f76f2a7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>having chosen a therapeutic area of great biological complexity and with very high failure rates in product development;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8760ed2e78b6489cad9f74986a535fbe" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>not choosing the appropriate drug modality; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z415418c2e9cc4aa0919a21516e0196bc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>not having sufficient knowledge, expertise, personnel or capabilities in our chosen therapeutic area to identify the right unmet
        medical needs, or drug targets or drug candidates, or to timely, properly and efficiently validate the targets and/or select the appropriate
        therapeutic antibody for further development as therapeutic product candidates, or to timely, properly or efficiently further them in
        development.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In each case, our failure could be due to lack of experience and expertise, delays
in our internal research programs or applying the wrong criteria or experimental systems and procedures, or selecting an inappropriate
drug modality, or unanticipated scientific, safety, activity or efficacy issues with our selected drug targets or product candidates,
with the possible result that none of our product candidates result in licensed or marketable products. If any of these risks should materialize,
our business, financial condition and results of operations would be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Risks Related to Our Dependence on Third Parties</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We rely and expect to continue to rely on third
parties to conduct our clinical trials. These third parties may not successfully or professionally carry out their contractual duties,
comply with regulatory requirements or meet expected deadlines, and we may experience significant delays in the conduct of our clinical
trials as well as significant increased expenditures.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We do not have the ability to independently conduct clinical trials. We rely and will
continue to rely on medical institutions, clinical investigators, contract manufacturing research organizations, contract laboratories,
outsourced preclinical and clinical service providers and other third parties, such as CROs and advisors, to conduct or otherwise support
our clinical trials. We rely heavily and will continue to rely heavily on these parties for execution of clinical trials for COM701 and
COM902, GS-0321 (previously COM503) and any other future product candidates we may take to the clinic, and we control only certain aspects
of their activities. Nevertheless, we are responsible for ensuring that each of the clinical trials we pursue is conducted in accordance
with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties, including
our CROs, will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our
clinical trials, we could be subject to untitled and warning letters or enforcement action that may include civil penalties up to and
including criminal prosecution.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">15</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">We believe that our financial results and the commercial prospects for COM701, COM902,
GS-0321 (previously COM503) and any other future therapeutic product candidates we may take to the clinic, would be harmed, our costs
could materially increase and our ability to conduct our clinical trials and generate revenue could be significantly adversely impacted,
if our clinical investigators, CROs or other third parties providing us services fail to successfully carry out their contractual duties
or obligations diligently and in a professional manner or fail to meet their expected deadlines.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We depend significantly on third parties (including
partners) to carry out the research, development and commercialization of our therapeutic product candidates. If we are unable to maintain
our existing agreements or to enter into additional agreements with such third parties, mainly collaborators, in the future, our business
will likely be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Our primary strategy for the development and commercialization
of products based on our drug targets and therapeutic product candidates depends on third parties to carry out and/or finance, the research,
development and commercialization of such products, principally by pharmaceutical and biotechnology companies and other healthcare related
organizations and CROs, either on their own or in collaboration with us. To date, we have entered into four partnership agreements with
respect to our drug target candidates, two of which, one with AstraZeneca and one with Gilead, are in effect. We cannot be sure that the
partnership agreements with AstraZeneca or Gilead will result in the successful development or commercialization of any product. Further,
we cannot provide assurance that we will succeed in identifying additional suitable parties or entering into any other additional agreements
on satisfactory terms or at all for the discovery, research, development and/or commercialization of our drug target or therapeutic product
candidates. If we are unable to identify such additional suitable parties or enter into new agreements on satisfactory terms, or at all,
our business will likely be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We rely and expect to continue to rely completely
on third parties to manufacture and supply our preclinical and clinical drug supplies. Our business could be harmed if those third parties
fail to provide us with sufficient quantities of drug product or fail to do so at acceptable quality and quantity levels, prices or timelines.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We do not currently have, nor do we plan to acquire, the infrastructure or capability
internally to manufacture our preclinical and clinical drug supplies for use in the conduct of preclinical testing and our clinical trials,
and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. In order
to develop products, apply for regulatory approvals and commercialize our products, we need to develop, contract for, or otherwise arrange
for access to the necessary manufacturing capabilities. We rely and expect to continue to rely on contract manufacturing organizations,
or CMOs, and other third-party contractors to manufacture formulations and produce larger scale amounts and/or commercial scale of drug
substance and drug products required for any clinical trials that we initiate and other related services. Such third parties may not be
able to deliver in a timely manner, or at all, or may fail to comply with the FDA&#8217;s current Good Manufacturing Practice, or cGMP,
to manufacture our drugs in the required quality or quantity. We have entered into manufacturing and supply agreements with third parties
for the manufacturing and respective analytics of each of COM701, COM902 and GS-0321 (previously COM503).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are unable to obtain or maintain adequate manufacturing sources for these product
candidates, or to do so on commercially reasonable terms and adequate timeline, quality and quantity, we may not be able to successfully
develop and commercialize our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are also dependent upon these third parties with respect to critical reagents supply,
supplies required for our manufacturing and quality control, packaging, labelling, storage and others. The failure of a third-party manufacturer
or supplier to perform its obligations as expected could adversely affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">16</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">If a third-party manufacturer or supplier with whom we contract fails to perform its
obligations, we may be forced to manufacture or otherwise obtain the materials ourselves, for which we do not currently and may not in
the future have the capabilities or resources, or identify and qualify a different third-party manufacturer, which we may not be able
to do timely or on reasonable terms, if at all. In some cases, the technical skills or processes required to manufacture our product may
be unique to the original manufacturer, or specific to a certain manufacturing site of the same manufacturer, and we may have difficulty
transferring such skills or processes to a back-up or alternate manufacturer or supplier, or we may be unable to transfer such skills
or processes at all. In addition, if we are required to change manufacturers for any reason, we will be required to verify that the new
manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines.
We will also be required to demonstrate that the newly manufactured material is similar to the previously manufactured material, or we
may need to repeat clinical trials with the newly manufactured material. The delays associated with the verification of a new manufacturer,
or the inability to repeat the manufacturing process, could negatively affect our ability to develop product candidates or commercialize
approved products in a timely manner or within budget. Furthermore, a manufacturer may possess technology related to the manufacture of
our product candidate that such manufacturer owns independently, which would increase our reliance on such manufacturer or require us
to obtain a license from such manufacturer in order to have another third-party manufacture our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our dependence on collaboration agreements
with third parties presents number of risks.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The risks that we face in connection with our existing collaborations
and other business alliances as well as those that we may enter into in the future include, among others, the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zae4b3c9f779f4ac9bbc8c0b038e41917" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may be unable to reach mutually agreeable terms and conditions with respect to potential new collaborations;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za448cf53efc54f099b8f630f6175758c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we or our current and/or future collaborators may be unable to comply or fully comply with the obligations under collaboration agreements
        to which we are (or will become) a party, and as a result, we may not generate milestone payments or royalties from such agreements, and
        our ability to enter into additional agreements may be harmed;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za4b65affb60a4502a7d180ea82b37742" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our obligations under existing or future collaboration agreements may harm our ability to enter into additional collaboration agreements;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z63eca22fd1a24475b065e7a261755bb8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>collaborators generally have significant discretion in electing whether to pursue any of the planned activities and the manner in
        which it will be done, including the amount and nature of the resources to be devoted to the development and commercialization of our
        product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd4710d1106c5482193bfc00ad1c02826" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>collaborators generally have significant discretion in terminating the collaborations or exercise different rights for scientific,
        clinical, financial, business or other reasons;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5b01f4cf2f99442ebbae1e102c44f395" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>if our current and/or future collaborators breach or terminate an agreement with us, the development and commercialization of our
        therapeutic product candidates could be adversely affected because at such time we may not have sufficient financial or other resources
        or capabilities or access to the other partner&#8217;s data and drug(s) to successfully develop and commercialize these therapeutics on
        our own or find other partners or enforce our rights under breached or terminated agreement;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1a9e45d041b6440ea92415a4e1e492f9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our current and/or future collaborators may require us changing or adopting the trial design to fit their business priorities, standards
        and other objectives;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z378445c0d35049bf808b840ff282ce11" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in a collaborator&#8217;s business strategy may negatively affect its willingness or ability to complete its obligations
        under its arrangement or to continue with its collaboration with us;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf4c4417558d34a869881f72d3f2421b3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our current and/or future collaborators may terminate the program or the agreement and then compete against us in the development
        or commercialization of similar therapeutics;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf6e30b5c8ce944098a4ede15777b35eb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>disagreements between us and our current and/or future collaborators may lead to delays in, or termination of, the collaboration;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z705671a2fc3b45a08228a92fd9530db9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 14.2pt"><br/> </td>
    <td style="width: 14.15pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our current and/or future collaborations may face internal competition by their internal pipelines;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze564fed493df4cb69c39e805b19ed84f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 14.2pt"><br/> </td>
    <td style="width: 14.15pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>prospective collaborators may hesitate to pursue collaborations on novel target candidates that lack robust validation to serve as
        a basis for the development of therapeutics; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4a1d9809b67d4e89b9e795eb390de4ea" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our current and/or future collaborators may be acquired by, acquire, or merge with, another company, and the resulting entity may
        have different priorities or competitive products to the collaboration product being developed previously by these collaborators.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">If any of these risks should materialize, our business, financial condition and results of operations may
be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">17</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our existing partnership agreement with AstraZeneca
is subject to many risks.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In March 2018, we entered into an exclusive license agreement with MedImmune Limited,
the global biologics research and development arm of AstraZeneca, which is currently part of AstraZeneca. Under the terms of the license
agreement, we provided an exclusive license to AstraZeneca to use our monospecific antibodies that bind to TIGIT, including COM902, for
the development of bi-specific and multi-specific antibody products, excluding such bi-specific and multi-specific antibodies that also
bind to PVRIG, PVRL2 and/or TIGIT. In connection with such license agreement, AstraZeneca developed rilvegostomig, a PD-1/TIGIT bi-specific
antibody with a TIGIT component that is derived from our COM902. Subject to termination rights for material breach, bankruptcy or by us
for patent challenge by AstraZeneca, the term of the license agreement continues until the expiration of the last royalty term in the
territory as further specified in the license agreement. In addition, AstraZeneca may terminate the agreement for convenience upon prior
written notice.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Rilvegostomig is currently being evaluated in multiple Phase 3 clinical trials and
multiple Phase 2 and Phase 1 clinical trials. If significant adverse unforeseen safety events occur in these trials or lack of efficacy
or the collaboration is terminated, particularly prior to our signing additional collaboration agreements at that scale, our business
and financial condition may be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our existing partnership agreement with Gilead
is subject to many risks.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In December 2023, we entered into the License Agreement with Gilead. Under the terms
of the License Agreement, we granted Gilead an exclusive license under our preclinical antibody program against IL-18 binding protein
and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including
GS-0321 (previously COM503), and additional products that may be so developed by Gilead, together with GS-0321 (previously COM503), or
the Licensed Products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the License Agreement, we are responsible for conducting a Phase 1 clinical
trial for GS-0321 (previously COM503), including handling the regulatory matters in connection therewith, and will bear the costs of such
trial (including the GS-0321 (previously COM503) drug supply), with Gilead having the obligation to provide at no cost zimberelimab antibody
for such trial. Nevertheless, in certain circumstances, Gilead may require us to transfer to them the role of conducting the Phase 1 clinical
trial, before the Phase 1 clinical trial is initiated or completed. In such case, our business and financial condition may be harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, Gilead may terminate the agreement for material breach, bankruptcy and
even for convenience and therefore, if this agreement is terminated, particularly prior to our signing additional collaboration agreement
at that scale, our business and financial condition may be materially harmed. If significant adverse unforeseen events occur in this collaboration
or it is terminated, our business and financial condition may be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our reliance on third parties for the performance
of key activities heightens the risks faced by our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We outsource many of our activities and many key functions to third parties, including
major preclinical activities, drug development activities, manufacturing operations, research, validation, discovery and others. We do
not control the third parties to whom we outsourced these functions and have limited internal expertise to appropriately manage their
activities. However, we are dependent on them to undertake activities and provide services, results, our product candidates or materials,
including the production of certain biological reagents, which may be significant to us. If these third parties fail to properly or timely
perform these activities or provide us with incorrect or incomplete services or results or fail to produce and/or provide certain materials,
tests or analysis, this could lead to significant delays in the program or even program failure, along with significant additional costs
and damage. In addition, should any of these third parties fail to comply with the applicable laws and regulations and/or research and
development or manufacturing accepted standards in the course of their performance of services for us, there is a risk that we could be
held responsible for such violations of law as well. Any such failures by third parties could have a material adverse effect on our business,
financial condition or results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">18</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Moreover, we do not always independently verify the results obtained by such third
parties and in some cases, primarily with respect to clinical data, we have to rely upon the data provided by the third parties. If we
fail to identify and obtain accurate and quality data, services and/or technologies from such third parties, or if the contractual demands
of such third parties become unreasonable and we are not able to reach satisfactory agreements with such third parties, we may lose our
investment in these services, fail to receive the expected benefits from our discoveries, and our validation and development capabilities,
clinical trials or other activities or our final products, may be significantly harmed, delayed or terminated.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may need to obtain third-party drugs for
combination with our clinical programs that may not be available to us or are available only on commercially unreasonable terms or may
not serve us as well as other drugs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We&#160;may&#160;need to obtain certain drugs from third&#160;parties&#160;or to acquire
marketed drugs to&#160;further&#160;develop&#160;our drug candidates to work in combinations with other drugs for selected indications.
If we fail to obtain these drugs or license thereof, our drug candidates may not be sufficiently efficient, and we may not be able to
pursue them through development. We will also need to obtain certain drugs from third&#160;parties&#160;to register and commercialize&#160;our&#160;drug
candidates. If we fail to enter into collaboration with the marketing authorization holder, we may not be able to pursue our combination
drugs through registration and commercialization. Furthermore, if we pursue clinical trials with third parties to&#160;further&#160;develop&#160;our
drug candidates to work in combinations with such other drugs for selected indications and those third parties&#8217; drugs have not received
regulatory approval for an indication of interest to us, such clinical trials may not provide us a path for registration and therefore
may not serve us best as other drug(s) in the relevant indication.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-weight: bold">Risks Related to Competition and Commercialization</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our business model is challenging to implement
and to date has not yielded significant revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our discovery and development capabilities are designed to identify and develop novel
products in the field of immuno-oncology and enter into collaborations with potential partners with respect to such novel products in
different stages of development. Our objective under our current and any potential future collaboration agreements is that under these
collaborations, we will have the right to receive various forms of revenues from such products or product candidates. To date, we have
entered into four collaboration agreements with respect to our pipeline programs, only two of which are currently in effect. There can
be no assurance that our current or any future agreements for novel targets based on our discoveries and associated product candidates
will be successful and thus provide significant revenues to us, nor can there be any assurance that we will be able to enter into additional
future agreements. If we are unable to succeed in securing additional license agreements or other collaboration arrangements related to
our discoveries and product candidates, our business may be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">Currently we have an ongoing collaboration with AstraZeneca, pursuant to which rilvegostomig, a PD-1/TIGIT
bispecific antibody with a TIGIT component that is derived from our COM902 program, entered into the first Phase 3 clinical trial in the
fourth quarter of 2023 and is currently in multiple Phase 3 clinical trials and multiple Phase 2 and Phase 1 clinical trials, and a collaboration
with Gilead, pursuant to which we granted Gilead an exclusive license under our preclinical antibody program against IL-18 binding protein
and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including
our GS-0321 (previously COM503) product candidate, which is currently in a Phase 1 clinical trial, and additional products that may be
so developed by Gilead. In addition, we have two clinical programs fully owned by us, COM701 and COM902, that are available for partnering
arrangements.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">There can be no assurance that we will be able to establish collaborations for COM701
or COM902 or any collaboration for our early-stage programs or maintain our existing collaborations. Failure to enter into collaborations
may materially harm our business. The research and validation data generated to date for our early-stage pipeline and the clinical data
generated to date for COM701 and COM902 may not be sufficient to attract interest from prospective collaborators and we may fail to generate
data suitable to draw interest with potential partners. Furthermore, our drug target candidates or therapeutic product candidates may
not fit their corporate or clinical strategy or will present an insufficient market competitive edge, or not at all. These companies may
require more data, including their independent testing of our early-stage therapeutic product candidate, before considering a collaboration.
We are therefore dependent on the potential fit of our programs with individual pharmaceutical company strategies and there can be no
assurance that we will be able to identify additional partners interested in our programs at their current stages. This may adversely
affect our ability to enter into additional agreements for the research, development, license or other form of collaborative arrangements
of our therapeutic product candidates, and as a result may harm our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">19</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We operate in a highly competitive and rapidly
changing industry which may result in others discovering, developing or commercializing competing products ahead of us or more successfully
than we do.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The biotechnology and biopharmaceutical industries are highly competitive, characterized
by rapid and significant technological advancements. Our success is highly dependent upon our ability to identify, research and develop
therapeutic products based on our discovered novel drug targets. In doing so, we face and will continue to face intense competition from
a variety of businesses, including large, fully integrated, well-established pharmaceutical companies, specialty pharmaceutical and biopharmaceutical
companies, biotech companies, academic institutions, government agencies and other private and public companies and research institutions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Many of the companies against which we are competing or against which we may compete
in the future have significantly greater resources and expertise in research and development, manufacturing, preclinical testing, conducting
clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. These competitors and others may develop competing
products targeting the same mechanisms, the same drug targets and pathways as our products, or the same therapeutic indications and they
can leverage their resources or use different approaches than we do to receive marketing approval before our products. For example, see
&#8220;Item 3. Key Information - D. Risk Factors &#8211; Risks Related to Development, Manufacturing, Clinical Trials and Government Regulation
- We depend on enrollment of patients in our clinical trials in order to continue development of our product candidates.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While in the cancer immunotherapies space there have been positive clinical results
reported by others resulting in some products obtaining approval from the FDA, there have been several failures recently, such as TIGIT
failures in Keyvibe-008 and in SKYSCRAPER-01 and pembrolizumab failure in KEYNOTE-867. This contrasts with some the positive clinical
results reported for other drug modalities, specifically ADCs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">These third parties also compete with us in recruiting and retaining qualified scientific,
drug development and management personnel and advisors, establishing clinical trial sites and patient enrollment for clinical trials,
as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the biopharmaceutical
industry could result in even more resources being concentrated among a small number of our competitors or a change in potential acquirers&#8217;
preferences.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to the competition we face in the drug target space, we also face competition
in the drug modality field. Technological breakthroughs in new modalities will be a key driver of growth for the&#160;biopharma industry
over the next decade. Drug discovery and development has undergone an impressive transformation over recent years driven by the emergence
of new drug modalities. This expansion in innovative drug modalities has provided an impressive drug modality toolbox to enhance the drug
effectiveness and also allow to enhance the potential from such targets that the efficacy of a naked antibody targeting these drug targets
has been limited. Such drug modalities include, among others, bi-specifics, T cell engagers (TCE), cell therapies, antibody drug conjugates
(ADC), protein degraders, molecular glues, and mRNA therapeutics. An example of a drug modality gaining a lot of interest and attention
are the ADC, with thirteen (13) FDA approvals as of March 2024 and more than 100 ADC drugs at different stages of clinical trials and
76 deals on ADCs in 2023 and 52 deals in 2024. Another field which has gained a lot of pharma interest is the T cell Engagers (TCE) field,
following the FDA approval for tarlatamab, a DDL3 TCE, for extensive-stage Small Cell Lung Cancer in May 2024.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">20</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">Competition may further increase as a result of advances in the commercial applicability of technologies
similar to our Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup> platform and greater availability
of capital for investment in these industries. Over the last several years, there has been an increase in the interest of pharmaceutical
companies, the healthcare community and the investment community in applying computational methodologies, mostly Artificial Intelligence
(AI) and Machine Learning (ML) algorithms, to the field of drug discovery, development, precision medicine and healthcare. This interest
may be seen in the increase in the number of companies within the pharmaceutical and biotech industries which focus on this area, including
by way of establishing internal AI and/or ML capabilities or receiving investments or entering into partnerships or acquisitions in furtherance
thereof. Several companies that utilize AI/ML for target discovery in the field of immuno-oncology/cancer and have done recent deals on
target discovery include Cartography, Caris Life Sciences, TrexBio and Recursion (which now also includes Exscienta), and InSilico Medicine.
Our competitors may succeed in discovering targets and therefore also develop product candidates that are competitive with ours either
with or without the use of advanced technologies such as AI and ML, which could have a material adverse impact on our business, operations
and financial results. In addition, there are additional competitors that in addition to utilizing a computational platform for target
discovery, also perform the drug discovery. Such companies include Tentarix, Merus, DrenBio, Moma, and Kronos Bio, each of which has recently
entered into collaboration agreements.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">In addition, recently there has been a surge in China based deals and in 2023, for
the first time, the number of out-licensing deals in China exceeded in-licensing deals, indicative of a burgeoning&#160;innovative biotech
scene that&#8217;s attracting cross-region interest. &#160;This trend presents several risks for us, particularly in terms of intense
competition for potential collaborations from Chinese companies. These companies may be able to conduct research and development and advance
their pipeline at potentially lower costs than us and therefore may be able to reach market faster than us or become more attractive collaboration
partners.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">In addition, there is a trend towards mergers and acquisitions in the pharmaceutical, diagnostic and biotechnology
industry, which may result in the remaining companies having greater financial resources and discovery and technological capabilities,
thus intensifying competition in our industry. Although the overall volume of M&amp;A activity in the pharma and life sciences sectors
remained robust in 2024 compared to historical levels, the deals tended to be smaller, leading to a reduction in the total deal value
for the year. Over the past 12 months, the number of M&amp;A transactions in these sectors decreased by 8% compared to 2023, while the
total deal value declined by 2%. The highest-value deal in pharma for the year was&#160;Novo Holdings acquisition of Catalent for $16.5
billion, and the 2024&#8217;s top biotech deal was Vertex Pharmaceuticals&#8217;&#160;$4.9 billion&#160;acquisition of Alpine Immune Sciences.
Additional top M&amp;As include Gilead Sciences&#8217;s purchase of CymaBay Therapeutics for $4.3 billion, Eli Lilly&#8217;s acquisition
of Morphic Therapeutics for $3.2 billion, Merck&#8217;s acquisition of EyeBio for $3 billion, and Novartis acquisition of MorphoSys for
2.7B Euros. These deals are smaller compared to M&amp;As in previous years such as Pfizer&#8217;s acquisition of Seattle Genetics for
$43 billion, Amgen&#8217;s acquisition of Horizon Therapeutics for approximately $27.8 billion, and Merck&#8217;s acquisition of Promethus
for approximately $10.8 billion. In addition, it is possible that because of adverse or volatile capital market conditions, companies
may be willing to enter into mergers and acquisition transactions or other sale of asset transactions on terms more favorable to acquirer
and thereby further intensify competition. This trend together with the surge in China based out-licensing deals as specified above may
also result in fewer potential collaborators or licensees for our therapeutic product candidates. Also, if a consolidating company is
already doing business with our competitors, we may lose existing or potential licensees or collaborators as a result of such consolidation.
In addition, if a consolidating company is already doing business with us, we may lose the interest of the consolidating parties in our
discovery capabilities or individual discoveries or product candidates as a result of a modified strategy, new priorities, competition
and revised capabilities or portfolio of such consolidated entity. This trend may adversely affect our ability to enter into agreements
for the development and commercialization of our therapeutic product candidates or to keep current collaboration in place or on-track
and as a result may harm our business.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">Established biopharmaceutical companies may invest heavily to accelerate discovery
and development of novel drug targets or therapeutic products or to in-license novel drug targets or therapeutic products that could make
our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling
advantages in efficacy, compliance regimen, tolerability, safety and more in order to overcome price competition and to be commercially
successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving FDA approval for
or commercializing drugs before we do, which would have an adverse impact on our business and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Potential collaborators, including major pharmaceutical
companies, might be hesitant to pursue target validation and preclinical and clinical development programs based on novel targets lacking
robust experimental scientific support particularly those discovered through a computational discovery approach.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">There is a need for new drug targets generating new treatment options for patients
who are non-responsive or refractory to current immunotherapies. Our business model includes selectively entering into collaborations
for novel targets and related therapeutic product candidates at various stages of research and development under various revenue-sharing
arrangements. Entering into collaborations with product candidates and targets at an early validation stage or drug discovery stage is
significantly more challenging than identifying partnerships for later-stage products that would have a more complete data package to
support their clinical, business and commercial potential. In addition, although we have demonstrated success in validating our predictive
computational discovery capabilities with product candidates in human clinical trials, major pharmaceutical companies may be hesitant
to enter into early-stage collaborations based on newly discovered targets, more so if discovered by computer prediction and has no or
limited published scientific support, as opposed to drug targets backed with human clinical trial data, or product candidates with significant
published experimental validation and scientific support. Therefore, we cannot assure that our business model to enter into partnering
arrangements for our early-stage novel targets and product candidates will be successful.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">21</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic"><span style="font-weight: bold">The process relating to entering
into potential collaboration agreements is complex and long to implement and, if we are not able to establish collaborations on commercially
reasonable terms, we may expend substantial funds and management resources with no assurance of success</span>.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In general, each potential license agreement or other form of collaboration we may
enter into will require negotiating with our potential collaborator, a large number of scientific, legal and business terms and conditions
that can vary significantly in each instance due to the specific drug target or therapeutic product candidate or candidates involved,
the potential market opportunity, the potential collaborator&#8217;s licensing, development and business operations and strategy, and
competition in the partnering and business development space. The accommodation of these requirements mandates a thorough consideration
of both the scientific and business aspects of each transaction.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Whether we reach a definitive agreement for new collaborations will depend, among
other things, upon our assessment of the collaborator&#8217;s resources, capabilities and expertise, the terms and conditions of the proposed
collaboration, the proposed collaborator&#8217;s evaluation of our business, drug targets and therapeutic product candidates, and the
competition in the business development space. We may not be successful in our efforts to establish a collaboration or other alternative
arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort
and third parties may not view them as having the requisite potential to demonstrate safety and efficacy or may find any other development
hurdles and challenges as a limiting factor. If we are unable to do so, we will need to expend substantial funds and substantial key personnel
time and effort into these business development activities with no assurance of successfully entering into agreements with potential collaborators
and this could harm our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We rely on our predictive computational discovery
capabilities to identify drug targets. Our competitive position could be materially harmed if our competitors develop capabilities similar
to ours and identify and develop rival drug targets and product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We rely on know-how and other proprietary computational processes, data and tools
to maintain our competitive computational discovery position. We consider know-how to be our primary intellectual property with respect
to our predictive computational discovery capabilities. Know-how can be difficult to protect and enforce. In particular, we anticipate
that with respect to our capabilities, this know-how may over time be disseminated within the industry through independent development
and the movement of skilled personnel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We cannot rule out that our competitors may have or obtain the knowledge necessary
to identify and develop therapeutic products based on novel drug targets that could compete with the drug targets we identify. Our competitors
may have significantly greater experience in artificial intelligence, computer sciences, algorithmic tool development and alike to identify
targets and greater experience in using translational science to develop product candidates and may also have significantly greater financial,
product development, scientific, technical and human resources than we do to discover novel drug targets and develop product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may not be able to prohibit our competitors from using methods to identify and
develop product candidates, including such methods that are the same as or similar to our own. Since our competitors develop products
that compete with COM701, COM902 or GS-0321 (previously COM503) or any future product candidates we develop, our ability to develop and
commercialize these product candidates may diminish substantially, which could have a material adverse effect on our business prospects,
financial condition, and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">22</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The biotechnology and pharmaceutical industries
are highly competitive, and we may be unable to compete effectively.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The biotechnology and pharmaceutical industries in general, and the immuno-oncology
field in particular, are highly competitive. Numerous entities in the United States, Europe and elsewhere compete with our efforts to
discover, validate, develop and partner with licensees and/or collaborators to commercialize drug target and therapeutic products candidates.
Clinical trial failures of novel agents in the immuno-oncology field may adversely impact our ability to sign collaborations, and as a
result we may be required to advance our programs into clinical development and show clinical proof of concept before we may attract potential
collaborators, or we will need to discontinue the programs development. Our competitors include pharmaceutical and biotechnology companies,
academic and research institutions and governmental and other publicly funded agencies. We face, for COM701, COM902, and GS-0321 (previously
COM503), and expect to continue to face for our future therapeutic product candidates, competition from these entities to the extent they
develop products that have a function similar or identical to or competing with the function of our therapeutic product candidates in
the field of immuno-oncology that may attract our potential collaborators or that may reach the market sooner. We also face, and expect
to continue to face, competition from entities that seek to develop technologies that enable the discovery of novel targets and therapeutic
agents in the field of immuno-oncology. These competitors include traditional pharmaceutical and biotechnology companies and additionally,
an increasing number of new entities looking to apply computer science, bioinformatics, AI or ML technologies to the field of target discovery.
We also expect to face increasing competition from entities that develop new therapeutic modalities addressing the same drug targets or
clinical needs. Many of our competitors have one or more of the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z89c96d23d5a2428095fda474e3a1d23a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and
        commercialization process;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdd7887c7d5bb431fb9d4a9de84c7fff2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>more extensive experience in computational discovery, preclinical testing, conducting clinical trials, obtaining regulatory approvals,
        and in manufacturing and marketing therapeutics;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2d553bbeb4e94893afc1f361b0fce0d0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>more extensive experience in oncology and immuno-oncology and in the fields of therapeutic antibodies;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zead7cfb446c0417e9ad5a1cc84952eea" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>accessibility to enhanced technologies that may result in better products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb3393c84a11b4cbbb40bfb9238df8069" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>access to and experience in the development of therapeutic modalities that are competitive to mAb therapeutics;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc5b8f2c0e7694bd498a6910fc1763833" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>more extensive experience in oncology and immuno-oncology and in the field of target discovery;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6164a119535143d69feb5c6ddaba94a8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>more extensive experience in the research and development of biological or genetic markers to determine response of or responders
        to therapeutic agents or for patient selection;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z807bae7ff57e4276b4c9dffb0986582e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>greater accessibility to data and proprietary data from patients;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zae0bb01365a24b53854350c548f11d41" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>access to internally developed, proprietary technologies for the discovery, research, development, or manufacturing of therapeutic
        agents;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z49f963bb80a94a2fa7c6f7483ce1235d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>greater resources and means to compete with us on target discovery and as well as in acquiring or generating technologies complementary
        to, or necessary for, our programs as well as in recruiting and retaining qualified scientific and management personnel and establishing
        clinical trial sites;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2e450e80f1bd4b8c9a34bb46fc6c3bbd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>products that have been approved or are in late stages of development and in many cases, PD-1 or PDL-1 inhibitors that are serving
        or will be serving as the backbone of cancer immunotherapy;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z007953981e8c4b629791666d6361fb9e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>reduced reliance on collaborations or partnerships with third parties in order to further develop and commercialize competitive therapeutic
        products; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc4a0c8bd75564c5a883f8495ca8c17db" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>collaborative arrangements in our target markets with leading companies and research institutions.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Since we are a small company with limited human and financial resources, we are not
able to work with a large number of collaborators in parallel and/or advance a large number of drug target or therapeutic product candidates
in parallel. Our competitors may develop or commercialize products with significant advantages over any therapeutic products we, our collaborators
or third-party licensees may develop. They may also obtain patents and other intellectual property rights before us, or broader than ours,
and thereby prevent us from pursuing the development and commercialization of our discoveries. They may also develop products faster than
us and therefore limit our market share. Our competitors may therefore be more successful in developing and/or commercializing products
than we, our collaborators, or third-party licensees are, which could adversely affect our competitive position and business. If we are
unable to compete successfully against existing or potential competitors, our financial results and business may be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">23</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Healthcare policy is volatile and changes in
healthcare policy could increase our expenses, decrease our revenues and impact sales of, and reimbursement for, our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ability to commercialize our future therapeutic product candidates successfully,
alone or with collaborators, will depend in part on the extent to which coverage and reimbursement for these product candidates will be
available from government health programs, such as Medicare and Medicaid in the United States, private health insurers and other third-party
payors. At present, significant changes in healthcare policy, in particular the continuing efforts of the U.S. and other governments,
insurance companies, managed care organizations and other payors to contain or reduce health care costs are being discussed, considered
and proposed.&#160;Drug prices in particular are under significant scrutiny and continue to be subject to intense political and societal
pressures, which we anticipate will continue and escalate on a global basis.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For example, in the United States, there have been several initiatives implemented
to achieve these aims. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation
Act, or collectively, the ACA, represents the biggest regulatory overhaul to the health care system in decades and substantially changes
the way health care is financed by both governmental and private insurers. Since its enactment, there have been congressional, judicial,
and executive challenges and amendments to the ACA, which have resulted in delays in the implementation of, and action taken to repeal
or replace, certain aspects of the ACA. For example, on August 16, 2022, the Inflation Reduction Act of 2022, or the IRA, was signed into
law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through
plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly
lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the
ACA will be subject to judicial or congressional challenges or additional health reform measures of the Trump administration will impact
the ACA and our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, the IRA, among other things, (i) directs the Secretary the U.S. Department
of Health and Human Services, or HHS, to negotiate the price of certain high-expenditure, single-source drugs that have been on the market
for at least 7 years and biologics that have been on the market for at least 11 years covered under Medicare Part B and Medicare Part
D, and subjects drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or
less than the negotiated &#8220;maximum fair price&#8221; under the law, or the Medicare Drug Negotiation Program, and (ii) imposes rebates
under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect progressively
in fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon price of the first ten drugs that were subject to price negotiations,
although the Medicare Drug Price Negotiation Program is currently subject to legal challenges HHS will select up to fifteen additional
drugs covered under Part D negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare
Drug Price Negotiation Program. At the state level, legislatures have increasingly passed legislation and implemented regulations designed
to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, and restrictions
on certain product access. In some cases, such legislation and regulations have been designed to encourage importation from other countries
and bulk purchasing.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We expect that the ACA, the IRA, and any other healthcare reform measures that may
be adopted in the future, particularly in light of the recent U.S. Presidential and Congressional elections, may result in additional
reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward
pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs
may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare
reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The commercial success of our products depends
on the availability and sufficiency of third-party payor coverage and reimbursement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Market acceptance of drug products is dependent on the extent to which coverage and
reimbursement is available from third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any
products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost
therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may
not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses,
or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate
to cover all or a significant portion of the cost of our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">24</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Coverage and reimbursement policies for products can differ significantly from payor
to payor as there is no uniform policy of coverage and reimbursement for products among third-party payors in the United States. There
may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time
consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately,
with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities
and third-party payors will decide with respect to coverage and reimbursement for our drug products. Further, coverage policies and third-party
payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for a product for which
we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, we or our collaborators may develop companion diagnostic tests for use
with our product candidates. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate
and apart from the coverage and reimbursement we seek for our product candidates, once approved. While we have not yet developed any companion
diagnostic test for our product candidates, if we or our collaborators do, there is significant uncertainty regarding our ability to obtain
coverage and adequate reimbursement for the same reasons applicable to our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-weight: bold">Risks Related to our Operations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Given our level of managerial, operational,
financial and other resources, our current activities and future growth may be limited.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We manage our operations, including clinical trials and preclinical development activities
of our therapeutic candidates with a limited workforce, which is spread globally, and by using third parties to provide us with services
that we do not possess in-house. Our personnel, systems and facilities currently in place may not be adequate to support our current activities
or future growth.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are unable to maintain or expand our managerial, operational, financial and
other resources to the extent required to manage our development and commercialization activities, our business may be materially adversely
affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may be unable to hire or retain key personnel
or sufficiently qualified management, clinical and scientific personnel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business is highly dependent upon the continued services of our senior management
and key scientific and clinical personnel. While members of our senior management and other key personnel have entered into employment
or consulting agreements and non-competition and non-disclosure agreements with us, they can terminate these employment agreements at
any time without cause. We cannot be sure that these key personnel and others will not leave us or compete with us, which could harm our
business activities and operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">It can also be difficult for us to find employees with appropriate experience for
our business, which difficulty is further heightened when seeking experienced personnel in Israel and specifically considering the ongoing
war situation in Israel. We require a multidisciplinary approach and some of our researchers require an understanding of both exact and
biological sciences. In addition, we require experience in drug and clinical development and immuno-oncology, for which there is significant
competition for highly qualified personnel in these fields. As a result and taking into consideration the ongoing war in Israel and the
effect thereof outside of Israel, we may face higher than average employee turnover or challenges in hiring due to such competition.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The competition for qualified personnel in the pharmaceutical and biotech industry
is intense. The loss of service of any of our key personnel could harm our business. Due to our limited resources, we may not be able
to effectively retain our existing key personnel or attract and recruit additional qualified key personnel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our information technology systems, or those
of the third parties upon whom we rely, including our cloud and SaaS providers, CROs or other contractors or consultants, may fail or
suffer security breaches, which could result in a material disruption to our business, as well as to regulatory investigations or actions;
litigation; fines and penalties; reputational harm; loss of revenue and other adverse consequences.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We, and the third parties upon whom we rely, process, collect,
receive, store, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process)
proprietary, confidential, and sensitive data, including personal data (such as health-related data and clinical trial data), intellectual
property, trade secrets and other sensitive data (collectively, sensitive information). Our business is increasingly dependent on critical,
complex and interdependent information technology systems to support business processes as well as internal and external communications.
Despite the implementation of security measures, our information technology systems, cloud-based computers and those of the third parties
upon whom we rely, including without limitation our CROs and other contractors and consultants, are vulnerable to damage.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">25</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Cyber-attacks, malicious internet-based activity, online and offline fraud, and other
similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems,
and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect,
and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized
criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some
actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical
reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, including the
current situation in Israel, we or the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including
retaliatory cyber-attacks, that could materially disrupt our systems and operations. For example, we have operations in Israel, where
businesses have experienced an increase in cyberattacks in relation to the Israel/Hamas, Hezbollah and Iran conflict.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our information technology systems, and those of the third parties upon which we rely,
are vulnerable to a variety of evolving threats including, but are not limited to, social-engineering attacks (including through deep
fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses), malware,
denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain
attacks, server malfunctions, software or hardware failures, attacks enhanced or facilitated by artificial intelligence, or other disruptive
events including but not limited to natural disasters such as fire, storm, flood, power loss, earthquakes, telecommunications failures,
physical or software break-ins or similar events.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In particular, severe ransomware attacks are becoming increasingly prevalent and can
lead to significant interruptions in our operations, loss of sensitive information, reputational harm, and diversion of funds. Extortion
payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for
example, applicable laws or regulations prohibiting such payments.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Remote work has increased risks to our information technology systems and sensitive
information, as more of our employees utilize network connections, computers and devices outside our premises or network, including working
at home, while in transit and in public locations. Future business transactions (such as acquisitions or integrations) could expose us
to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired
or integrated entities&#8217; systems and technologies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We rely on certain third parties, including service providers, vendors, and partners,
and their technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without
limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email and other communication
functions, and other functions, and to provide other services necessary to operate our business, including our CROs and to keep our financial
and corporate records. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties
may not have adequate information security measures in place. If the third parties upon which we rely experience a security incident or
other interruption, we could experience adverse consequences. While we may be entitled to damages if the third parties upon which we rely
fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be
unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that
third parties&#8217; infrastructure in our supply chain or the third parties&#8217; upon whom we rely supply chains have not been or will
not be compromised.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">It may be difficult or costly to detect, investigate, mitigate, contain, and remediate
a security incident. Our efforts to do so may not be successful. Actions taken by us or the third parties upon whom we rely to detect,
investigate, mitigate, contain, and remediate a security incident could result in outages, data losses, and disruptions of our business.
Threat actors may also gain access to other networks and systems after a compromise of our networks and systems.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">26</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">If we or the third parties upon whom we rely were to suffer a security breach or other
interruption, we could experience unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption,
disclosure of, or access to our data or data held by us or the third parties upon whom we rely (including personally identifiable information,
personal data, other confidential information, or other sensitive information). For example, we have been the target of unsuccessful phishing
attempts in the past, and expect such attempts will continue in the future. A security incident or other interruption could disrupt our
ability (and that of third parties upon whom we rely) to continue our operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Although we have implemented security measures designed to protect against security
breaches and other incidents and maintain offsite back-ups of our data, such measures may fail. We maintain periodic security patches
and upgrades of third-party software that we rely on, yet the third-party software may still have undetected vulnerabilities. We may not
detect and remediate all vulnerabilities, including on a timely basis. Further, we may experience delays in developing and deploying remedial
measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may expend significant resources or modify our activities to try to protect against
security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures
or industry-standard or reasonable security measures to protect our information technology systems and sensitive information. Applicable
data privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected
individuals, customers, regulators, and investors, of security incidents, or take other actions. Such disclosures are costly, and the
disclosure or the failure to comply with applicable requirements could lead to adverse consequences.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we or the third parties upon whom we rely experience (or are perceived to have
experienced) a security breach or other incident or disruption, we may experience material adverse consequences, including but not limited
to, government enforcement actions (e.g., investigations, fines, penalties, audits, and inspections), federal, state and/or foreign data
breach notification obligations, additional reporting requirements and/or oversight, restrictions on processing data (including clinical
trial data and other personal data), litigation, indemnification obligations, loss of data (including clinical trial data and other sensitive
information) or damage to the integrity of that data, negative publicity, reputational harm, monetary fund diversions, interruptions in
our operations, financial loss, and other similar harms. Such attendant consequences may interrupt our clinical trials, reduce demand
for our product candidates, and delay or negatively impact the development and commercialization of our product candidates and ability
to grow and operate our business. For example, the loss of clinical trial data from the clinical trials of our therapeutic product candidates
could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore,
our contracts may not contain limitations of liability, and even where they do, there can be no assurances that limitations of liability
in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.
We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out
of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or
that such coverage will pay future claims.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are subject to stringent and changing obligations
related to data privacy and security. Failure or perceived failure to comply with current or future obligations could lead to government
enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively
affect our operating results and business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We and the third parties upon whom we rely process sensitive information and are subject
to numerous data privacy and security obligations, such as various federal, state, local and foreign data laws, regulations, guidance,
industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of
personal data by us and on our behalf. In addition to existing privacy regulations, the emergence of new regulatory frameworks, such as
those addressing artificial intelligence, increasingly intersect with privacy and data protection requirements. These regulations may
impose additional compliance obligations related to using, storing, and processing personally identifiable information.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">27</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">In the United States, numerous federal, state, and local laws and regulations, including
federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state
consumer protection laws, that govern the collection, use, disclosure and protection of health-related and other personal data may apply
to our operations or the operations of the third parties upon which we rely. For example, the federal Health Insurance Portability and
Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH,
imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. As
another example, the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, or the CAN-SPAM imposes specific
requirements on our correspondence with subscribers for email communication.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, California enacted the California Consumer Privacy Act, or the CCPA,
which provides for civil penalties for violations, as well as a private right of action for data breaches. The CCPA, as amended requires
businesses to, among other obligations, provide specific disclosures in privacy notices and honor requests of California residents (including
consumers, business representatives, and employees) to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per
intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although
the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with
respect to other personal data we maintain about California residents. Other states have also passed comprehensive privacy laws, and similar
laws are being considered in other states, as well as at the federal and local levels. While these states, like the CCPA, also exempt
some data processed in the context of clinical trials, these developments further complicate compliance efforts, and increase legal risk
and compliance costs for us and the third parties upon whom we rely.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, an increasing number of foreign data protection laws may also apply
to health-related and other personal data obtained from individuals outside of the United States. For example, the European Union&#8217;s
General Data Protection Regulation, or EU GDPR, imposes strict introduced new data protection requirements across the EU, including potential
fines for noncompliant companies of up to the greater of &#8364;20 million or 4% of annual global revenue, temporary or definitive bans
on data processing, and other corrective actions. Additionally, private litigation related to processing of personal data can be brought
under the EU GDPR by classes of data subjects or consumer protection organizations authorized by law to represent their interests. In
addition, the Israeli Privacy Protection Law&#160;5741-1981, as amended,&#160;and the regulations promulgated thereunder, or the PPL,
impose obligations with respect to the manner personal data is processed, maintained, transferred, disclosed, accessed and secured, as
well as severe fines and penalties, stringent notice requirements, and mandatory appointments of certain privacy and information security-related
roles. In August 2025, a comprehensive amendment to the PPL is expected to enter into effect. This amendment aims to strengthen the Israeli
Privacy Protection Authority&#8217;s enforcement powers and grant it significant authority to impose administrative fines for non-compliance.
The amendment is also expected to introduce broader oversight capabilities, alongside mechanisms for monitoring adherence to privacy guidelines,
thereby heightening the compliance requirements for organizations that handle personal data in Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, Europe and other jurisdictions have enacted data localization laws and
cross-border personal data transfer laws, which could make it more difficult to transfer information across jurisdictions (such as transferring
or receiving personal data that originates in the European Economic Area). In particular, the European Economic Area (EEA) and the United
Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it
generally believes are inadequate. Although there are currently various mechanisms that may be used to transfer personal data from the
EEA and UK to the United States in compliance with law, such as the EEA standard contractual clauses, the UK&#8217;s International Data
Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant
U.S.-based organizations who self-certify compliance and participate in the Framework), existing mechanisms that may facilitate cross-border
personal data transfers may change, be challenged or be invalidated, and there is no assurance that we can satisfy or rely on these measures
to lawfully transfer personal data to the United States. If we cannot implement a valid compliance mechanism for cross-border data transfers,
we could experience material adverse effects.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are also exposed to the risk that employees, independent contractors, consultants,
and vendors may fail to comply with applicable privacy and data protection laws. Such misconduct or negligence could result in unauthorized
access, misuse, or disclosure of sensitive information, leading to regulatory penalties, lawsuits, and reputational harm. Despite our
efforts to implement preventive measures, we cannot guarantee full compliance at all times, which could adversely impact our business
operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">28</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">We maintain privacy policies and other statements regarding data privacy and security.
Regulators in the United States are increasingly scrutinizing these statements. If these policies or statements are found to be deficient,
lacking in transparency, deceptive, unfair, misleading, or misrepresentative of our practices, we may be subject to investigation, enforcement
actions by regulators or other adverse consequences.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our obligations related to privacy and security are quickly changing in an increasingly
stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject
to differing applications and interpretations, which may be inconsistent or in conflict among jurisdictions. Preparing for and complying
with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources).
These obligations may necessitate changes to our practices and to those of any third parties upon whom we rely. In addition, these obligations
may require us to change our business model. Compliance with privacy and security obligations could require us to take on more onerous
obligations in our contracts, restrict our ability to collect, use and disclose sensitive information, or in some cases, impact our ability
to operate in certain jurisdictions. Failure or perceived failure by us or the third parties upon whom we rely to comply with U.S. and
foreign data privacy or security obligations could result in government enforcement actions (which could include civil or criminal penalties),
private litigation or mass arbitration demands, bans on processing personal data, additional reporting requirements or oversight, orders
to destroy or not use personal data, and/or adverse publicity and could negatively affect our operating results and business. Claims that
we have violated individuals&#8217; privacy rights or failed to comply with privacy or security obligations, even if we are not found
liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on
our business, financial condition, results of operations and prospects.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are exposed to risks associated with integrating
artificial intelligence tools into our operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We recently began integrating AI and ML technologies into our organizational operations.
For example, our method of identifying potential novel drug targets is based on our AI/ML powered predictive computational discovery platform,
Unigen&#8482;. As another example, our employees and personnel use generative AI to perform certain tasks in their work. The integration
of AI/ML introduces inherent risks such as data privacy, intellectual property disputes, cybersecurity vulnerabilities, confidentiality
concerns, and regulatory non-compliance that may arise from the deployment or misuse of AI systems.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The disclosure and use of personal data in AI/ML is subject to various privacy laws
and obligations, as well as increasing regulation and scrutiny. Several jurisdictions around the globe have proposed, enacted, or are
considering laws governing AI/ML, such as the EU&#8217;s AI Act. Additionally, certain privacy laws extend rights to individuals (such
as the right to delete certain personal data) and regulate automated decision making involving certain personal data, which may be incompatible
with certain of our AI/ML uses. These obligations may make it harder for us to operate our business, lead to regulatory fines or penalties,
prevent or limit our use of AI/ML, or otherwise harm our business. For example, the Federal Trade Commission has required other companies
to turn over (or disgorge) valuable insights or trainings generated through the use of AI/ML where they allege the company has violated
privacy and consumer protection laws. If we cannot use AI/ML or that use is restricted, our business may be less efficient, or we may
be at a competitive disadvantage.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, the complexity and opacity of AI algorithms can lead to unintended consequences
or outcomes. Due to inaccuracies or flaws in the inputs, outputs, or logic of the AI/ML, the model could be biased and could lead us to
make decisions that could bias certain individuals (or classes of individuals), and adversely impact their rights, employment, and ability
to obtain certain pricing, products, services, or benefits.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our use of AI/ML models hosted or developed by third party providers also presents
certain information security risks. For example, any sensitive information that we input into such AI/ML platform could be leaked or disclosed
to others, including if sensitive information is used to train third party AI/ML. Where an AI/ML model ingests sensitive information and
makes connections using such data, those technologies may reveal other sensitive information generated by the model. AI/ML models may
create flawed, incomplete, or inaccurate outputs, some of which may appear correct. This may happen if the inputs that the model relied
on were inaccurate, incomplete or flawed (including if a bad actor &#8220;poisons&#8221; the AI/ML with bad inputs or logic), or if the
logic of the AI/ML is flawed (a so-called &#8220;hallucination&#8221;).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Adopting and maintaining AI and ML technologies may increase operational costs due
to computing demands and specialized expertise requirements, and even if we are successful in maintaining such technologies, our competitors
or other third parties may incorporate AI and ML into their businesses more quickly or more successfully than us, which could impair our
ability to compete effectively and adversely affect our results of operations. If our technologies (including those of our vendors and
subcontractors) fail to perform as intended, our business, financial condition, and results of operations could be adversely affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">29</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Changes in legal or regulatory frameworks surrounding AI usage may further pose compliance
risks or limit the development and application of these technologies. For example, many U.S. federal and state and foreign government
bodies and agencies have introduced and/or are currently considering additional laws and regulations governing the use of AI technologies.&#160;Any
such changes could require us to expend significant resources to modify our products, services, or operations to ensure compliance or
remain competitive.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If a successful liability claim or other claim
for damages or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, we could be forced
to pay substantial damage awards.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The use of any of our therapeutic product candidates in clinical trials might expose
us to liability. We have obtained clinical trial insurance coverage in amounts that we believe are reasonable and customary in our industry
based on the size and design of our clinical trials. However, there can be no assurance that such insurance coverage will fully protect
us against some or all of the claims to which we might become subject. We might not be able to maintain adequate insurance coverage at
a reasonable cost or in sufficient amounts or scope to protect us against potential losses. For example, we will need to increase our
insurance coverage if we conduct clinical trials in additional countries or of additional product candidates or if we commence commercialization
of any product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable
cost or in an amount adequate to satisfy any liability that may arise. In the event a claim is brought against us, we might be required
to pay legal and other expenses to defend the claim, as well as uncovered damages awards resulting from a claim brought successfully against
us and retention amounts. Furthermore, whether or not we are ultimately successful in defending any such claims, we might be required
to direct financial and managerial resources to such defense and be subject to adverse publicity, all of which could harm our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If we fail to comply with laws regulating the
protection of the environment and health and human safety, our business could be adversely affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our research and development activities involve the use of hazardous materials and
chemicals, and we maintain quantities of microbial agents, various flammable and toxic chemicals in our facilities. Although we believe
our safety and other procedures for storing, handling and disposing these materials in our facilities comply with applicable governmental
and local regulations and guidelines, the risk to our employees or others of accidental contamination or injury from these materials cannot
be eliminated. If an accident occurs, we could be held liable for resulting damages, which may exceed our financial resources and may
seriously harm our business. We are also subject to numerous environmental, health and workplace safety laws and regulations, including
those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials. We may be subject
to liability and may be required to comply with new or existing laws and regulations regulating pharmaceuticals or be subject to substantial
fines or penalties if we violate any of these laws or regulations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to Intellectual Property.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If the scope of any patent protection we obtain
is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar
or identical product candidates would be adversely affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have applied for patents covering proteins, therapeutic and diagnostic product
candidates and their method of use, and the success of our business depends, to a large extent, on our ability to obtain and maintain
such patents and any additional patents covering our future product candidates. We design our patent strategy to fit the business competitive
landscape and continual legislative changes. In addition, we periodically analyze and examine our patent portfolio to align it with our
pipeline strategy and business needs. We have issued patents and pending patent applications that are related to our product candidates
in the U.S., Europe, and other territories. We plan to continue to apply for patent protection for our therapeutic and diagnostic inventions,
but we cannot be sure that any of our patent applications will be accepted, or that they will be accepted to the extent that we seek or
that they will not be challenged. Additionally, we file for patent protection in selected countries and not in all countries of the world.
Therefore, we are exposed to competition in those countries in which we have no patent protection. Also, due to our early-stage pipeline
and various business considerations, we may be required to seek patent protection at a very early-stage. This may cause us to file with
insufficient supportive data, possibly making it difficult to obtain patents in jurisdictions that do not accept post filing evidence
to support the claims, and thus enabling others to compete with us. This may also cause issuance of a patent at an earlier stage creating
a shorter commercialization period under patent protection, possibly enabling others to compete with us. Delays in filing patents may
preclude us from obtaining protection on some or all of our product candidates due to others filing ahead of us. Patent applications filed
before us, but yet unpublished, may cause us to spend significant resources in areas that due to these previously filed patents or applications
we will not be able to obtain patent protection, practice the claimed invention without infringing upon such earlier patents (if granted),
or will only be able to obtain a narrower scope of protection than contemplated.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">30</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Because the patent position of biopharmaceutical companies involves complex legal
and factual questions, we cannot predict the validity, scope or enforceability of patents with certainty. The issuance of a patent is
not conclusive as to its inventorship, scope, validity or enforceability and our patents may be subject to a third party pre issuance
submission of prior art to the patent authorities or become involved in opposition, derivation, revocation, reexamination, post-grant
and <span style="font-style: italic">inter partes</span> review, or other similar proceedings challenging our patent rights in the United
States and other jurisdictions which may result in such patents being narrowed, invalidated, or held unenforceable, and thus could limit
our ability to stop competitors from marketing related products or limit the length of the term of patent protection that we may have
for our product candidates. Such proceedings may also result in substantial cost and require our pending patent applications, and those
we may file in the future may not result in patents being issued. Furthermore, even if our patents do issue, and even if they are unchallenged,
our patents may not adequately protect all our intellectual property or prevent others from designing their products in a way to avoid
being covered by our claims. If the breadth or strength of protection provided by the patents we hold is threatened, this could dissuade
companies from collaborating with us to develop and could threaten our ability to commercialize product candidates and expose us to unexpected
competition that could have a material adverse impact on our business. For example, in October 2020, two parties, one being GSK (following
an assignment), filed oppositions in the European Patent Office, or EPO, requesting revocation of our granted European patent relating
to anti-PVRIG antibodies and following different proceedings, on July 11, 2023 in an oral proceedings hearing, the opposition division
of the&#160;European Patent Office ruled in favor of maintaining the broad claims in the patent as granted to us. The opposition division&#8217;s
written decision was received on January 18, 2024, and thereafter, on March 18, 2024, the opponents filed an appeal. Statement of grounds
of appeal was filed on May 17, 2024 and we filed a response to the appeal on September 26, 2024. In January 2023, another opposition was
filed by GSK, requesting revocation of our granted European patent relating to method of screening for inhibitors of the binding association
of PVRIG polypeptide with PVRL2. Following different proceedings, on January 14, 2025, in an oral proceedings hearing, the opposition
division of the&#160;European Patent Office ruled in favor of maintaining the patent in its amended form, with the amended patent recites
method of screening for anti-PVRIG antibodies that are inhibitors of the binding association of PVRIG polypeptide with PVRL2. The opponents
can still appeal this decision. In May 2023, two other European oppositions were filed by GSK and another party, with respect to anti-PVRIG
antibodies competing with COM701 and we already provided our response. The summons to attend oral proceedings in these oppositions and
preliminary opinion by the opposition division were received on October 21, 2024. A written response to the preliminary opinion is due
from us by October 2, 2025 and the oral proceedings are scheduled to take place between December 3 to December 5, 2025. There can be no
guarantee that we are successful with this or any other opposition proceeding.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, changes in either the patent laws or interpretation of the patent laws
in the United States or other jurisdictions could weaken our ability to obtain new patents or to enforce our existing patents and patents
that we might obtain in the future and increase the uncertainties and costs surrounding the prosecution of patent applications, and the
enforcement or defense of our issued patents. Such changes could diminish the value of our patents and applications, thereby impairing
our ability to protect our product candidates, and could have a material adverse effect on our business, financial condition, results
of operations and prospects. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the
scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In October
2017, in <span style="font-style: italic">Amgen v. Sanofi</span>, the Federal Circuit overturned the &#8220;newly characterized antigen&#8221;
test, which permitted patentees to claim a genus of antibodies by describing the structure of a corresponding antigen, on the grounds
that it failed to satisfy the requirements found in Section 112 of the Patent Act, 35 U.S.C. &#167; 112. In doing so, the Federal Circuit
called into question the validity of numerous existing patents. On May 18, 2023, the Supreme Court affirmed the Federal Circuit&#8217;s
judgement in <span style="font-style: italic">Amgen v. Sanofi</span>. Thus, in the current IP environment in the U.S., we may not be able
to obtain or defend broad patent protection on our antibody inventions. In addition, recent U.S. court decisions raise questions regarding
the award of patent term adjustment (PTA) for patens in families where related patents have issued without PTA. Thus, it cannot be said
without certainty how PTA will/will not be viewed in the future and whether patent expiration dates may be impacted. Similarly, changes
in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in
how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce
patents. For example, the complexity and uncertainty of European patent laws have increased in recent years. In Europe, a new unitary
patent system took effect June 1, 2023, which will significantly impact European patents, including those granted before introduction
of the system. Under the unitary patent system, European applications have the option, upon receipt of a patent, of becoming a Unitary
Patent subject to the jurisdictions of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the
court, increasing the uncertainty of any litigation. Patents granted before implementation of the UPC have the option of opting out of
the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under jurisdiction of the UPC
will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries
who are signatories to the UPC. All our patents and patent applications for which a request for opt out was available in the sunrise period
were opted out. We cannot predict with certainty the long-term effects of any potential changes.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">31</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Moreover, because of the extensive time required for development, testing and regulatory
review of a potential product, it is possible that, before any particular product candidate can be commercialized, any related patent
may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent protection.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The process of obtaining patents for inventions that cover our products is uncertain
for a number of reasons, including but not limited to:</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z50ef8f0031a04c2cb909c5dab4d4a3d1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the patenting of inventions involves complex legal issues relating to intellectual property laws, prosecution and enforcement of
        patent claims across a number or patent jurisdictions, many of which have not yet been settled;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4ce2bb15fc1e4cb2895f2caf7d6fd966" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>legislative and judicial changes, or changes in the examination guidelines of governmental patent offices may negatively affect our
        ability to obtain patent claims to certain biological molecules- and/or use of certain therapeutic targets;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z112878c4eb3b4476867d3c786485ebb5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>if we are not the first to file a patent application on one of our inventions, we may not be able to obtain a patent on our invention,
        and may not be able to protect one or more of our therapeutic product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z22396a204a9349e6950ce6bb599fa07e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>competition from other biotechnology and pharmaceutical companies who have already sought patent protection relating to proteins
        and protein based products, as well as therapeutic antibodies or other modulators specifically binding these proteins, and their utility
        based discoveries that we may intend to develop and commercialize; such prior patents may negatively affect our ability to obtain patent
        claims on antibodies or certain proteins or other biologic modulators, or may hinder our ability to obtain sufficiently broad patent claims
        for our inventions, and/or may limit our freedom to operate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb3644f9b7daa43b7a4d400fb7334a481" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>publication of data on gene products or proteins by non-commercial and commercial entities may hinder our ability to obtain sufficiently
        broad patent claims for our inventions;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za1210521ff334e988f36787656ba5e2d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>even if we succeed in obtaining patent protection, such protection may not be sufficient to prevent third parties from circumventing
        our patent claims;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7bd8ab93475d4e3e8017a93b25c016ea" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>even if we succeed in obtaining patent protection, we may face freedom to operate issues;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z15621176eb2c400d81d2e30afbe2e0bd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>even if we succeed in obtaining patent claims protecting our inventions and product candidates, our patents could be subject to challenge
        and litigation by our competitors, and may be partially or wholly invalidated as a result of such legal/judicial challenges and in connection
        with such challenges;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb03350c8cf1a489d8ecc35189575746d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>significant costs that may need to be incurred in registering and filing patents;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z88bbcf17a1fa49d4b45b9d5cf5e2e0ba" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>insufficient data to support our claims and/or may support others in strengthening their patents;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8f5e5fce96e141f18b5de850492c02dc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>seeking patent protection at an early stage may prevent us from providing comprehensive data supporting the patent claims and may
        prevent allowance of certain patent claims or limit the scope of patent claim coverage;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">32</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc9eedcb9938d4c50a249e73ff03ffdee" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may not be able to supply sufficient data to support our claims, within the legally prescribed time following our initial filing
        in order to support our patent claims and this may harm our ability to get appropriate patent protection or protection at all;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd5641d26f6cf40a384b1cf71c5fe31cb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our claims may be too broad and not have sufficient enablement, in which case such claims might be rejected by patent offices or
        invalidated in court; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z872886077583404598c948395cec8cd2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we might fail to demonstrate a unique technical feature for our antibodies as compared to existing prior art, in which case our claims
        might be rejected by the respective patent office, requiring superiority over prior art.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we fail in obtaining patent protection for our inventions (should it be discoveries,
drug targets candidates and product candidates) to the fullest extent for which we seek protection, or if we fail to select the best inventions
to seek such protection, our business and financial results could be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may not be able to protect
our intellectual property rights throughout the world.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Patents are of national or regional effect, and filing, prosecuting and defending
patents on all of our investigational products throughout the world would be extremely expensive. Thus, we may not be able to prevent
third parties from practicing or from selling or importing products made using our inventions in all countries. Further, the legal systems
of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property
protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation
of our proprietary rights generally. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled
to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if
we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This
could limit our potential revenues. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate
to obtain a significant commercial advantage from the intellectual property that we develop or license.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">The existence of third-party
intellectual property rights may prevent us from developing our discoveries and/or discoveries we licensed to partners or require us to
expend financial and other resources to be able to continue to do so.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In selecting a drug target or a therapeutic product candidate for
development, we consider, among other considerations, the existence of third-party intellectual property rights that may hinder our right
to develop and commercialize that product candidate. To our knowledge, third parties, including our competitors, have been filing patent
applications covering an increasing portion of the human proteome or antibodies directed thereto. As a result of the existence of third-party
intellectual property rights, we may be further required to:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0d7e464db1314902bdb692a160cc2f7d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>forgo the research, development and commercialization of certain drug target candidates and product candidates that we discover,
        notwithstanding their promising scientific and commercial merits; or</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb29caa80548d450f952e99fd99eeb7c6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>invest substantial management and financial resources to either challenge or in-license such third-party intellectual property, and
        we cannot be sure that we will succeed in doing so on commercially reasonable terms, if at all.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We do not always have available to us, in a timely manner, information
of the existence of third-party intellectual property rights related to our own discoveries. The content of U.S. and other patent applications
remains unavailable to the public for a period of approximately 18 months from the filing date and therefore we cannot be certain that
we were the first to file any patent application related to our product candidate. In some instances, the content of U.S. patent applications
remains unavailable to the public until the patents are issued. Moreover, when patents ultimately are issued, the claims may be substantially
different from those that were originally published and may vary from country to country. Furthermore, there may be issued patents or
pending patent applications that we are aware of, but that we believe are irrelevant to our therapeutic product candidates, but which
may ultimately be found to be infringed by the manufacture, sale, or use of such product candidates. As a result, we can never be certain
that programs that we commence will be free of third-party intellectual property rights. If we become aware of the existence of third-party
intellectual property rights only after we have commenced a particular program, we may have to forgo such project after having invested
substantial resources in it or, to the extent such third-party right has not expired, obtain a license which may involve substantial financial
resources.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">33</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may need to obtain additional
licenses of third-party technology or other rights that may not be available to us or are available only on commercially unreasonable
terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We may be required to license technology or other rights from third
parties to further develop or commercialize our investigational products. Should we be required to obtain licenses for any third-party
technology, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party
license required to develop or commercialize any of our products could cause us to abandon any related efforts, which could seriously
harm our business and operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We, or potential collaborators
and licensees, may infringe third-party rights and may become involved in litigation, which may materially harm our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">If a third-party accuses us, our collaborators or a potential collaborator
and licensee of infringing its intellectual property rights or if a third-party commences litigation against us, our collaborators or
a potential collaborator and licensee for the infringement of patent or other intellectual property rights, we may incur significant costs
in obtaining a license or defending such action, whether or not we ultimately prevail. We are aware of U.S. and foreign issued patents
and pending patent applications controlled by third parties that may relate to the areas in which we are developing therapeutic products.
Because all issued patents are entitled to a presumption of validity in many countries, including the United States and many European
countries, issued patents held by others with claims related to products, may limit our freedom to operate unless and until these patents
expire or are declared invalid or unenforceable in a court of applicable jurisdiction, if we do not obtain a license or other right to
practice the claimed inventions. Typically, patent litigation in the pharmaceutical and biotechnology industry is expensive and prolonged.
Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property
litigation to a greater degree and for longer periods of time than we could. Costs that we may incur in defending third-party infringement
actions would also result in the diversion of management&#8217;s and technical personnel&#8217;s time. In addition, parties making claims
against us may be able to obtain injunctive or other equitable relief that could prevent us or our collaborators and licensees from further
developing our discoveries or commercializing our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In the event of a successful claim of infringement against us or
a potential collaborator and licensee, we may be required to pay damages, including treble damages and attorney&#8217;s fees if we are
found to be willfully infringing a third-party&#8217;s patent, or obtain one or more licenses from the prevailing third-party (if not
obtained prior to such litigation), which may not be available to us on commercially reasonable terms, if at all. Even if we were able
to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property. If we
are not able to obtain such a license or not able to obtain such a license at a reasonable cost, we could be prevented from commercializing
a product until the relevant patents expired, or we could be forced to redesign our products, or to cease some aspect of our business
operations, and we could encounter delays in product introductions and loss of substantial resources while we attempt to develop alternative
products. Defense of any lawsuit or failure to obtain any such license could prevent us or our partners from commercializing available
products and could cause us to incur substantial expenditures and would divert management&#8217;s attention from our core business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may become involved in
lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Competitors may infringe, misappropriate or otherwise violate our
patents, trademarks, copyrights or other intellectual property, or those of our licensors. To counter infringement, misappropriation,
unauthorized use or other violations, we may be required to file legal claims, which can be expensive and time consuming and divert the
time and attention of our management and scientific personnel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Additionally, after a patent is granted, it can be annulled, or
its scope of protection restricted through an appeal, revocation or invalidation procedure. Such procedures are lengthy, expensive and
time consuming, and may have an adverse effect on us.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">34</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We may not be able to prevent, alone or with our licensees or any
future licensees, infringement, misappropriation or other violations of our intellectual property rights, particularly in countries where
the laws may not protect those rights as fully as in the United States. Any claims we assert against perceived infringers could provoke
these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement or opposition
proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that
we do not have the right to stop the other party from using the invention at issue. In this respect, as stated above, we are currently
facing two outstanding European oppositions filed by GSK and another party, with respect to our European patent relating to anti-PVRIG
antibodies competing with COM701; another opposition filed by GSK, in respect to our European patent relating to method of screening for
inhibitors of the binding association of PVRIG polypeptide with PVRL2, in which the opposition division of the&#160;European Patent Office
ruled in our favor and the claims of the patent were maintained in an amended form as specified above and one opposition filed by GSK
and another party, with respect to our European patent relating to anti-PVRIG antibodies, in which we prevailed but is under appeal. There
is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide
that we do not have the right to stop the other party from using the invention at issue on the grounds that our patents do not cover the
invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against
those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or
competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial
condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or
unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In
this case, we could ultimately be forced to cease using such trademarks.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In any infringement, misappropriation or other intellectual property
litigation, any award of monetary damages we receive may not be commercially valuable. Even if we establish infringement, the court may
decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be
an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation,
there is a risk that some of our confidential information could be compromised by disclosure during litigation. The results of hearings,
motions or other interim proceedings or developments are public. If securities analysts or investors perceive these results to be negative,
it could have an adverse effect on our share price. Moreover, there can be no assurance that we will have sufficient financial or other
resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately
prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel
could outweigh any benefit we receive as a result of the proceedings.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Increased progress in our scientific and technological
environment may reduce our chances of obtaining a patent.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In order to obtain a patent to protect one of our therapeutic product candidates,
we must show that the underlying invention (that is, the product candidate itself or its use) is inventive. As an increasing amount of
scientific knowledge is becoming available regarding genes, proteins, biological mechanisms, and the relevance of the genes and proteins
to various clinical indications, the bar is increasingly raised to show sufficient inventiveness, as inventiveness is judged against all
publicly available information available prior to filing of the patent application (the exact date may vary by country or due to other
circumstances). As an increasing amount of scientific knowledge is becoming available for various proteins and their potential use as
drug targets, with time we may be limited or may not be able to obtain patents for our product candidates due to the increased information
published in this area. Our own published patent applications and other publications also serve as prior art against our new inventions
and patent applications and may prevent us from obtaining new patents.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">We may become subject to claims for remuneration or royalties for
assigned service invention rights by our employees, which could result in litigation and adversely affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We enter into assignment of invention agreements with our employees pursuant to which
such individuals agree to assign to us all rights to any inventions created in the scope of their employment or engagement with us. A
significant portion of our intellectual property has been developed by our employees in the course of their employment for us. Under the
Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee due to and during his or her employment with a company
are regarded as &#8220;service inventions&#8221;, which belong to the employer, unless the employee and employer have entered into a specific
agreement stating otherwise, except if the employer waived the service invention within six months of receipt of a notice by the employee
regarding the creation of the service invention (in accordance with provisions of the Patent Law). The Patent Law also provides that if
there is no agreement with respect to whether the employee is entitled to remuneration for his or her service invention, to what extent
and under what conditions, such entitlement and terms shall be determined by the Israeli Compensation and Royalties Committee, or the
Committee, a body constituted under the Patent Law. Decisions by the Committee and Israeli courts have created some uncertainty in this
area. Although our employees have agreed to assign to us service invention rights and have waived any rights for additional compensation
for such service inventions, we may still face claims demanding remuneration in consideration for assigned service inventions. As a consequence
of such claims, we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced
to litigate such claims, which could negatively affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">35</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The USPTO and various foreign patent agencies require compliance with a number of
procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. Noncompliance with these
requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights
in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the
case.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may be subject to claims that we or our
employees or consultants have infringed, misappropriated or otherwise violated the intellectual property of a third-party, or claiming
ownership of what we regard as our own intellectual property.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may be subject to claims that we or our employees or consultants have inadvertently
or otherwise used or disclosed confidential information of former employers, competitors or other third-parties. We may be further subject
to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing
our product candidates, resulting, among others, in disputes regarding ownership interest in our patents or other intellectual property.
Although we have implemented reasonable measures to ensure that our employees and consultants do not use the intellectual property of
others in their work for us, we may become subject to claims that we caused an employee or consultant to breach, among others, the terms
of his or her non-competition, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged proprietary
information of a former employer, competitor or other third-party.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While we may litigate to defend ourselves against these claims, even if we are successful,
litigation could result in substantial costs and could distract the attention of our management. If our defenses to these claims fail,
in addition to requiring us to pay monetary damages, a court could deprive our rights in such technologies or features that are essential
to our investigational products, if such technologies or features are found to incorporate or be derived from the proprietary information
of third parties and prohibit us from using them. Moreover, any such litigation may adversely affect our ability to form strategic alliances,
engage with scientific advisors or hire employees or consultants.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, while we typically require our employees, consultants and contractors
who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may
be unsuccessful in executing such an agreement with each party who in fact develops intellectual property. To the extent that we fail
to obtain such assignments, or such assignments do not contain a self-executing assignment of intellectual property rights, or such assignments
are breached, we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership
of what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights. Such intellectual property rights could be awarded to a third party, and we
could be required to obtain a license from such third-party to commercialize our technology or products. Such a license may not be available
on commercially reasonable terms or at all. Even if we are successful in prosecuting or defending against such claims, litigation could
result in substantial costs and be a distraction to our management and scientific personnel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may become subject to claims challenging
the inventorship or ownership of our patents.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may be subject to claims that former employees, collaborators or other third parties
have an interest in our patents as co-inventors. The failure to name the proper inventors on a patent application can result in the patents
issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals,
the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations
of third parties involved or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary
to resolve claims challenging inventorship and/or ownership. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such
an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to management and other employees.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">36</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Patent terms may be inadequate to protect our
competitive position on our product candidates for an adequate amount of time.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Patents have a limited lifespan. In the United States, if all maintenance fees are
timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions
may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates
are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars.
Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such
candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio
may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours and may cause a
significant reduction to our potential future revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may rely on trade secrets and proprietary
know-how which can be difficult to trace and enforce.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to seeking patent protection for some of our technology and investigational
products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our
competitive position. Trade secrets and know-how can be difficult to protect. Any disclosure, either intentional or unintentional, by
our employees or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities,
or misappropriation by third parties (such as through a security breach) of our trade secrets or proprietary information could enable
competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We require our employees to enter into written employment agreements containing provisions
of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We further seek to protect
our potential trade secrets and proprietary know-how by entering into non-disclosure and confidentiality agreements with any third parties
who are given access to them, including our collaborators, contract manufacturers, consultants, advisors and other third parties. With
our consultants, contractors, and collaborators, these agreements typically include invention assignment obligations. Despite these efforts,
any of these parties may breach the agreements and disclose our proprietary information or assign our inventions to third parties, which
may be difficult to trace, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally
disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are unable to adequately protect our proprietary know-how and trade secrets,
competitors may be able to develop technologies and resulting discoveries and inventions that are identical, similar to or better than
our own discoveries and inventions, which could materially harm our business, financial condition and results of operations. Costly and
time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade
secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop
our trade secrets and proprietary information, and the existence of&#160;our own trade secrets affords no protection against such independent
discovery.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to Operations in Israel</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Conditions in Israel and in the Middle East may adversely affect
our operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our headquarters and research and development facilities are located in Israel. Accordingly,
we are directly influenced by the political, economic and military conditions affecting Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Since the establishment of the State of Israel in 1948 and in recent years, armed
conflicts between Israel and its neighboring countries and terrorist organizations active in the region have involved missile strikes,
hostile infiltrations,&#160;terrorism against civilian targets in various parts of Israel, and recently abduction of citizens and soldiers.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">37</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">On October 7, 2023, the &#8220;Swords of Iron&#8221; war broke between Israel and
the terrorist organizations in the Gaza Strip, following a surprise attack on Israel led by certain armed groups in the Gaza Strip that
included massacres, terrorism and crimes against humanity. As of the date hereof, the majority of the fighting is concentrated in the
southern region of the State of Israel, and there have been additional active hostilities, including with the Hezbollah (a&#160;Shia&#160;Islamist&#160;political
party and&#160;militant&#160;group based in&#160;Lebanon), [culminating in a 60-day cease fire agreed to between Israel and the Hezbollah
on November 27, 2024, the result of which is uncertain] and the Houthi movement which controls parts of Yemen. The Houthi movement in
Yemen has targeted marine vessels in the Red Sea, affecting those enroute to Israel or partly owned by Israeli businesses. This has led
shipping companies to reroute or halt shipments to Israel. The Red Sea is crucial for Israel&#8217;s trade, and disruptions could cause
delays in supplier deliveries, longer lead times, and increased costs for freight, insurance, materials, and labor, and have a general
adverse effect on the Israeli market. In addition, Israel has experienced hostilities with Iran, which is perceived by Israel as sponsor
of Hamas (a militia group and political party controlling the Gaza Strip), Hezbollah and the Houthi movement&#160;and attacked Israel
and has threatened to do so in the future, as well as with Iranian-backed militias in Syria. All these hostilities may escalate in the
future into a greater regional conflict. Israel responded to the attacks against it with airstrikes and extensive mobilization of armed
forces, including reserves, in the Gaza Strip and in the north of Israel in Lebanon and Syria and with airstrikes in Iran and Yemen. In
addition, most recently Israel has been involved in an armed operation with armed groups in the West Bank, which also included mobilization
of armed forces.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our headquarters and research and development facilities are located in Holon, which
is about 50 kilometers from the Gaza Strip and about 150 kilometers from the western border with Lebanon. Our facilities did not sustain
any damage and in accordance with the instructions of the Israeli National Emergency Management Authority, there is currently no limitation
or denial of access or activity limitation in our facilities. None of our employees were directly harmed as a result of the war. As of
the date hereof, we operate continuously, and so far, the situation in Israel does not have a material effect on our operations and business.
We monitor closely the directives of the Israeli National Emergency Management Authority and where needed, make required adjustments to
our operations in accordance with such directives, including by instructing our workforce to work remotely.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All of the above raise a concern as to the stability in the region which may affect
the security, social, economic and political landscape in Israel and therefore could adversely affect our business, financial condition
and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, certain countries, primarily in the Middle East but also in Malaysia
and Indonesia, as well as certain companies and organizations in different parts of the world, continue to participate in a boycott of
Israeli brands and others doing business with Israel and Israeli companies. The boycott, restrictive laws, policies or practices directed
towards Israel or Israeli businesses could, individually or in the aggregate, have a material adverse effect on our business in the future.
In addition, should the BDS Movement, the movement for boycotting, divesting and sanctioning Israel and Israeli institutions (including
universities) and products become increasingly influential in the United States and Europe, this may also adversely affect our business
and financial condition. Further deterioration of Israel&#8217;s relationship with the Palestinians or countries in the Middle East could
expand the disruption of international trading activities in Israel, may materially and negatively affect our business conditions, could
harm our results of operation and adversely affect the share price of our Company. In addition, in January 2024 the International Court
of Justice, or ICJ, issued an interim ruling in a case filed by South Africa against Israel in December 2023, in connection with the &#8220;Swords
of Iron&#8221; war, and ordered Israel, among other things, to take steps to provide basic services and humanitarian aid to civilians
in Gaza and in November, 2024, the International Criminal Court, or ICC, issued arrest warrants for Israeli Prime Minister Benjamin Netanyahu
and former Israeli Minister of Defense Yoav Gallant based on allegations of war crimes. Companies and businesses may terminate, and may
have already terminated, certain commercial relationships with Israeli companies following the ICJ and ICC decisions. The foregoing efforts
by countries, activists and organizations, particularly if they become more widespread, as well as rulings by the ICJ, ICC and other international
tribunals, may materially and adversely impact our business and supply chains. There are concerns that companies and businesses will terminate,
and may have already terminated, certain commercial relationships with Israeli companies following the ICJ and the ICC decisions. The
foregoing efforts by countries, activists and organizations, particularly if they become more widespread, as well as rulings by the ICJ,
ICC and other international tribunals, may adversely impact our ability to cooperate with research institutions and collaborate with other
third parties.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">38</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Our business may also be disturbed by the obligation of personnel to perform military
service. Our employees who are Israeli citizens are generally subject to a periodic obligation to perform reserve military service, until
they reach the age of 40 (currently 41, pursuant to a temporary provision enacted in light of the &#8220;Swords of Iron&#8221; war, or
older, for reservists with certain occupations), but during military conflicts, these employees may be called to active duty for long
periods of time, as occurred, and may continue to occur, during the &#8220;Swords of Iron&#8221; war. In response to the increase in violence
and terrorist activity in the past years, and especially during the &#8220;Swords of Iron&#8221; war, there have been, and may continue
to be, periods of significant call-ups for military reservists. In case of further regional instability such employees, who may include
one or more of our key employees, may be absent for extended periods of time which may materially adversely affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, recent political and civil actions in Israel which began in early 2023,
resulting from, among other things, proposed changes to certain Israeli constitutional legislation, have had and may continue to have
an adverse effect on the Israeli social, economic and political landscape and in turn, on us. However, it is difficult to predict at this
time what the effect of such actions will be, if any.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Moreover, on February 9, 2024, the international rating agency Moody&#8217;s announced
the downgrade of Israel&#8217;s credit rating to A2 (from a level of A1) and also lowered the rating outlook from &#8220;stable&#8221;
to &#8220;negative&#8221;. In its report, Moody&#8217;s estimated that the broad implications of the &#8220;Swords of Iron&#8221; war
significantly increase the political risks in the State of Israel, weaken the legislative and executive authorities, and significantly
impact Israel&#8217;s budgetary stability in the foreseeable future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In April 2024, S&amp;P Global Ratings also announced the downgrade of Israel&#8217;s
rating from AA- to A+, and maintained the rating outlook as &#8220;negative&#8221;, mainly due to the escalation of tensions between Israel
and Iran, as detailed above, and the geopolitical risks that Israel has been dealing with since the outbreak of the &#8220;Swords of Iron&#8221;
war.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We can give no assurance that the political, economic and security situation in Israel
will not have a material adverse impact on our business in the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, our insurance does not cover any loss arising from events related to
the security situation in the Middle East. While the Israeli government generally covers the reinstatement value of direct damages caused
by acts of war or terror attacks, we cannot be certain that such coverage will be maintained or that it will sufficiently cover our damages.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our results of operations may be adversely
affected by the exchange rate fluctuations between the dollar and the New Israeli Shekel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We hold most of our cash, cash equivalents and short-term and long-term bank deposits
in dollars but incur a significant portion of our expenses, principally salaries and related personnel expenses and administrative expenses
for our Israeli based operations, in NIS. As a result, we are exposed to exchange rate fluctuations between the dollar and the NIS, which
may have a material adverse effect on our financial condition. For example, if the dollar significantly devaluates against the NIS, then
the dollar cost of our operations in Israel would increase and our results of operations would be adversely affected.&#160;In 2024, 2023
and 2022 the dollar appreciated against the NIS by 0.6%, 3.1% and 13.2%. As a result of these fluctuations, our NIS denominated expenses
were affected.&#160; </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The dollar cost of our operations in Israel
will increase to the extent increases in the rate of inflation in Israel are not offset by a devaluation of the NIS in relation to the
dollar, which would harm our results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Inflation in Israel, was 3.2% and 3.0% in 2024 and 2023, respectively,
has affected us by increasing the costs of materials and labor needed to operate our business and could continue to adversely affect us
in future periods. Additionally, since a considerable portion of our expenses such as employees&#8217; salaries are linked to an extent
to the rate of inflation in Israel, the dollar cost of our operations is influenced by the extent to which any increase in the rate of
inflation in Israel is or is not offset by the devaluation of the NIS in relation to the dollar. As a result, we are exposed to the risk
that the NIS, after adjustment for inflation in Israel, will appreciate in relation to the dollar. In that event, the dollar cost of our
operations in Israel will increase and our dollar-measured results of operations will be adversely affected. We cannot predict whether
the NIS will appreciate against the dollar or vice versa in the future. Any increase in the rate of inflation in Israel, unless the increase
is offset on a timely basis by a devaluation of the NIS in relation to the dollar, will increase labor and other costs, which will increase
the dollar cost of our operations in Israel and harm our results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may not be entitled to certain Israeli tax
benefits.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the future, we may be entitled to benefit from certain Israeli government programs
and enjoy certain tax benefits resulting from the &#8216;Preferred Enterprise&#8217; status, or Preferred Enterprise, we are entitled
to under the Israel Law for Encouragement of Capital Investments, 1959, or the Investment Law. The availability of these tax benefits,
however, is subject to us meeting certain conditions under the Investment Law. The tax benefits that we anticipate receiving under the
Preferred Enterprise program may not be continued in the future at their current levels or at all. To date, we have not actually received
any such tax benefits because we have not yet generated any taxable income.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">39</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">It may be difficult to enforce certain U.S.
judgments against us, or our officers and directors or to assert U.S. Securities law claims in Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are incorporated under the laws of the State of Israel. Service of process upon
our directors and officers, the majority of whom reside outside the United States, may be difficult to obtain within the United States.
Furthermore, because the majority of our assets and investments, and a majority of our directors and officers are located outside the
United States, any judgment obtained in the United States against us or any of them may not be collectible within the United States.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, it may be difficult for an investor, or any other person or entity, to
assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged
violation of U.S. securities laws reasoning that Israel is not the most appropriate forum to bring such a claim. In addition, even if
an Israeli court agrees to hear such a claim, it is not certain whether Israeli law or U.S. law will be applicable to the claim. If U.S.
law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming
and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that
addresses the matters described above. Under certain circumstances, Israeli courts might not enforce judgments rendered outside Israel,
which may make it difficult to collect on judgments rendered against us or our non-U.S.&#160;officers and directors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Moreover, an Israeli court will not enforce a non-Israeli judgment if it was given
in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases), if its enforcement
is likely to prejudice the sovereignty or security of the State of Israel, if it was obtained by fraud or in the absence of due process,
if it is at variance with another valid judgment that was given in the same matter between the same parties, or if a suit in the same
matter between the same parties was pending before a court or tribunal in Israel at the time the foreign action was brought.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our amended and restated Articles of Association
provide that unless we consent to an alternative forum, the federal district courts of the United States of America shall be the exclusive
forum of resolution of any claims arising under the Securities Act which may impose additional litigation costs on our shareholders.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our amended and restated Articles of Association, or Articles, provide that unless
we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive
forum for the resolution of any complaint asserting a cause or causes of action, or a claim or claims arising under the Securities Act,
including all causes of action or claims asserted against any defendant to such complaint and that such provision may be enforced by us,
our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional or entity whose
profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying
the offering. Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities
Act actions. Accordingly, both U.S.&#160;state and federal courts have jurisdiction to entertain such claims. This choice of forum provision
may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers or other employees and may increase the costs associated with such lawsuits, which may discourage such lawsuits against us and
our directors, officers and employees. Alternatively, if a court were to find these provisions of our Articles inapplicable to, or unenforceable
in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such
matters in other jurisdictions, which could adversely affect our business and financial condition. Any person or entity purchasing or
otherwise acquiring any interest in our share capital shall be deemed to have notice of and to have consented to the choice of forum provisions
of our Articles described above. This provision does not apply to causes of action arising under the Exchange Act.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our Articles of Association provide that unless
the Company consents otherwise, the competent courts of Tel Aviv, Israel shall be the sole and exclusive forum for substantially all disputes
between the Company and its shareholders under the Companies Law and the Israeli Securities Law, which could limit its shareholders ability
to bring claims and proceedings against, as well as obtain favorable judicial forum for disputes with the Company, its directors, officers
and other employees.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25">Our Articles provide that unless we consent in writing to the selection of an alternative
forum, the competent courts of Tel Aviv, Israel shall be the exclusive forum for (i) any derivative action or proceeding brought on behalf
of the Company, (ii) any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Company
to the Company or the Company&#8217;s shareholders, or (iii) any action asserting a claim arising pursuant to any provision of the Companies
Law, 5759-1999, as amended together with all regulations promulgated thereunder, or the Companies Law, or the Securities Law, 5728-1968,
as amended and the regulations promulgated thereunder, or the Israeli Securities Law. Such exclusive forum provision in our Articles will
not relieve the Company of its duties to comply with federal securities laws and the rules and regulations thereunder, and shareholders
of the Company will not be deemed to have waived the Company&#8217;s compliance with these laws, rules and regulations. Any person or
entity purchasing or otherwise acquiring any interest in our share capital shall be deemed to have notice of and to have consented to
the choice of forum provisions of our Articles described above. This exclusive forum provision may limit a shareholder&#8217;s ability
to bring a claim in a judicial forum of its choosing for disputes with the Company or its directors or other employees which may discourage
lawsuits against the Company, its directors, officers and employees.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">40</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Provisions of Israeli law may delay, prevent
or make undesirable an acquisition of all or a significant portion of our shares or assets.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Israeli corporate law regulates mergers and acquisitions and requires that a tender
offer be affected when certain thresholds of percentage ownership of voting power in a company are exceeded (subject to certain conditions),
which may have the effect of delaying, preventing or making more difficult a merger with, or acquisition of, us. See &#8220;Item 10. Additional
Information &#8211; B. Memorandum and Articles of Association.&#8221; Further, Israeli tax considerations may make potential transactions
undesirable to us or to some of our shareholders whose country of residence does not have a tax treaty with Israel granting tax relief
to such shareholders from Israeli tax. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes
the deferral contingent on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction
during which certain sales and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain
share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition
of the shares has occurred. See &#8220;Item 10. Additional Information &#8211; E. Taxation &#8211; Israeli Taxation.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, in accordance with the Restrictive Trade Practices Law, 1988 and under
the Israeli Law for the Encouragement of Industrial Research and Development of 1984 and regulations promulgated thereunder, together,
the R&amp;D Law, approvals regarding a change in control (such as a merger or similar transaction) may be required in certain circumstances.
For more information regarding such required approvals please see &#8220;Item 5. Operating and Financial Review and Prospects - C. Research
and Development, Patents and Licenses &#8211; The Israel Innovation Authority.&#8221; In addition, as a corporation incorporated under
the laws of the State of Israel, we are subject to the Israeli Economic Competition Law, 1988 and the regulations promulgated thereunder
(formerly known as the Israeli Antitrust Law, 1988), under which we may be required in certain circumstances to obtain the approval of
the Israel Competition Authority (formerly known as the Israel Antitrust Authority) in order to consummate a merger or a sale of all or
substantially all of our assets.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">These provisions of Israeli law could have the effect of delaying
or preventing a change in control and may make it more difficult for a third-party to acquire us, even if doing so would be beneficial
to our shareholders and may limit the price that investors may be willing to pay in the future for our ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We received grants from the IIA that may require
us to pay royalties and restrict the transfer of know-how that we develop.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We have received governmental grants from the Israeli Innovation
Authority, or the IIA, for the financing of certain activities within the framework of our research and development expenditures. Accordingly,
we are obligated to repay the grants by way of royalty payments from revenues generated by the sale of products and/or services developed
in the framework of the approved R&amp;D program using financing from such grants, or Financed Know-How or as otherwise designated by
the applicable IIA programs, approvals and the R&amp;D Law. Such royalties are payable until 100% of the amount of the grant (as adjusted
for fluctuation in the USD/NIS exchange rate) is repaid with applicable interest (as long as we do not grant licenses thereunder nor transfer
production or development outside of the State of Israel). Even following full repayment of any IIA grants (together with the applicable
interest), and unless agreed otherwise by the applicable authority of the IIA, we must continue to comply with the requirements of the
R&amp;D Law with respect to the Financed Know-How. In addition to the obligation to pay royalties to the IIA, the R&amp;D Law requires
that products which incorporate Financed Know-How be manufactured in Israel and prohibits the transfer of the Financed Know-How and any
right derived therefrom to third parties, unless otherwise approved in advance by the IIA; Such prior approval, to the extent given by
the IIA, can be conditioned upon the payment of increased royalties and an increase in the overall repayment obligation. Failure to comply
with the requirements under the R&amp;D Law may subject us to financial sanctions, to mandatory repayment of grants received by us (together
with interest and penalties), as well as expose us to criminal proceedings. Although such restrictions do not apply to the export from
Israel of Company&#8217;s products developed with such Financed Know-How, they may prevent us, unless preapproval is obtained as detailed
above, from engaging in transactions involving the sale, licensing, outsourcing of development activities, transfer, the grant of access
rights and the like, with respect to such Financed Know-How or of manufacturing activities with respect to any product or technology based
on Financed Know-How, outside of Israel, which might otherwise be beneficial to us. Furthermore, the consideration received, and if applicable,
available to our shareholders in a transaction involving the transfer outside of Israel of Financed Know-How (such as a merger or similar
transaction) may be reduced by any amounts that we are required to pay to the IIA up to six times the amount of the grant (as adjusted
for fluctuation in the USD/NIS exchange rate) with applicable interest. Moreover, the government of Israel may, from time to time, audit
sales of products which it claims incorporate Financed Know-How and this may lead to royalties being payable on additional products, and
may subject such products to the restrictions and obligations specified hereunder.&#160;For more information regarding such restrictions
please see &#8220;Item 5. Operating and Financial Review and Prospects - C. Research and Development, Patents and Licenses - The Israel
Innovation Authority.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">41</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Being a foreign private issuer exempts us from
certain SEC requirements and Nasdaq rules, which may result in less protection that is afforded to investors under rules applicable to
domestic issuers.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are a &#8220;foreign private issuer&#8221; within the meaning of rules promulgated
by the SEC. As such, we are exempt from certain provisions under the Exchange Act,<span style="font-weight: bold">&#160;</span>applicable
to U.S. domestic public companies, including:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z120bf61d7f064eefbdedc8d7b4137a78" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the rules under the Exchange Act requiring the filing with the SEC of annual reports on Form 10-K, quarterly reports on Form 10-Q
        and current reports on Form 8-K;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9617d8f277a84ef88e6f8ac39f6248e7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered
        under the Exchange Act, including extensive disclosure of compensation paid or payable to certain of our highly compensated executives
        as well as disclosure of the compensation determination process;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z104dbe3f29974eeab27b8451e11030da" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the provisions of Regulation FD aimed at preventing issuers from making selective disclosures of material information; and</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z54cd38c3531c475abd316b1b0b235b85" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and establishing
        insider liability for profits realized from any &#8220;short-swing&#8221; trading transaction (a purchase and sale, or sale and purchase,
        of the issuer&#8217;s equity securities within less than six months).</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In addition, we may follow home country corporate governance practices
and law instead of those rules and practices otherwise required by Nasdaq for domestic issuers. For instance, we have relied on the foreign
private issuer exemption with respect to shareholder approval requirements for equity-based incentive plans for our employees. For the
list of specific exemptions that we chose to adopt, please see &#8220;Item 16G &#8211; Corporate Governance.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Following our home country corporate governance practices as opposed
to the requirements that would otherwise apply to a U.S. company listed on Nasdaq may provide less protection to investors than is afforded
to investors under the Nasdaq Listing Rules applicable to domestic issuers.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may lose our status as
a foreign private issuer, which would increase our compliance costs and could negatively impact our operations results.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We may lose our foreign private issuer status if (a) a majority
of our outstanding voting securities are either directly or indirectly owned of record by residents of the United States and (b)(i) a
majority of our executive officers or directors are U.S. citizens or residents, (ii) more than 50% of our assets are located in the United
States or (iii) our business is administered principally in the United States. If we were to no longer qualify as a foreign private issuer,
we would be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more extensive
than the forms available to a foreign private issuer. We would also be required to follow U.S. proxy disclosure requirements, including
the requirement to disclose, under U.S. law, more detailed information about the compensation of our senior executive officers on an individual
basis. We may also be required to modify certain of our policies to comply with accepted governance practices associated with U.S. domestic
issuers. Such conversion and modifications would involve increased costs. In addition, we would lose our ability to rely upon exemptions
from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers, as described in
the previous risk factor above.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">42</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Our shareholders rights
and responsibilities are governed by Israeli law which differs in some material respects from the rights and responsibilities of shareholders
of U.S. companies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Because we are incorporated under Israeli law, the rights and responsibilities of
our shareholders are governed by our Articles and Israeli law. These rights and responsibilities differ in some respects from the rights
and responsibilities of shareholders in U.S.-based corporations. In particular, a shareholder of an Israeli company has a duty to act
in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders
and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting of shareholders
on certain matters, such as an amendment to a company&#8217;s articles of association, an increase of a company&#8217;s authorized share
capital, a merger of a company and approval of interested party transactions that require shareholder approval. A shareholder also has
a general duty to refrain from discriminating against other shareholders. In addition, a controlling shareholder or a shareholder who
knows that it possesses the power to determine the outcome of a shareholders&#8217; vote or to appoint or prevent the appointment of an
office holder in a company or has another power with respect to a company, has a duty to act in fairness towards such company. Israeli
law does not define the substance of this duty of fairness and there is limited case law available to assist us in understanding the nature
of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities
on our shareholders that are not typically imposed on shareholders of U.S. corporations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to our Ordinary Shares</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may not be able to meet
the continued listing standards of Nasdaq, which require a minimum closing bid price of $1.00 per share, which could result in our delisting
and negatively impact the price of our ordinary shares and our ability to access the capital markets.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Our ordinary shares are listed on The Nasdaq Capital Market.&#160;The
Nasdaq Stock Market LLC, or the Nasdaq, provides various continued listing requirements that a company must meet in order for its shares
to continue trading on the exchange. Among these requirements is the requirement that our shares trade at a minimum bid price of $1.00
per share.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While currently we are in compliance with the applicable Nasdaq minimum bid price
rules, there is no assurance that our share price will trade&#160;at or above a minimum bid price of $1.00 per share and if we fail to
meet minimum listing requirements,&#160;there can be no assurance that we will be able to regain compliance with the applicable minimum
bid price rules or will otherwise be in compliance with other Nasdaq listing criteria. Any such delisting could adversely affect our ability
to obtain financing for the continuation of our operations and could result in the loss of confidence of investors, collaborators and
employees.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Future sales of our ordinary
shares or securities convertible or exchangeable for our ordinary shares may depress our share price.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If our existing shareholders or holders of our options sell, or indicate an intention
to sell, substantial amounts of our ordinary shares on the public market, the trading price of our ordinary shares could decline. The
perception in the market that these sales may occur could also cause the trading price of our ordinary shares to decline. As of December
31, 2024, we had a total of 89,541,246 ordinary shares outstanding.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Based on the number of shares subject to awards under our 2010 Share Incentive Plan,
as amended, or 2010 Plan, as of December 31, 2024, 9,864,993 ordinary shares that are subject to outstanding options and RSUs or reserved
for future issuance under our 2010 Plan were eligible for sale in the public market (with none under our 2021 Employee Shares Purchase
Plan, or ESPP), subject to vesting, and in the case of shares issued to directors, executive officers and other affiliates, the volume
limitations under Rule 144 under the Securities Act. If these additional ordinary shares are sold, or if it is perceived that they will
be sold, on the public market, the trading price of our ordinary shares could decline.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">43</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">In addition, our directors, executive officers and other affiliates may establish,
and certain executive officers and directors have established, programmed selling plans under Rule 10b5-1 of the Exchange Act, for the
purpose of effecting sales of our ordinary shares. Any sales of securities by these shareholders, or the perception that those sales may
occur, including the entry into such programmed selling plans, could have a material adverse effect on the trading price of our ordinary
shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">If we sell ordinary shares
in future financings, shareholders may experience immediate dilution and, as a result, our share price may decline.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In order to raise additional capital, we may at any time offer additional ordinary
shares or other securities convertible into or exchangeable for our ordinary shares, through our &#8220;at the market offering&#8221;
(ATM) facility pursuant to a sales agreement entered with Leerink Partners, or Leerink, on January 31, 2023 or other manners, at prices
that may not be the same as the price paid for our ordinary shares by our shareholders. The price per share at which we sell additional
ordinary shares, or securities convertible or exchangeable into ordinary shares, in future transactions may be higher or lower than the
price per share paid by our existing shareholders. If we issue ordinary shares or securities convertible into ordinary shares, our shareholders
will experience additional dilution and, as a result, our share price may decline.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, as opportunities present themselves, we may enter into financing or similar
arrangements in the future, including the issuance of debt securities or ordinary shares with or without additional securities convertible
or exchangeable into ordinary shares. Whether or not we issue additional shares at a discount, any issuance of ordinary shares will, and
any issuance of other equity securities or of options, warrants or other rights to purchase ordinary shares may, result in additional
dilution of the percentage ownership of our shareholders and could cause our share price to decline. New investors could also gain rights,
preferences and privileges senior to those of our shareholders, which could cause the price of our ordinary shares to decline. Debt securities
may also contain covenants that restrict our operational flexibility or impose liens or other restrictions on our assets, which could
also cause the price of our ordinary shares to decline.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Our share price and trading
volume have been volatile and may be volatile in the future and that could limit investors&#8217; ability to sell our shares at a profit
and could limit our ability to successfully raise funds.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During the 2024 calendar year, our closing share price on Nasdaq ranged from a low
of $1.41 to a high of $2.95 and trading volume was volatile. The volatile price of our shares and periodic volatile trading volume may
make it difficult for investors to predict the value of their investment, to sell shares at a profit at any given time, or to plan purchases
and sales in advance. A variety of factors may affect the market price of our ordinary shares including:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5fc6b810411b47c1ba7fe1f589c75063" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>global or regional macroeconomic developments;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc87954a57f65485fa24f3e4d54d66016" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>general market, political and economic conditions in the countries in which Compugen operates, including Israel, outbreak of disease,
        boycotts, curtailment of trade and other business restrictions and implementation of tariffs and the different effects of the evolving
        nature of global or regional events, including the current &#8220;Swords of Iron&#8221; war in Israel;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z34198a14d75a4695bcfe66a9da491a51" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>clinical data disclosed by us, our collaborators or our competitors;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8d018d2e861f48368db9942dcb918642" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>massive purchase or sell of our shares by a large shareholder;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zba16de9a87884d2ea3f9789550ab6826" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our success (or lack thereof) in entering into collaboration agreements and achieving certain research and developmental milestones
        thereunder;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2d4ff63959fe480ba892e73dbe62d12c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our need to raise additional capital and our success or failure in doing so;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z06221ac752134ed09a5b284cbc07e5b7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>achievement or denial of regulatory approvals by us, our collaborators or our competitors;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za1c8a5de938e47ae92c4fb169da1ac4f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>announcements of technological innovations or new commercial products by our competitors;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2165f2b73faf4654b6ffddc784a64421" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>trends in share price of companies in our field or industry;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z431b0c7c67c346cf8e9626cf2e5daa28" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>announcement of corporate transactions, merger and acquisition activities or other similar events by companies in our field or industry;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z028f88425e8c4c2bb7ff2247d9526cd1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes and developments effecting our field or industry;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2461a398689d4ff8ac68434b706e02b3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>developments concerning our existing or new collaborations;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zefc73e2e0fd64e2ba44d56dfedb93883" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>regulatory developments in the United States, Israel and other countries;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf88c5e077d0544e2935ce165f98bd228" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in the structure of healthcare payment systems;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">44</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc326bc392a16409abbd4b1e8a3b9fd20" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delay or failure by us or our collaborators in initiating, completing or analyzing preclinical or clinical trials or the unsatisfactory
        design or results of such trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z62893dd083b9469eb2aeefa5f9211c48" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>period to period fluctuations in our results of operations;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z36b75c3a94a147c4988136e4b9779670" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in estimates by securities analysts;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z70290064436240d688e530992db0c3db" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in senior management or the board of directors or changes in the size or structure of the company;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z92dbc4e6c7344cd0913cefedb7145440" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability (or lack thereof) to disclose the commercial terms of, or progress under, our collaborations; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfa08048e49c54040a56068731fbaabfa" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>transactions with respect to our ordinary shares by insiders or institutional investors.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are not able to control many of these factors, and we believe that period-to-period
comparisons of our financial results will not necessarily be indicative of our future performance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In addition, the stock market in general, and the market for biotechnology
companies in particular, have experienced extreme price and volume fluctuations that may be unrelated or disproportionate to the operating
performance of individual companies. These broad market and industry factors may seriously harm the market price of our ordinary shares,
regardless of our operating performance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Furthermore, the market prices of equity securities of companies
that have a significant presence in Israel may also be affected by the current and changing security situation in the Middle East and
particularly in Israel and the effect of the evolving nature of the &#8220;Swords of Iron&#8221; war and the general situation in the
area. As a result, these companies may experience volatility in their stock prices and/or difficulties in raising additional financing
required to effectively operate and grow their businesses. Thus, market and industry-wide fluctuations and political, economic and military
conditions in the Middle East, but also in the United States and worldwide may adversely affect the trading price of our ordinary shares,
regardless of our actual operating performance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">As a result of the volatility of our share price, in addition to
other potential adverse effect on us, we could be subject to securities litigation, which could result in substantial costs and divert
management&#8217;s attention and company resources from our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Because we do not intend to declare cash dividends
on our ordinary shares in the foreseeable future, shareholders must rely on appreciation of the value of our ordinary shares for any return
on their investment and may not receive any funds without selling their ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We have never declared or paid cash dividends on our ordinary shares
and do not anticipate declaring or paying any cash dividends in the foreseeable future. In addition, the terms of any future debt agreements
may preclude us from paying dividends. As a result, we expect that only appreciation of the price of our ordinary shares, if any, could
provide a return to investors in the foreseeable future. In addition, because we do not intend to declare cash dividends on our ordinary
shares in the foreseeable future, if our shareholders want to receive funds in respect of our ordinary shares, they must sell their ordinary
shares to do so.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Our ordinary shares are traded on more than one market and this
may result in price variations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to being traded on The Nasdaq Capital Market, our ordinary shares are
also traded on the Tel Aviv Stock Exchange, or TASE. Trading in our ordinary shares on these markets take place in different currencies
(dollars on Nasdaq and NIS on the TASE), and at different times (resulting from different time zones, trading days and public holidays
in the United States and Israel). The trading prices of our ordinary shares on these two markets may differ due to these and other factors.
Any decrease in the price of our ordinary shares on one market could cause a decrease in the trading price of our ordinary shares on the
other market.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If we are a passive foreign investment company,
or PFIC, our U.S. shareholders may be subject to adverse U.S. federal income tax consequences.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">For U.S. federal income tax purposes, we generally will be classified
as a PFIC for any taxable year in which, after the application of certain look-through rules with respect to our subsidiaries, either:
(i) 75% or more of our gross income is passive income or (ii) at least 50% of the average value (determined on the basis of a weighted
quarterly average) of our total assets for the taxable year produce or are held for the production of passive income. For purposes of
these tests, passive income includes, among other things, dividends, interest, and gains from the sale or exchange of investment property
and certain rents or royalties (excluding rents and royalties that are received from unrelated parties in connection with the active conduct
of a trade or business). Assets that produce or are held for the production of passive income may include cash (unless held in a non-interest
bearing account for short term working capital needs), marketable securities, and other assets that may produce passive income. Generally,
in determining whether a non-U.S. corporation is a PFIC, a non-U.S. corporation that directly or indirectly owns at least 25% by value
of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such
corporation.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">45</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Based on our analysis of our estimated income, estimated assets,
activities and market capitalization, we believe that we were not a PFIC for the taxable year ended December 31, 2024. However, the determination
of whether or not we are a PFIC is a fact-intensive determination made on an annual basis and because the applicable law is subject to
varying interpretations, we cannot provide any assurance regarding our PFIC status and our U.S. counsel expresses no opinion with respect
to our PFIC status for any taxable year. If we are classified as a PFIC for any taxable year during which a U.S. shareholder holds our
ordinary shares, U.S. investors could be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including
the treatment of gains realized on the sale of our ordinary shares as ordinary income, rather than as capital gain, the loss of the preferential
rate applicable to dividends received on our ordinary shares by individuals who are U.S. holders (as defined in &#8220;Item 10. Additional
Information - E. Taxation - Certain Material U.S. Federal Income Tax Considerations to U.S. Holders&#8221;), the addition of interest
charges on certain taxes treated as deferred taxes, and additional reporting requirements. A U.S. shareholder of a PFIC generally may
mitigate these adverse U.S. federal income tax consequences by making a &#8220;qualified electing fund&#8221; election, or QEF election,
or, in some circumstances, a &#8220;mark to market&#8221; election. We may provide the information necessary for U.S. holders to make
QEF elections if we were treated as a PFIC for any taxable year. There is no assurance that we will have timely knowledge of our status
as a PFIC in the future. Accordingly, U.S. holders may be unable to make a timely QEF election with respect to our ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">For further discussion of the PFIC rules and the adverse U.S. federal
income tax consequences in the event we are classified as a PFIC, as well as certain elections that may be available to U.S. holders,
see &#8220;Item 10. Additional Information - E. Taxation - Certain Material U.S. Federal Income Tax Considerations to U.S. Holders &#8211;
Passive Foreign Investment Company Rules&#8221;.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If we are a controlled foreign corporation,
there could be materially adverse U.S. federal income tax consequences to certain U.S. Holders of our ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in
a non-U.S. corporation that is classified as a controlled foreign corporation, or a &#8220;CFC&#8221;, for U.S. federal income tax purposes
generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s
&#8220;Subpart F income&#8221; (as defined below), &#8220;global intangible low taxed income,&#8221; and investment of earnings in U.S.
property, regardless of whether we make any distributions. Subpart F income generally includes dividends, interest, rents, royalties,
gains from the sale of securities and income from certain transactions with related parties. In addition, a Ten Percent Shareholder that
realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather
than capital gain. An individual that is a Ten Percent Shareholder with respect to a CFC generally would not be allowed certain tax deductions
or foreign tax credits that would be allowed to a Ten Percent Shareholder that is a U.S. corporation. We cannot provide any assurance
that we will assist investors in determining whether we or any of our future non-U.S. subsidiaries are treated as a CFC or furnish to
any U.S. holder the information required to comply with the reporting and tax-paying obligations discussed above. Failure to comply with
these reporting obligations may subject a Ten Percent Shareholder to significant monetary penalties and may prevent the statute of limitations
with respect to such Ten Percent Shareholder&#8217;s U.S. federal income tax return for the year for which reporting was due from starting.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">A non-U.S. corporation generally will be classified as a CFC for
U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting
power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten
Percent Shareholder&#8221; is a United States person (as defined by the Internal Revenue Code of 1986, as amended, or, the Code) who owns
(directly or indirectly) 10% or more of the total combined voting power of all classes of stock entitled to vote or 10% or more of the
total value of all classes of stock of such corporation.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">46</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The determination of CFC status is complex and includes attribution
rules, the application of which is not entirely certain. In addition, changes to the attribution rules relating to the determination of
CFC status may make it difficult to determine our CFC status for any taxable year. Because our group includes at least one U.S. subsidiary
(Compugen USA, Inc.), those changes to the attribution rules may cause any non-U.S. subsidiaries that we form or acquire in the future
to be treated as controlled foreign corporations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Each U.S. holder (as defined in Item 10. Additional Information
&#8211; E. Taxation &#8211; Certain Material U.S. Federal Income Tax Considerations to U.S. Holders) should consult its own tax advisors
with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC. If we are classified as both
a CFC and a PFIC (as defined above), we generally will not be treated as a PFIC with respect to those U.S. holders that meet the definition
of a Ten Percent Shareholder during the period in which we are a CFC.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Shareholder activism can negatively affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In recent years, shareholder activists have become involved in
numerous public companies. Shareholder activists could propose involving themselves in the governance, strategic direction and operations
of a company. In general, shareholder activism, including potential proxy contests, diverts management&#8217;s and board of directors&#8217;
attention and resources from the company&#8217;s business, could give rise to perceived uncertainties as to the company&#8217;s future
direction and could result in the loss of potential business opportunities and make it more difficult to attract and retain qualified
personnel for positions in both management and on the board level and to raise funds. If nominees advanced by activist shareholders are
elected or appointed to our board of directors with a specific agenda, it may adversely affect our ability to effectively and timely implement
our strategic plans or to realize long-term value from our assets. Also, we may be required to incur significant expenses including legal
fees related to activist shareholder matters. Further, our share price could be subject to significant fluctuations or otherwise be adversely
affected by the events, risks and uncertainties of any shareholder activism.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-weight: bold">General Risks</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Unfavorable global or domestic political or economic conditions
could adversely affect our business, financial condition or results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The global economy continues to experience significant volatility,
and the economic environment may continue to be, or become, less favorable than that of past years. Higher costs for goods and services,
inflation, deflation, trade tensions, global geopolitical tensions, the imposition of tariffs or other measures that create barriers to
or increase the costs associated with international trade, overall economic slowdown or recession and other economic factors in Israel,
the United States or in any other markets in which we operate could adversely affect our operations and operating results. A severe or
prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including inability
to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our CDMOs and CROs,
possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which
the current economic climate and financial market conditions could adversely impact our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In addition, the effect of the &#8220;Swords of Iron&#8221; war
and the hostilities as specified in our risk factors, as and stated above together with the political and civil actions in Israel which
commenced in the beginning of 2023, resulting from, among other things, proposed changes to certain Israeli constitutional legislation,
and the downgrading in Israel&#8217;s credit rating as stated above, may have an adverse effect on the Israeli social, economic and political
landscape and in turn, on us. Furthermore, although to date we have not been directly impacted by the current military conflict between
Russia and Ukraine, this conflict, or any expansion thereof, could disrupt or otherwise adversely impact our operations and those of third
parties upon which we rely. Related sanctions, export controls or other actions have been or may in the future be initiated by nations
including the United States, the European Union or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could
adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with whom we conduct business. Any of the
foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market
conditions could adversely impact our business.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Environmental, social and governance matters may impact our business
and reputation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In addition to the importance of their financial performance, companies
are being increasingly judged by their performance on a variety of environmental, social and governance, or ESG, matters, which are considered
to contribute to the long-term sustainability of companies&#8217; performance.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">47</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">A variety of organizations measure the performance of companies
on such ESG topics, and the results of these assessments are widely publicized. In addition, investment in funds that specialize in companies
that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance
of such ESG measures to their investment decisions. Topics taken into account in such assessments include, among others, the company&#8217;s
efforts and impacts on&#160;climate&#160;change&#160;and human rights, ethics and compliance with the law, and the role of the company&#8217;s
board of directors in supervising various sustainability issues. In addition to the topics typically considered in such assessments, in
the healthcare industry, issues of the public&#8217;s ability to access a company&#8217;s medicines are of particular importance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In light of investors&#8217; increased focus on ESG matters, there
can be no certainty that we will manage such issues successfully, or that we will successfully meet society&#8217;s expectations as to
our proper role. Our actual or perceived failure to meet investors, partners or employees&#8217; expectations on ESG matters could adversely
affect our brand and reputation, our employees&#8217; engagement and reputation, and the willingness of our partners to do business with
us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Global trade issues and
changes in and uncertainties with respect to trade policies and export regulations, including import and export license requirements,
trade sanctions, tariffs and international trade disputes, could adversely impact our business and operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">There is inherent risk, based on the complex relationships among
the United States and the countries in which we conduct our business, that political, diplomatic, and national security factors can lead
to global trade restrictions and changes in trade policies and export regulations that may adversely affect our business and operations.
The United States and other countries have imposed and may continue to impose new trade restrictions and export regulations, have levied
tariffs and taxes on certain goods, and could significantly increase tariffs on a broad array of goods. While pharmaceutical products
have customarily been granted exemptions from tariffs, recent proposals do not contemplate such exemptions. Trade restrictions and export
regulations, or increases in tariffs and additional taxes, including any retaliatory measures, can negatively impact demand, increase
our supply chain complexity and our manufacturing costs, decrease margins, reduce the competitiveness of our products, or restrict our
ability to sell products, provide services or purchase necessary equipment and supplies, any or all of which could have a material and
adverse effect on our business, results of operations, or financial condition.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Climate&#160;change, or
legal or regulatory measures to address&#160;climate&#160;change, may negatively affect us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Climate&#160;change resulting from increased concentrations of
carbon dioxide and other greenhouse gases in the atmosphere could present risks to our operations. For example, we have operations in
California, where serious drought has made water less available and more costly and has increased the risk of wildfires as experienced
in January 2025. Changes in&#160;climate&#160;patterns leading to extreme heat waves or unusual cold weather at some of our locations
can lead to increased energy usage and costs, or otherwise adversely impact our facilities and operations and disrupt our supply chains
and distribution systems. Concern over&#160;climate&#160;change can also result in new or additional legal or regulatory requirements
designed to reduce greenhouse gas emissions or mitigate the effects of&#160;climate&#160;change on the environment. Any such new or additional
legal or regulatory requirements may increase the costs associated with, or disrupt, sourcing, manufacturing and distribution of our products,
which may adversely affect our business and financial results. In addition, our adoption of certain standards or mandated compliance with
certain requirements could necessitate additional investments that could impact our cash position and expected cash runway.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold"><span id="ITEM4."><!--Anchor--></span>ITEM 4.</span> <span style="font-weight: bold">INFORMATION
ON THE COMPANY</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HISTORY AND DEVELOPMENT OF THE COMPANY</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">History</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our legal and commercial name is Compugen Ltd. We were incorporated on February 10,
1993, as an Israeli corporation and operate under the Companies Law. Our principal offices are located at 26 Harokmim Street, Holon 5885849,
Israel, and our telephone number is +972-3-765-8585. Our web address is <span style="font-style: italic">www.cgen.com</span>. Information
contained on our website does not constitute a part of this Annual Report. The SEC maintains an internet site, http://www.sec.gov that
contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Neither
such internet addresses are a part of this Annual Report.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">48</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Our agent for service of process in the United States is Compugen USA, Inc., our wholly
owned U.S. subsidiary located at 225 Bush Street, Suite 348, San Francisco, CA 94104, which was incorporated in Delaware in March 1997
and is qualified to do business in California. This subsidiary did not have any significant operations from 2008 to March 2012.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-weight: bold">Principal Capital Expenditures</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the years ended December 31, 2024, 2024 and 2022, our capital expenditures were
0.1 million, $0.2 million and $0.4 million, respectively. As of December 31, 2024, we had no significant commitments for capital expenditures.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">B. BUSINESS OVERVIEW</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Summary</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">We are a clinical-stage therapeutic discovery and development company utilizing our AI/ML powered predictive
computational discovery platform, recently branded as Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>,
to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapy. Our innovative immuno-oncology pipeline
consists of four clinical stage programs, COM701, COM902, rilvegostomig and GS-0321 (previously COM503). Two programs that we are pursuing
internally, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody,
are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1,
PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. We have two ongoing clinical trials (that completed enrollment) initiated in 2023
evaluating the triple combination treatment of COM701, COM902 and pembrolizumab, one in platinum resistant ovarian cancer and the other
in microsatellite stable colorectal cancer, both of which have together a few patients on treatment as of the middle of February 2025.
In addition, we are initiating our new adaptive platform trial in relapsed platinum sensitive ovarian cancer. In this trial we will first
evaluate COM701 as a monotherapy randomized to placebo in double-blinded sub-trial 1 in total of 60 patients. We plan to start enrollment
in the second quarter of 2025 and we expect to share interim analysis data from this sub-trial in the second half of 2026. Rilvegostomig,&#160;a
PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from our COM902 program, is being developed by AstraZeneca pursuant
to an exclusive license agreement between us and AstraZeneca and is being evaluated in multiple Phase 3 clinical trials and in multiple
Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503) our potential first-in-class high affinity antibody, which blocks the
interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being developed by us in a recently initiated Phase
1 clinical trial. In addition, we have an early-stage immuno-oncology therapeutic pipeline that consists of research programs aiming to
address various mechanisms to enhance anti-cancer immunity.</div> </div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">Our business model is to selectively enter into collaborations for our novel targets
and drug product candidates at various stages of research and development under various revenue-sharing arrangements. Integrating cutting
edge computational capabilities with ground-breaking immuno-oncology research and drug development expertise is our differentiator and
has enabled us to advance drug targets from computer prediction through successful preclinical studies to the clinic. Therefore, we believe
that we are uniquely positioned to discover and develop potential novel, first-in-class treatment options for cancer patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our Strategy</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We aim to transform patient lives by developing first-in-class therapeutics in the
field of cancer immunotherapy based on our AI/ML powered predictive computational discovery platform, named Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>.
We employ and leverage our key differentiator, the integration of cutting edge computational capabilities with ground-breaking immuno-oncology
research and drug development expertise &#8211; in the competitive landscape of immuno-oncology to build our pipeline with potential first-in-class
drugs:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zcd35d663060b4dfe8ddca58446b2350a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We discover novel drug targets with the potential to address the unmet need of patients non-responsive to current cancer immunotherapies</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z23c83eb5cd5d4168b7dfebeebe6362ac" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We harness our Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup> capabilities to inform our
        target validation and drug development process; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z3a31ff9d64494c4a821b9298ed18b7b2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We apply our capabilities to inform on the program&#8217;s mechanism of action, relevant indication/patient population, drug combinations
        and potential biomarker that may fit for future patient selection.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">49</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">We believe that the totality of these capabilities uniquely positions us in the discovery
and the development of first-in-class drugs for cancer immunotherapy.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">In our clinical therapeutic pipeline, our most advanced programs are:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zcae68144d12042b5a65c290cf3bbb672" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">COM701 </span>is our internal lead immuno-oncology pipeline program. COM701 is a humanized antibody
        that binds with high affinity to PVRIG, a novel immune checkpoint target candidate discovered by us that blocks the interaction with its
        ligand, PVRL2. Our data suggests that PVRIG has a unique biology, differentiated from other checkpoints. PVRIG is dominantly expressed
        in stem-like memory T cells (TSCM) and PVRL2 is expressed in dendritic cells. Therefore, PVRIG blockade might induce potent induction
        of T cell numbers in tumors and unleash antitumor immunity also in indications less responsive to other checkpoint inhibitors, such as
        ovarian cancer. In addition, our data suggests that the PVRIG pathway is parallel and complementary to the TIGIT pathway. These two pathways
        intersect with DNAM-1, a costimulatory receptor on T cells and NK cells. The PD-1 pathway also intersects with DNAM-1. We believe that
        in certain tumors, and in certain patient populations, the simultaneous blockade of these pathways may be required to stimulate an antitumor
        immune response. Phase 1 clinical trials for COM701 were initiated in September 2018.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zd622b751bec4458c9872e5e97e1e5072" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">COM902</span> is a high affinity, fully human antibody developed by us, targeting TIGIT, an immune
        checkpoint discovered computationally by us. COM902 blocks the interaction of TIGIT with PVR, its ligand. COM902 is potential best-in-class
        antibody with a non-active Fc tail. COM902 prevents depletion of major TIGIT<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">+</sup>
        expressing lymphocytes (NK, CD4 and CD8 T cells), supporting rationale for selecting a high affinity anti-TIGIT antibody with an IgG4
        backbone and low Fc effector function. Phase 1 clinical trials for COM902 were initiated in March 2020.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z7ecca5243815444e86e287cc70f486dd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Rilvegostomig</span>&#160;is a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived
        from COM902 and is being developed by AstraZeneca pursuant to an exclusive license agreement with AstraZeneca. AstraZeneca initiated its
        first Phase 3 clinical trial at the end of 2023 dosing its first patient in such trial in December 2023 and now rilvegostomig&#160;is
        being evaluated in multiple Phase 3 clinical trials and in multiple Phase 2 and Phase 1 clinical trials. In addition, AstraZeneca is also
        running several Phase 1 and 2 clinical trials with rilvegostomig in additional indications.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zb8b6663dd24144b4b3c0829fbcce168e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">GS-0321 (previously COM503) </span>is a potential first-in-class high affinity antibody, which blocks
        the interaction between interleukin-18 binding protein (IL18BP) and interleukin-18 (IL-18). The inflammasome-induced pro-inflammatory
        cytokine, IL-18, is present at high levels in the tumor microenvironment, where it is expected to naturally activate anti-tumor effector
        cells, such as T and NK cells. Nevertheless, IL-18 is one of the rare cytokines that is naturally blocked by an endogenous high affinity
        inhibitor, called IL-18BP. GS-0321 (previously COM503) was designed to free natural IL-18 activity in the tumor microenvironment by releasing
        it from IL-18BP, thereby increasing the local concentrations of IL-18 within the tumor where it can potentiate anti-tumor immune responses,
        potentially overcoming the limitations of systemically administered cytokines. GS-0321 (previously COM503) is licensed to Gilead and is
        being developed by us in a Phase 1 clinical trial and recently entered into the clinic with the first patient having been dosed on January
        7, 2025. The Phase 1 clinical trial is design to assess the safety and tolerability of GS-0321 (previously COM503) as monotherapy and
        in combination with zimberelimab in participants with advanced solid tumors.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25">In addition to our clinical therapeutic pipeline, we also have rights to bapotulimab,
an antibody targeting ILDR2, a drug target discovered by us, which was licensed for further research and development to Bayer, under a
research and discovery collaboration and license agreement, the RDCLA. Bapotulimab has been evaluated in Phase 1 clinical trials in na&#239;ve
head and neck squamous cell carcinoma patients and as of February 27, 2023, the license granted to Bayer was terminated, and the rights
previously licensed to Bayer reverted us, at which time, we also exercised our right to get a license to certain intellectual property
rights developed by Bayer under such license agreement. We have the right to continue the development and commercialization of bapotulimab,
should we choose to do so.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Research Focus - Immuno-Oncology</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our research and development efforts focus on identifying novel drug targets and developing
first-in-class therapeutics in the field of cancer immunotherapy.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">50</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Cancer immunotherapies represent a significant commercial market. The global immune
checkpoint inhibitors market size is estimated at $50.28 billion in 2024 and is anticipated to reach around $229.60 billion by 2034, expanding
at a compounded annual growth rate of 16.40% from 2024 to 2034, as reported by Precedence Research.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The immune system is naturally programmed to seek out and destroy abnormal cells.
Cancer is believed to thrive, in part, because of a number of cellular mechanisms that aid in the evasion of immune response. Such mechanisms
of immune system evasion include masking or reducing the expression of tumor antigens to avoid detection, recruiting T-cell suppressor
cells or expressing inhibitory molecules that suppress immune activation, inducing conditions in the tumor microenvironment that promote
tumor cell proliferation and survival, and a number of other factors. Immuno-oncology therapies that overcome immune suppression by stimulating
responses directed to cancer cells are emerging as a powerful means of counteracting the cellular mechanisms that enable the growth and
spread of tumors. Immuno-oncology agents are expanding as a potential path to durable and long-lasting responses in certain patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">Our discovery strategy is focused on the discovery of novel drug targets which may provide new cancer immunotherapies
for enhancing anti-tumor immune responses in cancer patients.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">While immunotherapy revolutionized the landscape for oncology treatments by providing
a new treatment option leading to lasting benefits for some patients; the response rates to immunotherapy vary greatly across different
cancer indications. However, only a small proportion of patients respond to these therapies, averaging approximately between 15% to 30%
overall, and by some reports 20%-40%, thereby leaving a significant unmet medical need for many patients that may be addressed by the
discovery of new biological pathways that could serve for the development of new cancer immunotherapies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Therapeutic Pipeline</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf75d74fb878e458d934afb3a44db64b0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-style: italic; font-weight: bold">COM701 - a therapeutic antibody targeting PVRIG</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="margin-left: 36pt; line-height: 1.25; font-style: italic">Pathway expression and preclinical data</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">COM701 is a potentially first-in-class humanized antibody that
binds with high affinity to PVRIG, a novel immune checkpoint target candidate discovered by Compugen, blocking the interaction with its
ligand, PVRL2. Blockade of PVRIG by COM701 has demonstrated potent, reproducible enhancement of T cell activation, consistent with the
desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. In addition,
COM701 combined with PD-1 pathway blockers have demonstrated synergistic effects in enhancing human T cell stimulation and inhibiting
tumor growth in murine models, supporting the suggested intersection of the PVRIG and PD-1 inhibitory pathways and the potential of these
combinations to further enhance immune response against tumors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">PVRIG and TIGIT constitute parallel immune checkpoint pathways
that interact with DNAM-1, a costimulatory molecule on T cells and NK cells. While PVRIG and TIGIT are complementary and part of the same
biological axis,&#160;our research&#160;shows that they are in fact distinct. PVRIG and TIGIT bind to different ligands (PVRL2 and PVR,
respectively), they are expressed on different immune cell types and their ligands have different expression patterns.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">51</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">Furthermore, our data show that PVRIG is expressed in stem-like memory T cells (TSCM) and PVRL2 is expressed
in dendritic cells, as well as in PD-L1 low&#160;less inflamed tumors. Therefore, this unique expression pattern and resulted biology
might enable PVRIG blockade to be active in patients with less inflamed tumors, such as ovarian cancer. In addition, expression studies
showed that PVRIG, TIGIT, and their respective ligands, are expressed in a broad variety of tumor types, with ovarian cancer having one
of the highest expressions of the pathway. <span style="font-family: Times New Roman, Times, serif">These two pathways intersect with
DNAM-1, a costimulatory receptor on T cells and NK cells. The PD-1 pathway also intersects with DNAM-1. In certain tumors, and in certain
patient populations, the simultaneous blockade of these pathways may be required to stimulate an antitumor immune response. We have two
ongoing clinical trials (that completed enrollment) that were both initiated in 2023 evaluating the triple combination treatment of COM701,
COM902 and pembrolizumab, one in platinum resistant ovarian cancer and the other in microsatellite stable colorectal cancer, both of which
have together a few patients on treatment as of the middle of February 2025. We plan to start a new adaptive platform trial in relapsed
platinum sensitive ovarian cancer. In this trial we will first evaluate COM701 in total of 60 patients in a randomized, double-blinded&#160;sub-trial
1 as a monotherapy versus placebo. We plan to start enrolling patients to this sub-trial in the second quarter of 2025</span>.</div>

<div style="line-height: 1.25">&#160;</div> </div> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-weight: bold">COM701 Clinical Programs</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In September 2018, we dosed our first patient in the Phase 1 clinical
trial of COM701 and through December 31, 2024, we conducted multiple Phase 1 studies across tumor types, patient populations and combinations.
Below is a table showing key COM701 expansion cohorts efficacy data as monotherapy and in combinations disclosed in scientific conferences.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="3" border="0" id="z99a9a8023aa241e7a8f9846a93f4f437" style="font: 10pt Times New Roman,Times,serif; width: 100%; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.62%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Tumor</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.73%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Treatment</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 13.3%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Median prior lines</div>
        </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 19.34%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Best Response</div>
        </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.91%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Description</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 14.09%; vertical-align: middle; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Reference</div> </td>
        </tr>
  <tr>
    <td rowspan="4" style="border-top: rgb(0, 0, 0) 2px solid; width: 16.62%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Platinum resistant<br/> ovarian cancer</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.73%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">COM701</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 13.3%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">6 across indications</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 19.34%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">1/6 ORR (16.6%)</div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">4/6 DCR (66%)</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.91%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">1 PR &gt;18 months~* in immune desert TME</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 14.09%; vertical-align: middle; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">ASCO 2021</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.73%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">COM701 + nivolumab</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 13.3%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">6</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 19.34%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">2/20 ORR (10%)</div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">9/20 DCR (45%)</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.91%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">1 PR in patient refractory to nivolumab</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 14.09%; vertical-align: middle; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">ESMO IO 2022</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.73%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">COM701 + nivolumab + BMS-986207</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 13.3%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">4</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 19.34%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">4/20 ORR (20%)</div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">9/20 DCR (45%)</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.91%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">3 PR &gt;16 months*</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 14.09%; vertical-align: middle; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">ESMO IO 2022</div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">SITC 2023</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.73%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">COM701 + pembrolizumab +COM902</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 13.3%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">4</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 19.34%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">4/24 ORR (17%)</div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">11/24 DCR (46%)</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.91%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">5 patients on treatment for &gt;200 days</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 14.09%; vertical-align: middle; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">SITC 2024</div> </td> </tr>
  <tr>
    <td rowspan="2" style="border-top: rgb(0, 0, 0) 2px solid; width: 16.62%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">MSS CRC with liver metastases</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.73%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">COM701 + nivolumab</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 13.3%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">4</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 19.34%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">2/17 ORR (12%)</div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">4/17 DCR (24%)</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.91%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">1 PR in patient with immune desert TME</div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">1 PR &gt;11 months</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 14.09%; vertical-align: middle; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">SITC 2022</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.73%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">COM701+ COM902+ pembrolizumab</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 13.3%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">3</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 19.34%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">1/15 ORR (7%)</div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">6/15 DCR (40%)</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.91%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">1 PR &gt; 9 months* in patient who had PD on chemo + bev (post data cut patient reassessed as non- target
        liver lesion of uncertain etiology at baseline)</div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">2 SD &gt;7 months*</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 14.09%; vertical-align: middle; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">ASCO 2024</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.62%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">ICI experienced NSCLC</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.73%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">COM701 &#177; nivolumab</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 13.3%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">6, &#8805; 2 prior ICI</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 19.34%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">5/7 DCR (71%)</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.91%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">3 SD on COM701 monotherapy</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 14.09%; vertical-align: middle; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">ESMO IO 2022</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.62%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Recurrent metastatic MSS endometrial cancer</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.73%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">COM701 + nivolumab + BMS-986207</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 13.3%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">2, 33% prior PD1x</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 19.34%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">2/9 ORR (22%)</div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">4/9 DCR (44%)</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.91%; vertical-align: middle; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">1 PR in patient refractory to lenvatinib/ pembrolizumab</div>
        </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 14.09%; vertical-align: middle; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">ASCO 2023</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.62%; vertical-align: middle; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Metastatic breast cancer</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.73%; vertical-align: middle; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">COM701 + nivolumab</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 13.3%; vertical-align: middle; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">5</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 19.34%; vertical-align: middle; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">2/17 ORR (12%)</div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">5/17 DCR (30%)</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.91%; vertical-align: middle; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">1 CR &gt; 21 months*, low immunogenic HER2 negative tumor</div>
        </td>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 14.09%; vertical-align: middle">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">SITC 2023</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In connection with the table above, BMS-986207 is Bristol Myers
Squibb anti-TIGIT; ICI is Immune checkpoint inhibitor; CR is Complete Response; PR is Partial Response; SD is Stable Disease; PD is Progressed
Disease; ORR is Overall Response Rate; DCR is Disease Control Rate. *Ongoing at time of data cut-off; ~ means that patient had primary
peritoneal cancer.</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"> <br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">52</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="text-decoration: underline">Clinical data disclose
from COM701 related studies in 2024 (covered in the table above as well)</span>:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">On June 1, 2024, at the American Society of Clinical Oncology (ASCO)
annual meeting in Chicago, Illinois we presented a poster with new clinical data on COM701 (anti-PVRIG) in triple combination with&#160;COM902
(anti-TIGIT) and pembrolizumab&#160;in microsatellite stable colorectal cancer (MSS-CRC).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Conclusions from the poster provided that:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z14088e368a4043b1a8a59ef46929b42a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>In this phase Ib expansion cohort of participants with heavily pre-treated advanced MSS-CRC, majority with liver metastases, the
        triplet combination administered every 3 weeks was well tolerated.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z90e84e8531e84f98997e60827ffde142" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The safety profile of the triplet combination was generally consistent with that of pembrolizumab and other approved PD-[L]1 inhibitors.</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z232e75f2f2084272a34235a77d025e91" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Exploratory analysis demonstrated antitumor activity: overall response rate (ORR) (1/20, 5%), disease control rate (DCR) (8/20) 40%,
        best response of partial response (PR) in 1 patient with 3 patients (1PR, 2stable diseases (SDs)) remaining on treatment at the data cut
        of April 5, 2024.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zad10d05db6454883915c698c2a71de7c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Pharmacodynamic activation of the immune system in the tumor and blood was observed, supportive of COM701 driven anti-tumor activity.
        Such activation was not previously reported in MSS-CRC with PD-[L]1 inhibitors.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z951edca4eca74265915671f614b3987c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Among the cohort reported here and in the prior reported data, we have shown that COM701 has a clinical benefit, is well tolerated
        and induced immune activation in a traditionally immune therapy resistant population of MSS-CRC.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">On November 8, 2024, at the 39<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>&#160;Annual
Meeting of SITC in Houston, Texas we presented a poster with new clinical data on triple combination of COM701, COM902 and pembrolizumab
in advanced heavily pre-treated patients with platinum resistant ovarian cancer (PROC).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Conclusions from the poster provided that:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf4ef05594ffd4b5ab2e06097fa63f493" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>This ongoing Phase I expansion cohort confirms previous findings showing encouraging efficacy and safety of triple blockade of the
        DNAM-1 axis in advanced heavily pre-treated PROC patients, where 36% of the population had been on other investigational agents prior
        to trial entry.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z0b7e9d36f70740499f23ce0165fc488b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The safety and tolerability profile were generally consistent with approved anti-PD-(L)1s.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z62eb038d46d2460c83fe41b3b1bb08e8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Clinical benefit, with deep and durable responses was observed in patients with high-grade adenocarcinoma, in a patient with carcinosarcoma
        - historically nonresponsive to immune checkpoint inhibitors (ICIs), and in patients previously exposed to ADCs and other investigational
        drugs.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z6e7c8e3f34484b4ab8bba432f5a2cc88" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>ORR 17%, DCR 46%, clinical benefit rate (CBR) 29%, with 4 patients still on treatment at data cut of August 29, 2024.</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="ze6af6a0bf22c439ebf0250cc7b01f651" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Robust pharmacodynamic activation of the immune system was observed on treatment.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="za8d85e44c0f447aeac780c40ab2ab650" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Lower concentrations of immunosuppressive cytokines prior to and on treatment were associated with a clinical benefit.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z8070bd2824a046499ef00001e50e06f6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-style: italic; font-weight: bold">COM902 - a therapeutic antibody targeting TIGIT</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-style: italic">Pathway expression and preclinical data</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">COM902 is a high affinity, fully human and a potentially best-in-class
antibody targeting TIGIT with a non-active Fc tail. COM902 was shown to have superior binding affinity to T cells with similar and or
greater in vitro function compared to several clinical anti-TIGIT antibodies. COM902 is a mouse-cross reactive Ab and inhibited tumor
growth and increased survival when combined with anti-PVRIG or anti-PD-[L]1 antibodies in in-vivo studies. Preclinical data demonstrated
that TIGIT inhibition, either alone or in combination with other checkpoint inhibitors, can enhance T&#160;cell activation and increase
anti-tumor immune responses. In preclinical studies, parallel inhibition of TIGIT and PVRIG, two coinhibitory arms of the DNAM-1 axis,
resulted in synergistic effects on effector T&#160;cell function and tumor growth inhibition in various model systems that can be further
increased with the addition of PD-1 blockade. Based on preclinical data these combinations may be clinically important for enhancing anti-tumor
immune response and expanding the patient population responsive to checkpoint inhibition.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">53</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">We discovered TIGIT in 2009 with our immune checkpoint computational
discovery capabilities through which PVRIG was also discovered. The TIGIT discovery was published by us in October 2009 in the Proceedings
of the National Academy of Sciences (PNAS).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Expression studies show that PVRIG and TIGIT, and their respective
ligands, are expressed in a broad variety of tumor types, such as breast, endometrial, ovarian, lung, kidney, and head &amp; neck cancers.
These results indicate that within the same tumor indications there are variations with respect to the possible dominance of the two pathways,
and that in patient populations where the two pathways are operative, the blockade of both TIGIT and PVRIG may be required to sufficiently
stimulate an anti-tumor immune response.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-style: italic">Clinical Development</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In March 2020, we dosed our first patient in the Phase 1 clinical
trial of COM902. COM902 was primarily evaluated in combination with COM701.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">While we completed enrollment of our clinical trials with COM902
as combination and as of the middle of February 2025 we continue monitoring a few of the patients that are still on treatment, our newly
planned adaptive platform trial in patients with relapsed platinum sensitive ovarian cancer in the maintenance setting is expected to
first evaluate single agent COM701 and only then may cover future combinations, which may include COM902. Therefore, in the near future
we do not expect to have new meaningful data from our COM902 program, however we do expect data of other companies that develop their
own anti-TIGIT antibodies and from our partner AstraZeneca for rilvegostomig (a PD-1/TIGIT bi-specific antibody with a TIGIT component
that is derived from our COM902).</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">For information regarding the evaluation of COM902 in combination
with COM701, see &#8220;COM701 Clinical Programs&#8221; above.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2f12c3aa12dd416abd6d836c7ff00c5d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div><span style="font-weight: bold; font-style: italic">Rilvegostomig - a therapeutic PD-1/TIGIT bi-specific antibody with a TIGIT component
        that is derived from our COM902</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Rilvegostomig is a PD-1/TIGIT bi-specific antibody with a TIGIT
component that is derived from our COM902 being developed by AstraZeneca pursuant to an exclusive license between us and AstraZeneca.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In March 2018, we entered into an exclusive license agreement with
AstraZeneca, pursuant to which, we granted to AstraZeneca an exclusive license to use our monospecific antibodies that bind to TIGIT,
including COM902, for the development of bi-specific and multi-specific antibody products, excluding such bi-specific and multi-specific
antibodies that also bind to PVRIG, PVRL2 and/or TIGIT.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Rilvegostomig is currently being evaluated by AstraZeneca in multiple
Phase 3 clinical trials and multiple Phase 2 and Phase 1 clinical trials with the first patient having been dosed in the first Phase 3
clinical trial in December 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcca8f34998eb46f2a419ee9324c7202b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div><span style="font-weight: bold">GS-0321 (previously COM503) - </span><span style="font-weight: bold; font-style: italic">a therapeutic
        antibody targeting IL-18 binding protein</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">GS-0321 (previously COM503) is a potential first-in-class high
affinity antibody, which blocks the interaction between interleukin-18 binding protein (IL18BP) and interleukin 18 (IL-18). The inflammasome-induced
pro-inflammatory cytokine, IL-18, is present at high levels in the tumor microenvironment, where it is expected to naturally activate
anti-tumor effector cells, such as T and NK cells. Nevertheless, IL-18 is one of the rare cytokines that is naturally blocked by an endogenous
high affinity inhibitor, called IL-18BP. GS-0321 (previously COM503) was designed to free natural IL-18 activity in the tumor microenvironment
by releasing it from IL-18BP, where it can potentiate anti-tumor immune responses, potentially overcoming the limitations of systemically
administered cytokines. GS-0321 (previously COM503) is licensed to Gilead and is being developed by us in a Phase 1 clinical trial.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">54</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-style: italic">Clinical Development</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In January 2025 we dosed the first patient in the dose escalation
monotherapy cohort of the Phase 1 clinical trial, which is expected to enroll up to 200 participants, to evaluate GS-0321 (previously
COM503) as monotherapy and in combination with zimberelimab in advanced solid tumors.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zb42fd42535054a04b8863c826e541eed" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-style: italic; font-weight: bold">Bapotulimab (formerly known as BAY1905254) &#8211; a therapeutic antibody targeting
        CGEN-15001T/ILDR2</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Bapotulimab (formerly known as BAY1905254, an antibody to ILDR2
(formerly CGEN-15001T), a novel immune checkpoint target discovered by Compugen, was developed with Bayer pursuant to a research and discovery
collaboration and license agreement signed in August 2013. See &#8220;Business Strategy and Partnerships - Bayer Collaboration&#8221;
below. Studies testing the immune function of ILDR2 demonstrated inhibitory effects on T cells consistent with it being an immune checkpoint
ligand. ILDR2 appears to have a unique mechanism of action relative to other immune checkpoints currently being targeted in clinical testing.
ILDR2 is expressed in lymph nodes, suggesting that bapotulimab&#160;exerts its effects on immune cell priming rather than on directly
enhancing immune cell killing effects in the tumor microenvironment.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In April 2018, Bayer disclosed bapotulimab&#160;a human/monkey/mouse
cross-reactive antibody blocking the immunosuppressive activity of ILDR2. Bapotulimab has exhibited anti-tumor activity as a monotherapy
in various mouse models and was also shown to have additive anti-tumor effects in combination with other cancer therapy approaches, indicating
the possibility for multiple combination uses in cancer immunotherapy.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Under the collaboration agreement, bapotulimab&#160;was previously
evaluated by Bayer in a Phase 1 expansion trial in combination with Keytruda, in head and neck cancer that has returned or is discovered
to be metastatic and is expressing PDL1 to evaluate the combination treatment.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">On November 29, 2022, Bayer notified us that it has resolved to
terminate, effective as of February 27, 2023, our 2013 research and development collaboration and license agreement.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In accordance with the terms of said agreement, we obtained from
Bayer such rights necessary to allow us to continue the development and commercialization of bapotulimab, should we choose to do so.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Biomarker Driven Strategy</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We recognize that one of the major limitations of current immunotherapy approaches
is the lack of tools to help predict patient responses. By applying the integration of Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>
with our ground-breaking immuno-oncology research and drug development expertise, we aim to identify biomarkers that can help us predict
which patients are most likely to respond to our novel therapies. This long-term approach also seeks to improve the probability of success
of our clinical studies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">We currently&#160;apply these capabilities in three different areas.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">Firstly, we are computationally analyzing omics data using our Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>
platform to identify tumor indications in which the pathway of our target plays a role. This analysis is thereafter validated experimentally,
and the validated data is used for indication selection for our clinical trials.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">55</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Secondly, the identification of potential biomarkers for future patient selection.
In this approach, we are using various cutting-edge technologies and methodologies on both biopsies, liquid biopsies, and blood samples.
The different technologies may include immunohistochemistry, transcriptomic, genomic and proteomic analysis. The generated data is added
to the Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM </sup>platform databases and then analyzed computationally
to identify potential biomarkers for patient selection and used in discovery projects aimed at uncovering potential novel drug targets.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Thirdly, we apply a pharmacodynamic biomarker approach where we measure immune modulation
induced by our drug candidates in peripheral and tumor patient samples obtained before and during treatment in our clinical trials. In
this analysis we may measure both protein and sequence analytics, such as cytokine analysis, immune phenotyping, proteomic changes, transcriptomics
analysis, and TCR clonality. This again may serve for the identification of potential biomarkers and may also inform us on the suggested
mechanism of action of our drug candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Early-Stage Pipeline</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Immuno-oncology represents a paradigm shift in the treatment of cancer, and biological
drugs blocking immune checkpoint targets have already resulted in long-term patient survival in certain cancer types. Despite their potential,
current checkpoint inhibitors are limited to a few targets and are only effective in certain patients and in certain cancers. We believe
that the identification of novel drug targets has the potential to broaden the reach of cancer immunotherapies to more types of cancers
and many more patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">Our early-stage research programs are discovered using our Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>
platform and consist of drug targets which may provide new cancer immunotherapies for patients non-responsive to current cancer therapies.</div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Our Predictive Computational Discovery Approach</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our target discovery is a predictive, proprietary computational process that we initiate
based on a clinical need. The unmet clinical need and the therapeutic strategy dictate the target discovery approach, the appropriate
tools and most relevant data to be employed. We have developed predictive drug target discovery capabilities that leverage the power of
computational modeling, guided by our scientific expertise and extensive public and proprietary datasets, to identify novel drug targets
towards the development of new cancer immunotherapy treatments. Our multi-omics data analysis is designed to identify novel drug target
candidates, which are generally difficult to identify using traditional experimental approaches.&#160;We believe that our cutting-edge
computational capabilities integrated with our ground-breaking immuno-oncology research and drug development expertise is a key differentiator
from others employing computational discovery approaches.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our broadly applicable predictive drug target discovery capabilities employ a suite
of cloud-based computational solutions and purpose-built algorithms to sort through both public and proprietary datasets encompassing
genomics, single cell and spatial transcriptomics, proteomics and machine learning based analysis of IHC images. From these massive datasets,
our platforms analyze characteristics, such as gene structure, protein domains, predicted cellular localization, expression pattern, as
well as other characteristics to identify potential druggable targets and predict their biological functions. Over the past decade, we
have continued to refine our analysis by incorporating new public and in-house experimental data and added AI/ML powered tools and recently
branded this entire platform as Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM </sup>platform.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have demonstrated the applicability of our discovery approach in computationally
identifying multiple in-silico targets, including&#160;PVRIG,&#160;TIGIT, IL-18BP&#160;and&#160;ILDR2, the first three now serve as the
targets for therapeutic antibodies currently being evaluated in the clinic by us and others. The antibodies designed to block these targets
are or have been evaluated in clinical trials by us (COM701, COM902 and GS-0321 (previously COM503)) or by our partners (bapotulimab and
rilvegostomig).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Business Strategy and Partnerships</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business strategy includes entering into various forms of revenue-sharing collaborations
with pharmaceutical or biotechnology partners for our novel drug targets and product candidates at various stages of research and development.
Such collaborations or other types of partnering arrangements might include one or more of our therapeutic pipeline programs. Through
these collaborations we seek to generate, further develop and commercialize our therapeutic product candidates. Additionally, our discovery
capabilities designed to feed our internal pipeline may allow for future research and discovery collaborations aimed at harnessing our
capabilities towards a potential partner&#8217;s pipeline needs. Potential revenue sources in line with this business strategy could include
upfront fees, research funding, in-kind funding, milestones payments, license fees, royalties and other revenue sharing payments. We may
also seek co-development arrangements pursuant to which we would further advance partnered programs under any such partnership in order
to potentially retain a higher share of proceeds from future collaborations.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">56</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Gilead License Agreement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On December 18, 2023, we entered into the License Agreement, pursuant to which we
granted Gilead an exclusive license under our preclinical antibody program against IL-18 binding protein and all intellectual property
rights subsisting therein, to use, research, develop, manufacture and commercialize products, including GS-0321 (previously COM503), and
additional products that may be so developed by Gilead, together with GS-0321 (previously COM503), referred to herein as the Licensed
Products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">Pursuant to the License Agreement, Gilead paid us a $60 million upfront license payment ($51 million net
after $9 million were withheld at source) in January 2024 and additional $30 million ($25.5 million net after $4.5 million were withheld
at source) as a milestone payment upon clearance of the IND application for GS-0321 (previously COM503) in the third quarter of 2024.
We are also eligible to receive up to approximately $758 million in additional milestone payments upon the achievement of certain development,
regulatory and commercial milestones. We are further eligible to receive single-digit to low double-digit tiered royalties on worldwide
net sales of Licensed Products. We are required to make certain upstream payments to certain service providers with respect to the Licensed
Products.</div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are responsible for conducting a Phase 1 clinical trial for GS-0321 (previously
COM503), including handling the regulatory matters in connection therewith, and will bear the costs of such trial (including the GS-0321
(previously COM503) drug supply), with Gilead providing at no cost its anti-PD-1 antibody, zimberelimab, for such trial. In certain circumstances,
Gilead may assume the role of conducting the Phase 1 clinical trial.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Upon completion of the Phase 1 clinical trial for GS-0321 (previously COM503), we
will initiate the transfer of development activities related to GS-0321 (previously COM503) to Gilead, following which, Gilead will have
sole responsibility to develop and commercialize the Licensed Products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During the term of the License Agreement, we are prohibited from researching, developing,
making and commercializing any compounds, molecules, products or treatment methods that are directed to IL-18 or any companion diagnostics
for an IL-18 product.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Unless terminated early by a party pursuant to its terms, the License Agreement will
continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term
in such country.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Gilead withheld at source 15% from the upfront payment and the milestone payment amount
paid to us in January 2024 and in September 2024, respectively, and is expected to continue to withhold at source all taxes required by
law from all payments payable to us under the License Agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The License Agreement contains customary representations, warranties, covenants, and
terms governing the prosecution and enforcement of certain intellectual property and issues related to technology transfer, manufacturing
transfer, provisions with respect to establishment of joint steering committee and its governance covenants with respect change of control
and others.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">AstraZeneca License</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In March 2018, we entered into an exclusive license agreement with AstraZeneca, to
enable the development of bi-specific and multi-specific immuno-oncology antibody products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the terms of the license agreement, we granted an exclusive license to AstraZeneca
to use our monospecific antibodies that bind to TIGIT, including COM902, for the development of bi-specific and multi-specific antibody
products, excluding such bi-specific and multi-specific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. AstraZeneca has the right
to create multiple products under this license and is solely responsible for all research, development and commercial activities under
the agreement. In connection with such license agreement, AstraZeneca developed rilvegostomig, a novel PD-1/TIGIT bi-specific antibody
with a TIGIT component that is derived from our COM902 and entered the clinic in September 2021 and initiated Phase 3 with first patient
dosing in December 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">57</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">We received a $10&#160;million upfront payment and are eligible to receive up to $200
million in development, regulatory and commercial milestones for the first product as well as mid-single-digit tiered royalties on future
product sales, out of which we accrued $2 million in 2020 as a preclinical milestone, $6 million in 2021 as a clinical milestone (triggered
by the dosing of the first patient in a Phase 1/2 clinical trial evaluating rilvegostomig), additional $7.5 million in 2022 as a clinical
milestone (triggered by the dosing of the first patient in its ARTEMIDE Phase 2 clinical trial evaluating rilvegostomig), additional $10
million in 2023 as a clinical milestone (triggered by the dosing of the first patient in its ARTEMIDE-Bil01&#160;Phase 3 clinical trial
evaluating rilvegostomig), and an additional $5 million in 2024 (triggered by dosing of the first patient in the second Phase 3 clinical
trial evaluating rilvegostomig). If additional products are developed, additional milestones and royalties would be due to us for each
product. In 2024, AstraZeneca provided a non-risk adjusted peak year revenue target for rilvegostomig of over $5 billion.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Subject to termination rights for material breach, bankruptcy or by us for patent
challenge by AstraZeneca, the term of the license agreement continues until the expiration of the last Royalty Term in the Territory,
each as defined in the license agreement. In addition, AstraZeneca may terminate the agreement for convenience upon prior written notice.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Bayer Collaboration</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On August 5, 2013, we entered into a collaboration with Bayer, or the Bayer Collaboration,
for the research, development, and commercialization of antibody-based therapeutics against two novel Compugen-discovered immune checkpoint
regulators, CGEN 15001T/ILDR2 and CGEN 15022.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the terms of the Bayer Collaboration, we received an upfront payment of $10
million, and, following the return of the CGEN 15022 program to us, we were eligible to receive an aggregate of over $250 million in potential
milestone payments for bapotulimab&#160;(formerly known as BAY1905254) (an antibody against CGEN 15001T/ILDR2), not including aggregate
milestone payments of approximately $23 million received to date for four different milestones achieved.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On November 29, 2022, Bayer notified us that it has resolved to terminate, effective
as of February 27, 2023, our 2013 research and development collaboration and license agreement.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In connection with the termination, we obtained from Bayer the rights necessary to
allow us to continue the development and commercialization of bapotulimab, should we choose to do so.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Bristol Myers Squibb Collaboration</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On October 10, 2018, we entered into a master clinical trial collaboration agreement,
or the MCTC, with Bristol Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol Myers Squibb&#8217;s
PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The collaboration was also designed to address potential future combinations. The
parties agreed that Bristol Myers Squibb and Compugen will each supply the other company with its own compound for the other party&#8217;s
trial, and otherwise each party will be responsible for all costs associated with the trial that it is conducting.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the terms of MCTC, as amended from time to time, we conducted triple combination
clinical trials to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and
Bristol Myers Squibb&#8217;s investigational antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, and
dual combination clinical trials to evaluate the dual combination of COM701 and Opdivo&#174; in patients with advanced solid tumors. In
all these clinical trials we were responsible for and sponsored all the clinical trials and Bristol Myers Squibb provided us with Opdivo&#174;
and BMS-986207 at no cost to us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The MCTC provided Bristol Myers Squibb a right to negotiate a license for commercialization
and further provided Bristol Myers Squibb with certain exclusivity rights.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In conjunction with the signing of the MCTC in October 2018, Bristol Myers Squibb
made a $12&#160;million investment in us and in conjunction with the signing one of the amendments to the MCTC in November 2021, Bristol
Myers Squibb made additional $20 million investment in us. In both investments, the share price paid by Bristol Myers Squibb represented
a 33% premium over the closing price of our ordinary shares on the last trading day immediately prior to the execution of the applicable
securities purchase agreement. In these two investments, we issued to Bristol Myers Squibb 4,757,058 ordinary shares aggregately.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On August 3, 2022, we entered into a letter agreement with Bristol Myers Squibb pursuant
to which the MCTC between the parties was terminated as of such date and all ongoing clinical trials at the time of the termination entered
into a winding down process. Please see &#8220;Item 5. Operating and Financial Review and Prospects - B. Liquidity and Capital Resources.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">58</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold">Competition</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The biotechnology and pharmaceutical industries are highly competitive and characterized
by the rapid evolution of new technologies and the adoption of new therapies. Additionally, the oncology therapeutic space, represents
the therapeutic area with what we believe to be one of the highest industry focus and investment. In addition, in recent years, computational
approaches and systems are being integrated into multiple life science aspects, including the formation of new companies focusing on computational
drug target discovery. Our competitors include biotechnology and pharmaceutical companies both small and large, the research and discovery
groups within pharmaceutical companies, computational discovery and development companies, academic and research institutions, newly founded
companies and governmental and other publicly funded agencies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any product candidates that we successfully develop will compete with currently approved
therapies and new therapies that may become available in the future. We face, and expect to continue to face, ongoing competition from
entities that discover novel targets and develop novel products, and that have therapeutic product candidates or products that address
the same drug targets or act by similar, or possibly identical, mechanism of action (MOA) as well as by different mechanisms but address
the same drug target or patient population or unmet clinical need. Our potential competitors are also comprised of companies that discover
and develop monoclonal antibody therapies and/or therapeutic proteins to novel targets, and/or other modalities, including cell therapies
for oncology diseases. Specifically, in the field of immune checkpoints for cancer immunotherapy, there are several leading pharmaceutical
and biotechnology companies as well as smaller biotechnology companies and academic institutions that are developing cancer immunotherapies
to enhance immune response towards tumors, some of which may be based on the same targets we pursue. For examples of the competition we
face, see &#8220;Item 3. Key Information - D. Risk Factors - Risks Related to Intellectual Property - If the scope of any patent protection
we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing
similar or identical product candidates would be adversely affected.&#8221; and &#8220;Item 3. Key Information &#8211; D. Risk Factors
- Risks Related to Competition and Commercialization - We operate in a highly competitive and rapidly changing industry which may result
in others discovering, developing or commercializing competing products ahead of us or more successfully than we do.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our discovery program depends, in large part, on our computational discovery capabilities
in integration with our immuno-oncology experimental capabilities and drug development capabilities as well as our proprietary data to
make inventions and establish intellectual property rights in our drug target candidates and product candidates. There are additional
companies exploring computational approaches and systems for drug target discovery and other means by which such inventions and intellectual
property can be generated. We believe that our computational capabilities, and specifically our Unigen<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>
platform, provide us with a competitive advantage in predicting protein functions and linking proteins to specific mechanisms and diseases,
and as a result, predicting novel immuno-oncology drug targets. We believe that this advantage is made possible by building an integrated
immuno-oncology platform for predictive discovery based on the integration of scientific understanding and predictive models as well as
our unique team of multidisciplinary research scientists, who have vast experience in computational discovery, including developing and
handling advance data science approaches, and who over time discovered four drug targets that entered clinical trials and have generated
peer reviewed publications in scientific journals.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We also face competition from companies that utilize AI/ML for target discovery in
the field of immuno-oncology/cancer, some of which besides utilizing a computational platform for target discovery, also perform the molecule
discovery. For more information on this matter, please see relevant information &#8220;Item 3. Key Information - D. Risk Factors - Risks
Related to Intellectual Property - If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our
patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely
affected.&#8221; and &#8220;Item 3. Key Information &#8211; D. Risk Factors - Risks Related to Competition and Commercialization - We
operate in a highly competitive and rapidly changing industry which may result in others discovering, developing or commercializing competing
products ahead of us or more successfully than we do.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We anticipate that we will face intense and increasing competition as advanced technologies
or new therapy modalities become available.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">59</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold">Intellectual Property Rights</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our intellectual property assets are our principal assets. These assets include the
intellectual property rights subsisting in our proprietary know-how and trade secrets underlying our predictive biology capabilities and
discovery capabilities, our patents and patent applications, particularly with respect to our discovered proteins, therapeutic and diagnostic
product candidates. We seek to vigorously protect our rights and interests in our intellectual property. We expect that our commercial
success will depend on, among other things, our ability to obtain commercially valuable patents, especially for our therapeutic and diagnostic
product candidates, maintain the confidentiality of our proprietary know-how and trade secrets, and otherwise protect our intellectual
property. We design our patent strategy to fit the business competitive landscape and continual legislative changes. In addition, we periodically
analyze and examine our patent portfolio to align it with our pipeline strategy and business needs. We seek patent protection for certain
promising inventions that relate to our therapeutic and diagnostic product candidates. As of February 1, 2025, we had a total of 62 issued
and allowed patents, of which 15 are U.S. patents, 6 are European patents and additional 41 patents in other territories. Our issued and
allowed patents expire between 2028 and 2038. As of February 1, 2025, we had over 184 pending patent applications that have been filed
in the United States, Europe and in other territories as well as pending patent applications that have been filed under the Patent Cooperation
Treaty for which we have not yet designated the countries of filing. The patents issued in the U.S. and Europe for COM701 and COM902 were
issued between 2017 and 2024 and should expire no earlier than 2036. These patents include issued claims directed to, among others, the
composition of these product candidates and/or methods of using the same to treat cancer by activating T cells and/or NK cells, and/or
combinations of our product candidates with other checkpoint inhibitors. Our general policy is to continue patent filings and maintenance
for our therapeutic and diagnostic product candidates, only with respect to candidates or programs that are being actively pursued internally
or with partners, or that we believe to have future commercial value. We routinely abandon patent applications and may choose to abandon
maintenance of patents supporting candidates or programs that do not meet these criteria.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We also seek protection for our proprietary know-how and trade secrets that are not
protectable or protected by patents, by way of safeguarding them against unauthorized disclosure. This is done through the extensive use
of confidentiality agreements and assignment agreements with our employees, consultants and third parties as well as by technological
means. We use license agreements both to access third-party technologies and to grant licenses to third parties to exploit our intellectual
property rights.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are currently party to several oppositions in different stages. For information
about our oppositions, see &#8220;Item 3. Key Information &#8211; D. Risk Factors - Risks Related to Intellectual Property - If the scope
of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors
from commercializing similar or identical product candidates would be adversely affected.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Manufacturing</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently rely on contract manufacturers or our collaborative partners to produce
and control materials, drug substances and drug products required for the research and development activities. We do not currently own
or operate manufacturing facilities for the production of clinical or commercial quantities of our therapeutic drug candidates. We do
not have, and we do not currently plan to acquire or develop the facilities or capabilities to manufacture bulk drug substance or filled
drug product for use in human clinical trials. We rely on CMOs, advisors and third-party contractors to generate formulations and produce
small scale and larger scale amounts of GLP, cGMP clinical and commercial drug substance and the drug product required for our clinical
trials for the foreseeable future. We also contract with CMOs and third-party contractors for the labeling, packaging, storage and distribution
of investigational drug products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We entered into agreements with certain CMOs for the manufacturing and respective
analytics of COM701, COM902 and GS-0321 (previously COM503). Our manufacturing strategy is currently structured to support the current
clinical development of COM701 and COM902 and GS-0321 (previously COM503) (for which we are responsible for the Phase 1 development).
Although we believe the general manufacturing strategy developed for the United States or in Europe will be applicable in other geographies,
specific strategies for other geographies will be developed, if required, as part of our clinical and commercial plans for such other
geographies. See &#8220;Item 3. Key Information - D. Risk Factors - Risks Related to Our Dependence on Third Parties - We rely and expect
to continue to rely completely on third parties to manufacture and supply our preclinical and clinical drug supplies. Our business could
be harmed if those third parties fail to provide us with sufficient quantities of drug product or fail to do so at acceptable quality
and quantity levels, prices or timelines.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">60</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold">Government Regulation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Regulation of Therapeutic Product Candidates</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the United States, the FDA regulates pharmaceutical and biologic products under
the Federal Food, Drug, and Cosmetic Act, or FDCA, the&#160;Public Health Service Act, other statutes and regulations and implementing
regulations. We anticipate that our product candidates will be regulated as biologics. The process of obtaining regulatory approvals and
the subsequent compliance with applicable federal, state and local statutes and regulations require the expenditure of substantial time
and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process,
approval process or after approval, may subject an applicant to administrative or judicial sanctions. The process required by the FDA
before a biologic may be marketed in the United States generally involves the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z517ed798608244a98d078b1d2c6a703d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>completion of preclinical laboratory tests and animal studies in compliance with the FDA&#8217;s GLP or other applicable regulations;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z42ebd57273164954bce23560573bcace" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>submission to the FDA of an IND, which must become effective before human clinical trials may begin;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1d7ba7cfdf514911bc9add02a7fbf384" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>performance of adequate and well-controlled human clinical trials in accordance with GCPs to establish the safety and efficacy of
        the product for its intended use;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6a03cd7a910d4ca2b4d0474973bcb07e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>submission of annual reports to regulatory authorities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb60e9c149a6048b380baa854dc584c8e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>submission to the FDA of a biologics license application, or BLA;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z544b13b8b0484238a4a69731ef9a62bb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug or biologic is produced
        to assess compliance with current Good Manufacturing Practice, or cGMP, to assure that the facilities, methods and controls are adequate
        to preserve the product&#8217;s identity, strength, quality and purity; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6ea388cd978c4637a9aded2353006fa9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>FDA review and approval of the BLA.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Once a pharmaceutical candidate is identified for development, it enters the preclinical
testing stage. Preclinical tests include, among others, laboratory evaluations of product function, toxicity and formulation as well as
animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical
data, among other information, to the FDA as part of the IND. The sponsor will also include a clinical protocol detailing, among other
things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. The IND automatically becomes effective 30 days after
receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND
sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the
FDA at any time before or during a clinical trial due to, among other things, safety concerns or non-compliance with applicable requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All clinical trials must be conducted under the supervision of one or more qualified
investigators in accordance with GCPs. An IRB at each institution participating in the clinical trial must review and approve the trial
plan for any clinical trial before it commences at that institution. An IRB considers, among other things, whether the risks to individuals
participating in the trials are minimized and are reasonable in relation to anticipated benefits. The IRB also reviews the information
regarding the trial, participant recruiting materials and the informed consent form that must be provided to each trial subject or his
or her legal representative before participating in the trial. In addition, the IRB will monitor the trial until completed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Each new clinical trial protocol must be submitted to the FDA, and to the IRBs. Protocols
detail, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety and determine efficacy.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Human clinical trials are typically conducted in three phases that may overlap or
be combined:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z46aa4ffd80864b2d8efdbb329d17c5f7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-style: italic">Phase 1: </span>The product candidate is initially introduced into healthy human subjects and tested
        for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of<span style="font-style: italic">&#160;</span>some
        products, usually for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer
        to healthy volunteers, the initial human testing may be conducted in patients.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7c85f9a794a44466a2c77981fb9c860f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-style: italic">Phase 2: </span>Involves studies in a limited patient population to identify possible adverse effects
        and safety risks, to preliminarily evaluate the efficacy of the product for specific<span style="font-style: italic">&#160;</span>targeted
        diseases and to determine dosage tolerance and optimal dosage.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc56240cb96054d76b77af83e8b9b708d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-style: italic">Phase 3: </span>Involves studies undertaken to further evaluate dosage, clinical efficacy and safety
        in an expanded patient population at geographically dispersed clinical trial sites.<span style="font-style: italic">&#160;</span>These
        studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling and
        approval.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">61</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Progress reports detailing the results of the clinical trials must be submitted at
least annually to the FDA and safety reports for serious and unexpected adverse events must be submitted to the FDA and the investigators
more frequently. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding
that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval
of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the applicable regulations or IRB
requirements or if the drug has been associated with unexpected serious harm to patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Concurrent with clinical trials, companies usually complete additional nonclinical
studies and must also finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.
The manufacturing process must be capable of consistently producing quality batches of the product within required specifications and,
among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the product. Additionally,
appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product does not undergo
unacceptable deterioration over its shelf life.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic">United States Review and Approval Processes</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The results of product development, nonclinical studies and clinical trials, along
with descriptions of the manufacturing process, analytical tests, proposed labeling, and other relevant information are submitted to the
FDA as part of a BLA requesting approval to market the product for one or more indications. The FDA initially reviews all BLAs submitted
to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional
information rather than accept a BLA for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review.
The FDA may refer the BLA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved
and under what conditions. The FDA is not bound by the recommendation of an advisory committee.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The review process is lengthy, and the FDA may issue a complete response letter rather
than approve a BLA if the applicable regulatory criteria are not satisfied or may require the submission of additional clinical or other
data and information. Even if such data and information are submitted, the FDA may ultimately decide that the BLA does not satisfy the
criteria for approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If a product receives regulatory approval, the approval will be limited to specific
diseases and dosages or the approved indications for use may otherwise be limited, which could restrict the commercial value of the product.
In addition, the FDA may require a company to conduct post-approval testing and clinical trials, to further assess a product&#8217;s safety
and effectiveness after BLA approval and may require testing and surveillance programs to monitor the safety of approved products which
have been commercialized including Risk Evaluation and Mitigation Strategy (REMS) programs to ensure that the benefits of a product outweigh
its risks.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic">Post-approval Requirements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Approved biologics are subject to extensive and continuing regulation by the FDA,
including, among other things, cGMP compliance, record-keeping requirements, reporting of adverse experiences, providing the FDA with
updated safety and efficacy information, and complying with FDA promotion and advertising requirements. After an approval is granted,
the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if serious problems occur after the
product reaches the market. Biologics may be promoted for use only for the approved indication or indications and in accordance with the
provisions of the approved label. The FDA and other federal and state agencies actively enforce the laws and regulations prohibiting the
promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to criminal and civil
penalties.<span style="font-style: italic">&#160;</span>However, physicians may, in their independent medical judgment, prescribe legally
available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA
does restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic">Other Healthcare Laws</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our current and future business operations, including, among other things, our clinical
research activities and our business and financial arrangements and relationships with healthcare providers, physicians and other parties
through which we may market, sell and distribute our products, once approved, may be subject to extensive U.S. federal, U.S. state and
foreign healthcare fraud and abuse, transparency, and data privacy and security laws. For example, U.S. federal civil and criminal laws
and regulations prohibit, among other things: knowingly and willfully soliciting, receiving, offering or providing remuneration, directly
or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending or arranging for a good or service,
for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs; knowingly presenting or
causing to be presented, a false or fraudulent claim for payment by a federal healthcare program; and knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program (including a private payor), or knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for,
healthcare benefits, items or services. Many U.S. states and foreign countries have analogous prohibitions that may be broader in scope
and apply regardless of payor. In addition, we may be subject to U.S. federal, U.S. state and foreign laws that require us to report information
related to certain payments and other transfers of value to certain health care professionals, as well as ownership and investment interests
in our company held by those health care professionals and their immediate family members, and data security and privacy laws that restrict
our practices with respect to the use and storage of certain data.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">62</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Efforts to ensure that our current and future business arrangements with third parties
comply with applicable healthcare laws and regulations may involve substantial costs. If we are found to be in violation of any of these
laws, we could be subject to significant civil, criminal and administrative penalties, including damages, fines, disgorgement, imprisonment,
exclusion from participation in government healthcare programs, additional integrity oversight and reporting obligations, contractual
damages, reputational harm and the curtailment or restructuring of our operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic">Healthcare Policy and Reform</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ability to commercialize our future therapeutic product candidates successfully,
alone or with collaborators, will depend in part on the extent to which coverage and reimbursement for these product candidates will be
available from government health programs, such as Medicare and Medicaid in the United States, private health insurers and other third-party
payors. At present, significant changes in healthcare policy, in particular the continuing efforts of the U.S. and other governments,
insurance companies, managed care organizations and other payors to contain or reduce health care costs are being discussed, considered
and proposed.&#160;Drug prices in particular are under significant scrutiny and continue to be subject to intense political and societal
pressures, which we anticipate will continue and escalate on a global basis.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For example, in the United States, there have been several initiatives implemented
to achieve these aims. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation
Act, collectively, the ACA, substantially changed the way healthcare is financed by both governmental and private insurers and significantly
affects the pharmaceutical industry. With regard to biopharmaceutical products, the ACA has, among other things, expanded and increased
industry rebates for products covered under Medicaid programs and changed the coverage requirements under the Medicare Part D program.
There have been congressional, judicial, and executive branch challenges and amendments to the ACA, which has resulted in delays in the
implementation of, and action taken to repeal or replace, certain aspects of the ACA. For example, on August 16, 2022, the Inflation Reduction
Act of 2022, or the IRA, was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance
coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program
beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount
program. It is possible that the ACA will be subject to judicial or congressional challenges in the future. It is unclear how other such
challenges and any additional healthcare reform measures of the Biden administration will impact the ACA and the pharmaceutical industry.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, other legislative changes have been proposed and adopted since the ACA
was enacted. The Budget Control Act of 2011, triggered automatic reduction to several government programs, including reductions to Medicare
payments to providers, which went into effect in April 2013 and will remain in effect until 2032, unless additional congressional action
is taken.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">63</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Additionally, there has been increasing legislative and enforcement interest in the
United States with respect to drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries, presidential
executive orders and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription
drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement
methodologies for drugs. For example, the IRA, among other things, (i) directs the Secretary of HHS to negotiate the price of certain
high-expenditure, single-source drugs that have been on the market for at least 7 years and biologics that have been on the market for
at least 11 years covered under Medicare Part B and Medicare Part D, and subjects drug manufacturers to civil monetary penalties and a
potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law,
or the Medicare Drug Price Negotiation Program, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases
that outpace inflation. These provisions began to take effect progressively in fiscal year 2023. On August 15, 2024, the U.S. Department
of Health and Human Services, or HHS, announced the agreed-upon price of the first ten drugs that were subject to price negotiations,
although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. HHS will select up to fifteen additional
drugs covered under Part D negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare
Drug Price Negotiation Program.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We cannot predict what healthcare reform initiatives may be adopted in the future,
particularly in light of recent U.S. Presidential and Congressional elections. However, we anticipate that Congress, state legislatures,
and third-party payors may continue to review and assess alternative healthcare delivery and payment systems and may in the future propose
and adopt legislation or policy changes or implementations effecting additional fundamental changes in the healthcare delivery system.
We also expect ongoing legislative and regulatory initiatives to increase pressure on drug pricing.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Coverage and Reimbursement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Market acceptance of products is dependent on the extent to which coverage and reimbursement
is available from third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any products for which
we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives
are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover
our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments
that patients find unacceptably high. Coverage and reimbursement policies for products can differ significantly from payor to payor as
there is no uniform policy of coverage and reimbursement for products among third party payors in the United States. Further, coverage
policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained
for a product for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in
the future. Additionally, we, or our collaborators, may develop companion diagnostic tests for use with our product candidates, once approved.
We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and
reimbursement we seek for our product candidates, once approved.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Non-U.S. Regulations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to regulations in the United States, biologics are subject to a variety
of foreign laws and regulations governing clinical trials and commercial sales and distribution before they may be sold outside the United
States. Whether or not we obtain FDA approval for a product, we must obtain the necessary approvals from comparable regulatory authorities
of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies
from country to country and the time may be longer or shorter than that required for FDA approval. In some countries, we will also have
to get pricing approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Environmental Regulation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Some of our research and development activities involve the controlled use of biological
and chemical materials, a small amount of which could be considered to be hazardous. We are subject to laws and regulations in the U.S.,
European Union and Israel governing the use, storage, handling and disposal of all these materials and resulting waste products. We store
relatively small amounts of biological and chemical materials. To our knowledge, we substantially comply with these laws and regulations.
However, the risk of accidental contamination or injury from these materials cannot be entirely eliminated. In the event of an accident,
we could be held liable for any resulting damages, and any liability could exceed our resources.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">64</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Regulation of Use of Human Tissue</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We need to access and use various human or non-human tissue samples for the purpose
of research, development and/or validation of some of our product candidates. Our access and use of these samples are subject to government
regulation, in the United States, Israel and elsewhere and may become subject to further regulation. The use of clinical data associated
with human tissue samples is also heavily regulated in the United States, Israel and elsewhere. United States and other governmental agencies
may also impose restrictions on the use of data derived from human or other tissue samples.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Regulations Concerning the Use of Animals in Research</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We also are subject to various laws and regulations regarding laboratory practices
and the use of animals in our research. In the United States, the FDA regulations describe good laboratory practices, or GLPs, for various
types of nonclinical laboratory studies that support or are intended to support applications for research or marketing permits for products
regulated by the FDA, including INDs. Nonclinical animal studies conducted by us or third parties on our behalf may be subject to the
U.S. Animal Welfare Act, the U.S. Public Health Service Policy on Humane Animal Care and Use, U.S. Department of Agriculture regulations
for certain animal species or applicable laws and regulations of other countries where we or third parties on our behalf conduct these
studies. In Israel, the Council on Animal Experimentation has regulatory and enforcement powers, including the ability to suspend, change
or withdraw approvals, among other powers. To our knowledge, we and the third-party service providers we work with, as applicable, substantially
comply with these regulatory requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Regulation of Products Developed with the Support of Research and
Development Grants</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For a discussion of regulations governing products developed with research and development
grants from the Government of Israel, see &#8220;Item 5. Operating and Financial Review and Prospects - C. - Research and Development,
Patents and Licenses - The Israel Innovation Authority.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. ORGANIZATIONAL STRUCTURE</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We were incorporated under the laws of the State of Israel on February 10, 1993, as
Compugen Ltd., which is both our legal and commercial name. Compugen USA, Inc., our wholly owned subsidiary, was incorporated in Delaware
in March 1997 and is qualified to do business in California.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. PROPERTY, PLANTS AND EQUIPMENT</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In December 2015, we moved to our facilities in Holon, Israel where we leased an aggregate
of approximately 35,250 square feet of office, biology laboratory facilities and warehouse. Following the exercise of our first option,
we lease 30,140 square feet under that lease that expires on March 14, 2026 (with an option to extend the lease for additional five-year
period). In addition, Compugen USA, Inc. currently leases approximately 400 square feet of office space in San Francisco, California,
under a lease that expires on October 31, 2025.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">To our knowledge, there are no environmental issues that affect our use of the properties
that we lease.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold"><span id="ITEM4A."><!--Anchor--></span>ITEM 4A.</span> <span style="font-weight: bold">UNRESOLVED
STAFF COMMENTS</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">None</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold"><span id="ITEM5."><!--Anchor--></span>ITEM 5.</span> <span style="font-weight: bold">OPERATING
AND FINANCIAL REVIEW AND PROSPECTS</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">The following discussion of our operating and financial
review and prospects should be read in conjunction with our consolidated financial statements and related notes, prepared in accordance
with U.S. GAAP as of December 31, 2024, and with any other financial data included elsewhere in this Annual Report</span>.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">65</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Background</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">We are a clinical-stage therapeutic discovery and development company utilizing our AI/ML powered predictive
computational discovery platform, recently branded as Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>,
to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapy. Our innovative immuno-oncology pipeline
consists of four clinical stage programs, COM701, COM902, rilvegostomig and GS-0321 (previously COM503). Two programs that we are pursuing
internally, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody,
are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1,
PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. We have two ongoing clinical trials that were both initiated in 2023 (with enrollment
completed) evaluating the triple combination treatment of COM701, COM902 and pembrolizumab, one in platinum resistant ovarian cancer and
the other in microsatellite stable colorectal cancer, both of which have together a few patients on treatment as of the middle of February
2025. In addition, we are initiating our new adaptive platform trial in relapsed platinum sensitive ovarian cancer. In this trial we will
first evaluate COM701 as a monotherapy randomized to placebo in double-blinded sub-trial 1 in total of 60 patients. We plan to start enrollment
to this sub-trial in the second quarter of 2025 and we expect to share interim analysis data from this sub-trial in the second half of
2026. Rilvegostomig,&#160;a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from our COM902 program, is being developed
by AstraZeneca pursuant to an exclusive license agreement between us and AstraZeneca and is being evaluated in multiple Phase 3 clinical
trials and in multiple Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), our potential first-in-class high affinity antibody,
which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being developed by us in a recently
initiated Phase 1 clinical trial. In addition, we have an early-stage immuno-oncology therapeutic pipeline that consists of research programs
aiming to address various mechanisms to enhance anti-cancer immunity.</div> </div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">Our business model is to selectively enter into collaborations for our novel targets
and drug product candidates at various stages of research and development under various revenue-sharing arrangements. Integrating cutting
edge computational capabilities with ground-breaking immuno-oncology research and drug development expertise is our differentiator and
has enabled us to advance drug targets from computer prediction through successful preclinical studies to the clinic. Therefore, we believe
that we are uniquely positioned to discover and develop potential novel, first-in-class treatment options for cancer patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">A. OPERATING RESULTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Overview</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Since our inception, we have incurred significant losses and, as of December 31, 2024,
we had an accumulated deficit of $488.8 million. We expect to continue to incur net losses in the foreseeable future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While our Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>
platform has potentially broad applicability and is not limited to a certain indication or therapeutic field, we are focusing our efforts
on the discovery of novel drug targets for the development of novel therapeutic antibodies for cancer, in which we believe there is a
significant unmet medical need for cancer patients. We have discovered novel targets through our Unigen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>
platform with four different product candidates currently being clinically evaluated, potentially supporting the power and validity of
our computational capabilities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are currently pursuing clinical development of our internal programs COM701 and
COM902 as well as GS-0321 (previously COM503) on behalf of our partner, Gilead, for which we are only responsible for the Phase 1 development.
We have two partnerships in place, one with AstraZeneca, who is developing rilvegostomig,&#160;an anti PD-1/TIGIT bispecific antibody
with a TIGIT-specific component that is derived from our COM902 antibody and is in multiple Phase 3 clinical trials and other earlier
phases, and the second, with Gilead, pursuant to the License Agreement for our GS-0321 (previously COM503) program, with the first patient
having been dosed in January 2025.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We incurred net losses of approximately $14.2 million in 2024, approximately $18.8
million in 2023 and approximately $33.7 million in 2022. We expect to continue to incur net losses for the foreseeable future due in part
to the costs and expenses associated with our research, discovery and development activities. While we currently have two active collaborations,
our business model primarily involves establishing collaborations for our novel targets and therapeutic product candidates at various
stages of research and development to provide us with potential milestone payments and royalties on product sales or other forms of payments.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our research and development expenditures have always comprised a significant portion
of our total cash expenditures, and they are expected to remain our major operating expense in 2025.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We believe that we have sufficient cash and cash equivalents, short-term bank deposits
and investment in marketable securities in order to sustain our operations into 2027, based on our current plans without considering the
possible receipt of any additional funds, such as proceeds from existing or additional licensing and/or collaborative agreements, or from
financings.&#160;However, if our plans change or if our burn-rate increases, our cash balances may only be sufficient for a shorter period
of time. For a detailed description of our cash and cash equivalents position, see &#8220;Item 5. Operating and Financial Review and Prospects
- B. Liquidity and Capital Resources.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">66</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Years Ended December 31, 2024 and 2023</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Revenues.</span> Revenues for the year ended December
31, 2024, were approximately $27.9 million, compared with $33.5 million in the comparable period of 2023. The revenues for 2024 include
the portion of the upfront payment and the IND milestone payment from the License Agreement with Gilead allocated to the IND and Phase
1 research and development activities and to the license in addition to the clinical milestone from the license agreement with AstraZeneca
in the amount of $5 million, while the revenues for 2023 reflect the portion of the upfront payment from the license agreement with Gilead
allocated to the license and the clinical milestones from the license agreement with AstraZeneca in the amount of $10.0 million.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Cost of Revenues. </span>During the year ended December
31, 2024, cost of revenues was approximately $7.9 million compared with approximately $2.0 million cost of revenues in the comparable
period of 2023. Cost of revenues for the year ended December 31, 2024, represents the cost of IND and Phase 1 activities and royalty payments
in connection with our revenues, offset by royalty reversal in 2024 due to exemption from royalties on IL-18BP received from the IIA,
while cost of revenues for the year ended December 31, 2023, represents milestone and royalty payments in connection with our revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Research and Development Expenses, net. </span>Research
and development expenses during 2024 decreased by 28% and totaled approximately $24.8 million compared with approximately $34.5 million
in the comparable period of 2023. The decrease was mainly due to the classification of expenses related to GS-0321 (previously COM503)
to cost of revenues and to lower CMC and IND enabling activities related to GS-0321 (previously COM503), partially offset by an increase
in clinical expenses. Research and development expenses, as a percentage of total operating expenses, were 71% in 2024 compared to 78%
in 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Marketing and Business Development Expenses</span>.
Marketing and business development expenses increased by 136% to approximately $0.6 million in 2024 compared with approximately $0.2 million
in the comparable period of 2023. The increase was mainly due to higher headcount. Marketing and business development expenses, as a percentage
of total operating expenses, were 2% in 2024 compared to 1% in 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">General and Administrative Expenses. </span>General
and administrative expenses during 2024 decreased by 3% to approximately $9.4 million in 2024 compared with approximately $9.7 million
in the comparable period of 2023. The decrease during 2024 was mainly attributed to lower D&amp;O insurance premium costs, coupled with
lower salaries related expenses and legal fees partially offset by an increase in travel and consulting expenses. General and administrative
expenses, as a percentage of total operating expenses, were 27% in 2024 compared to 22% in 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Financial and Other Income, Net. </span>Financial
and other income increased by 62% to approximately $5.2 million in 2024 up from approximately $3.2 million in the comparable period of
2023. The increase was mainly attributed to higher cash balances which resulted in higher financial income.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Taxes on Income. </span>Taxes on income were approximately
$4.5 million in 2024 compared with $9.0 million in the comparable period of 2023. The taxes on income in 2024 and 2023 represent primarily
taxes withheld by Gilead on the upfront the IND milestone payments.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Net loss.</span> Net loss was approximately $14.2
million in 2024, compared with $18.8 million in the comparable period of 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Net Loss per share. </span>Net loss per share was
16 cents per basic and diluted share in 2024, compared with 21 cents per basic and diluted share in the comparable period of 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Years Ended December 31, 2023 and 2022</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Revenues.</span> Revenues for the year ended December
31, 2023, were approximately $33.5 million, compared with $7.5 million in the comparable period of 2022. The revenues for 2023 include
the portion of the upfront payment from the license agreement with Gilead allocated to the license and the clinical milestone from the
license agreement with AstraZeneca in the amount of $10.0 million, while the revenues for 2022 reflect the previous clinical milestones
from the license agreement with AstraZeneca.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Cost of Revenues. </span>During the year ended December
31, 2023, the Company had approximately $2.0 million in cost of revenues compared with approximately $1.0 million cost of revenues in
the comparable period of 2022. Cost of revenues for the years ended December 31, 2023 and 2022, represent milestone and royalty payments
in connection with our revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">67</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Research and Development Expenses, net. </span>Research
and development expenses during 2023 increased by 12% and totaled approximately $34.5 million compared with approximately $30.6 million
in the comparable period of 2022. The increase is mainly due to lower amortization of the deferred participation in R&amp;D expenses following
the termination of the agreement with Bristol Myers Squibb offset by a decrease in headcount related expenses. Research and development
expenses, as a percentage of total operating expenses, were 78% in 2023 compared to 73% in 2022.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Marketing and Business Development Expenses</span>.
Marketing and business development expenses decreased by 74% and totaled in approximately $0.2 million in 2023 compared with approximately
$0.9 million in the comparable period of 2022. The decrease is mainly due to headcount reduction. Marketing and business development expenses,
as a percentage of total operating expenses, were 1% in 2023 compared to 2% in 2022.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">General and Administrative Expenses. </span>General
and administrative expenses during 2023 decreased by 6% and totaled approximately $9.7 million in 2023 compared with approximately $10.3
million in the comparable period of 2022. The decrease during 2023 was attributed mostly to decrease in D&amp;O insurance premium costs
and in non-cash stock option related expenses. General and administrative expenses, as a percentage of total operating expenses, were
22% in 2023 compared to 25% in 2022.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Financial and Other Income, Net. </span>Financial
and other income increased by 85% to approximately $3.2 million in 2023 up from approximately $1.7 million in the comparable period of
2022. The increase is attributed mainly to increased interest income due to higher interest rates in the market offset by a lower level
of cash and deposits balances.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Taxes on Income. </span>Taxes on income were approximately
$9.0 million in 2023 compared with $0.1 million in 2022. The taxes on income in 2022 represent state income taxes of our U.S. subsidiary,
and in 2023, taxes withheld by Gilead on the upfront payment, offset by a negligible U.S. state income tax benefit.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Governmental Policies that Materially Affected
or Could Materially Affect Our Operations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Our income tax obligations consist of those of Compugen Ltd. in Israel and of Compugen
USA, Inc. in its taxing jurisdictions.</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25">The corporate tax rate in Israel was 23% in 2024, 2023 and 2022.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the future, if and when we generate taxable income, our effective tax rate may
be influenced by, among others: (a) the split of taxable income between the various tax jurisdictions; (b) the availability of tax loss
carry forwards, R&amp;D credits carry forwards and the extent to which valuation allowance has been recorded against deferred tax assets;
(c) the tax benefits we will be entitled to pursuant to the Investment Law; and (d) the changes in the exchange rate of the dollar to
the NIS. We may benefit from certain government programs and tax legislation, particularly as a result of the entitlement to Preferred
Enterprise status that resulted from our eligibility for tax benefits under the Investment Law. To be eligible for these benefits, we
need to meet certain conditions. Should we fail to meet such conditions, these benefits could be cancelled, and we might be required to
refund the amount of the benefits previously received, if any, in whole or in part, together with interest and linkage differences to
the Israeli CPI, or other monetary penalty. We also received grants from the IIA pursuant to approved IIA programs and accordingly, we
are subject to the terms of such programs and approvals as well as to the terms of the R&amp;D Law. For more information, please see &#8220;Item
5 Operating and Financial Review and Prospects - C. Research and Development, Patents and Licenses - The Israel Innovation Authority.&#8221;
There can be no assurance that these programs and tax legislation will continue in the future or that the available benefits will not
be reduced.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The termination or curtailment of these programs or the loss or reduction of benefits
under the Investment Law could have a material adverse effect on our business, financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Currently we are entitled to a Preferred Enterprise status under the Investment Law.
These benefits should result in income recognized by us being taxed at a lower rate. However, these benefits may not be applied to reduce
the U.S. federal tax rate for any income that our U.S. subsidiary may generate.</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">68</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25">In April 2005, substantive amendments to the Investment Law came into effect. Under
these amendments, eligible investment programs of the type in which we participated prior to the amendment were eligible to qualify for
substantially similar benefits as a &#8216;Benefiting Enterprise&#8217;, subject to meeting certain criteria. This replaced the previous
terminology of &#8216;Approved Enterprise&#8217;, which required pre-approval from the Investment Center of the Ministry of the Economy
of the State of Israel. As a result of these amendments, tax-exempt income generated from Benefiting Enterprises under the provisions
of the amended law will, if distributed upon liquidation or if paid to a shareholder for the purchase of his or her shares, be deemed
distributed as a dividend and will subject the Company to the applicable corporate tax that would otherwise have been payable on such
income. Therefore, a company may be required to record deferred tax liability with respect to such tax-exempt income, which would have
an adverse effect on its results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additional amendments to the Investment Law became effective in January 2011, or the
2011 Amendment. Under the 2011 Amendment, income derived by &#8216;Preferred Companies&#8217; from &#8216;Preferred Enterprises&#8217;
(both as defined in the 2011 Amendment) would be subject to a uniform rate of corporate tax for an unlimited period as opposed to the
incentives prior to the 2011 Amendment that were limited to income from Approved or Benefiting Enterprises during their benefits period.
According to the 2011 Amendment, the uniform tax rate on such income, referred to as &#8216;Preferred Income&#8217;, would be 10% in areas
in Israel that are designated as Development Zone A and 15% elsewhere in Israel during 2011-2012, 7% and 12.5%, respectively, in 2013,
and 9% and 16%, respectively, thereafter. Income derived by a Preferred Company from a &#8216;Special Preferred Enterprise&#8217; (as
defined in the Investment Law) would enjoy further reduced tax rates for a period of ten years of 5% in Development Zone A and 8% elsewhere.
As of January 1, 2014, dividends distributed from Preferred Income would subject the recipient to a 20% tax (or lower, if so provided
under an applicable tax treaty, subject to the receipt in advance of a valid tax certificate from the Israel Tax Authority allowing for
a reduced tax rate), which would generally be withheld by the distributing company, provided however that dividends distributed from &#8216;Preferred
Income&#8217; from one Israeli corporation to another, would not be subject to tax. Under the transitional provisions of the 2011 Amendment,
companies may elect to irrevocably implement the 2011 Amendment with respect to their existing Approved and Benefiting Enterprises while
waiving benefits provided under the legislation prior to the 2011 Amendment or keep implementing the legislation prior to the 2011 Amendment.
Should a company elect to implement the 2011 Amendment with respect to its existing Benefiting Enterprises prior to June 30, 2015 dividends
distributed from taxable income derived from Benefiting Enterprises to another Israeli company would not be subject to tax. While a company
may incur additional tax liability in the event of distribution of dividends from tax exempt income generated from its Benefiting Enterprise,
as previously described, no additional tax liability will be incurred by a company in the event of distribution of dividends from Preferred
Income. We have elected to implement the 2011 Amendment and we currently have a Preferred Enterprise.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying
the Economic Policy for the 2017 and 2018 Budget Years), 2016 which includes Amendment 73 to the Law, or Amendment 73, was published.
According to Amendment 73, a Preferred Enterprise located in development area A will be subject, under certain conditions, to a tax rate
of 7.5% instead of 9% effective from January 1, 2017, and thereafter (the tax rate applicable to preferred enterprises located in other
areas remains at 16%). Amendment 73 also prescribes special tax tracks for Technological Enterprises, which are subject to regulations
issued by the Minister of Finance on May 16, 2017.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The new tax tracks under the Amendment are as follows:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Technological Preferred Enterprise - an enterprise for which total consolidated revenues
of its parent company and all subsidiaries are less than NIS 10 billion. A Technological Preferred Enterprise, as defined in the Law,
which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development
area A - a tax rate of 7.5%).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Special Technological Preferred Enterprise - an enterprise for which total consolidated
revenues of its parent company and all subsidiaries exceed NIS 10 billion. Such enterprise will be subject to tax at a rate of 6% on profits
deriving from intellectual property, regardless of the enterprise&#8217;s geographical location.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any dividends distributed to &#8220;foreign companies&#8221;, as defined in the Law,
deriving from income from the Technological Enterprises will be subject, under certain conditions, including holding at least 90% of the
share capital, to tax at a rate of 4%.</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2024, our net operating loss carry-forward for Israeli tax purposes
amounted to approximately $413.9 million. Under Israeli law, these net operating losses may generally be carried forward indefinitely
and offset against certain future taxable income.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2024, the net operating loss carry-forward of our U.S. subsidiary
for federal income tax purposes amounted to approximately $1.4 million. Approximately $0.3 million of these losses are available to offset
any future U.S. taxable income of our U.S. subsidiary and will expire between 2027 and 2032.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">69</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">Use of our U.S. net operating losses may be subject to substantial annual limitation
due to the &#8220;change in ownership&#8221; provisions of the Code and similar state provisions. The annual limitation may result in
the expiration of net operating losses before utilization.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For a description of Israel government policies that affect our research and development
expenses, and the financing of our research and development, see &#8220;Item 5. Operating and Financial Review and Prospects - C. Research
and Development, Patents and Licenses - The Israel Innovation Authority.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. LIQUIDITY AND CAPITAL RESOURCES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Public Offering of Ordinary Shares</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic">Sales Agreement with Leerink Partners LLC</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On January 31, 2023, we entered into a Sales Agreement, or the Sales Agreement with
Leerink, as sales agent, pursuant to which we may offer and sell, from time to time through Leerink, our ordinary shares. The offer and
sale of our ordinary shares, if any, will be made pursuant to our shelf registration statement on Form F-3, as supplemented by the prospectus
supplement filed on January 31, 2023. Pursuant to the said prospectus supplement, we may offer and sell up to $50 million of our ordinary
shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are not obligated to make any sales under the Sales Agreement and no assurance
can be given that we will sell any ordinary shares under the Sales Agreement, or, if we do, as to the price or number of ordinary shares
that we will sell, or the dates on which any such sales will take place.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For the year ended December 31, 2023, and for the year ended December 31, 2024 and
for the period between January 1, 2025 and February 28, 2025, the Company sold 2,612,822, 292,728 and 3,961,641 ordinary shares, respectively,
pursuant to the Sales Agreement, for gross proceeds of approximately $3.6 million, $0.6 million, and $9.1 million, respectively, and net
proceeds (after deducting commissions paid) of approximately $3.5 million, $0.6 million, and $8.9 million respectively.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Shelf Registration Statement</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25">On March 30, 2023, we filed a shelf registration statement on Form F-3 with the SEC
under which we may offer and sell from time to time in one or more offerings, our ordinary shares, debt securities, rights, warrants and
units having an aggregate offering price of up to $350 million, $50 million of which may be offered, issued and sold under the above mentioned
Sales Agreement with Leerink. This registration statement was declared effective by the SEC on June 27, 2023.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Securities Purchase Agreement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Bristol Myers Squibb Securities Purchase Agreement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">On November 10, 2021, the Company and Bristol Myers Squibb entered into a securities
purchase agreement pursuant to which Bristol Myers Squibb made a $20 million investment in Compugen comprised of the purchase of 2,332,815
ordinary shares of Compugen at $8.57333 per share, which represented a 33% premium over the closing price of our ordinary shares on the
last trading day immediately prior to the execution of this agreement. This investment is in addition to Bristol Myers Squibb&#8217;s
$12 million investment (at $4.95 per share, which represented a 33% premium over the average closing price on the last 20 Nasdaq trading
days prior to signing) that took place in October 2018.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">License Agreement</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">AstraZeneca License Agreement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">On March 30, 2018, we and AstraZeneca, entered into an exclusive license agreement
to enable the development of bi-specific and multi-specific immuno-oncology antibody products&#160;based on the Company&#8217;s monospecific
antibodies that bind to TIGIT, including COM902, pursuant to which the Company received an upfront payment of $10 million and is eligible
to receive up to $200 million in development, regulatory and commercial milestones for the first product as well as mid-single-digit tiered
royalties on future product sales, out of which we accrued $2 million in 2020 as a preclinical milestone, $6 million in 2021 as a clinical
milestone (triggered by the dosing of the first patient in a Phase 1/2 clinical trial evaluating rilvegostomig), $7.5 million in 2022
as a clinical milestone (triggered by the dosing of the first patient in its ARTEMIDE Phase 2 clinical trial evaluating rilvegostomig),
$10 million in 2023 as a clinical milestone (triggered by the dosing of the first patient in its ARTEMIDE-Bil01 Phase 3 clinical trial
evaluating rilvegostomig), and an additional $5 million in 2024 (triggered by dosing of the first patient in the second Phase 3 clinical
trial evaluating rilvegostomig). If additional products are developed, additional milestones and royalties would be due to us for each
product. In 2024, AstraZeneca provided a non-risk adjusted peak year revenue target for rilvegostomig of over $5 billion.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">70</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Gilead License Agreement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">On December 18, 2023, we and Gilead, entered into an exclusive license agreement,
or the License Agreement, pursuant to which we granted Gilead an exclusive license under our preclinical antibody program against IL-18
binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products,
including our GS-0321 (previously COM503) product candidate, or together, the GS-0321 (previously COM503),<span style="font-weight: bold">&#160;</span>and
additional products that may be developed by Gilead, together with GS-0321 (previously COM503), the Licensed Products.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the License Agreement, Gilead paid us a gross amount of $60 million upfront
license payment ($51 million net, after $9 million were withheld at source) in January 2024 and additional $30 million ($25.5 million
net, after $4.5 million were withheld at source) as a milestone payment upon clearance of the IND application for GS-0321 (previously
COM503) in the third quarter of 2024. We are also eligible to receive up to approximately $758 million in additional milestone payments
upon the achievement of certain development, regulatory and commercial milestones. We are further eligible to receive single-digit to
low double-digit tiered royalties on worldwide net sales of Licensed Products.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Unless terminated early by a party pursuant to its terms, the License Agreement will
continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term
in such country.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Gilead withheld at source 15% from the upfront payment and the milestone payment amount
specified above and is expected to continue to withhold at source all taxes required by law from all payments payable to us under the
License Agreement.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">If additional products are developed, additional milestones and royalties would be
due to us. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Capital Resources</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">In 2024, our primary sources of cash were mainly:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb99a30273ec14a9e9d0871d31c1a090e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>cash at hand and yield on investment of such cash balances;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7b31e4d773ad4f6195aceaf38652ef5d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>cash received from our partners, Gilead and AstraZeneca; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdf4bbe7757fc419199a9b7ed0b7cfae3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>proceeds from ordinary shares sold through the Sales Agreement with Leerink.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -34pt; margin-left: 34pt; line-height: 1.25">We used these funds primarily to finance our
business operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We expect that our sources of cash for 2025 will include cash at hand at the end of
2024. Additional potential sources of cash may include proceeds generated from agreements with collaborators and other third parties with
respect to our novel targets and therapeutic drug candidates and proceeds from issuance of ordinary shares pursuant to our equity plans,
and issuance of ordinary shares from financing transactions. In addition, if we choose to do so, we may generate additional proceeds from
sales of our ordinary shares pursuant to the Sales Agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Net Cash Used in Operating Activities</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Net cash provided by operating activities was approximately $49.6 million in 2024,
compared with net cash used in operating activities of approximately $35.9 million in 2023 and approximately $34.1 million in 2022. Increase
in net cash provided by operating activities in 2024 compared to 2023 was mainly due to $91.5 million derived from upfront payment and
clinical milestones payments collected from Gilead and from AstraZeneca, net of withholding taxes, offset by increase in operating expenses
(including cost of revenues) on cash basis.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Net Cash Provided by Investing Activities</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Net cash used in investing activities was approximately $46.3 million in 2024, compared
with net cash provided by investing activities of approximately $35.5 million in 2023 and approximately $37.1 million in 2022. Increase
in net cash used in investing activities in 2024 compared to 2023 was mainly due to net upfront and milestone payments received from Gilead
and AstraZeneca.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic"><span style="font-weight: bold">Net Cash Provided by Financing
Activitie</span>s</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Net cash provided by financing activities was approximately $0.6 million in 2024,
approximately $3.1 million in 2023 and approximately $0.4 million in 2022. The principal source of cash provided by financing activities
in 2024 and 2023 was proceeds received from sale of ordinary shares through the Sales Agreement with Leerink.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">71</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Net Liquidity</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Liquidity refers to the liquid financial assets available to fund our business operations
and pay for near-term obligations. These liquid financial assets mostly consist of cash and cash equivalents as well as short-term bank
deposits and investment in marketable securities. As of December 31, 2024, we had cash and cash equivalents, short-term bank deposits
and investment in marketable securities of approximately $103.3 million compared to approximately $50.7 million on December 31, 2023.
We believe that our existing cash, cash equivalents, short-term bank deposits and investment in marketable securities will be sufficient
to fund our operations over the next 12 months. We believe we will meet longer-term expected future cash requirements into 2027 based
on our current plans. We believe that our working capital is sufficient for our present requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The table below summarizes our contractual obligations as of December 31, 2024, and
should be read together with the accompanying comments that follow.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z471f299e9c1c4af6aae935593a2786f4" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="18" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Payments due by period</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">(US$ in thousands)</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Total</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Less than 1 year</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">1-3 years</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">3-5 years</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">More than 5 years</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 40%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Operating Lease Obligations<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">3,608</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">650</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,149</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,129</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">680</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 40%; padding-bottom: 2px">
        <div style="line-height: 1.25">Accrued Severance Pay, net<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">340</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">340</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 40%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">3,948</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">650</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,149</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,129</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,020</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -14.15pt; margin-left: 28.35pt; line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup>&#160;
Consists of operating leases for our facilities and for motor vehicles. Includes the first and second five-year option periods of the
lease of the Israeli facility. The first option was exercised during 2020.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -14.15pt; margin-left: 28.35pt; line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup>&#160;
Severance pay obligations to our Israeli employees. For more information, see &#8220;Item 6. Directors, Senior Management and Employees
&#8211; D. Employees.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The above table does not include royalties that we may be required to pay to the IIA.
For more information, see &#8220;Item 5. Operating and Financial Review and Prospects - C. Research and Development, Patents and Licenses
- The Israel Innovation Authority.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The above table also does not include contingent contractual obligations or commitments
that may enter into effect in the future, such as contractual undertakings to pay royalties subject to certain conditions occurring.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We invest heavily in research and development. Research and development expenses were
our major operating expenses representing approximately 71% of total operating expenses in 2024 and approximately 78% in 2023 and approximately
73% 2022. Our research and development expenses, net, were approximately $24.8 million in 2024, approximately $34.5 million in 2023 and
approximately $30.6 million in 2022. As of December 31, 2024, 53 of our employees were engaged in research and development on a full-time
basis. This represents approximately 70% of our entire work force at that time.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We focus our efforts on the development of our discovery capabilities and related
technologies, and the discovery and validation of our drug targets and the preclinical and clinical development of the respective therapeutic
product. Our pipeline programs are continuously evolving, and we expect that in 2025 our research and development expenses will continue
to be our major operating expense.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We believe that our future success will depend, in large part, on our ability to discover
promising drug target candidates and therapeutic product candidates and to successfully advance the research and development of certain
of our product candidates in our internal pipeline towards preclinical and clinical studies and to successfully enter into revenue-sharing
partnering agreements with pharmaceutical companies with respect to our product candidates at the various development stages.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">72</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Research and Development Grants</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have participated in programs offered by the IIA that support research and development
activities. See Note 8b to our 2024 consolidated financial statement. We have not applied for additional grants from the IIA for research
and technological development since 2012.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The Israel Innovation Authority</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The government of Israel encourages research and development projects in Israel through
the IIA, pursuant to and subject to the provisions of the R&amp;D Law. Under the R&amp;D Law, research and development projects which
are approved by the Research Committee of the IIA are eligible for grants, in exchange for payment of royalties from revenues generated
from Financed Know-How or otherwise from all revenues generated by the Company, as designated by the applicable IIA programs, approvals
and the R&amp;D Law, and are subject to compliance with certain requirements and restrictions under the R&amp;D Law as detailed below,
which must generally continue to be complied with even following full repayment of all IIA grants (as adjusted for fluctuation in the
USD/NIS exchange rate), with applicable interest, assuming we neither grant licenses thereunder nor transfer production or development
outside of the State of Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We received grants from the IIA for several projects and may receive additional grants
in the future. Under the terms of the grants received, we are required to pay royalties ranging between 3% to 5% of the revenues we generate
from our products and/or services which incorporate Financed Know-How, or IIA Products, or as otherwise designated by the applicable IIA
programs, approvals and the R&amp;D Law, until 100% of the dollar value of the grant is repaid, plus, as follows: (i) with respect to
grants received on or after January 1, 1999 and until December 31, 2023, the applicable interest is (a) LIBOR interest until December
31, 2023, and (b) from January 1, 2024, the 12 months Term SOFR interest as published on the first trading day of each year by CME Group,
or by any other party authorized by the Federal Reserve, or in alternative publication by the Bank of Israel, together with an additional
0.71513% to the applicable interest rate, and (ii) with respect to grants received on or after January 1, 2024, the applicable interest
shall be the 12 months Term SOFR interest as detailed in section (b) above. As of December 31, 2024, we received grants from the IIA in
the principal amount of approximately $7.3 million. Therefore, our contingent obligation for royalties, net of royalties already paid
or accrued in the sum of approximately $2.5 million, along with the accumulated LIBOR/SOFR interest to date of approximately $5.1 million,
totaled to approximately $9.9 million as of December 31, 2024.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">With respect to the Company&#8217;s requirement to pay royalties, in February 2025,
the IIA approved that the Company will be required to pay royalties from all revenues of the Company, other than from income derived from
sales associated with products related to IL-18BP (which currently include, GS-0321 (previously COM503)).</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">73</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">In addition, the Company participated in four MAGNET Consortium programs - Drugs and
Diagnostic Kits, or DAAT Consortium, Tevel Biotechnology Consortium, Pharmalogica Consortium and Rimonim Consortium &#8211; for which
it received from the IIA a total amount of approximately $2.1 million, and in two MAGNETON programs, for which it received from the IIA
approximately $0.5 million. These grants do not bear any royalty obligations, but as the R&amp;D Law applies to these programs, the restrictions
on transfer of know-how or manufacturing outside of Israel, as detailed below, do apply. The R&amp;D Law requires that the manufacture
of products which incorporate Financed Know-How will be carried out in Israel, unless the IIA provides its approval to the contrary. This
approval, to the extent given by the IIA, may be subject to various conditions, including the repayment of increased royalties equal to
up to 300% of the total grant amount plus applicable interest and an increase of 1% in the royalty rate, depending on the extent of the
manufacturing that is to be conducted outside of Israel. The R&amp;D Law also provides that Financed Know-How and any right derived therefrom
may not be sold, licensed, outsourced for development activities or otherwise transferred to third parties, unless such transfer was approved
in accordance with the R&amp;D Law. The Research Committee operating under the IIA may approve the sale, license, outsourcing for development
activities or otherwise transfer of Financed Know-How between Israeli entities, provided that the transferee undertakes all the obligations
in connection with the grant as prescribed under the R&amp;D Law. In certain cases, the research committee may also approve a transfer
of the Financed Know-How outside of Israel, in both cases, subject to the receipt of certain payments calculated according to a formula
set forth in the R&amp;D Law. In the case of transfer outside of Israel, a payment of up to six times the amount of the grant (as adjusted
for fluctuation in the USD/NIS exchange rate) with applicable interest; and in the case the R&amp;D activity related to the Financed Know-How
remains in Israel, a payment of up to 3 times of such total amount. These approvals are not required for the sale or export of any products
resulting from such R&amp;D activity or based on such Financed Know-How. In addition, the government of Israel may from time to time audit
sales of products which it claims incorporate Financed Know-How and this may lead to royalties being payable on additional products, and
may subject such products to the restrictions and obligations specified hereunder. Failure to comply with the requirements under the R&amp;D
Law may subject us to financial sanctions, to mandatory repayment of grants received by us (together with interest and penalties), as
well as expose us to criminal proceedings.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For a discussion regarding the effects of the grants we received from the IIA on our
business, see &#8220;Item 3. Key Information - D. Risk Factors - Risks Related to Operations in Israel -<span style="font-weight: bold">&#160;</span>We
received grants from the IIA that may require us to pay royalties and restrict the transfer of know-how that we develop.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. TREND INFORMATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are unable to predict with a reasonable degree of accuracy the outcome of our research
and development efforts. As such, it is not possible for us to predict with a reasonable degree of accuracy any material trends, uncertainties,
or other events that are reasonably likely to have a material effect on our net loss, liquidity or capital resources, or that would cause
financial information to not necessarily be indicative of our future operating results or our financial condition. However, subject to
such limitation, we did identify certain trends that may have an effect on us, some of which are as specified below, and as covered in
the risk factors set forth under &#8220;Item 3. Key Information - D. Risk Factors.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Access to Additional Funds</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Should we need to secure additional sources of liquidity, we believe that we could
finance our needs through the issuance of equity securities, including through our Sales Agreement with Leerink, debt securities or other
arrangements. However, we cannot guarantee that we will be able to obtain financing through the issuance of any of the above arrangements
on reasonable terms.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Unfavorable Global or Domestic Political or Economic Conditions</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The global economy continues to experience significant volatility,
and the economic environment may continue to be, or become, less favorable than that of past years. Higher costs for goods and services,
inflation, deflation, the imposition of tariffs or other measures that create barriers to or increase the costs associated with international
trade, overall economic slowdown or recession and other economic factors in Israel, the U.S. or in any other markets in which we operate
could adversely affect our operations and operating results and can result in increased operations costs. In February 2024, the international
rating agency Moody&#8217;s announced the downgrade of Israel&#8217;s credit rating to A2 (from a level of A1), and also lowered the rating
outlook from &#8220;stable&#8221; to &#8220;negative&#8221;. In its report, Moody&#8217;s estimated that the broad implications of the
&#8220;Swords of Iron&#8221; war significantly increase the political risks in the State of Israel, weaken the legislative and executive
authorities, and significantly impact Israel&#8217;s budgetary stability in the foreseeable future. In April 2024, S&amp;P Global Ratings
also announced the downgrade of Israel&#8217;s rating from AA- to A+, and maintained the rating outlook as &#8220;negative&#8221;, mainly
due to the escalation of tensions between Israel and Iran, as detailed above, and the geopolitical risks that Israel has been dealing
with since the outbreak of the &#8220;Swords of Iron&#8221; war. While these downgrades did not have an immediate nor direct impact on
us, an extended period of economic disruption, including a continued market downfall in Israel, which may be impacted by such downgrades,
by future downgrades, by the continuing armed conflict between Israel and its surrounding countries, including as a result of the &#8220;Swords
of Iron&#8221; war and the political and civil actions in Israel which began in early 2023, resulting from, among other things, proposed
changes to certain Israeli constitutional legislation, as well as a continued market downfall in the United States or any other major
market in which we or our partners operate, could materially affect our ability to secure additional funds and could further materially
affect our business, strategy, results of operations and financial condition.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">74</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">To date, our operations and business have not been materially impacted
by the hostilities involving Israel, including the &#8220;Swords of Iron&#8221; war and the additional armed conflicts between Israel
and its surrounding countries (including Iran, Hezbollah (a&#160;Shia&#160;Islamist&#160;political party and&#160;militant&#160;group
based in&#160;Lebanon), the Houthi movement which controls parts of Yemen, and Iranian-backed militias in Syria), nor by the political
and social condition in Israel, including the effects of the ICJ Interim Ruling and the recent political and civil actions in Israel which
began in early 2023, resulting from, among other things, proposed changes to certain Israeli constitutional legislation. In addition,
to date, our operations and business have not been materially impacted by the Russia and Ukraine conflict. However, the hostilities involving
Israel and the political and social condition in Israel mentioned above, as well as the ongoing Russia and Ukraine conflict and other
global economic factors, have caused a negative impact on the outlook for the global economy and created significant volatility and disruption
of financial markets. In addition, the &#8220;Swords of Iron&#8221; war and the other hostilities involving Israel have a potential of
creating a greater effect for companies that have a significant presence in Israel. For instance, the &#8220;Sword of Iron&#8221; war
and the other hostilities involving Israel, may have an adverse effect on the Israeli social, economic and political landscape and in
turn, on us, and may cause, among other things, major devaluation in the NIS. Should any of these conflicts still persist or expand to
include additional countries or regions, we could be impacted. We will continue to assess global and regional conflicts and the situation
in the financial markets and any impact they may have on our ability to access additional funds.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Exchange Rate</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A significant portion of our expenses is denominated in currencies other than the
dollar. The Company is therefore subject to non-U.S. currency risks and non-U.S. exchange exposure, especially the NIS. Exchange rates
can be volatile and a substantial change in foreign currencies against the dollar could increase or reduce the Company&#8217;s expenses
and net loss and impact the comparability of results from period to period. The appreciation (devaluation) of the dollar against the NIS
was 0.6%, 3.1% and 13.2% in 2024, 2023 and 2022, respectively. For example, for the year ended December 31, 2024, assuming a 10% devaluation
of the dollar against the NIS, we would have experienced an increase in our net loss of approximately $1.5 million, while assuming a 10%
appreciation of the dollar against the NIS, we would experience a decrease in our net loss of approximately $1.3 million. Should Moody&#8217;s,
S&amp;P Global Ratings or other financial rating firms further downgrade the Government of Israel&#8217;s foreign-currency and local-currency
issuer ratings, this could have a negative impact on the value of our NIS denominated holdings. For more information regarding exchange
rate risk please see &#8220;Item 11. Quantitative And Qualitative Disclosures About Market Risk &#8211; Interest Rate Risk.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Interest rate</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A significant portion of our cash and cash equivalents is invested in bank deposits
or in marketable securities and bear interest or yield that depends on the interest rate. The Company&#8217;s financial income is therefore
subject to interest rate risk. Interest rates can be volatile, and a substantial change in interest rates could increase or reduce the
Company&#8217;s financial income and net loss. In addition to the impact on our cash and cash equivalents, rising interest rates, or the
perception thereof, may have wide economic impacts, including an adverse impact on capital markets, the price of our shares and on supplies
that we require to conduct our different operations. For more information regarding interest rate risk please see &#8220;Item 11. Quantitative
And Qualitative Disclosures About Market Risk &#8211; Interest Rate Risk.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Trend Towards Biologics</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Biologics (monoclonal and bispecific antibodies, ADCs, enzymes and engineered proteins)
represent one of the fastest growing segments in the drug industry, making up 31% of FDA approved drugs in 2023 and 32% in 2024. The growth
of this class has driven a large number of companies to invest in new technologies (e.g., bi-specific monoclonal antibodies, multi-specific
antibodies, ADCs, antibody fragments, T cell engagers) and new approaches to fully exploit the potential of this class. In addition, the
striking efficacy and recent approval of cell therapies for the treatment of cancer, such as CAR-T therapies, has also captured much attention
in the pharma industry. The availability of such new technologies and approaches to address drug targets may increase the bar for differentiation
and decrease the attractiveness of our novel therapeutic candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">E. CRITICAL ACCOUNTING ESTIMATES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The preparation of our consolidated financial statements and other financial information
appearing in this Annual Report requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate on an on-going basis these estimates,
mainly related to share-based payments, deferred participation in research and development expenses, revenue recognition, and research
and development expenses.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We base our estimates on our experience and on various assumptions that we believe
are reasonable under the circumstances. The results of our estimates form the basis for our management&#8217;s judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under
different assumptions or conditions.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">75</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Share Based Payments</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We account for stock-based compensation in accordance with ASC 718, &#8220;Compensation
- Stock Compensation&#8221;, or ASC 718, which requires companies to estimate the fair value of equity-based payment awards on the date
of grant using an option-pricing model. We account for forfeitures as they occur. The value of the pro-rata portion of the award, assuming
no forfeiture, is recognized in our consolidated statement of comprehensive loss as an expense over the requisite service periods. Upon
forfeiture the expense is adjusted so that expense is recognized for the portion of the award that actually vested.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We selected the Black-Scholes-Merton option pricing model as the most appropriate
method for estimating the fair value of our share-based awards. The resulting cost of an equity incentive award is recognized as an expense
over the requisite service period of the award, which is usually the vesting period. We recognize compensation expense over the vesting
period using the straight-line method and classify these amounts in the consolidated financial statements based on the department to which
the related employee reports.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">This model evaluates the options as if there is a single exercise point, and thus
considers expected option life (expected term). The input factored in this model is constant for the entire expected life of the option.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The determination of the grant date fair value is affected by estimates and assumptions
regarding a number of complex and subjective variables, including the expected term of the options, the expected volatility of our share
price over the expected term, risk-free interest rates and expected dividends. The computation of expected volatility is based on the
historical volatility of our shares. The risk-free interest rate assumption is the implied yield currently available on United States
treasury zero-coupon issues with a remaining term equal to the expected life term of the options. We determined the expected life of the
options based on historical experience, representing the period of time that options granted are expected to be outstanding.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The fair value of RSUs is the fair value of the ordinary share at the date of grant.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Share-based compensation expense recognized under ASC 718 was approximately $3.0 million,
$3.6 million and $4.3 million for the years ended December 31, 2024, 2023 and 2022, respectively.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Revenue Recognition</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our revenues are generated mainly from collaborative and license agreements. In the
agreements, revenues are typically derived mainly from upfront payment and contingent payments related to milestone achievements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Company recognizes revenue in accordance with ASC 606 - &#8220;Revenue from Contracts
with Customers.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As such, the Company analyzes its collaborative and license agreements to assess whether
they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations
under each of its agreements, the Company performs the following five steps: (i) identification of the contract, or contracts, with a
customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation
of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when, or as, we satisfy a performance
obligation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The consideration promised in a contract with a customer may include fixed amounts,
variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained.
We use assumptions to determine the standalone selling price of each performance obligation identified in the contract. We then allocate
the total transaction price to each performance obligation based on the estimated standalone selling prices of each performance obligation.
We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance
obligation is satisfied.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">After contract inception, the transaction price is reassessed at every period end
and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations
on the same basis as at contract inception.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In December 2020 the program under the exclusive license agreement with AstraZeneca
achieved a preclinical milestone and in September 2021, November 2022, December 2023 and May 2024 such program achieved clinical milestones
and in connection with such milestones, we recognized revenues in an amount of $2 million, $6 million, $7.5 million, $10 million and $5
million, in the years 2020, 2021, 2022, 2023 and 2024, respectively, in accordance with the criteria prescribed under ASC 606. See Note
2j to our 2024 consolidated financial statements.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">76</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In December 2023, following entrance into license agreement with Gilead, we assessed
the promises under the license agreement and concluded that its promise to deliver the GS-0321 (previously COM503) License, the promise
to perform IND research and development activities and Phase 1 research and development activities represented separate performance obligations
in the license agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We also evaluated as a possible variable consideration all milestones and royalties.
With respect to clinical development and regulatory milestones, we concluded that all such amounts should be fully constrained and are
not included in the initial transaction price. Accordingly, we did not include any potential clinical development, regulatory and sales
milestones and royalties in the initial transaction price.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We allocated the transaction price to each performance obligation on a relative estimated
standalone selling price basis. We developed the estimated standalone selling price for the license. In developing such an estimate, we
applied judgement in determining the timing needed to develop the licensed product, the probability of success, and the discount rate.
We developed the estimated standalone selling price for the IND research and development activities using a &#8220;cost plus&#8221; reasonable
margin approach. To determine the estimated standalone selling price of the Phase 1 research and development activities obligation, we
estimated the standalone selling price of the underlying performance obligations and estimated the probability of our performance of such
obligations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We determined that the license granted was a functional license since the underlying
intellectual property has significant standalone functionality and recognized the entirety of the initial transaction price allocated
to the license performance obligation during the year ended December 31, 2023, in the amount of $23.5 million.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The IND research and development activities and Phase 1 research and development activities
performance obligations are recognized over time. We determined that the input method under ASC 606 is the best measure of progress towards
satisfying the performance obligation and reflects a faithful depiction of the transfer of goods and services. The method of measuring
progress towards delivery of the services incorporates actual internal and external costs incurred, relative to total internal and external
costs expected to be incurred to satisfy the performance obligation. The period over which total costs were estimated reflected the period
over which it performed the activities to achieve clearance of an IND application and our best estimate of the period over which it would
take to perform the completion of the phase 1 clinical trial.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">During the year ended December 31, 2024, the Company recognized $22,864 of license, IND services and Phase
1 services revenues, and during the year ended December 31, 2023, the Company recognized $23,459 of license revenues.&#160; The Company
included deferred revenues of $9,632 in current liabilities and $34,045 in non-current liabilities.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Research and Development Expenses</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Research and development costs are charged to the statement of comprehensive loss
as incurred.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Company accrues costs for preclinical and clinical trial activities based upon
estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or
other preclinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable
advance payments to vendors for goods or services that will be received in the future for use in research and development activities.
In such circumstances, the nonrefundable advance payments are deferred and capitalized, even when there is no alternative future use for
the research and development, until related goods or services are provided.&#160;Payments made in advance of the performance of the related
services are recorded as prepaid expenses until the services are rendered.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The portion of the Bristol Myers Squibb $12.0 million investment in 2018 over the
fair market value of the shares issued in the amount of approximately $4.1 million and the portion of the Bristol Myers Squibb $20.0 million
investment in 2021 over the fair market value of the shares issued in the amount of $5.0 million were considered as deferred participation
of Bristol Myers Squibb in research and development expenses which was amortized over the period of the clinical trial based on the progress
in the research and development, see Note 1f and Note 89 to our 2024 consolidated financial statements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">There was no amortization of participation in research and development expenses for
the year ended December 31, 2024, while for the years 2023 and 2022 such expenses were approximately $0.3 million and $6.0 million, respectively.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Recent Accounting Pronouncements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">See Notes 2t and 2u to our 2024 consolidated financial statement.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">77</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25"><span style="font-weight: bold"><span id="ITEM6."><!--Anchor--></span>ITEM 6. DIRECTORS, SENIOR MANAGEMENT
AND EMPLOYEES</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. DIRECTORS AND SENIOR MANAGEMENT</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following table sets forth information with respect to Compugen&#8217;s directors
and senior management as of February 28, 2025:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z5e31b574b3a044ab826c3b8df8923f07" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 40.85%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Name</div> </div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 12.15%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Age<br/> </div> </div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 45%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Positions</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 40.85%; vertical-align: top">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 12.15%; vertical-align: top">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 45%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Paul Sekhri<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: middle">&#160;</td>
    <td style="width: 12.15%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">66</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle">&#160;</td>
    <td style="width: 45%; vertical-align: middle">
        <div style="line-height: 1.25">Chairman of the Board of Directors (Chairman of the Nomination and Corporate Governance Committee)</div>
        </td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Anat Cohen-Dayag, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle">&#160;</td>
    <td style="width: 12.15%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">58</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle">&#160;</td>
    <td style="width: 45%; vertical-align: middle">
        <div style="margin-right: 2.55pt; line-height: 1.25">President and Chief Executive Officer, Director</div> </td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: middle">
        <div style="line-height: 1.25">Mathias Hukkelhoven, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle">&#160;</td>
    <td style="width: 12.15%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">71</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle">&#160;</td>
    <td style="width: 45%; vertical-align: middle">
        <div style="margin-right: 2.55pt; line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Gilead Halevy<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: middle">&#160;</td>
    <td style="width: 12.15%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">58</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle">&#160;</td>
    <td style="width: 45%; vertical-align: middle">
        <div style="margin-right: 2.55pt; line-height: 1.25">Director (Chairman of the Audit Committee)</div> </td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Kinneret Livnat Savitzky, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(3)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: middle">&#160;</td>
    <td style="width: 12.15%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">57</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle">&#160;</td>
    <td style="width: 45%; vertical-align: middle">
        <div style="line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Eran Perry<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(2)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 12.15%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">54</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 45%; vertical-align: top">
        <div style="line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Sanford (Sandy) Zweifach<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(2)(3)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 12.15%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">68</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 45%; vertical-align: top">
        <div style="line-height: 1.25">Director (Chairman of the Compensation Committee)</div> </td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">David Silberman</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 12.15%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">41</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 45%; vertical-align: top">
        <div style="line-height: 1.25">Chief Financial Officer</div> </td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: top">
        <div style="line-height: 1.25">Michelle Mahler, MD</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 12.15%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">47</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 45%; vertical-align: top">
        <div style="line-height: 1.25">Chief Medical Officer</div> </td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Zurit Levine, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 12.15%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">57</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 45%; vertical-align: top">
        <div style="line-height: 1.25">Senior Vice President, Technology Innovation</div> </td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Yaron Turpaz, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 12.15%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">54</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 45%; vertical-align: top">
        <div style="line-height: 1.25">Senior Vice President and Senior Advisor, Data and Informatics Solutions</div> </td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Eran Ophir, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 12.15%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">47</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 45%; vertical-align: top">
        <div style="line-height: 1.25">Chief Scientific Officer</div> </td> </tr>
  <tr>
    <td style="width: 40.85%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Pierre Ferre, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 12.15%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">48</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top">&#160;</td>
    <td style="width: 45%; vertical-align: top">
        <div style="line-height: 1.25">Senior Vice President, Preclinical Development and Corporate Operations</div> </td> </tr>
  </table>

<div> <br/> </div>

<div style="text-align: justify; margin-left: 18pt; line-height: 1.25">____________________</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 18pt; line-height: 1.25">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Member
of our Compensation Committee</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Member
of our Audit Committee</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Member
of our Nomination and Corporate Governance Committee</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">78</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Paul Sekhri </span>has extensive experience both as
a leader and a Board member in the Biotech and Pharmaceutical industry including those with a focus on immunology. Mr. Sekhri joined Compugen&#8217;s
Board of Directors as its Chairman in October 2017. Mr. Sekhri serves as the Chairman, President and Chief Executive Officer of vTv Therapeutics
Inc. Prior to joining vTv Therapeutics Inc., from January 2019 until April 2022, Mr. Sekhri served as the President and CEO of eGenesis,
Inc. Prior to joining eGenesis, Inc., Mr. Sekhri served as President and CEO of Lycera Corp. from February 2015 through December 2018.
From April 2014 through January 2015, Mr. Sekhri served as Senior Vice President, Integrated Care for Sanofi. From May 2013 through March
2014, Mr. Sekhri served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical
Industries Ltd. Prior to joining Teva, Mr. Sekhri spent five years as Operating Partner and Head of the Biotechnology Operating Group
at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004 to 2009, Mr. Sekhri was Founder, President, and Chief
Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD
Pharmaceuticals, Inc. Previously, Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global Search and Evaluation,
Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri also developed the Disease Area Strategy for Novartis, identifying
those specific therapeutic areas upon which the company would focus. Mr. Sekhri&#8217;s first role at Novartis was as Global Head, Early
Commercial Development. Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he
also received his BS in Zoology. Mr. Sekhri is currently a member of the Board of Directors of eGenesis, Inc., Veeva Systems Inc., and
Spring Discovery&#160;and Chairman of the Board of Directors of vTv Therapeutics Inc., Longboard Pharmaceuticals, Inc. and Resolution
Therapeutics. Additionally, Mr. Sekhri is the Chairman of the Board of the Young Concert Artists (YCA), and a member of Board of The Metropolitan
Opera. Mr. Sekhri is also an active member of the Patrons Council of Carnegie Hall, where he established the Life Sciences Council of
Carnegie Hall.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Anat Cohen-Dayag, Ph.D. </span>joined Compugen&#8217;s
Board of Directors in February 2014. Dr. Anat Cohen-Dayag has over 25 years of experience in the biotech industry, both in R&amp;D and
executive leadership roles. Dr. Cohen-Dayag joined Compugen in 2002, and has held various senior managerial positions, including VP R&amp;D,
before being appointed President and CEO in 2010. Under her leadership, Compugen transformed from a service provider in the field of computational
biology to a therapeutic discovery and development company advancing an innovative immuno-oncology pipeline originating from the company&#8217;s
computational discovery platforms. Dr. Cohen-Dayag joined Compugen&#8217;s Board of Directors in 2014 and is also a member of the Board
of Directors of Pyxis Ltd. and Genopore Ltd. Prior to Compugen, Dr. Cohen-Dayag was the Head of R&amp;D and was a member of the executive
management team of Mindsense Biosystems Ltd. Dr. Cohen-Dayag holds a B.Sc. in Biology from Ben-Gurion University, and an M.Sc. in Chemical
Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Dr. Mathias (Math) Hukkelhoven </span>joined Compugen&#8217;s
Board of Directors in March 2022 and serves as a Venture Partner for Panacea Venture Management Company Ltd. Dr. Hukkelhoven has a wealth
of experience in global regulatory affairs and drug development, evidenced by his contribution to more than 50 NCEs and hundreds of new
indications and line extensions over his career to date. Dr. Hukkelhoven has participated in activities that have shaped health authority
interactions for the industry, including serving as chairperson of the Regulatory Affairs Coordinating Committee at PhRMA, and recently
as a PhRMA negotiator for the PDUFA VII negotiations with the FDA. Since his retirement from Bristol Myers Squibb in July 2021, Dr. Hukkelhoven
has been a consultant for several biotech companies and Senior Advisor for McKinsey and on July 1, 2022 he joined the Board of Directors
of Centessa Pharmaceuticals plc. Dr. Hukkelhoven joined Bristol Myers Squibb in March 2010 as the Senior Vice President, Global Regulatory,
Safety &amp; Biometrics and was also responsible for the R&amp;D group in BMS China and the Clinical Pharmacology and Pharmacometrics
group. As such, he had responsibility for a large part of the global Bristol Myers Squibb development organization. Since the acquisition
of Celgene by Bristol Myers Squibb, he was responsible for Global Regulatory and Safety Sciences at Bristol Myers Squibb. He was accountable
for setting regulatory strategy and driving execution of global regulatory and pharmacovigilance plans for Bristol Myers Squibb. He led
the regulatory and development efforts across the product development and commercialization process to ensure optimal regulatory strategy
and interactions at each step of the process &#8211; research and development, manufacturing, and commercialization. Prior to joining
Bristol Myers Squibb, Dr. Hukkelhoven held the role of Chairman Portfolio Stewardship Board at Novartis Pharmaceuticals. From 2001 to
2009, he was the Senior Vice President, Global Head Drug Regulatory Affairs at Novartis. Dr. Hukkelhoven received&#160;his B.S. and Ph.D.
honors degrees in Biology and Biochemistry from the University of Nijmegen, the Netherlands.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">79</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Gilead Halevy </span>joined Compugen&#8217;s Board
of Directors in June 2018. Mr. Halevy serves as a general partner of Kedma Capital Partners, a leading Israeli private equity fund, of
which he is also a founding member, since 2006. Prior to establishing Kedma, Mr. Halevy served as a Director at Giza Venture Capital from
2001 to 2006, where he led investments in communication and information technology companies and directed Giza&#8217;s European business
activities. From 1998 to 2001, Mr. Halevy practiced law at White &amp; Case LLP. Mr. Halevy was also a founding member of the White &amp;
Case Israel practice group during that time. Mr. Halevy currently serves as chairman of board of directors of Carmel Corp. Ltd.; Continuity
Software Ltd., Zriha Hlavin Industries Ltd. and a director of Keter Holdings Ltd., S. AL Holdings Ltd., Plastfit Ltd. and AA Politiv (1999)
Ltd. Mr. Halevy holds a B.A. in Humanities (multidisciplinary program for exceptional students) and an LL.B. (Magna Cum Laude) both from
the Hebrew University of Jerusalem.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Dr. Kinneret Livnat Savitzky </span>joined Compugen&#8217;s
Board of Directors in June 2018. Dr. Livnat Savitzky currently serves as an entrepreneur in residence at Team8. Dr. Livnat Savitzky also
serves on the boards of the following biotechnology or healthcare companies: Ramot (TTO of Tel-Aviv University), and Biomica Ltd. Between
2017 and 2021 she served as the CEO of FutuRx Ltd., an Israeli biotechnology accelerator established by OrbiMed Israel Partners, Johnson
&amp; Johnson Innovation, Takeda Ventures Inc., and LEAPS, the venture arm of Bayer. From 2010 to 2016, Dr. Livnat Savitzky served as
CEO of BioLineRX Ltd., a Nasdaq-listed drug development company focused on oncology and immunology. During her tenure, BioLineRX signed
a strategic collaboration with Novartis as well as licensing agreements with Merck (MSD), Genentech and others. Prior to being appointed
CEO of BioLineRX, Dr. Livnat Savitzky held various R&amp;D management positions at BioLineRX and Compugen. Dr. Livnat Savitzky holds a
B.Sc. in Biology from The Hebrew University of Jerusalem, and an M.S.c and Ph.D. with distinction in Human Genetics from Tel Aviv University.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Eran Perry </span>joined Compugen&#8217;s Board of
Directors in July 2019. Mr. Perry brings to Compugen over 20 years of diverse experience across various segments of the healthcare industry
as an entrepreneur and venture capital investor as well as in general management and strategy. In 2018, Mr.&#160;Perry co-founded MII
Fund &amp; Labs, an immunology dermatology-focused venture capital fund where he also serves as Managing Director and Chairman of the
Investment Committee. Mr. Perry is also the co-founder and board member of several pharmaceutical companies including Seanergy Dermatology,
Follicle Pharma, Silverskate Bio and Upstream Bio. Mr. Perry also serves on the board of directors of MyBiotics Pharma and Noon Aesthetics.
From 2006 to 2016, he served as Managing Director and Partner of Israel Healthcare Ventures (IHCV) and represented IHCV in numerous portfolio
companies. Prior to IHCV, Mr. Perry was a consultant in McKinsey &amp; Company, serving clients worldwide in the pharmaceutical industry,
among others. Prior to that, he was a member of the Global Marketing group at Novartis Oncology.&#160;Before moving to the private sector,
Mr.&#160;Eran Perry served in the Israeli Ministry of Justice. Mr. Perry holds an MBA from Columbia University, and an LL.B. in Law and
a B.Sc. in Mathematics and Computer Science, both from Tel Aviv University.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Sanford (Sandy) Zweifach </span>joined Compugen&#8217;s
Board of Directors in June 2018. Mr. Zweifach is a senior executive with over 32 years of experience in the life sciences industry. He
has extensive experience in corporate partnering, business development, operations, private and public investing, and capital raising.
Mr. Zweifach founded and served as CEO of both Nuvelution Pharma, Inc. and Ascendancy Healthcare, Inc. Mr. Zweifach was also a Partner
at Reedland Capital Partners, a boutique investment bank, where he headed its life sciences M&amp;A and advisory efforts. Prior to this,
he was CEO of Pathways Diagnostics, a biomarker development company. Mr. Zweifach was a Managing Director/CFO of Bay City Capital, a venture
capital/merchant banking firm, specializing in the biotech and the life science industry, where he was President of the firm&#8217;s M&amp;A
and financing division and was also responsible for oversight of the firm&#8217;s finance department. Prior to this, he was President
and CFO of Epoch Biosciences, which was acquired by Nanogen. Currently Mr. Zweifach serves as the Chairman of the Board of Directors of
Carisma Therapeutics, Inc., President and CBO and member of the Board of Directors of IMIDomics, Inc. and a member of the Board of Directors
of Essa Pharma, Inc. In addition, he sits on several other private boards and has advisory roles with two investment funds. Earlier in
his career, Mr. Zweifach was a Certified Public Accountant (US) for Coopers &amp; Lybrand and held various investment banking positions
focusing on biotech. He received his B.A. in Biology from UC San Diego and an M.S. in Human Physiology from UC Davis.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">David Silberman</span>&#160;joined Compugen on August
15, 2024, as Chief Financial Officer. Before joining Compugen, Mr. Silberman served from 2021 to 2024 as Chief Financial Officer of Oramed
Pharmaceuticals (NASDAQ: ORMP, TASE: ORMP), a pharmaceutical company engaged in the research and development of innovative pharmaceutical
solutions with a technology platform that allows for the oral delivery of therapeutic proteins. Prior to joining Oramed Pharmaceuticals
as Chief Financial Officer in 2021, Mr. Silberman served as a Corporate Financial Planning and Analysis Director and as Global Internal
Audit Senior Manager at Teva Pharmaceutical Industries Ltd. Earlier in his career, Mr. Silberman provided internal audit and risk management
services in the advisory department of Grant Thornton Fahn Kanne Control Management and served in the audit department of KPMG. Mr. Silberman
holds degrees in accounting and management from the French Ministry of Higher Education and Research and is a certified public accountant
in Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">80</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Dr. Michelle Mahler</span> joined Compugen in October
2023 as Vice President of Clinical Development and was promoted to Chief Medical Officer, effective March 1, 2024. Before joining Compugen,
Dr. Mahler was most recently the Chief Medical Officer of 1 E Therapeutics Ltd., a drug development company, creating a novel class of
programmable oligonucleotide therapeutics and Aummune Therapeutics Ltd., a clinical stage company developing a first-of-its-kind approach
for individualized treatment of solid tumors. Dr. Mahler was Vice President of Clinical Development at C4 Therapeutics, Inc., helping
to build up the clinical development group and leading the successful submission of two INDs and initiation of Phase 1 studies. Prior
to C4 Therapeutics, Dr. Mahler worked in R&amp;D for 9 years at Janssen (now Johnson &amp; Johnson). During her time there she gained
experience in late-stage clinical development, pediatric development and global medical affairs while being a key member of the ibrutinib
development team and held positions of increasing responsibility. In addition, Dr. Mahler supported key due diligence projects including
the acquisition of Momenta Pharmaceuticals, Inc., by Johnson &amp; Johnson. Prior to starting in industry in 2011, Dr. Mahler trained
at Memorial Sloan Kettering Cancer Center and New York Presbyterian Hospital/Weill Cornell. She also spent time at Columbia Presbyterian
and Mount Sinai Medical Center in New York. Dr. Mahler obtained her medical degree from University of the Witwatersrand, South Africa
and is a board-certified pediatric hematologist and oncologist.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Zurit Levine, Ph.D. </span>was appointed as Senior
Vice President, Strategic Collaborations in 2024 responsible for identifying and establishing strategic partnerships, competitive market
intelligence and Compugen&#8217;s IP strategy and portfolio. Dr. Levine joined Compugen in 1999 and has held several positions in Compugen&#8217;s
Research &amp; Development department. In 2004, she was appointed Director of Therapeutic Selection &amp; Validation, which position she
held until 2007 when she was appointed Director of Therapeutic Discovery. In 2009, she was appointed Executive Director of Research &amp;
Development. From January 2010 to August 2011, she held the position of Vice President, Research and Development. In August 2011 she was
appointed Vice President, Research and Discovery and in 2018, Dr. Levine was appointed as Senior Vice President, Technology Innovation.
Dr. Levine holds a B.Sc. in Biology, a M.Sc. in Biochemistry and a Ph.D. in Biochemistry, all from the Tel Aviv University, Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Yaron Turpaz, Ph.D.</span> was appointed as Senior
Vice President and Senior Advisor, Data and Informatics Solutions in May 2023. In his role, Dr. Turpaz is responsible for the overall
data flow inside and outside the organization. Dr. Turpaz supports the Computational Discovery unit in the ongoing development of the
computational platforms, and also oversees the establishment of systems for data analytics across the organization. Dr. Turpaz joined
Compugen in November 2019 as Senior Vice President and Senior Advisor, Computational Discovery. Dr. Turpaz has over 15 years of experience
in the fields of research and development informatics, data sciences and technology in the biotech and pharma space with hands-on experience
using cloud-based high throughput computational, machine learning and genomics platforms for drug discovery and development applications
in precision medicine. In his extensive pharma and biotech career, he held senior R&amp;D Informatics roles at Human Longevity, AstraZeneca,
Eli Lilly, Global Gene Corp. and Affymetrix. Dr. Turpaz continues to serve as Chief Information Officer and Senior Advisor at Engine Biosciences.
Dr. Turpaz received a B.Sc. in Biology from Tel Aviv University, a Ph.D. in Bioengineering from the University of Illinois and an MBA
from the University of Chicago, Booth School of Business. He also held an Adjunct Assistant Professor position at the Centre for Quantitative
Medicine of Duke-National University of Singapore, Graduate Medical School.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Eran Ophir, Ph.D.</span> joined Compugen in 2015 and
was appointed Vice President of Research and Drug Discovery in March 2020 and became a Senior Vice President, Research and Drug Discovery
in March 2022 and Chief Scientific Officer in May 2023. In his role, Dr. Ophir is overseeing the Company&#8217;s computational discovery
and the research and drug discovery activities and is responsible for the scientific, translational medicine and biomarker strategy of
the Company&#8217;s innovative portfolio of product candidates. Dr. Ophir brings significant expertise in immunology and immuno-oncology
from his research work at the Weizmann Institute of Science and the Ludwig Institute for Cancer Research in Lausanne, Switzerland. Dr.
Ophir joined Compugen as a senior scientist and has since held various positions in the Research and Development department, with increasing
responsibilities, including appointment to the management team in March 2020. Dr. Ophir received a B.Sc. in Bioinformatics from Tel Aviv
University and a Ph.D. in Biology from the Weizmann Institute of Science.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">81</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Pierre Ferre, Ph.D.</span> joined Compugen in April
2021 as Vice President Preclinical Development and in 2024 was appointed as Senior Vice President, Preclinical Development and Corporate
Operations. In his role, Dr. Ferre leads the preclinical development, CMC and drug supply management, clinical biomarker operations, project
management team and activities across the Company, quality assurance organization and CROs/vendors partnering. Dr. Ferre has two decades
of experience in all aspects of clinical and non-clinical drug development in oncology and immuno-oncology. Dr. Ferre joined Compugen
from Pierre Fabre Pharmaceuticals, France, where he spent most of his career in multiple positions, lastly as Director of Oncology Programs
in which he led the development strategy of a portfolio of R&amp;D programs in oncology from initiation and discovery, through preclinical
and clinical development. Previously, at Pierre Fabre Oncology R&amp;D, he acted as Director, Pharmacokinetics/Pharmacodynamics, overseeing
also translational, biomarker-related activities. Before that Dr. Ferre was in charge of oncology preclinical pharmacokinetics. Dr. Ferre
is a Doctor in Veterinary Medicine, holds a PhD in biology from Toulouse INP (Institut National Polytechnique), and a MSc from Aix-Marseille
University and Paris INA-PG (Institut National Agronomique) for his research work conducted in experimental pathophysiology and toxicology.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Arrangements Involving Directors and Senior Management</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">There are no arrangements or understandings of which we are aware relating to the
election of our directors or the appointment of executive officers in our Company. In addition, there are no family relationships among
any of the individuals listed in this Item 6.A.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. COMPENSATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Aggregate Executive Compensation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During 2024, the aggregate compensation paid or accrued by us to all persons listed
in Item 6.A above (Directors and Senior Management) and two former members of senior management (Dr. Henry Adewoye and Mr. Alberto Sessa)
who ceased to serve before the end of 2024, was approximately $4.9 million. This amount includes approximately $0.8 million set aside
or accrued to provide pension, severance, retirement or similar benefits, but excludes expenses (including business travel, professional
and business association dues and expenses) reimbursed to our executives and other fringe benefits commonly reimbursed or paid by companies
in Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During 2024, we granted to our Directors and Senior Management listed in Item 6.A
a total of 596,250 options to purchase ordinary shares and a total of 124,375 restricted share units, or RSUs. The options are exercisable
at a weighted average exercise price of $2.00 per share and generally expire ten years after their respective dates of grant. As of December
31, 2024, there were a total of 4,171,250 outstanding options to purchase ordinary shares and 124,375 RSUs that were held by our Directors
and Senior Management listed in Item 6.A.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Individual Compensation of Covered Office Holders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">The table below outlines the compensation granted to our five most highly compensated
Office Holders (as such term is defined in the Companies Law - see below under &#8220;Approvals Required for Office Holders Terms of Office
and Employment&#8221;) with respect to the year ended December&#160;31, 2024. All amounts reported in the table reflect the cost to the
Company, as recognized in our financial statements for the year ended December&#160;31, 2024. We refer to the five individuals for whom
disclosure is provided herein as our &#8220;Covered Office Holders&#8221;.</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div> </div>

<table cellspacing="0" cellpadding="0" id="za88b30e05588453ab0b55ae7d79feadf" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">Information Regarding the Covered Office Holders</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="14" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Compensation for Services<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Name and Principal Position<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Base Salary ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Benefits and Perquisites ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Stock-Based Compensation ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Total ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Dr. Anat Cohen-Dayag</div>
        <div style="line-height: 1.25">President &amp; Chief Executive Officer</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">486,526</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">256,619</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">500,388</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,243,533</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%; padding-bottom: 2px">
        <div style="line-height: 1.25">Dr. Pierre Ferre</div>
        <div style="line-height: 1.25">SVP, Preclinical Development and Corporate Operations</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">238,204</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">233,205</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">132,588</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">603,997</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Dr. Michelle Mahler<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(5)</sup></div>
        <div style="line-height: 1.25">Chief Medical Officer</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">351,380</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">230,387</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">11,226</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">592,993</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%; padding-bottom: 2px">
        <div style="line-height: 1.25">Dr. Eran Ophir</div>
        <div style="line-height: 1.25">Chief Scientific Officer</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">201,097</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">111,138</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">165,984</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">478,219</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Dr. Zurit Levine</div>
        <div style="line-height: 1.25">SVP, Strategic Collaborations</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">193,529</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">110,168</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">158,101</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">461,798</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">82</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25"><br/>

<table cellspacing="0" cellpadding="0" id="zeb796d7232a04952a99379d3a3d14f8a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 54pt; vertical-align: top">1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>All Covered Office Holders listed in the table were full-time officers of the Company during their term of service in 2024, other
        than Dr. Michelle Mahler who became an officer on March 1, 2024. See footnote 5 below regarding Dr. Mahler&#8217;s compensation.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5376c8b767c64ab3a5361d58ac84aedf" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 54pt; vertical-align: top">2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Cash compensation amounts denominated in currencies other than the dollar were converted into dollars at an exchange rate of NIS
        3.6997 = $1.00, which reflects the average conversion rate for 2024, or the Representative Rate.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2ba084716a324fec9cb561611ed250f3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 54pt; vertical-align: top">3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Amounts reported in this column include benefits and perquisites, including those mandated by applicable law. Such benefits and perquisites
        may include, to the extent applicable to the respective Covered Office Holder, bonuses, payments, contributions and/or allocations for
        savings funds, pension, severance, vacation, car or car allowance, medical insurances and benefits, risk insurance (e.g., life, disability,
        accident), phone, convalescence pay, payments for social security, tax gross-up payments and other benefits and perquisites consistent
        with the Company&#8217;s policies.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z06d7b8a72e63430e926a5b9ca4a5e5f4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 54pt; vertical-align: top">4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Amounts reported in this column represent the expense recorded in our financial statements for the year ended December 31, 2024,
        with respect to options to purchase our ordinary shares and RSUs granted to our Covered Office Holders. Assumptions and key variables
        used in the calculation of such amounts are discussed in Note 2n to our 2024 consolidated financial statements set forth elsewhere in
        this report.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zca4aaaf5cc86417eb599113f613811ae" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 54pt; vertical-align: top">5)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>While the compensation components stated herein reflect Dr. Michelle Mahler annual compensation starting January 2024, Dr. Michel
        Mahler became an officer on March 1, 2024.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation Policy</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law we are required to adopt a compensation policy, which sets
forth company&#8217;s policy regarding the terms of office and employment of Office Holders (as such term is defined in the Companies
Law), including compensation, equity awards, severance and other benefits, exemption from liability and indemnification. Such compensation
policy should take into account, among other things, the provision of proper incentives to Office Holders, management of risks by the
company, the Office Holders&#8217; contribution to achieving corporate objectives and increasing profits, and the function of the officer
or director.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our compensation policy, or the Compensation Policy, is designed to balance between
the importance of incentivizing Office Holders to reach personal targets and the need to assure that the overall compensation meets our
long-term strategic performance and financial objectives. The Compensation Policy provides our compensation committee and our board of
directors with adequate measures and flexibility to tailor each of our Office Holder&#8217;s compensation package based, among other matters,
on geography, tasks, role, seniority and capability. Moreover, the Compensation Policy is intended to motivate our Office Holders to achieve
ongoing targeted results in addition to high-level business performance in the long term, without encouraging excessive risk taking. The
Company draws upon a pool of talent that is highly sought after by large and established global pharmaceutical and biotechnology companies,
as well as by other development-stage life science companies which operate both within and outside of the Company&#8217;s geographic areas.
The Company believes that it therefore must offer its Office Holders compensation terms that are competitive with the compensation standards
that exist in the companies with whom it competes for such talents.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">83</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In accordance with the Companies Law, an Israeli public company&#8217;s compensation
policy and any amendments thereto must be approved by the board of directors, after considering the recommendations of the compensation
committee, and generally by a special majority of our shareholders, or a Special Majority, which include (i) at least a majority of the
shareholders who are not controlling shareholders and who do not have a personal interest in the matter, present and voting (abstentions
are disregarded), or (ii) the non-controlling shareholders and shareholders who do not have a personal interest in the matter who were
present and voted against the matter hold two percent or less of the voting power of the company. The compensation policy must be reviewed
from time to time by the board and must be re-approved or amended by the board of directors and generally by the shareholders at least
once every three years. If the compensation policy is not approved by the shareholders, the compensation committee and the board of directors
may nonetheless, in special circumstances, approve the policy, following further discussion of the matter and for detailed reasons.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our Compensation Policy for Office Holders was originally approved by our shareholders
in September 2013, with the most recent amendment adopted at the 2023 Annual General Meeting of Shareholders held on September 20, 2023,
or the 2023 AGM.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Approvals Required for Office Holders Terms of Office and Employment</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The term &#8220;Office Holder&#8221; as defined in the Companies Law includes a director,
the chief executive officer, chief business manager, deputy chief executive officer, vice chief executive officer, any other person fulfilling
or assuming any of the foregoing positions without regard to such person&#8217;s title, and any manager who is directly subordinated to
the chief executive officer. In addition to each person listed in the table under &#8220;Item 6. Directors, Senior Management and Employees
- A. Directors and Senior Management&#8221;, two other individuals have been Office Holders as of December 31, 2024.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#8220;Terms of Office and Employment&#8221; means the terms of office and employment
of our Office Holders, including exemption and release of the Office Holder from liability for breach of his or her duty of care to the
Company, an undertaking to indemnify the Office Holder, post factum indemnification or insurance; any grant, payment, remuneration, compensation,
or other benefit provided in connection with termination of service and any benefit, other payment or undertaking to provide any payment
as aforesaid.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Compensation for Office Holders subordinated to the
Chief Executive Officer.</span> The Terms of Office and Employment of Office Holders (other than directors and the chief executive officer)
require the approval of the compensation committee and the board of directors, in that order, provided that such terms are in line with
the company&#8217;s compensation policy. In the event that the Terms of Office and Employment of such Office Holder are not in line with
such policy, additional shareholder approval is also required. However, in special circumstances the compensation committee and then the
board of directors may nonetheless approve such Terms of Office and Employment even if such terms were not approved by the shareholders,
following a further discussion and for detailed reasoning.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Compensation for Office Holders who are Directors
or Chief Executive Officers.</span> The Terms of Office and Employment of directors, other than directors who serve as chief executive
officers and/or who possess a controlling interest in a company or who are external directors (to the extent applicable), require the
approval of the compensation committee, board of directors and shareholders by a simple majority, as long as they are in line with the
compensation policy. With respect to our president and chief executive officer, who is also a director, or with respect to any chief executive
officer who is not a director (to the extent applicable in the future), further approval of the shareholders by the Special Majority is
required. However: (A) under certain circumstances, and to the extent that the proposed Terms of Office and Employment are in line with
the compensation policy, a company may be exempt from receiving shareholder approval with respect to the Terms of Office and Employment
of a candidate for the position of chief executive officer (provided that the candidate is not a director) (i) provided that the company&#8217;s
compensation committee and board of directors approved such terms and that such terms: (a) are not more beneficial than the terms of the
former chief executive officer, or are essentially the same in their effect; (b) are in line with the compensation policy; and (c) are
brought for shareholder approval at the next general meeting of shareholders; and (B) a company&#8217;s compensation committee and board
of directors are permitted to approve Terms of Office and Employment of a director, without convening a general meeting of shareholders,
provided that such terms are only beneficial to the Company or that such terms are in line with the terms set forth in the Israeli Companies
Regulations (Rules Regarding Compensation and Expenses of External Directors), 2000, or the Compensation Regulations. To the extent applicable,
external directors are entitled to Terms of Office and Employment as set forth in the Compensation Regulations, as supplemented by the
Israeli Companies Regulations (Alleviation for Public Companies whose shares are Traded on the Stock Exchange Outside of Israel), 2000,
or the Alleviation Regulations. In addition, the Israel Securities Authority may issue from time to time bulletins or staff position statements
relating to, among other things, compensation payable to external directors. Since our board of directors determined to opt out of the
requirement to elect and have external directors and composition criteria of the audit committee and compensation committee under the
Companies Law pursuant to the relief available under the Alleviation Regulations, as further detailed in this Item below under &#8220;Board
Practices - External Directors and Independent Directors Under the Companies Law&#8221;, we are not subject to such bulletins or staff
position statements.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">84</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Variable Compensation and Annual Cash Bonuses of
Office Holders</span>. The Companies Law requires that all variable compensation of directors and chief executive officers be based on
measurable criteria, with the exception of a non-substantial portion of up to 3 monthly salaries, which should take into consideration
the applicable Office Holder&#8217;s contribution to the company. With respect to Office Holders who are not directors or chief executive
officers, the Companies Law allows that 100% of the variable compensation be based on non-measurable criteria. Our Compensation Policy
allows for a non-substantial portion of up to 20% of the bonus objectives for each year to be based on non-measurable criteria, provided,
however, that with respect to (i) our Office Holders who are not directors nor our chief executive officer, our compensation committee
and board of directors may increase the portion of targets based on non-measurable criteria above the rate of 20%, up to 50% and with
respect to our chief executive officer, our compensation committee and board of directors may increase the portion of targets based on
non-measurable criteria for up to three (3) monthly base salaries. Further, the annual cash bonus of each of our Office Holders who is
not a director is determined according to a formula that is consistent with the Compensation Policy and that links the bonus payment score
to measurable and qualitative objectives relating to both the Company&#8217;s performance and to the performance by each such Office Holder
of his responsibilities. In the case of our Office Holders, other than the chief executive officer, assuming that the bonus terms conform
to the Compensation Policy, the annual bonus objectives and subsequent payment scores are determined by the compensation committee and
board of directors, while the bonus terms for our chief executive officer generally require the additional approval by our shareholders.
Our board of directors established a policy that sets forth the maximum target bonus for each of our Office Holders, including our chief
executive officer and targets are being approved annually.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation Paid to our Non-Executive Directors (other than Mr.
Paul Sekhri)</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On August 6, 2018, our shareholders approved, following previous resolutions made
by our audit committee (then sitting as a compensation committee) and the board of directors, and consistent with our Compensation Policy,
to compensate each of our non-executive directors whether currently in office or appointed in the future, excluding the Chairman of the
Board (each a &#8220;non-executive director&#8221;) as follows:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic"><span style="text-decoration: underline">Cash Fee</span></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-left: 7.1pt; line-height: 1.25">(i)&#160; an annual fee of $45,000; and</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-left: 9pt; line-height: 1.25">(ii) an additional annual amount to be paid to non-executive directors
for service as members on each of the Company&#8217;s committees, as follows:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zd373de417ead43d3a77b1f957b863b52" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt"><br/> </td>
    <td style="width: 32pt; vertical-align: top; font-family: Times New Roman,Times,serif">(a)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Audit Committee - $2,500 for a member, or $5,000 for the chairperson;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zbbf5b57a083c470c8215426a7a1d6ed1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt"><br/> </td>
    <td style="width: 32pt; vertical-align: top; font-family: Times New Roman,Times,serif">(b)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Compensation Committee - $2,000 for a member, or $4,000 for the chairperson; and</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z2417255a6fe5484391b00a8c10befe69" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt"><br/> </td>
    <td style="width: 32pt; vertical-align: top; font-family: Times New Roman,Times,serif">(c)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Nomination and Governance Committee - $1,000 for a member, or $3,000 for the chairperson.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25">No additional compensation shall be paid for attendance at a board or committee meeting.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">VAT is added to the above compensation in accordance with applicable law.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic"><span style="text-decoration: underline">Equity</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to the cash compensation detailed above, at the 2024 Annual General Meeting
of Shareholders held&#160;on September 12, 2024, or the 2024 AGM, our shareholders approved, following previous resolutions made by our
compensation committee and the board of directors, and consistent with our Compensation Policy, that each non-executive director is entitled
to a yearly grant of options to purchase the Company&#8217;s ordinary shares, so that in the first year of service as a director, each
non-executive director shall be entitled to a one-time grant of 50,000 options, or Initial Equity Grant, and, in addition, to a yearly
grant of 25,000 options in each of the following years of service, or the Annual Equity Grant, as detailed below.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">85</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The grant date of each Initial Equity Grant is the date of appointment for service
as director, whether initially appointed by the Board or by the general meeting of shareholders, with an exercise price equal to the closing
price of the Company&#8217;s ordinary shares on the Nasdaq on the last trading day prior to the date of their initial appointment to serve
on the Board. The grant date of each Annual Equity Grant shall be such date in each year on which the Board approves the annual equity
grants to other management Office Holders (provided that the service as director continues at the time of each grant), with an exercise
price equal to the closing price of the Company&#8217;s ordinary shares on the Nasdaq on the last trading day prior to such Board approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Both the Initial and the Annual Equity Grants are subject (other than as described
herein) to the terms and conditions of the 2010 Plan, or any other equity-based incentive plan the Company may adopt in the future and
pursuant to which these equity awards would be granted. All such grants vest over a four-year period as follows: twenty five percent (25%)
of the options granted vest on the first day of the quarter one calendar year immediately following the quarter in which the options were
granted; and an additional 6.25% of the options granted vest each quarter thereafter, for the next 36 months.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Notwithstanding the terms of the relevant plan, all options granted to non-executive
directors become fully vested immediately upon the completion of one or more of the following events, whether by way of a consolidation,
merger or reorganization of the Company or otherwise: (a) a sale of all or substantially all of Company&#8217;s issued share capital or
assets to any other company, entity, person or a group of persons, or (b) the acquisition of more than 50% of the Company&#8217;s equity
or voting power by any shareholder or group of shareholders. Further, notwithstanding the terms of the relevant plan, all options granted
which shall be vested as of the date of final termination of office as a non-executive director of the Company may be exercised within
one year following such termination of office. To the extent legally available and applicable, such options will be granted to the non-executive
directors through a trustee under Section 102 of the Israel Income Tax Ordinance [New Version], 5721-1961, or the Tax Ordinance, under
the capital gains route.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">At the Company&#8217;s Annual General Meeting of Shareholders for 2020, held on September
16, 2020, or the 2020 AGM, and the 2024 AGM, our shareholders approved, following previous resolutions made by our compensation committee
and the board of directors, and consistent with our Compensation Policy, that the compensation committee and the board may issue to all
non-executive directors RSUs or other equity awards which are not options, or Other Equity in connection with the Initial Equity Grant
and the Annual Equity Grant, and that each such grants shall be adjusted, on a pro rata basis, to give effect to the relative portion
of each type of equity awarded. For the purpose of determining the respective number of Other Equity, Other Equity shall be given a &#8220;double
weight&#8221; relative to options, so that each unit of Other Equity will be equal to two (2) option units, such that for illustration
purposes, if the compensation committee and board of directors approve the grant of 2,500 RSUs to the non-executive directors, the relevant
annual equity grant will be comprised of a total of 22,500 units, out of which 20,000 will be options and 2,500 will be RSUs. The same
weight will apply to the Initial Equity Grant.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The provisions relating to vesting, acceleration and exercise period applicable to
options, as specified above, shall apply to Other Equity that may be granted,&#160;<span style="font-style: italic">mutatis mutandis</span>.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation to the Company&#8217;s Chairman of the Board of Directors,
a Non-Executive Director</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On October 19, 2017, our shareholders approved, following previous resolutions made
by our audit committee (then sitting as a compensation committee) and the board of directors, and consistent with our Compensation Policy,
the following Terms of Office and Employment of for our non-executive Chairman of the Board, Mr. Paul Sekhri:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Cash Fees: </span>An annual cash fee in the amount
of $150,000. No meeting fees will be paid in addition to such annual cash fee.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Grant of Options to Purchase Ordinary Shares:</span>
In connection with his appointment as the Chairman of the Board, we issued to Mr. Sekhri an initial grant of options to purchase 500,000
ordinary shares. These options were issued pursuant to the terms and conditions applicable to options granted under the Company&#8217;s
2010 Option Plan. Such grant vested over a four-year period as follows: twenty five percent (25%) vested on the first day of the quarter
one calendar year immediately following the quarter in which the options were granted; and an additional 6.25% vested each quarter thereafter
for the next 36 months. These options expire ten years after the grant date, unless they expire earlier in accordance with the terms of
the Company&#8217;s 2010 Option Plan. The acceleration provisions applicable to options granted to other non-executive directors also
apply to the options granted to Mr. Sekhri and all options granted which shall be vested as of the date of final termination of office
as a director of the Company may be exercised within one year following such termination date.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">86</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">At the 2020 AGM, our shareholders approved, following previous resolutions made by
our compensation committee and the board of directors, and consistent with our Compensation Policy, that Mr. Sekhri, in his role as the
non-executive chairman of the Board, shall be entitled to an annual option grant of 10,000 options to purchase Ordinary Shares each year,
or Chairman&#8217;s Annual Equity Grant, starting from 2020 and for each of the following years of service, similar to the terms of the
Annual Equity Grant to the other non-executive directors as specified above. At the 2024 AGM, our shareholders approved an increase in
the Chairman&#8217;s Annual Equity Grant to 25,000 options (as approved for the other non-executive directors) and it was further approved
that similarly to the other non-executive directors, instead of Chairman&#8217;s Annual Equity Grant (as increased in the 2024 AGM), the
compensation committee and the board may issue to Mr. Sekhri Other Equity,&#160;in which case the Chairman&#8217;s Annual Equity Grant
of 25,000 options shall be&#160;adjusted in accordance with the weights specified above if Other Equity awards are awarded.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The provisions relating to vesting, acceleration and exercise period applicable to
the options, as specified above, shall apply to Other Equity that may be granted as set forth above,&#160;<span style="font-style: italic">mutatis
mutandis</span>.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In accordance with the approval of the 2024 AGM, in 2024, we issued to each of our
non-executive directors (including the Chairman of our Board) an Annual Equity Grant comprised of 20,000 options and 2,500 RSUs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation to our President and Chief Executive Officer</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Pursuant to Dr. Anat Cohen-Dayag&#8217;s employment agreement (and in accordance with
the approval of her updated Terms of Office and Employment at the 2023 AGM), as the chief executive officer of the Company she is entitled
to a gross monthly salary of NIS 150,000 (approximately $40,650 according to the Representative Rate). Dr. Cohen-Dayag is also entitled
to certain benefits and perquisites customary in Israel, including those mandated by applicable law. In addition, Dr. Anat Cohen-Dayag
is eligible for an annual grant of equity-based compensation and to an annual cash bonus based upon achievement of objectives determined
by the Company, both subject to receipt of all approvals required by applicable law and to the terms of our Compensation Policy.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">At the 2023 AGM, our shareholders approved that Dr. Cohen-Dayag shall be eligible
to receive an annual cash bonus of up to nine monthly salaries for each of the calendar years 2024, 2025 and 2026, without the need for
further shareholder approval, subject to meeting the specific performance criteria determined by the compensation committee and board
with respect to each such year, in accordance with the objectives and terms thereof and the continuous employment of Dr. Cohen-Dayag as
the Company&#8217;s chief executive officer through the last day of the calendar year with respect to which the annual cash bonus is proposed
to be paid. In addition, in accordance with our Compensation Policy, in addition to annual cash bonuses, our compensation committee and
board of directors may approve a special bonus for significant or extraordinary achievements or efforts that produced an exceptional result,
up to a total maximum amount (to any calendar year) equal to 6 monthly base salaries of the relevant Office Holder. Accordingly, at the
2024 AGM, our shareholders approved the grant of a special cash bonus in the amount of NIS 202,000 (approximately $79,140 based on the
NIS/USD representative rate used in connection with the 2024 AGM) to Dr. Cohen-Dayag in connection with her significant contribution to
the engagement with Gilead in the License Agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, at the 2023 AGM, our shareholders approved an annual equity grant plan
for Dr. Cohen-Dayag for each of the calendar years 2024, 2025 and 2026, according to which Dr. Cohen-Dayag shall be granted options to
purchase up to 300,000 Ordinary Shares, or Equity Framework, in each of these years, as shall be determined by the compensation committee
and board of directors with respect to each such year. In order to align such grants (including the exercise price and vesting period)
with the annual grant of options to other executive Office Holders (for whom shareholder approval is not required), our shareholders resolved
that the annual grant to Dr. Cohen-Dayag will be made on such date in 2024, 2025 and 2026 on which the board of directors approves the
respective year&#8217;s annual option grants to management Office Holders in such year.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">87</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The compensation committee and the board of directors may nevertheless determine that
as part of an annual equity grant, they wish to issue&#160;Dr. Cohen-Dayag Other Equity. For the purpose of demining the applicability
of the Equity Framework to Other Equity, Other Equity shall be given a &#8220;double weight&#8221; relative to options, so that each unit
of Other Equity will be equal to two (2) option units as illustrated above under &#8220;<span style="font-style: italic">Compensation
to our Non-Executive Directors (other than Mr. Paul Sekhri)</span>&#8221;. In any event, at least 30% of the value of any annual equity
grant to Dr. Cohen-Dayag shall be based on either (i) options granted with fair market value exercise price; or (ii) Other Equity which
vesting is based on both time and performance criteria, as shall be determined by the compensation committee and board of directors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The options granted in each respective year shall be subject to the terms and conditions
applicable to options granted under the 2010 Plan (or any other option plan adopted by the Company). Each annual equity grant will vest
over a four-year period as follows: twenty five percent (25%) will vest on the last day of the quarter one calendar year from the date
of grant; and an additional 6.25% will vest each quarter thereafter for the next 36 months. These options granted in these equity grants
will have an exercise price equal to the closing price of the Company&#8217;s ordinary shares on Nasdaq on the last trading day prior
to the approval of each year&#8217;s grant by the board of directors. These equity grants will expire ten years after the grant date,
unless they expire earlier in accordance with the terms of the 2010 Plan or the terms of the option agreement to be entered into between
the Company and Dr. Cohen-Dayag. If applicable, the equity grants will be granted through a trustee under Section 102 of the Tax Ordinance
and, in accordance with the Company&#8217;s previous election in this regard, be subject to the capital gains route for tax purposes.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All vested options and Other Equity (to the extent applicable) granted to Dr. Cohen-Dayag
under the Equity Framework shall have a one-year exercise period following the termination of her employment as the Company&#8217;s chief
executive officer, other than in the event of termination for &#8220;cause&#8221; (as defined in her employment agreement as shall be
in effect from time to time). In addition to the foregoing, and not as part of the Equity Framework, Dr. Anat Cohen-Dayag will be entitled
to participate in the ESPP or any other employee share purchase plan(s) that may be adopted by the Company from time to time until the
end of 2026, as long as the fair market value of the benefit provided to her under such employee share purchase plan(s) (determined by
the Company at the beginning of the respective offering period) in any given twelve (12) month period does not exceed ten percent (10%)
of her annual base salary.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">In addition to the foregoing annual equity grant plan for 2024 through 2026 and the
annual grant for 2023, in 2024 Dr. Cohen-Dayag was granted with 195,000 options with an exercise price of $1.69 and with 52,500 RSUs.
As of December 31, 2024, Dr. Cohen-Dayag held options to purchase a total of 1,515,000 ordinary shares and 52,500 RSUs. Out of the outstanding
options: (i) options to purchase 1,038,750 ordinary shares, with a weighted average exercise price of $5.70 per share, were exercisable
as of December 31, 2024; and (ii) options to purchase 476,250 ordinary shares, with a weighted average exercise price of $1.86 per share,
had not vested as of December 31, 2024. Of the unvested options on December 31, 2024, options to purchase 201,557 ordinary shares are
expected to vest during 2025, options to purchase 133,127 ordinary shares are expected to vest during 2026 and options to purchase the
remaining 141,566 ordinary shares are expected to vest during the period between March 31, 2027, and September 30, 2028. These unvested
options were granted under the Company&#8217;s 2010 Plan. For additional information on Dr. Cohen-Dayag&#8217;s holdings see &#8220;Item
6. Directors, Senior Management and Employee - E. Share Ownership - Share Ownership by Directors and Other Executive Officers.&#8221;</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div> </div>

<div style="text-align: justify; line-height: 1.25">Dr. Cohen-Dayag&#8217;s employment agreement may generally be terminated by either
party by providing six (6) months advance written notice, provided that in the event of termination by the Company for &#8220;justifiable
cause&#8221; (as such term is defined in her employment agreement as shall be in effect from time to time) the Company may terminate Dr.
Cohen-Dayag&#8217;s employment without advance notice and that Dr. Cohen-Dayag may resign with advance notice of only two (2) months in
the event of resignation for &#8220;good reason&#8221; (as such term is defined in her employment agreement as shall be in effect from
time to time). Upon termination, Dr. Anat Cohen-Dayag will be entitled to receive certain payments associated with termination.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the event that Dr. Cohen-Dayag&#8217;s employment is: (a) terminated by the Company,
other than for &#8220;justifiable cause&#8221;; or (b) terminated by Dr. Cohen-Dayag for &#8220;good reason&#8221; (hereinafter, (a) and
(b) shall be referred to together as &#8220;Dismissal&#8221;), Dr. Cohen-Dayag will also be entitled to an additional one-time payment
equal to six (6) monthly salaries, or the Termination Payment, and upon Dismissal within one year following certain &#8220;change of control&#8221;
events (as defined in her employment agreement as shall be in effect from time to time), Dr. Cohen-Dayag will be entitled to a special
termination payment (in addition to the Termination Payment) in an amount equal to six (6) monthly salaries.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">88</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">In addition, upon Dismissal, or in the event of a &#8220;change of control&#8221;,
all outstanding unvested options granted to Dr. Cohen-Dayag as of such time will be accelerated and become immediately exercisable as
of the effective date of such Dismissal or change of control. Upon Dismissal, Dr. Cohen-Dayag will also be entitled to exercise all outstanding
vested options (including those options vested as a result of such accelerated vesting) for a period of one (1) year from the date of
such Dismissal, provided that such period does not extend beyond ten (10) years from the date of grant. Upon an event of change of control,
following which Dr. Cohen-Dayag&#8217;s employment is, within 12 months of the closing of such an event: (a) terminated by the Company,
other than for &#8220;justifiable cause&#8221;; or (b) terminated by Dr. Cohen-Dayag for any reason, Dr. Cohen-Dayag will be entitled
to exercise all outstanding vested options (including those vested as a result of such accelerated vesting) for a period of one (1) year
from the date of termination of her employment, provided that such period does not extend beyond ten (10) years from the date of grant.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Dr. Cohen-Dayag is not entitled to any compensation (including in connection with
her role as a director) in addition to that being paid to her as the chief executive officer of the Company. However, in the event of
termination of Dr. Cohen-Dayag employment agreement, she will be entitled to receive such compensation to the extent and for as long as
she will serve as a non-executive director of the Company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Insurance, Indemnification and Exemption</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, exemption and indemnification of, and procurement of insurance
coverage for, our Office Holders, must be approved by our compensation committee and our board of directors and, with respect to an Office
Holder who is the CEO or a director, also by our shareholders. However, according to regulations promulgated under the Companies Law,
shareholders and board of directors approvals for the procurement of such insurance are not required if the insurance policy is approved
by our compensation committee and: (i) the terms of such policy are within the framework for insurance coverage as approved by our shareholders
and set forth in our Compensation Policy; (ii) the premium paid under the insurance policy is at fair market value; and (iii) the insurance
policy does not and may not have a substantial effect on the Company&#8217;s profitability, assets or obligations. <span style="font-style: italic">Our
Office Holder&#8217;s Insurance</span>. Our Articles provide that, subject to the provisions of the Companies Law, we may enter into contracts
to insure the liabilities of our Office Holders for any liabilities or expenses incurred by or imposed upon them as a result of any act
(or omission) carried out by them as our Office Holders, including with respect to any of the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z599ce7bfa9e9479dae6d3b9faff7cefd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>a breach of duty of care to us or to another person;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zabca6823289f4834b649de40fbcc29d3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>a breach of duty of loyalty to us, provided that the Office Holder acted in good faith and had reasonable grounds to assume that
        such act would not prejudice our interests;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2c1ab9313cfc44cebd9a916416dc710c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>monetary liabilities or obligations imposed upon him or her in favor of another person;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5d0e68ac7284476a9ccd2be5617df14a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>A payment which the Office Holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Securities
        Law, and expenses that the Office Holder incurred in connection with a proceeding under Chapters H&#8217;3, H&#8217;4 or I&#8217;1 of
        the Securities Law, including reasonable litigation expenses, including attorney&#8217;s fees, or in connection with Article D of Chapter
        Four of Part Nine of the Companies Law; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7196cb2fabf14324a0fe2bd77ee809e3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Expenses incurred by the Office Holder in connection with a proceeding under Chapter G&#8217;1, of the Israel Restrictive Trade Practices
        Law, 5748-1988, or Restrictive Trade Law, including reasonable litigation expenses, including attorney&#8217;s fees.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In accordance with our Compensation Policy, approved by our shareholders at the 2023
AGM,&#160;we are currently entitled to hold directors&#8217; and officers&#8217; liability insurance policy for the benefit of our Office
Holders with insurance coverage of up to $100 million and with such annual premium reflecting market&#160;terms&#160;and not having a
substantial effect on our profitability, assets or obligations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Our Office Holders&#8217; Indemnification.&#160;</span>Our
Articles provide that, subject to the provisions of the Companies Law, we may indemnify any of our Office Holders for all liabilities
and expenses incurred by them arising from or as a result of any act (or omission) carried out by them as Office Holders of the Company,
including as follows:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc70a882dc5764c40ad8776aacb6cec0d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>For any monetary liabilities or obligations imposed on our Office Holder in favor of another person pursuant to a court judgment,
        including a compromise judgment or an arbitrator&#8217;s decision approved by a court;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z851e0d7a2b41417cac6339e23acf67d8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>For any payments which our Office Holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the
        Israeli Securities Law and expenses the Office Holder incurred in connection with a proceeding under Chapters H&#8217;3, H&#8217;4 or
        I&#8217;1 of the Israeli Securities Law, including reasonable litigation expenses, including attorney&#8217;s fees, or in connection with
        Article D of Chapter Four of Part Nine of the Companies Law;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">89</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze7e77c5618984cc1a163237e8d183749" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>For reasonable litigation expenses, including attorney&#8217;s fees, incurred by the Office Holder in consequence of an investigation
        or proceeding instituted against the Office Holder by an authority that is authorized to conduct such investigation or proceeding, and
        which was concluded without filing of an indictment against the Office Holder and without imposing on the Office Holder a financial obligation
        in lieu of criminal proceedings, or which was concluded without filing of an indictment against the Office Holder but with imposing on
        such Office Holder a financial obligation in lieu of criminal proceedings in respect of an offense that does not require proof of criminal
        intent or in connection with a financial sanction; For the purposes hereof: (i) &#8220;a proceeding that concluded without filing an indictment
        in a matter in respect of which an investigation was conducted&#8221;; and (ii) &#8220;financial obligation in lieu of a criminal proceeding&#8221;,
        shall have the meanings specified in Section 260(a)(1A) of the Companies Law;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z261eeadcdc9f4513a25d2758f17b9c96" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>For reasonable litigation expenses, including attorney&#8217;s fees, incurred by the Office Holder or which the Office Holder is
        ordered to pay by a court, in a proceeding filed against the Office Holder by the Company or on its behalf or by another person, or in
        a criminal action of which the Office Holder is acquitted, or in a criminal action in which the Office Holder is convicted of an offense
        that does not require proof of criminal intent;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z71b0d7f7523e4cee9453944bfacbbf3c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>For expenses incurred by our Office Holder in connection with a proceeding under Chapter G&#8217;1, of the Restrictive Trade Law,
        including reasonable litigation expenses, including attorney&#8217;s fees; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbcf5505b659945ee9df13b02c737a599" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>For any other liability, obligation or expense indemnifiable or which our Officer Holders may from time to time be indemnifiable
        by law.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Company may undertake to indemnify an office holder as mentioned above: (a) prospectively,
provided that with respect of the first act (financial liability) the undertaking is limited to events which in the opinion of the board
of directors are foreseeable in light of the Company&#8217;s actual operations when the undertaking to indemnify is given, and to an amount
or criteria set by the board of directors as reasonable under the circumstances, and further provided that such events and amount or criteria
are set forth in the undertaking to indemnify, and (b) retroactively.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Indemnification letters, covering indemnification of those liabilities discussed above,
were granted to each of our present Office Holders and were amended at the Company&#8217;s Annual General Meeting of Shareholders for
2021, held on September 2, 2021. Under the letters of indemnification and exemption and release (i) our undertaking to indemnify each
Office Holder for monetary liabilities or obligations imposed by a court judgment (including a settlement or an arbitrator&#8217;s award
approved by a court) is limited to matters that result from or are connected to those events or circumstances set forth therein, and (ii)
the indemnification that we undertake towards all persons whom it resolved to indemnify for the matters and circumstances described therein,
jointly and in the aggregate, do not exceed the higher of the: (i) an amount equal to 25% of the Company&#8217;s shareholders&#8217; equity,
per the most recent financial statements (audited or reviewed) after the time that notice is provided to the Company; or (y) $20 million.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Our Office Holder&#8217;s Exemption. </span>Our Articles
provide that, subject to the provisions of the Companies Law, we may exempt and release our Office Holders, including in advance, from
all or part of such Office Holder&#8217;s liability for monetary or other damages due to a breach of their duty of care to the Company.
Our directors are released and exempted from all liability as aforesaid to the fullest extent permitted by law with respect to any such
breach which has been or may be committed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Limitations on Insurance, Indemnification and Exemption.</span>&#160;The
Companies Law provides that a company may not insure, exempt or indemnify an Office Holder for any breach of his or her liability arising
from any of the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0b5c0be0759d4db4948898d3a822798b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>a breach by the Office Holder of his or her duty of loyalty, except that the company may enter into an insurance contract or indemnify
        an Office Holder if the Office Holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z85988156416d4978a232a6cffc432292" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>a breach by the Office Holder of his or her duty of care if such breach was intentional or reckless, but unless such breach was solely
        negligent;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zded7246e39304367a09e3f169fb2a177" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>any act or omission done with the intent to derive an illegal personal benefit; or</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7a7823ce823e43e6b2080694a8e699bb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>any fine, civil fine, financial sanction or monetary settlement in lieu of criminal proceedings imposed on such Office Holder.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">90</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Administrative Enforcement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Israeli Securities Law includes an administrative enforcement procedure that may
be used by the Israeli Securities Authority, to enhance the efficacy of enforcement in the securities market in Israel. Pursuant to the
Companies Law and the Israeli Securities Law, the Israeli Securities Authority is authorized to impose administrative sanctions, including
monetary fines, against companies like ours and their officers and directors for certain violations of the Israeli Securities Law or the
Companies Law. Furthermore, the Israeli Securities Law requires that the CEO of a company supervise and take all reasonable measures to
prevent the company or any of its employees from breaching the Israeli Securities Law. The CEO is presumed to have fulfilled such supervisory
duty if the company adopts internal enforcement procedures designed to prevent such breaches, appoints a representative to supervise the
implementation of such procedures and takes measures to correct the breach and prevent its reoccurrence.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Israeli Securities Law, a company cannot obtain insurance against or indemnify
a third-party (including its officers and/or employees) for any administrative procedure and/or monetary fine (other than for payment
of damages to an injured party). The Israeli Securities Law permits insurance and/or indemnification for expenses related to an administrative
procedure, such as reasonable legal fees, provided that it is permitted under the company&#8217;s articles of association.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have adopted and implemented an internal enforcement plan to reduce our exposure
to potential breaches of sections in the Companies Law and the Israeli Securities Law, applicable to us. Our Articles and letters of indemnification
permit, among others, insurance and/or indemnification as contemplated under the Israeli Securities Law (see &#8220;<span style="font-style: italic">Insurance,
Indemnification and Exemption&#8221;</span> above).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. BOARD PRACTICES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are incorporated in Israel, and, therefore, are generally subject to various corporate
governance practices under Israeli law such as with respect to external directors, independent directors, audit committee, compensation
committee, an internal auditor and approvals of interested party transactions. These matters are in addition to the requirements of The
Nasdaq Capital Market and other relevant provisions of U.S. securities laws applicable to us. Under the Nasdaq Listing Rules, a foreign
private issuer may generally follow its home country practices for corporate governance in lieu of the comparable Nasdaq Capital Market
requirements, except for certain matters such as composition and responsibilities of the audit committee and the SEC-mandated standards
for the independence of its members. We currently comply with all the above-mentioned requirements. See &#8220;Item 3. Key Information
- D. Risk Factors - Risks related to operations in Israel - Being a foreign private issuer exempts us from certain SEC requirements and
Nasdaq rules, which may result in less protection that is afforded to investors under rules applicable to domestic issuers&#8221;. For
information regarding home country practices followed by us see &#8220;Item 16G - Corporate Governance&#8221;.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Board of Directors</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our Articles provide that we may have no less than five nor more than fourteen directors.
Currently our board of directors consists of seven members. Our directors are elected at the annual general meeting for a term of approximately
one year, ending at the annual general meeting immediately following the annual general meeting at which they were elected or upon earlier
termination in circumstanced referred to under the Companies Law or our Articles. Our directors may further be appointed by the board
of director and in this case shall hold office until the end of the immediately following annual general meeting or upon earlier termination
in circumstanced referred to under the Companies Law or our Articles.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">None of our directors is party to a service contract with us that provides for any
severance or similar benefits upon termination of his or her service, other than our president and chief executive officer, Dr. Anat Cohen-Dayag,
with whom we entered into an employment agreement. For additional information on the employment agreement entered into with Dr. Cohen-Dayag,
please see &#8220;Item 6 - Directors, Senior Management and Employees - B. Compensation - Compensation to our President and Chief Executive
Officer.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Board of Directors Diversity</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">The table below provides certain information regarding the diversity of our board of directors pursuant
to the information provided by them in connection with the preparation of this Annual Report.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="3" border="0" id="z51dbd08b33d443babbd747f9202e5f29" style="font: 10pt Times New Roman,Times,serif; width: 100%; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td colspan="5" style="border-top: rgb(0, 0, 0) 2px solid; width: 100%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">Board Diversity Matrix</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Total Number of Directors</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">7</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">Female</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">Male</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">Non-Binary</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; background-color: rgb(217, 217, 217); border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">Did Not Disclose Gender</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Part I: Gender Identity</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top; background-color: rgb(217, 217, 217); border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Directors</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">2</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">4</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">1</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Part II: Demographic Background</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top; background-color: rgb(217, 217, 217); border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">African American or Black</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Alaskan Native or Native American</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Asian</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Hispanic or Latinx</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Native Hawaiian or Pacific Islander</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">White</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">2</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">3</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Two or More Races or Ethnicities</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">1</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">LGBTQ+</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">1</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Did Not Disclose Demographic Background</div> </td>
    <td colspan="4" style="border: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">1</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">91</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Directors Under the Companies Law - General</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A nominee for service as a director in a public company may not be elected without
submitting a declaration to the company, prior to his or her election, specifying that he or she has the requisite qualifications to serve
as a director, an external director or an independent director, as applicable, and the ability to devote the appropriate time to performing
his or her duties as such.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A director, including an external director or an independent director, who ceases
to meet the statutory requirements to serve as a director, external director or independent director, as applicable, must notify the company
to that effect immediately and his or her service as a director will expire upon submission of such notice.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">External Directors and Independent Directors Under the Companies
Law</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, Israeli public companies are generally required to have on
their board of directors at least two external directors meeting certain independence criteria, provided under Israeli law. In accordance
with the Alleviation Regulations, we, as an Israeli public company with no controlling shareholder (within the meaning of the Companies
Law), whose shares are listed on The Nasdaq Capital Market, may opt out from the requirement of electing and having external directors
on our board of directors and related requirements concerning the composition of the audit and compensation committees of the board of
directors, provided that we do not have a controlling shareholder, we continue to comply with the U.S. securities laws and Nasdaq Listing
Rules applicable to U.S. domestic issuers regarding the independence of the board of directors and the composition of the audit and compensation
committee, or the Opt Out Criteria. On June 7, 2018, our board of directors determined to opt out of the requirement to elect and have
external directors and of the rules governing composition of the audit committee and compensation committee under the Companies Law pursuant
to the relief available under the Alleviation Regulations, since at that time (and since that time) we have complied and continue to comply
with the Opt Out Criteria. In accordance with this decision, we currently have no external directors on our board of directors and we
are subject to the U.S. securities laws and Nasdaq Listing Rules applicable to U.S. domestic issuers regarding the independence of our
board of directors and the composition of our audit and compensation committees.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The term controlling shareholder, as used in the Companies Law for purposes of all
matters related to external directors and for certain other purposes, means a shareholder that has the ability to direct the activities
of the company, other than by virtue of being an Office Holder. For purposes of all matters related to external directors, a shareholder
is presumed to be a controlling shareholder if the shareholder holds 50% or more of the voting rights in the company or has the right
to appoint the majority of the directors of the company or its chief executive officer.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, an &#8216;independent director&#8217; is either an external
director or a director appointed or classified as such who meets the same non-affiliation criteria as an external director, as determined
by the company&#8217;s audit committee, and who has not served as a director of the company for more than nine consecutive years. For
these purposes, ceasing to serve as a director for a period of two years or less would not be deemed to sever the consecutive nature of
such a director&#8217;s service. However, as our shares are listed on The Nasdaq Capital Market, pursuant to the Alleviation Regulations,
we may also classify directors who qualify as independent directors under the relevant non-Israeli rules, as &#8216;independent directors&#8217;
under the Companies Law. In addition, the Alleviation Regulations provide that &#8216;independent directors&#8217; may be elected for
additional terms that do not exceed three years each, beyond the 9 consecutive years, provided that, if the director is being re-elected
for an additional term or terms beyond the 9 consecutive years, the audit committee and board of directors must determine that, in light
of the director&#8217;s expertise and special contribution to the board of directors and its committees, the re-election for an additional
term is to the company&#8217;s benefit and the director must be re-elected by the required majority of shareholders and subject to the
terms specified in the Companies Law. Each of our directors, other than Dr. Anat Cohen-Dayag, who also serves as our chief executive officer,
meets the &#8216;independent directors&#8217; criteria under the Companies Law.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">92</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Independent Directors Under the Nasdaq Listing
Rules</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to the requirements of the Companies Law as described above, since our
shares are listed on The Nasdaq Capital Market, pursuant to the Nasdaq Listing Rules, a majority of our directors must be independent
(as defined under the Nasdaq Listing Rules). We comply with such Nasdaq independence requirement, as each of our directors, other than
Dr. Anat Cohen-Dayag, who also serves as our president and chief executive officer, has been determined by our board of directors to meet
the Nasdaq independence requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Financial and Accounting Expertise Under the
Companies Law</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the Companies Law, the board of directors of a publicly traded company
is required to make a determination as to the minimum number of directors who must have financial and accounting expertise according to
criteria set forth under the Companies Law and regulations promulgated there under and based, among other things, on the type of company,
its size, the volume and complexity of the company&#8217;s activities and the number of directors. Our board of directors has determined
that the minimum number of directors with financial and accounting expertise is one. Currently, each of Mr. Gilead Halevy, Mr. Eran Perry
and Mr. Sanford (Sandy) Zweifach qualifies as such.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Board Committees</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Audit Committee</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Companies Law requires public companies such as ours to appoint an audit committee,
the responsibilities of which include, among other things: (i) identifying flaws in the management of the company&#8217;s business, among
other things, in consultation with the company&#8217;s internal auditor or external auditor, and making recommendations to the board of
directors as to how to correct them, (ii) reviewing and considering certain related party transactions and certain actions involving conflicts
of interest (as well as deciding whether certain actions specified in the Companies Law are considered material or non-material and whether
certain transactions are considered exceptional or ordinary), (iii) establishing procedures to be followed with respect to related party
transactions with a &#8220;controlling shareholder&#8221; (where such are not extraordinary transactions), which may include, where applicable,
the establishment of a competitive process for such transaction, under the supervision of the audit committee, or individual, or other
committee or body selected by the audit committee, in accordance with criteria determined by the audit committee, (iv) determining procedures
for approving certain related party transactions with a &#8220;controlling shareholder&#8221;, which were determined by the audit committee
not to be extraordinary transactions, but which were also determined by the audit committee not to be negligible transactions, (v) reviewing
the internal auditor&#8217;s work program performance, examining the company&#8217;s internal control structure and processes and determining
whether the internal auditor has the requisite tools and resources required to perform his or her role, (vi) examining the external auditor&#8217;s
scope of work as well as the external auditor&#8217;s fees and providing its recommendations to the appropriate corporate organ, (vii)
overseeing the accounting and financial reporting processes of the Company, and (viii) providing arrangements regarding employee complaints
with respect to flaws in the management of the Company&#8217;s business and the protection to be provided to such employees.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Nasdaq Listing Rules, we are required to maintain an audit committee that
operates under a formal written charter and has certain responsibilities and authority, including being directly responsible for the appointment,
compensation, retention and oversight of the work of our external auditor. However, under Israeli law and our Articles, the appointment
of external auditor requires the approval of the shareholders and their compensation requires the approval of our board of directors.
In addition, as described above, pursuant to the Companies Law, the audit committee is required to examine the external auditor&#8217;s
scope of work as well as the external auditor&#8217;s fees and to provide its recommendations with respect thereto to the appropriate
corporate organ. Accordingly, the appointment of our external auditor is approved by our shareholders at the audit committee&#8217;s recommendation
and its compensation for audit and non-audit services is approved by the board of directors following the audit committee&#8217;s recommendation.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">93</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">We have adopted a charter for the audit committee, which sets forth the purpose and
responsibilities of such committee.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In carrying out its duties, the audit committee meets with management at least once
in each fiscal quarter at which time, among other things, it reviews, and either approves or disapproves, the financial results of the
Company for the immediately preceding fiscal quarter and conveys its conclusions in this regard to the board of directors. The audit committee
also generally monitors the services provided by the Company&#8217;s external auditor to ensure their independence and reviews all audit
and non-audit services provided by them. The Company&#8217;s external and internal auditors also report regularly to the audit committee
and the audit committee discusses with our external auditor the quality, not just the acceptability, of the accounting principles, the
reasonableness of significant judgments and the clarity of disclosures in our financial statements, as and when it deems it appropriate
to do so.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Nasdaq Listing Rules, the audit committee is required to consist of at least
three independent directors, each of whom is financially literate and at least one of whom has accounting or related financial management
expertise.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have an audit committee consisting of three directors, Mr. Gilead Halevy,<span style="font-weight: bold">&#160;</span>who<span style="font-weight: bold">&#160;</span>serves
as the chairman of our audit committee, Mr. Eran Perry and Mr. Sanford (Sandy) Zweifach, all of whom are financially literate under the
applicable rules and regulations of the SEC and Nasdaq Listing Rules and each of whom is an audit committee financial expert, as defined
by the SEC rules, and has the requisite financial experience required under the Nasdaq Listing Rules. Additionally, each of the members
of the audit committee is &#8220;independent&#8221; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act, which is different
from the general test for independence of board and committee members under the Nasdaq Listing Rules.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The audit committee composition requirements referred to under Section 115 of the
Companies Law are not applicable to the Company as our board of directors, as part of its decision to opt out of the requirement to elect
external directors pursuant to the relief available under the Alleviation Regulations, also opted out of such composition requirements
on the basis that the Company complies, and will continue to comply, with the U.S. Securities Law and Nasdaq Listing Rules concerning
the composition of the audit committee, as described above.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Compensation Committee</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Companies Law generally provides that public companies such as the Company must
appoint a compensation committee, the responsibilities of which include, among others: (i) reviewing and making recommendations to the
board of directors with respect to our Compensation Policy and with respect to any updates which may be required thereto from time to
time, (ii) reviewing the implementation of the Compensation Policy by the Company, (iii) reviewing and considering arrangements with respect
to the Terms of Office and Employment of Office Holders, (iv) exempting, under certain circumstances, a transaction relating to the Terms
of Office and Employment of Office Holders from the requirement of approval of the shareholders, and (v) overseeing, subject to applicable
law, the administration of the Company&#8217;s various compensation plans and arrangements, including, incentive compensation and equity
based plans. Under the Companies Law, the compensation committee may need to seek the approval of the board of directors and the shareholders
for certain compensation-related decisions (see &#8220;Item 6 - Directors, Senior Management and Employees - B. Compensation - Approvals
Required for Office Holders Terms of Office and Employment&#8221;).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have adopted a charter for the compensation committee, which sets forth the purpose
and responsibilities of such committee.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Nasdaq Listing Rules, we are required to maintain a compensation committee
consisting of at least two independent directors (as defined under the Nasdaq Listing Rules). Each compensation committee member must
also be deemed by our board of directors to meet the enhanced independence requirements for members of the compensation committee under
the Nasdaq Listing Rules, which requires, among other things, that our board of directors considers the source of each such committee
member&#8217;s compensation in considering whether he or she is independent.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">94</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The compensation committee composition requirements referred to under Section 118A
of the Companies Law are not applicable to the Company as our board of directors, as part of its decision to opt out of the requirement
to elect external directors pursuant to the relief available under the Alleviation Regulations, also opted out of such composition requirements
on the basis that the Company complies, and will continue to comply, with the Nasdaq majority board independence requirement and with
US Securities Law and Nasdaq Listing Rules concerning the composition of the compensation committee, as described above.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have a compensation committee consisting of three directors, Mr. Sanford (Sandy)
Zweifach, who serves as the chairman of our compensation committee, Dr. Kinneret Livnat Savitzky and Eran Perry.&#160;Each member of our
compensation committee is an &#8216;independent director&#8217; in accordance with the Nasdaq listing standards.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Nomination and Corporate Governance Committee</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Nasdaq Listing Rules require that director nominees be selected or recommended
for the board&#8217;s selection either by a nomination committee composed solely of independent directors, or by a majority of independent
directors, in a vote in which only independent directors participate, subject to certain exceptions. Mr. Paul Sekhri, who serves as the
chairman of our nomination and corporate governance committee, Dr. Kinneret Livnat Savitzky and Mr. Sanford (Sandy) Zweifach, each an
independent director, are the members of our nomination and corporate governance committee, which, among other responsibilities, recommends
director nominees for our board&#8217;s approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Internal Auditor</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, the board of directors must appoint an internal auditor,
recommended by the audit committee. The role of the internal auditor is to examine, among other matters, whether the company&#8217;s actions
comply with the law and orderly business procedures. Under the Companies Law, an interested party or an Office Holder of a company, or
a relative of an interested party or of an Office Holder of a company, as well as the company&#8217;s external auditor or any one on behalf
of the external auditor may not serve as a company&#8217;s internal auditor. The internal auditor&#8217;s tenure cannot be terminated
without his or her consent, nor can he or she be suspended from such position unless the board of directors has so resolved after hearing
the opinion of the audit committee and after providing the internal auditor with the opportunity to present his or her position to the
board of directors and to the audit committee. An interested party is defined in the Companies Law as a holder of 5% or more of the company&#8217;s
outstanding shares or voting rights, any person or entity who has the right to designate one or more directors or the chief executive
officer of the company or any person who serves as a director or as a chief executive officer of the company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Ms. Tali Yaron of Brightman, Almagor, Zohar &amp; Co., a member firm of Deloitte Touche
Tohmatsu, has served as our internal auditor since 2023 (replacing a different partner at Brightman Almagor Zohar &amp; Co., a member
firm of Deloitte Touche Tohmatsu during 2023). Ms. Tali Yaron is not an employee, affiliate or Office Holder of the Company, or affiliated
with the Company&#8217;s external auditor.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Fiduciary Duties and Approval of Related Party Transactions Under
Israeli Law</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Fiduciary Duties of Office Holders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Companies Law codifies the fiduciary duties that Office Holders owe to a company.
All persons listed in the table under &#8220;Item 6. Directors, Senior Management and Employees - A. Directors and Senior Management&#8221;
are Office Holders. In addition to those persons listed in the table under Item 6.A, there were two additional individuals who were Office
Holders of the Company as of December 31, 2024.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">An Office Holder&#8217;s fiduciary duties consist of a duty of care and a duty of
loyalty. The duty of care requires an Office Holder to act with the standard of skills with which a reasonable Office Holder in the same
position would have acted under the same circumstances. The duty of care includes a duty to use reasonable means to obtain:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0d7a2383e5634ec9b72c5585d9d10835" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>information regarding the business advisability of a given action brought for the Office Holder&#8217;s approval or performed by
        the Office Holder by virtue of his or her position; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z60d8366479434a0d850d6373aaf9130d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>all other information of importance pertaining to the aforesaid actions.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The duty of loyalty requires an Office Holder to act in good faith and for the benefit
of the company and includes the duty to:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd3ce6f4e7c0e4bd1882a5ea3104bc378" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>refrain from any act involving a conflict of interest between the fulfillment of his or her position in the company and the fulfillment
        of any other position or his or her personal affairs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4775721db061473895398dc310c38c7b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>refrain from any act that is competitive with the business of the company;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">95</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z89fa9f91138a414b8491af47413619cf" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>refrain from exploiting any business opportunity of the company with the aim of obtaining a personal gain for himself or herself
        or for others; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8f725447d58a43478723276063099ba8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>disclose to the company all relevant information and provide it with all documents relating to the company&#8217;s affairs which
        the Office Holder obtained due to his or her position in the company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Disclosure of Personal Interests of Office
Holders and Approval of Certain Transactions</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Companies Law requires that an Office Holder promptly discloses to the company
any personal interest that the Office Holder may have, and all related material information known to him or her, in connection with any
existing or proposed transaction by the company. In addition, if the transaction is an extraordinary transaction, as defined under Israeli
law, the Office Holder must also disclose any personal interest held by the Office Holder&#8217;s spouse, siblings, parents, grandparents,
descendants, spouse&#8217;s descendants and the spouses of any of the foregoing, or a Relative. In addition, the Office Holder must also
disclose any interest held by any corporation in which the Office Holder: (i) holds at least 5% of the company&#8217;s outstanding share
capital or voting rights; (ii) is a director or general manager; or (iii) has the right to appoint at least one director or the general
manager. An extraordinary transaction is defined as a transaction which is either not in the ordinary course of business, not on market
terms, or likely to have a material impact on the company&#8217;s profitability, assets or liabilities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, unless the articles of association of a company provide otherwise,
a transaction in which an Office Holder has a personal interest and which is not an extraordinary transaction, requires board approval,
after the Office Holder complies with the above disclosure requirement and provided the transaction serves the company&#8217;s interest.
Our Articles do not provide for a different method of approval. Furthermore, if the transaction is an extraordinary transaction, then,
in addition to any approval stipulated by the articles of association, it also must be approved by the company&#8217;s audit committee
and then by the board of directors, and, under certain circumstances, by the shareholders of the company.</div>

<div style="line-height: 1.25">&#160;<br/>

<div style="text-align: justify; line-height: 1.25">A person with a personal interest in any matter may not generally be present at any
audit committee, compensation committee or board of directors meeting where such matter is being considered, and if he or she is a member
of the committee or a director, he or she may not generally vote on such matter at the applicable meeting.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Disclosure of Personal Interest of Controlling Shareholders and
Approval of certain Transactions</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The Companies Law extends the disclosure requirements applicable to an Office Holder
to a &#8216;controlling shareholder&#8217; in an Israeli a public company. For this purpose, a &#8216;controlling shareholder&#8217; is
a shareholder who has the ability to direct the activities of a company, including a shareholder or a group of shareholders who together
own 25% or more of the voting rights if no other shareholder holds more than 50% of the voting rights.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Extraordinary transactions of a public company with a controlling shareholder or in
which a controlling shareholder has a personal interest, as well as any engagement by a public company of a controlling shareholder or
of such controlling shareholder&#8217;s Relative, directly or indirectly, with respect to the provision of services to the company, and,
if such person is also an Office Holder of such company, with respect to such person&#8217;s Terms of Office and Employment as an Office
Holder, and if such person is an employee of the company but not an Office Holder, with respect to such person&#8217;s employment by the
company, generally require the approval of each of the audit committee (or with respect to Terms of Office and Employment, the compensation
committee), the board of directors and the shareholders of the company, in that order. The shareholder approval must fulfill one of the
following requirements: (i) it received the positive vote of at least a majority of the voting rights in the company who are present and
voting in the meeting and held by shareholders who do not have a personal interest in the transaction; (abstentions are disregarded) or
(ii) the voting rights held by shareholders who have no personal interest in the transaction and who have voted against the transaction,
do not exceed two percent of the voting rights in the company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any extraordinary transactions with a controlling shareholder or in which a controlling
shareholder has a personal interest with a term of more than three years generally need to be brought for re-approval in accordance with
the above procedure every three years, unless the audit committee determines that the duration of the transaction is reasonable given
the circumstances related thereto and has been approved by the shareholders for such longer duration.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">96</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Pursuant to regulations promulgated under the Companies Law, certain transactions
with a controlling shareholder or his or her Relative, or with directors, that would otherwise require approval of a company&#8217;s shareholders
may be exempt from shareholder approval upon certain determinations of the audit committee or the compensation committee and board of
directors.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">For information concerning the direct and indirect personal interests of certain of
our Office Holders and principal shareholders in certain transactions with us, see &#8220;Item 7. Major Shareholders and Related Party
Transactions - B. Related Party Transactions.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Shareholders Duties</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">Pursuant to the Companies Law, a shareholder has a duty to: (i) act in good faith in fulfilling his obligations
towards the company and the other shareholders; (ii) refrain from abusing his or her power with respect to the company, including, when
voting at a general meeting with respect to the following matters: (a) an amendment to the company&#8217;s articles of association; (b)
an increase of the company&#8217;s authorized share capital; (c) a merger; or (d) approval of interested party transactions that require
shareholders&#8217; approval.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">In addition, any controlling shareholder, any shareholder who knows that it possesses
power to determine the outcome of a shareholder vote and any shareholder who, pursuant to the provisions of a company&#8217;s articles
of association has the power to appoint or prevent the appointment of an office holder in the company, is under a duty of fairness towards
the company. The Companies Law does not describe the substance of such duty of fairness but states that the remedies generally available
upon a breach of contract will also apply in the event of a breach of the duty of fairness, taking into account such shareholder&#8217;s
position.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. EMPLOYEES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following table sets out the number of our full-time employees engaged in specified
activities, at the end of the fiscal years 2024, 2023 and 2022 (the numbers include employees of our wholly owned U.S. subsidiary Compugen
USA, Inc.):</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0333a100cfa64b27827a07ee7ca0ac6b" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">December 31, 2024</div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-weight: bold">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">December 31, 2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-weight: bold">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-weight: bold">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">December 31, 2022</div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="margin-right: 28.4pt; line-height: 1.25">Research &amp; Development</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">52</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">46</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">46</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 64%; padding-bottom: 2px">
        <div style="line-height: 1.25">Administration, Accounting and Operations</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">21</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">21</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">21</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Marketing and Business Development</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">2</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 64%; padding-bottom: 2px">
        <div style="line-height: 1.25">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">74</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">68</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">69</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to the headquarters in Holon, Israel, we maintain a subsidiary in the
U.S. On December 31, 2022, 57 of our employees were located in Israel, 8 were located in the United States and 4 employees were located
in Europe; on December 31, 2023, 58 of our employees were located in Israel, 7 were located in the United States and 3 employees were
located in Europe and on December 31, 2024, 66 of our employees were located in Israel, 5 were located in the United States and 3 employees
were located in Europe.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We consider our relations with our employees to be satisfactory and we have not experienced
a significant labor dispute or strike. We are not a party to any collective bargaining agreement with respect to our Israeli employees.
However, we are subject to certain labor related statutes and to certain provisions of expansion orders the Israeli Minister of the Economy
has given to collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordinating Bureau
of Economic Organizations and/or the Industrialists&#8217; Association, which are applicable to the employment of our Israeli employees.
These statutes and provisions and additional mandatory Israeli labor law provisions cover a wide range of subjects and provide certain
minimum employment standards, including the length of the workday and work week, minimum wages, travel expenses, contributions to a pension
fund, insurance for work-related accidents, determination of severance pay, annual and other vacations, sick pay and other conditions
of employment. We generally provide our employees with benefits and working conditions beyond the required minimum.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our employees are not represented by a labor union. We have written employment contracts
(including signed offers of employment) with each of our employees.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">97</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">E. SHARE OWNERSHIP</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Share Ownership by Directors and Other Executive Officers</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All of the persons listed above under the caption &#8220;Directors and Senior Management&#8221;
own ordinary shares of the Company and/or options to purchase ordinary shares of the Company and/or RSUs. Except as set forth in the table
below, none of those directors or senior management members beneficially owns ordinary shares and/or ordinary shares underlying options
and/or RSUs amounting together to 1% or more of the outstanding ordinary shares. The following table sets forth certain information as
of February 28, 2025, regarding the beneficial ownership by our directors and senior management. All numbers quoted in the table are inclusive
of options to purchase shares that are exercisable within 60 days after February 28, 2025, and RSUs that are vested during such period.
The shares that may be issued under these options are deemed to be outstanding for the purpose of computing the percentage of ownership
of such individual or group but are not deemed to be outstanding for the purpose of computing the percentage of ownership of the other
individual or group shown in the table. The information in this table is based on 93,512,982 ordinary shares outstanding as of February
28, 2025.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z299ffa40dacd4ae182a8d4b1dbbc38bd" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Beneficial Owner</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Amount Owned</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Percent of Class</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Anat Cohen-Dayag<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,132,372</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1.2</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="text-align: justify; line-height: 1.25">All directors and executive officers as a group (13 persons)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3,011,442</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3.1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 22.5pt; line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">___________________</sup></div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z558f3857283049a496cd5f76f3bb067d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt"><br/> </td>
    <td style="width: 32pt; vertical-align: top">&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Includes (i) 56,122 shares held by Dr. Cohen-Dayag, and (ii) 1,076,250 shares subject to options that are exercisable within 60 days
        after February 28, 2025, with a weighted average exercise price of $5.60 per share, and which expire between May 2025 and July 2034.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7510ec4d1bce49919cfa943a7b00762c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt"><br/> </td>
    <td style="width: 32pt; vertical-align: top"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;(2)</sup></td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Includes (i) a total of 72,059 ordinary shares held by directors and executive officers, and (ii) a total of 2,939,383 shares subject
        to options that are beneficially owned by directors and executive officers that are exercisable within 60 days after February 28, 2025,
        with a weighted average exercise price of $5.08 per share and which expire between May 2025 and September 2034.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Share Incentive Plan and Employee Share Purchase Plan</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently maintain one active share incentive plan, which is our 2010 Share Incentive
Plan, or the 2010 Plan. In addition to the discussion below, see Note 9 to our 2024 consolidated financial statements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Compugen 2010 Share Incentive Plan</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On July 25, 2010, our board of directors adopted the 2010 Plan which was also approved
by our shareholders on May 12, 2011. In addition, the board of directors and shareholders resolved that the options available for grants
under the 2000 Option Plan, at such time, as well as any options that may return to such pool in connection with terminated options, will
be made available for future grants under the 2010 Plan. In May 2020 the board of directors extended the term of the 2010 Plan by additional
ten (10) years. Subject to applicable law, our board of directors may amend the 2010 Plan, provided that any action by our board of directors
which will alter or impair the rights or obligations of an option holder requires the prior consent of that option holder. In August 2023,
our board of directors decreased the number of shares available under the 2010 Plan by 500,000 and in July 2024 our board of directors
increased the number of shares reserved under the 2010 Plan by 300,000.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The compensation committee administers the 2010 Plan and has the authority to designate
the terms of the equity granted thereunder, including the identity of the grantees, exercise prices (if applicable), grant dates, vesting
schedules and expiration dates (if applicable), which may be no more than ten years after the grant date. According to the 2010 Plan,
options may not be granted with an exercise price of less than the fair market value of our ordinary shares on the date of grant, unless
otherwise determined by our board of directors. The administration of the 2010 Plan by our compensation committee is subject to applicable
law, including with respect to the approval procedure of compensation to Office Holders required under the Companies Law (for additional
information on the approval procedure of compensation to Office Holders, see &#8220;Item 6. Directors, Senior Management and Employees
- B. Approvals Required for Office Holders Terms of Office and Employment&#8221;).</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">98</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">If a grantee of options leaves his or her employment or other relationship with us,
or if his or her relationship with us is terminated without cause (and other than by reason of death or disability, as defined in the
2010 Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by our board of directors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently grant our directors, officers and employees options and RSUs. As of December
31, 2024, options to purchase 8,655,721 ordinary shares at a weighted average exercise price of approximately $4.31 per share and 317,350
RSUs were outstanding (i.e., were granted but not canceled, expired nor exercised) under the 2010 Plan and 891,922 ordinary shares remained
available for future grant under the 2010 Plan. Options to purchase 4,330,159 ordinary shares under the 2010 Plan have previously been
exercised through December 31, 2024, at a weighted average exercise price of approximately $4.91. As of December 31, 2024, outstanding
options granted by the Company pursuant to the 2010 Plan expire between February 2025 and November 2034 (subject to terms of the plan).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Compugen 2021 Employee Share Purchase Plan</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In November 2020, we adopted the Compugen Ltd. 2021 Employee Share Purchase Plan,
or ESPP.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The ESPP currently applies to our employees and officers.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the ESPP, in each twelve (12) months period, there are two offering periods,
comprised of six (6) months each (except for the first offering period under the ESPP which was for five (5) months only). Each eligible
participant, has the right to contribute up to 15% of his or her monthly Compensation (as defined in the ESPP), in order to buy ordinary
shares from us at a price per share equal with respect to each offering period, to 85% of the Fair Market Value of a share on the Entry
Date or the Purchase Date (as such terms are defined in the ESPP), whichever is lower, until changed by the committee of the board administering
the ESPP prior to the commencement of the enrollment process for such offering period. The maximum number of ordinary shares a Participant
may purchase during any calendar year shall be that whole number of ordinary shares determined by dividing $40,000 by the Purchase Price.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The maximum number of shares that were available for issuance under the ESPP upon
its approval was 600,000.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2024, following issuance of shares in connection with offering
periods already ended and decreasing the number of shares available for issuance under the ESPP by 210,000 as approved by our board of
directors in August 2023 and by 114,146 as approved by our board of directors in July 2024, there were no ordinary shares available for
issuance under the ESPP. Currently our ESPP is suspended, though we reserve the right to resume it at any time.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Taxation of Equity Granted under our 2010 Plan
and ESPP to Israeli Grantees</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our board of directors elected the &#8220;Capital Gains Track&#8221; (as defined in
Section 102(b) (2) of the Tax Ordinance) for the grant of equity under the 2010 Plan and ESPP to Israeli grantees who are eligible for
grant under said Section 102 of the Tax Ordinance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to such election, and provided such eligible grantees comply with all the
requirements of the &#8220;Capital Gains Track&#8221;, gains derived by them, arising from the sale of shares acquired pursuant to the
ESPP or the exercise of options granted to them, or vesting of RSUs will generally be subject to a flat capital gains tax rate of 25%,
although these gains, or part of them, will also be considered part of a grantee&#8217;s regular salary and subject to such grantee&#8217;s
regular tax rate applicable to such salary. As a result of the Company&#8217;s election in the &#8220;Capital Gains Track&#8221; under
Section 102, the Company is not allowed to claim as an expense for tax purposes in Israel the amounts credited to the grantee as capital
gains, although it is generally entitled to do so in respect of the salary income component (if any) of such grant, if any, when the related
tax is paid by the grantee as long as the grantee complies with all the requirements of the &#8220;Capital Gains Track&#8221;.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">F. DISCLOSURE OF A REGISTRANT&#8217;S ACTION
TO RECOVER ERRONEOUSLY AWARDED COMPENSATION.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">99</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM7."><!--Anchor--></span>ITEM 7. MAJOR SHAREHOLDERS
AND RELATED PARTY TRANSACTIONS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. MAJOR SHAREHOLDERS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">As of February 28, 2025 we are not aware of any beneficial owner of more than 5% of our outstanding ordinary
shares. As of February 28, 2025, there were a total of 35 holders of record of our ordinary shares, of which 22 were registered with addresses
in the United States. Such United States holders were, as of such date, the holders of record of more than 99.0% of our outstanding ordinary
shares.<span style="font-weight: bold">&#160;</span>Our ordinary shares are traded on the Nasdaq Capital Market in the United States and
on the TASE in Israel. A significant portion of our shares are held in &#8220;street name&#8221;, therefore we cannot determine who our
shareholders are, their geographical location or how many shares a particular shareholder owns.</div> </div> </div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. RELATED PARTY TRANSACTIONS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">Other than as set forth below and transactions related to compensation (including insurance, indemnification
and exemption) of our executive officers and directors as described under &#8220;Item 6. Directors, Senior Management and Employees -
B. Compensation&#8221; since January 1, 2024, we have not entered into any material related party transaction.</div>

<div style="line-height: 1.25">&#160;</div> </div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. INTERESTS OF EXPERTS AND COUNSEL</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 8.<span id="ITEM8."><!--Anchor--></span> FINANCIAL INFORMATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. CONSOLIDATED STATEMENTS AND OTHER FINANCIAL
INFORMATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Consolidated Financial Statements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our consolidated financial statements are included beginning on page F-1 of this Annual
Report. See also &#8220;Item 18. Financial Statements.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Legal Proceedings</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Currently, we are not a party to any legal or arbitration proceedings, including governmental
proceedings, that are pending or known to be contemplated, that our management believes, individually or in the aggregate, may have, or
have had in the recent past, a significant effect on our financial position or profitability, nor are we party to any material proceeding
in which any director, member of our senior management or affiliate is a party adverse to us or our subsidiary or has a material interest
adverse to us or our subsidiary.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Dividend Distribution Policy</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have never paid any cash dividends on our ordinary shares, and we do not intend
to pay cash dividends on our ordinary shares in the foreseeable future. Our current policy is to retain any earnings we have (if any)
for use in our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">B. <span style="font-style: italic">SIGNIFICANT CHANGES</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM9."><!--Anchor--></span>ITEM 9. THE OFFER AND LISTING</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. OFFER AND LISTING DETAILS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ordinary shares were listed on The Nasdaq Global Market through June 16, 2009.
On June 17, 2009, the listing of our ordinary shares was transferred from The Nasdaq Global Market to The Nasdaq Capital Market, and on
January 27, 2014, the listing of our ordinary shares transferred back from The Nasdaq Capital Market to The Nasdaq Global Market. On May
4, 2023, our ordinary shares transferred back from The Nasdaq Global Market to The Nasdaq Capital Market. Our trading symbol on Nasdaq
is CGEN. Our ordinary shares have been dually listed on the Tel Aviv Stock Exchange since January 2002. Our trading symbol on each of
The Nasdaq Capital Market and the Tel Aviv Stock Exchange is CGEN.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. PLAN OF DISTRIBUTION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">100</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. MARKETS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ordinary shares are traded in the United States on The Nasdaq Capital Market and
in Israel on the Tel Aviv Stock Exchange (TASE).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. SELLING SHAREHOLDERS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">E. DILUTION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">F. EXPENSES OF THE ISSUE</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM10."><!--Anchor--></span>ITEM 10. ADDITIONAL INFORMATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. SHARE CAPITAL</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. MEMORANDUM AND ARTICLES OF ASSOCIATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Copies of our Amended and Restated Articles and our Amended and Restated Memorandum
of Association, as in effect as of the date of this Annual Report, are attached as Exhibits 1.1 and 1.2, respectively, to this Annual
Report. The information called for by this Item is set forth in Exhibit 2.1 to this Annual Report and is incorporated by reference into
this Annual Report.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. MATERIAL CONTRACTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Please see &#8220;Item 4. Information on the Company - B. Business Overview - Business
Strategy and Partnerships &#8211; Gilead License&#8221;, and &#8220;Item 4. Information on the Company - B. Business Overview - Business
Strategy and Partnerships - AstraZeneca License&#8221; and &#8220;Item 5. Operating and Financial Review and Prospects - B. Liquidity
and Capital Resources&#8221; for a discussion of our material contracts.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. EXCHANGE CONTROLS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">There are currently no exchange controls in effect in Israel that restrict the repatriation
by non-residents of Israel in non-Israeli currency of any dividends, if any are declared and paid, and liquidation distributions or the
Company&#8217;s ability to import and export capital, except that such restrictions may exist with respect to citizens of countries which
are in a state of war with Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">E. TAXATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following is a brief summary of certain material Israeli and U.S. federal tax
consequences concerning the ownership and disposition of our ordinary shares by purchasers or holders of our ordinary shares. Because
parts of this discussion are based on new or existing tax or other legislation that has not been subject to judicial or administrative
interpretation, there can be no assurance that the views expressed herein will be accepted by the tax or other authorities in question.
The summary below does not address all of the tax consequences that may be relevant to all purchasers or holders of our ordinary shares
in light of each purchaser&#8217;s or holder&#8217;s particular circumstances and specific tax treatment. For example, the summary below
does not address the tax treatment of residents of Israel and traders in securities who are subject to specific tax regimes. As individual
circumstances may differ, holders of our ordinary shares should consult their own tax advisors as to U.S., Israeli or other tax consequences
of the purchase, ownership and disposition of our ordinary shares. This discussion is not intended, nor should it be construed, as legal
or professional tax advice and it is not exhaustive of all possible tax considerations. Each person should consult his, her or its own
tax or legal advisor.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">101</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Israeli Taxation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Taxation of Capital Gains Applicable to Non-Israeli
Shareholders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Israeli law generally imposes a capital gains tax on the sale of securities of an
Israeli resident company traded on the TASE, on an authorized stock exchange outside Israel or on a regulated market (which includes a
system through which securities are traded pursuant to rules prescribed by the competent authority in the relevant jurisdiction), which
includes Nasdaq, in or outside Israel, or a &#8220;Recognized Exchange&#8221;. Pursuant to the Tax Ordinance, the capital gains tax rate
applicable to individuals upon the sale of such securities is such individual&#8217;s marginal tax rate but not more than 25%, or 30%
with respect to an individual who meets the definition of a &#8216;Substantial Shareholder&#8217; on the date of the sale of the securities
or at any time during the 12 months preceding such date. A &#8216;Substantial Shareholder&#8217; is defined as a person who, either alone
or together with any other person, holds, directly or indirectly, at least 10% of any of the means of control of a company (which includes,
among other things, the right to receive profits of the company, voting rights, the right to receive the company&#8217;s liquidation proceeds
and the right to appoint a director).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">With respect to corporate investors, capital gain tax equal to the corporate tax rate
(23% in 2024 and potentially the same thereafter) will be imposed on the sale of our traded shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">However, if our ordinary shares are traded on a Recognized Exchange gains on the sale
of our ordinary shares held by non-Israeli tax resident investors will generally be, subject to certain conditions, exempt from Israeli
capital gains tax so long as the gains were not derived from a permanent establishment that the non-Israeli tax resident investor maintains
in Israel. Furthermore, non-Israeli &#8220;Body of Persons&#8221; (as defined in the Ordinance, and includes corporate entities, partnerships,
and other entities) will not be entitled to such exemption if Israeli residents, whether directly or indirectly, (i) holds more than 25%
of the means of control in such non-Israeli corporation or (ii) are the beneficiaries of or are entitled to 25% or more of the revenues
or profits of such corporation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Notwithstanding the foregoing, dealers in securities in Israel are taxed at regular
tax rates applicable to business income.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, persons paying consideration for shares, including purchasers of shares,
Israeli securities dealers effecting a transaction, or a financial institution through which securities being sold are held, are required,
subject to any applicable exemptions and the demonstration by the selling shareholder of its non-Israeli residency and other requirements,
to withhold tax upon the sale of publicly traded securities at a rate of 25% for individuals and at the corporate tax rate (23% in 2024
and potentially the same thereafter) for corporations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The sale of shares may also be exempt from Israeli capital gain tax under the provisions
of an applicable tax treaty. For example, the Convention Between the Government of the United States and the Government of the State of
Israel With Respect to Taxes of Income, as amended, or the U.S.-Israel Tax Treaty), exempts U.S. residents for the purposes of the treaty
(who are entitled to claim the benefits of the U.S.-Israel Tax Treaty) from Israeli capital gain tax in connection with such sale, provided
(i) the U.S. resident owned, directly or indirectly, less than 10% of the Israeli resident company&#8217;s voting power at any time within
the 12-month period preceding such sale; (ii) the seller, being an individual, is present in Israel for a period or periods of less than
183 days during the taxable year; and (iii) the capital gain from the sale was not derived through a permanent establishment of the U.S.
resident in Israel. Under the U.S.-Israel Tax Treaty, U.S. residents for the purposes of the treaty may be permitted to claim a credit
for such taxes against U.S. federal income tax imposed on the sale, under the circumstances and subject to the limitations specified in
the U.S.-Israel Tax Treaty and U.S. tax legislation, as discussed below under &#8220;<span style="font-style: italic">Certain Material
U.S. Federal Income Tax Considerations to U.S. Holders &#8211; Distributions</span>.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Income Taxes on Dividend Distribution to Non-Israeli
Shareholders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In principle, non-Israeli residents (whether individuals or corporations) are generally
subject to Israeli income tax on the receipt of dividends paid by Israeli publicly traded companies at the rate of 25% if the shares are
registered with a nominee company (as such term is used in the Israeli Securities Law). If the shares are not registered with a nominee
company, the rate of 25% will apply to non-Israeli residents shareholders who are not considered Substantial Shareholders, as defined
above, and who were not considered Substantial Shareholders at any time during the 12 months preceding the date of the distribution, and
the rate of 30% will apply to dividends paid to Substantial Shareholders and to persons who were Substantial Shareholders at any time
during the 12 months preceding the date of the distribution. Notwithstanding the above, a lower tax rate may be provided under an applicable
tax treaty between Israel and the shareholder&#8217;s country of residence (subject to the receipt in advance of a valid tax certificate
from the Israel Tax Authority allowing for a reduced tax rate). The distribution of dividends to non-Israeli residents (either individuals
or corporations) from income derived from a company&#8217;s Approved Enterprises or Benefiting Enterprises during the applicable benefits
period or from Preferred Enterprises is subject to withholding tax at a rate of 20%, unless a lower tax rate is provided under an applicable
tax treaty (subject to the receipt in advance of a valid tax certificate from the Israel Tax Authority allowing for a 20% withholding
tax rate or a lower tax rate, provided by an applicable tax treaty).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">102</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A non-resident of Israel who has received dividend income derived from or accrued
in Israel, from which the full amount of tax was withheld, is generally exempt from the duty to file tax returns in Israel with respect
to such income, provided that: (i) such income was not derived from a business conducted in Israel by the taxpayer; (ii) the taxpayer
has no other taxable sources of income in Israel with respect to which a tax return is required to be filed; and (iii) the taxpayer is
not liable for Excess Tax (as described below).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Residents of the United States generally will have withholding tax in Israel deducted
at source. They may be entitled to a credit or deduction for U.S. federal income tax purposes for all or part of the amount of the taxes
withheld, subject to detailed rules contained in U.S. tax legislation, as discussed below under &#8220;<span style="font-style: italic">Certain
Material U.S. Federal Income Tax Considerations to U.S. Holders &#8211; Distributions</span>.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">U.S. Israel Tax Treaty</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the U.S.-Israel Tax Treaty, the maximum Israeli withholding tax rate on dividends
paid to a holder of our ordinary shares who is a U.S. resident for the purposes of the U.S.-Israel Tax Treaty, is generally 25%. The U.S.-Israel
Tax Treaty provides that a 15% or a 12.5% Israeli dividend withholding tax will apply to dividends paid to a U.S. corporation owning 10%
or more of an Israeli company&#8217;s voting shares during, in general, the current and preceding tax year of the Israeli company. The
15% rate applies to dividends distributed from income derived from an Approved Enterprise, or a Benefiting Enterprise, in each case within
the applicable period or, from a Preferred Enterprise, and the lower 12.5% rate applies to dividends distributed from income derived from
other sources. However, these provisions do not apply if the company has certain amounts of passive income. The aforementioned rates under
the U.S.-Israel Treaty will not apply if the dividend income was derived through a permanent establishment of the U.S. resident in Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Excess Tax</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, an additional tax liability at the rate of 3% is applicable on the annual
taxable income, including, but not limited to, income derived from dividends, interest and capital gains, of individuals who are subject
to tax in Israel (whether such individual is an Israeli resident or non-Israeli resident) exceeding a certain threshold (NIS 721,560 in
2024), which amount is linked to the Israeli consumer price index (while, according to the latest legislative acts, such linkage will
not take place for the years 2025-2027).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to the above, as of January 1, 2025, individuals whose taxable income
from capital sources (income from capital gains, dividends and interests) in the tax year exceeds the amount specified above, will be
subject to an additional tax at a rate of 2% (5% in total), on the portion of their taxable income from capital sources that exceeds the
amount above.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Estate and Gift Tax</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Israeli law currently does not impose estate or gift taxes.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Certain Material U.S. Federal Income Tax Considerations to U.S.
Holders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">General</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following is a summary of certain material U.S. federal income tax considerations
generally applicable to the acquisition, ownership and disposition of our ordinary shares by U.S. holders (as defined below) that hold
our ordinary shares as &#8220;capital assets&#8221; (generally, property held for investment) under the Code. For this purpose, a U.S.
holder is, a holder, who, for U.S. federal income tax purposes, is a beneficial owner of ordinary shares and who is: (a) a citizen or
individual resident of the United States; (b) a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes)
created or organized in or under the laws of the United States, any state thereof or the District of Columbia; (c) an estate the income
of which is subject to U.S. federal income tax regardless of its source; or (d) a trust that is subject to the primary supervision of
a court over its administration and one or more U.S. persons control all substantial decisions, or a trust that has validly elected to
be treated as a domestic trust under applicable Treasury Regulations. This summary does not address any tax consequences to persons other
than U.S. holders.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">103</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="text-align: justify; line-height: 1.25">The statements in this summary are based on the current U.S. federal income tax laws
as contained in the Code, Treasury Regulations, and relevant judicial decisions and administrative guidance, all as of the date hereof,
and such authorities may be replaced, revoked or modified, possibly with retroactive effect, so as to result in U.S. federal income tax
consequences different from those discussed below. No ruling has been sought from the U.S. Internal Revenue Service, or IRS, with respect
to any U.S. federal income tax consequences described below, and there can be no assurance that the IRS will not take a contrary position
or that a court will not sustain such a position in the event of a challenge.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following summary does not address all aspects of U.S. federal income tax consequences
that may apply to certain types of U.S. holders that are subject to special treatment, such as banks, insurance companies, tax-exempt
or governmental organizations, financial institutions, broker-dealers, dealers in securities or currencies, traders in securities that
elect to use the mark-to-market method of accounting for their securities, S corporations, partnerships or other pass-through entities
(or arrangements treated as a partnership) for U.S. federal tax purposes, regulated investment companies, real estate investment trusts,
&#8220;controlled foreign corporations&#8221; within the meaning of Section 957(a) of the Code, &#8220;passive foreign investment companies&#8221;
within the meaning of Section 1297(a) of the Code, certain expatriates, persons owning, directly, constructively or by attribution, 5%
or more, by voting power or value, of our ordinary shares, persons whose &#8220;functional currency&#8221; is not the U.S. dollar, persons
who hold ordinary shares as part of a hedging, constructive sale or conversion, straddle, or other risk-reducing transaction, former U.S.
citizens or long term residents of the United States, corporations that accumulate earnings to avoid U.S. federal income tax, persons
who hold our ordinary shares in connection with a trade or business, permanent establishment or fixed base outside the United States,
or persons that received an interest in our ordinary shares through the exercise of an option or otherwise in exchange for services.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">This summary is a general summary and does not address all aspects of U.S. federal
income taxation that may be relevant to particular U.S. holders based on their particular investment or tax circumstances.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">This summary relates only to U.S. federal income taxes and does not address any other
taxes, including but not limited to, U.S. state or local, or non-U.S., taxes and does not describe all of the U.S. federal income tax
consequences that may be relevant, including the special tax accounting rules under Section 451(b) of the Code, the U.S. federal non-income
tax considerations, including estate or gift tax considerations, the Medicare contribution tax on net investment income and the alternative
minimum tax.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If a partnership (including an entity or arrangement classified as a partnership for
U.S. federal income tax purposes) holds our ordinary shares, the tax treatment of a partner (including a person classified as a partner
for U.S. federal income tax purposes) will generally depend upon the status of the partner and the activities of the partnership. A partner
of a partnership holding our ordinary shares should consult its tax advisors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">This summary is not a substitute for careful tax planning. Investors
are urged to consult their own tax advisors regarding the specific U.S. federal, state, foreign and other tax consequences to them, in
light of their own particular circumstances, of the purchase, ownership and disposition of our ordinary shares and the effect of potential
changes in applicable tax laws.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Passive Foreign Investment Company Rules</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In general, a corporation organized outside the United States will be classified as
a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for any taxable year in which, after the application
of certain look-through rules with respect to income and assets of its subsidiaries, either:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze5d2f38754374705adcf02c4d3798e74" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>at least 75% of its gross income is passive income, or</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z745789a0884a45a8bbbdec6f5bdd82c2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>at least 50% of the value (determined on the basis of a quarterly weighted average) of its total assets for the taxable year is attributable
        to assets that produce or are held for the production of passive income.</div> </td> </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">104</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For this purpose, passive income generally includes, among other things, dividends,
interest, royalties and rents (other than royalties and rents derived in the active conduct of a trade or business and not derived from
a related person). Assets that produce or are held for the production of passive income may include cash (unless held in a non-interest
bearing account for short term working capital needs), marketable securities and other assets that may produce passive income. The 50%
passive asset test described above is generally based on the fair market value of each asset, with the value of goodwill and going concern
value determined in large part by reference to the market value of our ordinary shares, which may be volatile. Generally, in determining
whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly
or indirectly, at least a 25% interest (by value) is taken into account. Whether we are a PFIC for any taxable year will depend on the
composition of our income and the composition and value of our assets (which, may be determined in large part by reference to the market
price of the ordinary shares, which is likely to continue to fluctuate) in each year, and because this is a factual determination made
annually after the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Based on the composition of our income, and the composition and value of our assets,
in 2024, we believe that we were not a PFIC for the taxable year ended December 31, 2024. However, the determination of whether or not
we are a PFIC is a fact-intensive determination made on an annual basis and because the applicable law is subject to varying interpretations
we cannot provide any assurance regarding our non-PFIC status and our U.S. counsel expresses no opinion with respect to our non-PFIC status
for any taxable year. In particular, our status as a non-PFIC in current or any future tax year is uncertain because, among other things,
(i) we currently own a substantial amount of passive assets, including cash, (ii) we may not receive milestone payments under any of our
collaboration agreements, in which case, our income may be exclusively passive and (iii) the valuation of our assets that generate non-passive
income for PFIC purposes, including our intangible assets, is uncertain and may be determined in substantial part by our market capitalization,
which may vary substantially over time. Furthermore, there can be no assurance that the IRS will agree with our conclusion or that the
IRS would not successfully challenge our position. No ruling from the IRS concerning our status as a non-PFIC has been obtained or is
currently planned to be requested. Accordingly, we cannot provide any assurances regarding our non-PFIC status for the current or future
taxable years.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are classified as a PFIC in any taxable year during a U.S. holder&#8217;s holding
period of our ordinary shares, such U.S. holder could be liable for additional taxes and interest charges upon (1) a distribution paid
during a taxable year that is greater than 125% of the average annual distributions paid in the three preceding taxable years, or, if
shorter, the U.S. holder&#8217;s holding period for the ordinary shares, and (2) any gain recognized on a sale, exchange or other taxable
disposition, including a pledge, of the ordinary shares, whether or not we continue to be a PFIC. In these circumstances, the tax will
be determined by allocating such distribution or gain ratably over the U.S. holder&#8217;s holding period for the ordinary shares. The
amount allocated to the current taxable year (i.e., the year in which the distribution occurs, or the gain is recognized) and any year
prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount
allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable,
to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to
the tax. In addition, non-corporate U.S. Holders will not be eligible for reduced rates of taxation on any dividends received from us,
if we are a PFIC in the taxable year in which such dividends are paid or in the preceding taxable year.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are a PFIC for any year during which a U.S. holder holds the ordinary shares,
we must generally continue to be treated as a PFIC by that holder for all succeeding years during which the U.S. holder holds the ordinary
shares, unless we cease to meet the requirements for PFIC status and the U.S. holder makes a &#8220;deemed sale&#8221; election with respect
to the ordinary shares. If such election is made, the U.S. holder will be deemed to have sold the ordinary shares it holds at their fair
market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain from such deemed sale would be subject
to the consequences described above. After the deemed sale election, the U.S. holder&#8217;s ordinary shares with respect to which the
deemed sale election was made will not be treated as shares in a PFIC unless we subsequently again become a PFIC.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If a U.S. holder has made a qualified electing fund, or QEF election covering all
taxable years during which the holder holds ordinary shares and in which we are a PFIC, distributions and gains will not be taxed as described
above. Instead, a U.S. holder that makes a QEF election is required for each taxable year to include in income (i) the holder&#8217;s
pro rata share of the PFIC&#8217;s ordinary earnings as ordinary income or (ii) the holder&#8217;s pro rata share of the QEF net capital
gain as capital gain, regardless of whether such earnings or gain have in fact been distributed, for each taxable year that the entity
is classified as a PFIC. If a U.S. holder makes a QEF election with respect to us, any distributions paid by us out of our earnings and
profits that were previously included in the U.S. holder&#8217;s income under the QEF election would not be taxable to the holder. A U.S.
holder will increase its tax basis in its ordinary shares by an amount equal to any income included under the QEF election and will decrease
its tax basis by any amount distributed on the ordinary shares that is not included in the holder&#8217;s income. If a U.S. holder has
made a QEF election with respect to its ordinary shares, any gain or loss recognized by the U.S. holder on a sale or other disposition
of such ordinary shares will constitute capital gain or loss. In addition, if a U.S. holder makes a timely QEF election, our ordinary
shares will not be considered shares in a PFIC in years in which we are not a PFIC, even if the U.S. holder had held ordinary shares in
prior years in which we were a PFIC.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">105</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">U.S. holders should consult their tax advisors regarding making QEF elections in their
particular circumstances. If a U.S. holder does not make and maintain a QEF election for the U.S. holder&#8217;s entire holding period
for our ordinary shares by making the election for the first year in which the U.S. holder owns our ordinary shares, the U.S. holder will
be subject to the adverse PFIC rules discussed above unless the U.S. holder can properly make a &#8220;purging election&#8221; with respect
to our ordinary shares in connection with the U.S. holder&#8217;s QEF election. A purging election may require the U.S. holder to recognize
taxable gain on the U.S. holder&#8217;s ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In order to comply with the requirements of a QEF election, a U.S. holder must receive
certain information from us. The QEF election is made on a shareholder-by-shareholder basis and can be revoked only with the consent of
the IRS. A shareholder makes a QEF election by attaching a completed IRS Form 8621, including the information provided in the PFIC annual
information statement, to a timely filed U.S. federal income tax return and by filing a copy of the form with the IRS. We may provide
the information necessary for U.S. holders to make QEF elections if we were treated as a PFIC for any taxable year. There is no assurance
that we will have timely knowledge of our status as a PFIC in the future. Accordingly, U.S. holders may be unable to make a timely QEF
election with respect to our ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">U.S. holders should consult their tax advisors to determine whether any of these above
elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The tax consequences that would apply if we are a PFIC would also be different from
those described above if a timely and valid &#8220;mark-to-market&#8221; election is made by a U.S. holder for the ordinary shares held
by such U.S. holder. An electing U.S. holder would generally take into account as ordinary income or loss each year an amount equal to
the difference between the U.S. holder&#8217;s adjusted tax basis in such ordinary shares and their fair market value; however, losses
would be allowed only to the extent of the excess of amounts previously included in income over ordinary losses deducted in prior years
as a result of the mark-to-market election. Any gain from a sale, exchange or other taxable disposition of the ordinary shares in any
taxable year in which we are a PFIC would be treated as ordinary income and any loss from such sale, exchange or other taxable disposition
would be treated first as ordinary loss (to the extent of any net mark-to-market gains previously included in income) and thereafter as
capital loss. The adjusted tax basis of a U.S. holder&#8217;s ordinary shares is increased by the amount included in gross income under
the mark-to-market regime, or is decreased by the amount of the deduction allowed under the regime. If a U.S. holder makes a mark-to-market
election it will be effective for the taxable year for which the election is made and all subsequent taxable years unless the shares are
no longer regularly traded on a qualified exchange or the IRS consents to the revocation of the election.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A mark-to-market election is available to a U.S. holder only for &#8220;marketable
stock.&#8221; Generally, stock will be considered marketable stock if it is &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221;
within the meaning of applicable Treasury Regulations. A class of stock is regularly traded during any calendar year during which such
class of stock is traded, other than in <span style="font-style: italic">de minimis</span> quantities, on at least 15 days during each
calendar quarter. The ordinary shares will be marketable stock as long as they remain listed on a qualified exchange, such as Nasdaq,
and are regularly traded. However, we can provide no assurances that our ordinary shares will continue to be listed on a qualified exchange
or will be regularly traded. A mark-to-market election will not apply to the ordinary shares for any taxable year during which we are
not a PFIC but will remain in effect with respect to any subsequent taxable year in which we become a PFIC. U.S. holders are urged to
consult their tax advisor about the availability of the mark-to-market election, and whether making the election would be advisable in
such holder&#8217;s particular circumstances.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">106</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are a PFIC and, at any time, have a non-U.S. subsidiary that is classified as
a PFIC (a &#8220;lower-tier&#8221; PFIC), U.S. holders of our ordinary shares generally would be deemed to own, and also would be subject
to the PFIC rules with respect to, their indirect ownership interests in that lower-tier PFIC. If we are a PFIC and a U.S. holder of our
ordinary shares does not make a QEF election in respect of a lower-tier PFIC, the U.S. holder could incur liability for the deferred tax
and interest charge described above if either (1) we receive a distribution from, or dispose of all or part of our interest in, the lower-tier
PFIC or (2) the U.S. holder disposes of all or part of its ordinary shares. We may provide the information necessary for U.S. holders
to make QEF elections with respect to any lower-tier PFIC. A mark-to-market election under the PFIC rules with respect to our ordinary
shares would not apply to a lower-tier PFIC, and a U.S. holder would not be able to make such a mark-to-market election in respect of
its indirect ownership interest in that lower-tier PFIC. Consequently, U.S. holders of our ordinary shares could be subject to the PFIC
rules with respect to income of the lower-tier PFIC the value of which already had been taken into account indirectly via mark-to-market
adjustments. U.S. holders are urged to consult their own tax advisors regarding the issues raised by lower-tier PFICs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Each U.S. holder who is a shareholder of a PFIC must file an annual information report
on IRS Form 8621 containing such information as the U.S. Treasury Department may require (whether or not a QEF election or a mark-to-market
election is made). The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations
with respect to U.S. federal income tax.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">THE RULES DEALING WITH PFICS AND WITH THE QEF AND MARK-TO-MARKET
ELECTIONS ARE VERY COMPLEX AND ARE AFFECTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE, INCLUDING OUR OWNERSHIP OF ANY NON-U.S.
SUBSIDIARIES. AS A RESULT, U.S. HOLDERS OF ORDINARY SHARES ARE STRONGLY ENCOURAGED TO CONSULT THEIR TAX ADVISORS ABOUT THE PFIC RULES
IN CONNECTION WITH THEIR PURCHASING, HOLDING OR DISPOSING OF ORDINARY SHARES.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold; font-style: italic">U.S. Federal Income Tax Consequences
If We Are Not a PFIC</span>.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The description of the U.S. federal income tax consequences of the receipt of distributions
and the sale or other taxable exchange of our ordinary shares, described in the following two sections &#8220;- <span style="font-style: italic">Distributions</span>&#8221;
and &#8220;<span style="font-style: italic">- Disposition of Ordinary Shares</span>,&#8221; apply only if we are not a PFIC in the relevant
year and our ordinary shares are not subject to the rules described above under &#8220;-<span style="font-style: italic">Passive Foreign
Investment Company Rules</span>&#8221;.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Distributions</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Subject to the discussion under &#8220;<span style="font-style: italic">- Passive
Foreign Investment Company Rules</span>&#8221; above, the gross amount of any distributions with respect to our ordinary shares (including
any amounts withheld to reflect Israeli withholding taxes) will be taxable as dividends, to the extent paid out of our current or accumulated
earnings and profits, as determined under U.S. federal income tax principles. Such income (including any withheld taxes) will be includable
in a U.S. holder&#8217;s gross income as ordinary income on the day actually or constructively received. Distributions in excess of earnings
and profits will be non-taxable to the U.S. holder to the extent of, and will be applied against and reduce (but not below zero), the
U.S. holder&#8217;s adjusted tax basis in the ordinary shares. Distributions in excess of earnings and profits and such adjusted tax basis
will generally be taxable to the U.S. holder as described below under &#8220;<span style="font-style: italic">- Disposition of Ordinary
Shares</span>.&#8221; However, since we do not calculate our earnings and profits under U.S. federal income tax principles, it is expected
that any distribution will be reported as a dividend, even if that distribution would otherwise be treated as a non-taxable return of
capital or as capital gain under the rules described above. The amount of any dividend paid by us will be treated as foreign-source dividend
income to U.S. holders, and the dividends received deduction will not be available to a U.S. holder that is taxed as a corporation as
a result.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">With respect to non-corporate U.S. holders, certain dividends received from a &#8220;qualified
foreign corporation&#8221; that is not a PFIC may be subject to reduced rates of taxation. A qualified foreign corporation includes a
foreign corporation that is eligible for the benefits of a comprehensive income tax treaty with the United States which the United States
Treasury Department determines to be satisfactory for these purposes and which includes an exchange of information provision. The United
States Treasury Department has determined that the US-Israel Tax Treaty meets these requirements. A foreign corporation is also treated
as a qualified foreign corporation with respect to dividends paid by that corporation on shares that are readily tradable on an established
securities market in the United States. As discussed under &#8220;- <span style="font-style: italic">Passive Foreign Investment Company
Rules</span>&#8221; above, there can be no assurance that our ordinary shares will be considered readily tradable on an established securities
market in any year. If we are a qualified foreign corporation, and we are not classified as a PFIC for the taxable year in which a dividend
is paid or in the preceding taxable year (as discussed above under &#8220;<span style="font-style: italic">- Passive Foreign Investment
Company Rules</span>&#8221;), dividend income will generally qualify as &#8220;qualified dividend income&#8221; in the hands of individual
U.S. holders, which is generally taxed at the lower applicable long term capital gains rates, provided certain holding period and other
requirements for treatment of such dividends as &#8220;qualified dividend income&#8221; are satisfied. U.S. holders should consult their
own tax advisors regarding the availability of the lower rate for dividends paid with respect to our ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">107</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Although, to the extent we pay dividends in the future, we intend to pay dividends
to U.S. holders in dollars, the amount of any dividend paid in Israeli currency will equal its dollar value for U.S. federal income tax
purposes, calculated by reference to the exchange rate in effect on the date the dividend is received by the U.S. holder, regardless of
whether the Israeli currency is converted into dollars. If the Israeli currency received as a dividend are converted into United States
dollars on the date they are received, the U.S. holder generally will not be required to recognize foreign currency gain or loss in respect
of the dividend income. If the Israeli currency is not converted into dollars on the date of receipt, the U.S. holder will have a basis
in the Israeli currency equal to its dollar value on the date of receipt. Any subsequent gain or loss upon the conversion or other disposition
of the Israeli currency will be treated as ordinary income or loss, and generally will, for U.S. federal income tax purposes, be treated
as income or loss from U.S. sources.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Certain U.S. holders generally may be eligible, subject to a number of complex limitations,
to claim Israeli taxes withheld from distributions and paid over to the Israeli taxing authorities either as a deduction from gross income
or as a credit against U.S. federal income tax liability. To the extent a refund of the tax withheld is available to a U.S. holder under
Israeli law or under the US-Israel Tax Treaty, the amount of tax withheld that is refundable will not be eligible for credit against a
U.S. holder&#8217;s United States federal income tax liability. The foreign tax credit is subject to numerous complex limitations that
must be determined and applied on an individual basis. U.S. holders should consult their own tax advisors regarding the foreign tax credit
rules.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Disposition of Ordinary Shares</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In general, subject to the discussion under &#8220;- <span style="font-style: italic">Passive
Foreign Investment Company Rules</span>&#8221;, above, a U.S. holder will recognize U.S.-source capital gain or loss upon a taxable disposition
of an ordinary share equal to the difference between the sum of the fair market value of any property and the amount of cash received
in such disposition (including the amount of any foreign taxes withheld therefrom) and the U.S. holder&#8217;s adjusted tax basis in such
share. A U.S. holder&#8217;s adjusted tax basis generally will equal the U.S. holder&#8217;s acquisition cost less any distributions treated
as a return of capital as described under &#8220;- <span style="font-style: italic">Distributions</span>&#8221; above. Such capital gain
or loss will be long-term capital gain or loss if a U.S. holder&#8217;s holding period in the ordinary share is more than one year at
the time of the taxable disposition. Under current law, subject to certain exceptions (including but not limited to those described under
&#8220;<span style="font-style: italic">- Passive Foreign Investment Company Rules</span>&#8221; above), long-term capital gain realized
by a non-corporate U.S. holder generally will be eligible for reduced rates of tax. The deduction of capital losses may be subject to
limitation. Because gain from the sale or other taxable disposition of an ordinary share will generally be treated as U.S.-source income
and, subject to certain exceptions, Treasury Regulations generally preclude U.S. taxpayers from claiming a foreign tax credit with respect
to any non-U.S. tax imposed on gains from dispositions of shares held as capital assets unless the tax is creditable under an applicable
income tax treaty, your ability to claim a foreign tax credit with respect to Israeli tax imposed on any such sale or other taxable disposition,
if any, may be significantly limited. U.S. holders should consult their own tax advisors regarding the foreign tax credit rules with respect
to any foreign taxes withheld from a taxable disposition of ordinary shares, as well as regarding any foreign currency gain or loss in
connection with such a disposition.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Backup Withholding and Information Reporting</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In general, information reporting will apply to dividends in respect of our ordinary
shares and the proceeds from the sale or exchange of our ordinary shares that are paid to a U.S. holder within the United States (and
in certain cases, outside the United States), unless such holder is an exempt recipient. A backup withholding tax generally applies to
such payments if the U.S. holder fails to provide a taxpayer identification number and a duly executed IRS Form W-9 or other certification
of exempt status unless the U.S. holder otherwise establishes that it is exempt from such rules.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any amounts withheld under the backup withholding rules will be allowed as a refund
or a credit against a U.S. holder&#8217;s U.S. federal income tax liability provided the required information is furnished to the IRS
in a timely manner.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Individuals who own &#8220;specified foreign financial assets&#8221; with an aggregate
value in excess of $50,000 may be required to file an information report on IRS Form 8938, &#8220;Statement of Specified Foreign Financial
Assets,&#8221; with respect to such assets with their tax returns. &#8220;Specified foreign financial assets&#8221; include any financial
accounts maintained by foreign financial institutions, as well as any of the following, but only if they are not held in accounts maintained
by financial institutions: (i) stocks and securities issued by non-U.S. persons; (ii) financial instruments and contracts held for investment
that have non-U.S. issuers or counterparties; and (iii) interests in foreign entities. U.S. holders that are individuals are urged to
consult their tax advisors regarding the application of these rules to their ownership of our ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">108</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">F. DIVIDENDS AND PAYING AGENTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">G. STATEMENT BY EXPERTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">H. DOCUMENTS ON DISPLAY</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are required to file reports and other information with the SEC under the Exchange
Act, and the regulations thereunder applicable to foreign private issuers. As a &#8220;foreign private issuer&#8221; we are exempt from
the rules and regulations under the Securities Exchange Act prescribing the furnishing and content of proxy statements, and our officers,
directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions contained
in Section 16 of the Securities Exchange Act, with respect to their purchase and sale of our shares. In addition, we are not required
to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under
the Securities Exchange Act. Furthermore, as a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair
Disclosure) promulgated under the Exchange Act. Nasdaq rules generally require that companies send an annual report to shareholders prior
to the annual general meeting, however we rely upon an exception under the Nasdaq Listing Rules and follow the generally accepted business
practice for companies in Israel. Specifically, we file annual reports on Form 20-F, which contain financial statements audited by an
independent accounting firm, electronically with the SEC and post a copy on our website. We also furnish to the SEC reports on Form 6-K
containing unaudited financial information after the end of each of the first three quarters.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">You may review a copy of our filings with the SEC, including any exhibits and schedules,
at the offices of the Israel Securities Authority at 22 Kanfei Nesharim St., Jerusalem, Israel. As a foreign private issuer, we were only
required to file through the SEC&#8217;s EDGAR system as of November 2002. Our periodic filings are therefore available on the SEC&#8217;s
Website <span style="font-style: italic">www.sec.gov</span> from that date. You may read and copy any reports, statements or other information
that we file with the SEC, through the SEC&#8217;s EDGAR system available on the SEC&#8217;s website. These SEC filings are also available
to the public on the Israel Securities Authority&#8217;s website at <span style="font-style: italic">www.isa.gov.il</span> and from commercial
document retrieval services.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any statement in this Annual Report about any of our contracts or other documents
is not necessarily complete. If the contract or document is filed as an exhibit to this Annual Report, the contract or document is deemed
to modify the description contained in this Annual Report. We urge you to review the exhibits themselves for a complete description of
the contract or document.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">I. SUBSIDIARY INFORMATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM11."><!--Anchor--></span>ITEM 11. QUANTITATIVE AND
QUALITATIVE DISCLOSURES ABOUT MARKET RISK</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are exposed to a variety of risks, including changes in interest rates and foreign
currency exchange risk and inflation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Interest Rate Risk</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2024, we had approximately $103.3 million in cash, cash equivalents,
short-term bank deposits, and investment in marketable securities. We mostly invest our cash surplus in bank deposits and U.S. government
securities. Since these investments typically carry fixed interest rate or yields, financial income over the holding period is not sensitive
to changes in interest rates. For more information, see Note 2 to our 2024 consolidated financial statements.</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25; font-weight: bold">Foreign Currency Exchange Risk and Inflation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">The cost of our Israel operations, as expressed in dollars, is influenced by the extent to which any increase
in the rate of inflation in Israel is not offset (or is offset on a lagging basis) by a devaluation of the NIS in relation to the dollar.
The inflation rate in Israel was 3.2%, 3.0% and 5.3% in 2024, 2023 and 2022, respectively. The appreciation (devaluation) of the dollar
against the NIS was 0.6%, 3.1% and 13.2% in 2024, 2023 and 2022, respectively. For 2024, assuming a 10% devaluation of the dollar against
the NIS, we would experience an increase in our net loss of approximately $1.5 million, while assuming a 10% appreciation of the dollar
against the NIS, we would experience a decrease in our net loss of approximately $1.3 million. A significant portion of our expenditures
is employee compensation related. Salaries for Israel-based employees are paid in NIS and may be adjusted for changes in the Israeli consumer
price index, or CPI, through salary increases or adjustments. These upward adjustments increase salary expenses in dollar terms. The devaluation/appreciation
of the NIS against the dollar decreases/increases employee compensation expenditures as expressed in dollars proportionally. Some of our
other NIS based expenses are either currently adjusted to dollars or are adjusted to the CPI. We currently have no foreign currency derivative
contracts to hedge against currency exchange risk fluctuation but may consider entering into such contracts in the future.</div> </div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">109</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <br/>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 12.<span id="ITEM12."><!--Anchor--></span> DESCRIPTION OF
SECURITIES OTHER THAN EQUITY SECURITIES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">PART II<span id="PARTII"><!--Anchor--></span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 13.<span id="ITEM13."><!--Anchor--></span> DEFAULTS, DIVIDEND
ARREARAGES AND DELINQUENCIES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">None.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -45pt; margin-left: 45pt; line-height: 1.25; font-weight: bold"><span id="ITEM14."><!--Anchor--></span>ITEM
14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM15."><!--Anchor--></span>ITEM 15. CONTROLS AND PROCEDURES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. DISCLOSURE CONTROLS AND PROCEDURES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our disclosure controls and procedures are designed to ensure that information required
to be disclosed in the reports we are required to file is recorded, processed, summarized and reported on a timely basis. Under the supervision
of our chief executive officer (principal executive officer) and chief financial officer (principal financial officer), we conducted an
evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(f) and 15d-15(f)
promulgated under the Exchange Act. Based on this evaluation, our chief executive officer and chief financial officer concluded that our
disclosure controls and procedures were effective as of the end of the period covered by this Annual Report.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. MANAGEMENT&#8217;S ANNUAL REPORT ON INTERNAL
CONTROL OVER FINANCIAL REPORTING</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our management, with the involvement of our board of directors and audit committee,
is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial
reporting (as defined in Rules 13a-15(e) and 15(d) - 15(e) of the Exchange Act) has been designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of our consolidated financial statements for external purposes in accordance
with generally accepted accounting principles.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the supervision of our chief executive officer (principal executive officer)
and chief financial officer (principal financial officer), our management conducted an evaluation of the effectiveness of our internal
control over financial reporting, as such term is defined under Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act. In making
this assessment, our management used the criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). Based on this evaluation, our chief executive officer and chief financial officer have
concluded that our internal control over financial reporting was effective as of the end of the period covered by this Annual Report.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Notwithstanding the foregoing, all internal control systems no matter how well designed
have inherent limitations. Therefore, even those systems determined to be effective may not prevent or detect misstatements and can provide
only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Kost Forer Gabbay &amp; Kasierer, a member firm of Ernst &amp; Young Global, an independent
registered public accounting firm in Israel,&#160;which has audited our financial statements for the year ended December 31, 2024, that
are included in this Annual Report, has issued an attestation report on our internal control over financial reporting as of December&#160;31,
2024.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">110</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. ATTESTATION REPORT OF THE REGISTERED PUBLIC
ACCOUNTING FIRM</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The attestation report of Kost Forer Gabbay &amp; Kasierer, a member firm of Ernst
&amp; Young Global, an independent registered public accounting firm in Israel, on our internal control over financial reporting as of
December 31, 2024, is provided on page F-4, as included under Item 18 of this Annual Report and is incorporated herein by reference.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. CHANGES IN INTERNAL CONTROL OVER FINANCIAL
REPORTING</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Based on the evaluation conducted by our management, with the participation of our
chief executive officer and chief financial officer, pursuant to Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act, our
management (including such officers) have concluded that, there were no changes in our internal control over financial reporting that
occurred during the period covered by this Annual Report that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM16."><!--Anchor--></span>ITEM 16. RESERVED</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16A.<span id="ITEM16A."><!--Anchor--></span> AUDIT COMMITTEE
FINANCIAL EXPERT</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our board of directors has determined that each of Mr. Gilead Halevy, Mr. Eran Perry
and Mr. Sanford (Sandy) Zweifach, each of whom serves on our audit committee and who meets the &#8220;independence&#8221; definition under
the Nasdaq Listing Rules, qualifies as an &#8220;audit committee financial expert&#8221; as defined in the instructions to this Item 16A
of Form 20-F. See<span style="font-style: italic">&#160;</span>&#8220;Item 6.A &#8211; Directors, Senior Management and Employees &#8211;
Directors and Senior Management&#8221; for a summary of Mr. Gilead Halevy, Mr. Eran Perry and Mr. Sanford (Sandy) Zweifach relevant professional
experience.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16B.<span id="ITEM16B."><!--Anchor--></span> CODE OF ETHICS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have adopted a code of business conduct that applies to all of our employees, officers
and directors as well as a code of ethics for senior financial officers that applies to our chief executive officer, chief financial officer,
director of finance, controller, assistant controller and persons performing similar functions at our subsidiary.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">The code of ethics for senior financial officers is available on our website, www.cgen.com. However, information
contained on our website does not constitute a part of this Annual Report.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">We intend to post on our website all disclosures that are required by the rules and
regulations of the SEC or by the Nasdaq Listing Rules concerning any amendments to, or waivers from, any provision of the code of business
conduct or the code of ethics.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16C.<span id="ITEM16C."><!--Anchor--></span> PRINCIPAL ACCOUNTANT
FEES AND SERVICES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following table presents the fees billed or accrued to us by our principal accountant
for professional services rendered in the years ended December 31, 2024, and 2023:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc2fd872e478149d6b3ea0bf0af2cf082" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2024</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2023</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Audit Fees</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">222,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">163,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25">Audit Related Fees</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">15,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">65,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Tax Fees</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">5,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">4,500</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25">All Other Fees</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,500</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px">
        <div style="margin-right: 2.85pt; line-height: 1.25; font-weight: bold">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">245,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">235,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#8220;Audit Fees&#8221; are fees for professional services rendered by our principal
accountant in connection with the integrated audit (including review of internal control over financial reporting) of our consolidated
annual financial statements and review of our unaudited interim financial statements;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#8220;Audit Related Fees&#8221; are fees for professional services rendered by our
principal accountant in connection with the audit and other assignments, including consultancy, comfort letters and consents with respect
to registration statements filed with the SEC;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">111</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#8220;Tax Fees&#8221; are fees for services rendered by our principal accountant
in connection with tax compliance, tax advice and tax planning; and</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#8220;All Other Fees&#8221; are fees for other consulting services rendered by our
principal accountant to us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Pre-Approval Policies for Non-Audit Services</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our audit committee oversees a policy and procedures for approval of audit and non-audit
services rendered by our external auditor. This policy generally provides that we will not engage our independent registered public accounting
firm to render audit or non-audit services unless the service is specifically approved in advance by our audit committee or the engagement
is entered into pursuant to the pre-approval procedure described below. Annually, our audit committee pre-approves specified types of
services that are expected to be provided to us by our independent registered public accounting firm during the next 12 months. Any such
pre-approval is detailed as to the particular service or type of services to be provided and is also generally subject to a maximum dollar
amount. All of the fees listed in the table above were approved by our audit committee.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -81pt; margin-left: 81pt; line-height: 1.25; font-weight: bold">ITEM 16D.<span id="ITEM16D."><!--Anchor--></span>
EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -54pt; margin-left: 54pt; line-height: 1.25; font-weight: bold">ITEM 16E.<span id="ITEM16E."><!--Anchor--></span>
PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16F.<span id="ITEM16F."><!--Anchor--></span> CHANGE IN REGISTRANT&#8217;S
CERTIFYING ACCOUNTANT</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16G.<span id="ITEM16G."><!--Anchor--></span> CORPORATE GOVERNANCE</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Nasdaq Listing Rules require companies with securities listed thereon to comply
with its corporate governance standards. As a foreign private issuer whose shares are listed on Nasdaq, we are permitted to follow certain
home country corporate governance practices instead of those followed by U.S. companies under the Nasdaq Listing Rules, including:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Shareholder Approval.</span> Pursuant to Israeli
law, we seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, which
are different from the requirements for seeking shareholder approval under Nasdaq Listing Rule 5635. We seek shareholder approval in specified
situations, including upon issuance of equity grants to directors in their capacity as directors, as required by Israeli law.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Quorum at an Adjourned General Meeting of Shareholders.</span>
Consistent with Israeli law, generally, a quorum for an adjourned general meeting of shareholders of the Company is any two shareholders
present in person, by proxy, by proxy card or by electronic vote at such meeting. As such, the Israeli quorum requirements for an adjourned
meeting are different from the Nasdaq requirement that an issuer listed on Nasdaq have a quorum requirement that in no case be less than
33 1/3% of the outstanding shares of the company&#8217;s common voting stock.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Distribution of Annual Reports</span>. We have chosen
to follow our home country practice in lieu of the requirements of Nasdaq Rule 5250(d)(1), relating to an issuer&#8217;s furnishing of
its annual report to shareholders. Specifically, we file annual reports on Form 20-F, which contain financial statements audited by an
independent accounting firm, electronically with the SEC and post a copy on our website.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16H.<span id="ITEM16H."><!--Anchor--></span> MINE SAFETY DISCLOSURE</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16I.<span id="ITEM16I."><!--Anchor--></span> DISCLOSURE REGARDING
FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">112</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <br/> </div>
<!-- Field: /Include-Text -->

<p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif; text-align: left"></p>

      <div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span id="ITEM16J"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM 16J. INSIDER TRADING POLICIES</span></span></span></div><a id="a_001"></a>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20250228163143155" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">We have adopted an insider trading policy governing</ix:nonNumeric> the purchase, sale, and other dispositions of our securities by directors, senior management, and employees that are reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and any listing standards applicable to us. Our insider trading policy is filed as an exhibit to this Form 20-F.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span id="ITEM16K"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM 16K. CYBERSECURITY</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div>
          <ix:nonNumeric id="Fxbrl_20250228163309020" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">
                <ix:nonNumeric id="Fxbrl_20250228172033563" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, certain third party hosted services, our communications systems, our hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and employees&#8217; information, or the Information Systems and Data.</span></span></span></ix:nonNumeric>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our Senior Vice President/Senior Advisor, Data and Informatics Solutions helps in identifying, assessing and managing the Company&#8217;s cybersecurity threats and risks by monitoring and evaluating our threat environment using various methods including, for example, by engaging third parties to conduct penetration tests on our behalf.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depending on the environment and system, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example, incident response policy, business continuity plan, cybersecurity insurance, firewalls and access controls for certain environments and systems, physical security measures, and employee cybersecurity trainings.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our overall risk assessment and management processes covers material risks from cybersecurity threats.&#160; For example, cybersecurity risk is a component in our internal auditor&#8217;s risk assessment report. Our Senior Vice President/Senior Advisor, Data and Informatic Solutions works with relevant management members to prioritize and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We use <ix:nonNumeric id="Fxbrl_20250228172141502" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">third-party service</ix:nonNumeric> providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including, for example, professional services firms, including legal counsel, cybersecurity and cloud consultants, and a penetration testing firm.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20250228172202943" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">We use third-party service providers to perform a variety of functions throughout our business, including in connection with our clinical data management, antibody development, financial information management, payments and others. We review and require certain security measures of certain of these third parties, such as encryption at rest and in transit and access controls, and in certain cases, we seek to confirm their compliance with different industry standards and certifications, such as SOC1, SOC2, SOC3, ISO 27001, and ISO 27017.</ix:nonNumeric></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">
                <ix:nonNumeric id="Fxbrl_20250228174643711" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20250228174708096" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">For a description of the risks from cybersecurity threats that may materially affect the Company</ix:nonNumeric> and how they may do so, see our risk factors under Part 1. Item 3D. Risk Factors in this Annual Report on Form 20-F, including the applicable risk factors under &#8220;Risk Factors - Risks Related to our Operations.&#8221;</span></span></span></ix:nonNumeric>
              </div>
            </div>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div>
          <ix:nonNumeric id="Fxbrl_20250228163335599" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Governance</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <ix:nonNumeric id="Fxbrl_20250228174931968" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" contextRef="C_20240101to20241231" escape="true">
                <div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">
                    <ix:nonNumeric id="Fxbrl_20250228172524272" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function through its audit committee.</span></span></span></ix:nonNumeric>
                  </div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20250228174839002" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman">Our cybersecurity risk assessment and management processes are under the responsibility of our Senior Vice President/Senior Advisor</span></ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20250228174907959" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman">Data and Informatics Solutions, who has over 15 years of experience in the data science, technology, and machine learning spaces.</span></ix:nonNumeric></span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">
                    <ix:nonNumeric id="Fxbrl_20250228175111815" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our <ix:nonNumeric id="Fxbrl_20250228175151355" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">Senior Vice President/Senior Advisor, Data and Informatics Solutions</ix:nonNumeric>, is responsible for hiring appropriate personnel, helping to <ix:nonNumeric id="Fxbrl_20250228174432444" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">integrate cybersecurity risk</ix:nonNumeric> considerations into the Company&#8217;s overall risk management strategy, communicating key priorities to relevant personnel (such as the Chief Executive Officer), helping to prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></span></span></ix:nonNumeric>
                  </div>
                </div>
              </ix:nonNumeric>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our cybersecurity incident response policy is designed to escalate certain cybersecurity incidents to certain members of management, including our Senior Vice President/Senior Advisor, Data and Informatics Solutions, our Chief Financial Officer and our General Counsel. Under our cybersecurity incident response policy, those members of management will work with the Company&#8217;s incident response team member(s) to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#8217;s cybersecurity incident response policy includes reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></span></div>
              <div>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">
                  <ix:nonNumeric id="Fxbrl_20250228175213514" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20250228175249251" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">The audit committee receives periodic reports at least twice a year from our Senior Vice President/Senior Advisor, Data and Informatics Solutions</ix:nonNumeric> concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also receives various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></span></span></ix:nonNumeric>
                </div>
              </div>
            </div>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
          <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">113</span></span></span></div>
          <div style="page-break-after:always">
            <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
          </div>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span id="PARTIII"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PART III</span></span></span></div><a id="a_002"></a>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span id="ITEM17"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM 17. FINANCIAL STATEMENTS</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">See Item 18.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span id="ITEM18"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM 18. FINANCIAL STATEMENTS</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our consolidated financial statements and related notes are included in this Annual Report beginning on page F-1.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
          <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">114</span></span></span></div>
          <div style="page-break-after:always">
            <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
          </div>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span id="ITEM19"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM 19. EXHIBITS</span></span></span></div><a id="a_003"></a>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Index to Exhibits</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exhibit</span></span></div>
                <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
              </td>
              <td style="width:90%;vertical-align:bottom">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891324002401/exhibit_99-1.htm">1.1</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891324002401/exhibit_99-1.htm">Amended and Restated Articles of Association of Compugen, as amended (incorporated by reference to Exhibit A to Exhibit 99.1 to Compugen&#8217;s report on Form 6-K filed with the SEC on August 5, 2024 (File No. 000-30902)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/exhibit_99-4.htm">1.2</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/exhibit_99-4.htm">Memorandum of Association of Compugen, as amended (incorporated by reference to Annex A2 of Exhibit 99.4 to Compugen&#8217;s report on Form 6-K filed with the SEC on August 5, 2019 (File No. 000-30902)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_2-1.htm">2.1*</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_2-1.htm">Description of Securities.</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320003355/exhibit_10-1.htm">4.1</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320003355/exhibit_10-1.htm">Compugen Ltd. 2021 Employee Share Purchase Plan (incorporated by reference to Exhibit 10.1 to Compugen&#8217;s Registration Statement on Form S-8 filed with the SEC on December 12, 2020 (File No. 333-251263)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320002176/exhibit_4-1.htm">4.2</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320002176/exhibit_4-1.htm">Compugen Ltd. 2010 Share Incentive Plan, as amended (incorporated by reference to Exhibit 4.1 to Compugen&#8217;s Registration Statement on Form S-8, filed with the SEC on July 30, 2020 (File No.333-240182)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-8.htm">4.3</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-8.htm">Amended and Restated Form of Indemnification Undertaking and Exemption and Release between Compugen Ltd. and its directors and office holders (incorporated by reference to Exhibit 4.8 to Compugen&#8217;s Annual Report on Form 20-F/A for the year ended December 31, 2021, filed with the SEC on February 28, 2022 (File No. 000-30902)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891315001448/exhibit_99-2.htm">4.4</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891315001448/exhibit_99-2.htm">Office Lease Agreement (&#8220;Holon Lease&#8221;), dated March 2015, by and between Kanit Hashalom Investments Ltd. and Compugen Ltd. (incorporated by reference to Exhibit 99.2 to Compugen&#8217;s Form 6-K filed with the SEC on May 5, 2015 (File No. 000-30902)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891316004622/exhibit_4-10.htm">4.5</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891316004622/exhibit_4-10.htm">Amendment to Holon Lease made and entered into on November 26, 2015, by and between Kanit Hashalom Investments Ltd. and Compugen Ltd. (incorporated by reference to Exhibit 4.10 to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2015, filed with the SEC on March 7, 2016 (File No. 000-30902)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-11.htm">4.6</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-11.htm">Addendum to Holon Lease made and entered into on October 14, 2020 by and between Kanit Hashalom Investments Ltd. and Compugen Ltd. (incorporated by reference to Exhibit 4.11 to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC on February 25, 2021 (File No. 000-30902))</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318001533/exhibit_10-1.htm">4.7@</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318001533/exhibit_10-1.htm">License Agreement, between the Company and MedImmune Limited (&#8220;MedImmune&#8221;), entered into as of March 30, 2018 (incorporated by reference to Exhibit 10.1 to Compugen&#8217;s Form 6-K, filed with the SEC on May 9, 2018 (File No. 000-30902)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318002228/exhibit_10-1.htm">4.8@</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318002228/exhibit_10-1.htm">Amendment No. 1 to the License Agreement, between the Company and MedImmune, dated May 9, 2018 (incorporated by reference to Exhibit 10.1 to Compugen&#8217;s Form 6-K, filed with the SEC on August 1, 2018 (File No. 000-30902)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-14.htm">4.9</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-14.htm">Amendment No. 2 to the License Agreement, between the Company and MedImmune, dated September 16, 2020 (incorporated by reference to Exhibit 4.14 to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC on February 25, 2021 (File No. 000-30902)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-15.htm">4.10#</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-15.htm">Amendment No. 3 to the License Agreement, between the Company and MedImmune, dated August 4, 2021 (incorporated by reference to Exhibit 4.15 to Compugen&#8217;s Annual Report on Form 20-F/A for the year ended December 31, 2021, filed with the SEC on February 28, 2022 (File No. 000-30902)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891324000818/exhibit_4-11.htm">4.11#</a></span></span></div>
              </td>
              <td rowspan="1" style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891324000818/exhibit_4-11.htm">License Agreement, between Compugen Ltd. and Gilead Sciences, Inc., dated December 18, 2023 (incorporated by reference to Exhibit 4.11 to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on March 5, 2024 (File No. 000-30902)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_8-1.htm">8.1*</a></span></span></div>
              </td>
              <td rowspan="1" style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_8-1.htm">Subsidiaries.</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_11-b.htm">11(b)*</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_11-b.htm">Insider Trading Policy</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_12-1.htm">12.1*</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_12-1.htm">Certification by Principal Executive Officer pursuant to Rule 13a-14(a)/Rule 15d-14(a) under the Exchange Act and Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_12-2.htm">12.2*</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_12-2.htm">Certification by Principal Financial Officer pursuant to Rule 13a-14(a)/Rule 15d-14(a) under the Exchange Act and Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_13-1.htm">13.1*</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_13-1.htm">Certification by Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b)/Rule 15d-14(b) under the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_15-1.htm">15.1*</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_15-1.htm">Consent of Kost Forer Gabbay &amp; Kasierer, a member firm of Ernst &amp; Young Global.</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891324000818/exhibit_4-11.htm">97.1</a></span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891324000818/exhibit_4-11.htm">Compugen&#8217;s Policy for Recovery of Erroneously Awarded Compensation (incorporated by reference to Exhibit 4.11 to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on March 5, 2024 (File No. 000-30902)).</a></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101*</span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following financial information from Compugen Ltd.&#8217;s Annual Report on Form 20-F for the year ended December 31, 2024, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2024 and 2023; (ii) Consolidated Statements of Comprehensive Loss for the years ended December 31, 2024, 2023 and 2022; &#160;(iii) Statements of Changes in Shareholders&#8217; Equity for the years ended December 31, 2024, 2023 and 2022; (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022; and (v) Notes to Consolidated Financial Statements.</span></span></div>
              </td>
            </tr>

        </table>
        <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.INS</span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Instance Document</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.SCH</span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Schema Document</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.PRE</span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.CAL</span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Calculation Linkbase Document</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.LAB</span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Label Linkbase Document</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.DEF</span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:10%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104</span></span></div>
              </td>
              <td style="width:90%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cover Page Interactive Data File&#160;(Formatted as Inline XBRL and contained in Exhibit 101).</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">
          <div style="line-height:1.25">&#160;</div>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Filed herewith.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">@</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Confidential treatment has been granted by the Securities and Exchange Commission as to certain portions.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">#</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Portions of this exhibit (indicated by asterisks therein) have been omitted as these portions are both not material and private or confidential.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
          <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">115</span></span></span></div>
          <div style="page-break-after:always">
            <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
          </div>
        </div>
        <div style="text-align:center;margin-right:28.4pt;margin-left:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span id="SIGNATURES"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SIGNATURES</span></span></span></div><a id="a_004"></a>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</span></span></div>
        <div style="line-height:1.25">&#160;<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;color:#000000;width:100%">

              <tr>
                <td style="width:50%">&#160;</td>
                <td style="width:50%">
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Signature: /s/ Dr. Anat Cohen-Dayag</span></span></span></div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name: Dr. Anat Cohen-Dayag</span></span></div>
                  <div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title: President and Chief Executive Officer, Director</span></span></div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date: March 4, 2025</span></span></div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div style="text-align:center;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">116</span></span></div>
        </div>
      </div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
      </div>

  <div>
    <div>
      <div>
        <div>
          <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:22pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED FINANCIAL STATEMENTS</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AS OF DECEMBER 31, 2024</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. DOLLARS IN THOUSANDS</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INDEX</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                <td style="width:14.64%;vertical-align:bottom;border-bottom:2px solid #000000">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                <td style="width:14.64%;vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="width:85.36%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOUNTINGFIRM">Report of Independent Registered Public Accounting Firm</a> (</span><span style="font-style:italic">PCAOB ID: <ix:nonNumeric id="FFact_0000000000042" name="dei:AuditorFirmId" contextRef="C_20240101to20241231">1281</ix:nonNumeric></span><span style="font-weight:bold">)</span></span></span></div>
                </td>
                <td style="width:14.64%;vertical-align:bottom">
                  <div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 2 - F - 4</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                <td style="width:14.64%;vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="width:85.36%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CONSOLIDATEDBALANCESHEETS">Consolidated Balance Sheets</a></span></span></div>
                </td>
                <td style="width:14.64%;vertical-align:bottom">
                  <div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 5 - F - 6</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                <td style="width:14.64%;vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="width:85.36%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">Consolidated Statements of Comprehensive Loss</a></span></span></div>
                </td>
                <td style="width:14.64%;vertical-align:bottom">
                  <div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 7</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                <td style="width:14.64%;vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="width:85.36%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#STATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"><span style="font-weight:bold">Statements of Changes in Shareholders</span>&#8217;<span style="font-weight:bold"> Equity</span></a></span></span></div>
                </td>
                <td style="width:14.64%;vertical-align:bottom">
                  <div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 8</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                <td style="width:14.64%;vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="width:85.36%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS">Consolidated Statements of Cash Flows</a></span></span></div>
                </td>
                <td style="width:14.64%;vertical-align:bottom">
                  <div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 9 - F - 10</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                <td style="width:14.64%;vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="width:85.36%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS">Notes to Consolidated Financial Statements</a></span></span></div>
                </td>
                <td style="width:14.64%;vertical-align:bottom">
                  <div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 11 - F - 44</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
            <div style="page-break-after:always">
              <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
            </div>
          </div>
          <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000;width:100%;width:100%">

              <tr>
                <td style="vertical-align:top;width:15%">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><img alt="image0.jpg" src="image0.jpg" style="width:99px;height:114px"/></span></span></div>
                  </div>
                </td>
                <td style="vertical-align:bottom;width:25%">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Kost Forer Gabbay &amp; Kasierer</span></span></div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">144 Menachem Begin Road, Building A,</span></span></div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel-Aviv 6492102, Israel</span></span></div>
                </td>
                <td style="vertical-align:bottom;width:60%">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel: +972-3-6232525</span></span></div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fax: +972-3-5622555</span></span></div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ey.com</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOUNTINGFIRM"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To the Shareholders and Board of Directors of</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Opinion on the Financial Statements</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have audited the accompanying consolidated balance sheets of Compugen Ltd. and its subsidiary (the Company) as of December&#160;31, 2024 and 2023, the related consolidated statements of comprehensive loss, changes in shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2024, and related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated March 4, 2025 expressed an unqualified opinion thereon.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis for Opinion</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Critical Audit Matter</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
            <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 2</span></span></span></div>
            <div style="page-break-after:always">
              <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
            </div>
          </div>
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><img alt="image0.jpg" src="image0.jpg" style="width:99px;height:114px"/></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">License Agreement with Gilead</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:13.36%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description of the matter</span></span></div>
                </td>
                <td style="width:2.03%;vertical-align:top">&#160;</td>
                <td style="width:84.6%;vertical-align:top">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As described in Note 1 to the consolidated financial statements, in December 2023, the Company entered into a license agreement with Gilead Sciences, Inc. The Company&#8217;s obligations under the license agreement include: (i) delivery of exclusive license; (ii) certain research activities through the clearance of an IND; and (iii) research and development activities in connection with Phase 1 clinical trial. The Company recognize revenues for research and development activities for phase 1 clinical trial using the input method, based on progress of the performance obligations, which were measured by the proportion of actual costs incurred to the total costs expected to complete the agreement. Costs included in the measure of progress include direct labor and third-party costs. Collaboration revenue from research and development activities from the Company's License Agreement with Gilead, for which management used an input method, was 22.8 million for the year ended December 31, 2024.</span></span></div>
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></span></div>
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Auditing management&#8217;s estimated measure of progress for the research and development activities in connection with phase 1 clinical trial was challenging and complex due to the assumptions used by management and high degree of auditor&#8217;s judgment required to determine the total expected costs to complete the obligations under the agreement, specifically the estimation of direct labor and third-party costs. The Company&#8217;s estimate of costs expected to be incurred in the future requires estimation of the amounts it expects to incur for research and development activities in connection with phase 1 clinical trial. In addition, changes in these estimates can have a material effect on revenue recognized.</span></span></div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:13.36%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">How we addressed the matter in our audit</span></span></div>
                </td>
                <td style="width:2.03%;vertical-align:top">&#160;</td>
                <td style="width:84.6%;vertical-align:top">
                  <div style="line-height:1.25">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the management&#8217;s collaboration revenue process. As part of our testing, we considered controls over the management&#8217;s estimation for measure of progress for the research and development activities in connection with phase 1 clinical trial, including identification of actual costs incurred and management&#8217;s estimation of total expected costs used in its measure of progress calculations, as well as controls over the completeness and accuracy of data used in the calculations.</span></span></div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></span></div>
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our audit procedures performed included, gaining an understanding and testing the significant assumptions used in the management&#8217;s estimates of total expected costs for the agreement and testing the completeness and accuracy of the underlying data used by the Company in its revenue recognition model. We performed inquiries of the research and development personnel responsible for the specific development projects to corroborate management&#8217;s assumptions used in the Company&#8217;s estimates of total expected costs, evaluated any changes in the product development timeline and/or increases or decreases in the total expected costs by project on a quarterly basis, and examined evidence supporting key inputs of the revenue recognition model including assessing whether actual costs incurred were appropriate under the terms of the agreement. We compared the estimates of total expected costs to actual costs incurred on a quarterly basis to evaluate management&#8217;s ability to forecast costs. We also tested the amount of historical costs incurred and the calculation of amounts recognized under the revenue recognition model.</span></span></div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">KOST FORER GABBAY &amp; KASIERER</span></span></div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A Member of EY Global</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have served as the Company&#8217;s auditor since 2002</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:100%;vertical-align:top">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel-Aviv, Israel</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:100%;vertical-align:top">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March 4, 2025</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
            <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 3</span></span></span></div>
            <div style="page-break-after:always">
              <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
            </div>
          </div>
          <div style="line-height:1.25">
            <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000;width:100%;width:100%">

                <tr>
                  <td style="vertical-align:top;width:15%">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><img alt="image0.jpg" src="image0.jpg" style="width:99px;height:114px"/></span></span></div>
                    </div>
                  </td>
                  <td style="vertical-align:bottom;width:25%">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Kost Forer Gabbay &amp; Kasierer</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">144 Menachem Begin Road, Building A,</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel-Aviv 6492102, Israel</span></span></div>
                  </td>
                  <td style="vertical-align:bottom;width:60%">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel: +972-3-6232525</span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fax: +972-3-5622555</span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ey.com</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To the Shareholders and Board of Directors of</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Opinion on Internal Control over Financial Reporting</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have audited Compugen Ltd. and its subsidiary&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Compugen Ltd. and its subsidiary (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on the COSO criteria.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of comprehensive loss, changes in shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and our report dated March 4, 2025, expressed an unqualified opinion thereon.&#160;</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis for Opinion</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Definition and Limitations of Internal Control Over Financial Reporting</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000043" name="dei:AuditorName" contextRef="C_20240101to20241231">KOST FORER GABBAY &amp; KASIERER</ix:nonNumeric></span></span></div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A Member of EY Global</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:100%;vertical-align:top">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000044" name="dei:AuditorLocation" contextRef="C_20240101to20241231">Tel-Aviv, Israel</ix:nonNumeric></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:100%;vertical-align:top">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March 4, 2025</span></span></div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div style="clear:both;margin-top:10pt;margin-bottom:0pt">
            <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 4</span></span></span></div>
            <div style="page-break-after:always">
              <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>

  <div>
    <div>
      <div>
        <div>
          <div>
            <div>
              <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:15pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></div>
            </div>
            <div style="line-height:1.25">
              <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span id="CONSOLIDATEDBALANCESHEETS"></span>CONSOLIDATED BALANCE SHEETS</span></div>
              <div style="text-align:justify;line-height:1.25;font-weight:bold">
                <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
              </div>
            </div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands</span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">December 31,</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Note</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2024</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2023</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:14.2pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">ASSETS</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">CURRENT ASSETS:</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000045" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,229</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000046" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,890</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000047" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000048" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000049" name="us-gaap:OtherShortTermInvestments" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,397</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000050" name="us-gaap:OtherShortTermInvestments" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,053</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64.66%;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Investment in marketable securities</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-family:Times New Roman,Times,serif">3, 4</span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227231100990_Fact_0000000000049" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,629</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227231100990_Fact_0000000000050" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,742</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Trade receivables</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227231059015_Fact_0000000000049" name="us-gaap:ReceivablesNetCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227231059015_Fact_0000000000050" name="us-gaap:ReceivablesNetCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,000</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64.66%;padding-bottom:2px;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Other accounts receivable and prepaid expenses</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-family:Times New Roman,Times,serif">5</span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000053" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,742</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000054" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,529</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64.66%;padding-bottom:2px;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> current assets</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:center;width:9.08%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000055" name="us-gaap:AssetsCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,997</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000056" name="us-gaap:AssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,579</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64.66%;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT ASSETS:</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Restricted long-term bank deposits</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224184103804" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">343</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224184107099" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64.66%;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Long-term prepaid expenses</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000057" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,888</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000058" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Severance pay fund</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000059" name="cgen:SeverancePayFundNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,072</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000060" name="cgen:SeverancePayFundNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,977</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64.66%;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Operating lease right of use asset</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-family:Times New Roman,Times,serif">6</span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000061" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,843</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000062" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,329</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;padding-bottom:2px;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Property and equipment, net</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-family:Times New Roman,Times,serif">7</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000063" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">852</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000064" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,216</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64.66%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;padding-bottom:2px;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> non-current assets</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000065" name="us-gaap:AssetsNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,998</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000066" name="us-gaap:AssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,755</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64.66%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;padding-bottom:4px;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> assets</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000067" name="us-gaap:Assets" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,995</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000068" name="us-gaap:Assets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,334</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></div>
            <div style="text-align:justify;line-height:1.25;margin-bottom:0pt">&#160;</div>
            <div style="clear:both;margin-top:0pt;margin-bottom:10pt">
              <div>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 5</span></span></span></span></p><div style="text-align:center"><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/></div>
              </div>
            </div>
            <div style="line-height:1.25">
              <div style="text-align:justify;line-height:1.25;font-weight:bold">
                <div>
                  <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:15pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></div>
                </div>
              </div>
              <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED BALANCE SHEETS</span></div>
              <div style="text-align:justify;line-height:1.25;font-weight:bold">
                <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
              </div>
            </div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share and per share data)</span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">December 31,</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Note</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2024</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2023</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:17pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">CURRENT LIABILITIES:</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000069" name="us-gaap:AccountsPayableCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,838</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000070" name="us-gaap:AccountsPayableCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,502</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Deferred revenues</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224184239781" name="us-gaap:DeferredRevenueCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,632</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224184245908" name="us-gaap:DeferredRevenueCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,149</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Current maturity of operating lease liability</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-family:Times New Roman,Times,serif">6</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000073" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000074" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">632</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Accrued expenses</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224185219347" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,168</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224185226324" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,858</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;padding-bottom:2px;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Employees and related accruals</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224185300088" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,074</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224185306141" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,125</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;padding-bottom:2px;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> current liabilities</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000077" name="us-gaap:LiabilitiesCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,160</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000078" name="us-gaap:LiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,266</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT LIABILITIES:</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Deferred revenues</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224185857857" name="us-gaap:DeferredRevenueNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,045</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224185904182" name="us-gaap:DeferredRevenueNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,392</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Operating lease liability</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224190059221_xbrl_20250224185857857" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,464</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224190059221_xbrl_20250224185904182" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">719</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Accrued severance pay</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000083" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,412</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000084" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,398</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> non-current liabilities</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000085" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,921</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000086" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,509</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS AND CONTINGENT LIABILITIES</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-family:Times New Roman,Times,serif">8</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom"><ix:nonFraction id="Fxbrl_20250225101052443" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20241231" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom"><ix:nonFraction id="Fxbrl_20250225101058499" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20231231" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">SHAREHOLDERS&#8217; EQUITY:</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-family:Times New Roman,Times,serif">9</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Share capital:</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:28.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Ordinary shares of NIS <ix:nonFraction id="Fxbrl_20230214011115128" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="NIS_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214011053357" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20241231" unitRef="NIS_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction id="Fxbrl_s_20230214011030882" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214011030883" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20241231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2024 and 2023; <ix:nonFraction id="Fxbrl_20230214101530012" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20241231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000092" name="us-gaap:CommonStockSharesIssued" contextRef="C_20241231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,541,246</ix:nonFraction></ix:nonFraction> and <ix:nonFraction id="Fxbrl_20230214011437479" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000094" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,237,465</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2024 and 2023, respectively.</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000095" name="us-gaap:CommonStockValue" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">248</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000096" name="us-gaap:CommonStockValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">247</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Additional paid-in capital</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000097" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">543,413</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000098" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">539,837</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Accumulated other comprehensive income</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227232850023_Fact_0000000000097" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227232850023_Fact_0000000000098" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;padding-bottom:2px;vertical-align:bottom">
                    <div style="margin-left:11.35pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Accumulated deficit</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000099" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">488,758</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">)</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000100" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">474,527</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">)</span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;padding-bottom:2px;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> shareholders&#8217; equity</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000101" name="us-gaap:StockholdersEquity" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,914</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000102" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,559</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64.66%;padding-bottom:4px;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> liabilities and shareholders&#8217; equity</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000103" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,995</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000104" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,334</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span>
              <p style="margin:0pt">&#160;</p>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="text-align:justify;line-height:1.25">
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 6</span></span></span></span></p><div style="text-align:center"><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/></div>
    </div>
  </div>

  <div>
    <div>
      <div style="line-height:1.25">
        <div style="text-align:justify;line-height:1.25;font-weight:bold">
          <div style="line-height:1.25;font-weight:bold">
            <div>
              <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:15pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
            </div>
          </div>
        </div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"></span>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></span></div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold">
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share and per share data)</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000105" name="us-gaap:Revenues" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,864</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000106" name="us-gaap:Revenues" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,459</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012425376" name="us-gaap:Revenues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenue</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000108" name="us-gaap:CostOfRevenue" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,930</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000109" name="us-gaap:CostOfRevenue" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,004</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012430928" name="us-gaap:CostOfRevenue" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">975</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross profit</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000111" name="us-gaap:GrossProfit" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,934</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000112" name="us-gaap:GrossProfit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,455</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012436309" name="us-gaap:GrossProfit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,525</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating expenses:</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses, net</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115443735_Fact_0000000000117" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,810</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115443735_Fact_0000000000118" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,472</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115443735_Fact_0000000000119" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,648</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000117" name="us-gaap:BusinessDevelopment" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">576</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000118" name="us-gaap:BusinessDevelopment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000119" name="us-gaap:BusinessDevelopment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">932</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115622478_Fact_0000000000117" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,439</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115622478_Fact_0000000000118" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,731</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115622478_Fact_0000000000119" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,319</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> operating expenses</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115529913" name="us-gaap:OperatingExpenses" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,825</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000124" name="us-gaap:OperatingExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,447</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000125" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,899</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating loss</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000126" name="us-gaap:OperatingIncomeLoss" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,891</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000127" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,992</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000128" name="us-gaap:OperatingIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">35,374</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;padding-bottom:2px;vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000129" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,182</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000130" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,208</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000131" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,738</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before taxes on income</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000132" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,709</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000133" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,784</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000134" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,636</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes on income, net</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012403897" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,522</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012406780" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,970</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000137" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:center;width:9.08%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000138" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,231</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000139" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,754</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000140" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted net loss per share</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224174645707" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20241231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_0000000000141" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20241231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.16</ix:nonFraction></ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224174709901" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20231231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_0000000000142" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.21</ix:nonFraction></ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224174800107" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_0000000000143" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.39</ix:nonFraction></ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other comprehensive loss:</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unrealized gain arising during the period from marketable securities</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228001617126_Fact_0000000000129" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228001617126_Fact_0000000000130" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228001617126_Fact_0000000000131" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total comprehensive loss</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000147" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,222</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000148" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,752</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000149" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52.53%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228001903510" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20240101to20241231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000153" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240101to20241231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,528,031</ix:nonFraction></ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228001918048" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000154" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">87,633,298</ix:nonFraction></ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228001929235" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000155" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,555,628</ix:nonFraction></ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 7</span></span></span></span></p><div style="text-align:center"><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/></div>
    </div>
  </div>

  <div>
    <div>
      <div>
        <div>
          <div>
            <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:15pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
          </div>
          <div style="line-height:1.25">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="STATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"></span><span style="font-weight:bold">STATEMENTS OF CHANGES IN SHAREHOLDERS</span>&#8217;<span style="font-weight:bold"> EQUITY</span></span></span></div>
            <div style="text-align:justify;line-height:1.25">
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share data)</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary shares</span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional paid-in</span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated other comprehensive</span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated</span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total shareholders&#8217;</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amount</span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">capital</span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">income</span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">deficit</span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">equity</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2022</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000173" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,433,432</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000174" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000175" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">528,533</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010711681" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000176" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">422,079</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000177" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,693</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options and ESPP shares</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000199" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">191,211</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000200" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000201" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013718917" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013728837" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224175055453" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation issued to employees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224180339449" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000211" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224180414715" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224180434405" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000212" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224180533427" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224180546817" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224180550362" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000213" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000214" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2022</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000215" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,624,643</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000216" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000217" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">533,213</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010718949" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000218" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">455,773</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000219" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,680</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228004702895_Fact_0000000000165" name="cgen:IssuanceOfSharesAndWarrantsNetShares" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,612,822</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228004702895_Fact_0000000000166" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228004702895_Fact_0000000000167" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,074</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000166" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000167" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228004702895_Fact_0000000000168" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,081</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation issued to employees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182621810" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228004651156_Fact_0000000000211" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,550</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182627052" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182644309" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228004651156_Fact_0000000000212" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,550</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other comprehensive income from marketable securities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182709791" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182713378" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228005606782" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182721113" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224181409213" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182736559" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182740340" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182743304" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228004710783_Fact_0000000000213" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,754</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228004710783_Fact_0000000000214" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,754</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2023</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228003430903_Fact_0000000000215" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,237,465</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228003430903_Fact_0000000000216" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">247</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228003430903_Fact_0000000000217" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">539,837</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010218091" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228003430903_Fact_0000000000218" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">474,527</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228005626619" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,559</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224181658809" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">11,053</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<span style="-sec-ix-hidden:Fxbrl_20250224182302928">*</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224181849098" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183710836" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183717971" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224181857069" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224181915623" name="cgen:IssuanceOfSharesAndWarrantsNetShares" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">292,728</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224181927559" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224181950893" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">543</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183658456" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183701490" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182103901" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">544</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation issued to employees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183640629" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182159337" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,023</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183643810" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183646763" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182204714" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,023</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other comprehensive income from marketable securities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183732283" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183728638" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182213962" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183738392" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224182230211" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183746510" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183749235" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224183752462" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224182239490" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,231</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224182244882" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,231</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;padding-bottom:4px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2024</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224175231100_xbrl_20240228003430903_Fact_0000000000215" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,541,246</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224175231100_xbrl_20240228003430903_Fact_0000000000216" name="us-gaap:StockholdersEquity" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">248</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224175231100_xbrl_20240228003430903_Fact_0000000000217" name="us-gaap:StockholdersEquity" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">543,413</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224175231100_xbrl_20240228010218091" name="us-gaap:StockholdersEquity" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224175231100_xbrl_20240228003430903_Fact_0000000000218" name="us-gaap:StockholdersEquity" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">488,758</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224175231100_xbrl_20240228005626619" name="us-gaap:StockholdersEquity" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,914</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(*) Representing amount lower than $&#160;1.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
          <div style="text-align:justify;line-height:1.25;margin-bottom:0pt">&#160;</div>
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 8</span></span></span></span></p><div style="text-align:center"><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/></div>
      </div>
    </div>
  </div>

  <div>
    <div>
      <div>
        <div>
          <div>
            <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:15pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
          </div>
          <div style="line-height:1.25">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS"></span>CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span></div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold">
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from operating activities:</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000220" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,231</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000221" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,754</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224185520749" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments required to reconcile net loss to net cash used in operating activities:</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25">Share-based compensation</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000223" name="us-gaap:ShareBasedCompensation" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,023</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000224" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,550</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000225" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000226" name="us-gaap:Depreciation" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">486</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000227" name="us-gaap:Depreciation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">476</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000228" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">482</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in severance pay, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000229" name="cgen:SeverancePayNet" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">81</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015430934" name="cgen:SeverancePayNet" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">50</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000231" name="cgen:SeverancePayNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">81</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss from property and equipment sales and disposals</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224185641065" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224185646941" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224185650553" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange rate differences loss (gain) on cash balances</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240301111210380" name="cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240301111218731" name="cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240301111232004" name="cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">393</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in interest receivables from short-term bank deposits and long-term restricted deposit</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224191156710" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">855</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224191201240" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">92</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224191203268" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of discount and accrued interest on marketable securities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228013916179_xbrl_20230214015610319" name="cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,575</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228013916179_Fact_0000000000251" name="cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">280</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013916179_Fact_0000000000252" name="cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in trade receivables</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000238" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">61,000</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000239" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,000</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015520285" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in other accounts receivable and prepaid expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000241" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">213</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000242" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000243" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,043</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in long-term prepaid expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000244" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">655</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000245" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">666</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015551570" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in operating lease right of use asset</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000247" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">550</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000248" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">568</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000249" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">658</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase (decrease) in trade payables and employees and related accruals and accrued expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224190735907" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,410</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224190741453" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,509</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224190744120" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,601</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in deferred participation in R&amp;D expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224190823689" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224190806504" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">325</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224190828721" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,019</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase in deferred revenues</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013913681_xbrl_20230214015610319" name="cgen:IncreaseDecreaseInDeferredRevenues" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,136</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013913681_Fact_0000000000251" name="cgen:IncreaseDecreaseInDeferredRevenues" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,541</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013913681_Fact_0000000000252" name="cgen:IncreaseDecreaseInDeferredRevenues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in operating lease liability</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000256" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">503</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000257" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">645</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000258" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,062</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by (used in) operating activities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224185433978" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,604</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224185439147" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">35,886</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224185444630" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,113</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from investing activities:</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from maturity of short-term bank deposits</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000262" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,717</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000263" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,242</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000264" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,445</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in short-term bank deposits</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000265" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,219</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000266" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,100</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000267" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,900</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from maturity of marketable securities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013918979_xbrl_20230214015610319" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,230</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013918979_Fact_0000000000251" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,145</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013918979_Fact_0000000000252" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in marketable securities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228013920658_xbrl_20230214015610319" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,533</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228013920658_Fact_0000000000251" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,605</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013920658_Fact_0000000000252" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in long term restricted deposit</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250224194420319" name="us-gaap:PaymentsToAcquireRestrictedInvestments" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">330</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224194432849" name="us-gaap:PaymentsToAcquireRestrictedInvestments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224194443396" name="us-gaap:PaymentsToAcquireRestrictedInvestments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000268" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000269" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000270" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">477</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Costs of disposal of property and equipment</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115924752_Fact_0000000000268" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115924752_Fact_0000000000269" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230222115924752_Fact_0000000000270" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from sale of property and equipment</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222112447073" name="cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000272" name="cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000273" name="cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by (used in) investing activities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000274" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">46,252</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000275" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,510</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015724492" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,060</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
          <div style="text-align:justify;line-height:1.25">&#160;</div>
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 9</span></span></span></span></p><div style="text-align:center"><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/></div>
          <div style="line-height:1.25">
            <div style="text-align:justify;line-height:1.25;font-weight:bold">
              <div>
                <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:15pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
              </div>
            </div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span></div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold">
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from financing activities:</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from issuance of ordinary shares, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000277" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">544</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000278" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,081</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000279" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25">Proceeds from exercise of share-based awards</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000283" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000284" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000285" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by financing activities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000286" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">554</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000287" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,081</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000288" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effect of exchange rate changes on cash</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240301111348803" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240301111408147" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240301111411299" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">393</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase in cash, cash equivalents and restricted cash</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000289" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,974</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000290" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,834</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015801453" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,907</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at the beginning of the year</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224201122601" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,255</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224201149235" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,421</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224201210319" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,514</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at the end of the year</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224194820349" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,229</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224194822717" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,255</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224194825126" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,421</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Supplemental disclosure of non-cash investing and financing activities:</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000298" name="cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000299" name="cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2.8pt;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250228010101761" name="cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2.8pt;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right-of-use asset obtained in exchange for operating lease liability</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015821971" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,064</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000305" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">71</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015838501" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Reconciliation of cash, cash equivalents and restricted cash:</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000310" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,229</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000311" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,890</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000312" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,059</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000313" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000314" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000315" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">362</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total cash, cash equivalents and restricted cash</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000316" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,229</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000317" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,255</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000318" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,421</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
          <div style="text-align:justify;line-height:1.25">&#160;</div>
          <div style="clear:both;margin-top:10pt;margin-bottom:0pt">
            <div style="text-align:center;margin-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 10</span></span></span></div>
            <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/>
          </div>
        </div>
      </div>
    </div>
  </div>

  <div>
    <div>
      <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:15pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
      <div style="line-height:1.25">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS"></span>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></span></div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold">
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share and per share data)</span></span></div>
    </div>
    <div style="line-height:1.25">&#160;</div>
    <ix:nonNumeric id="Fxbrl_20240228025141975" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
      <div>
        <div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 1:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">GENERAL</span></span></span></td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.5pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compugen Ltd. (the &#8220;Company&#8221;) is a clinical-stage therapeutic discovery and development company utilizing its AI/ML powered predictive computational discovery platform, recently branded as Unigen<sup style="vertical-align:text-top;line-height:1;font-size:smaller">TM</sup>, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapy. The Company&#8217;s innovative immuno-oncology pipeline consists of four clinical stage programs, COM701, COM902, rilvegostomig and GS-0321 (previously COM503). Two programs that the Company is pursuing internally, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. <span>The Company&#8217;s two ongoing clinical trials (that completed enrollment) were initiated in 2023 and are evaluating the triple combination treatment of COM701, COM902 and pembrolizumab, one in platinum resistant ovarian cancer and the other in microsatellite stable colorectal cancer, </span> In addition, the Company is planning to start enrolling patients to our adaptive platform trial in platinum sensitive ovarian cancer, evaluating COM701 as a monotherapy randomized to placebo in sub-trial 1, in the second quarter of 2025. Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from the Company&#8217;s COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between the Company and AstraZeneca and is being evaluated in multiple Phase 3 clinical trials and in multiple Phase 2 and Phase 1 trials. GS-0321 (previously COM503), the Company&#8217;s potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being developed by the Company in a recently initiated Phase 1 trial. In addition, the Company has an early-stage immuno-oncology therapeutic pipeline that consists of programs aiming to address various mechanisms of immune resistance.</span></span></div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is headquartered in Holon, Israel. Its clinical development activities operate from the Company&#8217;s headquarters in Israel and from its United States subsidiary, Compugen USA, Inc., located in San Francisco, CA.</span></span></div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred losses in the amount of $ <ix:nonFraction id="FFact_0000000000319" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,231</ix:nonFraction> during the year ended December 31, 2024, has an accumulated deficit of $ <ix:nonFraction id="FFact_0000000000320" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">488,758</ix:nonFraction> as of December 31, 2024 and has positive cash flows from operating activities in the amount of $ <ix:nonFraction id="FFact_0000000000321" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,604</ix:nonFraction> for the year ended December 31, 2024. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures for a period at least twelve months from the reporting date.</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#8220;Bayer Agreement&#8221;) with Bayer Pharma AG (&#8220;Bayer&#8221;) for the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators.</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the Bayer Agreement, the Company received an upfront payment of $ <ix:nonFraction id="FFact_0000000000323" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20130801to20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction>, and additional aggregate milestone payments of $ <ix:nonFraction id="FFact_0000000000325" name="cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" contextRef="C_20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,200</ix:nonFraction>.&#160;</span></span></div>
        </div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div>
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 11</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 1:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">GENERAL (Cont.)</span></span></span></td>
                </tr>
                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold">&#160;</td>
                  <td style="width:auto;vertical-align:top;text-align:justify">&#160;</td>
                </tr>

            </table>
          </div>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 29, 2022, Bayer notified the Company that it has resolved to terminate the Bayer Agreement, effective as of February 27, 2023.</span></span></div>
        <div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and is solely responsible for all research, development, and commercial activities under the agreement. In connection with such license agreement, AstraZeneca developed rilvegostomig, a novel PD-/TIGIT bi-specific antibody with a TIGIT component that is derived from COM902.&#160; Rilvegostomig entered the clinic in September 2021, initiated first patient dosing in the first indication in Phase 3 study in December 2023, and first patient dosing in the second indication in Phase 3 study in May 2024. Compugen received a $ <ix:nonFraction id="FFact_0000000000326" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction>&#160;upfront payment, and $ <ix:nonFraction id="FFact_0000000000327" name="cgen:AccruedMilestonePayment" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,500</ix:nonFraction> milestone payments out of up to $ <ix:nonFraction id="Fxbrl_20240228095106065" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,000</ix:nonFraction> </span></span>it is eligible to receive in development, regulatory and commercial milestones for the first product in addition to royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.</span></span></div>
                    <div style="line-height:1.25">&#160;</div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:54pt">&#160;</td>
                <td style="width:31.5pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Agreement&#8221;) with Bristol-Myers Squibb Company (&#8220;Bristol&#160;Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol&#160;Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.</span></span></div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the Master Clinical Agreement, as amended from time to time, Compugen sponsored the trials, which included the evaluation of the combination of COM701 and Opdivo&#174; &#177; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Bristol Myers Squibb and Compugen each <span>supplied their</span> own compounds for the studies.</span></span></div>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the Agreement in October 2018, Bristol-Myers Squibb made a $ <ix:nonFraction id="FFact_0000000000329" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> investment in Compugen, see Note 9b.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;text-indent:-1.2pt;margin-left:85.5pt;line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Among several amendments to the Master Clinical Agreement, on November 10, 2021, the <span>Agreement</span> was further amended and in conjunction with the signing of the amendment to the Agreement, Bristol Myers Squibb made a $<ix:nonFraction id="FFact_0000000000330" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="C_20211130" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in Compugen, see Note 9b.</span></span></div>
          </div>
          <div style="text-align:justify;text-indent:-1.2pt;margin-left:85.5pt;line-height:1.25">&#160;</div>
          <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 3, 2022, the Company and Bristol Myers Squibb entered into a letter agreement pursuant to which the Agreement, as amended from time to time, was terminated as of such date.</span></span></div>
          </div>
        </div>
        <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25">
          <p style="margin:0pt">&#160;</p>
        </div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div>
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 12</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 1:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">GENERAL (Cont.)</span></span></span></td>
                </tr>
                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold">&#160;</td>
                  <td style="width:auto;vertical-align:top;text-align:justify">&#160;</td>
                </tr>

            </table>
          </div>
        </ix:exclude></div>
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 18, 2023, the Company entered into an exclusive license agreement (the &#8220;License Agreement&#8221;) with Gilead Sciences, Inc. (&#8220;Gilead&#8221;), pursuant to which the Company granted Gilead an exclusive license under the <span>Company&#8217;s</span> pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including the Company&#8217;s COM503 product candidate<span>, now named GS-0321 (&#8220;GS-0321</span> License&#8221;), and additional products that may be so developed by Gilead (together with <span>GS-0321</span>, the &#8220;Licensed Products&#8221;).</span></span></div>
                  </div>
                  <div>&#160;<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the License Agreement, Gilead paid the Company a one-time, upfront payment of $<ix:nonFraction id="Fxbrl_20240228025953345" name="cgen:NonRefundableUpfrontPayment" contextRef="C_20230101to20231218" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">60,000</ix:nonFraction> in January 2024. The Company has continued to develop <span>GS-0321</span> during the initial development term, which included conducting activities defined within the agreement to advance <span>GS-0321</span> through the clearance of an investigational new drug application (&#8220;IND&#8221;). The Company received from Gilead $<ix:nonFraction id="Fxbrl_20240228031257594" name="cgen:MilestonePaymentReceivable" contextRef="C_20230101to20231218" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">30,000</ix:nonFraction> in the form of a milestone payment upon clearance of the IND for <span>GS-0321</span>, see also Note 2k. The Company is also eligible to receive up to approximately $<ix:nonFraction id="Fxbrl_20240228030428945" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" contextRef="C_20231218" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">758,000</ix:nonFraction> in additional milestone payments upon the achievement of certain development, regulatory and commercial milestones. The Company is further eligible to receive royalties on worldwide net sales of Licensed Products.</span></span></div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;</span></span>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company <span>is</span> responsible for conducting a Phase 1 clinical trial for <span>GS-0321</span>, including handling the regulatory matters in connection therewith, and will bear the costs of such trial (including the <span>GS-0321</span> drug supply), with Gilead providing at no cost <span>its zimberelimab</span> antibody for such trial. In certain circumstances, Gilead may assume the role of conducting the Phase 1 clinical trial.</span></span></div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Upon completion of the Phase 1 clinical trial for GS-0321, the Company will initiate the transfer of development activities related to GS-0321 to Gilead, following which, Gilead will have sole responsibility to develop and commercialize the Licensed Products.</span></span></span></span></div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="text-align:justify;line-height:1.25">&#160;<table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56pt">&#160;</td>
                  <td style="font-size:10pt;vertical-align:top;width:28pt">&#160;</td>
                  <td style="font-size:10pt;vertical-align:top;width:auto">
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>During the term of the License Agreement, the Company is prohibited from researching, developing, making, and commercializing any compounds, molecules, products or treatment methods that are directed to IL-18 or any companion diagnostics for an IL-18 product.</span></span></span></p>
                  </td>
                </tr>
                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56pt">&#160;</td>
                  <td style="font-size:10pt;vertical-align:top;width:28pt">&#160;</td>
                  <td style="font-size:10pt;vertical-align:top;width:auto">&#160;</td>
                </tr>
                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56pt">&#160;</td>
                  <td style="font-size:10pt;vertical-align:top;width:28pt">&#160;</td>
                  <td colspan="1" rowspan="2" style="font-size:10pt;vertical-align:top;width:auto">
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Unless terminated early by a party pursuant to its terms, the License Agreement will continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term in such country.</span></span></span></p>
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="text-align:justify"><span style="text-align:justify"><span><span>Gilead withheld at source <ix:nonFraction id="Fxbrl_20240228030716817" name="cgen:PercentageOfExpectedFromPaymentAmountPaid" contextRef="C_20240101to20240131" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction>% from the upfront payment and IND clearance milestone amounts paid to the Company in January 2024 and in September 2024, respectively, and is expected to continue and withhold at source all taxes required by law from all payments payable to the Company under the License Agreement.</span></span></span></span></span></span></span></span></p>
                  </td>
                </tr>
                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56pt">&#160;</td>
                  <td style="font-size:10pt;vertical-align:top;width:28pt">&#160;</td>
                </tr>
                <tr>
                  <td style="width:56pt">&#160;</td>
                  <td style="width:28pt">&#160;</td>
                  <td style="width:auto">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:56pt">&#160;</td>
                  <td style="vertical-align:top;width:28pt">&#160;</td>
                  <td style="vertical-align:top;width:auto">
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The License Agreement contains customary representations, warranties, covenants, and terms governing the prosecution and enforcement of certain intellectual property and issues related to technology transfer, manufacturing transfer, provisions with respect to establishment of joint steering committee and its governance covenants with respect change of control and others.</span></p>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
  </div>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 13</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <div>
    <ix:nonNumeric id="Fxbrl_20240228140455566" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20240101to20241231" escape="true">
      <div>
        <div style="text-align:justify;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;text-align:left;color:rgb(0, 0, 0)">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span>NOTE 2:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span>SIGNIFICANT ACCOUNTING POLICIES</span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <div>&#160;</div>
          <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</span></span></div>
          <ix:nonNumeric id="F20240228054857421_1" name="us-gaap:UseOfEstimates" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Use of estimates:</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company&#8217;s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></span></div>
            </div>
          </ix:nonNumeric>
          <ix:nonNumeric id="F20240228054857421_2" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>b.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Financial statements in U.S. dollars:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The reporting and functional currency of the Company is the U.S. dollar, as the Company&#8217;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No.&#160;830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.</span></span></div>
            </div>
          </ix:nonNumeric>
          <ix:nonNumeric id="F20240228054857422_3" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>c.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Basis of consolidation:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.</span></span></div>
            </div>
          </ix:nonNumeric>
          <ix:nonNumeric id="F20240228054857423_5" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>d.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Cash, Cash equivalents and Restricted cash:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents consist of cash in banks and cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. The Company&#8217;s restricted cash primarily consists of bank deposits collateralizing the Company&#8217;s operating leases and credit cards.</span></span></div>
            </div>
          </ix:nonNumeric>
          <div style="line-height:1.25">&#160;</div>
          <div><ix:exclude>
            <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 14</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            </div>
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                <tr style="margin-top:0pt;margin-bottom:0pt">
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                    <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></div>
                  </td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </ix:exclude></div>
          <ix:nonNumeric id="Fxbrl_20250224191009709" name="cgen:ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div>
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits and restricted long-term bank deposits:</span></span></div>
                      </div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-family:Times New Roman, Times, serif;font-size:10pt">Short-term bank deposits include deposits with maturities of more than three months but less than one year. Long-term bank deposits include deposits with maturities of more than one year. Bank deposits are stated at cost which approximates market values.</span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank deposits as of December 31, 2024 and 2023 are in U.S. dollars and bear an annual weighted average interest rate of <ix:nonFraction id="Fxbrl_20250228020158248" name="cgen:ShortTermBankDepositsWeightedAverageRateForeign" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.51</ix:nonFraction>% and <ix:nonFraction id="Fxbrl_20250228020206464" name="cgen:ShortTermBankDepositsWeightedAverageRateForeign" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.20</ix:nonFraction>%, respectively.</span></span></div>
              </div>
            </div>
          </ix:nonNumeric>
          <ix:nonNumeric id="F20240228054857466_78" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>f.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Investments in marketable securities:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#8220;Investments - Debt Securities&#8221;.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#8220;AFS&#8221;). The Company classifies its marketable securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#8217; equity. Realized gains and losses on sale of investments are included in financial income, net.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#8217;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#8217;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in shareholders&#8217; equity. No credit loss impairment was identified in the year ended December 31, 2024.</span></span></div>
            </div>
          </ix:nonNumeric>
          <div style="line-height:1.25">&#160;</div>
          <div><ix:exclude>
            <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 15</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            </div>
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                <tr style="margin-top:0pt;margin-bottom:0pt">
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                    <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></div>
                  </td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </ix:exclude></div>
          <ix:nonNumeric id="F20240228054857425_9" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>g.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Property and equipment, net:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:90pt">
                <ix:nonNumeric id="F20240228054857451_53" name="cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" contextRef="C_20240101to20241231" escape="true">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;width:68%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:30%;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                        </td>
                        <td style="width:30%;vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:68%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:68%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857425_10" name="cgen:AnnualDepreciationRate" contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></div>
                        </td>
                        <td style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:68%;vertical-align:bottom">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857426_11" name="cgen:AnnualDepreciationRate" contextRef="C_20240101to20241231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction> - <ix:nonFraction id="F20240228054857426_12" name="cgen:AnnualDepreciationRate" contextRef="C_20240101to20241231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction> (mainly <ix:nonFraction id="F20240228054857431_13" name="cgen:AnnualDepreciationRate" contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction>)</span></span></div>
                        </td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr style="background-color:rgb(204, 238, 255)">
                        <td style="width:68%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                        <td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240228113754899" name="cgen:AnnualDepreciationRateDescription" contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">Shorter of the term of the lease or useful life</ix:nonNumeric></span></span></div>
                        </td>
                        <td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                      </tr>

                  </table>
                </ix:nonNumeric>
              </div>
            </div>
          </ix:nonNumeric>
          <ix:nonNumeric id="F20240228054857432_15" name="us-gaap:PropertyPlantAndEquipmentImpairment" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>h.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Impairment of long-lived assets:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The long-lived assets of the Company. are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant, and Equipment&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset (assets group) with the future undiscounted cash flows expected to be generated by the asset (assets group). If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets group exceeds the fair value of the assets group. During the years 2024, 2023 and 2022, no impairment losses have been recorded.</span></span></div>
            </div>
          </ix:nonNumeric>
          <ix:nonNumeric id="F20240228054857465_76" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>i.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Leases:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for its leases according to ASC 842 - Leases (&#8220;ASC 842&#8221;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of twelve months or less. The Company elected the practical expedient to combine its lease and non-lease components for its leases.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div><ix:exclude>
                <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 16</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                </div>
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></div>
                      </td>
                    </tr>

                </table>
                <div>&#160;</div>
                <div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                      <tr style="vertical-align:top">
                        <td style="width:56.7pt">&#160;</td>
                        <td style="text-align:right;vertical-align:top;width:28.35pt">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>i.</span></span></span></div>
                        </td>
                        <td style="text-align:left;vertical-align:top;width:auto">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Leases (Cont.):</span></span></span></div>
                        </td>
                      </tr>

                  </table>
                  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </div>
              </ix:exclude></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.</span></span></div>
            </div>
          </ix:nonNumeric>
          <div style="line-height:1.25">&#160;</div>
          <ix:nonNumeric id="F20240228054857465_77" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>j.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Revenue recognition:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes revenue in accordance with ASC 606 &#8211; &#8220;Revenue from Contracts with Customers&#8221;.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As such, the Company analyzes its contracts to assess whether they are within the scope of ASC&#160;606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Identification of the contract, or contracts, with a customer</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Identification of the performance obligations in the contract</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Determination of the transaction price</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Allocation of the transaction price to the performance obligations in the contract</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recognition of revenue when, or as, the Company satisfies a performance obligation</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (&#8220;IP&#8221;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $ <ix:nonFraction id="F20240228054857433_16" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction> upfront payment and is eligible to receive up to $ <ix:nonFraction id="F20240228054857433_17" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,000</ix:nonFraction> for development, regulatory and commercial milestones for the first product, of which $&#160;<ix:nonFraction id="F20240228054857434_18" name="cgen:AccruedMilestonePayments" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,500</ix:nonFraction> was received as well as tiered royalties on future product sales.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div><ix:exclude>
                <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 17</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                </div>
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;margin-top:0pt;margin-bottom:0pt">

                      <tr style="vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                        <td style="width:56.7pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="text-align:right;vertical-align:top;width:28.35pt;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">j.</span></span></span></div>
                        </td>
                        <td style="text-align:left;vertical-align:top;width:auto;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Revenue recognition (Cont.):</span></span></span></div>
                        </td>
                      </tr>

                  </table>
                  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </div>
              </ix:exclude></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#8220;probable&#8221; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 18, 2020, the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ <ix:nonFraction id="Fxbrl_20240301103700585" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="C_20201201to20201218" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction> in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 29, 2021, the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ <ix:nonFraction id="F20240228054857467_79" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="C_20210901to20210929" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction> in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ <ix:nonFraction id="F20240228054857446_43" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="C_20221101to20221111" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction> in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 27, 2023, the fourth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ <ix:nonFraction id="Fxbrl_20240228115609016" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="C_20231201to20231227" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction> in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div><ix:exclude>
                <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 18</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                </div>
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;margin-top:0pt;margin-bottom:0pt">

                      <tr style="vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                        <td style="width:56.7pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="text-align:right;vertical-align:top;width:28.35pt;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">j.</span></span></span></div>
                        </td>
                        <td style="text-align:left;vertical-align:top;width:auto;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Revenue recognition (Cont.):</span></span></span></div>
                        </td>
                      </tr>

                  </table>
                  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </div>
              </ix:exclude></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 30, 2024, the fifth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ <ix:nonFraction id="Fxbrl_20250225134915853" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="C_20240501to20240530" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction> in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 18, 2023, the Company entered into an exclusive License Agreement with Gilead. Under the terms of the agreement, the Company granted Gilead an exclusive license under the Company&#8217;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products derived from a Compugen pipeline program. Compugen received an upfront payment of $&#160;<ix:nonFraction id="Fxbrl_20240228120200198" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20231210to20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,000</ix:nonFraction> and an IND clearance milestone payment of $&#160;<ix:nonFraction id="Fxbrl_20250225135355836" name="cgen:MilestonePaymentReceivable" contextRef="C_20231210to20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,000</ix:nonFraction> and is also eligible to receive up to approximately $ <ix:nonFraction id="Fxbrl_20240228120212438" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">758,000</ix:nonFraction> additional milestone payments subject to and upon the achievement of certain development, regulatory and commercial milestones and as detailed in the agreement.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gilead may terminate the Gilead Collaboration Agreement for convenience by giving a certain prior written notice to the Company at any time after the effective date of the agreement.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services, all of which are outputs of the Company&#8217;s ongoing activities, in exchange for consideration.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company assessed the promises under the License Agreement and concluded that (i) the delivery of the GS-0321 License; (ii) the preclinical research and development activities towards IND approval of GS-0321 (the &#8220;IND research and development activities&#8221;) and (iii) the contingent promise to additional research and development activities in connection with Phase 1 clinical trial (the &#8220;Phase 1 research and development activities&#8221;), are capable of being distinct and are distinct within the context of the License Agreement. The Company considered that the license has standalone functionality, considered to be functional intellectual property, and is capable of being distinct. The Company also determined that the IND research and development activities and Phase 1 research and development activities could be provided by resources otherwise available to Gilead and thus are capable of being distinct. Also, the Company concluded that the Company&#8217;s contingent promise to additional research and development activities in connection with Phase 1 clinical trial represents a material right.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As a result, the Company concluded that its promise to deliver the GS-0321 License, the promise to perform IND research and development activities and Phase 1 research and development activities represented separate performance obligations in the License Agreement.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div><ix:exclude>
                <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 19</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                </div>
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;margin-top:0pt;margin-bottom:0pt">

                      <tr style="vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                        <td style="width:56.7pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="text-align:right;vertical-align:top;width:28.35pt;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">j.</span></span></span></div>
                        </td>
                        <td style="text-align:left;vertical-align:top;width:auto;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Revenue recognition (Cont.):</span></span></span></div>
                        </td>
                      </tr>

                  </table>
                  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </div>
              </ix:exclude></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company also evaluated all milestones and royalties as a possible variable consideration. With respect to clinical development and regulatory milestones, based upon the high degree of uncertainty and risk associated with these potential payments, the Company concluded that all such amounts should be fully constrained and are not included in the initial transaction price as the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Accordingly, the Company did not include any potential clinical development, regulatory and sales milestones and royalties in the initial transaction price.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company allocated the transaction price to each performance obligation on a relative estimated standalone selling price basis. The Company developed the estimated standalone selling price for the GS-0321 License based on the present value of expected future cash flows associated with the license and related clinical development and regulatory milestones. In developing such estimate, the Company applied judgement in determining the timing needed to develop the Licensed Product, the probability of success, and the discount rate. The Company developed the estimated standalone selling price for the IND research and development activities using a &#8220;cost plus&#8221; reasonable margin approach. To determine the estimated standalone selling price of the material right for the Phase 1 research and development activities obligation, the Company estimated the standalone selling price of the underlying performance obligations included in the material right and estimated the probability of the Company&#8217;s performance of such obligations.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company determined that the GS-0321 License was a functional license since the underlying intellectual property (the &#8220;IP&#8221;) has significant standalone functionality. In addition, the Company determined that December 18, 2023, represents (i) the date at which the Company made available the IP to Gilead and (ii) the beginning of the period during which Gilead is able to use and benefit from its right to use the IP. Based upon these considerations, the Company recognized the entirety of the initial transaction price allocated to the GS-0321 License performance obligation during the year ended December 31, 2023.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Further, the IND research and development activities and Phase 1 research and development activities performance obligations are recognized over time. The Company using the input method in order to measure the progress of the services, based on the actual internal and external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs were estimated reflected the Company&#8217;s best estimate of the period over which it would perform the activities to achieve clearance of an IND application for GS-0321 and the phase 1 clinical trial. The Company determined that the input method is the best measure of progress towards satisfying the performance obligation as incurred labor effort represents work performed that corresponds with, and thereby best depicts the transfer of goods and services.</span></span></div>
              </div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
                <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 20</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                </div>
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;margin-top:0pt;margin-bottom:0pt">

                      <tr style="vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                        <td style="width:56.7pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="text-align:right;vertical-align:top;width:28.35pt;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">j.</span></span></span></div>
                        </td>
                        <td style="text-align:left;vertical-align:top;width:auto;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Revenue recognition (Cont.):</span></span></span></div>
                        </td>
                      </tr>

                  </table>
                  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </div>
              </ix:exclude></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the year ended December 31, 2024, the Company recognized $ <ix:nonFraction id="Fxbrl_20240228121336624" name="cgen:LicenseRevenue" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,864</ix:nonFraction> of license, IND services and Phase 1 services revenues, and during the year ended December 31, 2023, the Company recognized $ <ix:nonFraction id="Fxbrl_20250224191115062" name="cgen:LicenseRevenue" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,459</ix:nonFraction> of license revenues.</span></span></div>
              </div>
              <div style="text-align:justify;line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.3pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Of the $<ix:nonFraction id="Fxbrl_20250224191436866" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,541</ix:nonFraction> of deferred revenue recorded as of December 31, 2023, and additional deferred revenues incurred during the year ended December 31, 2024, the Company recognized $<ix:nonFraction id="Fxbrl_20250224191538634" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,864</ix:nonFraction> as revenue during the year ended December 31, 2024. The Company had no deferred revenues as of December 31, 2022. The milestone payment was accounted for as an available consideration and was allocated to the separate performance obligations.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, the Company included deferred revenues of $ <ix:nonFraction id="Fxbrl_20240228121352406" name="cgen:DeferredRevenuesIncludedInCurrentLiabilities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,632</ix:nonFraction> in current liabilities and $ <ix:nonFraction id="Fxbrl_20240228121407737" name="cgen:DeferredRevenuesIncludedInNonCurrentLiabilities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,045</ix:nonFraction> in non-current liabilities.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s remaining performance obligations represent contracted revenue that has not yet been recognized. As of December 31, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations that the Company expects to recognize as revenue was $<ix:nonFraction id="Fxbrl_20250224192453825" name="cgen:TotalRemainingPerformanceObligations" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,677</ix:nonFraction>. As of December 31, 2024, the Company expects to recognize <ix:nonFraction id="Fxbrl_20250224192519729" name="cgen:RemainingPerformanceObligationsRecognizedPercentage" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">22</ix:nonFraction>% of its remaining performance obligations as revenue over the next 12 months, and the remainder through 2029.</span></span></div>
                <div style="line-height:1.25">&#160;</div>
              </div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For additional information regarding revenues, please refer to Note 11 below.</span></span></div>
            </div>
          </ix:nonNumeric>
          <ix:nonNumeric id="F20240228054857434_19" name="cgen:CostOfSalesContractWithCustomerPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>k.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Cost of revenues:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenues consist of certain royalties and milestones paid or accrued in addition to research and development services allocated in relation to Gilead license agreement.</span></span></div>
            </div>
          </ix:nonNumeric>
          <div style="line-height:1.25">&#160;</div>
          <ix:nonNumeric id="F20240228054857434_20" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>l.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research and development expenses, net:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div><ix:exclude>
                <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 21</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                </div>
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></div>
                      </td>
                    </tr>

                </table>
                <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </ix:exclude></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The portion of the Bristol&#160;Myers Squibb $ <ix:nonFraction id="F20240228054857451_54" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> investment in 2018 over the fair market value of the shares issued in the amount of $ <ix:nonFraction id="F20240228054857452_55" name="cgen:DeferredParticipationOfBMSInRAndDExpenses" contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,121</ix:nonFraction> and the portion of the $ <ix:nonFraction id="F20240228054857453_56" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in 2021 over the fair market value of the shares issued in the amount of $ <ix:nonFraction id="F20240228054857453_57" name="cgen:DeferredParticipationOfBMSInRAndDExpenses" contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction> were considered as deferred participation of Bristol&#160;Myers Squibb in R&amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;D, see Note 1f and Note 9b.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of participation in R&amp;D expenses for the years ended December 31, 2024, 2023 and 2022 were $ <ix:nonFraction id="F20240228054857435_21" name="us-gaap:AdjustmentForAmortization" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>, $&#160;<ix:nonFraction id="F20240228054857435_22" name="us-gaap:AdjustmentForAmortization" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction> and $ <ix:nonFraction id="F20240228054857436_23" name="us-gaap:AdjustmentForAmortization" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,019</ix:nonFraction>, respectively.</span></span></div>
            </div>
          </ix:nonNumeric>
          <div style="line-height:1.25">&#160;</div>
          <ix:nonNumeric id="F20240228054857436_24" name="cgen:ServerancePayPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>m.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Severance pay:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset on the Company&#8217;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#8217;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#8217;s monthly salary for each year of service, no additional payments are required to be made by the Company to the employee to cover severance obligation.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Severance expenses for the years ended December 31, 2024, 2023 and 2022 amounted to approximately $&#160;<ix:nonFraction id="F20240228054857437_25" name="us-gaap:SeveranceCosts1" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction>, $&#160;<ix:nonFraction id="F20240228054857437_26" name="us-gaap:SeveranceCosts1" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">432</ix:nonFraction> and $&#160;<ix:nonFraction id="F20240228054857438_27" name="us-gaap:SeveranceCosts1" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">468</ix:nonFraction>, respectively.</span></span></div>
            </div>
          </ix:nonNumeric>
          <ix:nonNumeric id="F20240228054857438_28" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>n.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25">Share-based compensation<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for share-based compensation to employees and non-employees in accordance with ASC 718, &#8220;Compensation - Share Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div><ix:exclude>
                <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 22</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                </div>
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                  <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;margin-top:0pt;margin-bottom:0pt">

                      <tr style="vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                        <td style="width:56.7pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="text-align:right;vertical-align:top;width:28.35pt;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">n.</span></span></span></div>
                        </td>
                        <td style="text-align:left;vertical-align:top;width:auto;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Share-based compensation (Cont.):</span></span></span></div>
                        </td>
                      </tr>

                  </table>
                  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </div>
              </ix:exclude></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company selected the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Share Purchase Plan (&#8220;ESPP&#8221;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:</span></span></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>
              <ix:nonNumeric id="Fxbrl_20250228015358695" name="cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions" contextRef="C_20240101to20241231" escape="true">
                <div>
                  <div style="margin-left:90pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee options</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857454_58" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20240101to20241231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">90.45</ix:nonFraction>%-<ix:nonFraction id="F20240228054857454_59" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20240101to20241231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">95.88</ix:nonFraction>%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857455_60" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">75.93</ix:nonFraction>%-<ix:nonFraction id="F20240228054857455_61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">80.95</ix:nonFraction>%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857456_62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">69.44</ix:nonFraction>%-<ix:nonFraction id="F20240228054857456_63" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">74.61</ix:nonFraction>%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857457_64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20240101to20241231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.47</ix:nonFraction>%-<ix:nonFraction id="F20240228054857458_65" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20240101to20241231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.54</ix:nonFraction>%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857459_66" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.37</ix:nonFraction>%-<ix:nonFraction id="F20240228054857460_67" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.81</ix:nonFraction>%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857460_68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.54</ix:nonFraction>%-<ix:nonFraction id="F20240228054857461_69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.39</ix:nonFraction>%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857439_29" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20240101to20241231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857439_30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228114441654" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20240228054857461_70" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20240101to20241231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">4.02</ix:nonNumeric>-<ix:nonNumeric id="F20240228054857462_71" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20240101to20241231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">4.97</ix:nonNumeric></span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20240228054857463_72" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">4.02</ix:nonNumeric>-<ix:nonNumeric id="F20240228054857463_73" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.06</ix:nonNumeric></span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20240228054857464_74" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.05</ix:nonNumeric>-<ix:nonNumeric id="F20240228054857464_75" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.4</ix:nonNumeric></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="margin-left:90pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ESPP</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857440_31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20240101to20241231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857447_44" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857467_80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">69.74</ix:nonFraction>%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857440_32" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20240101to20241231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857448_46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857468_81" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.63</ix:nonFraction>%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857440_33" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20240101to20241231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857449_48" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20240228054857450_51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20240228054857468_82" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" format="ixt-sec:duryear">0.50</ix:nonNumeric></span></span></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </ix:nonNumeric>
          <ix:nonNumeric id="F20240228054857441_35" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>o.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Concentration of credit risks:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits, restricted long-term bank deposit and investment in marketable securities.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents, restricted cash, short-term bank deposits and restricted long-term bank deposit are invested in major banks in Israel and in the United States. Generally, these deposits may be redeemed upon demand and bear minimal risk. The Company's marketable securities consist of investments, which are highly rated by credit agencies, in government debentures.</span></span></div>
              </div>
            </div>
          </ix:nonNumeric>
          <div style="line-height:1.25">&#160;</div>
          <div><ix:exclude>
            <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 23</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            </div>
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                <tr style="margin-top:0pt;margin-bottom:0pt">
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                    <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></div>
                  </td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </ix:exclude></div>
          <ix:nonNumeric id="F20240228054857442_36" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>p.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Basic and diluted loss per share:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic loss per share is calculated by dividing net loss for each reporting period by the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated by dividing net loss for each reporting period by the weighted average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during the period in accordance with ASC 260, &#8220;Earnings per Share&#8221;.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All outstanding share options and warrants for the years ended December 31, 2024, 2023 and 2022 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2024, 2023 and 2022 the average number of shares related to outstanding options, RSUs and warrants excluded from the calculations of diluted net loss per share were <ix:nonFraction id="F20240228054857442_37" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20240101to20241231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,496,655</ix:nonFraction>, <ix:nonFraction id="F20240228054857443_38" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">7,921,020</ix:nonFraction> and <ix:nonFraction id="F20240228054857445_39" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,405,615</ix:nonFraction>, respectively.</span></span></div>
            </div>
          </ix:nonNumeric>
          <ix:nonNumeric id="F20240228054857445_40" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>q.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Income taxes:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2024 and 2023, a full valuation allowance was provided by the Company.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.</span></span></div>
            </div>
          </ix:nonNumeric>
          <ix:nonNumeric id="F20240228054857446_41" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>r.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Fair value of financial instruments:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div><ix:exclude>
                <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 24</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                </div>
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                  <div style="margin-top:0pt;margin-bottom:0pt">
                    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;margin-top:0pt;margin-bottom:0pt">

                        <tr style="vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                          <td style="width:56.7pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                          <td style="text-align:right;vertical-align:top;width:28.35pt;margin-top:0pt;margin-bottom:0pt">
                            <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">r.</span></span></span></div>
                          </td>
                          <td style="text-align:left;vertical-align:top;width:auto;margin-top:0pt;margin-bottom:0pt">
                            <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Fair value of financial instruments (Cont.):</span></span></span></div>
                          </td>
                        </tr>

                    </table>
                    <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
                  </div>
                </div>
              </ix:exclude></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</span></span></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The hierarchy is broken down into three levels based on the inputs as follows:</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:56.7pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1 -</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:56.7pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2 -</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:56.7pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3 -</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, marketable securities, restricted long-term bank deposit, other accounts receivable and prepaid expenses, trade payable and employees and related accruals and accrued expenses approximate their fair values due to the short-term maturities of such instruments.</span></span></div>
            </div>
          </ix:nonNumeric>
          <div style="line-height:1.25">&#160;</div>
          <div><ix:exclude>
            <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 25</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            </div>
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                <tr style="margin-top:0pt;margin-bottom:0pt">
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                    <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></div>
                  </td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </ix:exclude></div>
          <ix:nonNumeric id="Fxbrl_20250225133021418" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">s.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently adopted accounting pronouncement :</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:28.1pt">&#160;</td>
                    <td style="width:56.7pt;vertical-align:top">&#160;</td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280),&#160;Improvements to Reportable Segment Disclosures&#160;requiring public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for the fiscal years beginning after December 15, 2024. The Company adopted the ASU 2023-07 during the year ended December 31, 2024, on a retrospective basis which resulted in updated segment disclosures. See Note 11 in the accompanying notes to the consolidated financial statements for further detail.</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </ix:nonNumeric>
          <div>
            <ix:nonNumeric id="Fxbrl_20250228015334197" name="cgen:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
              <div>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:56.7pt">&#160;</td>
                      <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">t.</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently issued accounting pronouncements not yet adopted</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) -&#160;<span style="font-style:italic">Improvements to Income Tax Disclosures</span>. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. The Company is currently evaluating the effect of adopting the ASU on its financial statements disclosures.</span></span></div>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40) -&#160;<span style="font-style:italic">Disaggregation of Income Statement Expenses</span>. The ASU requires, among other items, additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the consolidated Statements of Operations. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the effect of adopting the ASU on its financial statements disclosures.</span></span></div>
              </div>
            </ix:nonNumeric>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
  </div>
  <p style="margin:0pt">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 26</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <div>
    <ix:nonNumeric id="F20250224141027742_18" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">MARKETABLE SECURITIES</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:59.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following is a summary of available-for-sale marketable securities as of December 31, 2024 and 2023:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="F20250224141027742_16" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="C_20240101to20241231" escape="true">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortized cost</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross unrealized gains</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross unrealized losses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">&#160;</div>
                      <div style="line-height:1.25">&#160;</div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Available-for-sale &#8211; matures within one year:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">U.S. Treasury</p>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20250224141027740_0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_20241231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,618</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20250224141027740_1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_20241231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20250224141027740_2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_20241231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20250224141027741_3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_20241231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,629</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Available-for-sale &#8211; matures within one year:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">U.S. Treasury</p>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730211801692_20250224141027740_0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,740</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730211801692_20250224141027740_1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730211801692_20250224141027740_2">*</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730211801692_20250224141027741_3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,742</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:58.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Represents an amount lower than $1</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:58.5pt;line-height:1.25">The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2024 and December 31, 2023, and the length of time that those investments have been in a continuous loss position:</div>
        <div style="text-align:justify;margin-left:58.5pt;line-height:1.25">&#160;</div>
        <ix:nonNumeric id="F20250224141027742_17" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" contextRef="C_20240101to20241231" escape="true">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less than 12 months</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12 months or greater</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross unrealized loss</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Gross unrealized loss</strong></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20250224141027741_8" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20250224141027741_9" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20250224141027742_10" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20250224141027742_11" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730224938615_20250224141027741_8" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">992</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730224938615_20250224141027741_9">*</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730224938615_20250224141027742_10" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730224938615_20250224141027742_11" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:58.5pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents an amount lower than $1.</span></span></div>
                  </td>
                </tr>

            </table>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:58.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, the Company had no significant unrealized losses related to marketable securities and determined the unrealized losses are not due to credit related losses. Therefore, the Company did not record an allowance for credit losses for its available-for-sale marketable securities.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:58.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, all of the Company&#8217;s available-for-sale marketable securities were due within one year.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:58.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company had no sales of marketable securities during the years ended December 31, 2024 and 2023, and accordingly no realized gains or losses were recorded.&#160;Proceeds from maturities of available-for-sale marketable securities during the year ended December 31, 2024, and 2023 were $&#160;<ix:nonFraction id="Fxbrl_20250225054513616" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,230</ix:nonFraction>&#160;and $&#160;<ix:nonFraction id="Fxbrl_20250225054519696" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,145</ix:nonFraction>, respectively.</span></span></div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 27</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
  </div>

  <div>
    <ix:nonNumeric id="F20250224141027750_3" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_20240101to20241231" escape="true">
      <div>
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 4:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">FAIR VALUE MEASUREMENTS</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:54pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The company evaluates assets and liabilities subject to fair value measurements on recurring basis to determine the appropriate level to classify them for each reporting period. There have been no transfers between fair value measurements levels during the years ended December 31, 2024 and 2023. The carrying amounts of cash and cash equivalents marketable securities, trade receivables, short term deposits and trade payables approximate their fair value due to the short-term maturity of such instruments.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:54pt;line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the Company&#8217;s assets that were measured at fair values of December 31, 2024 and <span>2023 by</span> level within the fair value hierarchy:</span></span></div>
          </div>
        </div>
        <div style="text-align:justify;margin-left:54pt;line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">
          <ix:nonNumeric id="F20250224141027750_2" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="C_20240101to20241231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair&#160;value&#160;measurements&#160;as&#160;of</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;margin-left:4.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair Value</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Hierarchy</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cash equivalents:</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Money market funds</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224200043634_20250224141027750_0" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_20241231_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,919</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224200043634_20250224141027750_1" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_20231231_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,966</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketable securities:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25">U.S. Treasury</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20250224141027750_0" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_20241231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,629</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20250224141027750_1" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,742</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
      </div>
    </ix:nonNumeric>
    <div style="line-height:1.25">&#160;</div>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20230222132226340" name="cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock" contextRef="C_20240101to20241231" escape="true">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold">NOTE 5:-</td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">
          <ix:nonNumeric id="Fxbrl_20240228020440395" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="C_20240101to20241231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">December 31,</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25">Prepaid expenses</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">$</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000406" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,473</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">$</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000407" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,211</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25">Government authorities</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000408" name="cgen:GovernmentAuthorities" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">127</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000409" name="cgen:GovernmentAuthorities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25">Other</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000410" name="us-gaap:OtherAssetsCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">142</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000411" name="us-gaap:OtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">226</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">$</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000412" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,742</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">$</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000413" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,529</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
      </div>
    </ix:nonNumeric>
  </div>
  <p style="margin:0pt">&#160;</p>

  <div>
    <ix:nonNumeric id="FFact_0000000000441" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_20240101to20241231" escape="true">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 6:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LEASES</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company leases all its real estate, storage area and cars under various operating lease agreements that expire on various dates.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s operating leases have original lease periods expiring between 2021 and 2027. The offices in Israel lease include two options to renew, one of which was exercised in 2020. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain. The Company has an option to extend the lease of its offices in Israel until 2031, which is reasonably certain to be assured.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments and payments for optional renewal periods where it is reasonably certain the renewal period will be exercised.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div style="width:100%;margin-top:0pt;margin-bottom:0pt">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 28</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            </div>
          </div>
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

              <tr style="margin-top:0pt;margin-bottom:0pt">
                <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 6:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                  <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LEASES (Cont.)</span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under ASC 842, all leases, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled Operating lease right of use asset. The corresponding lease liabilities are split between current maturity of operating lease liability within current liabilities and long-term operating lease liability within long-term liabilities. The Company&#8217;s leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate based on information available on the commencement date to determine the present value of lease payments.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table represents the weighted-average remaining lease term and discount rate:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">
          <ix:nonNumeric id="Fxbrl_20230222013426728" name="cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" contextRef="C_20240101to20241231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%">

                <tr>
                  <td style="vertical-align:bottom;width:90%">&#160;</td>
                  <td style="vertical-align:bottom;width:10%">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="padding-bottom:2px;vertical-align:bottom;width:90%">&#160;</td>
                  <td style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:10%">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:90%">&#160;</td>
                  <td style="vertical-align:bottom;width:10%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:90%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining lease term</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%">
                    <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000421" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_20241231" format="ixt-sec:duryear">6.05</ix:nonNumeric></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:90%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average discount (annual) rate</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:10%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000422" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_20241231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.96</ix:nonFraction>%</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease expenses were approximately $&#160;<ix:nonFraction id="FFact_0000000000424" name="us-gaap:OperatingLeaseExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">775</ix:nonFraction>, $ <ix:nonFraction id="FFact_0000000000425" name="us-gaap:OperatingLeaseExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">800</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000426" name="us-gaap:OperatingLeaseExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">884</ix:nonFraction> in the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Variable payments as CPI, included in the lease expenses, were approximately $&#160;<ix:nonFraction id="Fxbrl_20240301102821130" name="us-gaap:VariableLeasePayment" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction>, $&#160;<ix:nonFraction id="Fxbrl_20240301102854023" name="us-gaap:VariableLeasePayment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction> and $&#160;<ix:nonFraction id="Fxbrl_20240301102901175" name="us-gaap:VariableLeasePayment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction> in the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash paid for amounts included in the measurement of lease liabilities was approximately $&#160;<ix:nonFraction id="FFact_0000000000427" name="cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">761</ix:nonFraction>, $&#160;<ix:nonFraction id="FFact_0000000000428" name="cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">852</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000429" name="cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">959</ix:nonFraction> in the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Maturities of operating lease liabilities were as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">
          <ix:nonNumeric id="Fxbrl_20230222013609784" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_20240101to20241231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></div>
                    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2024</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000431" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">650</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000432" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000433" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">565</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:2px;vertical-align:bottom;width:88%">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2028 and on</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250224211559627" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,809</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating lease payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000435" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,608</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: imputed interest</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000436" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">696</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000437" name="us-gaap:OperatingLeaseLiability" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,912</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td rowspan="1" style="vertical-align:bottom;width:88%">&#160;</td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, current</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000438" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:2px;vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, non- current</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000439" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,464</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:4px;vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214024012785" name="us-gaap:OperatingLeaseLiability" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,912</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div style="width:100%;margin-top:0pt;margin-bottom:0pt">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 29</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            </div>
          </div>
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

              <tr style="margin-top:0pt;margin-bottom:0pt">
                <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 6:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                  <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">LEASES (Cont.)</span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above annual minimum future rental commitments include both of the period covered by the first exercised option with respect to the leased facility of Compugen Ltd. through March 2026 and the second option to extend the lease of the Company facility for additional five-year period following expiration of the current lease period.</span></span></div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
  </div>

  <ix:nonNumeric id="FFact_0000000000468" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 7:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PROPERTY AND EQUIPMENT, NET</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">
          <ix:nonNumeric id="FFact_0000000000460" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_20240101to20241231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000442" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">719</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000443" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">739</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000444" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,567</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000445" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,519</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000446" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,314</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000447" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,314</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000448" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,600</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000449" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,572</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation:</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000450" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">622</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000451" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">609</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000452" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,059</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000453" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,909</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000454" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,067</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000455" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,838</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000456" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,748</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000457" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,356</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciated cost</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000458" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">852</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000459" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,216</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2024 and 2023 total cost of $&#160;<ix:nonFraction id="FFact_0000000000461" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000462" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,357</ix:nonFraction>, respectively and total accumulated depreciation of $&#160;<ix:nonFraction id="FFact_0000000000463" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000464" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,350</ix:nonFraction>, respectively were disposed from the consolidated balance sheets.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2024 and 2023 the Company sold equipment with cost of $&#160;<ix:nonFraction id="Fxbrl_20250225030006205" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction> and $&#160;<ix:nonFraction id="Fxbrl_20250225030011327" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>, respectively and accumulated depreciation of $&#160;<ix:nonFraction id="Fxbrl_20250225030033500" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction> and $&#160;<ix:nonFraction id="Fxbrl_20250225030045690" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" contextRef="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>, respectively. Gains from the sale during 2024 were $ <ix:nonFraction id="Fxbrl_20250225030100373" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2024, 2023 and 2022, depreciation expenses were approximately $&#160;<ix:nonFraction id="FFact_0000000000465" name="us-gaap:Depreciation" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">486</ix:nonFraction>, $&#160;<ix:nonFraction id="FFact_0000000000466" name="us-gaap:Depreciation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">476</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000467" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">482</ix:nonFraction>, respectively.</span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 30</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000498" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 8:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS AND CONTINGENCIES</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company provided bank guarantees in the amount of $ <ix:nonFraction id="Fxbrl_20250228031216265" name="us-gaap:GuaranteeObligationsMaximumExposure" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">342</ix:nonFraction> related to its offices in Israel, leased cars fueling in Israel and credit card security for its U.S. subsidiary.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the Office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (the &#8220;IIA&#8221;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from the results of the funded research programs. If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between <ix:nonFraction id="FFact_0000000000478" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>% to <ix:nonFraction id="FFact_0000000000479" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMaximumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of future revenue arising from such research programs, and up to a maximum of <ix:nonFraction id="FFact_0000000000480" name="cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived" contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is 100% plus interest at LIBOR until December 31, 2023, and from January 1, 2024, the 12 months Term SOFR interest). For the years ended December 31, 2024, 2023 and 2022, the Company had an aggregate of paid or accrued royalties costs (income) to the IIA, recorded as cost of revenue in the consolidated statements of comprehensive loss in the amount of $&#160;(<ix:nonFraction id="FFact_0000000000481" name="us-gaap:RoyaltyExpense" contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">554</ix:nonFraction>), $&#160;<ix:nonFraction id="FFact_0000000000482" name="us-gaap:RoyaltyExpense" contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,004</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000483" name="us-gaap:RoyaltyExpense" contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction>, respectively.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December&#160;31, 2024, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $ <ix:nonFraction id="FFact_0000000000484" name="cgen:RoyaltyContingentObligations" contextRef="C_20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,872</ix:nonFraction>.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Following IIA approval that sales related to IL-18BP are excluded from sales subject to IIA royalties payment, the Company decreased previous year royalties accrual related to revenues under the Gilead Agreement in the amount of $ <ix:nonFraction id="Fxbrl_20250228034607242" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenGileadAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">704</ix:nonFraction> and reduced the cost of revenues for the year ended December 31, 2024, by this amount.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as &#8220;Contingent Fees&#8221;). For the years ended December 31, 2024, 2023 and 2022, the Company incurred such Contingent Fees in the amounts of $ <ix:nonFraction id="Fxbrl_20250228035035553" name="cgen:ContingentFees" contextRef="C_20241231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>, $ <ix:nonFraction id="Fxbrl_20250228035049625" name="cgen:ContingentFees" contextRef="C_20231231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction> and $ <ix:nonFraction id="Fxbrl_20250228035058377" name="cgen:ContingentFees" contextRef="C_20221231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">750</ix:nonFraction>.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On <ix:nonNumeric id="FFact_0000000000488" name="cgen:AgreementStartDate" contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember" format="ixt:date-monthname-day-year-en">May 9, 2012</ix:nonNumeric>, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the agreement the Advisor was entitled to <ix:nonFraction id="FFact_0000000000489" name="cgen:ParticipationRights" contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>% of the cash considerations that may be received under such transactions. <ix:nonNumeric id="FFact_0000000000490" name="cgen:AgreementTerminationDescription" contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember">In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</ix:nonNumeric></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Bayer Agreement was terminated effective February 27, 2023 and no further payments are expected under the May 2012 Agreement.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 31</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
              </div>
              <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                  <tr style="margin-top:0pt;margin-bottom:0pt">
                    <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 8:-</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                      <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">COMMITMENTS AND CONTINGENCIES (Cont.)</span></span></div>
                    </td>
                  </tr>

              </table>
              <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
            </ix:exclude></div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the years ended December 31, 2024, 2023 and 2022, the Company has not paid and did not accrue payments under this agreement.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (CLA) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and <ix:nonFraction id="FFact_0000000000491" name="cgen:RoyaltyPercentage" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction>% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the years ended December 31, 2024, 2023 and 2022, the Company did not incur any amount in the research and development expenses in connection with such milestone payment.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the years ended December 31, 2024, 2023 and 2022, the Company incurred in the research and development expenses such milestone payment in the amounts of $&#160;<ix:nonFraction id="FFact_0000000000495" name="cgen:ResearchAndDevelopmentExpensesMilestonePayment" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction>, $ <ix:nonFraction id="Fxbrl_20250228130721702" name="cgen:ResearchAndDevelopmentExpensesMilestonePayment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction> and $ <ix:nonFraction id="FFact_0000000000497" name="cgen:ResearchAndDevelopmentExpensesMilestonePayment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>.</span></span></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <div>
    <ix:nonNumeric id="Fxbrl_20240228135111319" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" contextRef="C_20240101to20241231" escape="true">
      <div>
        <div style="text-align:justify;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;text-align:left;color:rgb(0, 0, 0)">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>NOTE 9:-</span></span></span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>SHAREHOLDERS</span>&#8217;<span> EQUITY</span></span></span></span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>a.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Ordinary shares:</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends, and to participate in the distribution of the assets of the Company upon its winding-up,&#160;in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 32</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
              </div>
              <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">NOTE 9:-</span></span></span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">SHAREHOLDERS</span>&#8217;<span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"> EQUITY</span> (Cont.)</span></span></span></span></div>
                      </td>
                    </tr>

                </table>
                <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </div>
            </ix:exclude></div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>b.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Issuance of shares:</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol-Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol Myers Squibb made a $ <ix:nonFraction id="Fxbrl_20250228040347903" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> equity investment in the Company.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Under the terms of the securities purchase agreement, Bristol Myers Squibb purchased <ix:nonFraction id="Fxbrl_20250228040609767" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,424,243</ix:nonFraction> ordinary shares of the Company at a purchase price of $ <ix:nonFraction id="Fxbrl_20250228040619735" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">4.95</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="Fxbrl_20250228040627063" name="cgen:PercentageOfClosingPrice" contextRef="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction>% premium over the average closing price of Compugen&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The premium over the fair market value in the amount of $ <ix:nonFraction id="Fxbrl_20250228040703383" name="cgen:DeferredParticipationOfBMSInRAndDExpenses" contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,121</ix:nonFraction> represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D) and $ <ix:nonFraction id="Fxbrl_20250228040714504" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,788</ix:nonFraction> (net of $ <ix:nonFraction id="Fxbrl_20250228040736815" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction> issuance expenses) were considered equity investment.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $&#160;<ix:nonFraction id="FFact_0000000000523" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in the Company, purchasing <ix:nonFraction id="FFact_0000000000524" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,332,815</ix:nonFraction> ordinary shares of the Company at a purchase price of $&#160;<ix:nonFraction id="FFact_0000000000525" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">8.57333</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="FFact_0000000000526" name="cgen:PercentageOfClosingPrice" contextRef="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction>% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.</span></span></span></span></div>
            <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
            <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 33</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
              </div>
              <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">NOTE 9:-</span></span></span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">SHAREHOLDERS</span>&#8217;<span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"> EQUITY</span> (Cont.)</span></span></span></span></div>
                      </td>
                    </tr>

                </table>
                <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </div>
            </ix:exclude></div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>b.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Issuance of shares: (Cont.)</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The premium over the fair market value in the amount of $&#160;<ix:nonFraction id="Fxbrl_20230221122449076" name="cgen:DeferredParticipationOfBMSInRAndDExpenses" contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction> represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D) and $&#160;<ix:nonFraction id="Fxbrl_20230221122456788" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,958</ix:nonFraction> (net of $&#160;<ix:nonFraction id="Fxbrl_20230221122504540" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction> issuance expenses) were considered equity investment.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#8220;Leerink Partners&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#8220;at the market offering&#8221; (ATM). The offer and sale of the Company&#8217;s ordinary shares, if any, are made pursuant to the Company&#8217;s shelf registration statement on Form F-3, as supplemented by a prospectus supplement filed on January 31, 2023. Pursuant to the applicable prospectus supplement, the Company may offer and sell up to $<ix:nonFraction id="Fxbrl_20250228041614607" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20230101to20230131_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,000</ix:nonFraction> of its ordinary shares. From the date the Company started selling ordinary shares in 2023 through its ATM and through December 31, 2024, <ix:nonFraction id="Fxbrl_20250228041623503" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,905,550</ix:nonFraction> ordinary shares were issued and sold through the ATM, with proceeds of approximately $ <ix:nonFraction id="Fxbrl_20250228041634475" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,625</ix:nonFraction> (net of $ <ix:nonFraction id="Fxbrl_20250228041714726" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">548</ix:nonFraction> issuance expenses).</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>c.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Share option plan:</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Under the Company&#8217;s 2010 Share Option Plan, as amended (the &#8220;Plan&#8221;), options and RSUs may be granted to employees, directors and non-employees of the Company and Compugen USA, Inc.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">Under the 2010 Share Option Plan the Company reserved for issuance up to an aggregate of <ix:nonFraction id="Fxbrl_20250303204407061" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">14,195,152</ix:nonFraction> options and RSUs.&#160;The Company&#8217;s board of directors last amended the Plan in July 2024, to increase the number of shares available under the 2010 Plan. As of December 31, 2024, an aggregate of <ix:nonFraction id="Fxbrl_20250303204414573" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">891,922</ix:nonFraction> options and RSUs under the 2010 Share Option Plan of the Company were still available for future grants.</div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In general, options granted under the Plan vest over a <ix:nonNumeric id="Fxbrl_20250228044847837" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> period and expire <ix:nonNumeric id="Fxbrl_20250228044900553" name="cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company&#8217;s ordinary shares on the date of grant, unless otherwise determined by the Company&#8217;s board of directors. The exercise price of the options granted under the Plan may not be less than the nominal value of the shares into which such options are exercisable, and the expiration date may not be later than 10 years from the date of grant. RSUs vest over a four-year period as well. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 34</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
              </div>
              <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">NOTE 9:-</span></span></span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">SHAREHOLDERS</span>&#8217;<span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"> EQUITY</span> (Cont.)</span></span></span></span></div>
                      </td>
                    </tr>

                </table>
                <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </div>
            </ix:exclude></div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>c.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Share option plan (Cont.):</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Any options that are cancelled, forfeited or expired become available for future grants.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2024, were as follows:</span></span></span></span></div>
          </div>
        </div>
        <div style="font-family:'Times New Roman',Times,serif">
          <div style="line-height:1.25;margin-left:85.05pt">&#160;</div>
        </div>
        <div style="margin-left:90pt">
          <ix:nonNumeric id="Fxbrl_20240228135136508" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div>
                <div>
                  <div>
                    <div style="margin-left:0pt">
                      <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Number of options</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Weighted average exercise</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">price</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Weighted average remaining contractual life</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Aggregate intrinsic</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">value</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Years</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options outstanding at beginning of year</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000541" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,373,745</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000542" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">4.65</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonNumeric id="FFact_0000000000543" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" format="ixt-sec:duryear">6.61</ix:nonNumeric></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20250225035705811" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,912</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options granted</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000545" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,027,200</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000546" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">1.88</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options exercised</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20250225040326886_Fact_0000000000545" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">11,053</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20250225040326886_Fact_0000000000546" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">0.94</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options forfeited</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="FFact_0000000000549" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">495,781</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000550" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">3.33</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options expired</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="FFact_0000000000551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">238,390</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000552" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">7.67</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options outstanding at end of year</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000553" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,655,721</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000554" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">4.31</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonNumeric id="FFact_0000000000555" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" format="ixt-sec:duryear">6.05</ix:nonNumeric></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000556" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">802</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Exercisable at end of year</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000557" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">5,920,552</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000558" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">5.36</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonNumeric id="FFact_0000000000559" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" format="ixt-sec:duryear">4.93</ix:nonNumeric></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000560" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">286</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>

                      </table>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div>
          <div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Weighted average fair value of options granted to employees, directors and non-employees during the years 2024, 2023 and 2022 was $&#160;<ix:nonFraction id="FFact_0000000000562" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">1.20</ix:nonFraction>, $&#160;<ix:nonFraction id="FFact_0000000000563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">0.70</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000564" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">1.51</ix:nonFraction> per share, respectively.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Aggregate intrinsic value of exercised options by employees, directors and non-employees during the years 2024, 2023 and 2022 was $&#160;<ix:nonFraction id="FFact_0000000000565" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction>, $ <ix:nonFraction id="FFact_0000000000566" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000567" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction>, respectively. The aggregate intrinsic value of the exercised options represents the total intrinsic value (the difference between the sale price of the Company&#8217;s share at the date of exercise, and the exercise price) multiplied by the number of options exercised.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#8217;s closing share price on the last trading day of calendar 2024 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2024. This amount is impacted by the changes in the fair market value of the Company&#8217;s shares.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>As of December 31, 2024, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $ <ix:nonFraction id="FFact_0000000000568" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,602</ix:nonFraction> which is expected to be recognized over a weighted average period of approximately <ix:nonNumeric id="FFact_0000000000569" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember" format="ixt-sec:duryear">2.56</ix:nonNumeric> years.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 35</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
              </div>
              <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">NOTE 9:-</span></span></span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">SHAREHOLDERS</span>&#8217;<span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"> EQUITY</span> (Cont.)</span></span></span></span></div>
                      </td>
                    </tr>

                </table>
                <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </div>
            </ix:exclude></div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="vertical-align:top;width:56pt">&#160;</td>
                  <td style="vertical-align:top;width:28pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>d.</span></span></span></span></td>
                  <td style="vertical-align:top;text-align:justify;width:auto">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="text-align:justify;text-indent:0pt;margin-left:85pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0pt;margin-left:85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>A summary of RSUs activity for the year ended December 31, 2024 is as follows:</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:90pt">
              <ix:nonNumeric id="Fxbrl_20250225120800994" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="C_20240101to20241231" escape="true">
                <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%">

                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Number of RSUs</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Weighted average grant date per value</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs outstanding at beginning of year</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20250225051213220_33" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:76%">
                        <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs granted</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20250225051213220_43" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_20240101to20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">319,150</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20250225051213220_47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20240101to20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="NIS_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.70</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    </tr>
                    <tr>
                      <td style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                        <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs forfeited</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20250225051213220_53" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_20240101to20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,800</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20250225051213220_57" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_20240101to20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="NIS_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.69</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:76%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    </tr>
                    <tr>
                      <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                        <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs outstanding at end of year</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20250225051213220_73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">317,350</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                      <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20250225051213220_77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="NIS_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.70</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    </tr>

                </table>
              </ix:nonNumeric>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>e.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Employee Share Purchase Plan:</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The Company adopted an ESPP in November 2020, with the first offering period starting on January 1, 2021. In connection with its adoption, a total of <ix:nonFraction id="Fxbrl_20240228002524767" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">600,000</ix:nonFraction> ordinary shares were reserved for issuance under this plan.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.5pt;margin-left:85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The ESPP is implemented through six-month offering periods (except for the first offering period that was <ix:nonNumeric id="FFact_0000000000571" name="us-gaap:InitialOfferingPeriod" contextRef="C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">five months</ix:nonNumeric>). According to the ESPP, eligible employees and non-employees may use up to <ix:nonFraction id="FFact_0000000000572" name="cgen:PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" contextRef="C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction>% of their base salaries to purchase ordinary shares up to an aggregate limit of $&#160;40 per participant for every calendar year. The price of an ordinary share purchased under the ESPP is equal to <ix:nonFraction id="FFact_0000000000574" name="cgen:PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" contextRef="C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction>% of the lower of the fair market value of the ordinary share on the first day of each offering period or on the last day of such period.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.5pt;margin-left:85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In the years ended December 31, 2024, 2023 and 2022, <ix:nonFraction id="Fxbrl_20240301101934967" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction>, <ix:nonFraction id="Fxbrl_20240301101942293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction> and <ix:nonFraction id="Fxbrl_20240301101953685" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">158,025</ix:nonFraction> ordinary shares, respectively, had been purchased under the ESPP and as of December 31, 2024, no ordinary shares were available for issuance under the ESPP.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>f.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The share-based compensation expenses related to options, RSUs and ESPP are included as follows in the expense categories:</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:90pt">
              <ix:nonNumeric id="Fxbrl_20240228135148323" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_20240101to20241231" escape="true">
                <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Year ended December 31,</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2024</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2023</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2022</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Research and development expenses</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_0000000000577" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,460</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_0000000000578" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,933</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_0000000000579" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,158</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Marketing and business development expenses</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_0000000000580" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="FFact_0000000000581" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">41</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_0000000000582" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>General and administrative expenses</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20250225040210122" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,448</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_0000000000584" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,658</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_0000000000585" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,901</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_0000000000586" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,023</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_0000000000587" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,550</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_0000000000588" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </ix:nonNumeric>
            </div>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
    <div style="line-height:1.25">
      <p style="margin:0pt">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 36</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
    </div>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20250225051833820" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
      <div>
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 10:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">TAXES ON INCOME, NET</span></span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israeli taxation:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax rates applicable to the income of the Company.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxable income of the Company is subject to a corporate tax rate of <ix:nonFraction id="Fxbrl_20230214114856319" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214114847978" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214114839776" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2024, 2023 and 2022.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Measurement of taxable income in U.S. dollars:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has elected to measure its taxable income and file its tax return under the Israeli Income Tax Regulations (Principles Regarding the Management of Books of Account of Foreign Invested Companies and Certain Partnerships and the Determination of Their Taxable Income), 1986. Accordingly, results for tax purposes are measured in terms of earnings in dollars.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (the &#8220;Investment Law&#8221;):</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 1, 2005, an amendment to the Investment Law came into effect (the &#8220;Amendment 60&#8221;) that significantly changed the provisions of the Investment Law. The Amendment 60 limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as a &#8220;Beneficiary Enterprise&#8221; including a provision generally requiring that at least <ix:nonFraction id="FFact_0000000000594" name="cgen:ReducedTaxRate" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction>% of the Beneficiary Enterprise&#8217;s income will be derived from export.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Another condition for receiving the benefits under the alternative track in respect of expansion programs pursuant to Amendment 60 is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2012 as its &#8220;year of election&#8221;.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additionally, Amendment 60 enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits. However, the Investment Law provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the Investment Law as they were on the date of such approval.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, there was no taxable income attributable to the Beneficiary Enterprise.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 37</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                <tr style="margin-top:0pt;margin-bottom:0pt">
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 10:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                    <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">TAXES ON INCOME, NET (Cont.)</span></span></span></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israeli taxation (Cont.):</span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January 2011, another amendment to the Investment Law came into effect (the &#8220;2011 Amendment&#8221;). According to the 2011 Amendment, the benefit tracks in the Investment Law were modified and a flat tax rate applies to the Company&#8217;s entire income subject to this amendment (the &#8220;Preferred Income&#8221;).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Once an election is made, the Company&#8217;s income will be subject to the amended tax rate of 16% from 2015 and thereafter (or 9% for a preferred enterprise located in development area A).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commencing 2011 tax year, the Company can elect (without possibility of reversal) to apply the Amendment in a certain tax year and from that year and thereafter, it will be subject to the amended tax rates.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company adopted the 2011 Amendment in 2024. Accordingly, the Company did not adjust its deferred tax balances as of December 31, 2024.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2016 and 2017 Budget Years), 2016, which includes Amendment 73 to the Law (the &#8220;Amendment 73&#8221;) was published. According to Amendment 73, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2016 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amendment 73 also prescribes special tax tracks for technological enterprises, which are subject to rules that were issued by the Minister of Finance in May 2017. The new tax tracks under the Amendment are as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred Technological Enterprise (&#8220;PTE&#8221;) - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion in a tax year. A PTE, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above changes in the tax rates relating to PTE tax track were not taken into account in the computation of deferred taxes as of December 31, 2024 and 2023, since the Company estimates that it will not implement the PTE tax track.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 38</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                <tr style="margin-top:0pt;margin-bottom:0pt">
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 10:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                    <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">TAXES ON INCOME, NET (Cont.)</span></span></span></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israeli taxation (Cont.):</span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax benefits under the law for the Encouragement of Industry (Taxes), 1969 (the &#8220;Encouragement Law&#8221;):</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Encouragement Law provides several tax benefits for industrial companies. An industrial company is defined as a company resident in Israel, at least 90% of the income of which in a given tax year exclusive of income from specified Government loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose major activity in a given tax year is industrial production activity.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management believes that the Company is currently qualified as an &#8220;industrial company&#8220; under the Encouragement Law and, as such, is entitled to tax benefits, including: (1) deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period; (2) the right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial companies and an industrial holding company; (3) accelerated depreciation rates on equipment and buildings; and (4) expenses related to a public offering on the Tel-Aviv Stock exchange and on recognized stock markets outside of Israel, are deductible in equal amounts over three years.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Eligibility for benefits under the Encouragement Law is not subject to receipt of prior approval from any Governmental authority. No assurance can be given that the Israeli tax authorities will agree that the Company qualifies, or, that the Company will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating losses carryforward and capital loss:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December&#160;31, 2024, </span></span>Compugen Ltd.&#8217;s<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"> net operating losses carryforward for tax purposes in Israel amounted to approximately $&#160;<ix:nonFraction id="FFact_0000000000595" name="us-gaap:OperatingLossCarryforwards" contextRef="C_20241231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">413,900</ix:nonFraction>. These net operating losses may be carried forward indefinitely and may be offset against future taxable income.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 39</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                <tr style="margin-top:0pt;margin-bottom:0pt">
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 10:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                    <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">TAXES ON INCOME, NET (Cont.)</span></span></span></div>
                  </td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </div>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-Israeli subsidiary, Compugen USA, Inc.:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221; or &#8220;TCJA&#8221;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include several key tax provisions that might impact the Company, among others: (i) a permanent reduction to the statutory federal corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017; (ii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain new rules designed to prevent erosion of the U.S. income tax base - &#8220;BEAT&#8221;); (iii) establishing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits; and (iv) providing a permanent deduction to corporations generating revenues from non-US markets (known as a deduction for foreign derived intangible income - &#8220;FDII&#8221;) .</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, Compugen USA, Inc. has net operating loss carryforwards for federal income tax purposes of approximately $&#160;<ix:nonFraction id="FFact_0000000000597" name="cgen:NetOperatingLossCarryforwardExpired" contextRef="C_20241231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,400</ix:nonFraction>. Approximately $<ix:nonFraction id="Fxbrl_20240228003646758" name="cgen:NetOperatingLossCarryforwardExpired" contextRef="C_20241231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapSubsidiaryOfCommonParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">300</ix:nonFraction> of these losses are available to offset any future U.S. taxable income of our U.S. subsidiary and will expire in the years 2027 to 2032. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Neither Israeli income taxes, foreign withholding taxes nor deferred income taxes were provided in relation to undistributed earnings of the Company&#8217;s foreign subsidiary. This is because the Company has the intent and ability to reinvest these earnings indefinitely in the foreign subsidiary and therefore those earnings are continually redeployed in those jurisdictions.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss (income) before taxes is comprised as follows:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:90pt">
          <ix:nonNumeric id="Fxbrl_20230214044607742" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="C_20240101to20241231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Domestic (Israel)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000600" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,129</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000601" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,164</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000602" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,096</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000603" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">420</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000604" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">380</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000605" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">460</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000606" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,709</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000607" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,784</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000608" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,636</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes on income for the years ended December 31, 2024 and 2023, represent withholding taxes on the upfront payment and the IND milestone pursuant to the Gilead license agreement, write-off of tax assets and state income taxes in the United States.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 40</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                <tr style="margin-top:0pt;margin-bottom:0pt">
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 10:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                    <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">TAXES ON INCOME, NET (Cont.)</span></span></span></div>
                  </td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </div>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred taxes:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#8217;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:90pt">
          <ix:nonNumeric id="Fxbrl_20230214044633836" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_20240101to20241231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;loss carryforward</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000610" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,485</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000611" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,885</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000612" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,779</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000613" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,109</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued social benefits and other</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000614" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,535</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000615" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,072</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000618" name="cgen:DeferredIncomeTaxLeaseLiabilities" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">670</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000619" name="cgen:DeferredIncomeTaxLeaseLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">312</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000620" name="cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000621" name="cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset before valuation allowance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000622" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,469</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000623" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,380</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000624" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,814</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000625" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,073</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset after valuation allowance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010347732_Fact_0000000000622" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">655</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010347732_Fact_0000000000623" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">307</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right of use assets</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000616" name="cgen:DeferredIncomeTaxRightOfUseAssets" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">655</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000617" name="cgen:DeferredIncomeTaxRightOfUseAssets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">307</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228010350775_Fact_0000000000622" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">655</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228010350775_Fact_0000000000623" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">307</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010353797_Fact_0000000000622" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010353797_Fact_0000000000623" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and<span style="font-weight:bold">&#160;</span>Compugen USA, Inc. due to the uncertainty of the realization of such tax benefits and withholding taxes on the upfront payment and the IND milestone pursuant to the Gilead license agreement.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax assessments:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has tax assessments through 2019 that are deemed to be final.</span></span></div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 41</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
  </div>

  <ix:nonNumeric id="Fxbrl_20230222123726446" name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;color:rgb(0, 0, 0)">

                    <tr>
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span>NOTE 11:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div style="font-weight:bold"><span style="font-size:10pt"><span>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASC 280, &#8220;Segment Reporting,&#8221; establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company&#8217;s business is comprised of <ix:nonFraction id="Fxbrl_20250228050756758" name="us-gaap:NumberOfOperatingSegments" contextRef="C_20240101to20241231" unitRef="Segment" scale="0" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment<span>.</span></span></span></div>
                </div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company's CODM is its Chief Executive Officer (&#8220;CEO&#8221;), who reviews financial information presented on a consolidated basis.</span></span></div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">
                  <div style="line-height:1.25">The CODM uses consolidated net loss to assess financial performance and allocate resources. These financial metrics are used by the CODM to make key operating decisions, such as the allocation of budget between Research and development, Sales and Marketing, and General and Administrative expenses. Segment assets that are reviewed by the CODM is reported within the Consolidated Balance Sheet as consolidated total assets.</div>
                </div>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-indent:0.5pt;margin-left:56.2pt;line-height:1.25">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table presents selected financial information with respect to the Company&#8217;s single operating segment <span>and includes information about segment revenues and significant segment expenses, </span>for the years ended December&#160;31, 2024, 2023 and 2022:</span></span></div>
                  <div style="text-align:justify;line-height:1.25">&#160;</div>
                </div>
                <ix:nonNumeric id="Fxbrl_20250228093519033" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" contextRef="C_20240101to20241231" escape="true">
                  <div>
                    <div style="margin-left:63pt">
                      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total Revenues</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110108919_Fact_0000000000631" name="us-gaap:Revenues" contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,864</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110108919_Fact_0000000000632" name="us-gaap:Revenues" contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,459</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110108919_xbrl_20230214023238881" name="us-gaap:Revenues" contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less:</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160; &#160; &#160; &#160; R&amp;D expenses</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Preclinical</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110138411_xbrl_20250228110108919_Fact_0000000000631" name="cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment" contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,374</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110138411_xbrl_20250228110108919_Fact_0000000000632" name="cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment" contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,948</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110138411_xbrl_20250228110108919_xbrl_20230214023238881" name="cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment" contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,477</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; Clinical</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110140733_xbrl_20250228110108919_Fact_0000000000631" name="cgen:ClinicalAmountOfExpenseForResearchAndDevelopment" contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,267</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110140733_xbrl_20250228110108919_Fact_0000000000632" name="cgen:ClinicalAmountOfExpenseForResearchAndDevelopment" contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,627</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110140733_xbrl_20250228110108919_xbrl_20230214023238881" name="cgen:ClinicalAmountOfExpenseForResearchAndDevelopment" contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,357</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SG&amp;A</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110144645_xbrl_20250228110108919_Fact_0000000000631" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,485</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110144645_xbrl_20250228110108919_Fact_0000000000632" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,320</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110144645_xbrl_20250228110108919_xbrl_20230214023238881" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,690</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income, net</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250228110146997_xbrl_20250228110108919_Fact_0000000000631" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,182</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250228110146997_xbrl_20250228110108919_Fact_0000000000632" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,215</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250228110146997_xbrl_20250228110108919_xbrl_20230214023238881" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,738</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Taxes on income</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110149186_xbrl_20250228110108919_Fact_0000000000631" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,522</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110149186_xbrl_20250228110108919_Fact_0000000000632" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,970</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110149186_xbrl_20250228110108919_xbrl_20230214023238881" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other segment expenses*</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110151261_xbrl_20250228110108919_Fact_0000000000631" name="cgen:OtherSegmentExpenses" contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,629</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110151261_xbrl_20250228110108919_Fact_0000000000632" name="cgen:OtherSegmentExpenses" contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,563</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250228110151261_xbrl_20250228110108919_xbrl_20230214023238881" name="cgen:OtherSegmentExpenses" contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,350</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250228110153451_xbrl_20250228110108919_Fact_0000000000631" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,231</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250228110153451_xbrl_20250228110108919_Fact_0000000000632" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,754</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250228110153451_xbrl_20250228110108919_xbrl_20230214023238881" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                          </tr>

                      </table>
                    </div>
                  </div>
                </ix:nonNumeric>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>*Other </span></span>segment expense (income) during the years ended December 31, 2024, 2023 and 2022 includes property and equipment depreciation, participation in R&amp;D expenses, share-based compensation and other adjustments.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25">
                    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operations in Israel and the United States include research and development, clinical operations, general and administrative, marketing and business development.&#160;Total revenues are attributed to geographic areas based on the location of the end customer.</span></span></p>
                  </div>
                </div>
                <div style="line-height:1.25">&#160;</div>
              </div>
              <div><ix:exclude>
                <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 42</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                </div>
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                  <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">NOTE 11:-</span></span></span></span></td>
                        <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                          <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA <span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">(Cont.)</span></span></span></span></span></div>
                        </td>
                      </tr>

                  </table>
                  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </div>
              </ix:exclude></div>
              <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following represents the total revenue for the years ended December 31, 2024, 2023 and 2022 and long-lived assets as of December 31, 2024 and 2023:</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <ix:nonNumeric id="Fxbrl_20250225144752809" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" contextRef="C_20240101to20241231" escape="true">
                <div>
                  <div style="margin-left:63pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended December 31,</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Revenue from sales to customers:</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Europe</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000631" name="us-gaap:Revenues" contextRef="C_20240101to20241231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000632" name="us-gaap:Revenues" contextRef="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230214023238881" name="us-gaap:Revenues" contextRef="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>United States</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240228002914108_Fact_0000000000631" name="us-gaap:Revenues" contextRef="C_20240101to20241231_cgenSegmentReportingGeographicAreaAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,864</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240228002914108_Fact_0000000000632" name="us-gaap:Revenues" contextRef="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,459</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240228002914108_xbrl_20230214023238881" name="us-gaap:Revenues" contextRef="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total revenue</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000634" name="us-gaap:Revenues" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,864</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000635" name="us-gaap:Revenues" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,459</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230214023305010" name="us-gaap:Revenues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                  <div style="line-height:1.25">&#160;</div>
                  <div>
                    <div style="margin-left:63pt">
                      <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>December 31,</span></strong></span></span></p>
                            </td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Long-lived assets:</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Israel</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000637" name="us-gaap:NoncurrentAssets" contextRef="C_20241231_cgenSegmentReportingGeographicAreaAxis_countryIL" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,677</ix:nonFraction></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000638" name="us-gaap:NoncurrentAssets" contextRef="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryIL" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,468</ix:nonFraction></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>United States</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000639" name="us-gaap:NoncurrentAssets" contextRef="C_20241231_cgenSegmentReportingGeographicAreaAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000640" name="us-gaap:NoncurrentAssets" contextRef="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total long-lived assets</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000641" name="us-gaap:NoncurrentAssets" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,695</ix:nonFraction></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000642" name="us-gaap:NoncurrentAssets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,545</ix:nonFraction></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>

                      </table>
                    </div>
                  </div>
                </div>
              </ix:nonNumeric>
              <div>
                <div style="line-height:1.25">&#160;</div>
                <div style="margin-left:63pt">
                  <ix:nonNumeric id="Fxbrl_20250225144739098" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" contextRef="C_20240101to20241231" escape="true">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended December 31,</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Sales to a single customer exceeding 10%:</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Customer A</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000644" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20240101to20241231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">18</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000645" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">30</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230214023433284" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Customer B</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240228002946105_Fact_0000000000644" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20240101to20241231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">82</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240228002946105_Fact_0000000000645" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240228002946105_xbrl_20230214023433284" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </ix:nonNumeric>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000665" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

        <tr>
          <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 12:-</span></td>
          <td style="width:auto;vertical-align:top;text-align:justify">
            <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">FINANCIAL AND OTHER INCOME, NET</span></div>
          </td>
        </tr>

    </table>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <div>
      <div>
        <div style="margin-left:63pt">
          <ix:nonNumeric id="FFact_0000000000664" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div>
                <div>
                  <div>
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000649" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,489</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000650" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,960</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000651" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,437</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of discount on marketable securities, net</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228002028020_Fact_0000000000649" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,747</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228002028020_Fact_0000000000650" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">281</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228002028020_Fact_0000000000651" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank fees and other finance expenses</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000652" name="us-gaap:InterestAndDebtExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000653" name="us-gaap:InterestAndDebtExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000654" name="us-gaap:InterestAndDebtExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency transaction adjustments</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000655" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214022140608" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000657" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">340</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gain (loss) from sales and disposals of fixed assets</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214022153855" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero" sign="-">-</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000659" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000660" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000661" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,182</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000662" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,208</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000663" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,738</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                </div>
              </div>
            </div>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 43</span></span></span></span></p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-top:0pt;margin-bottom:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><p style="margin:15pt 0pt 0pt"><strong style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000672" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div>
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 13:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">RELATED PARTY BALANCES AND TRANSACTIONS</span></span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20250225051438914" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20240101to20241231" escape="true">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif">December 31,</span></strong></p>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables and accrued expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000666" name="us-gaap:OtherLiabilities" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000667" name="us-gaap:OtherLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts charged to:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000668" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000669" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">147</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000670" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2024, 2023 and 2022 the Company received research and development services related with cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies. The transaction was at arm&#8217;s length.</span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20230222124735774" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 14:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LOSSES PER SHARE</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin:0px 0px 0px 85.5pt;line-height:1.25;text-align:justify;text-indent:-28.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the computation of basic and diluted losses per share:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">
          <ix:nonNumeric id="Fxbrl_20230222124750140" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div>
                <div>
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for basic and diluted loss per share</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000673" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,231</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000674" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,754</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000675" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000676" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240101to20241231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,528,031</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000677" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">87,633,298</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000678" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,555,628</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214135651704" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20241231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_0000000000679" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20241231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.16</ix:nonFraction></ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214135713278" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20231231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_0000000000680" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.21</ix:nonFraction></ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214135731057" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_0000000000681" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.39</ix:nonFraction></ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20230214053733944" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 15:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SUBSEQUENT EVENTS</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January and February 2025, the Company sold through the ATM <span><ix:nonFraction id="Fxbrl_20250228053725982" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20240101to20240131_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">3,961,641</ix:nonFraction></span> ordinary shares, with proceeds of approximately <span>$ <ix:nonFraction id="Fxbrl_20250228053737270" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20240101to20240131_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,870</ix:nonFraction></span> (net of <span>$ <ix:nonFraction id="Fxbrl_20250228053744926" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20240101to20240131_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">274</ix:nonFraction></span> issuance expenses).</span></span></div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
  <div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="line-height:1.25">-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-<span style="font-weight:bold">&#160;</span>-</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:10pt;margin-bottom:3pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F&#8201;-&#8201;44</span></span></p>
    <hr style="border:none;border-bottom:4px solid #000000;border-top:1px solid #000000;height:10px;width:100%;color:#000000;text-align:center;text-align:center"/>
  </div>
</div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>exhibit_2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit 2.1</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">DESCRIPTION OF SECURITIES</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The descriptions of the securities contained herein summarize the material terms and provisions of the ordinary shares of Compugen Ltd.
      (the &#8220;Company&#8221;), registered under Section 12 of the Securities Exchange Act of 1934.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">ORDINARY SHARES</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Our authorized share capital is NIS 2,000,000 divided into 200,000,000 ordinary shares, nominal (par) value NIS 0.01 per share. Subject
      to our amended and restated articles of association, or our Articles, fully paid ordinary shares of the Company confer on the holders thereof rights to attend and to vote at general meetings of the shareholders. Subject to the rights of holders of
      shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to vote, to receive dividends and to participate in the distribution of the assets of the
      Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made,
      without regard to any premium paid in excess of the nominal value, if any. All outstanding ordinary shares are validly issued and fully paid.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">The Nasdaq Capital Market and the Tel Aviv Stock Exchange</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Our ordinary shares are listed on each of The Nasdaq Capital Market and the Tel Aviv Stock Exchange&#160;under the symbol &#8220;CGEN&#8221;.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Rights Attached to Our Shares</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Subject to our Articles, fully paid ordinary shares confer on the holders thereof rights to attend and to vote at general meetings of
      the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, our ordinary shares confer upon the holders thereof equal rights to receive dividends and to participate in the
      distribution of our assets upon our winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such
      distribution is being made, without regard to any premium paid in excess of the nominal value, if any. No preferred shares are currently authorized. All outstanding ordinary shares are validly issued and fully paid.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Voting Rights</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Subject to the provisions of our Articles, holders of ordinary shares have one vote for each ordinary share held by such shareholder of
      record, on all matters submitted to a vote of shareholders. Shareholders may vote in person, by proxy or by proxy card. Alternatively, shareholders who hold shares through members of the Tel Aviv Stock Exchange may vote electronically via the
      electronic voting system of the Israel Securities Authority, or Electronic Vote. These voting rights may be affected by the grant of any special voting rights to the holders of a class of shares with preferential rights that may be authorized in the
      future. As our ordinary shares do not have cumulative voting rights in the election of directors, the holders of the majority of the shares present and voting at a shareholders meeting have the power to elect all of our directors. In the event that
      we cease meeting the Opt Out Criteria (as defined in the annual report on Form 20-F to which this Exhibit 2.1 is attached), or if our board of directors decides to opt in
        the requirement to elect and have external directors and comply with the composition criteria of the audit committee and compensation committee under the Companies Law, the external directors will be elected by a special majority vote, as set forth
        under the Companies Law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Transfer of Shares</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our ordinary shares which have been fully paid-up are transferable by submission of a proper instrument of transfer together with the
      certificate of the shares to be transferred and such other evidence of title, as our board of directors may require, unless such transfer is prohibited by another instrument or by applicable securities laws.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Dividends</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Under the Companies Law, dividends may be distributed only out of profits available for dividends as determined by the Companies Law
      (the &#8220;<font style="font-weight: bold;">profit test</font>&#8221;), provided that there is no reasonable concern that the distribution will prevent the Company from being able to meet its
      existing and anticipated obligations when they become due (the &#8220;<font style="font-weight: bold;">liquidity test</font>&#8221;). If the company does not meet the profit test, a court may
      nevertheless allow the company to distribute a dividend, as long as the court is convinced that there is no reasonable concern that such distribution will prevent the company from being able to meet the liquidity test.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Notwithstanding the foregoing, following the adoption of certain amendments to the Israeli Companies Regulations (Alleviation for Public Companies whose shares are Traded on the Stock Exchange Outside of Israel), 2000, on March 12, 2024, or the Amended Alleviation Regulations, a
      company entitled to avail itself of the Amended Alleviation Regulations, like us, may effect a distribution by means of buying our own securities (which is considered a dividend distribution under the Companies Law) upon meeting only the liquidity
      test and without the need to meet the profit test or seek Israeli court approval and after complying with certain procedural requirements set forth in the Amended Alleviation Regulations.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to our Articles, no dividend (other than for buying our own securities, as detailed above) shall be paid other than out of the
      profits of the Company. Generally, under the Companies Law, the decision to distribute dividends and the amount to be distributed is made by a company&#8217;s board of
      directors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles provide that our board of directors, may, subject to the Companies Law, from time to time, declare and cause the Company to
      pay such dividends as may appear to the board of directors to be justified. Subject to the rights of the holders of shares with preferential, special or deferred rights that may be authorized in the future, the amounts which shall be declared as
      dividends shall be distributed according to the proportion of the nominal (par) value paid up or credited as paid up on account of the shares held at the date so appointed by the Company and in respect of which such dividend is being paid, without
      regard to the premium paid in excess of the nominal (par) value, if any. The declaration of dividends does not require shareholders&#8217; approval.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">To date, we have not declared or distributed any dividend and we do not intend to pay cash dividends on our ordinary shares in the
      foreseeable future.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Liquidation Rights</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">In the event of our winding up on liquidation or dissolution, subject to applicable law and after satisfaction of liabilities to
      creditors, our assets available for distribution among the shareholders shall be distributed to the holders of ordinary shares in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them
      respectively and in respect of which such distribution is being made, without regard to any premium paid in excess of the nominal value, if any. This liquidation right may be affected by the grant of limited or preferential rights as to liquidation
      to the holders of a class of shares that may be authorized in the future.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Redemption Provisions</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">We may, subject to applicable law and to our Articles, issue redeemable shares and redeem the same upon such terms and conditions as
      determined by our board of directors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Limitation of Liability</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Under our Articles, the liability of each shareholder for the Company&#8217;s obligations is limited to the unpaid sum, if any, owing to the Company in consideration for the issuance of the shares held by such shareholder.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Modification of Class Rights</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our amended and restated Memorandum of Association, or Memorandum, provides that we may amend the Memorandum in order to increase,
      consolidate or divide or otherwise amend our share capital by a simple majority of the voting power present at a shareholders meeting as currently provided in our Articles or by such other majority as shall be set forth in our Articles from time to
      time.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to our Articles, if at any time our share capital is divided into different classes of shares, the rights attached to any
      class, unless otherwise provided by our Articles, may be modified or abrogated by the Company, subject to the consent in writing of, or sanction of a resolution passed by, the holders of a majority of the issued shares of such class at a separate
      general meeting of the holders of the shares of such class.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Limitations on the Rights to Own Securities</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles and Israeli law do not restrict the ownership or voting of ordinary shares by non-residents or persons who are not citizens
      of Israel, though such ownership is prohibited under applicable law with respect to subjects of nations which are in a state of war with Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Changes in Authorized Share Capital</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles enable us, among others, to increase or reduce our authorized share capital. Any such changes are subject to the provisions
      of the Companies Law and our Articles and must be approved by a resolution duly passed by a simple majority of our shareholders at a general meeting by voting on such change in capital.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Shareholders&#8217; Meetings and Resolutions</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles and the Companies Law provide that our annual general meeting shall be held once in every calendar year at such time
      (within a period of not more than fifteen months after the last preceding annual general meeting), and place determined by our board of directors. Our board of directors may, in its discretion, convene additional special shareholders meetings and,
      pursuant to the Companies Law, as supplemented by the Amended Alleviation Regulations, must convene a meeting upon the demand of: (a) two directors or one quarter of the directors in office; or (b) the holder or holders of (i) at least 10% of our
      issued share capital and at least one percent of our voting rights; or (ii) at least 10% of our voting rights. All demands for shareholders meetings must set forth the items to be considered at that meeting. If the board of directors does not convene
      a meeting upon a valid demand of any of the above, then the persons who made the demand, and in the case of shareholders, part of such demanding shareholders holding at least half of the voting rights of such demanding shareholders, may convene a
      meeting of the shareholders to be held within three months of the demand. Alternatively, upon petition by the individuals making the demand, a court may order that a meeting be convened.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The chairman of the board of directors, or any other director or office holder of the Company which may be designated for this purpose
      by the board of directors, shall preside as chairman at each of our general meetings. If there is no such chairman, or if the appointed chairman is unwilling to take the chair, or if he shall have indicated in advance that he will not be attending,
      or if at any meeting such chairman is not present within thirty (30) minutes after the time fixed for holding the meeting, then those present at the meeting shall choose someone present to be chairman of the meeting. The office of chairman shall not,
      by itself, entitle the holder thereof to vote at any general meeting nor shall it entitle a second or casting vote.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">According to regulations promulgated pursuant to the Companies Law and governing the terms of notice and publication of shareholder
      meetings of public companies, or the General Meeting Regulations, holder(s) of at least 1% of the Company&#8217;s voting rights may propose any matter appropriate for
      deliberation at a shareholder meeting to be included on the agenda of a shareholder meeting, unless such proposal refers to election or removal of a director, which requires such holder(s) to hold at least 5% of the Company&#8217;s voting rights, as set forth in the Amended Alleviation Regulations. Such proposal may be submitted within seven days of publicizing the convening of a shareholder meeting, or within
      fourteen days, if the Company publishes at least 21 days prior to publicizing the proxy materials for a shareholder meeting, a preliminary notice stating its intention to convene such meeting with all required information. Any such proposal must
      further comply with the information requirements under applicable law and our Articles, and in the event that such shareholders propose to appoint directors for service on the Company&#8217;s board of directors, the proposal must include information
      regarding the director candidates as well as certain declarations of the director candidates, as required pursuant to the General Meeting Regulations. The agenda for a shareholder meeting is determined by the board of directors and must include
      matters in respect of which the convening of a shareholder meeting was demanded and any matter requested to be included by holder(s) of the required Company&#8217;s voting
      rights, as detailed above.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the Companies Law and the General Meeting Regulations shareholder meetings generally require prior notice of not less than
      21 days, and not less than 35 days in certain cases. Pursuant to our Articles, we are not required to deliver or serve notice of a general meeting or of any adjournments thereof to any shareholder. However, subject to applicable law and stock
      exchange rules and regulations, we will publicize the convening of a general meeting in any manner reasonably determined by us, and any such publication shall be deemed duly made, given and delivered to all shareholders on the date on which it is
      first made, posted, filed or published in the manner so determined by us in our sole discretion.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The function of the general meeting is to elect directors, discuss the financial statement and the reports of the directors, appoint
      external auditor and approve its remuneration, approve certain interested party transactions requiring general meeting approval as provided in the Companies Law, approve the
        Company&#8217;s merger, approve increases and decreases in the Company&#8217;s authorized share capital as provided in the Companies Law, exercise of the powers of the board of directors if the board of directors is unable to exercise its powers and the
        exercise of any of its powers is vital for the Company&#8217;s proper management, approve the liquidation, dissolution or winding up of the Company approve amendments of
        the Articles and transact any other business which under our Articles or applicable law may be transacted by the shareholders of the Company in a general meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to our Articles, the quorum required for a meeting of shareholders consists of at least two shareholders, present in person, by
      proxy, by proxy card or by Electronic Vote and holding shares conferring in the aggregate twenty-five percent (25%) or more of the voting power of the Company. If within half an hour from the time appointed for the meeting a quorum is not present,
      the meeting shall stand adjourned to the same day in the following week at the same time and place or to such other later day, time and place as the board of directors may determine and specify in the publication with respect to the Meeting. At the
      adjourned meeting, any number of participants will constitute a quorum present, in person, by proxy, by proxy card or by Electronic Vote; provided, however, that special general meeting which was convened by the Board upon the demand of shareholders
      or directors then in office, as detailed above, or directly by such shareholders or directors, in accordance the terms of the Companies Law, shall be cancelled.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Generally, under the Companies Law and our Articles, shareholder resolutions are deemed adopted if approved by the holders of a simple
      majority of the voting rights represented at the meeting, in person, by proxy, by proxy card or by Electronic Vote, and voting on the matter, unless a different majority is required by law or pursuant to our Articles such as a resolution for the
      voluntary winding up of our Company which requires the approval of holders of 75% of the voting power presented and voting at the meeting, or resolutions concerning certain related party transactions as set forth in Sections 267 and 270-275 of the
      Companies Law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Change of Control</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Merger</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Under the Companies Law, a merger is generally required to be approved by the shareholders and board of directors of each of the merging
      companies. If the share capital of the company that will not be the surviving company is divided into different classes of shares, the approval of each class is also required, unless determined otherwise by the court. Similarly, unless an Israeli
      court determines otherwise, a merger will not be approved if it is objected to by shareholders holding a majority of the voting rights participating and voting at the meeting (abstentions are disregarded), after excluding the shares held by the other
      party to the merger, by any person who holds 25% or more of the other party to the merger or by anyone on their behalf, including by the relatives of, or corporations controlled by, these persons. In approving a merger, the board of directors of both
      merging companies must determine that there is no reasonable concern that, as a result of the merger, the surviving company will not be able to satisfy its obligations to its creditors. Similarly, upon the request of a creditor of either party to the
      proposed merger, an Israeli court may prevent or delay the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will not be able to satisfy the obligations of the merging parties. A
      court may also issue other instructions for the protection of the creditors&#8217; rights in connection with a merger. Further, a merger may not be completed unless at
      least (i) 50 days have passed from the time that the requisite proposals for the approval of the merger were filed with the Israeli registrar of companies; and (ii) 30 days have passed since the merger was approved by the shareholders of each party.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Special Tender Offer</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if
      as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This rule does not apply if there is already another holder of 25% or more of the voting rights in the company. Similarly, the
      Companies Law provides that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if
      there is no other shareholder of the company who holds more than 45% of the voting rights in the company. These requirements do not apply if the acquisition (i) occurs in the context of a private placement by the company that received shareholder
      approval for the purpose of allowing the purchaser to hold more than 25% of the voting rights in the company if there is no other holder of 25% or more of the voting rights
        in the company, or 45% of the voting rights in the company if there is no other holder of 45% or more of the voting rights in the company, as the case may be, (ii) was from a shareholder holding 25% or more of the voting rights in the
      company and resulted in the acquirer becoming a holder of 25% or more of the voting rights in the company, or (iii) was from a holder of more than 45% of the voting rights in the company and resulted in the acquirer becoming a holder of more than 45%
      of the voting rights in the company. A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company&#8217;s outstanding
      shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding controlling shareholders, holders of 25% or more of the voting rights in the
      company and any person having a personal interest in the acceptance of the special tender offer).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">In the event that a special tender offer is made, a company&#8217;s
      board of directors is required to express its opinion on the advisability of the offer or to abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. An office holder in a target company
      who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing or foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential purchaser
      and shareholders for damages, unless such office holder acted in good faith and had reasonable grounds to believe he or she was acting for the benefit of the company. However, office holders of the target company may negotiate with the potential
      purchaser in order to improve the terms of the special tender offer and may further negotiate with third parties in order to obtain a competing offer. Shares purchased in contradiction to the tender offer rules under the Companies Law will have no
      rights and will become dormant shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">If a special tender offer is accepted, then shareholders who did not respond to or that had objected the offer may accept the offer
      within four days of the last day set for the acceptance of the offer. In the event that a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling
      person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person
      or entity undertook to effect such an offer or merger in the initial special tender offer.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Full Tender Offer</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Under the Companies Law, a person may not acquire shares in a public company if, after the acquisition, the acquirer will hold more than
      90% of the shares or more than 90% of any class of shares of that company, unless a tender offer is made to purchase all of the shares or all of the shares of the particular class. The Companies Law also generally provides that as long as a
      shareholder in a public company holds more than 90% of the company&#8217;s shares or of a class of shares, that shareholder shall be precluded from purchasing any
      additional shares. In order for all of the shares that the purchaser offered to purchase be transferred to him by operation of law, one of the following needs to have occurred: (i) the shareholders who declined or do not respond to the tender offer
      hold less than 5% of the company&#8217;s outstanding share capital or of the relevant class of shares and the majority of offerees who do not have a personal interest in
      accepting the tender offer accepted the offer, or (ii) the shareholders who declined or do not respond to the tender offer hold less than 2% of the company&#8217;s
      outstanding share capital or of the relevant class of shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">A shareholder that had his or her shares so transferred, whether he or she accepted the tender offer or not, has the right, within six
      months from the date of acceptance of the tender offer, to petition the court to determine that the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, the purchaser may provide in its
      offer that shareholders who accept the tender offer will not be entitled to such rights.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">If the conditions set forth above are not met, the purchaser may not acquire additional shares of the company from shareholders who
      accepted the tender offer to the extent that following such acquisition, the purchaser would own more than 90% of the company&#8217;s issued and outstanding share capital.
      The above restrictions apply, in addition to the acquisition of shares, to the acquisition of voting power.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Significant Private Placement</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Under the Companies Law, a significant private placement of securities requires approval by the board of directors and the shareholders
      by a simple majority. A private placement is considered a significant private placement if it results in a person becoming a controlling shareholder, or if all of the following conditions are met: the securities issued amount to 20% or more of the
      company&#8217;s outstanding voting rights before the issuance; some or all of the consideration is other than cash or listed securities or the transaction is not on market terms; and the transaction will increase the relative holdings of a shareholder who
      holds 5% or more of the company&#8217;s outstanding share capital or voting rights or will cause any person to become, as a result of the issuance, a holder of more than 5% of the company&#8217;s outstanding share capital or voting rights. Notwithstanding, in
      accordance with the Alleviation Regulations, the provisions of the Companies Law governing the approval of significant private placements will not apply to Israeli public companies which are listed for trading on certain stock exchanged outside of
      Israel (including the Nasdaq) if applicable law in the foreign jurisdiction in which the company&#8217;s securities are so listed for trading includes rules governing a private placement and the company follows such rules as applicable to companies
      incorporated in such foreign jurisdiction.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Forum for Adjudication of Disputes</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles provide that unless the Company consents in writing to the selection of an alternative forum, the federal district courts
      of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a claim, cause of action, claims, or causes of action arising under the United States Securities Act of 1933, as amended, including all claims
      and causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the Company, its officers and directors, the underwriters to any offering giving rise to
      such complaint, and any other professional or entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles further provide that unless the Company consents in writing to the selection of an alternative forum, the competent courts
      in Tel Aviv, Israel shall be the exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of the Company; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the
      Company to the Company or the Company&#8217;s shareholders; or (iii)&#160;any action asserting a claim arising pursuant to any provision of the Companies Law or the Securities Law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Any person or entity purchasing or otherwise acquiring&#160;or holding&#160;any interest in&#160;shares of the Company shall be deemed to have notice
      of and consented to the provisions set forth under the heading &#8220;Forum for Adjudication of Disputes&#8221;.</div>
    <div><br>
    </div>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>3
<FILENAME>exhibit_8-1.htm
<DESCRIPTION>EXHIBIT 8.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit 8.1</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">SUBSIDIARIES</div>
      <div style="line-height: 1.25">&#160;
        <table cellspacing="0" cellpadding="0" border="0" id="z7fb6d3854825436a9d53ee23f77ed49d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 50%;"><font style="font-weight: bold;"><u>Subsidiary</u></font></td>
              <td style="width: 50%;"><font style="font-weight: bold;"><u>Jurisdiction</u></font></td>
            </tr>
            <tr>
              <td style="width: 50%;"><br>
              </td>
              <td style="width: 50%;"><br>
              </td>
            </tr>
            <tr>
              <td style="width: 50%;">Compugen USA, Inc.</td>
              <td style="width: 50%;">Delaware</td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11
<SEQUENCE>4
<FILENAME>exhibit_11-b.htm
<DESCRIPTION>EXHIBIT 11.B
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%Page %%-->
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-variant: small-caps; font-weight: bold;"><u><font style="font-weight: bold; font-variant: normal;"> Exhibit 11(b)</font></u><br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Compugen Ltd.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Insider Trading Policy</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">Revised by the Board of Directors on January 22, 2025</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">This Insider Trading Policy (this &#8220;<font style="font-weight: bold;">Policy</font>&#8221;) provides guidelines to all personnel, including directors, officers, employees and consultants (&#8220;<font style="font-weight: bold;">Company</font>&#160;<font style="font-weight: bold;">Personnel</font>&#8221;) of Compugen Ltd. and its subsidiary (&#8220;<font style="font-weight: bold;">Compugen</font>&#8221;
        or the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), for transactions<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">*</sup> in the Company&#8217;s securities<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">**</sup> and the handling of confidential information about the
        Company and others with which it does business.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25; font-weight: bold;">All Company Personnel should read this Policy very carefully. Failure to observe the
        prohibitions and procedures set forth below could result in serious legal enforcement actions, both civil and criminal, for you and possibly the Company under both United States and Israeli Law. In addition, failure to comply with this Policy may
        subject you to Company-imposed sanctions, including dismissal, regardless of whether or not such failure to comply with this Policy results in a violation of law.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-right: 2.1pt; line-height: 1.25; font-weight: bold;">POLICY</div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">As a publicly traded company, whose ordinary shares are listed on both The Nasdaq Stock Market (&#8220;<font style="font-weight: bold;">Nasdaq</font>&#8221;) and the Tel Aviv Stock Exchange (&#8220;<font style="font-weight: bold;">TASE</font>&#8221;),
        Compugen is subject to certain provisions of United States federal securities laws and regulations, as well as Israeli securities laws and regulations. Pursuant to these laws and regulations, &#8220;insider trading&#8221;, which is the use of material
        information about the Company that is not known to the investing public, and, if it were known to the public, would likely cause a significant change in the price of the
          Company&#8217;s securities (such information is referred to in this Policy as &#8220;<font style="font-weight: bold;">material non-public information</font>,&#8221; and is more fully explained
        in Section 3 of the Guidelines below (the &#8220;<font style="font-weight: bold;">Guidelines</font>&#8221;)), including, for example, for personal benefit or for the benefit of others or to &#8220;tip&#8221;
        others who might make an investment decision on the basis of such information, is illegal. You can be held liable both for your own transactions and for transactions effected by a tippee, or even a tippee of a tippee. Furthermore, it is important
        that the appearance of insider trading in securities be avoided. It is the policy of the Company to comply with all applicable insider trading laws and regulations.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-right: 2.1pt; line-height: 1.25; font-weight: bold;">RESPONSIBILITY</div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">Company Personnel may create, use or have access to material non-public information. Each individual has an
        important ethical and legal obligation to maintain the confidentiality of such information, not to engage in any transactions in the Company&#8217;s securities while in possession of material non-public information and not to provide such information or
        an opinion on any security of the Company while in possession of material non-public information to any person who &#8211; the person delivering such information knows or has reasonable grounds to believe &#8211; will make use of the such information or will
        utilize the opinion for purposes of a transaction or will pass it on to another. Company Personnel or Related Parties (as defined below) may, from time to time, have to forego a proposed transaction in the Company&#8217;s securities even if he or she
        planned to make the transaction before the Company Personnel learned of the material non-public information and even though he or she may suffer an economic loss or forego anticipated profit by waiting. Trading in securities in violation of these
        requirements or providing others with material non-public information (whether or not you derive any benefit from such actions or were aware of the intent by such persons to trade), may subject you to severe civil and criminal penalties, in
        addition to disciplinary action by the Company as more fully set out in Section 14 of the Guidelines. It is not an excuse that you did not &#8220;use&#8221; the information in deciding whether or not to engage in the transaction.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">The Compliance Officer is our General Counsel. The Compliance Officer is responsible for the administration of
          this Policy.</div>
        <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;"> <br>
        </div>
        <div style="line-height: 1.25;">
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">*</sup>&#160;&#8220;transaction&#8221;
        may also include the exercise of options (see Section 7 of the Guidelines) and a commitment to do any transaction in the securities of the Company, whether the person making any of the foregoing is acting on its own behalf or on the behalf of
        another person or through an agent or a trustee.</div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">** </sup>All types of &#8220;securities&#8221; are covered by this policy, including ordinary shares, partnership
        interests, futures, warrants, restricted share units, options, debt securities (e.g., bonds, notes, debentures) and other securities, whether or not convertible or exchangeable into ordinary shares.</div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">Page 1</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">If you have any questions about specific information or proposed transactions, or as to the applicability or
        interpretation of this Policy or the propriety of any desired action, you are encouraged to contact the Compliance Officer. Do not try to resolve uncertainties on your own.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">Remember, however, the ultimate responsibility for complying with this Policy and avoiding improper transactions
        rests with you. In this regard, it is imperative that you use your best judgment. A claim of lack of understanding of the Company&#8217;s policies or of governing legal standards in this sensitive area will not excuse any non-compliance.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-right: 2.1pt; line-height: 1.25; font-weight: bold;">GUIDELINES</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 28.35pt; margin-right: 2.1pt; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Prohibition</font>. In general, United States and Israeli securities laws and/or this Policy prohibit Company Personnel from:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zace70b0ed5c24e48afe077645c51fc36" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>buying, selling or otherwise trading (including for the benefit of another) in the Company&#8217;s securities while in possession of material non-public (or &#8220;<font style="font-weight: bold;">inside</font>&#8221;) information;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z753f582b0a6e46f0b86a11d4a30c87b4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>communicating (or &#8220;<font style="font-weight: bold;">tipping</font>&#8221;) such information to third parties,
                including family members, friends, social acquaintances and anyone who lives in your household;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z5275968b902d4082975df191b01dca27" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>recommending any transaction in the Company&#8217;s securities while in the possession of material information that has not been publicly disclosed by the Company (under
                Israeli law, an actual trade is not required);</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z1d01fb8d49e14d958c5f1390b410f438" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>assisting anyone engaged in any of the above activities; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zce962df6235a4d31841a9c30bf622bd8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>answering questions or providing material non-public information about the Company and its affairs to Company outsiders unless you are specifically authorized to do
                so or it is a regular part of your position, as further detailed under the Company Disclosure Policy.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 2.1pt; line-height: 1.25;">This prohibition also applies to material, non-public information about, and the securities
        of, other companies (<font style="font-style: italic;">e.g.,</font> collaboration partners, customers or suppliers, or companies with whom Compugen has a business relationship).&#160;For example, you may be involved in a proposed transaction involving a prospective business relationship or transaction with another company. If information about that
        transaction constitutes material nonpublic information for that other company, you are prohibited from engaging in transactions involving the securities of that other company. It is important to note that &#8220;materiality&#8221; is different for different
        companies. Information that is not material to the Company may be material to another company.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 2.1pt; line-height: 1.25;">There are no exceptions to this Policy other than those described in Section 7 of the
        Guidelines. For example, if you possess material non-public information, you are prohibited from engaging in transactions in the Company&#8217;s securities even if such transactions are otherwise necessary or justifiable for independent reasons (such as
        personal financial commitments or the need to raise money for a personal emergency expenditure).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 2.1pt; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Transactions by Family Members; Entities Controlled by You. </font>The prohibitions outlined in this Policy also apply to your family
          members, others living in your household and any entities under your or your family member&#8217;s control and any other individuals or entities whose transactions in securities you influence, direct or control (including, for example, a venture or
          investment fund, if you influence, direct or control transactions by the fund) (&#8220;<font style="font-weight: bold;">Related Parties</font>&#8221;). Company Personnel are expected to be
          responsible for the compliance of all Related Parties to this Policy.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 2.1pt; line-height: 1.25;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Material Non-Public Information. </font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;"><font style="font-style: italic;">Material
          Information.</font><font style="font-weight: bold;">&#160;</font>Information is &#8220;material&#8221; for the purposes of the United States securities laws and this Policy if such information, if
        publicly known, would likely affect either the market price of the Company&#8217;s securities, for better or for worse, or a person&#8217;s decision to buy, sell or hold the Company&#8217;s securities. Certainly, if the information makes you want to trade, it would
        probably have the same effect on others. If you possess material (and non-public) information, you may not trade in a company&#8217;s share, advise anyone else to do so or communicate the information to anyone else until you know that the information has
        been publicly disseminated. Under Israeli law, &#8220;inside information&#8221; includes information that relates to developments or expected developments in the Company, changes or
          expected changes in the Company&#8217;s condition or any other information relating to the Company, which is not known to the public and, if it were known to the public, would likely cause a significant change in the price of the Company&#8217;s
        securities or in the price of other securities of which the Company&#8217;s securities are the underlying asset.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">Page 2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;"><font style="font-style: italic;">Non-public
          Information.</font><font style="font-weight: bold;">&#160;</font>Non-public information is any information that has not been disclosed effectively to the investing public. Disclosure by
        press release or in the Company&#8217;s reports that it files with the SEC and ISA is necessary to make the information public. For information to be considered public, it must not only be disclosed publicly, but there also should be sufficient time for
        the investing public to absorb and evaluate the information before you trade in the Company&#8217;s securities. Although timing may vary depending upon the circumstances and jurisdiction, a good rule of thumb is that information is considered non-public
        until one full trading day has passed after public disclosure. If the information released is complex, such as a prospective major financing or other transaction, it may be necessary to allow additional time for the information to be absorbed by
        the investing public. In such circumstances, you will be notified by the Compliance Officer regarding a suitable waiting period before trading in the event it differs from the Company&#8217;s standard policy.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 0.55pt; margin-right: 2.1pt; line-height: 1.25;">Either positive or negative information may be material. No simple &#8220;bright line&#8221; test exists
        to determine when information is material; assessments of materiality involve a highly fact-specific inquiry and will be more often than not determined in hindsight based on the impact on the share trading price. For this reason, you should direct
        any questions about whether information is material to the Compliance Officer. Although it is not possible to list all types of material information, the following are a few examples of information that is particularly sensitive and should be
        treated as material:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="ze780a2f0a2654569888febf852991ff7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the status (positive of negative) of material existing collaborations;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6e53dbd7e19e431c9c315d730420be99" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>potential new material collaborations;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zde537ea93ce241aca28d847f97eef9df" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>significant clinical or regulatory developments;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zfeb2578672e54867a002ee45afa23c63" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>significant new products, product development or discoveries;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6c3bea92eda74f13a48ea000c1cd52bc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the results, favorable or not, of preclinical studies or clinical trials;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6728ae7e60d5408a982f92ddbafa585c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the results, favorable or not, of material legal proceedings, including litigation, mediation and arbitration;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="ze0b763549b35468e9b5284f160bc1a3d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the gain or loss of a material contract, customer, license or collaboration;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z17aae353f5904479ad9141cad33ca78d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>a financing transaction;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z0a227df439ca4205a5ca5e2b212ecd37" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>quarterly or annual earnings results;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zcd9ff1fbfbe74c899335f39b91b83096" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>projections of future results or sales;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z7b3e67e89b2b46948ba64de38a41bb59" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>earnings or losses;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zd2c072b3d9fc4b6f94c14069234e53b5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>a pending or proposed merger, acquisition, material joint venture, tender offer or other similar material strategic transaction;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z7bdc50f3f1844a2ca339b862331d36fd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>changes in dividend policies, a stock split or the offering of additional securities;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z100015f1646449b4b262ffd33abf2838" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>changes in senior management; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z3c8189483a7049dd886c3a3ac4651e74" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.6pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>impending bankruptcy or financial liquidity problems.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">The Company emphasizes that this list is merely illustrative. If you have any question as to whether particular
        information is material or non-public, you should not trade or communicate the information to anyone without prior approval by the Compliance Officer. Remember, however, the ultimate responsibility for complying with this Policy and avoiding
        improper transactions rests with you.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 2.1pt; line-height: 1.25;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">&#8220;Tipping.&#8221;</font>&#160; Company Personnel also are prohibited from recommending or suggesting to anyone else (including Related Parties or
          friends) to buy, sell or hold the securities of any company, including those of the Company, while they are in the possession of material non-public information of the Company or other companies, as relevant. In fact, Company Personnel should not
          recommend to any other person that they buy, sell or hold securities of the Company, even when not in possession of material non-public information, because such a recommendation could be imputed to the Company and could be misleading if such
          Company Personnel is not aware of all relevant information. It is the Company&#8217;s policy to prohibit the disclosure of non-public information to any person, whether inside or outside the Company, unless the person receiving such information has a
          legitimate need to know such information and is subject to a confidentiality agreement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">Page 3</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 2.1pt; line-height: 1.25;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Short-term, Speculative Transactions.</font> The Company has determined that there is a substantial likelihood for the appearance of
          improper conduct by Company Personnel when they engage in short-term or speculative securities transactions. Therefore, Company Personnel are strictly prohibited from engaging in any of the following activities involving the Company&#8217;s securities,
          except with the prior written consent of the Compliance Officer:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6df1b374bfbd480486a051eec7af769a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 14.2pt; vertical-align: top;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>purchasing the Company&#8217;s securities on margin (borrowing money from a stock broker to fund the securities purchase);</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z32d5e354c03846f8af6870f711647374" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 14.2pt; vertical-align: top;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>pledging Company securities;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zf52ad4204d4645628b8cd06c844aead4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 14.2pt; vertical-align: top;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>short sales (selling short is a practice of selling more securities than you own, a technique used to speculate on a decline in the securities price);</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zcdf8300467d64848ae265a6fca8425ff" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 14.2pt; vertical-align: top;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>buying or selling puts or calls (a put is a right to sell at a specified price a specified number of securities by a certain date and is utilized in anticipation of a
                decline in the security price; a call is a right to buy at a specified price a specified number of securities by a certain date and is utilized in anticipation of a rise in the security price). The only equity securities of the Company that
                may generally be purchased or sold by Company Personnel are the Company&#8217;s ordinary shares; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z966299b2d3274b13968a0cc052efae43" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 14.2pt; vertical-align: top;">e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>engaging in derivative transactions relating to the Company&#8217;s securities (e.g., exchange traded options etc.) or hedging transactions designed to decrease the risks
                associated with holding our ordinary shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">This prohibition is not intended to apply to transactions that may involve one or more of the foregoing
        activities if those transactions are entered into solely for the purpose of deferring the effective date of a sale for tax or other non-speculative purposes. Thus, entering into so-called costless collars or forward sale transactions in which the
        economic terms of the transaction are not subject to the future control of Company Personnel and are established at the time the transaction is entered into do not require the prior consent of the Compliance Officer.&#160;Please note, however, that
        entering into any such transaction must be done at a time when trading in the Company&#8217;s securities is permitted. Where because of the unique nature of the proposed transaction or its complexity it is not clear whether there is a substantial
        likelihood for the appearance of improper conduct, Company Personnel should seek the consent of the Compliance Officer before entering into it.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 2.1pt; line-height: 1.25;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Influencing a Security&#8217;s Price.</font> It is prohibited to fraudulently influence the price of securities (such as by placing
          fictitious purchase or sale orders to create an impression of large demand or supply thereby intending to cause an increase or decrease in the price of the security).&#160;Pursuant to the Securities Exchange Act of 1934, as amended, the person
          committing such a fraudulent act may be subject, for each such fraudulent act, to fines of not more than $5,000,000 or imprisonment of not more than 20 years, or both, except that when such person is a person other than a natural person, a fine
          not exceeding $25,000,000 may be imposed. In addition, the person committing the fraudulent act may also expose him/herself to a civil action by the party who suffered damages as a result of the fraudulent acts. Therefore, Company Personnel are
          strictly prohibited from committing any acts or omissions which constitute or could constitute such manipulation of the Company&#8217;s securities and the Compliance Officer must be updated without delay in any event of a suspicion that such an act was
          committed.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 2.1pt; line-height: 1.25;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Certain Exceptions. </font>The exercise of options for the purchase of securities under any Company option plan is exempt from this
          Policy, because the other party to the transaction is the Company itself and the price does not vary with the market but is fixed by the terms of the option agreement or the plan. Nevertheless, based on legal bulletin of the ISA, the exercise of
          options for the purchase of securities under any Company option plan is exempt only if, among others, the exercise price of the option is below the market price of the share at the time of exercise and if the exercise is made immediately prior to
          the expiration of the option. However, the shares so acquired may not be sold, except in accordance with this Policy.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 2.1pt; line-height: 1.25;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Blackout Periods.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">Company Personnel and Related Parties are restricted from trading in Company securities at certain times
        throughout the year as described below (&#8220;<font style="font-weight: bold;">Blackout</font>&#160;<font style="font-weight: bold;">Period/s</font>&#8221;).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">Page 4</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">Company Personnel and Related Parties<font style="font-weight: bold;">&#160;</font>may not buy, sell or otherwise trade (including for the benefit of another) in Company securities during the period commencing on the first day of each fiscal quarter and ending one full trading day in the U.S. after
        the Company publicly discloses its results for the preceding fiscal period.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">It should be noted that even during permitted trading periods (&#8220;<font style="font-weight: bold;">Trading Windows</font>&#8221;), any Company Personnel or Related Party<font style="font-weight: bold;">&#160;</font>possessing material non-public
        information concerning the Company shall not engage in any transactions in the Company&#8217;s securities until such information has been known publicly for at least one full trading day. Furthermore, there are times when the management of the Company
        may be aware of a material non-public development but at its discretion does not disclose it to all Company Personnel. Although you may not know the specifics of the development, if you engage in a trade before such development is resolved or
        disclosed to the public you might expose yourself and the Company to a charge of insider trading that could be costly and difficult to refute. In addition, a trade by you during such time could result in adverse publicity for the Company.
        Therefore, the Company may from time to time prohibit any transactions in Company securities for specified periods, even during Trading Windows. This notice may be given to all Company Personnel or to Company Personnel involved with specific
        matters. In the event you are informed of any such Blackout Period, you should treat such notification in itself as material non-public information and it should not be disclosed to any third party.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">Each person is individually responsible at all times for compliance with the prohibitions against insider
        trading. Trading in the Company&#8217;s securities during Trading Windows should not be considered as &#8220;safe harbor,&#8221; and all Company Personnel should use good judgment at all times.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">Specific exceptions may be made, with prior approval, in special situations when the Company Personnel does not
        possess material non-public information or the exception would not otherwise contravene the law or the purposes of this Policy. Any request for an exception will be directed to the Company&#8217;s Compliance Officer.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 2.1pt; line-height: 1.25;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Trading Plans</font>. The restrictions set forth above will not apply to sales made pursuant to a Qualified Selling Plan. For purposes
          of this exception, a &#8220;Qualified Selling Plan&#8221; is a written plan, contract or instruction for selling the Company&#8217;s shares which meets each of the following requirements:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z7ae17d5fd18041e4957373c4dd4d6051" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 34.65pt;"><br>
            </td>
            <td style="width: 28.35pt; vertical-align: top;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the plan is adopted by the Company Personnel during a period when sales are permitted pursuant to this Policy;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zce6053dedbd247ed8ccad64b3964a6ab" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 34.65pt;"><br>
            </td>
            <td style="width: 28.35pt; vertical-align: top;">(2)&#160;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the plan is adopted during a period when the Company Personnel adopting the plan is not in possession of material non-public information;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zaa47e7a864d14646bd0c97477e23371c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 34.65pt;"><br>
            </td>
            <td style="width: 28.35pt; vertical-align: top;">(3)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the plan is adhered to strictly by the Company Personnel;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="ze35fb2a4cbe340b888ef31bf1360320c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 34.65pt;"><br>
            </td>
            <td style="width: 28.35pt; vertical-align: top;">(4)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the plan must either specify the amount, pricing and timing of transactions in advance or delegate discretion on these matters to an independent third party;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z836833a77fd64c249eba833105796571" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 34.65pt;"><br>
            </td>
            <td style="width: 28.35pt; vertical-align: top;">(5)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>at the time it is adopted the plan conforms to all other requirements of Rule 10b5-1(c) under the U.S. Securities Exchange Act of 1934, as amended, as then in effect;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z299e0a3653aa4d7ba71774cda3798263" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 34.65pt;"><br>
            </td>
            <td style="width: 28.35pt; vertical-align: top;">(6)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the plan provides that the sales be effected on Nasdaq or any other stock market located outside Israel; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z2eecbf949de94bb28ec6034903018005" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 34.65pt;"><br>
            </td>
            <td style="width: 28.35pt; vertical-align: top;">(7)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the plan provides that the sales be effected via a non-Israeli broker (although coordination with an Israeli affiliate, branch or agent of such broker will be
                permitted).</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">Once the Qualified Selling Plan is adopted, (i) Company Personnel may not exercise any influence over the amount
        of securities to be traded, the price at which they are to be traded or the dates of the trade and (ii) such plan may be terminated or altered only during a period that complies with the description in each of subsections (1), (2) and (5) above.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 2.1pt; line-height: 1.25;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Confidentiality Guidelines.</font> To provide more effective protection against the inadvertent disclosure of material
          non-public information about the Company or others with which the Company does business, the Company has adopted the following guidelines in addition to the prohibitions above. These guidelines are not intended to be exhaustive and should be read
          together with the Company&#8217;s Disclosure Policy. Additional measures to secure the confidentiality of information should be undertaken as deemed necessary under the circumstances. If you have any doubt as to your responsibilities with respect to
          confidential information, please seek clarification and guidance from the Compliance Officer before you act.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">Page 5</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">The following guidelines establish procedures with which Company Personnel should comply in order to maximize the
        security of confidential information:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z9848b174cefc4f4b903fb2704f5cf19b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 34.65pt;">&#160;</td>
            <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>do not discuss internal Company matters or developments with anyone outside the Company or even with other Company Personnel, except as required in the performance of
                your regular duties and provided the recipient is subject to a confidentiality agreement;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z824a9229bd454837aeb926b062a0933c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 34.65pt;">&#160;</td>
            <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>do not discuss any Company matter in public places, such as airplanes, elevators, hallways, restrooms or eating facilities, where conversations might be overheard;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zb80308701b1546c6b6098c99d21c97a8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 34.65pt;">&#160;</td>
            <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>use passwords to restrict access to the information on computers; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="ze42f6524e1934e678eca63a6b9ce6fd7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 34.65pt;">&#160;</td>
            <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>limit access of others to particular locations or physical areas where material non-public information is likely to be documented or discussed.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 2.1pt; line-height: 1.25;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Authorized Disclosure of Material Non-Public Information</font>. If any Company Personnel receives inquiries about the Company
          from securities analysts, reporters or others, he or she should decline comment and direct them to the Company&#8217;s CEO, CFO or other authorized spokesperson of the Company, as further detailed in the Company&#8217;s Disclosure Policy.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36.85pt; margin-right: 2.1pt; line-height: 1.25;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Presumption of Insider Trading Under Israeli Law</font>. Under Israeli law, if a director or other office holder, treasurer or
          internal auditor of the Company, any other person assuming the responsibilities of the foregoing persons under a different title, any shareholder holding at least 5% of the Company&#8217;s issued and outstanding share capital or voting rights or having
          the right to appoint at least one director, or a family member or entity controlled by any of the them, purchases securities of the Company within three months of the date that he or she sold securities of the Company (or sells securities of the
          Company within three months of the date that he or she purchased securities of the Company), it would be presumed that such person used inside information, and such person would have the burden to prove that he or she did not use inside
          information. Therefore, although this Policy does not prohibit purchases and sales by such individuals within a three-month period, this Policy strongly discourages such practice.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36.85pt; margin-right: 2.1pt; line-height: 1.25;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Reporting Violations</font>.<font style="font-weight: bold;">&#160;</font>If
          you know or have reason to believe that this Policy or the special trading procedures described above have been or are about to be violated, you should immediately bring the actual or potential violation to the attention of the Compliance
          Officer. Such information may be conveyed on an anonymous basis pursuant to the Company&#8217;s Whistleblower Procedures, but sufficient details should be given to enable a proper investigation.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36.85pt; margin-right: 2.1pt; line-height: 1.25;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Penalties for Violations</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">Under United States securities laws, an individual may be subject to criminal fines of up to $5,000,000 and up to
        20 years of imprisonment for violating the securities laws by engaging in transactions in securities at a time when they are in possession of material non-public information. In addition, the SEC may seek the imposition of a civil penalty of up to
        three times the profits made, or losses avoided from the trading. Insider traders must also disgorge any profits made and are often subjected to an injunction against future violations. Violators can also be barred from serving as officers or
        directors of public companies. Finally, under some circumstances, individuals may be subjected to civil liability in private lawsuits. In addition, under Israeli law, individuals may be subject to criminal penalties of up to NIS 1,130,000 and up to
        five years of imprisonment as well as administrative sanctions of up to NIS 1,000,000 and corporations may be subject to criminal penalties of up to NIS 5,650,000. Violators can also be barred from serving as officer or directors of public
        companies for up to five years.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">Failure to comply with this Policy could result in serious legal enforcement actions, both civil and criminal,
        for you and possibly the Company under both United States and Israeli Law. In addition, failure to comply with this Policy, or any refusal or failure by you to cooperate fully with the Company in any investigation of a possible violation of this
        Policy, will be regarded by the Company as a very serious matter and, may subject you to Company-imposed sanctions, including dismissal, regardless of whether or not such failure to comply with this Policy results in a violation of law.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">Page 6</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; margin-right: 2.1pt; line-height: 1.25; font-weight: bold;">This document states a policy of the Company and is not intended to be regarded as the
        rendering of legal advice.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Certification</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 2.1pt; line-height: 1.25;">This is to confirm that I have read and understand this Insider Trading Policy and will comply with the policies,
        prohibitions and procedures stated therein. I understand that, if I am an employee or consultant of Compugen Ltd. or any subsidiary of Compugen Ltd., my failure to comply in all respects with such policies, prohibitions and procedures is a basis
        for termination of my employment or engagement with the Company.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 81pt;">
        <table cellspacing="0" cellpadding="0" border="0" id="zbe76fe2e2f2148eaab0d1c831c1c8daf" style="width: 75%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div style="line-height: 1.25;">Please SIGN your name here:</div>
              </td>
              <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 81pt;">
        <table cellspacing="0" cellpadding="0" border="0" id="z9666562b41634d27861d44a1e9e3c669" style="width: 75%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div style="line-height: 1.25;">Please PRINT your name here:</div>
              </td>
              <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 81pt;">
        <table cellspacing="0" cellpadding="0" border="0" id="zec653b3e030c4663a571853f2724f87f" style="width: 75%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div style="line-height: 1.25;">Please date here:</div>
              </td>
              <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; text-indent: 0.55pt; margin-right: 9.2pt; line-height: 1.25; font-weight: bold;">UPON SIGNING THIS POLICY, PLEASE SAVE ONE COPY IN YOUR FILES AND RETURN A
        SIGNED COPY TO THE COMPLIANCE OFFICER.</div>
      <div style="text-align: center; text-indent: 0.55pt; margin-right: 9.2pt; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; text-indent: 0.55pt; margin-right: 9.2pt; line-height: 1.25; font-weight: bold;">
        <div class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">Page 7</font></div>
      </div>
      <div style="text-align: center; text-indent: 0.55pt; margin-right: 9.2pt; line-height: 1.25; font-weight: bold;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>exhibit_12-1.htm
<DESCRIPTION>EXHIBIT 12-1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit 12.1</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">CERTIFICATION</font>&#160;<font style="font-weight: bold;">PURSUANT TO</font></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">RULE 13a-14(a)/RULE 15d-14(a) UNDER</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE EXCHANGE ACT AND SECTION 302</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">I, Dr. Anat Cohen-Dayag, certify that:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">I have
          reviewed this annual report on Form 20-F of Compugen Ltd.;</font></div>
      <div style="line-height: 1.25; text-align: justify;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Based on
          my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
          respect to the period covered by this report;</font></div>
      <div style="line-height: 1.25; text-align: justify;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">3.</font>&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Based
          on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods
          presented in this report;</font></div>
      <div style="line-height: 1.25; text-align: justify;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">The
          company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in
          Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></div>
      <div style="line-height: 1.25; text-align: justify;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif;">a.</font>&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its
          consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
      <div style="line-height: 1.25; text-align: justify;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif;">b.</font>&#160;&#160; &#160;&#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
          financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
      <div style="line-height: 1.25; text-align: justify;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif;">c.</font>&#160;&#160; &#160; &#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman',Times,serif;">evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period
          covered by this report based on such evaluation; and</font></div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif;">d.</font>&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to
          materially affect, the company's internal control over financial reporting; and</font></div>
      <div style="line-height: 1.25; text-align: justify;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">The
          company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company's board of directors (or persons
          performing the equivalent functions):</font></div>
      <div style="line-height: 1.25; text-align: justify;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif;">a.</font>&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process,
          summarize and report financial information; and</font></div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif;">b.</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Date: March 4, 2025</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;"><u>/s/ Dr. Anat Cohen-Dayag</u></div>
      <div style="line-height: 1.25;">Title: President and Chief Executive Officer</div>
      <div style="line-height: 1.25">&#160;
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>6
<FILENAME>exhibit_12-2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit 12.2</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">AND SECTION 302</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">I, David Silberman, certify that:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this
          annual report on Form 20-F of Compugen Ltd.;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge,
          this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
          period covered by this report;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge,
          the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this
          report;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other
          certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
          Rules 13a-15(f) and 15d-15(f)) for the company and have:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif;">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its
          consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
      <div style="line-height: 1.25; text-indent: 36pt; text-align: justify;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif;">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
          financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
      <div style="line-height: 1.25; text-indent: 36pt; text-align: justify;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif;">c.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period
          covered by this report based on such evaluation; and</font></div>
      <div style="line-height: 1.25; text-indent: 36pt; text-align: justify;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif;">d.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to
          materially affect, the company's internal control over financial reporting; and</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other
          certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company's board of directors (or persons performing the equivalent
          functions):</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all
          significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial
          information; and</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any
          fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Date: March 4, 2025</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><u>/s/ David Silberman</u></div>
      <div style="text-align: justify; line-height: 1.25;">Title: Chief Financial Officer</div>
      <div style="line-height: 1.25">&#160;
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>7
<FILENAME>exhibit_13-1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit 13.1</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">RULE 13a-14(b)/RULE 15d-14(b)</font>&#160;<font style="font-weight: bold;">UNDER THE EXCHANGE ACT</font></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">AND 18 U.S.C. SECTION 1350,</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SECTION 906</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">In connection with the annual report of Compugen Ltd. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December 31, 2024 as filed
      with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company, certify, pursuant to Rule 13a-14(b)/Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended and 18 U.S.C.
      Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to such officer&#8217;s knowledge:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies
        with the requirements of Sections 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained
        in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><u>/s/ Dr. Anat Cohen-Dayag</u></div>
    <div style="text-align: justify; line-height: 1.25;">Title:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;President and Chief
        Executive Officer</div>
    <div style="text-align: justify; line-height: 1.25;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;March 4, 2025</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><u>/s/ David Silberman</u></div>
    <div style="text-align: justify; line-height: 1.25;">Title:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chief Financial
        Officer</div>
    <div style="line-height: 1.25;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;March 4, 2025</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>exhibit_15-1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit 15.1</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 11pt; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">We consent to the incorporation by reference in the following&#160;Registration
          Statements:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zf346c143341c44eb9e7917cfb602e9e8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Registration Statement (Form F-3 333-270985) of Compugen Ltd., and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z437aa876680c411e8bcbfd21790feeda" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Registration Statements (Form S-8 Nos. 333-169239, 333-204869, 333-223937,
                333-240182, 333-251263, 333-266508) pertaining to Compugen Ltd. 2010 Share Incentive Plan and 2021 Employee Share Purchase Plan;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">of our reports dated March 4, 2025, with respect to the consolidated financial statements of Compugen Ltd. and the effectiveness of
        internal control over financial reporting of Compugen Ltd. included in this Annual Report (Form 20-F) of Compugen Ltd. for the year ended December 31, 2024.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z08de3c3784414f99a6758ac2fe304fd0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50.16%; vertical-align: top;">
              <div style="line-height: 1.25;">/s/ KOST FORER GABBAY &amp; KASIERER</div>
              <div style="line-height: 1.25;">A Member Firm of EY Global</div>
              <div style="line-height: 1.25;">Tel-Aviv, Israel</div>
              <div style="line-height: 1.25;">March 4, 2025</div>
            </td>
            <td style="width: 49.84%; vertical-align: top;"><br>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;"></div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cgen-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:cgen="http://cgen.com/20241231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:cyd-af="http://xbrl.sec.gov/cyd-af/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" targetNamespace="http://cgen.com/20241231" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <import namespace="http://fasb.org/us-gaap-ebp/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/ebp/elts/us-gaap-ebp-2024.xsd"/>
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/cyd-af/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cgen.com/role/cgen-daei1" id="cgen-daei1">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cbsp" id="cgen-cbsp">
        <link:definition>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-csocl" id="cgen-csocl">
        <link:definition>0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/StatementsOfChangesInShareholdersEquity" id="StatementsOfChangesInShareholdersEquity">
        <link:definition>0005 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-g" id="cgen-g">
        <link:definition>0007 - Disclosure - GENERAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sap" id="cgen-sap">
        <link:definition>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/MARKETABLESECURITIES" id="MARKETABLESECURITIES">
        <link:definition>0009 - Disclosure - MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTS" id="FAIRVALUEMEASUREMENTS">
        <link:definition>0010 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oarape" id="cgen-oarape">
        <link:definition>0011 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/Leases" id="Leases">
        <link:definition>0012 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-paen" id="cgen-paen">
        <link:definition>0013 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cac1" id="cgen-cac1">
        <link:definition>0014 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-se12" id="cgen-se12">
        <link:definition>0015 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-it" id="cgen-it">
        <link:definition>0016 - Disclosure - TAXES ON INCOME, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-giamc" id="cgen-giamc">
        <link:definition>0017 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-faoin" id="cgen-faoin">
        <link:definition>0018 - Disclosure - FINANCIAL AND OTHER INCOME, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-rpbat" id="cgen-rpbat">
        <link:definition>0019 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-lps" id="cgen-lps">
        <link:definition>0020 - Disclosure - LOSSES PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SUBSEQUENTEVENTS" id="SUBSEQUENTEVENTS">
        <link:definition>0021 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapp" id="cgen-sapp">
        <link:definition>9960701 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapt" id="cgen-sapt">
        <link:definition>9960702 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/MARKETABLESECURITIESTables" id="MARKETABLESECURITIESTables">
        <link:definition>9960703 - Disclosure - MARKETABLE SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTSTables" id="FAIRVALUEMEASUREMENTSTables">
        <link:definition>9960704 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oarapet" id="cgen-oarapet">
        <link:definition>9960705 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesTables" id="LeasesTables">
        <link:definition>9960706 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-paent" id="cgen-paent">
        <link:definition>9960707 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-set1" id="cgen-set1">
        <link:definition>9960708 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-itt" id="cgen-itt">
        <link:definition>9960709 - Disclosure - TAXES ON INCOME, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-giamct" id="cgen-giamct">
        <link:definition>9960710 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-faoint" id="cgen-faoint">
        <link:definition>9960711 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables" id="RelatedPartyBalancesAndTransactionsTables">
        <link:definition>9960712 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-lpst" id="cgen-lpst">
        <link:definition>9960713 - Disclosure - LOSSES PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-gd" id="cgen-gd">
        <link:definition>9960714 - Disclosure - GENERAL (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapnd" id="cgen-sapnd">
        <link:definition>9960715 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapsodrfpaed" id="cgen-sapsodrfpaed">
        <link:definition>9960716 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails" id="SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails">
        <link:definition>9960717 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/MARKETABLESECURITIESNarrativeDetails" id="MARKETABLESECURITIESNarrativeDetails">
        <link:definition>9960718 - Disclosure - MARKETABLE SECURITIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/MARKETABLESECURITIESDetails" id="MARKETABLESECURITIESDetails">
        <link:definition>9960719 - Disclosure - MARKETABLE SECURITIES (Schedule of available-for-sale marketable securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails" id="MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails">
        <link:definition>9960720 - Disclosure - MARKETABLE SECURITIES (Schedule of gross unrealized losses and fair values on investments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails" id="FAIRVALUEMEASUREMENTSDetails">
        <link:definition>9960721 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oaraped" id="cgen-oaraped">
        <link:definition>9960722 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Schedule Of Other Accounts Receivable And Prepaid Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LEASESNarrative" id="LEASESNarrative">
        <link:definition>9960723 - Disclosure - LEASES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails" id="LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails">
        <link:definition>9960724 - Disclosure - LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails" id="LeasesScheduleOfOperatingLeasesDetails">
        <link:definition>9960725 - Disclosure - LEASES (Schedule of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" id="PROPERTYANDEQUIPMENTNETNarrativeDetails">
        <link:definition>9960726 - Disclosure - PROPERTY AND EQUIPMENT, NET (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-paend" id="cgen-paend">
        <link:definition>9960727 - Disclosure - PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>9960728 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sesopnd" id="cgen-sesopnd">
        <link:definition>9960729 - Disclosure - SHAREHOLDERS' EQUITY  (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails" id="ShareholdersEquityScheduleOfOptionActivityDetails">
        <link:definition>9960730 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Share Option Plan) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails" id="SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails">
        <link:definition>9960731 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of RSUs Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sesosced" id="cgen-sesosced">
        <link:definition>9960732 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock-Based Compensation Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesNarrativeDetails" id="IncomeTaxesNarrativeDetails">
        <link:definition>9960733 - Disclosure - TAXES ON INCOME, NET (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails" id="IncomeTaxesScheduleOfLossBeforeTaxesDetails">
        <link:definition>9960734 - Disclosure - TAXES ON INCOME, NET (Schedule of Loss (Income) Before Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>9960735 - Disclosure - TAXES ON INCOME, NET (Schedule of Deferred Tax Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails" id="GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails">
        <link:definition>9960736 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails" id="SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails">
        <link:definition>9960737 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Financial Information With Respect To Single Operating Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails" id="GeographicInformationAndMajorCustomersDetails">
        <link:definition>9960738 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Total Revenues And Long-Lived Assets By Geographic Area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details" id="SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details">
        <link:definition>9960739 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Sales To Single Customer Exceeding 10%) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails" id="FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails">
        <link:definition>9960740 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails" id="RelatedPartyBalancesAndTransactionsDetails">
        <link:definition>9960741 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Schedule of Related Party Transactions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails" id="LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails">
        <link:definition>9960742 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SubsequentEventsNarrativeDetails" id="SubsequentEventsNarrativeDetails">
        <link:definition>9960743 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccruedMilestonePayment" id="cgen_AccruedMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AccruedMilestonePayments" id="cgen_AccruedMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" id="cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AggregateLimitOfOrdinarySharesPerCalendarYear" id="cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementStartDate" id="cgen_AgreementStartDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementTerminationDescription" id="cgen_AgreementTerminationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" id="cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" id="cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AnnualDepreciationRate" id="cgen_AnnualDepreciationRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualDepreciationRateDescription" id="cgen_AnnualDepreciationRateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AntibodiesDiscoveryCollaborationAgreementMember" id="cgen_AntibodiesDiscoveryCollaborationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" id="cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" id="cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" id="cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" id="cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" id="cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" id="cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClinicalAmountOfExpenseForResearchAndDevelopment" id="cgen_ClinicalAmountOfExpenseForResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CollaborativeArrangementsMember" id="cgen_CollaborativeArrangementsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborativeArrangementsTwoMember" id="cgen_CollaborativeArrangementsTwoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContingentFees" id="cgen_ContingentFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CostOfSalesContractWithCustomerPolicyTextBlock" id="cgen_CostOfSalesContractWithCustomerPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CustomerOneMember" id="cgen_CustomerOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CustomerTwoMember" id="cgen_CustomerTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DeferredIncomeTaxLeaseLiabilities" id="cgen_DeferredIncomeTaxLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredIncomeTaxRightOfUseAssets" id="cgen_DeferredIncomeTaxRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredParticipationOfBMSInRAndDExpenses" id="cgen_DeferredParticipationOfBMSInRAndDExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DeferredRevenuesIncludedInCurrentLiabilities" id="cgen_DeferredRevenuesIncludedInCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DeferredRevenuesIncludedInNonCurrentLiabilities" id="cgen_DeferredRevenuesIncludedInNonCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" id="cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DerivativeRelatedExpense" id="cgen_DerivativeRelatedExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" id="cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesAndDirectorsMember" id="cgen_EmployeesAndDirectorsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesDirectorsAndNonEmployeesMember" id="cgen_EmployeesDirectorsAndNonEmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeeStockPurchasePlanMember" id="cgen_EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExtendLease" id="cgen_ExtendLease" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancialIncomeExpenseNet" id="cgen_FinancialIncomeExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="GileadAgreementMember" id="cgen_GileadAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAndOtherGrantsAxis" id="cgen_GovernmentAndOtherGrantsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="GovernmentAndOtherGrantsDomain" id="cgen_GovernmentAndOtherGrantsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAuthorities" id="cgen_GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseInDeferredRevenues" id="cgen_IncreaseDecreaseInDeferredRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" id="cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseOperatingLeaseRightOfUseAsset" id="cgen_IncreaseOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InterestPaidReceivedNet" id="cgen_InterestPaidReceivedNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IssuanceOfSharesAndWarrantsNetShares" id="cgen_IssuanceOfSharesAndWarrantsNetShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfSharesAndWarrantsNetValue" id="cgen_IssuanceOfSharesAndWarrantsNetValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="JmpSecuritiesLlcMember" id="cgen_JmpSecuritiesLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LaboratoryEquipmentAndOfficeFurnitureMember" id="cgen_LaboratoryEquipmentAndOfficeFurnitureMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LeerinkPartnersLlcMember" id="cgen_LeerinkPartnersLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAgreementWithGileadMember" id="cgen_LicenseAgreementWithGileadMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseRevenue" id="cgen_LicenseRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LongTermDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MasterClinicalAgreementMember" id="cgen_MasterClinicalAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MasterClinicalAgreementOneMember" id="cgen_MasterClinicalAgreementOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MasterClinicalAgreementTwoMember" id="cgen_MasterClinicalAgreementTwoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MaximumAuthorizedProceedsFromIssuanceOfCommonStock" id="cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MaximumRoyaltyRepaidAsPercentageOfGrantReceived" id="cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="May2012AgreementMember" id="cgen_May2012AgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MilestonePaymentReceivable" id="cgen_MilestonePaymentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" id="cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NetOperatingLossCarryforwardExpired" id="cgen_NetOperatingLossCarryforwardExpired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NonRefundableUpfrontPayment" id="cgen_NonRefundableUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" id="cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsExercised" id="cgen_NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" id="cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OrdinarySharesIssuedAndSoldThroughAtmMember" id="cgen_OrdinarySharesIssuedAndSoldThroughAtmMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherAccountsReceivableAndPrepaidExpensesTextBlock" id="cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherSegmentExpenses" id="cgen_OtherSegmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ParticipationRights" id="cgen_ParticipationRights" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" id="cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PercentageOfClosingPrice" id="cgen_PercentageOfClosingPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfConsolidatedRevenuesOfCollaborator" id="cgen_PercentageOfConsolidatedRevenuesOfCollaborator" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfExpectedFromPaymentAmountPaid" id="cgen_PercentageOfExpectedFromPaymentAmountPaid" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" id="cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" id="cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PeriodSinceApprovalWasGranted" id="cgen_PeriodSinceApprovalWasGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PeriodSinceEnterpriseBeganOperating" id="cgen_PeriodSinceEnterpriseBeganOperating" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PreclinicalAmountOfExpenseForResearchAndDevelopment" id="cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PurchaseOfPropertyAndEquipmentAsNonCashTransaction" id="cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReceivablesOnAccountOfShares" id="cgen_ReceivablesOnAccountOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" id="cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReducedCorporateIncomeTaxRate" id="cgen_ReducedCorporateIncomeTaxRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReducedTaxRate" id="cgen_ReducedTaxRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RegisteredDirectOfferingMember" id="cgen_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RemainingPerformanceObligationsRecognizedPercentage" id="cgen_RemainingPerformanceObligationsRecognizedPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentExpensesMember" id="cgen_ResearchAndDevelopmentExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ResearchAndDevelopmentExpensesMilestonePayment" id="cgen_ResearchAndDevelopmentExpensesMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" id="cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentGrantOneMember" id="cgen_ResearchAndDevelopmentGrantOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RetainerFee" id="cgen_RetainerFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RoyaltyContingentObligations" id="cgen_RoyaltyContingentObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RoyaltyPercentage" id="cgen_RoyaltyPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyPercentageBasedOnFutureRevenues" id="cgen_RoyaltyPercentageBasedOnFutureRevenues" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SalesAgreementWithSVBSecuritiesLLCMember" id="cgen_SalesAgreementWithSVBSecuritiesLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" id="cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfWeightedAverageAssumptionsForGrantedOptions" id="cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" id="cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SegmentReportingGeograhicAreaLineItems" id="cgen_SegmentReportingGeograhicAreaLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SegmentReportingGeographicAreaAxis" id="cgen_SegmentReportingGeographicAreaAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="SegmentReportingGeographicAreaDomain" id="cgen_SegmentReportingGeographicAreaDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SegmentReportingGeographicAreaTable" id="cgen_SegmentReportingGeographicAreaTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="ServerancePayPolicyTextBlock" id="cgen_ServerancePayPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeverancePayFundNoncurrent" id="cgen_SeverancePayFundNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SeverancePayNet" id="cgen_SeverancePayNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" id="cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" id="cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock" id="cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermBankDepositsPolicyTextBlock" id="cgen_ShortTermBankDepositsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermBankDepositsWeightedAverageRateForeign" id="cgen_ShortTermBankDepositsWeightedAverageRateForeign" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SingleOperatingSegmentMember" id="cgen_SingleOperatingSegmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" id="cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueWarrantsExercised" id="cgen_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SupplementalRightOfUseAssetAndOperatingLeaseLiability" id="cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SvbLeerinkLlcAndStifelNicolausAndCompanyMember" id="cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxExemptPeriod" id="cgen_TaxExemptPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxRateOnDistributions" id="cgen_TaxRateOnDistributions" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TotalRemainingPerformanceObligations" id="cgen_TotalRemainingPerformanceObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TwoThousandAndTwoThousandTenOptionsPlanMember" id="cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandTenShareOptionsPlanMember" id="cgen_TwoThousandTenShareOptionsPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnderwritersMember" id="cgen_UnderwritersMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>cgen-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#ConsolidatedBalanceSheets" roleURI="http://cgen.com/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-csocl" roleURI="http://cgen.com/role/cgen-csocl"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-oaraped" roleURI="http://cgen.com/role/cgen-oaraped"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#LeasesScheduleOfOperatingLeasesDetails" roleURI="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-paend" roleURI="http://cgen.com/role/cgen-paend"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#IncomeTaxesScheduleOfLossBeforeTaxesDetails" roleURI="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails" roleURI="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_OtherShortTermInvestments_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_ReceivablesNetCurrent_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_8" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_cgen_SeverancePayFundNoncurrent_10" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_11" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_12" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14" xlink:to="loc_us-gaap_LiabilitiesCurrent_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_us-gaap_AccountsPayableCurrent_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_us-gaap_DeferredRevenueCurrent_16" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_17" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_18" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_19" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_21" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_21" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_21" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_22" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14" xlink:to="loc_us-gaap_StockholdersEquity_25" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25" xlink:to="loc_us-gaap_CommonStockValue_25" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_26" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_13"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_OperatingIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_GrossProfit_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_BusinessDevelopment_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_cgen_FinancialIncomeExpenseNet_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_13" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_SeverancePayNet_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_5" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6" order="50" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_7" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_8" order="70" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9" order="80" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_10" order="90" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_11" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_12" order="110" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_13" order="120" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInDeferredRevenues_14" order="130" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_15" order="140" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_16" order="150" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_18" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_19" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_20" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_21" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_22" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_23" order="50" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_24" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_25" order="70" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_28" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oaraped">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GovernmentAuthorities" xlink:label="loc_cgen_GovernmentAuthorities_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_3"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_cgen_GovernmentAuthorities_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_OtherAssetsCurrent_3" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paend">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_9"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_cgen_DeferredIncomeTaxLeaseLiabilities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_9" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9" xlink:to="loc_cgen_DeferredIncomeTaxRightOfUseAssets_9" order="0" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails">
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_5"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_InterestAndDebtExpense_3" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_5" order="40" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>cgen-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-daei1" roleURI="http://cgen.com/role/cgen-daei1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#StatementsOfChangesInShareholdersEquity" roleURI="http://cgen.com/role/StatementsOfChangesInShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-sapnd" roleURI="http://cgen.com/role/cgen-sapnd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-sapsodrfpaed" roleURI="http://cgen.com/role/cgen-sapsodrfpaed"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails" roleURI="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-paend" roleURI="http://cgen.com/role/cgen-paend"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-sesopnd" roleURI="http://cgen.com/role/cgen-sesopnd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#ShareholdersEquityScheduleOfOptionActivityDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-sesosced" roleURI="http://cgen.com/role/cgen-sesosced"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#IncomeTaxesNarrativeDetails" roleURI="http://cgen.com/role/IncomeTaxesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#GeographicInformationAndMajorCustomersDetails" roleURI="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#SubsequentEventsNarrativeDetails" roleURI="http://cgen.com/role/SubsequentEventsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#PROPERTYANDEQUIPMENTNETNarrativeDetails" roleURI="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#MARKETABLESECURITIESDetails" roleURI="http://cgen.com/role/MARKETABLESECURITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#FAIRVALUEMEASUREMENTSDetails" roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails" roleURI="http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails" roleURI="http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details" roleURI="http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-daei1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_dei_OtherReportingStandardItemNumber_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_50"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1" xlink:to="loc_dei_BusinessContactMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentDescription_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentRegistrationStatement_13" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentAnnualReport_14" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentTransitionReport_15" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentShellCompanyReport_16" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_17" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFileNumber_18" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_ContactPersonnelName_19" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_20" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_21" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine1_22" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine2_23" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine3_24" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressCityOrTown_25" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressCountry_26" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressPostalZipCode_27" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CityAreaCode_28" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_LocalPhoneNumber_29" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_ContactPersonnelFaxNumber_30" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_ContactPersonnelEmailAddress_31" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_Security12bTitle_32" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_33" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_SecurityExchangeName_34" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_35" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_36" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_37" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_38" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_39" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_40" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_41" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_42" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityExTransitionPeriod_43" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentAccountingStandard_44" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_OtherReportingStandardItemNumber_45" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityShellCompany_46" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorName_47" order="420" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorLocation_48" order="430" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorFirmId_49" order="440" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_50" order="450" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/StatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_13" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_14" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_15" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_NumberOfWarrantsExercised_16" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_17" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_18" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_19" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_21" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_23" order="150" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="loc_cgen_MasterClinicalAgreementOneMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="loc_cgen_MasterClinicalAgreementTwoMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LicenseAgreementWithGileadMember" xlink:label="loc_cgen_LicenseAgreementWithGileadMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="loc_us-gaap_ImpairmentOfInvestments_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:label="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TotalRemainingPerformanceObligations" xlink:label="loc_cgen_TotalRemainingPerformanceObligations_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RemainingPerformanceObligationsRecognizedPercentage" xlink:label="loc_cgen_RemainingPerformanceObligationsRecognizedPercentage_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AccruedMilestonePayments" xlink:label="loc_cgen_AccruedMilestonePayments_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LicenseRevenue" xlink:label="loc_cgen_LicenseRevenue_35"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredRevenuesIncludedInCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_36"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredRevenuesIncludedInNonCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_37"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_38"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementOneMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementTwoMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_LicenseAgreementWithGileadMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7" xlink:to="loc_us-gaap_StockOptionMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentForAmortization_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ImpairmentOfInvestments_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DeferredRevenue_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_16" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_17" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_18" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SeveranceCosts1_19" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_20" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_21" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_22" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_TotalRemainingPerformanceObligations_23" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_RemainingPerformanceObligationsRecognizedPercentage_24" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DerivativeRelatedExpense_25" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_26" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_27" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_28" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_29" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_30" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_31" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_AccruedMilestonePayments_32" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_33" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_34" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_LicenseRevenue_35" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_36" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_37" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_MilestonePaymentReceivable_38" order="270" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapsodrfpaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AnnualDepreciationRate" xlink:label="loc_cgen_AnnualDepreciationRate_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_srt_RangeAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7" xlink:to="loc_srt_RangeMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7" xlink:to="loc_srt_MinimumMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7" xlink:to="loc_srt_MaximumMember_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_cgen_AnnualDepreciationRate_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_cgen_AnnualDepreciationRateDescription_14" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_cgen_EmployeeStockPurchasePlanMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6" xlink:to="loc_srt_RangeMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MinimumMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MaximumMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_15" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paend">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AntibodiesDiscoveryCollaborationAgreementMember" xlink:label="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GileadAgreementMember" xlink:label="loc_cgen_GileadAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_29"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_ResearchAndDevelopmentGrantOneMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_May2012AgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_GileadAgreementMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_RangeAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8" xlink:to="loc_srt_RangeMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8" xlink:to="loc_srt_MinimumMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8" xlink:to="loc_srt_MaximumMember_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_RoyaltyExpense_17" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_RoyaltyContingentObligations_18" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_19" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ParticipationRights_20" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_RetainerFee_21" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_22" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_AgreementStartDate_23" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_AgreementTerminationDescription_24" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ExtendLease_25" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ContingentFees_26" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_27" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_RoyaltyPercentage_28" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_29" order="160" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesopnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_JmpSecuritiesLlcMember" xlink:label="loc_cgen_JmpSecuritiesLlcMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LeerinkPartnersLlcMember" xlink:label="loc_cgen_LeerinkPartnersLlcMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TwoThousandTenShareOptionsPlanMember" xlink:label="loc_cgen_TwoThousandTenShareOptionsPlanMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_39"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_44"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_48"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_49"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InitialOfferingPeriod" xlink:label="loc_us-gaap_InitialOfferingPeriod_52"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_53"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_54"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_55"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_CollaborativeArrangementsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_CollaborativeArrangementsTwoMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_JmpSecuritiesLlcMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_LeerinkPartnersLlcMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_cgen_RegisteredDirectOfferingMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_WarrantMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_cgen_UnderwritersMember_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_cgen_TwoThousandTenShareOptionsPlanMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" xlink:to="loc_us-gaap_EmployeeStockMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24" xlink:to="loc_us-gaap_RelatedPartyDomain_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_24" xlink:to="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_29" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_30" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_31" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_32" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_34" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_36" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_37" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_38" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_39" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_40" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_41" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_42" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_43" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_44" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_45" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_46" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_47" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_48" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_PercentageOfClosingPrice_49" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_50" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_51" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_InitialOfferingPeriod_52" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_53" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_54" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_55" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56" order="280" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_22" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesosced">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7" xlink:to="loc_us-gaap_EmployeeStockMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_12" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="loc_cgen_NetOperatingLossCarryforwardExpired_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="loc_cgen_ReducedCorporateIncomeTaxRate_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ReducedTaxRate" xlink:label="loc_cgen_ReducedTaxRate_20"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_DomesticCountryMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6" xlink:to="loc_us-gaap_RelatedPartyDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_us-gaap_SubsidiaryOfCommonParentMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeTaxesPaid_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_NetOperatingLossCarryforwardExpired_17" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_18" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ReducedCorporateIncomeTaxRate_19" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ReducedTaxRate_20" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="loc_cgen_SegmentReportingGeographicAreaAxis_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="loc_cgen_SegmentReportingGeographicAreaDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_country_IL_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="loc_cgen_SegmentReportingGeographicAreaDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_srt_EuropeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_country_IL_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_country_US_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_Revenues_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_NoncurrentAssets_9" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/SubsequentEventsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OrdinarySharesIssuedAndSoldThroughAtmMember" xlink:label="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_12" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_EquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_Depreciation_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_12" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIESDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_10" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_10" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_15" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_15" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_15" order="0" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_12" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SingleOperatingSegmentMember" xlink:label="loc_cgen_SingleOperatingSegmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment" xlink:label="loc_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ClinicalAmountOfExpenseForResearchAndDevelopment" xlink:label="loc_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OtherSegmentExpenses" xlink:label="loc_cgen_OtherSegmentExpenses_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="loc_us-gaap_SegmentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1" xlink:to="loc_cgen_SingleOperatingSegmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="loc_us-gaap_SegmentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_Revenues_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_cgen_OtherSegmentExpenses_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="80" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CustomerTwoMember" xlink:label="loc_cgen_CustomerTwoMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:to="loc_us-gaap_SalesRevenueNetMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_srt_MajorCustomersAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9" xlink:to="loc_srt_NameOfMajorCustomerDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9" xlink:to="loc_cgen_CustomerOneMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9" xlink:to="loc_cgen_CustomerTwoMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9" xlink:to="loc_srt_NameOfMajorCustomerDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_15" order="10" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>cgen-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AccruedMilestonePayments" xlink:label="loc_cgen_AccruedMilestonePayments_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AccruedMilestonePayments" xlink:label="loc_cgen_AccruedMilestonePayments_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AccruedMilestonePayments" xlink:label="loc_cgen_AccruedMilestonePayments_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AnnualDepreciationRate" xlink:label="loc_cgen_AnnualDepreciationRate_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AnnualDepreciationRate" xlink:label="loc_cgen_AnnualDepreciationRate_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AntibodiesDiscoveryCollaborationAgreementMember" xlink:label="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AntibodiesDiscoveryCollaborationAgreementMember" xlink:label="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_35"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_36"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_37"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_39"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_40"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_41"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_42"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_43"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_44"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_45"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_46"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_47"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_48"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_49"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_50"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ClinicalAmountOfExpenseForResearchAndDevelopment" xlink:label="loc_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_51"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ClinicalAmountOfExpenseForResearchAndDevelopment" xlink:label="loc_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_52"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ClinicalAmountOfExpenseForResearchAndDevelopment" xlink:label="loc_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_53"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_54"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_55"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_56"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_57"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_58"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_59"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_60"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_61"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_62"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_63"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_64"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_65"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_66"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CustomerTwoMember" xlink:label="loc_cgen_CustomerTwoMember_67"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CustomerTwoMember" xlink:label="loc_cgen_CustomerTwoMember_68"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CustomerTwoMember" xlink:label="loc_cgen_CustomerTwoMember_69"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_70"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_71"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_72"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_73"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_74"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_75"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_76"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_77"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_78"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredRevenuesIncludedInCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_79"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredRevenuesIncludedInCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_80"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredRevenuesIncludedInCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_81"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredRevenuesIncludedInNonCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_82"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredRevenuesIncludedInNonCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_83"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredRevenuesIncludedInNonCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_84"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_85"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_86"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_87"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_88"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_89"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_90"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_91"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_92"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_93"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeesAndDirectorsMember" xlink:label="loc_cgen_EmployeesAndDirectorsMember_94"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeesAndDirectorsMember" xlink:label="loc_cgen_EmployeesAndDirectorsMember_95"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_96"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_97"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_98"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_99"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_100"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_101"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_102"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_103"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_104"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_105"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_106"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_107"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_108"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_109"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GileadAgreementMember" xlink:label="loc_cgen_GileadAgreementMember_110"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GileadAgreementMember" xlink:label="loc_cgen_GileadAgreementMember_111"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GileadAgreementMember" xlink:label="loc_cgen_GileadAgreementMember_112"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_113"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_114"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GovernmentAuthorities" xlink:label="loc_cgen_GovernmentAuthorities_115"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GovernmentAuthorities" xlink:label="loc_cgen_GovernmentAuthorities_116"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_117"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_118"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_119"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_120"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_121"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_122"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_123"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_124"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_125"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_126"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_127"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_128"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_InterestPaidReceivedNet" xlink:label="loc_cgen_InterestPaidReceivedNet_129"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_InterestPaidReceivedNet" xlink:label="loc_cgen_InterestPaidReceivedNet_130"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_InterestPaidReceivedNet" xlink:label="loc_cgen_InterestPaidReceivedNet_131"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_132"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_133"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_134"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_135"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_136"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_137"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_JmpSecuritiesLlcMember" xlink:label="loc_cgen_JmpSecuritiesLlcMember_138"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_JmpSecuritiesLlcMember" xlink:label="loc_cgen_JmpSecuritiesLlcMember_139"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_JmpSecuritiesLlcMember" xlink:label="loc_cgen_JmpSecuritiesLlcMember_140"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_141"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_142"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LeerinkPartnersLlcMember" xlink:label="loc_cgen_LeerinkPartnersLlcMember_143"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LeerinkPartnersLlcMember" xlink:label="loc_cgen_LeerinkPartnersLlcMember_144"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LeerinkPartnersLlcMember" xlink:label="loc_cgen_LeerinkPartnersLlcMember_145"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LicenseAgreementWithGileadMember" xlink:label="loc_cgen_LicenseAgreementWithGileadMember_146"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LicenseAgreementWithGileadMember" xlink:label="loc_cgen_LicenseAgreementWithGileadMember_147"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LicenseRevenue" xlink:label="loc_cgen_LicenseRevenue_148"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LicenseRevenue" xlink:label="loc_cgen_LicenseRevenue_149"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LicenseRevenue" xlink:label="loc_cgen_LicenseRevenue_150"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_151"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_152"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_153"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_154"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_155"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="loc_cgen_MasterClinicalAgreementOneMember_156"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="loc_cgen_MasterClinicalAgreementOneMember_157"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="loc_cgen_MasterClinicalAgreementTwoMember_158"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="loc_cgen_MasterClinicalAgreementTwoMember_159"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_160"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_161"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_162"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_163"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_164"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_165"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_166"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_167"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_168"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_169"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_170"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_171"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_172"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_173"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_174"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="loc_cgen_NetOperatingLossCarryforwardExpired_175"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="loc_cgen_NetOperatingLossCarryforwardExpired_176"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NonRefundableUpfrontPayment" xlink:label="loc_cgen_NonRefundableUpfrontPayment_177"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NonRefundableUpfrontPayment" xlink:label="loc_cgen_NonRefundableUpfrontPayment_178"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NonRefundableUpfrontPayment" xlink:label="loc_cgen_NonRefundableUpfrontPayment_179"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_180"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_181"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_182"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_183"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_184"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_185"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_186"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_187"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OrdinarySharesIssuedAndSoldThroughAtmMember" xlink:label="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_188"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OrdinarySharesIssuedAndSoldThroughAtmMember" xlink:label="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_189"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OrdinarySharesIssuedAndSoldThroughAtmMember" xlink:label="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_190"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_191"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_192"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_193"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OtherSegmentExpenses" xlink:label="loc_cgen_OtherSegmentExpenses_194"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OtherSegmentExpenses" xlink:label="loc_cgen_OtherSegmentExpenses_195"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OtherSegmentExpenses" xlink:label="loc_cgen_OtherSegmentExpenses_196"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_197"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_198"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_199"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_200"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_201"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_202"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_203"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_204"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_205"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_206"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_207"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_208"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfExpectedFromPaymentAmountPaid" xlink:label="loc_cgen_PercentageOfExpectedFromPaymentAmountPaid_209"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfExpectedFromPaymentAmountPaid" xlink:label="loc_cgen_PercentageOfExpectedFromPaymentAmountPaid_210"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfExpectedFromPaymentAmountPaid" xlink:label="loc_cgen_PercentageOfExpectedFromPaymentAmountPaid_211"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_212"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_213"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_214"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_215"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PeriodSinceApprovalWasGranted" xlink:label="loc_cgen_PeriodSinceApprovalWasGranted_216"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PeriodSinceApprovalWasGranted" xlink:label="loc_cgen_PeriodSinceApprovalWasGranted_217"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PeriodSinceEnterpriseBeganOperating" xlink:label="loc_cgen_PeriodSinceEnterpriseBeganOperating_218"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PeriodSinceEnterpriseBeganOperating" xlink:label="loc_cgen_PeriodSinceEnterpriseBeganOperating_219"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment" xlink:label="loc_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_220"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment" xlink:label="loc_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_221"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment" xlink:label="loc_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_222"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_223"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_224"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_225"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_226"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_227"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_228"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_229"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_230"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_231"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="loc_cgen_ReducedCorporateIncomeTaxRate_232"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="loc_cgen_ReducedCorporateIncomeTaxRate_233"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ReducedTaxRate" xlink:label="loc_cgen_ReducedTaxRate_234"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ReducedTaxRate" xlink:label="loc_cgen_ReducedTaxRate_235"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_236"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_237"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RemainingPerformanceObligationsRecognizedPercentage" xlink:label="loc_cgen_RemainingPerformanceObligationsRecognizedPercentage_238"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RemainingPerformanceObligationsRecognizedPercentage" xlink:label="loc_cgen_RemainingPerformanceObligationsRecognizedPercentage_239"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RemainingPerformanceObligationsRecognizedPercentage" xlink:label="loc_cgen_RemainingPerformanceObligationsRecognizedPercentage_240"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_241"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_242"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_243"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_244"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_245"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_246"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_247"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_248"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_249"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentExpensesMember" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMember_250"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentExpensesMember" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMember_251"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_252"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_253"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_254"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_255"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_256"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_257"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_258"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_259"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_260"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_261"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_262"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_263"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_264"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_265"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_266"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_267"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_268"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_269"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_270"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_271"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_272"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SalesAgreementWithSVBSecuritiesLLCMember" xlink:label="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_273"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SalesAgreementWithSVBSecuritiesLLCMember" xlink:label="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_274"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SalesAgreementWithSVBSecuritiesLLCMember" xlink:label="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_275"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_276"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_277"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_278"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" xlink:label="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_279"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" xlink:label="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_280"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" xlink:label="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_281"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" xlink:label="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_282"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" xlink:label="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_283"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" xlink:label="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_284"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SegmentReportingGeograhicAreaLineItems" xlink:label="loc_cgen_SegmentReportingGeograhicAreaLineItems_285"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SegmentReportingGeograhicAreaLineItems" xlink:label="loc_cgen_SegmentReportingGeograhicAreaLineItems_286"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="loc_cgen_SegmentReportingGeographicAreaAxis_287"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="loc_cgen_SegmentReportingGeographicAreaAxis_288"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="loc_cgen_SegmentReportingGeographicAreaDomain_289"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SegmentReportingGeographicAreaTable" xlink:label="loc_cgen_SegmentReportingGeographicAreaTable_290"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SegmentReportingGeographicAreaTable" xlink:label="loc_cgen_SegmentReportingGeographicAreaTable_291"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="loc_cgen_ServerancePayPolicyTextBlock_292"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="loc_cgen_ServerancePayPolicyTextBlock_293"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="loc_cgen_ServerancePayPolicyTextBlock_294"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_295"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_296"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_297"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_298"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_299"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_300"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_301"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_302"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_303"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_304"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_305"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_306"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_307"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_308"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_309"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsPolicyTextBlock_310"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsPolicyTextBlock_311"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsPolicyTextBlock_312"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_313"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_314"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_315"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_316"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_317"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_318"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SingleOperatingSegmentMember" xlink:label="loc_cgen_SingleOperatingSegmentMember_319"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SingleOperatingSegmentMember" xlink:label="loc_cgen_SingleOperatingSegmentMember_320"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_321"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_322"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_323"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_324"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_325"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_326"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_327"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_328"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_329"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_330"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_331"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_332"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TaxExemptPeriod" xlink:label="loc_cgen_TaxExemptPeriod_333"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TaxExemptPeriod" xlink:label="loc_cgen_TaxExemptPeriod_334"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TaxRateOnDistributions" xlink:label="loc_cgen_TaxRateOnDistributions_335"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TaxRateOnDistributions" xlink:label="loc_cgen_TaxRateOnDistributions_336"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TotalRemainingPerformanceObligations" xlink:label="loc_cgen_TotalRemainingPerformanceObligations_337"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TotalRemainingPerformanceObligations" xlink:label="loc_cgen_TotalRemainingPerformanceObligations_338"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TotalRemainingPerformanceObligations" xlink:label="loc_cgen_TotalRemainingPerformanceObligations_339"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_340"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_341"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_342"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TwoThousandTenShareOptionsPlanMember" xlink:label="loc_cgen_TwoThousandTenShareOptionsPlanMember_343"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TwoThousandTenShareOptionsPlanMember" xlink:label="loc_cgen_TwoThousandTenShareOptionsPlanMember_344"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TwoThousandTenShareOptionsPlanMember" xlink:label="loc_cgen_TwoThousandTenShareOptionsPlanMember_345"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_346"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_country_IL_348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_dei_OtherReportingStandardItemNumber_395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:label="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="loc_us-gaap_ImpairmentOfInvestments_593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InitialOfferingPeriod" xlink:label="loc_us-gaap_InitialOfferingPeriod_626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_667"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_668"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_669"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_670"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_671"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_672"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_673"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_674"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_675"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_676"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_677"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_678"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_679"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_680"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_681"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_683"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_684"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_685"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_686"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_687"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_688"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_689"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_690"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_691"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_692"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_693"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_694"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_695"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_696"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_697"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_698"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_699"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_700"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_701"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_702"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_703"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_704"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_705"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_706"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_707"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_708"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_709"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_710"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_711"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_712"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_713"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_714"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_715"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_716"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_717"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_718"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_719"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_720"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_721"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_722"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_723"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_724"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_725"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_726"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_727"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_728"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_729"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_730"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_731"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_732"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_733"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_734"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_735"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_736"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="loc_us-gaap_PaymentsForProceedsFromProductiveAssets_737"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="loc_us-gaap_PaymentsForProceedsFromProductiveAssets_738"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_739"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_740"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_741"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_742"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_743"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_744"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_745"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_746"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_747"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_748"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_749"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_750"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_751"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_752"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_753"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_754"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_755"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_756"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_757"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_758"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_759"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_760"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_761"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_762"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_763"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_764"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_765"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_766"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_767"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_768"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_769"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_770"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_771"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_772"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_773"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_774"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_775"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_776"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_777"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_778"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_779"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_780"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_781"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_782"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_783"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_784"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_785"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_786"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_787"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_788"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_789"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_790"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_791"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_792"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_793"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_794"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_795"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_796"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_797"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_798"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_799"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_800"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_801"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_802"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_803"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_804"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_805"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_806"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_807"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_808"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_809"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_810"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_811"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_812"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_813"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_814"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_815"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_816"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_817"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_818"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_819"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_820"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_821"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_822"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_823"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_824"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_825"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_826"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_827"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_828"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_829"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_830"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_831"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_832"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_833"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_834"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_835"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_836"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_837"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_838"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_839"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_840"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_841"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_842"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_843"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_844"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_845"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_846"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_847"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_848"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_849"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_850"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_851"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_852"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_853"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_854"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_855"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_856"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_857"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_858"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_859"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_860"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_861"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_862"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_863"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_864"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_865"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_866"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_867"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_868"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_869"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_870"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_871"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_872"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_873"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_874"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_875"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_876"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_877"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_878"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_879"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_880"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_881"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_882"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_883"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_884"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_885"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_886"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_887"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_888"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_889"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_890"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_891"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_892"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_893"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_894"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_895"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_896"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_897"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_898"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_899"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_900"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_901"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_902"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_903"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_904"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_905"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_906"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_907"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_908"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_909"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_910"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_911"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_912"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_913"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_914"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_915"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_916"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_917"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_918"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_919"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_920"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_921"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_922"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_923"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_924"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_925"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_926"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_927"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_928"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_929"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_930"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_931"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_932"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_933"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_934"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_935"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_936"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_937"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_938"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_939"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_940"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_941"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_942"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_943"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_944"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_945"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_946"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_947"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_948"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_949"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_950"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_951"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_952"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_953"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_954"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_955"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_956"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_957"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_958"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_959"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_960"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_961"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_962"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_963"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_964"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_965"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_966"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_967"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_968"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_969"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_970"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_971"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_972"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_973"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_974"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_975"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_976"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_977"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_978"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_979"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_980"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_981"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_982"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_983"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_984"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_985"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_986"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_987"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaap_VariableLeasePayment_988"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaap_VariableLeasePayment_989"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_990"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_991"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_992"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_993"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_994"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_995"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AccruedMilestonePayment_0" xml:lang="en-US">The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AccruedMilestonePayment_1" xml:lang="en-US">Accrued milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AccruedMilestonePayments_0" xml:lang="en-US">Accrued Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AccruedMilestonePayments_1" xml:lang="en-US">Amount of accrued milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AccruedMilestonePayments_2" xml:lang="en-US">Accrued milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_0" xml:lang="en-US">Adjustment For Exchange Rate Differences Loss (Gain) On Cash Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_1" xml:lang="en-US">Adjustment for Exchange rate differences loss (gain) on cash balances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_2" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_3" xml:lang="en-US">Foreign currency transaction adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_4" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_5" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_0" xml:lang="en-US">Aggregate limit of ordinary shares per calendar year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_1" xml:lang="en-US">Aggregate limit of ordinary shares per calendar year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementStartDate_0" xml:lang="en-US">Agreement start date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementStartDate_1" xml:lang="en-US">Agreement Start Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_AgreementStartDate_2" xml:lang="en-US">Agreement, start date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementTerminationDescription_0" xml:lang="en-US">Description of termination of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementTerminationDescription_1" xml:lang="en-US">Agreement Termination Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_AgreementTerminationDescription_2" xml:lang="en-US">Agreement termination description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_0" xml:lang="en-US">Amortization Of Cash Consideration Of Research And Development Funding Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_1" xml:lang="en-US">Decrease (increase) in interest receivables from short-term bank deposits and long-term restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_2" xml:lang="en-US">Amortization Of Cash Consideration Of Research And Development Funding Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_3" xml:lang="en-US">Amortization research and development component</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_0" xml:lang="en-US">Amortization Of Discount And Accrued Interest On Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_1" xml:lang="en-US">Represent the amount of Amortization of discount and accrued interest on marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_2" xml:lang="en-US">Amortization of discount and accrued interest on marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AnnualDepreciationRate_0" xml:lang="en-US">Annual Depreciation Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AnnualDepreciationRate_1" xml:lang="en-US">Annual depreciation rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AnnualDepreciationRateDescription_0" xml:lang="en-US">Annual Depreciation Rates, Description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AnnualDepreciationRateDescription_1" xml:lang="en-US">Annual Depreciation Rate, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_AnnualDepreciationRateDescription_2" xml:lang="en-US">Annual depreciation rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AntibodiesDiscoveryCollaborationAgreementMember_0" xml:lang="en-US">Antibodies Discovery Collaboration Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AntibodiesDiscoveryCollaborationAgreementMember_1" xml:lang="en-US">Information about the Antibodies Discovery Collaboration Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_0" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Greater Than 12 Months Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_1" xml:lang="en-US">Represents the amount of available for sale securities, continuous unrealized loss position, greater than 12 Months, fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_2" xml:lang="en-US">Available-for-Sale Securities, fair value, greater than 12 months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_0" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Greater Than 12 Months Gross Unrealized Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_1" xml:lang="en-US">Available-for-Sale Securities, gross unrealized losses, less than 12 months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_2" xml:lang="en-US">Represents the amount of available for sale securities, continuous unrealized loss position, greater than 12 Months, gross unrealized losses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_0" xml:lang="en-US">Available-for-Sale Securities, fair value, less than 12 months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_1" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_2" xml:lang="en-US">Represents the amount of available for sale securities, continuous unrealized loss position, less than 12 Months, fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_0" xml:lang="en-US">Available-for-Sale Securities, gross unrealized losses, less than 12 months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_1" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Gross Unrealized Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_2" xml:lang="en-US">Represents the amount of available for sale securities, continuous unrealized loss position, less than 12 Months, gross unrealized losses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_0" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_1" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_0" xml:lang="en-US">Expiration period of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_1" xml:lang="en-US">Class Of Warrant Or Rights Period From Which Warrants Or Rights Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_2" xml:lang="en-US">Expiration period of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_0" xml:lang="en-US">Clinical Amount Of Expense For Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_1" xml:lang="en-US">Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_2" xml:lang="en-US">Clinical R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborativeArrangementsMember_0" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborativeArrangementsMember_1" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborativeArrangementsTwoMember_0" xml:lang="en-US">Collaborative Arrangements Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborativeArrangementsTwoMember_1" xml:lang="en-US">Collaborative Arrangements Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ContingentFees_0" xml:lang="en-US">Contingent fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ContingentFees_1" xml:lang="en-US">Contingent Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ContingentFees_2" xml:lang="en-US">Contingent fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_1" xml:lang="en-US">Cost Of Sales Contract With Customer Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_2" xml:lang="en-US">Cost of revenues:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CustomerOneMember_0" xml:lang="en-US">Customer One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CustomerOneMember_1" xml:lang="en-US">Customer One Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_CustomerOneMember_2" xml:lang="en-US">Customer A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CustomerTwoMember_0" xml:lang="en-US">Customer Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CustomerTwoMember_1" xml:lang="en-US">This member stands for Customer two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_CustomerTwoMember_2" xml:lang="en-US">Customer B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredIncomeTaxLeaseLiabilities_0" xml:lang="en-US">Amount of deferred tax lease liability attributable to taxable temporary differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredIncomeTaxLeaseLiabilities_1" xml:lang="en-US">Deferred Income Tax Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredIncomeTaxLeaseLiabilities_2" xml:lang="en-US">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredIncomeTaxRightOfUseAssets_0" xml:lang="en-US">Amount of deferred tax Right of use assets attributable to taxable temporary differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredIncomeTaxRightOfUseAssets_1" xml:lang="en-US">Deferred Income Tax Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredIncomeTaxRightOfUseAssets_2" xml:lang="en-US">Right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_0" xml:lang="en-US">Deferred participation of BMS in R and D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_1" xml:lang="en-US">Deferred Participation Of B M S In R And D Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_2" xml:lang="en-US">Deferred participation of BMS in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredRevenuesIncludedInCurrentLiabilities_0" xml:lang="en-US">Deferred Revenues Included In Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredRevenuesIncludedInCurrentLiabilities_1" xml:lang="en-US">Amount of deferred revenues included in current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredRevenuesIncludedInCurrentLiabilities_2" xml:lang="en-US">Deferred revenues included in current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_0" xml:lang="en-US">Deferred Revenues Included In Non Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_1" xml:lang="en-US">Amount of deferred revenues included in non current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_2" xml:lang="en-US">Deferred revenues included in non current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_0" xml:lang="en-US">Deferred tax asset (liabilities) for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_1" xml:lang="en-US">Deferred Tax Assets Liabilities Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_2" xml:lang="en-US">Property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DerivativeRelatedExpense_0" xml:lang="en-US">Represents the derivative related expenses incurred during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DerivativeRelatedExpense_1" xml:lang="en-US">Derivative Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DerivativeRelatedExpense_2" xml:lang="en-US">Derivative related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_0" xml:lang="en-US">Percentage of domestic federal statutory tax rate applicable to pretax income (loss) for next fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_1" xml:lang="en-US">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate For Next Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_2" xml:lang="en-US">Israeli corporate tax rate for next fiscal year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EmployeesAndDirectorsMember_0" xml:lang="en-US">Represents information pertaining to employees and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EmployeesAndDirectorsMember_1" xml:lang="en-US">Employees and Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EmployeesDirectorsAndNonEmployeesMember_0" xml:lang="en-US">Employees Directors And Non Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EmployeesDirectorsAndNonEmployeesMember_1" xml:lang="en-US">Information about the employees, directors and non-employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EmployeeStockPurchasePlanMember_0" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EmployeeStockPurchasePlanMember_1" xml:lang="en-US">Employee Stock Purchase Plan Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_EmployeeStockPurchasePlanMember_2" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ExtendLease_0" xml:lang="en-US">Extend Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ExtendLease_1" xml:lang="en-US">Extend Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ExtendLease_2" xml:lang="en-US">Extend lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_FinancialIncomeExpenseNet_0" xml:lang="en-US">Financial Income (Expense), Net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_FinancialIncomeExpenseNet_1" xml:lang="en-US">Financial Income Expense Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_2" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_3" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_4" xml:lang="en-US">Financial income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_5" xml:lang="en-US">Financial income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GileadAgreementMember_0" xml:lang="en-US">Gilead Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GileadAgreementMember_1" xml:lang="en-US">Represent the member of Gilead Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_GileadAgreementMember_2" xml:lang="en-US">Gilead Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsAxis_0" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsAxis_1" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAuthorities_0" xml:lang="en-US">Government Authorities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAuthorities_1" xml:lang="en-US">Government authorities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Increase (decrease) in deferred participation in R and D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Increase Decrease In Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Decrease in deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInDeferredRevenues_0" xml:lang="en-US">Increase Decrease In Deferred Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInDeferredRevenues_1" xml:lang="en-US">Represent the amount of deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_IncreaseDecreaseInDeferredRevenues_2" xml:lang="en-US">Increase in deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Increase (decrease) in operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Decrease in operating lease right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating lease right of use asset increased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Increase Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_2" xml:lang="en-US">Operating lease right of use asset increased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_InterestPaidReceivedNet_0" xml:lang="en-US">Interest payments paid (received) from bank short-term deposits and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_InterestPaidReceivedNet_1" xml:lang="en-US">Interest Paid Received Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_InterestPaidReceivedNet_2" xml:lang="en-US">Interest payments received from short-term bank deposits and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_0" xml:lang="en-US">Issuance of shares and warrants, net, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_1" xml:lang="en-US">Issuance of shares and warrants, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_2" xml:lang="en-US">Issuance of shares, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_0" xml:lang="en-US">Issuance of shares and warrants, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_1" xml:lang="en-US">Issuance Of Shares And Warrants Net Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_2" xml:lang="en-US">Issuance of shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_JmpSecuritiesLlcMember_0" xml:lang="en-US">Jmp Securities Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_JmpSecuritiesLlcMember_1" xml:lang="en-US">This member stands for JMP Securities LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_JmpSecuritiesLlcMember_2" xml:lang="en-US">JMP Securities LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_0" xml:lang="en-US">Laboratory Equipment And Office Furniture [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_1" xml:lang="en-US">Laboratory equipment and office furniture [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LeerinkPartnersLlcMember_0" xml:lang="en-US">Leerink Partners Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LeerinkPartnersLlcMember_1" xml:lang="en-US">This member stands for Leerink Partners LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_LeerinkPartnersLlcMember_2" xml:lang="en-US">Leerink Partners LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LicenseAgreementWithGileadMember_0" xml:lang="en-US">License Agreement With Gilead [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LicenseAgreementWithGileadMember_1" xml:lang="en-US">This member represents about license agreement with Gilead.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LicenseRevenue_0" xml:lang="en-US">License Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LicenseRevenue_1" xml:lang="en-US">Amount of license revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_LicenseRevenue_2" xml:lang="en-US">License revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Long term deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Long Term Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Long-term deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MasterClinicalAgreementMember_0" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MasterClinicalAgreementMember_1" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MasterClinicalAgreementOneMember_0" xml:lang="en-US">Master Clinical Agreement One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MasterClinicalAgreementOneMember_1" xml:lang="en-US">Master Clinical Agreement One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MasterClinicalAgreementTwoMember_0" xml:lang="en-US">Master Clinical Agreement Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MasterClinicalAgreementTwoMember_1" xml:lang="en-US">Master Clinical Agreement Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Maximum Authorized Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Maximum Authorized Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Aggregate offering price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_3" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_0" xml:lang="en-US">Maximum Royalty Repaid As Percentage Of Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_1" xml:lang="en-US">Maximum Royalty Repaid As Percentage Of Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_2" xml:lang="en-US">Maximum royalty repaid as percentage of grant received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_May2012AgreementMember_0" xml:lang="en-US">May 2012 Agreement Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_May2012AgreementMember_1" xml:lang="en-US">May 2012 Agreement Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_May2012AgreementMember_2" xml:lang="en-US">May 2012 Agreement With Advisor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MilestonePaymentReceivable_0" xml:lang="en-US">Milestone Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MilestonePaymentReceivable_1" xml:lang="en-US">Amount of milestone payment receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_MilestonePaymentReceivable_2" xml:lang="en-US">Milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_0" xml:lang="en-US">Net Income Loss After Adjustment Of Change In Fair Value Of Research And Development Funding Arrangement Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1" xml:lang="en-US">Numerator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NetOperatingLossCarryforwardExpired_0" xml:lang="en-US">Net operating loss carryforward, Expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NetOperatingLossCarryforwardExpired_1" xml:lang="en-US">Net operating loss carryforward, Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NonRefundableUpfrontPayment_0" xml:lang="en-US">Non Refundable Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NonRefundableUpfrontPayment_1" xml:lang="en-US">Amount of non-refundable upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_NonRefundableUpfrontPayment_2" xml:lang="en-US">Non-refundable upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_0" xml:lang="en-US">Represents the number of licensed programs to achieve substantive milestones revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_1" xml:lang="en-US">Number of licensed programs to achieve substantive milestones revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NumberOfWarrantsExercised_0" xml:lang="en-US">Number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NumberOfWarrantsExercised_1" xml:lang="en-US">Number Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_NumberOfWarrantsExercised_2" xml:lang="en-US">Warrants exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_0" xml:lang="en-US">Represents information pertaining to obsolete property and equipment and certain nonfunctional Lab equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1" xml:lang="en-US">Obsolete property and equipment and nonfunctional Lab equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_2" xml:lang="en-US">Obsolete property and equipment and certain nonfunctional Lab equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_0" xml:lang="en-US">Ordinary Shares Issued And Sold Through Atm [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_1" xml:lang="en-US">This member stands for ordinary shares issued and sold through ATM.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_2" xml:lang="en-US">ATM [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0" xml:lang="en-US">The entire disclosure for other accounts receivable and prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" xml:lang="en-US">Other Accounts Receivable And Prepaid Expenses Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2" xml:lang="en-US">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_OtherSegmentExpenses_0" xml:lang="en-US">Other Segment Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_OtherSegmentExpenses_1" xml:lang="en-US">Other segment expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_OtherSegmentExpenses_2" xml:lang="en-US">Other segment expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ParticipationRights_0" xml:lang="en-US">Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ParticipationRights_1" xml:lang="en-US">Participation Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ParticipationRights_2" xml:lang="en-US">Participation Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_0" xml:lang="en-US">Amount of payments for Proceeds from Sales of equipment Investing Activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_1" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_2" xml:lang="en-US">Payments For Proceeds From Sales Of Property And Equipment Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_3" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_4" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfClosingPrice_0" xml:lang="en-US">Percentage of closing price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfClosingPrice_1" xml:lang="en-US">Percentage of closing price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_0" xml:lang="en-US">Percentage of consolidated revenues of collaborator.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_1" xml:lang="en-US">Percentage of consolidated revenues of collaborator</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfExpectedFromPaymentAmountPaid_0" xml:lang="en-US">Percentage Of Expected From Payment Amount Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfExpectedFromPaymentAmountPaid_1" xml:lang="en-US">Percentage of expected from payment amount paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_PercentageOfExpectedFromPaymentAmountPaid_2" xml:lang="en-US">Percentage of expected from payment amount paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_0" xml:lang="en-US">Percentage of fair market value of ordinary shares at time of offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_1" xml:lang="en-US">Percentage of fair market value of ordinary shares at time of offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_0" xml:lang="en-US">Percentage of use of base salary to purchase ordinary shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_1" xml:lang="en-US">Percentage of use of base salary to purchase ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PeriodSinceApprovalWasGranted_0" xml:lang="en-US">Period since approval was granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PeriodSinceApprovalWasGranted_1" xml:lang="en-US">Period since approval was granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PeriodSinceEnterpriseBeganOperating_0" xml:lang="en-US">Period since enterprise began operating.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PeriodSinceEnterpriseBeganOperating_1" xml:lang="en-US">Period since enterprise began operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_0" xml:lang="en-US">Preclinical Amount Of Expense For Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_1" xml:lang="en-US">Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_2" xml:lang="en-US">Preclinical R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_0" xml:lang="en-US">Purchase Of Property And Equipment As Non Cash Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_1" xml:lang="en-US">The amount of purchase property and equipment as non cash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_2" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_3" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_0" xml:lang="en-US">Receivables on account of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_1" xml:lang="en-US">Receivables on account of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_0" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_1" xml:lang="en-US">Accounting policy for Recently issued accounting pronouncements not yet adopted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_2" xml:lang="en-US">Recently issued accounting pronouncements not yet adopted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ReducedCorporateIncomeTaxRate_0" xml:lang="en-US">Reduced Corporate income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ReducedCorporateIncomeTaxRate_1" xml:lang="en-US">Reduced Corporate income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ReducedTaxRate_0" xml:lang="en-US">Reduced tax rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ReducedTaxRate_1" xml:lang="en-US">Reduced tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RegisteredDirectOfferingMember_0" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RegisteredDirectOfferingMember_1" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RemainingPerformanceObligationsRecognizedPercentage_0" xml:lang="en-US">Remaining Performance Obligations Recognized Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RemainingPerformanceObligationsRecognizedPercentage_1" xml:lang="en-US">The percentage of the total remaining performance obligations expected to be recognized as revenue within the next 12 months.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RemainingPerformanceObligationsRecognizedPercentage_2" xml:lang="en-US">Percentage of total remaining performance obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_0" xml:lang="en-US">Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2" xml:lang="en-US">Potential milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_0" xml:lang="en-US">Potential milestone compensation company is now eligible for.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_1" xml:lang="en-US">Research And Development Arrangement Payments Receivable On Remaining Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_2" xml:lang="en-US">Potential milestone compensation company is now eligible for</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_0" xml:lang="en-US">The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Preclinical Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_2" xml:lang="en-US">Preclinical milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMember_0" xml:lang="en-US">Research And Development Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMember_1" xml:lang="en-US">Research and Development expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_0" xml:lang="en-US">Research and development expenses milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_1" xml:lang="en-US">Research And Development Expenses Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_2" xml:lang="en-US">Research and development expenses milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_0" xml:lang="en-US">Research and development expenses milestone payment with connection.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_1" xml:lang="en-US">Research And Development Expenses Milestone Payment With Connection</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_2" xml:lang="en-US">Research and development expenses milestone payment with connection</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_0" xml:lang="en-US">Research and Development Grant One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_1" xml:lang="en-US">Research And Development Grant One Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_2" xml:lang="en-US">IIA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RetainerFee_0" xml:lang="en-US">Represents the retainer fee per month.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RetainerFee_1" xml:lang="en-US">Retainer Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RetainerFee_2" xml:lang="en-US">Retainer fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyContingentObligations_0" xml:lang="en-US">The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyContingentObligations_1" xml:lang="en-US">Royalty Contingent Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RoyaltyContingentObligations_2" xml:lang="en-US">Contingent royalty obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyPercentage_0" xml:lang="en-US">Royalty percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyPercentage_1" xml:lang="en-US">Royalty Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RoyaltyPercentage_2" xml:lang="en-US">Royalty percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_0" xml:lang="en-US">Royalty Percentage Based On Future Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_1" xml:lang="en-US">Royalty Percentage Based On Future Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_2" xml:lang="en-US">Royalty percentage based on future revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_0" xml:lang="en-US">Sales Agreement with SVB Securities LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_1" xml:lang="en-US">Sales Agreement With S V B Securities L L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_2" xml:lang="en-US">Sales Agreement with SVB Securities LLC. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_0" xml:lang="en-US">Tabular disclosure of the annual rates used to calculate depreciation for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_1" xml:lang="en-US">Schedule Of Property Plant And Equipment Depreciation Rates Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_2" xml:lang="en-US">Schedule of depreciation rates for property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_0" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of granted stock options, including, but not limited to: (a) expected term of granted share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_1" xml:lang="en-US">Schedule Of Weighted Average Assumptions For Granted Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_2" xml:lang="en-US">Schedule of weighted average assumptions for granted options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_0" xml:lang="en-US">Tabular disclosure of weighted-average remaining lease term and discount rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_1" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Term And Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_2" xml:lang="en-US">Schedule of weighted-average remaining lease term and discount rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SegmentReportingGeograhicAreaLineItems_0" xml:lang="en-US">Segment Reporting Geograhic Area [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SegmentReportingGeograhicAreaLineItems_1" xml:lang="en-US">Segment Reporting Geograhic Area [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SegmentReportingGeographicAreaAxis_0" xml:lang="en-US">Segment Reporting Geographic Area [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SegmentReportingGeographicAreaAxis_1" xml:lang="en-US">Segment Reporting Geographic Area [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SegmentReportingGeographicAreaDomain_0" xml:lang="en-US">Segment Reporting Geographic Area [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SegmentReportingGeographicAreaTable_0" xml:lang="en-US">Segment Reporting Geographic Area [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SegmentReportingGeographicAreaTable_1" xml:lang="en-US">Segment Reporting Geographic Area [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ServerancePayPolicyTextBlock_0" xml:lang="en-US">Serverance Pay [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ServerancePayPolicyTextBlock_1" xml:lang="en-US">Serverance Pay Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ServerancePayPolicyTextBlock_2" xml:lang="en-US">Severance pay:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SeverancePayFundNoncurrent_0" xml:lang="en-US">Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SeverancePayFundNoncurrent_1" xml:lang="en-US">Severance Pay Fund Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_SeverancePayFundNoncurrent_2" xml:lang="en-US">Severance pay fund</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SeverancePayNet_0" xml:lang="en-US">Severance pay, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SeverancePayNet_1" xml:lang="en-US">Severance Pay Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SeverancePayNet_2" xml:lang="en-US">Decrease in severance pay, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_2" xml:lang="en-US">Award expiration period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Remaining Contractual Term Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_2" xml:lang="en-US">Weighted average remaining contractual life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_0" xml:lang="en-US">Short Term Bank Deposits And Restricted Long Term Bank Deposits [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_1" xml:lang="en-US">Short Term Bank Deposits And Restricted Long Term Bank Deposits [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_2" xml:lang="en-US">Short-term bank deposits and restricted long-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermBankDepositsPolicyTextBlock_0" xml:lang="en-US">The entire disclosure for short-term bank deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermBankDepositsPolicyTextBlock_1" xml:lang="en-US">Short Term Bank Deposits Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShortTermBankDepositsPolicyTextBlock_2" xml:lang="en-US">Short-term bank deposits:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_0" xml:lang="en-US">The weighted average interest rate for short-term bank deposits outside of the domestic currency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_1" xml:lang="en-US">Short Term Bank Deposits Weighted Average Rate Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_2" xml:lang="en-US">Average interest rate, short-term bank deposits in U.S. dollars</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Short term deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Short Term Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Short-term deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SingleOperatingSegmentMember_0" xml:lang="en-US">Single Operating Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SingleOperatingSegmentMember_1" xml:lang="en-US">Single operating segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_0" xml:lang="en-US">Stock-based compensation relating to options issued to employees and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_1" xml:lang="en-US">Stock Based Compensation Relating To Options Issued To Employees, Directors And Non Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_2" xml:lang="en-US">Share-based compensation issued to employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_0" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_1" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_2" xml:lang="en-US">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_0" xml:lang="en-US">Change In right of use asset and operating lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_1" xml:lang="en-US">Supplemental Right Of Use Asset And Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_2" xml:lang="en-US">Right-of-use asset obtained in exchange for operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_0" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp;amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_1" xml:lang="en-US">Svb Leerink Llc And Stifel Nicolaus And Company Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_2" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TaxExemptPeriod_0" xml:lang="en-US">Tax exempt period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TaxExemptPeriod_1" xml:lang="en-US">Tax exempt period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TaxRateOnDistributions_0" xml:lang="en-US">Tax rate for dividends distributed to individuals or foreign residents from the preferred enterprise's earnings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TaxRateOnDistributions_1" xml:lang="en-US">Tax rate on distributions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TotalRemainingPerformanceObligations_0" xml:lang="en-US">Total Remaining Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TotalRemainingPerformanceObligations_1" xml:lang="en-US">Total transaction price allocated to remaining performance obligations yet to be recognized as revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_TotalRemainingPerformanceObligations_2" xml:lang="en-US">Total transaction price allocated to remaining performance obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_0" xml:lang="en-US">Two Thousand and Two Thousand Ten Options Plan [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_1" xml:lang="en-US">Two Thousand And Two Thousand Ten Options Plan Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_2" xml:lang="en-US">2000 and 2010 Share Option Plans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TwoThousandTenShareOptionsPlanMember_0" xml:lang="en-US">Two Thousand Ten Share Options Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TwoThousandTenShareOptionsPlanMember_1" xml:lang="en-US">Information about the share option plan 2010.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_TwoThousandTenShareOptionsPlanMember_2" xml:lang="en-US">2010 Share Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_UnderwritersMember_0" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_UnderwritersMember_1" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IL_0" xml:lang="en-US">Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US_0" xml:lang="en-US">Unites States [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription_0" xml:lang="en-US">Amendment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId_0" xml:lang="en-US">Auditor Firm Id</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation_0" xml:lang="en-US">Auditor Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName_0" xml:lang="en-US">Auditor Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember_0" xml:lang="en-US">Business Contact [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelEmailAddress_0" xml:lang="en-US">Contact Personnel Email Address</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelFaxNumber_0" xml:lang="en-US">Contact Personnel Fax Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName_0" xml:lang="en-US">Contact Personnel Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAccountingStandard_0" xml:lang="en-US">Document Accounting Standard</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag_0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement_0" xml:lang="en-US">Document Registration Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentShellCompanyReport_0" xml:lang="en-US">Document Shell Company Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine3_0" xml:lang="en-US">Entity Address, Address Line Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis_0" xml:lang="en-US">Entity Addresses Address Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityAddressesAddressTypeAxis_1" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation State Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag_0" xml:lang="en-US">Auditor Attestation Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_OtherReportingStandardItemNumber_0" xml:lang="en-US">Other Reporting Standard Item Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Name of Exchange on which Security is Registered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember_0" xml:lang="en-US">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EuropeMember_0" xml:lang="en-US">Europe [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis_0" xml:lang="en-US">Customer [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain_0" xml:lang="en-US">Customer [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_RangeAxis_1" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis_0" xml:lang="en-US">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0" xml:lang="en-US">OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xml:lang="en-US">Accumulated depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_1" xml:lang="en-US">Accumulated depreciation equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1" xml:lang="en-US">Accumulated other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1" xml:lang="en-US">Accumulated other comprehensive income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional paid-in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentForAmortization_0" xml:lang="en-US">Amortization in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Stock-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_0" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_1" xml:lang="en-US">Assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1" xml:lang="en-US">Gross unrealized gains</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0" xml:lang="en-US">Gross unrealized losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1" xml:lang="en-US">Amortized cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0" xml:lang="en-US">Fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1" xml:lang="en-US">Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDevelopment_0" xml:lang="en-US">Marketing and business development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0" xml:lang="en-US">Cash equivalents:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0" xml:lang="en-US">Restricted cash:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" xml:lang="en-US">Cash, Cash equivalents and Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3" xml:lang="en-US">Total cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">Increase in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Exercise price of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0" xml:lang="en-US">Warrants purchase to ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0" xml:lang="en-US">Warrants purchase to ordinary shares remain outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Ordinary shares, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Ordinary shares, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Share capital: Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2021 and 2020; 86,433,432 and 83,675,856 shares issued and outstanding at December 31, 2021 and 2020, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2024 and 2023; 89,541,246 and 89,237,465 shares issued and outstanding at December 31, 2024 and 2023, respectively.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_1" xml:lang="en-US">Total comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0" xml:lang="en-US">Comprehensive income (loss):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember_0" xml:lang="en-US">Computers, software and related equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_0" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0" xml:lang="en-US">Concentration of credit risks:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_0" xml:lang="en-US">Sales to a single customer exceeding 10%</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_0" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0" xml:lang="en-US">Basis of consolidation:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue_0" xml:lang="en-US">Cost of revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty_0" xml:lang="en-US">Amounts charged to research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_0" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0" xml:lang="en-US">Schedule of available-for-sale marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_1" xml:lang="en-US">Deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_2" xml:lang="en-US">Deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenue_0" xml:lang="en-US">Deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent_0" xml:lang="en-US">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent_1" xml:lang="en-US">Deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_0" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_1" xml:lang="en-US">Long-term deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_2" xml:lang="en-US">Deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1" xml:lang="en-US">Deferred tax asset before valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US">Deferred tax asset after valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_1" xml:lang="en-US">Deferred tax assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0" xml:lang="en-US">Operating loss carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_0" xml:lang="en-US">Accrued social benefits and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_0" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_1" xml:lang="en-US">Deferred tax liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_0" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_1" xml:lang="en-US">Restricted long-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet_0" xml:lang="en-US">Fair value of outstanding forward contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet_0" xml:lang="en-US">Net gain on derivative transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_0" xml:lang="en-US">Net gain on derivative recorded as financial and other income, net for the ineffective portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeNotionalAmount_0" xml:lang="en-US">Derivative, notional amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_0" xml:lang="en-US">Derivative instruments:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1" xml:lang="en-US">Schedule of share option plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember_0" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Basic net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic loss per ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_2" xml:lang="en-US">Basic net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Basic and diluted loss per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">LOSSES PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Israeli corporate tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0" xml:lang="en-US">U.S. income state and local taxes rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Effect of exchange rate changes on cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" xml:lang="en-US">Employees and related accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0" xml:lang="en-US">Unrecognized share-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Unrecognized compensation cost, recognition period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockMember_0" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0" xml:lang="en-US">Employee Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember_0" xml:lang="en-US">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost_0" xml:lang="en-US">Investment amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost_1" xml:lang="en-US">Equity investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1" xml:lang="en-US">Schedule of fair value measurements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xml:lang="en-US">Asset Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_0" xml:lang="en-US">Asset Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_0" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_1" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0" xml:lang="en-US">Fair value of financial instruments:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis_0" xml:lang="en-US">Financial Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_0" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_1" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, after Tax, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_2" xml:lang="en-US">Foreign currency transaction adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_3" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_4" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1" xml:lang="en-US">Foreign currency transaction adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0" xml:lang="en-US">Financial statements in U.S. dollars:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets_0" xml:lang="en-US">Gain (loss) from sales and disposals of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0" xml:lang="en-US">Loss from property and equipment sales and disposals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2" xml:lang="en-US">Gains from the sale of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0" xml:lang="en-US">General and administrative expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit_0" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit_1" xml:lang="en-US">Gross profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure_0" xml:lang="en-US">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfInvestments_0" xml:lang="en-US">Marketable securities impairment losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0" xml:lang="en-US">Domestic (Israel)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2" xml:lang="en-US">Domestic (Israel)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0" xml:lang="en-US">Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2" xml:lang="en-US">Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">TAXES ON INCOME, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid_0" xml:lang="en-US">Tax payment withheld</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Income tax expenses (tax benefits)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0" xml:lang="en-US">Income taxes:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0" xml:lang="en-US">Decrease (increase) in trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Increase (decrease) in trade payables and other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US">Increase (decrease) in trade payables and employees and related accruals and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0" xml:lang="en-US">Decrease (increase) in other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xml:lang="en-US">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0" xml:lang="en-US">Decrease in operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Decrease (increase) in long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_0" xml:lang="en-US">Increase (Decrease) in Royalties Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_1" xml:lang="en-US">Royalties accrual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InitialOfferingPeriod_0" xml:lang="en-US">Offering period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestAndDebtExpense_0" xml:lang="en-US">Bank fees and other finance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestAndDebtExpense_1" xml:lang="en-US">Interest and Debt Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_0" xml:lang="en-US">United States [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_0" xml:lang="en-US">Investment Income, Amortization of Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_1" xml:lang="en-US">Amortization of discount on marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest_0" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_0" xml:lang="en-US">Amount of investment in Compugen</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_0" xml:lang="en-US">Investments, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_1" xml:lang="en-US">Investment in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1" xml:lang="en-US">MARKETABLE SECURITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_0" xml:lang="en-US">Leasehold improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeDisclosureAbstract_0" xml:lang="en-US">Lessee Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeDisclosureAbstract_1" xml:lang="en-US">Lessee Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_1" xml:lang="en-US">Leases:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0" xml:lang="en-US">Schedule of Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" xml:lang="en-US">Schedule of operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US">Total operating lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" xml:lang="en-US">2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1" xml:lang="en-US">2028 and on</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" xml:lang="en-US">2027</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" xml:lang="en-US">2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0" xml:lang="en-US">Less: imputed interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1" xml:lang="en-US">Less: imputed interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0" xml:lang="en-US">Period of options to extend leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_0" xml:lang="en-US">LEASES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">NON- CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_0" xml:lang="en-US">Marketable Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_1" xml:lang="en-US">Investment in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_0" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_1" xml:lang="en-US">Investments in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember_0" xml:lang="en-US">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss for basic and diluted loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">Recently issued and recently adopted Accounting Standards:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Recently adopted accounting pronouncement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncurrentAssets_0" xml:lang="en-US">Long-lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments_0" xml:lang="en-US">Number of operating segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments_1" xml:lang="en-US">Number of operating segment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense_0" xml:lang="en-US">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense_1" xml:lang="en-US">Operating lease expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability_0" xml:lang="en-US">Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_1" xml:lang="en-US">Present value of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_2" xml:lang="en-US">Present value of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Current maturity of operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Lease liabilities, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Long-term operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1" xml:lang="en-US">Lease liabilities, non- current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2" xml:lang="en-US">Operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments_0" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments_1" xml:lang="en-US">Operating lease expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating lease right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0" xml:lang="en-US">Weighted average discount (annual) rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0" xml:lang="en-US">Weighted average remaining lease term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards_0" xml:lang="en-US">Net operating loss carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_0" xml:lang="en-US">Year of expiration of operating loss carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0" xml:lang="en-US">GENERAL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US">Other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent_0" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_0" xml:lang="en-US">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsTable_0" xml:lang="en-US">Other Commitments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0" xml:lang="en-US">Foreign Currency Translation income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1" xml:lang="en-US">Exchange rate income (loss) on lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1" xml:lang="en-US">Other comprehensive income from marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_0" xml:lang="en-US">Net gain on derivative classified to operating expenses as effective portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1" xml:lang="en-US">Unrealized gain arising during the period from marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2" xml:lang="en-US">Changes in other comprehensive income from marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_0" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0" xml:lang="en-US">FINANCIAL AND OTHER INCOME, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilities_0" xml:lang="en-US">Trade payables and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherShortTermInvestments_0" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherShortTermInvestments_1" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_0" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromProductiveAssets_0" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromProductiveAssets_1" xml:lang="en-US">Payments for (Proceeds from) Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_0" xml:lang="en-US">Payments to Acquire Held-to-Maturity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_1" xml:lang="en-US">Proceeds from maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_2" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_3" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_0" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_1" xml:lang="en-US">Payments to Acquire Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1" xml:lang="en-US">Investment in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_0" xml:lang="en-US">Payments to Acquire Restricted Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_1" xml:lang="en-US">Investment in long term restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0" xml:lang="en-US">Accrued severance pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US">Other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent_0" xml:lang="en-US">Long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds_0" xml:lang="en-US">Tax receivables refunded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0" xml:lang="en-US">Proceeds from ordinary shares in offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Proceeds from issuance of ordinary shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1" xml:lang="en-US">Proceeds from maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3" xml:lang="en-US">Proceeds from maturities of available-for-sale marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_0" xml:lang="en-US">Proceeds from Sale of Held-to-Maturity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_1" xml:lang="en-US">Proceeds from maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_2" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_3" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Proceeds from exercise of stock-based awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_1" xml:lang="en-US">Proceeds from exercise of share-based awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from warrant exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_2" xml:lang="en-US">Proceeds from exercise of stock-based awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals_0" xml:lang="en-US">Costs of disposal of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals_1" xml:lang="en-US">Property, Plant and Equipment, Disposals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals_2" xml:lang="en-US">Costs of disposal of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals_3" xml:lang="en-US">Sale of equipment,cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_0" xml:lang="en-US">Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment_0" xml:lang="en-US">Impairment of long-lived assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Depreciated cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0" xml:lang="en-US">Property and equipment, net:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0" xml:lang="en-US">Schedule of Property And Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xml:lang="en-US">Schedule of property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesNetCurrent_0" xml:lang="en-US">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReceivablesNetCurrent_1" xml:lang="en-US">Trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1" xml:lang="en-US">Upfront payment received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Research and Development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_2" xml:lang="en-US">Research and development expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and development expenses, net:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_1" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0" xml:lang="en-US">Revenue recognition under milestone method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0" xml:lang="en-US">Revenue recognition:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues_0" xml:lang="en-US">Total revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues_1" xml:lang="en-US">Revenue from sales to customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense_0" xml:lang="en-US">Royalty expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RoyaltyExpense_1" xml:lang="en-US">Royalty expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1" xml:lang="en-US">Number of shares issued and sold in transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember_0" xml:lang="en-US">Revenue [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Other Accounts Payable and Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0" xml:lang="en-US">Schedule of Stock-Based Compensation Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" xml:lang="en-US">Schedule of stock-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Summary Of Deferred Tax Assets And Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of computation of basic and diluted losses per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xml:lang="en-US">Schedule of stock-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0" xml:lang="en-US">Schedule Of Loss Before Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1" xml:lang="en-US">Schedule of loss (income) before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_0" xml:lang="en-US">Schedule Of Other Accounts Receivable And Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0" xml:lang="en-US">Schedule of Financial and Other Income, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" xml:lang="en-US">Schedule of financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0" xml:lang="en-US">Schedule of Related Party Balances and Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US">Schedule of related party balances and transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_0" xml:lang="en-US">Sales To A Single Customer Exceeding 10%:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_1" xml:lang="en-US">Schedule of sales to single customer exceeding 10%</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_0" xml:lang="en-US">Total Revenues And Long-Lived Assets By Geographic Area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1" xml:lang="en-US">Schedule of total revenues and long-lived assets by geographic area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1" xml:lang="en-US">Schedule of financial information with respect to single operating segment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1" xml:lang="en-US">Schedule Of RSUs activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0" xml:lang="en-US">Schedule Of Option Activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US">Schedule of option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_0" xml:lang="en-US">Schedule of unrealized loss on investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_1" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_2" xml:lang="en-US">Schedule of gross unrealized losses and fair values on investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain_0" xml:lang="en-US">Segments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract_0" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_0" xml:lang="en-US">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_1" xml:lang="en-US">SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember_0" xml:lang="en-US">Marketing and business development expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_1" xml:lang="en-US">SG&amp;A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1_0" xml:lang="en-US">Severance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" xml:lang="en-US">Aggregate intrinsic value of exercised options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xml:lang="en-US">RSUs forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1" xml:lang="en-US">RSUs forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xml:lang="en-US">RSUs granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">RSUs granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xml:lang="en-US">RSUs outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xml:lang="en-US">RSUs outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xml:lang="en-US">Number of RSUs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xml:lang="en-US">RSUs outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1" xml:lang="en-US">Weighted average grant date per value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Expected life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0" xml:lang="en-US">Ordinary shares reserved for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" xml:lang="en-US">Ordinary shares available for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0" xml:lang="en-US">Aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0" xml:lang="en-US">Total intrinsic value of options exercised during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0" xml:lang="en-US">Options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Options expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Weighted average fair value of stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Options outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Number of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Options outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0" xml:lang="en-US">Options vested and expected to vest at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Options vested and expected to vest at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0" xml:lang="en-US">Maximum percentage of total shares of common stock outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Options expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Stock-based compensation:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US">Share-based compensation:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0" xml:lang="en-US">SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_0" xml:lang="en-US">Offering price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract_0" xml:lang="en-US">Short-Term Investments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract_1" xml:lang="en-US">Short-term investments:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_0" xml:lang="en-US">Segments [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">SHAREHOLDERS' EQUITY:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0" xml:lang="en-US">Exercise of options and ESPP shares, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1" xml:lang="en-US">Exercise of options and ESPP shares, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Issuance of shares, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Issuance of shares, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3" xml:lang="en-US">Exercise of options,shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0" xml:lang="en-US">Exercise of options and ESPP shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1" xml:lang="en-US">Exercise of options and ESPP shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Issuance of shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xml:lang="en-US">Exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionMember_0" xml:lang="en-US">Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubleaseIncome_0" xml:lang="en-US">Sublease income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiaryOfCommonParentMember_0" xml:lang="en-US">Subsidiary of Common Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiaryOfCommonParentMember_1" xml:lang="en-US">Subsidiary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_0" xml:lang="en-US">Cash paid (received) during the year for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_1" xml:lang="en-US">Cash received during the year for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xml:lang="en-US">Financial Instruments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_0" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_1" xml:lang="en-US">Schedule of unrealized loss on investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_2" xml:lang="en-US">Schedule of gross unrealized losses and fair values on investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of estimates:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_0" xml:lang="en-US">US Treasury Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_1" xml:lang="en-US">U.S. Treasury [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeasePayment_0" xml:lang="en-US">Variable Lease, Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_VariableLeasePayment_1" xml:lang="en-US">Variable payments as CPI</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of ordinary shares used in computing diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0" xml:lang="en-US">Denominator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_1" xlink:to="lab_cgen_AccruedMilestonePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_2" xlink:to="lab_cgen_AccruedMilestonePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayments_3" xlink:to="lab_cgen_AccruedMilestonePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayments_4" xlink:to="lab_cgen_AccruedMilestonePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayments_5" xlink:to="lab_cgen_AccruedMilestonePayments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_6" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_7" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_8" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_9" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_10" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_11" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_12" xlink:to="lab_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_13" xlink:to="lab_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_14" xlink:to="lab_cgen_AgreementStartDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_15" xlink:to="lab_cgen_AgreementStartDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_16" xlink:to="lab_cgen_AgreementStartDate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_17" xlink:to="lab_cgen_AgreementTerminationDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_18" xlink:to="lab_cgen_AgreementTerminationDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_19" xlink:to="lab_cgen_AgreementTerminationDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_20" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_21" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_22" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_23" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_24" xlink:to="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_25" xlink:to="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_26" xlink:to="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRate_27" xlink:to="lab_cgen_AnnualDepreciationRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRate_28" xlink:to="lab_cgen_AnnualDepreciationRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRateDescription_29" xlink:to="lab_cgen_AnnualDepreciationRateDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRateDescription_30" xlink:to="lab_cgen_AnnualDepreciationRateDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRateDescription_31" xlink:to="lab_cgen_AnnualDepreciationRateDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_32" xlink:to="lab_cgen_AntibodiesDiscoveryCollaborationAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_33" xlink:to="lab_cgen_AntibodiesDiscoveryCollaborationAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_34" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_35" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_36" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_37" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_38" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_39" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_40" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_41" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_42" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_43" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_44" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_45" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_46" xlink:to="lab_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_47" xlink:to="lab_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_48" xlink:to="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_49" xlink:to="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_50" xlink:to="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_51" xlink:to="lab_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_52" xlink:to="lab_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_53" xlink:to="lab_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsMember_54" xlink:to="lab_cgen_CollaborativeArrangementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsMember_55" xlink:to="lab_cgen_CollaborativeArrangementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsTwoMember_56" xlink:to="lab_cgen_CollaborativeArrangementsTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsTwoMember_57" xlink:to="lab_cgen_CollaborativeArrangementsTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_58" xlink:to="lab_cgen_ContingentFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_59" xlink:to="lab_cgen_ContingentFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_60" xlink:to="lab_cgen_ContingentFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_61" xlink:to="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_62" xlink:to="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_63" xlink:to="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerOneMember_64" xlink:to="lab_cgen_CustomerOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerOneMember_65" xlink:to="lab_cgen_CustomerOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerOneMember_66" xlink:to="lab_cgen_CustomerOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerTwoMember_67" xlink:to="lab_cgen_CustomerTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerTwoMember_68" xlink:to="lab_cgen_CustomerTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerTwoMember_69" xlink:to="lab_cgen_CustomerTwoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxLeaseLiabilities_70" xlink:to="lab_cgen_DeferredIncomeTaxLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxLeaseLiabilities_71" xlink:to="lab_cgen_DeferredIncomeTaxLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxLeaseLiabilities_72" xlink:to="lab_cgen_DeferredIncomeTaxLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxRightOfUseAssets_73" xlink:to="lab_cgen_DeferredIncomeTaxRightOfUseAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxRightOfUseAssets_74" xlink:to="lab_cgen_DeferredIncomeTaxRightOfUseAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxRightOfUseAssets_75" xlink:to="lab_cgen_DeferredIncomeTaxRightOfUseAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_76" xlink:to="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_77" xlink:to="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_78" xlink:to="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_79" xlink:to="lab_cgen_DeferredRevenuesIncludedInCurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_80" xlink:to="lab_cgen_DeferredRevenuesIncludedInCurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_81" xlink:to="lab_cgen_DeferredRevenuesIncludedInCurrentLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_82" xlink:to="lab_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_83" xlink:to="lab_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_84" xlink:to="lab_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_85" xlink:to="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_86" xlink:to="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_87" xlink:to="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DerivativeRelatedExpense_88" xlink:to="lab_cgen_DerivativeRelatedExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DerivativeRelatedExpense_89" xlink:to="lab_cgen_DerivativeRelatedExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DerivativeRelatedExpense_90" xlink:to="lab_cgen_DerivativeRelatedExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_91" xlink:to="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_92" xlink:to="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_93" xlink:to="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeesAndDirectorsMember_94" xlink:to="lab_cgen_EmployeesAndDirectorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeesAndDirectorsMember_95" xlink:to="lab_cgen_EmployeesAndDirectorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_96" xlink:to="lab_cgen_EmployeesDirectorsAndNonEmployeesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_97" xlink:to="lab_cgen_EmployeesDirectorsAndNonEmployeesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeStockPurchasePlanMember_98" xlink:to="lab_cgen_EmployeeStockPurchasePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeStockPurchasePlanMember_99" xlink:to="lab_cgen_EmployeeStockPurchasePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeStockPurchasePlanMember_100" xlink:to="lab_cgen_EmployeeStockPurchasePlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ExtendLease_101" xlink:to="lab_cgen_ExtendLease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ExtendLease_102" xlink:to="lab_cgen_ExtendLease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ExtendLease_103" xlink:to="lab_cgen_ExtendLease_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_104" xlink:to="lab_cgen_FinancialIncomeExpenseNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_105" xlink:to="lab_cgen_FinancialIncomeExpenseNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_106" xlink:to="lab_cgen_FinancialIncomeExpenseNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_107" xlink:to="lab_cgen_FinancialIncomeExpenseNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_108" xlink:to="lab_cgen_FinancialIncomeExpenseNet_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_109" xlink:to="lab_cgen_FinancialIncomeExpenseNet_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GileadAgreementMember_110" xlink:to="lab_cgen_GileadAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GileadAgreementMember_111" xlink:to="lab_cgen_GileadAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GileadAgreementMember_112" xlink:to="lab_cgen_GileadAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_113" xlink:to="lab_cgen_GovernmentAndOtherGrantsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_114" xlink:to="lab_cgen_GovernmentAndOtherGrantsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAuthorities_115" xlink:to="lab_cgen_GovernmentAuthorities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAuthorities_116" xlink:to="lab_cgen_GovernmentAuthorities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_117" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_118" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_119" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredRevenues_120" xlink:to="lab_cgen_IncreaseDecreaseInDeferredRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredRevenues_121" xlink:to="lab_cgen_IncreaseDecreaseInDeferredRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredRevenues_122" xlink:to="lab_cgen_IncreaseDecreaseInDeferredRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_123" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_124" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_125" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_126" xlink:to="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_127" xlink:to="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_128" xlink:to="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_InterestPaidReceivedNet_129" xlink:to="lab_cgen_InterestPaidReceivedNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_InterestPaidReceivedNet_130" xlink:to="lab_cgen_InterestPaidReceivedNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_InterestPaidReceivedNet_131" xlink:to="lab_cgen_InterestPaidReceivedNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_132" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_133" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_134" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_135" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_136" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_137" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_JmpSecuritiesLlcMember_138" xlink:to="lab_cgen_JmpSecuritiesLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_JmpSecuritiesLlcMember_139" xlink:to="lab_cgen_JmpSecuritiesLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_JmpSecuritiesLlcMember_140" xlink:to="lab_cgen_JmpSecuritiesLlcMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_141" xlink:to="lab_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_142" xlink:to="lab_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LeerinkPartnersLlcMember_143" xlink:to="lab_cgen_LeerinkPartnersLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LeerinkPartnersLlcMember_144" xlink:to="lab_cgen_LeerinkPartnersLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LeerinkPartnersLlcMember_145" xlink:to="lab_cgen_LeerinkPartnersLlcMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LicenseAgreementWithGileadMember_146" xlink:to="lab_cgen_LicenseAgreementWithGileadMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LicenseAgreementWithGileadMember_147" xlink:to="lab_cgen_LicenseAgreementWithGileadMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LicenseRevenue_148" xlink:to="lab_cgen_LicenseRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LicenseRevenue_149" xlink:to="lab_cgen_LicenseRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LicenseRevenue_150" xlink:to="lab_cgen_LicenseRevenue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_151" xlink:to="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_152" xlink:to="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_153" xlink:to="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementMember_154" xlink:to="lab_cgen_MasterClinicalAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementMember_155" xlink:to="lab_cgen_MasterClinicalAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementOneMember_156" xlink:to="lab_cgen_MasterClinicalAgreementOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementOneMember_157" xlink:to="lab_cgen_MasterClinicalAgreementOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementTwoMember_158" xlink:to="lab_cgen_MasterClinicalAgreementTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementTwoMember_159" xlink:to="lab_cgen_MasterClinicalAgreementTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_160" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_161" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_162" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_163" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_164" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_165" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_166" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_167" xlink:to="lab_cgen_May2012AgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_168" xlink:to="lab_cgen_May2012AgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_169" xlink:to="lab_cgen_May2012AgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MilestonePaymentReceivable_170" xlink:to="lab_cgen_MilestonePaymentReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MilestonePaymentReceivable_171" xlink:to="lab_cgen_MilestonePaymentReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MilestonePaymentReceivable_172" xlink:to="lab_cgen_MilestonePaymentReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_173" xlink:to="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_174" xlink:to="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetOperatingLossCarryforwardExpired_175" xlink:to="lab_cgen_NetOperatingLossCarryforwardExpired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetOperatingLossCarryforwardExpired_176" xlink:to="lab_cgen_NetOperatingLossCarryforwardExpired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NonRefundableUpfrontPayment_177" xlink:to="lab_cgen_NonRefundableUpfrontPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NonRefundableUpfrontPayment_178" xlink:to="lab_cgen_NonRefundableUpfrontPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NonRefundableUpfrontPayment_179" xlink:to="lab_cgen_NonRefundableUpfrontPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_180" xlink:to="lab_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_181" xlink:to="lab_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_182" xlink:to="lab_cgen_NumberOfWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_183" xlink:to="lab_cgen_NumberOfWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_184" xlink:to="lab_cgen_NumberOfWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_185" xlink:to="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_186" xlink:to="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_187" xlink:to="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_188" xlink:to="lab_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_189" xlink:to="lab_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_190" xlink:to="lab_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_191" xlink:to="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_192" xlink:to="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_193" xlink:to="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OtherSegmentExpenses_194" xlink:to="lab_cgen_OtherSegmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OtherSegmentExpenses_195" xlink:to="lab_cgen_OtherSegmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OtherSegmentExpenses_196" xlink:to="lab_cgen_OtherSegmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_197" xlink:to="lab_cgen_ParticipationRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_198" xlink:to="lab_cgen_ParticipationRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_199" xlink:to="lab_cgen_ParticipationRights_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_200" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_201" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_202" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_203" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_204" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfClosingPrice_205" xlink:to="lab_cgen_PercentageOfClosingPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfClosingPrice_206" xlink:to="lab_cgen_PercentageOfClosingPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_207" xlink:to="lab_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_208" xlink:to="lab_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfExpectedFromPaymentAmountPaid_209" xlink:to="lab_cgen_PercentageOfExpectedFromPaymentAmountPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfExpectedFromPaymentAmountPaid_210" xlink:to="lab_cgen_PercentageOfExpectedFromPaymentAmountPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfExpectedFromPaymentAmountPaid_211" xlink:to="lab_cgen_PercentageOfExpectedFromPaymentAmountPaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_212" xlink:to="lab_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_213" xlink:to="lab_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_214" xlink:to="lab_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_215" xlink:to="lab_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PeriodSinceApprovalWasGranted_216" xlink:to="lab_cgen_PeriodSinceApprovalWasGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PeriodSinceApprovalWasGranted_217" xlink:to="lab_cgen_PeriodSinceApprovalWasGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PeriodSinceEnterpriseBeganOperating_218" xlink:to="lab_cgen_PeriodSinceEnterpriseBeganOperating_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PeriodSinceEnterpriseBeganOperating_219" xlink:to="lab_cgen_PeriodSinceEnterpriseBeganOperating_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_220" xlink:to="lab_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_221" xlink:to="lab_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_222" xlink:to="lab_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_223" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_224" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_225" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_226" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_227" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_228" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_229" xlink:to="lab_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_230" xlink:to="lab_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_231" xlink:to="lab_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReducedCorporateIncomeTaxRate_232" xlink:to="lab_cgen_ReducedCorporateIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReducedCorporateIncomeTaxRate_233" xlink:to="lab_cgen_ReducedCorporateIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReducedTaxRate_234" xlink:to="lab_cgen_ReducedTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReducedTaxRate_235" xlink:to="lab_cgen_ReducedTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RegisteredDirectOfferingMember_236" xlink:to="lab_cgen_RegisteredDirectOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RegisteredDirectOfferingMember_237" xlink:to="lab_cgen_RegisteredDirectOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RemainingPerformanceObligationsRecognizedPercentage_238" xlink:to="lab_cgen_RemainingPerformanceObligationsRecognizedPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RemainingPerformanceObligationsRecognizedPercentage_239" xlink:to="lab_cgen_RemainingPerformanceObligationsRecognizedPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RemainingPerformanceObligationsRecognizedPercentage_240" xlink:to="lab_cgen_RemainingPerformanceObligationsRecognizedPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_241" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_242" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_243" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_244" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_245" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_246" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_247" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_248" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_249" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMember_250" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMember_251" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_252" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_253" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_254" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_255" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_256" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_257" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_258" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_259" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_260" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_261" xlink:to="lab_cgen_RetainerFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_262" xlink:to="lab_cgen_RetainerFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_263" xlink:to="lab_cgen_RetainerFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_264" xlink:to="lab_cgen_RoyaltyContingentObligations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_265" xlink:to="lab_cgen_RoyaltyContingentObligations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_266" xlink:to="lab_cgen_RoyaltyContingentObligations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentage_267" xlink:to="lab_cgen_RoyaltyPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentage_268" xlink:to="lab_cgen_RoyaltyPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentage_269" xlink:to="lab_cgen_RoyaltyPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_270" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_271" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_272" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_273" xlink:to="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_274" xlink:to="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_275" xlink:to="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_276" xlink:to="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_277" xlink:to="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_278" xlink:to="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_279" xlink:to="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_280" xlink:to="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_281" xlink:to="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_282" xlink:to="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_283" xlink:to="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_284" xlink:to="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_285" xlink:to="lab_cgen_SegmentReportingGeograhicAreaLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_286" xlink:to="lab_cgen_SegmentReportingGeograhicAreaLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_287" xlink:to="lab_cgen_SegmentReportingGeographicAreaAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_288" xlink:to="lab_cgen_SegmentReportingGeographicAreaAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_289" xlink:to="lab_cgen_SegmentReportingGeographicAreaDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_290" xlink:to="lab_cgen_SegmentReportingGeographicAreaTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_291" xlink:to="lab_cgen_SegmentReportingGeographicAreaTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ServerancePayPolicyTextBlock_292" xlink:to="lab_cgen_ServerancePayPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ServerancePayPolicyTextBlock_293" xlink:to="lab_cgen_ServerancePayPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ServerancePayPolicyTextBlock_294" xlink:to="lab_cgen_ServerancePayPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNoncurrent_295" xlink:to="lab_cgen_SeverancePayFundNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNoncurrent_296" xlink:to="lab_cgen_SeverancePayFundNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNoncurrent_297" xlink:to="lab_cgen_SeverancePayFundNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_298" xlink:to="lab_cgen_SeverancePayNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_299" xlink:to="lab_cgen_SeverancePayNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_300" xlink:to="lab_cgen_SeverancePayNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_301" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_302" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_303" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_304" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_305" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_306" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_307" xlink:to="lab_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_308" xlink:to="lab_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_309" xlink:to="lab_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsPolicyTextBlock_310" xlink:to="lab_cgen_ShortTermBankDepositsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsPolicyTextBlock_311" xlink:to="lab_cgen_ShortTermBankDepositsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsPolicyTextBlock_312" xlink:to="lab_cgen_ShortTermBankDepositsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_313" xlink:to="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_314" xlink:to="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_315" xlink:to="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_316" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_317" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_318" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SingleOperatingSegmentMember_319" xlink:to="lab_cgen_SingleOperatingSegmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SingleOperatingSegmentMember_320" xlink:to="lab_cgen_SingleOperatingSegmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_321" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_322" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_323" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_324" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_325" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_326" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_327" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_328" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_329" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_330" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_331" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_332" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TaxExemptPeriod_333" xlink:to="lab_cgen_TaxExemptPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TaxExemptPeriod_334" xlink:to="lab_cgen_TaxExemptPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TaxRateOnDistributions_335" xlink:to="lab_cgen_TaxRateOnDistributions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TaxRateOnDistributions_336" xlink:to="lab_cgen_TaxRateOnDistributions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TotalRemainingPerformanceObligations_337" xlink:to="lab_cgen_TotalRemainingPerformanceObligations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TotalRemainingPerformanceObligations_338" xlink:to="lab_cgen_TotalRemainingPerformanceObligations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TotalRemainingPerformanceObligations_339" xlink:to="lab_cgen_TotalRemainingPerformanceObligations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_340" xlink:to="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_341" xlink:to="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_342" xlink:to="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandTenShareOptionsPlanMember_343" xlink:to="lab_cgen_TwoThousandTenShareOptionsPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandTenShareOptionsPlanMember_344" xlink:to="lab_cgen_TwoThousandTenShareOptionsPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandTenShareOptionsPlanMember_345" xlink:to="lab_cgen_TwoThousandTenShareOptionsPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnderwritersMember_346" xlink:to="lab_cgen_UnderwritersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnderwritersMember_347" xlink:to="lab_cgen_UnderwritersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL_348" xlink:to="lab_country_IL_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_349" xlink:to="lab_country_US_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription_350" xlink:to="lab_dei_AmendmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_351" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId_352" xlink:to="lab_dei_AuditorFirmId_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation_353" xlink:to="lab_dei_AuditorLocation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName_354" xlink:to="lab_dei_AuditorName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember_355" xlink:to="lab_dei_BusinessContactMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_356" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress_357" xlink:to="lab_dei_ContactPersonnelEmailAddress_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelFaxNumber_358" xlink:to="lab_dei_ContactPersonnelFaxNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName_359" xlink:to="lab_dei_ContactPersonnelName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_360" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_361" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard_362" xlink:to="lab_dei_DocumentAccountingStandard_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_363" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag_364" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_365" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_366" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_367" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement_368" xlink:to="lab_dei_DocumentRegistrationStatement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport_369" xlink:to="lab_dei_DocumentShellCompanyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_370" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_371" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_372" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_373" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3_374" xlink:to="lab_dei_EntityAddressAddressLine3_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_375" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_376" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_377" xlink:to="lab_dei_EntityAddressesAddressTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_378" xlink:to="lab_dei_EntityAddressesAddressTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_379" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_380" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_381" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_382" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_383" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_384" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_385" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_386" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_387" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_388" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_389" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_390" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_391" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_392" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag_393" xlink:to="lab_dei_IcfrAuditorAttestationFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_394" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_OtherReportingStandardItemNumber_395" xlink:to="lab_dei_OtherReportingStandardItemNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_396" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_397" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_398" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_399" xlink:to="lab_srt_DirectorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember_400" xlink:to="lab_srt_EuropeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_401" xlink:to="lab_srt_MajorCustomersAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_402" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_403" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_404" xlink:to="lab_srt_NameOfMajorCustomerDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_405" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_406" xlink:to="lab_srt_RangeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis_407" xlink:to="lab_srt_StatementScenarioAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_408" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_409" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_410" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_411" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_412" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_413" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_414" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_415" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_416" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_417" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_418" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_419" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_420" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_421" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization_422" xlink:to="lab_us-gaap_AdjustmentForAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_423" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_424" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_425" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_426" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_427" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_428" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_429" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_430" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_431" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_432" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_433" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_434" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_435" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_436" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_437" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_438" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_439" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_440" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_441" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_442" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_443" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_444" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_445" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_446" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDevelopment_447" xlink:to="lab_us-gaap_BusinessDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_448" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_449" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_450" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_451" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_452" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_453" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_454" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_455" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_456" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_457" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_458" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_459" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_460" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_461" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_462" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_463" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_464" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_465" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_466" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_467" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_468" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_469" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_470" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_471" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_472" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_473" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_474" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_475" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_476" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_477" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_478" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_479" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_480" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_481" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_482" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_483" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_484" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_485" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_486" xlink:to="lab_us-gaap_ComputerEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_487" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_488" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_489" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_490" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_491" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_492" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_493" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_494" xlink:to="lab_us-gaap_CostOfRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_495" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_496" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_497" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_498" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_499" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_500" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_501" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_502" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_503" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_504" xlink:to="lab_us-gaap_DeferredRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_505" xlink:to="lab_us-gaap_DeferredRevenueCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_506" xlink:to="lab_us-gaap_DeferredRevenueCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_507" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_508" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_509" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_510" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_511" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_512" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_513" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_514" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_515" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_516" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_517" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_518" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_519" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_520" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_521" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_522" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_523" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_524" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent_525" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent_526" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_527" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNet_528" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet_529" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_530" xlink:to="lab_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount_531" xlink:to="lab_us-gaap_DerivativeNotionalAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_532" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_533" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_534" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_535" xlink:to="lab_us-gaap_DomesticCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_536" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_537" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_538" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_539" xlink:to="lab_us-gaap_EarningsPerShareBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_540" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_541" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_542" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_543" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_544" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_545" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_546" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_547" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_548" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_549" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_550" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_551" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_552" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_553" xlink:to="lab_us-gaap_EmployeeStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_554" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_555" xlink:to="lab_us-gaap_EquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost_556" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost_557" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_558" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_559" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_560" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_561" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_562" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_563" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_564" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_565" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_566" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_567" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_568" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_569" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_570" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_571" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_572" xlink:to="lab_us-gaap_FinancialInstrumentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_573" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_574" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_575" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_576" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_577" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_578" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_579" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_580" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_581" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_582" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_583" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets_584" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_585" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_586" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_587" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_588" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_589" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_590" xlink:to="lab_us-gaap_GrossProfit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_591" xlink:to="lab_us-gaap_GrossProfit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure_592" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfInvestments_593" xlink:to="lab_us-gaap_ImpairmentOfInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_594" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_595" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_596" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_597" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_598" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_599" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_600" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_601" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_602" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_603" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_604" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_605" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_606" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_607" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_608" xlink:to="lab_us-gaap_IncomeTaxesPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_609" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_610" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_611" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_612" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_613" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_614" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_615" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_616" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_617" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_618" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_619" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_620" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_621" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_622" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_623" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_624" xlink:to="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_625" xlink:to="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialOfferingPeriod_626" xlink:to="lab_us-gaap_InitialOfferingPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense_627" xlink:to="lab_us-gaap_InterestAndDebtExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense_628" xlink:to="lab_us-gaap_InterestAndDebtExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember_629" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_630" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_631" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_632" xlink:to="lab_us-gaap_InvestmentIncomeInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_633" xlink:to="lab_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_634" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_635" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_636" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_637" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_639" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_640" xlink:to="lab_us-gaap_LesseeDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_641" xlink:to="lab_us-gaap_LesseeDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_642" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_643" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_644" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_645" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_646" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_647" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_648" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_649" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_650" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_651" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_652" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_653" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_654" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_655" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_656" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_657" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_658" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_659" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_660" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_661" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_662" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_663" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_664" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_665" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_666" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_667" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_668" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_669" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_670" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_671" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_672" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_673" xlink:to="lab_us-gaap_MoneyMarketFundsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_674" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_675" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_676" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_677" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_678" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_679" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_680" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_681" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_683" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_684" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_685" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_686" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_687" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_688" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_689" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_690" xlink:to="lab_us-gaap_NoncurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_691" xlink:to="lab_us-gaap_NumberOfOperatingSegments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_692" xlink:to="lab_us-gaap_NumberOfOperatingSegments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_693" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_694" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_695" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_696" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_697" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_698" xlink:to="lab_us-gaap_OperatingLeaseExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_699" xlink:to="lab_us-gaap_OperatingLeaseExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_700" xlink:to="lab_us-gaap_OperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_701" xlink:to="lab_us-gaap_OperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_702" xlink:to="lab_us-gaap_OperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_703" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_704" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_705" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_706" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_707" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_708" xlink:to="lab_us-gaap_OperatingLeasePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_709" xlink:to="lab_us-gaap_OperatingLeasePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_710" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_711" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_712" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_713" xlink:to="lab_us-gaap_OperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_714" xlink:to="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_715" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_716" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_717" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_718" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_719" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_720" xlink:to="lab_us-gaap_OtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_721" xlink:to="lab_us-gaap_OtherCommitmentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable_722" xlink:to="lab_us-gaap_OtherCommitmentsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_723" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_724" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_725" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_726" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_727" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_728" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_729" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_730" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_731" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_732" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities_733" xlink:to="lab_us-gaap_OtherLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments_734" xlink:to="lab_us-gaap_OtherShortTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments_735" xlink:to="lab_us-gaap_OtherShortTermInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_736" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromProductiveAssets_737" xlink:to="lab_us-gaap_PaymentsForProceedsFromProductiveAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromProductiveAssets_738" xlink:to="lab_us-gaap_PaymentsForProceedsFromProductiveAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_739" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_740" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_741" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_742" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_743" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_744" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_745" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_746" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_747" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_748" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_749" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_750" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_751" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_752" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_753" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_754" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_755" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_756" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_757" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent_758" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds_759" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_760" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_761" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_762" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_763" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_764" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_765" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_766" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_767" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_768" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_769" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_770" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_771" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_772" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_773" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_774" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_775" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_776" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_777" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_778" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_779" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_780" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_781" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals_782" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals_783" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals_784" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals_785" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_786" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment_787" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_788" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_789" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_790" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_791" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_792" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_793" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_794" xlink:to="lab_us-gaap_ReceivablesNetCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_795" xlink:to="lab_us-gaap_ReceivablesNetCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_796" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_797" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_798" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_799" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_800" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_801" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_802" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_803" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_804" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_805" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_806" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_807" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_808" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_809" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_810" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_811" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_812" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_813" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_814" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_815" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_816" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_817" xlink:to="lab_us-gaap_Revenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_818" xlink:to="lab_us-gaap_Revenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_819" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_820" xlink:to="lab_us-gaap_RoyaltyExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_821" xlink:to="lab_us-gaap_RoyaltyExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_822" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_823" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_824" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_825" xlink:to="lab_us-gaap_SalesRevenueNetMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_826" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_827" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_828" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_829" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_830" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_831" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_832" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_833" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_834" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_835" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_836" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_837" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_838" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_839" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_840" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_841" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_842" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_843" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_844" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_845" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_846" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_847" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_848" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_849" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_850" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_851" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_852" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_853" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_854" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_855" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_856" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_857" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_858" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_859" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_860" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_861" xlink:to="lab_us-gaap_SegmentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_862" xlink:to="lab_us-gaap_SegmentReportingAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_863" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_864" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember_865" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_866" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_867" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_868" xlink:to="lab_us-gaap_SeveranceCosts1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_869" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_870" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_871" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_872" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_873" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_874" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_875" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_876" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_877" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_878" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_879" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_880" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_881" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_882" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_883" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_884" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_885" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_886" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_887" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_888" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_889" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_890" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_891" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_892" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_893" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_894" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_895" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_896" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_897" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_898" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_899" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_900" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_901" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_902" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_903" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_904" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_905" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_906" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_907" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_908" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_909" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_910" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_911" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_912" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_913" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_914" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_915" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_916" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_917" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_918" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_919" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_920" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_921" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_922" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_923" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_924" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_925" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_926" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_927" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_928" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_929" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_930" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_931" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_932" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_933" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_934" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_935" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_936" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_937" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_938" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_939" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_940" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_941" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_942" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_943" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_944" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_945" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_946" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_947" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_948" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_949" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_950" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_951" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_952" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_953" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_954" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_955" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_956" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_957" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_958" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_959" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_960" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_961" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_962" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_963" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_964" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_965" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_966" xlink:to="lab_us-gaap_StockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome_967" xlink:to="lab_us-gaap_SubleaseIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_968" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_969" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_970" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_971" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_972" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_973" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_974" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_975" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOfCommonParentMember_976" xlink:to="lab_us-gaap_SubsidiaryOfCommonParentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOfCommonParentMember_977" xlink:to="lab_us-gaap_SubsidiaryOfCommonParentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_978" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_979" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_980" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_981" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_982" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_983" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_984" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_985" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_986" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_987" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeasePayment_988" xlink:to="lab_us-gaap_VariableLeasePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeasePayment_989" xlink:to="lab_us-gaap_VariableLeasePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_990" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_991" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_992" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_993" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_994" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_995" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>cgen-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-daei1" roleURI="http://cgen.com/role/cgen-daei1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#ConsolidatedBalanceSheets" roleURI="http://cgen.com/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-cbsp" roleURI="http://cgen.com/role/cgen-cbsp"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-csocl" roleURI="http://cgen.com/role/cgen-csocl"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#StatementsOfChangesInShareholdersEquity" roleURI="http://cgen.com/role/StatementsOfChangesInShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-g" roleURI="http://cgen.com/role/cgen-g"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-sap" roleURI="http://cgen.com/role/cgen-sap"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-oarape" roleURI="http://cgen.com/role/cgen-oarape"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#Leases" roleURI="http://cgen.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-paen" roleURI="http://cgen.com/role/cgen-paen"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-cac1" roleURI="http://cgen.com/role/cgen-cac1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-se12" roleURI="http://cgen.com/role/cgen-se12"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-it" roleURI="http://cgen.com/role/cgen-it"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-giamc" roleURI="http://cgen.com/role/cgen-giamc"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-faoin" roleURI="http://cgen.com/role/cgen-faoin"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-rpbat" roleURI="http://cgen.com/role/cgen-rpbat"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-lps" roleURI="http://cgen.com/role/cgen-lps"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-sapp" roleURI="http://cgen.com/role/cgen-sapp"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-sapt" roleURI="http://cgen.com/role/cgen-sapt"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-oarapet" roleURI="http://cgen.com/role/cgen-oarapet"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#LeasesTables" roleURI="http://cgen.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-paent" roleURI="http://cgen.com/role/cgen-paent"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-set1" roleURI="http://cgen.com/role/cgen-set1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-itt" roleURI="http://cgen.com/role/cgen-itt"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-giamct" roleURI="http://cgen.com/role/cgen-giamct"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-faoint" roleURI="http://cgen.com/role/cgen-faoint"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#RelatedPartyBalancesAndTransactionsTables" roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-lpst" roleURI="http://cgen.com/role/cgen-lpst"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-gd" roleURI="http://cgen.com/role/cgen-gd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-sapnd" roleURI="http://cgen.com/role/cgen-sapnd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-sapsodrfpaed" roleURI="http://cgen.com/role/cgen-sapsodrfpaed"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails" roleURI="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-oaraped" roleURI="http://cgen.com/role/cgen-oaraped"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails" roleURI="http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#LeasesScheduleOfOperatingLeasesDetails" roleURI="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-paend" roleURI="http://cgen.com/role/cgen-paend"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-sesopnd" roleURI="http://cgen.com/role/cgen-sesopnd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#ShareholdersEquityScheduleOfOptionActivityDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#cgen-sesosced" roleURI="http://cgen.com/role/cgen-sesosced"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#IncomeTaxesNarrativeDetails" roleURI="http://cgen.com/role/IncomeTaxesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#IncomeTaxesScheduleOfLossBeforeTaxesDetails" roleURI="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#GeographicInformationAndMajorCustomersDetails" roleURI="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails" roleURI="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#RelatedPartyBalancesAndTransactionsDetails" roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails" roleURI="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#SUBSEQUENTEVENTS" roleURI="http://cgen.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#SubsequentEventsNarrativeDetails" roleURI="http://cgen.com/role/SubsequentEventsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#LEASESNarrative" roleURI="http://cgen.com/role/LEASESNarrative"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#PROPERTYANDEQUIPMENTNETNarrativeDetails" roleURI="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails" roleURI="http://cgen.com/role/GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#MARKETABLESECURITIES" roleURI="http://cgen.com/role/MARKETABLESECURITIES"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#MARKETABLESECURITIESTables" roleURI="http://cgen.com/role/MARKETABLESECURITIESTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#MARKETABLESECURITIESDetails" roleURI="http://cgen.com/role/MARKETABLESECURITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails" roleURI="http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#FAIRVALUEMEASUREMENTSDetails" roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#FAIRVALUEMEASUREMENTSTables" roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTSTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#FAIRVALUEMEASUREMENTS" roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTS"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails" roleURI="http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails" roleURI="http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#MARKETABLESECURITIESNarrativeDetails" roleURI="http://cgen.com/role/MARKETABLESECURITIESNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20241231.xsd#SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details" roleURI="http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"/>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-daei1">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_dei_OtherReportingStandardItemNumber_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_48"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1" xlink:to="loc_dei_BusinessContactMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_6" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentType_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AmendmentFlag_9" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AmendmentDescription_10" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentRegistrationStatement_11" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentAnnualReport_12" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentTransitionReport_13" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentShellCompanyReport_14" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_15" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityFileNumber_16" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_ContactPersonnelName_17" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityRegistrantName_18" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_19" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine1_20" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine2_21" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine3_22" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressCityOrTown_23" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressCountry_24" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressPostalZipCode_25" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_CityAreaCode_26" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_LocalPhoneNumber_27" order="230" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_ContactPersonnelFaxNumber_28" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_ContactPersonnelEmailAddress_29" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_Security12bTitle_30" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_TradingSymbol_31" order="270" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_SecurityExchangeName_32" order="280" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_33" order="290" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_34" order="300" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_35" order="310" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_36" order="320" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityInteractiveDataCurrent_37" order="330" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityFilerCategory_38" order="340" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityEmergingGrowthCompany_39" order="350" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_40" order="360" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityExTransitionPeriod_41" order="370" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentAccountingStandard_42" order="380" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_OtherReportingStandardItemNumber_43" order="390" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityShellCompany_44" order="400" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AuditorName_45" order="410" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AuditorLocation_46" order="420" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AuditorFirmId_47" order="430" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_48" order="440" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_37"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_OtherShortTermInvestments_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_ReceivablesNetCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_cgen_SeverancePayFundNoncurrent_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_AssetsNoncurrent_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_AccountsPayableCurrent_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_DeferredRevenueCurrent_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_LiabilitiesCurrent_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_25" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_25" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_25" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_25" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommitmentsAndContingencies_30" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquityAbstract_31" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_CommonStockValue_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_32" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_33" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_StockholdersEquity_35" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_37" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbsp">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GrossProfit_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_BusinessDevelopment_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OperatingExpenses_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_15" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_16" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_17" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_19" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/StatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_NumberOfWarrantsExercised_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_15" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_NetIncomeLoss_21" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_23" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_41"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_InterestPaidReceivedNet" xlink:label="loc_cgen_InterestPaidReceivedNet_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_3" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_SeverancePayNet_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_12" order="100" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_13" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_14" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInDeferredRevenues_15" order="130" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_16" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_30" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_30" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_30" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38" xlink:to="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_38" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38" xlink:to="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_39" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_41" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_41" xlink:to="loc_cgen_InterestPaidReceivedNet_41" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_43" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_43" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_43" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_44" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_43" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-g">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sap">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oarape">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/Leases">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paen">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cac1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-se12">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-it">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-giamc">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-faoin">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-rpbat">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-lps">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapp">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsPolicyTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="loc_cgen_ServerancePayPolicyTextBlock_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_24"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ShortTermBankDepositsPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_12" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ServerancePayPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_17" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_18" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_19" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_20" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_21" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_22" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_23" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_24" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapt">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" xlink:label="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oarapet">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" xlink:label="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paent">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-set1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-itt">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-giamct">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-faoint">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-lpst">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-gd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NonRefundableUpfrontPayment" xlink:label="loc_cgen_NonRefundableUpfrontPayment_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfExpectedFromPaymentAmountPaid" xlink:label="loc_cgen_PercentageOfExpectedFromPaymentAmountPaid_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_NonRefundableUpfrontPayment_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_MilestonePaymentReceivable_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_AccruedMilestonePayment_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_PercentageOfExpectedFromPaymentAmountPaid_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="loc_cgen_MasterClinicalAgreementOneMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="loc_cgen_MasterClinicalAgreementTwoMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LicenseAgreementWithGileadMember" xlink:label="loc_cgen_LicenseAgreementWithGileadMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="loc_us-gaap_ImpairmentOfInvestments_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:label="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TotalRemainingPerformanceObligations" xlink:label="loc_cgen_TotalRemainingPerformanceObligations_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RemainingPerformanceObligationsRecognizedPercentage" xlink:label="loc_cgen_RemainingPerformanceObligationsRecognizedPercentage_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AccruedMilestonePayments" xlink:label="loc_cgen_AccruedMilestonePayments_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LicenseRevenue" xlink:label="loc_cgen_LicenseRevenue_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredRevenuesIncludedInCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredRevenuesIncludedInNonCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_35"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementOneMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementTwoMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_LicenseAgreementWithGileadMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6" xlink:to="loc_us-gaap_StockOptionMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_AdjustmentForAmortization_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_ImpairmentOfInvestments_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_DeferredRevenue_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_13" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_14" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_SeveranceCosts1_16" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_17" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_18" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_19" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_TotalRemainingPerformanceObligations_20" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_RemainingPerformanceObligationsRecognizedPercentage_21" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_DerivativeRelatedExpense_22" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_23" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_24" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_25" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_DerivativeNotionalAmount_26" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_27" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_28" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_AccruedMilestonePayments_29" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_30" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_31" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_LicenseRevenue_32" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_33" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_34" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_MilestonePaymentReceivable_35" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapsodrfpaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AnnualDepreciationRate" xlink:label="loc_cgen_AnnualDepreciationRate_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_srt_RangeAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6" xlink:to="loc_srt_RangeMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MinimumMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MaximumMember_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_cgen_AnnualDepreciationRate_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_cgen_AnnualDepreciationRateDescription_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_cgen_EmployeeStockPurchasePlanMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MinimumMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MaximumMember_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_12" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oaraped">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GovernmentAuthorities" xlink:label="loc_cgen_GovernmentAuthorities_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_cgen_GovernmentAuthorities_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherAssetsCurrent_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paend">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AntibodiesDiscoveryCollaborationAgreementMember" xlink:label="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_GileadAgreementMember" xlink:label="loc_cgen_GileadAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_26"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_ResearchAndDevelopmentGrantOneMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_May2012AgreementMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_GileadAgreementMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_RangeAxis_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7" xlink:to="loc_srt_RangeMember_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7" xlink:to="loc_srt_MinimumMember_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7" xlink:to="loc_srt_MaximumMember_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_11" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_us-gaap_RoyaltyExpense_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_cgen_RoyaltyContingentObligations_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_cgen_ParticipationRights_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_cgen_RetainerFee_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_19" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_cgen_AgreementStartDate_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_cgen_AgreementTerminationDescription_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_cgen_ExtendLease_22" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_cgen_ContingentFees_23" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_24" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_cgen_RoyaltyPercentage_25" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_11" xlink:to="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_26" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesopnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_JmpSecuritiesLlcMember" xlink:label="loc_cgen_JmpSecuritiesLlcMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_LeerinkPartnersLlcMember" xlink:label="loc_cgen_LeerinkPartnersLlcMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_TwoThousandTenShareOptionsPlanMember" xlink:label="loc_cgen_TwoThousandTenShareOptionsPlanMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_42"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_43"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InitialOfferingPeriod" xlink:label="loc_us-gaap_InitialOfferingPeriod_46"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_47"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_48"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_CollaborativeArrangementsMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_CollaborativeArrangementsTwoMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_JmpSecuritiesLlcMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_LeerinkPartnersLlcMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_cgen_RegisteredDirectOfferingMember_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_WarrantMember_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_cgen_UnderwritersMember_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_14" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_14" xlink:to="loc_us-gaap_PlanNameDomain_14" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_14" xlink:to="loc_cgen_TwoThousandTenShareOptionsPlanMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_17" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17" xlink:to="loc_us-gaap_EmployeeStockMember_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_20" xlink:to="loc_us-gaap_RelatedPartyDomain_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_20" xlink:to="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_23" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_27" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_29" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_30" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_31" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_32" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_33" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_34" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_35" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_36" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_37" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_38" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_39" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_40" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_41" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_42" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_PercentageOfClosingPrice_43" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_44" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_45" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_InitialOfferingPeriod_46" order="230" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_47" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_48" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_49" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50" order="270" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_10" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_11" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_16" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_22" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesosced">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_EmployeeStockMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="loc_cgen_NetOperatingLossCarryforwardExpired_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="loc_cgen_ReducedCorporateIncomeTaxRate_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ReducedTaxRate" xlink:label="loc_cgen_ReducedTaxRate_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_DomesticCountryMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_us-gaap_SubsidiaryOfCommonParentMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_IncomeTaxesPaid_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_12" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_OperatingLossCarryforwards_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_NetOperatingLossCarryforwardExpired_14" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_15" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_ReducedCorporateIncomeTaxRate_16" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_ReducedTaxRate_17" order="90" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_cgen_DeferredIncomeTaxLeaseLiabilities_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_10" xlink:to="loc_cgen_DeferredIncomeTaxRightOfUseAssets_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_10" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="loc_cgen_SegmentReportingGeographicAreaAxis_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="loc_cgen_SegmentReportingGeographicAreaDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_country_IL_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_srt_EuropeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_country_IL_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_country_US_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6" xlink:to="loc_us-gaap_Revenues_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6" xlink:to="loc_us-gaap_NoncurrentAssets_7" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InterestAndDebtExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_OtherLiabilities_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_2" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_EarningsPerShareBasic_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SubsequentEventsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OrdinarySharesIssuedAndSoldThroughAtmMember" xlink:label="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" xlink:to="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LEASESNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaap_VariableLeasePayment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseExpense_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_VariableLeasePayment_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_SubleaseIncome_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_7" order="60" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_EquipmentMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5" xlink:to="loc_us-gaap_Depreciation_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIESTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIESDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_11" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_11" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/FAIRVALUEMEASUREMENTSTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/FAIRVALUEMEASUREMENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_SingleOperatingSegmentMember" xlink:label="loc_cgen_SingleOperatingSegmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment" xlink:label="loc_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_ClinicalAmountOfExpenseForResearchAndDevelopment" xlink:label="loc_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_OtherSegmentExpenses" xlink:label="loc_cgen_OtherSegmentExpenses_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="loc_us-gaap_SegmentDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1" xlink:to="loc_cgen_SingleOperatingSegmentMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4" xlink:to="loc_us-gaap_Revenues_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4" xlink:to="loc_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4" xlink:to="loc_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4" xlink:to="loc_cgen_FinancialIncomeExpenseNet_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4" xlink:to="loc_cgen_OtherSegmentExpenses_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4" xlink:to="loc_us-gaap_NetIncomeLoss_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIESNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20241231.xsd#cgen_CustomerTwoMember" xlink:label="loc_cgen_CustomerTwoMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:to="loc_us-gaap_SalesRevenueNetMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_srt_MajorCustomersAxis_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7" xlink:to="loc_srt_NameOfMajorCustomerDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7" xlink:to="loc_cgen_CustomerOneMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7" xlink:to="loc_cgen_CustomerTwoMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_11" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_11" order="0" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" RG"P,# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN+BXD>:>XGF\2ZQ)----(S22S2R,SR2.S.[LS,Q8DT5#\#O^27>%_P#N-?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ)_V/\X_]6.)/6****_=SP HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"+_UW_#Q_$W%?_)4\2?]C_./_5CB3UBBBBOW<\ **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXD_['^<?^K'$GK%%%%?NYX 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/$581MRQK8JISXFLDUS?O:L_>O+XFVRBBBOR(]@**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
M0CX'?\DN\+_]QK_U(M6HH^!W_)+O"_\ W&O_ %(M6HK_ +0?HM?\HR?1S_[,
M1X1?^N_X>/XFXK_Y*GB3_L?YQ_ZL<2>L4445^[G@!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN:%2LG&@^7W;8:%&-K^[><W(HHHK^4#ZT**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _0CX'?\DN\+_P#<:_\ 4BU:BCX'?\DN\+_]QK_U(M6HK_M!^BU_
MRC)]'/\ [,1X1?\ KO\ AX_B;BO_ )*GB3_L?YQ_ZL<2>L4445^[G@!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#]"/@=_R2[PO_W&O_4BU:BCX'?\DN\+_P#<:_\ 4BU:BO\ M!^BU_RC
M)]'/_LQ'A%_Z[_AX_B;BO_DJ>)/^Q_G'_JQQ)ZQ1117[N> %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3G)LHHHK\7/;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH _0CX'?\DN\+_]QK_U(M6HH^!W_)+O
M"_\ W&O_ %(M6HK_ +0?HM?\HR?1S_[,1X1?^N_X>/XFXK_Y*GB3_L?YQ_ZL
M<2>L4445^[G@!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=337-S<S27%Q<7$CS3W$\SM)----(S22S2R,SR2.S.[LS,Q8DU_EIXR?MB^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]"/@=_P DN\+_ /<:
M_P#4BU:BCX'?\DN\+_\ <:_]2+5J*_[0?HM?\HR?1S_[,1X1?^N_X>/XFXK_
M .2IXD_['^<?^K'$GK%%%%?NYX 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<=XA^(/@O
MPL[0ZYXBT^SN8YHH9;&-Y+[48'G@-S$UQINGQW=_;Q/!MD6XFMT@Q)"#)NGA
M$GSW%'%W"G!&55,^XTXGX>X1R.C4C2JYSQ1G66Y!E5*K*%2I&G4S'-<3A,'"
MI*G1JU(PE64G"E4DERPDUTX7!XS'5EA\%A<3C*[5U0PM"KB*S2:3:IT8SFU>
M45=1M=I=4=C17R5XA_:8G+M%X5\.Q)&LT3)?>(97E>:#R#Y\;:7ITT*VTPN6
M BF&L7:-!$2]NLEQMMO /$OCKQ;XO\I?$6N7>HPP>68K7$%I8K)%YX2X_L^Q
MBMK)KM5N9X_MC6YNC"_DF8Q*B+_FKXP?M:/HZ<!1Q6!\.L'Q%XR9]1J5J,/[
M(H5>%>$E6P]6%.K#$<39_@GCYTZCE4>$Q>2<,9[@<4J,ZD<5"A4PU:O^FY-X
M0\29AR5,RGALEP\E&3]M)8O&<LDVG'"X>?LTUISPKXJA4@Y).',I1C]Q>(?C
M-\/?#R,&UV+6;D1131V?AX+JSS)+.8"JWL+KI$4T062>6WNM2MYU@0.L;--;
MI-\]^(?VC_%6H(T/A_3-/\.QO%$IN)&_MK48ITG,DDEO-<P6VG+%-"$MVAN-
M)NG0&:5+@220FW^=:*_RE\8_VGWTH_%/VN!R'B' >$?#]2A7PT\N\.</5P6;
MXF%:ZCB,7Q=F5;'\18;'T(2G3HU^',9P[047"I+"2Q5*GB%^M9+X6<*Y3:IB
M,-4SC$J49*KF4E.C%QM[L,'25/#2IR:3<<3#$R>JY^1N)K:UKVL^([Z34M<U
M*[U2]DWCSKN5I/*C>:6X^SVT?$-I:)+/,\-G:QPVL'F,L$,:G;63117^?>:9
MKFF>9CC,WSK,<?F^;9C7J8K,,SS3&8C,,QQV*JOFJXG&8W%U*N)Q->H]:E:O
M5G4F]92;/T2E2I4*<*-"E3HT:<5"G2I0C3ITXK:,(02C&*Z**278****X#0*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /T(^!W_)+O"__<:_
M]2+5J*/@=_R2[PO_ -QK_P!2+5J*_P"T'Z+7_*,GT<_^S$>$7_KO^'C^)N*_
M^2IXD_['^<?^K'$GK%%%%?NYX 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /<:_P#4BU:BO^T'Z+7_ "C)]'/_ +,1X1?^N_X>/XFXK_Y*GB3_ +'^<?\
MJQQ)ZQ1117[N> %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45%<7$%
MI!-=74T5M;6T4EQ<7%Q(D,%O!"C233332,L<444:L\DDC*B(K,S!037BWB/X
M^^!-$\Z'3IKOQ)>Q_;8A'I<)CL4NK7"0I/J5YY$3VEW,2L5]I4>K1^3')<*D
MBFW6X_,?$SQI\)_!O+(YMXH^(/"W!.%JTY5,)2SS-</0S/,HPJ0IU%D^2TY5
M<XSFI2E4BZM+*L!C*M*GSU:D(TJ=2<?4RO),WSJK['*LNQ>.FFE-T*,I4J3:
M;7MJ[2HT$[:.M4@F[)-MI/VZLG6M>T?PY8R:EKFI6FEV4>\>==RK'YLB0RW'
MV>VCYEN[MX8)GAL[6.:ZG\ME@AD8;:^*?%7Q_P#&FN/)#HS1>%M.>*:$PV7E
MWFHR)<0112-+JUS;K)%-%(L\EG<:7;Z7/;"?#23S0PW"^+7U_?ZI=2WVI7MW
MJ-[/L\Z\OKB:[NIO*C2&/S;BX>263RXHXXDWN=D:(BX50!_EQXR?MB/#3A^6
M8Y3X)\"9UX@X^C4J8;"<5<4SGPEPE4?LIRI9G@<K]GB.*LVPBJ^RA+ 9GA.#
ML943KOV]!4J3Q'ZMDO@SFF(]E6SS,*&74Y)2GA,(EC,8M5>E4JWCA*,[<S]I
M2GC8+W?=E=\OV9XA_:/\*Z>[0^'],U'Q%(DT2FXD;^Q=.E@> R226\UQ!<ZB
MTT,Q2W:&XTFU1R)I4N#''";CY[\0_&;XA>(78-KLVC6QFBFCL_#P;24A>* P
M%5O87;5Y8I2SSRV]UJ5Q T[AUC58;=(?+**_RE\8_I\_2C\:_:X3/O$C'\*\
M/SKUZT.%O#E5>#,HC"O=2PF+Q66XA\19W@*<.2-'!\1Y]G%"G*E"O&'UIU*\
M_P!:R7P^X5R.T\/EE/%XE1C%XO,K8VM>-O?A"K'ZM0J-W;GAL/1D[N-^2T44
M445_&Q]H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Z$? [_ ))=X7_[C7_J
M1:M11\#O^27>%_\ N-?^I%JU%?\ :#]%K_E&3Z.?_9B/"+_UW_#Q_$W%?_)4
M\2?]C_./_5CB3UBBBBOW<\ **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN<ZDYMRG.3<I2;E)MML^W244HQ2C&*2C%*R22LDDM$DM$EHD%%%%9C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _0CX'?\DN\+_P#<:_\ 4BU:BCX'?\DN\+_]QK_U
M(M6HK_M!^BU_RC)]'/\ [,1X1?\ KO\ AX_B;BO_ )*GB3_L?YQ_ZL<2>L44
M45^[G@!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX;#8.C##X3#T,+0II*%##TJ="C!)))0ITHQA%))))12226R"BBBO%-PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /T(^!W_ "2[PO\ ]QK_ -2+
M5J*/@=_R2[PO_P!QK_U(M6HK_M!^BU_RC)]'/_LQ'A%_Z[_AX_B;BO\ Y*GB
M3_L?YQ_ZL<2>L4445^[G@!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^A'P._Y)
M=X7_ .XU_P"I%JU%'P._Y)=X7_[C7_J1:M17_:#]%K_E&3Z.?_9B/"+_ -=_
MP\?Q-Q7_ ,E3Q)_V/\X_]6.)/6****_=SP HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'Z$? [_DEWA?_N-?^I%JU%'P._Y)=X7_ .XU_P"I%JU%
M?]H/T6O^49/HY_\ 9B/"+_UW_#Q_$W%?_)4\2?\ 8_SC_P!6.)/6****_=SP
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\M\0_&;X>^'D8-K
ML6LW(BBFCL_#P75GF26<P%5O8772(IH@LD\MO=:E;SK @=8V::W2;X?COQ,\
M//"_*GG?B+QOPMP1E;IXFI1Q?$^>9?D\<8\)"$Z]'+J>-Q%*MF6+BJE*,,%E
M]/$XRM5K4*-&A4K5Z4)]^ RO,LUK>PRW XO'5KQ3AA:%2LX<[:C*HX1<:4-&
MW4J.,(J,I2DHQ;7J55+Z_L=+M9;[4KVTTZR@V>=>7UQ#:6L/FR)#'YMQ</'#
M'YDTD<2;W&^1T1<LR@_&GB']H_Q5J"-#X?TS3_#L;Q1*;B1O[:U&*=)S)));
MS7,%MIRQ30A+=H;C2;IT!FE2X$DD)M_"]:U[6?$=])J6N:E=ZI>R;QYUW*TG
ME1O-+<?9[:/B&TM$EGF>&SM8X;6#S&6"&-3MK_+_ ,8OVO\ X*\*TL1@/![A
M;B+Q4S?V<U0SC,Z=?@C@^E*<:T*5=2S3!UN*L?4P]6%*O6R^IPYD]+$X>I&G
M2SG#UW4]A^IY+X-YYBW&IG.+PV4T;KFHTG''8QI<K<?W4UA*:DFXQJ+$UG&2
M;="4;<WVCXH_:#\':))<VFCPW?B>]@PJR6;)::,TR7307$)U28232>7%&]Q#
M<V&G7]C=*]NL-V5DDE@\!\5?'?QQXB22ULKB+PU8--,RIHIFBU%X#/%-:QW.
MKR2-<B:V6$(\VF+I278EN%N+=H)5@B\6HK_*+QD_:)?2E\9(YCEV)X\J<"<+
M9C3JX>?"_AU0_P!6L.\)5JSE/#XG/J<Z_%F-IXC#N&#QM#$9\\OQ>&A.E/ P
MIXK%PK_K>2^''"F2NG5AEZQ^+IM26*S*7UJ7.DK2AAVHX2FXR3G"4</[2$FF
MJC<(.,UQ<3W<\UU=337-S<S27%Q<7$CS3W$\SM)----(S22S2R,SR2.S.[LS
M,Q8DU#117\05:M6O5J5Z]2I6K5JDZM:M5G*I5JU:DG.I4J5)MSG4G-N4YR;E
M*3<I-MMGW22BE&*48Q248I6225DDEHDEHDM$@HHHK,84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?H1\#O\ DEWA?_N-?^I%JU%'P._Y)=X7_P"XU_ZD6K45_P!H/T6O
M^49/HY_]F(\(O_7?\/'\3<5_\E3Q)_V/\X_]6.)/6****_=SP HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHQ2****_+3U0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _0CX'?\DN\+_P#<:_\ 4BU:BCX'?\DN\+_]QK_U(M6HK_M!^BU_
MRC)]'/\ [,1X1?\ KO\ AX_B;BO_ )*GB3_L?YQ_ZL<2>L4445^[G@!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4G]J_P!@6\7EM]G\-&YTOS)D\\>=+>?:I]3?>D^R2V^W"Q;R8)?L@N(_./\
MGWXP?M._HM>%T<5@LCXFQ?BQQ#AZE:C_ &9X>8;Z]E4:M*K"DIU>+\<\'PU7
MPE6]6=+$9'CL\E*%!S=%0K8:=?\ 1,F\+>*\U<)U\+#*,-)1E[7,9<E:S3=E
M@Z?/BHS6B<:].@DY6YKQDH_<7B'QGX5\*HS>(-=T_39%BBN!:23>;J,L$TYM
MHYK?2[<3:C<Q&975I+>UE1!%,[LL<$S)\]^(?VF( C1>%?#LSR-%$R7WB&5(
MDAG\\^?&VEZ;-,US$;90(IAK%HZSRDO;M';[;GY)HK_*7QC_ &M/TAN/?:X#
MPVP&0^#.25:%>A.65PH<7<5U5B;PJ<_$>>Y;2P.&]G0Y886OD_#>4YAAJTZ^
M)ACW5>$^I?K62^$/#F7VJ9G4Q&=UU*,DJO-@\(N6S5L-0JRJ3O*[G&MB:U.4
M5&#IVY^?M_%'Q&\8^+Y+G^V-;NS97.%;1[.1[/1EA2Z:\MX3I\#K%<_9IF3R
M;F_^UWQ6&W\Z[F:"-EXBBBO\U>+>,^+N/<ZQ/$?&W$V?<6Y_B[K$9QQ%FN-S
MC,:D'5JUU2^M8^M7JPH0JUZTZ6'A*-"DZD_94X*31^FX/!8/+Z$<-@<+A\'A
MX?#1PU&%&FG91OR4XQ3DXQBG)WD[*[=@HHHKYHZ@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#]"/@=_R2[PO_ -QK_P!2+5J*/@=_R2[PO_W&O_4B
MU:BO^T'Z+7_*,GT<_P#LQ'A%_P"N_P"'C^)N*_\ DJ>)/^Q_G'_JQQ)ZQ111
M7[N> %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]"/@=_P DN\+_ /<:_P#4
MBU:BCX'?\DN\+_\ <:_]2+5J*_[0?HM?\HR?1S_[,1X1?^N_X>/XFXK_ .2I
MXD_['^<?^K'$GK%%%%?NYX 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ$? [_DEWA?_ +C7_J1:M11\#O\ DEWA?_N-?^I%JU%?]H/T6O\ E&3Z.?\
MV8CPB_\ 7?\ #Q_$W%?_ "5/$G_8_P X_P#5CB3UBBBBOW<\ **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLZF*JI<TK*I6DDFTK)L****_&SV@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^;FI5L;B)4+3CRS2H>T]C&,H^[*,8*+5TUJPHHHK]A/&"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF,DY.?-B\36Q$N=JSE>M.;YFE9RW:TN%%%%?6G&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD5ND/F5%%?YE<=>(_'WB=G53B+Q$XRXEXVSN?M(QS'B;.<?F]?#T:M659X3
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQV)=%<RM+EHJHJ4$UHU"$4UT"BBBOV0\4**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:/U?+,#AL#1TO##484^=J[3J2BN:I)<TO>J2E+5ZZA1117P9WA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9RJ5)<L5&/-.;<GRQ2BKO2*26B04445WF84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*6*JPMJXSC456,M54T5O$=+_ &??AUI_G_:[;5M<\WRO+_M35)8?LOE^9O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !17>Z;\+_B%JT[V]KX0UR*1(FG+:E9MHL!17CC*I=:P;&VDF+2*
M5MTF:=D$DBQF.*5D[?3?V>?B%?0/-=+HFC2+,T8M=2U-I9Y$"1L+A&T>UU:V
M$3,[1JKW"3AXI"T*QF)Y/W?A/Z+WTC>..27"W@=XI9IAJGMU#,?]2L^P63N>
M'M[:E_;68X+"92J\')+ZN\:J\F[0IR=T>!B^*N&L!=8O/<JI27+^[^O8>=:T
M_AE["G.=;E?\W)RI:MI'A=%?6VD_LR0*]I+KGBN:6/R@U_8Z3IJ6[B=H#F.T
MU2\N;E6BAN2I$TVCJ]S A!M[224-#WFE_L^_#K3_ #_M=MJVN>;Y7E_VIJDL
M/V7R_,W^1_8J:1N\[>OF_:?M&/*C\GRLR^;_ %/P=^RI^E]Q2J$\UX;X/X!I
M8BI42J<8\:9;5=*C'!QQ5+$U\/P93XPQE*GB:DOJ-.A+#?7Z.,C+Z[@\)A5]
M:?RF-\6>#L)S*CB<;F#BEI@L#55Y<_(XQEC7@X-Q7[QR4O9RA\$YS]P^#:T=
M-TC5M:G>UT?2]1U:YCB:X>WTVRN;Z=(%>.-IGAM8I9%B626)&D*A \D:EMSJ
M#^CVD_#WP/HB6BZ;X5T2*2PF%Q:7<UA#?:C#.LYN8YEU2^6YU%IH9CNMY'NF
M>W"1QP-''%&J=C7]4<&?L7,]K0PM?Q#\=,IRZ<?JTL;E7!G!V,SF%3FH)XNC
MA<_SS.,A=#V.);IX;$U>&\1]9H15:KA<+4FZ%/Y/&^-N'BYQR[(:U1>\H5<;
MC84&K2]QSP]"CB%*\=916)CRRT4YI<S_ #GTWX1?$C5H'N+7PGJ,4:3- 5U*
M2ST6<NJ1R%DM=8N;&YDB*R*%N$A:!G$D:R&2*54]'L?V:?%<EU$FI:]X>M+(
M[_.N+$ZEJ-U'B-S'Y5G<6.EQ3;YA&C[[Z#RXV>5?-9!#)]HT5_4_!?[(KZ+W
M#T:%3BC'^(_'^*C4P57%4\VXDPN1Y35>%JU*F(H8;"<+97E&9X;"9C"<*&,C
M5SS&8RG"E&67X[!595*DOD\=XP\58GF6%IY;ET+3471PTZ]9<Z2C*4\75K4I
M3IM-PM0A!N352G4227S+I?[,VA1>?_;7B?5M0W>5]F_LNSL](\G'F>=Y_P!K
M.N?:/,S%Y7E_9?*V2;_.\U?*]"L/@A\-+#[$_P#PCWVVXLOLS?:+_4=3N/M<
MUOL/G7MG]L33)_/=-]S;?84L9=[Q?9%MV\D>L45_4_!OT)OHG<!TZ5/(/ 7P
M\K2HZT<1Q1D[XZQU*:Q4\9&K3S#CBMQ%CH5Z=>;]CB(XA5Z-&-+#4JD,-1HT
MH?*8WCCB[,&WB.(,QCS?%'"UOJ%-KD4&G3P$<-3<7%:QY>5R;FTYRE)XFF^&
M?#>BSO=:/X?T32;F2)K=[C3=)L+&=X&>.1H7FM;>*1HFDBB=HRQ0O'&Q7<BD
M;=%%?TCE.2Y/D&#CE^193EF2X"-2=6.!RG 87+L'&K5:=2I'#8.E1HJI4:3G
M-0YIM)R;L?,UJ]?$3]I7K5:]2RC[2M4G4G9;+FFY2LNBO9= HHHKTS(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ***Q-<\2^'_#4 N->UC3]*C:*YFA6\NHHI[I+-%>X
M6RM2WVF^FC62,?9[.&>=GEBC2-I)8U;S,XSK)^'<LQ>=<09MEF19/@*<:N.S
M;.,=A<LRS!4I5(4HU,7C\;5H87#4Y5:E.G&=:K"+J3A!/FE%/6C1K8FK"AAZ
M-6O6J.U.C1ISJU9NS=H4X*4Y.R;M%-V3?0VZ*^:_%7[1^B6+R6OA/3)M=D\J
M95U2]:;3=.CG:")K62*TD@.HWT4<TDJ7D,ZZ.^;?;;7$D<ZW,?@'BCXO>._%
M<=S:WFK?V?IEU@2:5HT0T^U,9M6M)K>2=6DU.ZM+I))7N;.]U"ZM99)2?)"1
M6Z0_YZ>,G[4?Z,/A?+,<LX9SC,_%[B7!5*F&C@N \/"IPY]<C2G4INOQKF,L
M-D>*RV<HTZ<\RX7?%*C.M!4\-6]GB%0_1LE\*N*<U]E5Q5&EDV%J)3Y\PDUB
M>1M)\N!I<U>%57;5+%?5-(N\HWCS?;GBCXC>#O"$=S_;&MV@O;;"MH]G(EYK
M+3/:M>6\)T^%VFMOM,2IY-S?_9+$--;^==PK/&S> ^(?VF)R[1>%?#L21K-$
MR7WB&5Y7F@\@^?&VEZ=-"MM,+E@(IAK%VC01$O;K)<;;;Y4HK_*'QB_:N_22
M\0JN(P? ,LE\&^'ZE27LZ'#V'P_$'$U3#.5;DH8WBC/L#."J*$Z/-BLBR7A_
M$2J8=2A*G2K5J$_UO)?"3AG+E&>8>WSK$)*\L3*6'PJE:-Y0PF'FG:ZE:&(K
MXB-I6:<HQDNG\0^,_%7BIV;Q!KNHZE&TT5P+22;RM.BGA@-M'-;Z7;"'3K:8
M0LZM);VL3N99G=FDGF9^8HHK_-WB#B3B+BW-<5GW%6?YUQ-GF.J2JXW.>(,T
MQV<YKC*LYSJ3J8K,<QKXG&8BI.I4G4E.M6G*4YSDVY2;?Z7A\-AL'1AA\)AZ
M&%H4TE"AAZ5.A1@DDDH4Z48PBDDDDHI))+9!1117BFX4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQDW6J3;E&'N1ENH>ZG;0****^T.$**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML9B(+%8Q2BW)2AB*_/.D[N]J'LHWC%\MXQL4445_,Y]0%%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 45V]C\-?B!J-U%9V_@[Q#'+-OV/?:9<Z7:CRXWE;S;[4H[2R@R
MJ$)YUQ'YLA2&/?-)&C=OI?[/OQ%U#S_M=MI.A^5Y7E_VIJD4WVKS/,W^1_8J
M:OM\G8OF_:?L^?-C\GS<2^5^X<)_1H^D-QS4A#A3P1\4LXI3Q%?"O'T>".(:
M&3T<5A\*L95PV*SO%X##Y1@ZZPTZ4XT<7CJ-2HZ^&ITXSJXG#PJ>%B^*.',
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M6KU\1/VE>M5KU+*/M*U2=2=ELN:;E*RZ*]ET"BBBO3,@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR_*Z"Q$6I+%XGFQ>*4DXM2A5Q#FZ+3A%I8=4HIKF45)R;****_E\^J"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HJW8V%_JEU%8Z;97>HWL^_R;.QMIKNZF\J-YI/*M[=))9/+BCDE?
M8AV1H[MA5)'>Z;\(OB1JT#W%KX3U&*-)F@*ZE)9Z+.75(Y"R6NL7-C<R1%9%
M"W"0M SB2-9#)%*J?<<(>&7B3X@RE#@+P]XXXWG"I6I3CPAPGGW$LHU</2HU
M\13E')L!C7&I0HXBA6K0:4J5*O1J3485(.7#C,TRS+DGF&8X' II-/&8O#X5
M-2;C%KV]2&DI1E%/9M-+5,\WHKZ$L/V;_&MQ]BDOM2\/:=#/]F>\C^TWUW?6
M,<NQKA/)AL%LKF[ME9U\J+4A:S3)L2^$3"XKT+2_V9M"B\_^VO$^K:AN\K[-
M_9=G9Z1Y./,\[S_M9US[1YF8O*\O[+Y6R3?YWFKY7]3\&_LY?IB<:5*?L?"#
M'\.8*=O:YCQEG7#W#-/#<V%GB:7M,NS#-(Y_5]JXPPS^IY/BOJ^*JPIXSZM&
M-:=+Y/&^)/!F"3YLYIXF:VIX*AB,4Y>\HNU2G2>'5KN7OUH\T4W#F=D_CFBO
MOVQ^ WPTM+6*WN-'N]3FCW[[Z^U?4X[J??([KYJ:;<Z=9#RE984\FSAS'&AD
M\R8R2OZ1IOAGPWHL[W6C^']$TFYDB:W>XTW2;"QG>!GCD:%YK6WBD:)I(HG:
M,L4+QQL5W(I']3\%_L:_&K-)4*G'GBAX<<(86M3P565/(*'$/&F;815Z52>,
MP^+PF)P/"66?6\#/V%%1P6>8W!XJ<L1*GCH4J%&IB_D\;XTY)24EE^59GC)Q
M<TGB)8;!4I\K2A*$XU,95Y*BYI7G0A."44Z;<I*'YK:;X9\2:U ]UH_A_7-6
MMHYFMWN--TF_OH$G5(Y&A>:UMY8UF6.6)VC+!PDD;%=KJ3Z%I/P,^)&J/:%]
M%BTFVO(A.+S5M0LX$MD> SQK=V5O+=ZO;S.=L!MVTTSP3N$NHX%29X_T"HK^
MJ.#/V-7@UED\+6X[\4_$/BZI0^KU*V'R'!Y#P9EV-K4JZJ5Z6(I8C#<69C3P
M&*HKZO.AA,UPV.I*4ZE',X5.1T_E,;XU9U54XX#*<NP:ES*,L1/$8VI"+C:+
MBXRP=-U(2]Y2G2E3>B=)J]_CG2_V9M=E\_\ MKQ/I.G[?*^S?V79WFK^=GS/
M.\_[6=#^S^7B+RO+^U>=ODW^3Y2^=WND_LV^$;5+1]7U;7-6N89A)=+"]IIF
MG7J+.76W:U6WN[^WB>#9!<-#JXG<^9-!-:L\:P_1-%?U/P=^SA^ASP:Z%:CX
M0X3B/'T:=2E/'\8Y_P 3<2+%1GC(XR#KY/CLW?#2J4?9TL-3JX?(Z%66#A*A
M6G66*QLL3\GC?$KC3&\T99Q/#4Y--4\%A\+AN5J'(^6M3H_6K2NYM2KR7.[Q
M4>6"CYQIOPB^&^DSO<6OA/3Y9'B: KJ4EYK4 1GCD+):ZQ<WUM',&C4+<)"L
MZH9(UD$<LJOV^FZ1I6BP/:Z/I>GZ3;23-</;Z;96UC \[)'&TSPVL44;3-'%
M$C2%2Y2.-2VU% T**_JCA/PM\,> N3_4;PYX$X+]E[?V?^J?"'#_  [[/ZU;
MZSR?V/E^#Y/K'+'V_+;VUE[3FLCY3%YMFF87^OYEF&-ORW^MXS$8F_+\-_;5
M)WY?L]N@4445]V>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HJW8V%_JEU%8Z;97>HWL^_P FSL;::[NIO*C>:3RK>W2263RX
MHY)7V(=D:.[8521V^E_"CXBZQY_V3PCJT/V?RO,_M2.+0]WG>9L\C^VI=/\
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MEAOJ%;!RE]=P>+Q3^M+Y3&^+/&.+YE2Q.#R]2:TP6!I.T>3D<8RQKQDTI/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117$>
M*/B-X.\(1W/]L:W:"]ML*VCV<B7FLM,]JUY;PG3X7::V^TQ*GDW-_P#9+$--
M;^==PK/&S?-<6\9\)<!9+B>(^-N)LAX2R#"76(SCB+-<%D^74YJE5KJE]:Q]
M:A2G7G2H5ITL/"4J]54Y^RIS<6CJP>"QF85XX; X7$8S$3^&CAJ-2M4:NHWY
M*<9-14I13D[15U=JYV]%?)7B']IB<NT7A7P[$D:S1,E]XAE>5YH/(/GQMI>G
M30K;3"Y8"*8:Q=HT$1+VZR7&VV^>_$/C/Q5XJ=F\0:[J.I1M-%<"TDF\K3HI
MX8#;1S6^EVPATZVF$+.K26]K$[F69W9I)YF?_-7QC_:T_1YX"]K@/#; 9]XS
M9W2KUZ%265PK\(\*4GAKPJ<_$>>Y;5QV)]I7M#"U\GX;S;+\31A7Q,,>J2PG
MUW]-R7PAXCS"U3,ZF'R2@XQDE5Y<9BWS6:MAJ%6-.%HW<XUL31J1DXP=._/R
M?</B7XU> /#?E)_:O]OW$OEM]G\-&VU3RX7\\>=+>?:H-,38\&R2V^W&^7SH
M)?LAMY/.'@/B']H_Q5J"-#X?TS3_  [&\42FXD;^VM1BG2<R226\US!;:<L4
MT(2W:&XTFZ= 9I4N!))";?YUHK_*7Q@_:=_2E\498K!9'Q-A/"?A[$4ZU'^S
M/#S#?4<UE2JTH4E.KQ?CGC.):&+I6JSI8C(\=D<8SKN;HN='#3H?K63>%O"F
M5*$\1A9YOB8N,O:YC+GHW3;LL'3Y,+*#T3C7IUVU&W-:4E+1U+5]6UJ=+K6-
M3U'5KF.);=+C4KVYOIT@5Y)%A2:ZEED6)9)976,,$#R2,%W.Q.=117^?>/S#
M'YIC,1F&9XW%YCC\74=7%8['XFMB\9B:K23J8C$XB=2M6J-))SJ3E*R2OH?H
ME.G3I0C3I4X4J<%:%.G",(17:,8I1BO))(****Y"PHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **[+2?A[XXUM[1=-\*ZY+'?Q"X
MM+N:PFL=.F@: W,<RZI?+;:<L4T(W6\CW2I<%XXX&DDEC5^\TO\ 9]^(NH>?
M]KMM)T/RO*\O^U-4BF^U>9YF_P C^Q4U?;Y.Q?-^T_9\^;'Y/FXE\K]LX.^C
M;](+Q 5"IP=X+>)V?83$U*E*EFN$X*S^&1JK3P<<?*G6S_$X&ADN&J2PE2C6
MI0Q./I2K+$86%%5*F*P\*OAXWB;AW+N98W.\KP\XI-TIX[#NO:4_9IK#QJ2K
MR7.FFXTVH\LG*RA)KQ&BOJO2?V9)V2TEUSQ7%%)YP:_L=)TU[A# LYS'::I>
M7-LRS36P4B:;1V2VG<@V]W'$&F]"TW]GGX>V,[S72ZYK,;1-&+74M36*"-R\
M;"X1M'M=)N3,JHT:J]P\!260M"T@B>/^I^#/V6GTP.+(86MF'"'#7 F&Q?U>
M=.OQGQCE$)T\/B:"KQQ&*R_AB7%&;8/V2E&EB,'BLOHYG0KMTJF C*%3D^3Q
MOBMP;A'.-/&8K'RAS7C@L%6:<HRY>6%3%+"TIWU<9QJ.E*.JJ:J_PE5NQL+_
M %2ZBL=-LKO4;V??Y-G8VTUW=3>5&\TGE6]NDDLGEQ1R2OL0[(T=VPJDC]&=
M-^%_P]TF![>U\(:)+&\S3EM2LUUJ<.R1QE4NM8-]<QQ!8U*VZ3+ KF218Q)+
M*S]Y7]4<%_L7>+,3&A6\1/'+A[)IPJ8*>)R[@OA/,N)8XBE[6H\QPU#.<\S/
MA1X.HJ,:4,%C:F0X^+JUJE2O@(PPL:6+^4QOC;A(N4<NR'$UDU-1J8W&4L*X
MNR]G*5&A2Q?.N9R<Z:Q%.RBE&HW-N'YPZ7\*/B+K'G_9/".K0_9_*\S^U(XM
M#W>=YFSR/[:ET_[5CRF\W[-YODYC\[R_.BW^A6'[-_C6X^Q27VI>'M.AG^S/
M>1_:;Z[OK&.78UPGDPV"V5S=VRLZ^5%J0M9IDV)?")A<5]N45_4_!O[(3Z,^
M0TZ=3BK//$KCK&Z?6(XS/<MR#*)<F*G5A]6P.0Y/A<TH>TPOL\+B?;Y]C/:.
M-7$8;ZG*I"%'Y/&^,?%&(;6$H99@(?9<,/5Q%;6*3YIXBM.E*T[RCRX>%DU&
M7/9M_,&F_LR:5%.[:QXKU&_MC$RI#INFVVDSK/OC*R/<75SK4;Q",2JT(M8W
M9WC<7"K&T<O>6/P&^&EI:Q6]QH]WJ<T>_??7VKZG'=3[Y'=?-33;G3K(>4K+
M"GDV<.8XT,GF3&25_8Z*_J?A#Z#'T1>"(RCDW@%P!C5*G6IM\7Y?B/$&2C7J
MT:TW&?'N+XEG"I&=""HU82C5P]*5:AAYTJ.(KTZGRF,X\XPQS3K\09C"S3_V
M.I'+E[J:5UE\,*FK-W3TD[2DG*,6N>L?"/A32[J*^TWPQX>TZ]@W^3>6.BZ;
M:74/FQO#)Y5Q;VT<T?F1221/L<;XW=&RK,#T-%%?TSDV09%PYA:F"X>R7*<B
MP56O+%5<)DV6X/*\+4Q4Z=*C/$U,/@:-"E.O.C0H4I5I0=25.C2@Y.-."7R]
M;$8C$S4\17K8B:BH*=:I.K-03;45*<I-13E)J-[)MNVK"BBBO6,0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKX!_X>B_L*?]%R_\QG\8?_G?4?\ #T7]A3_HN7_F,_C#_P#.^H ^_J*^ ?\
MAZ+^PI_T7+_S&?QA_P#G?4?\/1?V%/\ HN7_ )C/XP__ #OJ /OZBO@'_AZ+
M^PI_T7+_ ,QG\8?_ )WU'_#T7]A3_HN7_F,_C#_\[Z@#[^HKX!_X>B_L*?\
M1<O_ #&?QA_^=]1_P]%_84_Z+E_YC/XP_P#SOJ /OZBO@'_AZ+^PI_T7+_S&
M?QA_^=]1_P /1?V%/^BY?^8S^,/_ ,[Z@#[^HKX!_P"'HO["G_1<O_,9_&'_
M .=]1_P]%_84_P"BY?\ F,_C#_\ .^H ^_J*^ ?^'HO["G_1<O\ S&?QA_\
MG?4?\/1?V%/^BY?^8S^,/_SOJ /OZBO@'_AZ+^PI_P!%R_\ ,9_&'_YWU'_#
MT7]A3_HN7_F,_C#_ /.^H ^_J*^ ?^'HO["G_1<O_,9_&'_YWU'_  ]%_84_
MZ+E_YC/XP_\ SOJ /OZBO@'_ (>B_L*?]%R_\QG\8?\ YWU'_#T7]A3_ *+E
M_P"8S^,/_P [Z@#[^HKX!_X>B_L*?]%R_P#,9_&'_P"=]1_P]%_84_Z+E_YC
M/XP__.^H ^_J*^ ?^'HO["G_ $7+_P QG\8?_G?4?\/1?V%/^BY?^8S^,/\
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MO_,9_&'_ .=]1_P]%_84_P"BY?\ F,_C#_\ .^H ^_J*^ ?^'HO["G_1<O\
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MKX!_X>B_L*?]%R_\QG\8?_G?4?\ #T7]A3_HN7_F,_C#_P#.^H ^_J*^ ?\
MAZ+^PI_T7+_S&?QA_P#G?4?\/1?V%/\ HN7_ )C/XP__ #OJ /OZBO@'_AZ+
M^PI_T7+_ ,QG\8?_ )WU'_#T7]A3_HN7_F,_C#_\[Z@#[^HKX!_X>B_L*?\
M1<O_ #&?QA_^=]1_P]%_84_Z+E_YC/XP_P#SOJ /OZBO@'_AZ+^PI_T7+_S&
M?QA_^=]1_P /1?V%/^BY?^8S^,/_ ,[Z@#[^HKX!_P"'HO["G_1<O_,9_&'_
M .=]1_P]%_84_P"BY?\ F,_C#_\ .^H ^_J*^ ?^'HO["G_1<O\ S&?QA_\
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MW]17P#_P]%_84_Z+E_YC/XP__.^H_P"'HO["G_1<O_,9_&'_ .=]0!]_45\
M_P##T7]A3_HN7_F,_C#_ /.^H_X>B_L*?]%R_P#,9_&'_P"=]0!]_45\ _\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ)!JSZL-'\/V6GP:KX-O-?U[4+SQ%XUDFN/Q2H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OW\_P"",W[2W_(U_LN>+-6_Y_?'WPE_M"^_W/\
MA//!6F?VEKW_ %[>.="\.>&O#_\ T5'Q-K-Y_JZ_ .O0/A5\2_%7P;^(_@OX
MH^"KO[)XF\#^(+#7],WSZC;V=]]DE'VS1=7_ +)O]+U"Z\/^(-/>[T+Q%IMO
MJ%I_:NA:CJ.F2S+!=R9 /[N**X#X5?$OPM\9/AQX+^*/@J[^U^&?''A^PU_3
M-\^G7%Y8_:XA]LT75_[)O]4T^U\0>']02[T+Q%IMOJ%W_96NZ=J.F2S-/:28
M[^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_E%_X*M_M%_P#"
MZ/VCKKP#HMQYO@GX"?VOX%L/W.S[;X[GNK;_ (67JG^EZ'I6K6WV;5M*TWP5
M]AFO-8T>;_A"/^$CT"[%MXEG\S]_/VZ/VB_^&8_V<?&7C[3;CR/&VL>7X%^&
MG[GS=GCOQ+:WWV#5/W^AZ_I+?\(II-CK7C7[#K]G%H^N_P#"-?\ ".37<%SK
M%IO_ (Q: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKZ/_9,_
M9_U7]IKX\^!?A39IJ$6B:CJ U;QWK&GK<I)X>\ Z*4O/$^IC4(M%U^TTG4+J
MT"Z#X8O-8TY]%G\9:UX;TO4)(HM1#4 ?L[_P1R_9>TK3/!NJ_M1>+]$T^]\1
M>)]0U'PW\([J\@M[NY\/>&=&DO\ 0O&'B?29X=7NXK/4/%6MG4O",@OM#TOQ
M#I6E>%-36PU"?P[XZO8;K]S*S])TG2M TK3-"T+3-/T71-%T^STG1]'TFRM]
M.TK2=*TZVCL]/TS3-/LXX;2PT^PM(8;6SL[6&*VM;:*.""-(D51H4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?R"_\ !47_ )/K^.7_ '3/_P!4]\/J^ :^_O\ @J+_
M ,GU_'+_ +IG_P"J>^'U? - !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/I/BGP[]LOM+T:?4_P#A&_$VGZOH/]KIIEI9ZQ_9W]J:<C:?=VLC@'K]%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /Y!?\ @J+_ ,GU_'+_ +IG_P"J>^'U? -??W_!47_D^OXY?]TS
M_P#5/?#ZO@&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#^KO_@E_^UO_ ,- _!N/P#X]\7?VU\;/A?\
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M !1110 4444 %%%% !1110 5_(+_ ,%(?VEO^&C?VCM>_L#5O[0^&7PO^T^
M?A_]DOOM>CZI_9]TW_"5^-;'[%KVN>'[W_A+?$$<W]E^(]%_L_\ M[P)H_@7
M^TK-+W3WQ^_G_!2']I;_ (9R_9QU[^P-6_L_XF_%#[3X!^'_ -DOOLFL:7_:
M%JW_  E?C6Q^Q:]H?B"R_P"$2\/R3?V7XCT7^T/[!\=ZQX%_M*S>RU!\_P @
MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5H:3I.JZ_JNF:%H6
MF:AK6MZUJ%GI.CZ/I-E<ZCJNK:KJ-S'9Z?IFF:?9QS7=_J%_=S0VMG9VL,MS
M=7,L<$$;RNJG/K]O?^"0O[)'_"6^*=0_:6^)'A'[3X2\)>58_!W^W],\S3M<
M\=PZB_\ :GCK1?,U.'[3_P *[_LQM)TV[O-!U/1Y/%.N37^B:I9>+?AW-]B
M/V<_9 _9LT+]E?X'^&_AGIA^T^(+GRO%/Q'U9-4O-5L];^(^JZ3I-EXEOM(D
MN[+2OLWA^V_LJRT;P[:QZ/I4O]A:5IUSJUO<^(+G5]3O_I^BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH _D%_X*B_\GU_'+_NF?\ ZI[X?5\ U]_?\%1?^3Z_
MCE_W3/\ ]4]\/J^ : "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCR/[1UZPTG3?^$[TE;CPO=_8=(U7Q%XG\4V7PTT2U\NVMGK^GNOX%])U;5=
MU73-=T+4]0T76]%U"SU;1]8TF\N=.U72=5TZYCO-/U/3-0LY(;NPU"PNX8;J
MSO+6:*YM;F*.>"1)45A_:S^R9^T!I7[3/P&\"_%:S?3XM;U'3QI/CO1]/:W2
M/P]X^T4)9^)],&GQ:SKUWI.GW5V%U[PQ9ZQJ+ZU/X-UKPWJFH1Q2ZB%H ^CZ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBOS"_X*M_M%_\ "E_V<;KP#HMQY7C;X]_V
MOX%L/W._[%X$@M;;_A9>J?Z7H>JZ3<_:=)U73?!7V&:\T?6(?^$W_P"$CT"[
M-SX:G\L _ /]NC]HO_AIS]H[QEX^TVX\_P $Z/Y?@7X:?N?*W^!/#5U??8-4
M_?Z'H&K+_P )7JU]K7C7[#K]G+K&A?\ "2_\(Y-=SVVCVFSY HHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /3_@Q\(?&7QZ^)_A#X1^ (-/F\
M5^,]0GL]/;5K]--TJRMK#3[S6-8U;4[QEEE33]%T33M1U>\CLK:_U6YMK*2U
MT?3-4U6:ST^Y_MJ^%7PT\+?!OX<>"_A=X*M/LGAGP/X?L- TS?!IT%Y??9(A
M]LUK5_[)L-+T^Z\0>(-0>[UWQ%J5OI]I_:NNZCJ.IRPK/=R9_*'_ ()"_LI7
MGPW\":A^TCXQB\GQ-\7?#\6D>!=)FM-=T[4?#WPXCUA[R[U'4H[V6RT^^_X6
M+J&D^'M?T5XM)O8K?PMH^@:SH_B*>#QAJFF6/[.T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!_(+_P5%_Y/K^.7_=,_P#U3WP^KX!K[^_X*B_\
MGU_'+_NF?_JGOA]7P#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _3[_@E)^T7_PI?]HZU\ ZU<>5X)^/?]D>!;_]SO\ L7CN"ZN?
M^%::I_HFAZKJUS]IU;5=2\%?88;S1]'A_P"$W_X2/7[LVWAJ#R_ZNJ_@'K^S
MK]A?]HO_ (:<_9Q\&^/M2N//\;:/YG@7XE_N?*W^._#5K8_;]4_<:'H&DK_P
ME>DWVB^-?L.@6<NCZ%_PDO\ PCD-W/<Z/=[ #Z^HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!_(+_P5%_Y/K^.7_=,_P#U3WP^KX!K[^_X*B_\GU_'+_NF
M?_JGOA]7P#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,W[2W_(U_LN>+-6_Y_?'WPE_M"^_W/\ A//!6F?VEKW_ %[>.="\.>&O#_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_"EX)-2U[Q#J%SX-D\5>)M0:^\41-* ?I=1110 4444 %%%% !1110 4444
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MM8\.1I>6^G"[T?4/&MW>GQ'XATFVU[4;&YTK3_ "ZG9Z5XDT75-/M?UMHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y!?^"HO_)]?QR_
M[IG_ .J>^'U? -??W_!47_D^OXY?]TS_ /5/?#ZO@&@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?R"_\%1?^3Z_CE_W3/\ ]4]\/J^ :^_O^"HO_)]?
MQR_[IG_ZI[X?5\ T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?R"_\%1?
M^3Z_CE_W3/\ ]4]\/J^ :^_O^"HO_)]?QR_[IG_ZI[X?5\ T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7[N?\$=_VKKS3]=N/V3/%LOGZ3KO_  DGC#X4
MZG<7>NWEYI^NVMG!JWB;P%:V?E:AI.G^']0TG3]>\=6,JOX<L]/UVS\4BY?7
M=6\::?'I_P"$==!X3\4Z[X'\4^&O&OA:^_LOQ-X/\0:-XI\.ZG]EL[W^SM=\
M/ZC;:MI%]]CU&WN]/N_LFH6EO<?9;ZTNK.?R_*NK>:!WC8 _O8HKYP_9,_:
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MOJ7_  @FK-<>%[O[#I&E>'?#'A:]^&FB6OF7-R]?K[0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y!\??C%H7[/_ ,&_B%\8?$</VO3_
M  /X?FU&WTSS+RW_ +<UV[G@TGPMX=^V6.EZS/IG_"2>)M0TC0?[7?3+NST?
M^T?[4U%%T^TNI$_B&\6>*==\<>*?$OC7Q3??VIXF\8>(-9\4^(M3^RV=E_:.
MN^(-1N=6U>^^QZ=;VFGVGVO4+NXN/LMC:6MG!YGE6MO# B1K^QO_  6&_:AT
MKQ]XR\,_LZ^!];T_6/#OPSU"Y\1_$6ZTR>WOK9OB>8]0T*Q\,23OI"RV^H>
M=$GU9-6.C^(+W3Y]5\97F@:]I]GXB\%20V_XI4 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@#^07_@J+_P GU_'+_NF?_JGOA]7P#7W]_P %1?\
MD^OXY?\ =,__ %3WP^KX!H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT7Q)I>GR2Q:<6H ^<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /7
M_@%\8M=_9_\ C)\/?C#X=A^UZAX'\00ZC<:9YEG;_P!N:%=P3Z3XI\._;+[2
M]9@TS_A)/#.H:OH/]KIIEW>:/_:/]J:<BZA:6LB?V\^$_%.A>./"WAKQKX6O
MO[4\,^,/#^C>*?#FI_9;RR_M'0O$&G6VK:1??8]1M[34+3[7I]W;W'V6^M+6
M\@\SRKJWAG1XU_@GK^CS_@C-^T7_ ,)+X$\5_LTZ_<;M6^'/VWQU\/\ ]SCS
M_ FOZPG_  E>E_Z%H<%M%_PC7C;6(=6^W:UKU]K&L?\ "P?L&FVD.D^%'\H
M_;RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^</VL_V@-*_9F^
M WCKXK7CZ?+K>G:>=)\":/J#6[Q^(?'VM![/PQIAT^76=!N]6T^UNRVO>)[/
M1]136H/!NB^)-4T^.673BM?1]?S"?\%>OVEO^%F?&33_ (&>%M6^T^"?@OYO
M_"1?8+[SM.UKXIZK G]K^?\ V=KU_I.I?\()I+6_A>T^W:1I7B+PQXIO?B7H
MEUYEM<I0!^26K:MJNOZKJ>NZ[J>H:UK>M:A>:MK&L:M>7.HZKJVJZC<R7FH:
MGJ>H7DDUW?ZA?W<TUU>7EU-+<W5S+)//(\KLQSZ** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OT._X)L_LK7/[27QYTW6-=TW3[_X3_"#4-#\6?$:'
M4)]*DCUBYF.J77@KP>="U/3M9BU_3_%&MZ#,OB>RNM/ATJ3P;IOB2SGUG3=8
MO] @U'X!TG2=5U_5=,T+0M,U#6M;UK4+/2='T?2;*YU'5=6U74;F.ST_3-,T
M^SCFN[_4+^[FAM;.SM89;FZN98X((WE=5/\ :3^R!^S9H7[*_P #_#?PSTP_
M:?$%SY7BGXCZLFJ7FJV>M_$?5=)TFR\2WVD27=EI7V;P_;?V59:-X=M8]'TJ
M7^PM*TZYU:WN?$%SJ^IWX!]/T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"[%MXEG\P _,&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^EO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_I[HH _F$_X<K?M3?]#]\ /_  J?B+_\ZJC_ (<K?M3?]#]\ /\ PJ?B+_\
M.JK^GNB@#^83_ARM^U-_T/WP _\ "I^(O_SJJ/\ ARM^U-_T/WP _P#"I^(O
M_P ZJOZ>Z* /YA/^'*W[4W_0_? #_P *GXB__.JH_P"'*W[4W_0_? #_ ,*G
MXB__ #JJ_I[HH _F$_X<K?M3?]#]\ /_  J?B+_\ZJC_ (<K?M3?]#]\ /\
MPJ?B+_\ .JK^GNB@#^83_ARM^U-_T/WP _\ "I^(O_SJJ/\ ARM^U-_T/WP
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MB+_\ZJC_ (<K?M3?]#]\ /\ PJ?B+_\ .JK^GNB@#^83_ARM^U-_T/WP _\
M"I^(O_SJJ/\ ARM^U-_T/WP _P#"I^(O_P ZJOZ>Z* /YA/^'*W[4W_0_? #
M_P *GXB__.JH_P"'*W[4W_0_? #_ ,*GXB__ #JJ_I[HH _F$_X<K?M3?]#]
M\ /_  J?B+_\ZJC_ (<K?M3?]#]\ /\ PJ?B+_\ .JK^GNB@#^83_ARM^U-_
MT/WP _\ "I^(O_SJJT-)_P""-G[7>@:KIFNZ%\4?@AHNMZ+J%GJVCZQI/C;X
MFZ=JNDZKIUS'>:?J>F:A9_"^&[L-0L+N&&ZL[RUFBN;6YBCG@D25%8?TUT4
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MLHKCPMK&OZSK'B*"#P?I>F7W\TE !1110 4444 %%%% !1110 4444 %%%%
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M%MJ^DW9U#0+NZM/'^IFR@US3[:VT+2="\4Z?!8^-M,:Z /V=_P"";/[*UO\
MLV_ ;3=8UW3=0L/BQ\7]/T/Q9\1X=0GU6.31[:$:I=>"O!YT+4].T:70-0\+
MZ)KTR^)[*ZT^;58_&6I>)+.?6=2T>PT"#3OT.HHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^07_ (*B_P#)
M]?QR_P"Z9_\ JGOA]7P#7W]_P5%_Y/K^.7_=,_\ U3WP^KX!H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KW_ /9/_P"3IOV:O^R__!O_ -6+X<KP"O?_ -D_
M_DZ;]FK_ ++_ /!O_P!6+X<H _MYHHHH **** "BBB@ HHHH **** "BBB@
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MVK7H!\0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCPY&EY;Z<+O1]0\:W=Z?$?B'2;;7M1L;G2M/\ +J=GI7B31=4T^U /T]\ >
M/!OPM\&^'OA]\/O#VG^%?!OA73TTS0M"TQ)!;6=L)))YI))IY)KN_P!0O[N:
MXU'5M6U&XN]5UG5;N\U75;R\U*\NKJ;L*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y!?^"HO_)]?
MQR_[IG_ZI[X?5\ U]_?\%1?^3Z_CE_W3/_U3WP^KX!H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KW_\ 9/\ ^3IOV:O^R_\ P;_]6+X<KP"O?_V3_P#DZ;]F
MK_LO_P &_P#U8OAR@#^WFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '\@O_!47_D^OXY?]TS_ /5/?#ZO
M@&OO[_@J+_R?7\<O^Z9_^J>^'U? - !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %>__LG_ /)TW[-7_9?_ (-_^K%\.5X!7O\ ^R?_ ,G3?LU?]E_^#?\ ZL7P
MY0!_;S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'Y!?\%>OV:?^%F?!O3_ (Y^%M)^T^-O@OYO_"1?8+#SM1UKX6:K.G]K^?\
MV=H-_J^I?\()JS6_BBT^W:OI7AWPQX6O?B7K=UYES<I7\PE?W\5_&K^W9^R]
MJO[+OQY\3>';/1-0L_A=XJU"^\2?"36)(+DZ5>>&;LV]Y<^&+/4+K5]>N[S4
M/A]=ZBOA34SK&I#Q#?6UII/BK4-/L['Q5I#7(!\8T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?V=?L+_ +1?_#3G[./@WQ]J5QY_C;1_,\"_$O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!_(+_P5%_Y/K^.7_=,__5/?#ZO@&OO[_@J+_P GU_'+_NF?_JGOA]7P
M#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7O_P"R?_R=-^S5_P!E_P#@W_ZL
M7PY7@%>__LG_ /)TW[-7_9?_ (-_^K%\.4 ?V\T444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5\0_M\_LI6?[5GP/U#1-,B\KXF
M^!/[3\8?"^]M[30FO-2UV#2;J.?P%=:GK4MA_9OA_P =[;.QOI8]<T>SLM=L
M/"WB35GU*R\--I-[]O44 ?P#T5^MO_!6?]E:W^#OQ<L_C3X,TW4$\"?&W4-;
MU/Q*TD^JZI;:'\7);ZYUCQ'&]Y/IPM-'T_QK:7H\1^'M)N=>U&^N=5T_Q^NF
M6>E>&]%TO3[7\DJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O[&OV!O
MVKK/]JSX'Z?K>IR^5\3? G]F>#_BA9W%WH37FI:[!I-K)!X]M=,T6*P_LWP_
MX[VWE]8Q2:'H]G9:[8>*?#>DIJ5EX:75KW^.6OO[_@F]^TM_PSE^T=H/]OZM
M_9_PR^*'V;P#\0/M=]]DT?2_[0NE_P"$4\:WWVW7M#\/V7_")>()(?[4\1ZU
M_:']@^!-8\=?V;9O>Z@F0#^OJOQ#_P""S/[1?_"->!/"G[-.@7&W5OB-]B\=
M?$#]SGR/ F@:P_\ PBFE_P"FZ'/;2_\ "2^-M'FU;[=HNO6.L:/_ ,*^^P:E
M:3:3XK3S?V<\6>*="\#^%O$OC7Q3??V7X9\'^']9\4^(]3^RWE[_ &=H7A_3
MKG5M7OOL>G6]WJ%W]DT^TN+C[+8VEU>3^7Y5K;S3ND;?Q#?'WXQ:[^T!\9/B
M%\8?$4/V34/''B";4;?3/,L[C^P]"M((-)\+>'?MECI>C0:G_P (WX9T_2-!
M_M=],M+S6/[._M344;4+NZD< \@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHKZ/_9,_9_U7]IKX\^!?A39IJ$6B:CJ U;QWK&GK<I)X>\ Z*4O/$^IC
M4(M%U^TTG4+JT"Z#X8O-8TY]%G\9:UX;TO4)(HM1#4 ?K[_P1R_96N;"VU7]
MJWQGINGO%K6GZCX3^#*R3Z5J-S#;1:K?Z/X_\8/9MIUU=Z!J!N])/@SP]>VV
MM:=JLVE2^/[;4]&?1-:T/4+_ />RN?\ "?A;0O WA;PUX*\+6/\ 9?AGP?X?
MT;PMX<TS[3>7O]G:%X?TZVTG2+'[;J-Q=ZA=_9-/M+>W^U7UW=7EQY?FW5Q-
M.[R-T% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?R"_\ !47_ )/K^.7_ '3/_P!4]\/J
M^ :^_O\ @J+_ ,GU_'+_ +IG_P"J>^'U? - !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>_\ [)__ "=-^S5_V7_X-_\ JQ?#E> 5[_\ LG_\G3?LU?\ 9?\
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MT NM(U_3;?48_P#KXT?6H;&\U;3M*\4Z3K^@VNM:M_9+WTW@%?U-_P#!5O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
M(+_P5%_Y/K^.7_=,_P#U3WP^KX!K[^_X*B_\GU_'+_NF?_JGOA]7P#0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7O_[)_P#R=-^S5_V7_P"#?_JQ?#E> 5[_
M /LG_P#)TW[-7_9?_@W_ .K%\.4 ?V\T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#\ /_"6^(O\ \]2@#^GNBOYA/^'U/[4W_0@_ #_PEOB+_P#/4H_X?4_M3?\
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M4H_X?4_M3?\ 0@_ #_PEOB+_ //4H _I[HK^83_A]3^U-_T(/P _\);XB_\
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M\);XB_\ SU*/^'U/[4W_ $(/P _\);XB_P#SU* /Z>Z*_F$_X?4_M3?]"#\
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M=U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1?$FEZ?)+%IQ:OG"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB^&]+U"2673@U?1] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?R"_
M\%1?^3Z_CE_W3/\ ]4]\/J^ :^_O^"HO_)]?QR_[IG_ZI[X?5\ T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7]C7[ W[*5G^RG\#]/T34XO-^)OCO^S/&'Q0O;
MBTT);S3==GTFUC@\!6NIZ++?_P!I>'_ FZ\L;&637-8L[W7;_P 4^)-)?3;+
MQ*NDV7XI?\$F/V5K?XQ?%R\^-/C/3=0?P)\$M0T34_#31SZKI=MKGQ<BOK;6
M/#D:7D&G&TUC3_!5I9'Q'XATFVU[3KZVU74/ "ZG9ZKX;UK5-/NOZBZ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^07_@J+_R?7\<O
M^Z9_^J>^'U? -??W_!47_D^OXY?]TS_]4]\/J^ : "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OZ>_P#@BM_R:SX^_P"R_P#B
MG_U77PJK^82OZ>_^"*W_ ":SX^_[+_XI_P#5=?"J@#]?:*** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?R"_\%1?^3Z_CE_W3/_U3WP^KX!K[
M^_X*B_\ )]?QR_[IG_ZI[X?5\ T %%%% !1110 4444 %%%% !1110 4444
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MB35GTV]\2MI-E\0T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^07_@J+_R?7\<O^Z9
M_P#JGOA]7P#7W]_P5%_Y/K^.7_=,_P#U3WP^KX!H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLWP_X[VV=C?2QZYH]G9:[8>%O$FK/J5EX:;2;W^.6O[^*_ET_P""L_[*UO\
M!WXN6?QI\&:;J">!/C;J&MZGXE:2?5=4MM#^+DM]<ZQXCC>\GTX6FCZ?XUM+
MT>(_#VDW.O:C?7.JZ?X_73+/2O#>BZ7I]J ?DE1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7]'G_!(7]DC_A$
MO"VH?M+?$CPC]F\6^+?*L?@[_;^F>7J.A^!)M.?^U/'6B^9J<WV;_A8G]IMI
M.FW=YH.F:Q'X6T.:_P!$U2]\)?$2;[;^,7[('[-FN_M4?'#PW\,],/V;P_;>
M5XI^(^K)JEGI5YHGPXTK5M)LO$M]I$EW9:K]I\07/]JV>C>';6/1]5B_MW5=
M.N=6M[;P_;:OJ=A_:3I.DZ5H&E:9H6A:9I^BZ)HNGV>DZ/H^DV5OIVE:3I6G
M6T=GI^F:9I]G'#:6&GV%I##:V=G:PQ6UK;11P01I$BJ #0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _D%_X*B_\
MGU_'+_NF?_JGOA]7P#7W]_P5%_Y/K^.7_=,__5/?#ZO@&@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_(+_
M ,%1?^3Z_CE_W3/_ -4]\/J^ :^_O^"HO_)]?QR_[IG_ .J>^'U? - !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5_3W_P16_Y-9\??]E_\4_\ JNOA57\P
ME?T]_P#!%;_DUGQ]_P!E_P#%/_JNOA50!^OM%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** -#2=)U77]5TS0M"TS4-:UO6M0L])T?1])LKG4=5
MU;5=1N8[/3],TS3[..:[O]0O[N:&UL[.UAEN;JYEC@@C>5U4_P!K/[)G[/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?T]_\$5O^36?'W_9?_%/_JNOA57\PE?T]_\ !%;_ )-9\??]
ME_\ %/\ ZKKX54 ?K[1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?R"_\%(?V:?^&<OVCM>_L#2?[/\ AE\4/M/C[X?_ &2P^R:/I?\ :%TW
M_"5^"K'[%H.A^'[+_A$O$$DW]E^'-%_M#^P? FL>!?[2O'O=0?/P#7]G7[='
M[.G_  TY^SCXR\ Z;;^?XVT?R_'7PT_?>5O\=^&K6^^P:7^_US0-)7_A*])O
MM:\%?;=?O)='T+_A)?\ A(YK2>YT>TV?QJZMI.JZ!JNIZ%KNF:AHNMZ+J%YI
M.L:/JUE<Z=JNDZKIUS)9ZAIFIZ?>1PW=AJ%A=PS6MY9W4,5S:W,4D$\:2HR@
M SZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU_X!?!W7?V
M@/C)\/?@]X=F^R:AXX\00Z=<:GY=G/\ V'H5I!/JWBGQ%]COM4T:#4O^$;\,
MZ?J^O?V0FIVEYK']G?V7ISMJ%W:QOY!7]-?_  2)_96M_AQ\,)/VC/%>FZA:
M_$'XM:??:9X6ANY]5LX](^$9U#3+JRDET*[T[3(O[0\;:WH<?B:WU9I]?L;[
MP;!X*O\ P[>:8NK>((-1 /U.^%7PT\+?!OX<>"_A=X*M/LGAGP/X?L- TS?!
MIT%Y??9(A]LUK5_[)L-+T^Z\0>(-0>[UWQ%J5OI]I_:NNZCJ.IRPK/=R9[^B
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /Y!?^"HO_)]?QR_[IG_ .J>^'U? -??W_!47_D^OXY?]TS_
M /5/?#ZO@&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?W_#KG]NO_HAO_F3/@]_\\&C_AUS^W7_ -$-_P#,F?![_P">#0!\ T5]_?\
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M^9,^#W_SP:/^'7/[=?\ T0W_ ,R9\'O_ )X- 'P#17W]_P .N?VZ_P#HAO\
MYDSX/?\ SP:/^'7/[=?_ $0W_P R9\'O_G@T ? -?T]_\$5O^36?'W_9?_%/
M_JNOA57Y!?\ #KG]NO\ Z(;_ .9,^#W_ ,\&OW<_X)@? 7XL?L[_  #\7>"O
MC%X4_P"$/\3:I\7]?\4V.F?V[X;\0>?H5[X+\ :3:WWVWPMK&MZ?%YNH:)JE
MO]EFNX[Q/LWFR6Z036\DH!^CU%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF;2M.TG4?&'BG5IS=:OK^I6^G1_]>^CZ+#?7FK:CI7A;2= T&ZUK5O[)2^F
M/?Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /Y!?^"HO_ "?7\<O^Z9_^J>^'U? -??W_  5%
M_P"3Z_CE_P!TS_\ 5/?#ZO@&@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O?_
M -D__DZ;]FK_ ++_ /!O_P!6+X<KP"O?_P!D_P#Y.F_9J_[+_P#!O_U8OAR@
M#^WFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_
MD%_X*B_\GU_'+_NF?_JGOA]7]?5?R"_\%1?^3Z_CE_W3/_U3WP^H ^ :***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ]_P#V3_\ DZ;]FK_LO_P;_P#5B^'*
M_MYK^(;]D_\ Y.F_9J_[+_\ !O\ ]6+X<K^WF@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M_D%_X*B_\GU_'+_NF?\ ZI[X?5\ U]_?\%1?^3Z_CE_W3/\ ]4]\/J^ : "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *]__9/_ .3IOV:O^R__  ;_ /5B^'*\
M KW_ /9/_P"3IOV:O^R__!O_ -6+X<H _MYHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "OY!?\ @J+_ ,GU_'+_ +IG_P"J>^'U
M?U]5_(+_ ,%1?^3Z_CE_W3/_ -4]\/J /@&BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /?_P!D_P#Y.F_9J_[+_P#!O_U8OARO[>:_B&_9/_Y.F_9J_P"R
M_P#P;_\ 5B^'*_MYH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y!?^"HO_ "?7\<O^Z9_^
MJ>^'U? -??W_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "O?_ -D__DZ;]FK_ ++_ /!O_P!6+X<KP"O?_P!D_P#Y.F_9
MJ_[+_P#!O_U8OAR@#^WFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *_D%_X*B_\GU_'+_NF?_JGOA]7]?5?R"_\%1?^3Z_CE_W3
M/_U3WP^H ^ :*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]_P#V3_\ DZ;]
MFK_LO_P;_P#5B^'*_MYK^(;]D_\ Y.F_9J_[+_\ !O\ ]6+X<K^WF@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _D%_X*B_\GU_'+_NF?\ ZI[X?5\ U]_?\%1?^3Z_CE_W
M3/\ ]4]\/J^ : "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]__9/_ .3IOV:O
M^R__  ;_ /5B^'*\ KW_ /9/_P"3IOV:O^R__!O_ -6+X<H _MYHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY!?\ @J+_ ,GU
M_'+_ +IG_P"J>^'U?U]5_(+_ ,%1?^3Z_CE_W3/_ -4]\/J /@&BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /?_P!D_P#Y.F_9J_[+_P#!O_U8OARO[>:_
MB&_9/_Y.F_9J_P"R_P#P;_\ 5B^'*_MYH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y!?^
M"HO_ "?7\<O^Z9_^J>^'U? -??W_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O?_ -D__DZ;]FK_ ++_ /!O_P!6+X<K
MP"O?_P!D_P#Y.F_9J_[+_P#!O_U8OAR@#^WFBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *_D%_X*B_\GU_'+_NF?_JGOA]7]?5?
MR"_\%1?^3Z_CE_W3/_U3WP^H ^ :*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ]_P#V3_\ DZ;]FK_LO_P;_P#5B^'*_MYK^(;]D_\ Y.F_9J_[+_\ !O\
M]6+X<K^WF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _D%_X*B_\GU_'+_NF?\ ZI[X?5\
MU]_?\%1?^3Z_CE_W3/\ ]4]\/J^ : "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *]__9/_ .3IOV:O^R__  ;_ /5B^'*\ KW_ /9/_P"3IOV:O^R__!O_ -6+
MX<H _MYHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OY!?\ @J+_ ,GU_'+_ +IG_P"J>^'U?U]5_(+_ ,%1?^3Z_CE_W3/_ -4]
M\/J /@&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /?_P!D_P#Y.F_9J_[+
M_P#!O_U8OARO[>:_B&_9/_Y.F_9J_P"R_P#P;_\ 5B^'*_MYH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /Y!?^"HO_ "?7\<O^Z9_^J>^'U? -??W_  5%_P"3Z_CE_P!T
MS_\ 5/?#ZO@&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O?_ -D__DZ;]FK_
M ++_ /!O_P!6+X<KP"O?_P!D_P#Y.F_9J_[+_P#!O_U8OAR@#^WFBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_D%_X*B_\GU_'
M+_NF?_JGOA]7]?5?R"_\%1?^3Z_CE_W3/_U3WP^H ^ :*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ]_P#V3_\ DZ;]FK_LO_P;_P#5B^'*_MYK^(;]D_\
MY.F_9J_[+_\ !O\ ]6+X<K^WF@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _D%_X*B_\GU_
M'+_NF?\ ZI[X?5\ U]_?\%1?^3Z_CE_W3/\ ]4]\/J^ : "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *]__9/_ .3IOV:O^R__  ;_ /5B^'*\ KW_ /9/_P"3
MIOV:O^R__!O_ -6+X<H _MYHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OY!?\ @J+_ ,GU_'+_ +IG_P"J>^'U?U]5_(+_ ,%1
M?^3Z_CE_W3/_ -4]\/J /@&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /?
M_P!D_P#Y.F_9J_[+_P#!O_U8OARO[>:_B&_9/_Y.F_9J_P"R_P#P;_\ 5B^'
M*_MYH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /Y!?^"HO_ "?7\<O^Z9_^J>^'U? -??W_
M  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O?_ -D__DZ;]FK_ ++_ /!O_P!6+X<KP"O?_P!D_P#Y.F_9J_[+_P#!O_U8
MOAR@#^WFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *_D%_X*B_\GU_'+_NF?_JGOA]7]?5?R"_\%1?^3Z_CE_W3/_U3WP^H ^ :
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ]_P#V3_\ DZ;]FK_LO_P;_P#5
MB^'*_MYK^(;]D_\ Y.F_9J_[+_\ !O\ ]6+X<K^WF@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _D%_X*B_\GU_'+_NF?\ ZI[X?5\ U]_?\%1?^3Z_CE_W3/\ ]4]\/J^
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *]__9/_ .3IOV:O^R__  ;_ /5B
M^'*\ KW_ /9/_P"3IOV:O^R__!O_ -6+X<H _MYHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OY!?\ @J+_ ,GU_'+_ +IG_P"J
M>^'U?U]5_(+_ ,%1?^3Z_CE_W3/_ -4]\/J /@&BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /?_P!D_P#Y.F_9J_[+_P#!O_U8OARO[>:_B&_9/_Y.F_9J
M_P"R_P#P;_\ 5B^'*_MYH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y!?^"HO_ "?7\<O^
MZ9_^J>^'U? -??W_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O0/A/XZ_P"%7_%/X:?$O^R_[<_X5W\0/!OCK^Q?MO\
M9G]L?\(EXBTW7_[+_M+[)J']G_VA_9_V3[=]@O?LGG>?]DN?+\E_/Z* /W\_
MX?F?]6N_^9L__%'1_P /S/\ JUW_ ,S9_P#BCK\ Z* /W\_X?F?]6N_^9L__
M !1T?\/S/^K7?_,V?_BCK\ Z* /W\_X?F?\ 5KO_ )FS_P#%'1_P_,_ZM=_\
MS9_^*.OP#HH _?S_ (?F?]6N_P#F;/\ \4='_#\S_JUW_P S9_\ BCK\ Z*
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M_,_ZM=_\S9_^*.OP#HH _?S_ (?F?]6N_P#F;/\ \4='_#\S_JUW_P S9_\
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M_P S9_\ BCK\ Z* /W\_X?F?]6N_^9L__%'1_P /S/\ JUW_ ,S9_P#BCK\
MZ* /W\_X?F?]6N_^9L__ !1T?\/S/^K7?_,V?_BCK\ Z* /W\_X?F?\ 5KO_
M )FS_P#%'1_P_,_ZM=_\S9_^*.OP#HH _?S_ (?F?]6N_P#F;/\ \4='_#\S
M_JUW_P S9_\ BCK\ Z* /W\_X?F?]6N_^9L__%'1_P /S/\ JUW_ ,S9_P#B
MCK\ Z* /W\_X?F?]6N_^9L__ !1T?\/S/^K7?_,V?_BCK\ Z* /W\_X?F?\
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M87V#_D*VOV?[5]J_?^1]FF_7VOY!?^"77_)]?P-_[J9_ZI[X@U_7U0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M_(+_ ,%1?^3Z_CE_W3/_ -4]\/J_KZK^07_@J+_R?7\<O^Z9_P#JGOA]0!\
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110![_\ LG_\G3?LU?\ 9?\ X-_^
MK%\.5_;S7\0W[)__ "=-^S5_V7_X-_\ JQ?#E?V\T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% '\@O_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&OO[_ (*B_P#)]?QR_P"Z9_\
MJGOA]7P#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ??W_!+K_D^OX&_P#=3/\ U3WQ!K^O
MJOY!?^"77_)]?P-_[J9_ZI[X@U_7U0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5_(+_ ,%1?^3Z_CE_W3/_ -4]
M\/J_KZK^07_@J+_R?7\<O^Z9_P#JGOA]0!\ T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110![_\ LG_\G3?LU?\ 9?\ X-_^K%\.5_;S7\0W[)__ "=-^S5_
MV7_X-_\ JQ?#E?V\T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '\@O_  5%_P"3Z_CE_P!T
MS_\ 5/?#ZO@&OO[_ (*B_P#)]?QR_P"Z9_\ JGOA]7P#0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ??W_!+K_D^OX&_P#=3/\ U3WQ!K^OJOY!?^"77_)]?P-_[J9_ZI[X
M@U_7U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5_(+_ ,%1?^3Z_CE_W3/_ -4]\/J_KZK^07_@J+_R?7\<O^Z9
M_P#JGOA]0!\ T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![_\ LG_\G3?L
MU?\ 9?\ X-_^K%\.5_;S7\0W[)__ "=-^S5_V7_X-_\ JQ?#E?V\T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '\@O_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&OO[_ (*B_P#)
M]?QR_P"Z9_\ JGOA]7P#0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ??W_!+K_D^OX&_P#=
M3/\ U3WQ!K^OJOY!?^"77_)]?P-_[J9_ZI[X@U_7U0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_(+_ ,%1?^3Z
M_CE_W3/_ -4]\/J_KZK^07_@J+_R?7\<O^Z9_P#JGOA]0!\ T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110![_\ LG_\G3?LU?\ 9?\ X-_^K%\.5_;S7\0W
M[)__ "=-^S5_V7_X-_\ JQ?#E?V\T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\@O_  5%
M_P"3Z_CE_P!TS_\ 5/?#ZO@&OO[_ (*B_P#)]?QR_P"Z9_\ JGOA]7P#0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ??W_!+K_D^OX&_P#=3/\ U3WQ!K^OJOY!?^"77_)]
M?P-_[J9_ZI[X@U_7U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5_(+_ ,%1?^3Z_CE_W3/_ -4]\/J_KZK^07_@
MJ+_R?7\<O^Z9_P#JGOA]0!\ T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M[_\ LG_\G3?LU?\ 9?\ X-_^K%\.5_;S7\0W[)__ "=-^S5_V7_X-_\ JQ?#
ME?V\T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% '\@O_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&
MOO[_ (*B_P#)]?QR_P"Z9_\ JGOA]7P#0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ??W_!
M+K_D^OX&_P#=3/\ U3WQ!K^OJOY!?^"77_)]?P-_[J9_ZI[X@U_7U0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M_(+_ ,%1?^3Z_CE_W3/_ -4]\/J_KZK^07_@J+_R?7\<O^Z9_P#JGOA]0!\
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110![_\ LG_\G3?LU?\ 9?\ X-_^
MK%\.5_;S7\0W[)__ "=-^S5_V7_X-_\ JQ?#E?V\T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% '\@O_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&OO[_ (*B_P#)]?QR_P"Z9_\
MJGOA]7P#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ??W_!+K_D^OX&_P#=3/\ U3WQ!K^O
MJOY!?^"77_)]?P-_[J9_ZI[X@U_7U0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5_(+_ ,%1?^3Z_CE_W3/_ -4]
M\/J_KZK^07_@J+_R?7\<O^Z9_P#JGOA]0!\ T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110![_\ LG_\G3?LU?\ 9?\ X-_^K%\.5_;S7\0W[)__ "=-^S5_
MV7_X-_\ JQ?#E?V\T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '\@O_  5%_P"3Z_CE_P!T
MS_\ 5/?#ZO@&OO[_ (*B_P#)]?QR_P"Z9_\ JGOA]7P#0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ??W_!+K_D^OX&_P#=3/\ U3WQ!K^OJOY!?^"77_)]?P-_[J9_ZI[X
M@U_7U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5_(+_ ,%1?^3Z_CE_W3/_ -4]\/J_KZK^07_@J+_R?7\<O^Z9
M_P#JGOA]0!\ T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![_\ LG_\G3?L
MU?\ 9?\ X-_^K%\.5_;S7\0W[)__ "=-^S5_V7_X-_\ JQ?#E?V\T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '\@O_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&OO[_ (*B_P#)
M]?QR_P"Z9_\ JGOA]7P#0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ??W_!+K_D^OX&_P#=
M3/\ U3WQ!K^OJOY!?^"77_)]?P-_[J9_ZI[X@U_7U0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_(+_ ,%1?^3Z
M_CE_W3/_ -4]\/J_KZK^07_@J+_R?7\<O^Z9_P#JGOA]0!\ T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110![_\ LG_\G3?LU?\ 9?\ X-_^K%\.5_;S7\0W
M[)__ "=-^S5_V7_X-_\ JQ?#E?V\T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\@O_  5%
M_P"3Z_CE_P!TS_\ 5/?#ZO@&OO[_ (*B_P#)]?QR_P"Z9_\ JGOA]7P#0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ??W_!+K_D^OX&_P#=3/\ U3WQ!K^OJOY!?^"77_)]
M?P-_[J9_ZI[X@U_7U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5_(+_ ,%1?^3Z_CE_W3/_ -4]\/J_KZK^07_@
MJ+_R?7\<O^Z9_P#JGOA]0!\ T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M[_\ LG_\G3?LU?\ 9?\ X-_^K%\.5_;S7\0W[)__ "=-^S5_V7_X-_\ JQ?#
ME?V\T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% '\@O_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&
MOO[_ (*B_P#)]?QR_P"Z9_\ JGOA]7P#0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ??W_!
M+K_D^OX&_P#=3/\ U3WQ!K^OJOY!?^"77_)]?P-_[J9_ZI[X@U_7U0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M_(+_ ,%1?^3Z_CE_W3/_ -4]\/J_KZK^07_@J+_R?7\<O^Z9_P#JGOA]0!\
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110![_\ LG_\G3?LU?\ 9?\ X-_^
MK%\.5_;S7\0W[)__ "=-^S5_V7_X-_\ JQ?#E?V\T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% '\@O_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&OO[_ (*B_P#)]?QR_P"Z9_\
MJGOA]7P#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ??W_!+K_D^OX&_P#=3/\ U3WQ!K^O
MJOY!?^"77_)]?P-_[J9_ZI[X@U_7U0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5_(+_ ,%1?^3Z_CE_W3/_ -4]
M\/J_KZK^07_@J+_R?7\<O^Z9_P#JGOA]0!\ T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110![_\ LG_\G3?LU?\ 9?\ X-_^K%\.5_;S7\0W[)__ "=-^S5_
MV7_X-_\ JQ?#E?V\T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '\@O_  5%_P"3Z_CE_P!T
MS_\ 5/?#ZO@&OO[_ (*B_P#)]?QR_P"Z9_\ JGOA]7P#0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ??W_!+K_D^OX&_P#=3/\ U3WQ!K^OJOY!?^"77_)]?P-_[J9_ZI[X
M@U_7U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5_(+_ ,%1?^3Z_CE_W3/_ -4]\/J_KZK^07_@J+_R?7\<O^Z9
M_P#JGOA]0!\ T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![_\ LG_\G3?L
MU?\ 9?\ X-_^K%\.5_;S7\0W[)__ "=-^S5_V7_X-_\ JQ?#E?V\T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '\@O_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&OO[_ (*B_P#)
M]?QR_P"Z9_\ JGOA]7P#0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\
M#E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T
M]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\P
ME%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5
M '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_
M )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3
M\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__
M .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?
MOC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]E
MG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#
ME;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU
M5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#
MK_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\
MA4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_
M /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H
M?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]
MEG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\
M#E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T
M]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\P
ME%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5
M '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_
M )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3
M\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__
M .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?
MOC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]E
MG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#
ME;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU
M5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#
MK_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\
MA4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_
M /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H
M?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]
MEG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\
M#E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T
M]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\P
ME%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5
M '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_
M )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3
M\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__
M .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?
MOC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#E;]E
MG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU5'_#
ME;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#K_YU
M5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\ A4_#
MK_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_ /\
MA4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H?OC_
M /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]EG_H
M?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\ #E;]
MEG_H?OC_ /\ A4_#K_YU5'_#E;]EG_H?OC__ .%3\.O_ )U5 '\PE%?T]_\
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M_#K_ .=51_PY6_99_P"A^^/_ /X5/PZ_^=50!_,)17]/?_#E;]EG_H?OC_\
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M/PZ_^=50!_,)17]/?_#E;]EG_H?OC_\ ^%3\.O\ YU5'_#E;]EG_ *'[X_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;X=?_/4H_P"'U/[+/_0@_'__ ,);X=?_ #U* /U]HK\@O^'U/[+/_0@_'_\
M\);X=?\ SU*/^'U/[+/_ $(/Q_\ _"6^'7_SU* /U]HK\@O^'U/[+/\ T(/Q
M_P#_  EOAU_\]2OK_P#92_;5^%G[8/\ PGO_  K30/B!H?\ PKO_ (1;^VO^
M$ZTKP[IGVK_A+?\ A(O[-_LO^P/%7B;S_(_X1F_^W?:_L7E^=:>1]I\R;[.
M?7U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !17R#^T7^W1^SC^S']HTWQ]XR_MCQM!Y/_%M/
M L5KXE\=IYO]AS_\32P^W6.D^%-VDZ_9Z_8_\)KK7AK^W='BNYO#G]L7,'V1
M_KZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***S],U;2M:MI+S1]3T_5K2'4-6TF:ZTR\M[^VBU70-5O-"UW3))[626)-
M0T76].U#1]6LV87.G:K87FGWD<-W:SPH :%%%% !1110 4444 %%%% !1110
M 4444 %%%% !16?JVK:5H&E:GKNNZGI^BZ)HNGWFK:QK&K7EOIVE:3I6G6TE
MYJ&IZGJ%Y)#:6&GV%I#-=7EY=316UK;123SR)$C,#2=6TK7]*TS7="U/3]:T
M36M/L]6T?6-)O+?4=*U;2M1MH[S3]3TS4+.2:TO]/O[2:&ZL[RUFEMKJVECG
M@D>)U8@&A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN] \1_\ "2VP\^3\P:* "O[^*_@'K^_B@ HHHH **** "BBB@ HHHH ****
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M0O)(;2PT^PM(9KJ\O+J:*VM;:*2>>1(D9A^27[2W_!7KX-_#/^UO"WP,T_\
MX71XVMOM]A_PD7FSZ5\+-%U&'^WM.\_^U]BZMX[_ +-U:PTB^^R>%[>R\*^)
M_#NJ_:M$^)=M<Q[*_!/]H#]K/X\_M,ZJ]Y\5O'6H:CHD6H-J&C^!-)+:+X!\
M/2)<ZU+IYTSPQ9N+2ZU#2;37]1T>S\3Z\VM>,I]%>/3]4\1ZC%$IKYPH ^C_
M -H#]K/X\_M,ZJ]Y\5O'6H:CHD6H-J&C^!-)+:+X!\/2)<ZU+IYTSPQ9N+2Z
MU#2;37]1T>S\3Z\VM>,I]%>/3]4\1ZC%$IK^NK]D_P#Y-9_9J_[(!\&__5=>
M'*_B&K^WG]D__DUG]FK_ +(!\&__ %77AR@#W^BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "O[>?V3_^36?V:O\ L@'P;_\ 5=>'*_B&K^WG]D__ )-9_9J_[(!\&_\
MU77AR@#W^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_ /_ (+F?\VN
M_P#=;/\ WD=?OY7X!_\ !<S_ )M=_P"ZV?\ O(Z /P#HHHH **** "O[^*_@
M'K^_B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^ ?^"HO_)BG
MQR_[IG_ZN'X?5]_5\ _\%1?^3%/CE_W3/_U</P^H _D%HHHH **** "OZ^O^
M"77_ "8I\#?^ZF?^KA^(-?R"U_7U_P $NO\ DQ3X&_\ =3/_ %</Q!H ^_J*
M** "BBB@ HHHH **** "OR"_X+4_\FL^ ?\ LO\ X6_]5U\5:_7VOR"_X+4_
M\FL^ ?\ LO\ X6_]5U\5: /YA**** "BBB@ K^WG]D__ )-9_9J_[(!\&_\
MU77AROXAJ_MY_9/_ .36?V:O^R ?!O\ ]5UX<H ]_HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^07_@J+_P GU_'+_NF?
M_JGOA]7P#7W]_P %1?\ D^OXY?\ =,__ %3WP^KX!H **** "O?_ -D__DZ;
M]FK_ ++_ /!O_P!6+X<KP"O?_P!D_P#Y.F_9J_[+_P#!O_U8OAR@#^WFBBB@
M HHHH **** "BBB@ K/U;2=*U_2M3T+7=,T_6M$UK3[S2=8T?5K*WU'2M6TK
M4;:2SU#3-3T^\CFM+_3[^TFFM;RSNH9;:ZMI9()XWB=E.A10!_'+^WS^RE>?
MLI_'#4-$TR+S?AEX[_M/QA\+[VWM-=6STW0I]6NHY_ 5UJ>M2W_]I>(/ FZS
ML;Z6/7-8O+W0K_PMXDU9]-O?$K:39?$-?UE?\%:_!6E>*OV+O&&NZA<:A#=_
M#7QAX \:Z%'9RV\=M=ZK?^([;X=36^K)/:7$L^GKHGC_ %BZCBLYK"Y&JVVF
M3M=O:0W5C>?R:T %%%% !1110!^QO_!%'5M5A_:1^)6A0ZGJ$6B:C\$-7U;4
M-'CO+E-*O]5T7QYX L]'U.\T]9!:76H:3::_KMKIEY/"]S86VM:M!:R11:C>
M+-_377\BO_!*W5M5T[]N+X1V>GZGJ%A::_I_Q(TG7;6SO+FUMM:TJ'X9^+M=
MATS5H()$BU'3XM;T71]8CL[Q9K9-5TG3-06,7=A:S1?UU4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '\PG_!:G_DZ;P#_V0#PM_P"K%^*M?D%7
MZ^_\%J?^3IO /_9 /"W_ *L7XJU^05 !1110 4444 ?W\4444 %%%% !1110
M 4444 %%%% !117/^*?%GA;P/H5]XI\:^)?#_@_PSI?V7^T_$7BG6=.\/Z%I
MWVV\M].L_MVKZM<VFGVGVO4+NTL;7[1<1_:+RZM[6+?/-&C '045X!_PUA^R
MS_T<K\ /_#R?#K_YHZ] \"_%CX6?%#^U/^%:?$OP!\1/[#^P_P!M?\(+XR\.
M^+?['_M/[7_9O]J?V!J6H?V?_:']GW_V'[7Y/VO[%=^1YGV:;8 =_1110 5^
M ?\ P7,_YM=_[K9_[R.OW\K\ _\ @N9_S:[_ -UL_P#>1T ?@'1110 4444
M%?W\5_ /7]_% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !17'^-?B%X!^&NE6^N_$7QQX/\  &B7>H1:3:ZQXU\2
MZ+X5TJYU6>VN[R#3+?4-=O;"TFU":TL+ZZBLXYFN9+:SNYTC,5O,R>8?\-8?
MLL_]'*_ #_P\GPZ_^:.@#W^BN \"_%CX6?%#^U/^%:?$OP!\1/[#^P_VU_P@
MOC+P[XM_L?\ M/[7_9O]J?V!J6H?V?\ VA_9]_\ 8?M?D_:_L5WY'F?9IMG?
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445YAXU^-WP7^&N
MJV^A?$7XN_##P!K=WI\6K6NC^-?'WA3PKJMSI4]S=V<&IV^GZ[JUA=S:?-=V
M%]:Q7D<+6TES9W<"2&6WF5 #T^BO /\ AK#]EG_HY7X ?^'D^'7_ ,T=>WZ3
MJVE:_I6F:[H6IZ?K6B:UI]GJVCZQI-Y;ZCI6K:5J-M'>:?J>F:A9R36E_I]_
M:30W5G>6LTMM=6TL<\$CQ.K$ T**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **X_QK\0O /PUT
MJWUWXB^./!_@#1+O4(M)M=8\:^)=%\*Z5<ZK/;7=Y!IEOJ&NWMA:3:A-:6%]
M=16<<S7,EM9W<Z1F*WF9/,/^&L/V6?\ HY7X ?\ AY/AU_\ -'0![_17@'_#
M6'[+/_1ROP _\/)\.O\ YHZ]/\%?$+P#\2M*N-=^'7CCP?X_T2TU"72;K6/!
M7B71?%6E6VJP6UI>3Z9<:AH5[?VD.H0VE_8W4MG),MS';7EI.\8BN(6< ["B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\ _^"YG
M_-KO_=;/_>1U^_E?@'_P7,_YM=_[K9_[R.@#\ Z*** "BBB@ K^_BOX!Z_OX
MH **** "BBO$-6_::_9NT#5=3T+7?V@_@AHNMZ+J%YI.L:/JWQ7\!Z=JNDZK
MIUS)9ZAIFIZ?>:_#=V&H6%W#-:WEG=0Q7-K<Q203QI*C* #V^BO(/"W[0GP#
M\<:[8^%O!7QP^$'C#Q-JGVK^S/#OA;XE^"_$&NZC]BL[C4;S[#I&DZU=ZA=_
M9-/M+N^NOL]O)]GL[6XNI=D$,CKZ_0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 45Q_C7XA> ?AKI5OKOQ%\<>#_  !HEWJ$6DVNL>-?
M$NB^%=*N=5GMKN\@TRWU#7;VPM)M0FM+"^NHK..9KF2VL[N=(S%;S,GF'_#6
M'[+/_1ROP _\/)\.O_FCH ]_HKG_  MXL\+>.-"L?%/@KQ+X?\8>&=4^U?V9
MXB\+:SIWB#0M1^Q7EQIUY]AU?2;F[T^[^R:A:7=C=?9[B3[/>6MQ:R[)X9$7
MH* "BBB@ HHHH **** "BBB@ HHHH *^ ?\ @J+_ ,F*?'+_ +IG_P"KA^'U
M??U? /\ P5%_Y,4^.7_=,_\ U</P^H _D%HHHH **** "OZ^O^"77_)BGP-_
M[J9_ZN'X@U_(+7]?7_!+K_DQ3X&_]U,_]7#\0: /OZBBB@ HHHH **** "BB
MB@ K\@O^"U/_ ":SX!_[+_X6_P#5=?%6OU]K\@O^"U/_ ":SX!_[+_X6_P#5
M=?%6@#^82BBB@ HHHH *_MY_9/\ ^36?V:O^R ?!O_U77AROXAJ_MY_9/_Y-
M9_9J_P"R ?!O_P!5UX<H ]_HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH _D%_X*B_\ )]?QR_[IG_ZI[X?5\ U]_?\
M!47_ )/K^.7_ '3/_P!4]\/J^ : "BBB@ KW_P#9/_Y.F_9J_P"R_P#P;_\
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M10 4444 ?R"_\/1?VZ_^BY?^8S^#W_SOJ/\ AZ+^W7_T7+_S&?P>_P#G?5\
MT4 ??W_#T7]NO_HN7_F,_@]_\[ZC_AZ+^W7_ -%R_P#,9_![_P"=]7P#10!]
M_?\ #T7]NO\ Z+E_YC/X/?\ SOJ_7W_@E-^U'\=?VD_^%\_\+J\<_P#":?\
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M%% !1110!^$?_!3_ /;+_:3_ &=_CYX1\%?!WXC_ /"'^&=4^$&@>*;[3/\
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MR/5M2T>ZU7S+/3%:\,6E::EI\X44 %%%% !78>"OB%X^^&NJW&N_#KQQXP\
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M7-QI=KX<^(/B6;51%X5U"\UNTO+'4=/T_3?$WB;PY;6%U?ZQX8A6YT*WUO\
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M_?"[_@IS^V1\+_["M/\ A9__  L3P_H?]I_\4]\4='L?%O\ ;']I_P!H2_\
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MI%]]CU&WM-0M/M>GW=O<?9;ZTM;R#S/*NK>&='C4 ^G_ /AZ+^W7_P!%R_\
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M HHHH *_ /\ X+F?\VN_]UL_]Y'7[^5^ ?\ P7,_YM=_[K9_[R.@#\ Z***
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MV6&[CLT^R^;';I/-<22_G#_P]%_;K_Z+E_YC/X/?_.^KW_\ X+4_\G3> ?\
ML@'A;_U8OQ5K\@J /O[_ (>B_MU_]%R_\QG\'O\ YWU<!\4?V]/VL/C1X$UW
MX:?$OXK?\)+X)\2_V9_;6B_\(-\-M'^V_P!CZQI^OZ;_ ,3+0/!VE:M;?9M6
MTJPN_P#1+^#SO(\B?S;:6:&3Y HH **** "BBB@ KZ_^%W[>G[6'P7\":%\-
M/AI\5O\ A&O!/AK^T_[%T7_A!OAMK'V+^V-8U#7]2_XF6O\ @[5=6N?M.K:K
M?W?^EW\_D^?Y$'E6T4,,?R!10!]_?\/1?VZ_^BY?^8S^#W_SOJ/^'HO[=?\
MT7+_ ,QG\'O_ )WU? -% 'W]_P /1?VZ_P#HN7_F,_@]_P#.^H_X>B_MU_\
M1<O_ #&?P>_^=]7P#10!_?Q1110!_+)^T)_P4=_;-\#_ !\^.'@KPM\9/[+\
M,^#_ (O_ !+\+>'=,_X5Y\*KW^SM"\/^--:TG2+'[9J/@:[U"[^R:?:6]O\
M:KZ[NKR?R_-NKB:=WD;R#_AZ+^W7_P!%R_\ ,9_![_YWU> ?M8?\G3?M*_\
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M??W_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&@ HHHH *]_\ V3_^3IOV:O\ LO\
M\&__ %8OARO *]?_ &>_%.A>!_CY\#_&OBF^_LOPSX/^+_PT\4^(]3^RWE[_
M &=H7A_QIHNK:O??8].M[O4+O[)I]I<7'V6QM+J\G\ORK6WFG=(V /[F:*^
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M_!<S_FUW_NMG_O(Z_?ROP#_X+F?\VN_]UL_]Y'0!^ =%%% !1110 5_?Q7\
M]?W\4 %%%% !1110!_ /1110 4444 %?OY_P0S_YNB_[HG_[UROP#K]_/^"&
M?_-T7_=$_P#WKE '[^4444 %%%% '\PG_!:G_DZ;P#_V0#PM_P"K%^*M?D%7
MZ^_\%J?^3IO /_9 /"W_ *L7XJU^05 !1110 4444 ?W\4444 %%%% !117Q
MC^W9^U#I7[+OP&\3>(;/6]/L_BCXJT^^\.?"31Y)[<ZK>>)KL6]G<^)[/3[K
M2->M+S3_ (?6FHKXKU,:QIH\/7US::3X5U#4+.^\5:0MR ?"/_!2'_@I#_P@
M']O?L]?L]:]_Q<#_ $G1_B7\2]'N?^1 ^]!?^#O!U_ W_)0/OVWB'Q#;2?\
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MYYNGZOJ'B#3]6U#0? M]$R>([S4-"O/"QMDT+2?!>H2:A_/'0 4444 %%%%
M!1110 4444 %%%% !1110!V'@#Q_XR^%OC+P]\0?A]XAU#PKXR\*Z@FIZ%KN
MF.@N;.Y$<D$T<D,\<UI?Z??VDUQIVK:3J-O=Z5K.E7=YI6JV=YIMY=6LW];7
M[#G[<?@W]KSP:]K=)I_A7XT>%=/AE\>> XII!;7=L)(;3_A-?!7VN::[O_!]
M_=S00W=I-/=ZKX-U6[M]"UVXO+:\\->)/%7\>M>O_ +XQ:[^S_\ &3X>_&'P
M[#]KU#P/X@AU&XTSS+.W_MS0KN"?2?%/AW[9?:7K,&F?\))X9U#5]!_M=-,N
M[S1_[1_M33D74+2UD0 _N9HK@/A5\2_"WQD^''@OXH^"KO[7X9\<>'[#7],W
MSZ=<7EC]KB'VS1=7_LF_U33[7Q!X?U!+O0O$6FV^H7?]E:[IVHZ9+,T]I)CO
MZ "BBB@ HHHH **** "BBB@ HHHH **** "OP#_X+F?\VN_]UL_]Y'7[^5^
M?_!<S_FUW_NMG_O(Z /P#HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
MG_V4OVKOB/\ LE_$>+QKX*E_M7P_JOV2Q\?^ +Z[EMM"\<:%;2RO';W$B17/
M]E>(-*^TW=QX6\4V]I<WF@WES=12VNJ^']5\0^'M;^8** /[F?@7\=/AQ^T7
M\.-&^*'POUG^U?#^J[K6\L[I8K;7?#&NVT4$FI^%O%.F1SW/]E>(-*^TP-<6
MZSW-G>V=S8ZUHM]JOA_5=)U:^]?K^27_ ()F_M76?[-7QPDT3Q;+Y7PR^,G_
M  C_ (/\57CW>A:99^%M=@U8Q^$/'NKZGK,4'E>'_#7]L:]8^(HEUS1[.VT+
MQ!J/B2Y36+WPUI6DW/\ 6U0 4444 %%%% !117 ?%7XE^%O@W\./&GQ1\:W?
MV3PSX'\/W^OZGLGTZWO+[[)$?L>BZ1_:U_I>GW7B#Q!J#VFA>'=-N-0M/[5U
MW4=.TR*99[N/(!X_^U;^U=\./V2_AQ+XU\:R_P!J^(-5^UV/@#P!8W<5MKOC
MC7;:*)Y+>WD>*Y_LKP_I7VFTN/%/BFXM+FST&SN;6**UU7Q!JOA[P]K?\BOQ
MX_:*^+G[2/C*]\9_%7Q9J&M2OJ&H7FA>&HKJ^B\&^";;48["WFTGP5X<GN[J
MTT#3S::3I-M=R1&75=;DTZWU/Q)J>M:V]UJEP?M%?'CQE^TC\7/%GQ5\9WNH
M/+K6H747AK0KS4$U&V\$^#8KZ[G\.>"M)FM[#2;0Z?H%I=&*2[MM)TZ36]5E
MU/Q)J=N^MZUJEU<>(4 %%%% !1110 4444 %%%% !1110 5]W?L.?MQ^,OV0
M_&3VMTFH>*O@OXJU"&7QYX#BF0W-I<F.&T_X37P5]KFAM+#QA86D,$-W:33V
MFE>,M*M+?0M=N+.XL_#?B3PK\(T4 ?WD> /'_@WXI>#?#WQ!^'WB'3_%7@WQ
M5IZ:GH6NZ8\AMKRV,DD$T<D,\<-W8:A87<-QIVK:3J-O::KHVJVEYI6JV=GJ
M5G=6L/85_-I_P22_;$N?!'C*']F+X@ZQJ%QX-\?:@#\*;S4]8TJ#1? GC)H]
M6U#4?#D:ZI]FNTT_XE7<EO!I.GZ=JD\<7CY;.VTGPQ<:EX^U[6+;^DN@ HHH
MH _F$_X+4_\ )TW@'_L@'A;_ -6+\5:_(*OU]_X+4_\ )TW@'_L@'A;_ -6+
M\5:_(*@ HHHH **** "BBB@ HHHH **** "BBB@#^_BBBB@#^(;]K#_DZ;]I
M7_LO_P 9/_5B^(Z\ KW_ /:P_P"3IOVE?^R__&3_ -6+XCKP"@ HHHH ****
M "BBB@ HHHH **** "BBB@#^WG]D_P#Y-9_9J_[(!\&__5=>'*]_KP#]D_\
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M&DWEOJ.E:MI6HVT=YI^IZ9J%G)-:7^GW]I-#=6=Y:S2VUU;2QSP2/$ZL="@
MHHHH *_(+_@M3_R:SX!_[+_X6_\ 5=?%6OU]K\@O^"U/_)K/@'_LO_A;_P!5
MU\5: /YA**** "BBB@ KL/&7C_QE\0;G0+KQGXAU#7Y?"O@_POX \-+>.@MM
M!\&^#=*AT?PYX>TFSMXX;2PT^PM(3-(EM!')J.JW>IZ[J<EYK>K:IJ%WQ]%
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M51H444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^OK_ ()=?\F*? W_ +J9_P"KA^(-?R"U_7U_P2Z_Y,4^!O\ W4S_ -7#\0:
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M>F:E:V^LZ9KNE6%]+H^H>$-$MM=\;V=S/)I<=Y<^&8](M=8T[5-2TZ<?QJT
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M?V>FF_\ %P- &E>-K;[-;:58:;_HFOP>=H\']BS^;I,LUE)^(?[3O_!'37?
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M/6M(_M:PTO4+KP_X@T][37?#NI7&GVG]JZ%J.G:G%"L%W'D \_HHHH ****
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MO(YK2_T^_M)IK6\L[J&6VNK:62">-XG92 ?P+T5_5W^T7_P2D_9Q^-'VC6_
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MS_ZNB_\ ,)__ (W*/^'&?_5T7_F$_P#\;E '[^4444 ?Q#?M8?\ )TW[2O\
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ME_PM#3_[0_L_^T/LGVW[!9?:_)\_[);>9Y* 'XA45^_G_#C/_JZ+_P PG_\
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M9_\ 8?D?9+W^T_.T\ _H[HHHH ***^4/VZ/&NE> ?V/_ -HC7=8M]0N;2_\
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M\JE?W\5_$-^UA_R=-^TK_P!E_P#C)_ZL7Q'0!X!1110 4444 ?K[_P $5O\
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M6I/I^M>,M1\?W.F:MK N)+RYMM6TRRO'M-"6RT_];: "BBB@ KX!_P""HO\
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M?@5]2U;5)[O3[O[)J%IXQ\*Z+IVCSVT6@^%O">@:;+I%E EE>:I_+)7[&_\
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M_P#1#?\ S)GP>_\ G@T?\.N?VZ_^B&_^9,^#W_SP:_KZHH _D%_X=<_MU_\
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M?\02:;\8T %%%% !1110!_3W_P $O_VZ/^%U>%H_@?\ &+QE_:'QL\,_:?\
MA#]2UJ+R-1^)'@33].MYD\[6I;Z?_A)OB!X9\C5&U_SK73]8U?PM!IOB63_A
M)M3T_P >Z_:?K[7\(_PJ^)?BKX-_$?P7\4?!5W]D\3>!_$%AK^F;Y]1M[.^^
MR2C[9HNK_P!DW^EZA=>'_$&GO=Z%XBTVWU"T_M70M1U'3)9E@NY,_P!O/PJ^
M)?A;XR?#CP7\4?!5W]K\,^./#]AK^F;Y].N+RQ^UQ#[9HNK_ -DW^J:?:^(/
M#^H)=Z%XBTVWU"[_ +*UW3M1TR69I[23 !W]%%% !7P#_P %1?\ DQ3XY?\
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MMXH-0;6_ .CVLDMY#?VQTJYU.!;1+N:UOK, _K*HHHH *_*+_@LAXIUWP_\
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MVH2RZU\.M-U-WEM=5UJVATE8X[^TT"5M._H,K^83_@BM_P G3>/O^R >*?\
MU8OPJK^GN@ KY!_;[\=?\*[_ &-_VA-?_LO^V/[0\ 7G@7[)]M_L_P G_A:%
M]8?#3^U//^R7OF?V'_PEO]M?8?)3^T_[/_LW[7I_VO[?;?7U?D%_P6I_Y-9\
M _\ 9?\ PM_ZKKXJT ?S"4444 %%%% !7]A7_!,S2=5T7]AWX$6>L:9J&DW<
MVG^-M6AM=3LKFPN9=*U_XF>--=T+4XX+J.*5]/UK1-1T_6-)O%4VVHZ5?V>H
M6<DUI=03/_'K7M^D_M-?M(Z!I6F:%H7[0?QOT71-%T^STG1]'TGXK^/-.TK2
M=*TZVCL]/TS3-/L]?AM+#3["TAAM;.SM88K:UMHHX((TB15 !_<317\0W_#6
M'[4W_1ROQ_\ _#R?$7_YHZ/^&L/VIO\ HY7X_P#_ (>3XB__ #1T ?V\T5_$
M-_PUA^U-_P!'*_'_ /\ #R?$7_YHZ/\ AK#]J;_HY7X__P#AY/B+_P#-'0!_
M;S17\0W_  UA^U-_T<K\?_\ P\GQ%_\ FCH_X:P_:F_Z.5^/_P#X>3XB_P#S
M1T ?V\U_-)_P6R\+:[:?'SX4>-;BQ\OPSX@^$$?A;2-3^TV;_:]=\'^-/%.K
M>(K'[$EPVH6_]G:?XY\+7'VJZM(;.[_M3RK&XNI[+48[3\X?^&L/VIO^CE?C
M_P#^'D^(O_S1UP'CKXL?%/XH?V7_ ,++^)?Q ^(G]A_;O[%_X3KQEXB\6_V/
M_:?V3^TO[+_M_4M0_L_^T/[/L/MWV3R?M?V*T\_S/LT.P \_HHHH **** /V
M]_X(B>.O[/\ BG\</AI_9?G?\);X \/>.O[:^V^7_9__  KOQ$^@?V7_ &;]
MD?[7_;'_  M#[7]N^WVW]G_V'Y'V2]_M/SM/_H[K^17_ ()6ZMJNG?MQ?".S
MT_4]0L+37]/^)&DZ[:V=Y<VMMK6E0_#/Q=KL.F:M!!(D6HZ?%K>BZ/K$=G>+
M-;)JNDZ9J"QB[L+6:+^NJ@ HHHH *^ ?^"HO_)BGQR_[IG_ZN'X?5]_5\ _\
M%1?^3%/CE_W3/_U</P^H _D%HHHH **** "OZ^O^"77_ "8I\#?^ZF?^KA^(
M-?R"U_7U_P $NO\ DQ3X&_\ =3/_ %</Q!H ^_J*** "BBB@ HHHH **** "
MOR"_X+4_\FL^ ?\ LO\ X6_]5U\5:_7VOR"_X+4_\FL^ ?\ LO\ X6_]5U\5
M: /YA**** "BBB@ K^WG]D__ )-9_9J_[(!\&_\ U77AROXAJ_MY_9/_ .36
M?V:O^R ?!O\ ]5UX<H ]_HHHH **** "BBB@ K^$?XL>.O\ A:'Q3^)?Q+_L
MO^P_^%B?$#QEXZ_L7[;_ &G_ &/_ ,);XBU+7_[+_M+[)I_]H?V?_:'V3[=]
M@LOM?D^?]DMO,\E/[.?VL/\ DUG]I7_L@'QD_P#5=>(Z_B&H **** "BBB@#
M][/^"&^DZ5-JO[2NNS:9I\NMZ=I_PFTG3]8DLK=]5L-*UJY^(UYK&F6>H-&;
MNUT_5KO0-"NM3LX)DMK^YT729[J.673K-H?Z#*_A'\"_%CXI_"_^U/\ A6GQ
M+^('P[_MS[#_ &U_P@OC+Q%X2_MC^S/M?]F_VI_8&I:?_:']G_VA?_8?M?G?
M9/MMWY'E_:9M_?\ _#6'[4W_ $<K\?\ _P /)\1?_FCH _MYHK^(;_AK#]J;
M_HY7X_\ _AY/B+_\T='_  UA^U-_T<K\?_\ P\GQ%_\ FCH _MYHK^(;_AK#
M]J;_ *.5^/\ _P"'D^(O_P T='_#6'[4W_1ROQ__ /#R?$7_ .:.@#^WFBOX
MAO\ AK#]J;_HY7X__P#AY/B+_P#-'1_PUA^U-_T<K\?_ /P\GQ%_^:.@#^CS
M_@KOX&_X2W]C?6M?_M3^S_\ A5_Q \">.OLGV'[7_;G]H7UU\-/[+\_[7;?V
M9Y/_  L3^VOMODZAYG]C_P!F_9$_M#[?9?RB5Z_XI_:$^/OCC0K[PMXU^.'Q
M?\8>&=4^R_VGX=\4_$OQIX@T+4?L5Y;ZC9_;M(U;6KO3[O[)J%I:7UK]HMY/
ML]Y:V]U%LGAC=?(* "BBB@ KZ_\ V!/'7_"N_P!LC]GO7_[+_MC^T/B!9^!?
MLGVW^S_)_P"%H6-_\-/[4\_[)>^9_8?_  EO]M?8?)3^T_[/_LW[7I_VO[?;
M?(%:&DZMJN@:KIFNZ%J>H:+K>BZA9ZMH^L:3>7.G:KI.JZ=<QWFGZGIFH6<D
M-W8:A87<,-U9WEK-%<VMS%'/!(DJ*P /[Z**** "OR"_X+4_\FL^ ?\ LO\
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MU? -??W_  5%_P"3Z_CE_P!TS_\ 5/?#ZO@&@ HHHH *]_\ V3_^3IOV:O\
MLO\ \&__ %8OARO *]__ &3_ /DZ;]FK_LO_ ,&__5B^'* /[>:*** "BBB@
M HHHH **** "BBB@#C_'_@#P;\4O!OB'X??$'P]I_BKP;XJT]],UW0M320VU
MY;&2.>&2.:"2&[L-0L+N&WU'2=6TZXM-5T;5;2SU72KRSU*SM;J'^,;]K/\
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M_E?@'_P7,_YM=_[K9_[R.@#\ Z*** "BBB@ K^_BOX!Z_OXH **** "BBB@
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M@;_W4S_U</Q!K^06OZ^O^"77_)BGP-_[J9_ZN'X@T ??U%%% !1110 4444
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M@ HHHH *^_O^"77_ "?7\#?^ZF?^J>^(-? -??W_  2Z_P"3Z_@;_P!U,_\
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M/^36?VE?^R ?&3_U77B.O?Z\ _:P_P"36?VE?^R ?&3_ -5UXCH _B&HHHH
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M+?0OB+K?BK1+34!+9PK%JUKI\.JP6SW=G!>1VE_?07'I_P#PR?\ LL_]&U?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _D%_P""HO\ R?7\<O\ NF?_
M *I[X?5\ U]_?\%1?^3Z_CE_W3/_ -4]\/J^ : "BBB@ KW_ /9/_P"3IOV:
MO^R__!O_ -6+X<KP"O?_ -D__DZ;]FK_ ++_ /!O_P!6+X<H _MYHHHH ***
M* "BBB@ HHHH **** "OR"_X+,_%'_A%/V<?"GPTL-<^P:M\6/B!9?VEHO\
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M>^%WA'Q+_:?^_P"+/B+H7]C0:A_V2Z__ +3U/2O^G70M0_Y&*VH _?RBBB@
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MB@ HHHH _OXHHHH **** "BBB@ HHHH _D%_X*B_\GU_'+_NF?\ ZI[X?5\
MU]_?\%1?^3Z_CE_W3/\ ]4]\/J^ : "BBB@ K[^_X)=?\GU_ W_NIG_JGOB#
M7P#7W]_P2Z_Y/K^!O_=3/_5/?$&@#^OJBBB@ K\PO^"N_@;_ (2W]C?6M?\
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M 'D=?OY7X!_\%S/^;7?^ZV?^\CH _ .BBB@ HHHH *_OXK^ >O[^* "BBB@
MHHHH **** /@'_@IS\4?^%7_ +&_Q/\ LFN?V'X@^(G]C_"[P]_Q+/[3_MC_
M (2V^7_A,="_>Z?J%EI_]H?#+3_'7_$SO?L7V3R?^)7J%MX@DT??_(+7[>_\
M%JOC-_;?Q'^&7P+TG4?,T_P+X?NO'7BVWT[Q-]JLY?%/C"7[#H.E^(O"UL@@
MTWQ!X6\,Z1)K.D7VISS:C+H7Q,=K.TT[3[UKK6_Q"H **** "BBB@#^AS_@A
MWX6UVT\+?M$^-;BQ\OPSX@\0?#CPMI&I_:;-_M>N^#].\8:MXBL?L27#:A;_
M -G:?XY\+7'VJZM(;.[_ +4\JQN+J>RU&.T_=ROS1_X)*>"M*\*_L7>#]=T^
MXU":[^)7C#Q_XUUV.\EMY+:TU6P\1W/PZAM])2"TMY8-/;1/ &CW4D5Y-?W)
MU6YU.=;M+2:UL;/]+J "OB'_ (*-?#3_ (6A^QO\:=.M[3P_-JWA+P_#\2](
MOM?@\S^Q_P#A7=];>*?$5WHMTEAJ%SI_B#4/!.G^*?#FFSVJ6WVO^W)M(OK^
MRTG4]1N$^WJS]6TG2M?TK4]"UW3-/UK1-:T^\TG6-'U:RM]1TK5M*U&VDL]0
MTS4]/O(YK2_T^_M)IK6\L[J&6VNK:62">-XG92 ?P+T5T'BSPMKO@;Q3XE\%
M>*;'^R_$W@_Q!K/A;Q%IGVFSO?[.UWP_J-SI.KV/VW3KB[T^[^R:A:7%O]JL
M;NZL[CR_-M;B:!TD;GZ "BBB@ K^MK_@E#XIT+Q!^Q-\.=)TB^^UZAX'\0?$
M3PMXIM_LMY!_9>NW?CC6_&MO8^;=6\,%[YGAGQAX<U/[5ITEW9I_:/V-[A=0
MM+ZTM?Y):_5W_@D+\=+/X8?M':A\.?$.L_V7X9^.'A^+PY:1S+H5OITWQ'\/
MW3ZGX%?4M6U2>TU"T^UZ?=^,?"NBZ=H\]S+KWBGQ9H&FRZ1>SO8WFE@']3=%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\ _P#!47_DQ3XY?]TS
M_P#5P_#ZOOZO@'_@J+_R8I\<O^Z9_P#JX?A]0!_(+1110 4444 %?U]?\$NO
M^3%/@;_W4S_U</Q!K^06OZ>_^"*W_)K/C[_LO_BG_P!5U\*J /U]HHHH ***
M* "BBB@ HHHH *_(+_@M3_R:SX!_[+_X6_\ 5=?%6OU]K\@O^"U/_)K/@'_L
MO_A;_P!5U\5: /YA**** "BBB@ K^WG]D_\ Y-9_9J_[(!\&_P#U77AROXAJ
M_M9_8J\4Z%XP_9(_9RU;PY??VCI]I\(/ _A:XN/LMY:>7KO@?1+7P5XIL?*O
MK>UG?^R_$WA_5],^U)&UG>_9/MFG7%WI\]K=S 'T_1110 4444 %%%% &?JV
MDZ5K^E:GH6NZ9I^M:)K6GWFDZQH^K65OJ.E:MI6HVTEGJ&F:GI]Y'-:7^GW]
MI--:WEG=0RVUU;2R03QO$[*?X1_B%X*U7X:^/O''PZUVXT^[UOP!XP\2^"M8
MNM)EN9]*N=5\*ZU>Z%J%QID]Y:6%W-I\UW8326<MU8V=S);-&\]I;REH4_O(
MK^27_@JQ\-/^%=_MD>-=1M[3P_I^D_%#P_X6^)>D6.@0?9/)_M"QD\+>(KO6
MK5+"RMH_$&N>-O"7BGQ'J4]J^H?VG_;$.KWU^^K:AJ-O; 'YPT444 %%%% '
M[6_\$4?BAI7A[XN?%KX4:@NGVUW\3/!^A>(]"U"\UJWL;FZU7X:WVK+-X8TG
M1YX/-US4-3T3QMK'B.0V=ZESIFE>#=3N6T^\M)+J\TK^DNOX9O@%\8M=_9_^
M,GP]^,/AV'[7J'@?Q!#J-QIGF6=O_;FA7<$^D^*?#OVR^TO68-,_X23PSJ&K
MZ#_:Z:9=WFC_ -H_VIIR+J%I:R)_;SX3\4Z%XX\+>&O&OA:^_M3PSXP\/Z-X
MI\.:G]EO++^T="\0:=;:MI%]]CU&WM-0M/M>GW=O<?9;ZTM;R#S/*NK>&='C
M4 Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\@O^"U/_)K/@'_ ++_
M .%O_5=?%6OU]K\@O^"U/_)K/@'_ ++_ .%O_5=?%6@#^82BBB@ HHHH *_M
MY_9/_P"36?V:O^R ?!O_ -5UX<K^(:O[>?V3_P#DUG]FK_L@'P;_ /5=>'*
M/?Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH _D%_X*B_\ )]?QR_[IG_ZI[X?5\ U]_?\
M!47_ )/K^.7_ '3/_P!4]\/J^ : "BBB@ KW_P#9/_Y.F_9J_P"R_P#P;_\
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M1WPMI,&G^&?#?]IP:-ICZO\ V#I&G?VQ>6B:CJGVO4&DNG /T^_;Y_X*@?\
M"Z-"U#X,_L\2>(/#_P .=2_M/3?'_CG4;;^QM=^(&G)>75C'H'AVT2XEU#1/
M &MZ?%#J.KS:JFE^*O%%GJ">&=8T7PWHUKXATOQ;^,5%% !1110 4444 %?V
M%?\ !-GX0V_P@_8_^%D!@T]=;^(^GM\7O$=YIE_JM];:E<^/X+74/#4\BZHL
M*V&H6'P^A\&:%JUAIEK;Z5%JND7DULVHRSW&L:E_-I^PO^SI_P -.?M'>#?
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MUS=VVD30:MX8\'Z[IYUOQ5J%G%=ZY8F/Q=IOA32M*\0Z7I]^VF>.O#L\UE=
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M_FZ+_NB?_O7*_ .OW\_X(9_\W1?]T3_]ZY0!^_E%%% !1110!_,)_P %J?\
MDZ;P#_V0#PM_ZL7XJU^05?K[_P %J?\ DZ;P#_V0#PM_ZL7XJU^05 !1110
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M[D1R031R0SQS6E_I]_:37&G:MI.HV]WI6LZ5=WFE:K9WFFWEU:S?T=_LK?\
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MW<MGXP\5:(9;'PWIFFM8>(=#TK51X]75O#\\/@QO$O\ +I110 4444 %%%%
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M HHHH **** "O[^*_@'K^_B@ HHHH **** "BBB@ HHHH **** "BBB@ K\
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MBFTTFV_X2W6K'=8:7/=?\)!XF?5M=NM2O-/M-1U6\U&XU/4X5U"[N<^OT44
M%%%% '\FO_!5;X#V_P '/VHM7\3:%9:A#X4^-FGR?$RWFDT[54TJV\97^IWM
MK\0=&L]=U&_U&+6M0?6XH?&^IVUK)81^'[;Q[I.D0:/9:7#I4][^:-?U]?\
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MCKOB#P7K6DZ18_;=1N+33[3[7J%W;V_VJ^N[6SM_,\VZN(8$>10#^&:BBB@
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MU3Q/H=]X=\.>&SHOA_P]CQ!X&\*ZMJ]KHNF6%GXEO-)23Q+;ZM]JOA=?U=4
M%?BE_P %G?@/<^*OAAX(^/VA66G_ &OX5ZA-X8\<S1Z=I4&JW?@WQKJ&F6OA
M_4+S79[^TU*\T_PKXR$.F:9X;M;'6)!<_$?5M;@&E6EEK4]Y^UM<!\5?AIX6
M^,GPX\:?"[QK:?:_#/CCP_?Z!J>R#3I[RQ^UQ'['K6D?VM8:II]KX@\/Z@EI
MKOAW4KC3[O\ LK7=.T[4XH6GM(\ '\(U%>@?%7X:>*O@W\1_&GPN\:VGV3Q-
MX'\07^@:GL@U&"SOOLDI^QZUI']K6&EZA=>'_$&GO::[X=U*XT^T_M70M1T[
M4XH5@NX\^?T %%%% !7[&_\ !+K]NS2O@IJMS\"?C1XFU"S^%WBK4+63X?\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?R"_\
M!47_ )/K^.7_ '3/_P!4]\/J^ :^_O\ @J+_ ,GU_'+_ +IG_P"J>^'U? -
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117]!G_  2I
M_83TH:5I'[4OQE\,Z@^MOJ$=_P#!+PMXAL;:+2K72HK:RN].^+TEE)<37=_J
M%_=S7$?@!=6L-.MM)MM.3Q]I<&M2ZUX)\0:  ?7W_!+K]E[5?V>/@-<^(O&^
MB:AH'Q1^,.H6OB3Q/H^K07-CJOASPSHPOK/P)X8U/3SJ]_:0ZA#:7^K^*[PR
M:;H/B'3[GQE)X5\3:>M]X7B6+]+J** "BBB@ HHHH _/'_@IO^S_ *5\;OV7
M?&.NJFGVOC+X*Z?JOQ4\,:Q=K;P2+I7A[3)[SQWX=EU :+JVJC3]?\*6MY=6
M^D:?-I5MJGC+0O!4^L:C!INF2LO\BM?W\5_'+^WS^RE>?LI_'#4-$TR+S?AE
MX[_M/QA\+[VWM-=6STW0I]6NHY_ 5UJ>M2W_ /:7B#P)NL[&^ECUS6+R]T*_
M\+>)-6?3;WQ*VDV0!\0T444 %%%% !1110!H:3JVJZ!JNF:[H6IZAHNMZ+J%
MGJVCZQI-Y<Z=JNDZKIUS'>:?J>F:A9R0W=AJ%A=PPW5G>6LT5S:W,4<\$B2H
MK#T_Q3^T)\??'&A7WA;QK\</B_XP\,ZI]E_M/P[XI^)?C3Q!H6H_8KRWU&S^
MW:1JVM7>GW?V34+2TOK7[1;R?9[RUM[J+9/#&Z^044 %%%% !1110 4444 %
M%%% !7]_%?P#U_?Q0 4444 %%%% '\ ]%%% !1110 5^_G_!#/\ YNB_[HG_
M .]<K\ Z_?S_ ((9_P#-T7_=$_\ WKE '[^4444 %%%% '\PG_!:G_DZ;P#_
M -D \+?^K%^*M?D%7Z^_\%J?^3IO /\ V0#PM_ZL7XJU^05 !1110 4444 ?
MW\4444 %%%% !7\>O_!0_P#9DU7]FW]H7Q&L%MIX^'WQ1U#7_B'\.I]!\/7/
MA[P]H^E:MK]_-??#ZVM4MUT2WU#P!+/:Z>VG:%>75M'X9OO"6L36NB-K\>A:
M=_857Q#^WS^RE9_M6? _4-$TR+ROB;X$_M/QA\+[VWM-":\U+78-)NHY_ 5U
MJ>M2V']F^'_'>VSL;Z6/7-'L[+7;#PMXDU9]2LO#3:3>@'\<M%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5_?Q7\ ]?W\4 %%%% !7@'[6'_)K/
M[2O_ &0#XR?^JZ\1U[_7@'[6'_)K/[2O_9 /C)_ZKKQ'0!_$-1110 4444 %
M?OY_P0S_ .;HO^Z)_P#O7*_ .OW\_P""&?\ S=%_W1/_ -ZY0!^_E%%% !11
M10!_,)_P6I_Y.F\ _P#9 /"W_JQ?BK7Y!5^OO_!:G_DZ;P#_ -D \+?^K%^*
MM?D%0 4444 %%%% ']_%%%% !1110 4444 %%%% '\@O_!47_D^OXY?]TS_]
M4]\/J^ :^_O^"HO_ "?7\<O^Z9_^J>^'U? - !1110 5]_?\$NO^3Z_@;_W4
MS_U3WQ!KX!K[^_X)=?\ )]?P-_[J9_ZI[X@T ?U]4444 %%%% 'SA^UG^S_I
M7[37P&\=?"F\33XM;U'3SJW@36-06W2/P]X^T4/>>&-3.H2Z+K]WI.GW5V&T
M'Q/>:/ISZU/X-UKQ)I>GR12ZB6K^*;5M)U70-5U/0M=TS4-%UO1=0O-)UC1]
M6LKG3M5TG5=.N9+/4-,U/3[R.&[L-0L+N&:UO+.ZABN;6YBD@GC25&4?WT5_
M.G_P6-_9>U73/&6E?M1>$-$U"]\.^)]/T[PW\7;JS@N;NV\/>)M&CL-"\'^)
M]6GFU>[EL]/\5:(=-\(QBQT/2_#VE:KX4TQ;_4)_$7CJRAN@#\,Z*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#]??^"*W_)TWC[_ +(!XI_]6+\*
MJ_I[K^83_@BM_P G3>/O^R >*?\ U8OPJK^GN@ HHHH **** "BBB@ HHHH
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MM"N?$-S!=:Q'X8T)I1HGA73[R6TLE.D^'-/TO2H+:PT^SMK.&TL+."#S"B@
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MO]C5 !1110 4444 %?R"_P#!1#]D/_AE/XR#_A%K+[-\'/B3]OUGX7>=KO\
M;6HZ;_94&C_\)=X3U+[5%!JT7_"-:MK-O_8MS??VK]M\+:GH'VKQ+KGB2V\2
M_8OZ^J\0_:*^ _@W]I'X1^+/A5XSLM/>+6M/NI?#6NWFG2:C<^"?&45C=P>'
M/&NDPP7^DW9U#0+NZ,LEI;:MIT>MZ5+J?AO4[A]$UK5+6X /X=J*]/\ C/\
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M6%W#JMUX2CU6;4;G7/!L%M./$/B'7]%\8MI@!^>-%%% !1110 4444 %%%%
M!1110 4444 %>O\ P+^.GQ'_ &=/B/HWQ0^%^L_V5X@TK=:WEG=++<Z%XGT*
MYE@DU/PMXITR.>V_M7P_JOV:!KBW6>VO+*\MK'6M%OM*\0:5I.K6/D%% ']K
M/[*7[5WPX_:T^'$7C7P5+_97B#2OLECX_P# %]=Q7.N^!]=N8I7CM[B1(K;^
MU?#^J_9KNX\+>*;>TMK/7K.VNHI;72O$&E>(?#VB?3]?P[?LZ_%[XN?!/XN>
M$_&?P3FU"7QW+J%KX?L_#5G87VM6WCVVUJ^M+=O FK>'-/9+OQ'I_B.[2RMH
M]*LRFJIJJ:9J?AZZT[Q)IVCZI9?VT^$]1UW5_"WAK5O%/AS_ (0_Q-JGA_1M
M1\1>$O[7L_$'_"+:[>Z=;7.K^'?[>TY(M/UO^Q-0EN-,_M>QCCL]2^R_;+5$
M@F10 =!1110 5^07_!:G_DUGP#_V7_PM_P"JZ^*M?K[7Y!?\%J?^36? /_9?
M_"W_ *KKXJT ?S"4444 %%%% !7]O/[)_P#R:S^S5_V0#X-_^JZ\.5_$-7]O
M/[)__)K/[-7_ &0#X-_^JZ\.4 >_T444 %%%% !1110 4444 %%%% !1110
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MX;O_ (0KP5]KAFM+_P 87]I-!-=W<T%WI7@W2KNWUW7;>\N+SPWX;\5?7_\
MP5N^#'PP^ O@W]E?P!\(_"&G^#/"D.H?'O5FT^SGU"_N;W5=2D^$+7FIZMK&
ML7FHZWK6H/%%;64=YJ^HWMS;:58:9H]K)#I6EZ?9VP!^*5%%% !1110 5_?Q
M7\ ]?W\4 %%%% !1110!_ /1110 4444 %?OY_P0S_YNB_[HG_[UROP#K]_/
M^"&?_-T7_=$__>N4 ?OY1110 4444 ?S"?\ !:G_ ).F\ _]D \+?^K%^*M?
MD%7Z^_\ !:G_ ).F\ _]D \+?^K%^*M?D%0 4444 %%%% ']_%%%% !1110
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MCXE_#31[;_D0/O3W_C'P=80+_P B!_K+GQ#X>MD_XM_^]U72HO\ A7_VNT\
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M:ZIJUI>:=IRPZG>V\&GW=I<S_P!K-% '\ ]%?W<^.OA/\+/BA_9?_"R_AIX
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MEBO(+:S\4Z%K]MHT>MZ]=>'H](U75KK46_#/XU?\$;OV@O _V"[^#OB'P_\
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M_P"Q?^$%U7Q%J?V7_A$O^$Y_M+^U/[?\*^&?(\__ (2:P^P_9/MOF>3=^?\
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M444 %%%% '[6_P#!$GP5JM_\:/C'\18;C3UT3PK\,+#P5J%K)+<C59M5\?\
MBO3-=T>XLX%M'M)-/MK3X:Z['J<L]];W,-S=Z2EK:7D4]Y-8?TEU^&?_  1
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MI7A_2O#]S#;:)8ZKX2\::[<WFE*NL>*;G^UY+_2ORB\=?L"?MD?#O^R_[?\
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M:F_Z'[X ?^%3\1?_ )U5?T]T44 ?(/[1?["_[./[3GVC4O'W@W^QO&T_D_\
M%R_ LEKX:\=OY7]AP?\ $TO_ +#?:3XKVZ3H%GH%C_PFNB^)?["T>6[A\.?V
M/<S_ &M/P#^,W_!);]JOX9?VCJ?@_3?#_P 9_#-I_P )-?)=^!=26T\4V^A:
M%LN-.N-4\%>(_P"R]0NO$'B#3W>2Q\+> KSX@7@U&TN])BNKN>32)=7_ *NJ
M* /X)_%/A/Q5X'UV^\+>-?#7B#P?XFTO[+_:?AWQ3HVH^']=T[[;9V^HV?V[
M2-6MK34+3[7I]W:7UK]HMX_M%G=6]U%O@FC=N?K^]CQ3X3\+>.-"OO"WC7PU
MX?\ &'AG5/LO]I^'?%.C:=X@T+4?L5Y;ZC9_;M(U:VN]/N_LFH6EI?6OVBWD
M^SWEK;W46R>&-U\@_P"&3_V6?^C:O@!_X9OX=?\ S.4 ?Q#45_;S_P ,G_LL
M_P#1M7P _P##-_#K_P"9RO7_  MX3\+>!]"L?"W@KPUX?\'^&=+^U?V9X=\+
M:-IWA_0M.^VWEQJ-Y]ATC2;:TT^T^UZA=W=]=?9[>/[1>75Q=2[YYI'8 _CF
M^#/[!W[5?QT_LZ]\'_"3Q!I7AG4?^$9ND\:^.HU\#>%FT+Q7OET[Q3I=WXC-
MEJ'C#P_#I\;ZM?7'@+3/%=Y%IS6DD5C<3ZKI%O?_ *N_ O\ X(JZ%I5YHVO?
MM#_$W_A*/LVZXU/X=_#>UO-*T*YO+378)K.UO/B#JWV;Q!JOA_5?#]M-;:W8
MZ5X2\%Z[;7FJLNC^*;;^R([_ %7]W** .?\ "WA/PMX'T*Q\+>"O#7A_P?X9
MTO[5_9GAWPMHVG>']"T[[;>7&HWGV'2-)MK33[3[7J%W=WUU]GMX_M%Y=7%U
M+OGFD=N@HHH **** "BBB@ HHHH **** "BBB@ KX!_:6_X)O?LX_M&_VMK_
M /8/_"K_ (FZA]ON_P#A8'@&VM=/_M36+O\ MZ]^W>-?"FV/P_XM^V^(-<_M
MKQ'JGDZ/X[U[^S[/3?\ A.M/LDV#[^HH _F4^+W_  1A^//A"VGU'X2>-_!_
MQBM+;3["1M'O(6^&OC*^U6YU5K.\L])T_6-3UKP;+I^G::]MK$FIZOX_T.YN
M8TU.RM=)DN[73UUC\T?B7^S]\</@W]KD^*/PF^('@?3[3Q!/X6_M[7_"^K6G
MA:^UVW^WM]AT7Q;]F?PSX@^U0:7J%YIMUH6K:C9ZKIUI-J>F7%WIZ_:3_<S1
M0!_ /17]Y'C7X>^ ?B5I5OH7Q%\#^#_'^B6FH1:M:Z/XU\,Z+XJTJVU6"VN[
M.#4[?3]=LK^TAU"&TO[ZUBO(X5N8[:\NX$D$5Q,K^8?\,G_LL_\ 1M7P _\
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M:6<^IW&GZ%97]W#I\-W?V-K+>20K;1W-Y:0/();B%7_N)\"_"?X6?"_^U/\
MA6GPT\ ?#O\ MS[#_;7_  @O@WP[X2_MC^S/M?\ 9O\ :G]@:;I_]H?V?_:%
M_P#8?M?G?9/MMWY'E_:9M_?T ?RZ?"'_ ((Y?M+>-;F"X^*6J^#_ (*Z(NH7
M]G?0WFHVGC_QD+:#2ENK#5M)T+PA?S>%+_3[_59HM*DCU+X@Z%JME';ZGJ+:
M9/%!IL&L?J=\"_\ @DY^S+\']=T;Q;XD_P"$@^,WB#3_  ^VG7FE?$BW\,:A
M\.+C7;RS@M=3\16?@2/P_P#]A!=$TCQ/KWBZST6+4%N2^H>(-,TGQ!9?I[10
M 4444 %%%% !1110 5\(_P#!0K]F#Q]^UE\%_#'PZ^'6K^#]%UO1?B?HOC6Z
MNO&M_K6G:5)I6G>%/&NA3V]O/H7A_P 1W;Z@]WXCL9(HI+&*V:VBNW>[25(8
M9_NZB@#^83_ARM^U-_T/WP _\*GXB_\ SJJ/^'*W[4W_ $/WP _\*GXB_P#S
MJJ_I[HH _F$_X<K?M3?]#]\ /_"I^(O_ ,ZJC_ARM^U-_P!#]\ /_"I^(O\
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MN8-*MM5\5:U9:%I]QJ<]G:7]W#I\-W?PR7DMK8WES';+(\%I<2A87 /ZVO\
M@FEX N?A]^Q=\&K74O#VGZ!K?BK3]<\?ZJUFFE&YUZV\9>(]5UCPCXAU:\TJ
M29;_ %"_^'TWA"&-[^>35=.TJTTS0KZ.SETD:?:?=U<_X3\+:%X&\+>&O!7A
M:Q_LOPSX/\/Z-X6\.:9]IO+W^SM"\/Z=;:3I%C]MU&XN]0N_LFGVEO;_ &J^
MN[J\N/+\VZN)IW>1N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#/X?7QGXE -#_@E_^Q3_ ,* \"1_&?XA:9X@TKXV?$OP_<Z;=>'-:7^S?^$
M\"7.L6^HV.@3:1;WL_F^(/$O]CZ%XFU^;7H[;6/#^--\)#1?#VIZ5XI?Q!^K
MM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;C3= TBU'_7G8S:UK%QJWBG5=.TG1;77M?U;^R;%X?YA*_?S_@AG_P W1?\
M=$__ 'KE '[^4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 ?R"_\%1?^3Z_CE_W3/_U3WP^KX!K[^_X*B_\ )]?QR_[IG_ZI[X?5\ T
M%%%% !7W]_P2Z_Y/K^!O_=3/_5/?$&O@&OO[_@EU_P GU_ W_NIG_JGOB#0!
M_7U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OR"_X+4_\FL^ ?\
MLO\ X6_]5U\5:_7VOR"_X+4_\FL^ ?\ LO\ X6_]5U\5: /YA**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_DUGP#_V7_PM_P"JZ^*M?K[7Y!?\%J?^36? /_9?_"W_ *KKXJT ?S"4444
M%%%% !7]O/[)_P#R:S^S5_V0#X-_^JZ\.5_$-7]O/[)__)K/[-7_ &0#X-_^
MJZ\.4 >_T444 %%%% !117XY?MQ_\%3;?X#>,D^%7P$TWP?X^\=^'M0FB^).
MN^)X]5U/P;X8N8(YH'\%:?#X?UO0;O5O&%K=E)?$EVFK+I7A.2U/ANXM]5\2
M7&MVO@P _8VBOYA/^'U/[4W_ $(/P _\);XB_P#SU*/^'U/[4W_0@_ #_P )
M;XB__/4H _I[HK^83_A]3^U-_P!"#\ /_"6^(O\ \]2C_A]3^U-_T(/P _\
M"6^(O_SU* /Z>Z*_F$_X?4_M3?\ 0@_ #_PEOB+_ //4KZ?_ &4OV_/V[?VM
M/B/%X*\%?#SX :5X?TK[)?>/_']]X*^)5SH7@?0KF65([BXC3XLVW]J^(-5^
MS7=OX6\+6]W;7FO7EM=2RW6E>']*\0^(=$ /W<HHHH **** "BOPC_;+_P""
MG_Q]_9W_ &D_B/\ !WP5X1^$&J>&?!__  A_]F7WBG0/&E[KL_\ PD'@+POX
MIO/MUUI/C_1-/E\K4-;NX;7[/I=MLLX[>.7SITDN)?F#_A]3^U-_T(/P _\
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M?_9?_"R_B7X ^'?]N?;O[%_X3KQEX=\)?VQ_9GV3^TO[+_M_4M/_ +0_L_\
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M3?\ 0@_ #_PEOB+_ //4H _I[HK^83_A]3^U-_T(/P _\);XB_\ SU*_I[H
M**** "BBB@ HHHH **** "BBB@ HHHH **_-'_@HW^U_\:/V1-*^$VN_"[P;
MX/\ $.B>,M0\8Z3XKUCQKX>\5ZMI6CZKIEMX<O/"NF6^H>'O$WAJTT_4-=M+
MCQ9=16>I375SJ=MH%W/IT<<6E:DS?EE_P^I_:F_Z$'X ?^$M\1?_ )ZE ']/
M=%?S"?\ #ZG]J;_H0?@!_P"$M\1?_GJ4?\/J?VIO^A!^ '_A+?$7_P">I0!_
M3W17\PG_  ^I_:F_Z$'X ?\ A+?$7_YZE'_#ZG]J;_H0?@!_X2WQ%_\ GJ4
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M3XLM-5T^XM/#]]I,NF1V^E7*W.IVFJ)JWE:9-I6J@'[F4444 %%%% !1110
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M[2O_ &7_ .,G_JQ?$=?V\U_$-^UA_P G3?M*_P#9?_C)_P"K%\1T > 4444
M%%%% 'Z^_P#!%;_DZ;Q]_P!D \4_^K%^%5?T]U_,)_P16_Y.F\??]D \4_\
MJQ?A57]/= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3M7UVXM=->[\3Z7X/\,:_/\ H]0 4444 %%%% '\@O\ P5%_Y/K^.7_=,_\
MU3WP^KX!K[^_X*B_\GU_'+_NF?\ ZI[X?5\ T %%%% !7W]_P2Z_Y/K^!O\
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M_;W[/7[/6O?\7 _TG1_B7\2]'N?^1 ^]!?\ @[P=?P-_R4#[]MXA\0VTG_%
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M-3\+>*=,CGN?[*\0:5]I@:XMUGN;.]L[FQUK1;[5?#^JZ3JU]^<-% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(+7]?7_!47_DQ3XY?]TS_P#5P_#ZOY!: "BBB@ HHHH **** "BBB@ HHHH
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M6^MM2N?'T%UI_B6"-M+:%;#4+#X?0^,]=TF_U.ZM]*BU72+.&Y7499[?1]2
M/Y-?BQXZ_P"%H?%/XE_$O^R_[#_X6)\0/&7CK^Q?MO\ :?\ 8_\ PEOB+4M?
M_LO^TOLFG_VA_9_]H?9/MWV"R^U^3Y_V2V\SR4\_HHH **** "BBB@#]W/\
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M*_ .OW\_X(9_\W1?]T3_ />N4 ?OY1110 4444 %?SB?\%>OVM_^$M\4Z?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@GK^OK_@F-\4?^%H?L;_  P^UZY_;GB#X=_VQ\+O$/\ Q+/[,_L?_A$KYO\
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M_M/^QOMO@31KH:_\0/\ B9)J&E7-M]F\$Z5K]W_Q+;^#6)O(\C1?-U:6RAD
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M/^(-/>TUWP[J5QI]I_:NA:CIVIQ0K!=QY //Z*** "BBB@ K^_BOX!Z_OXH
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M_P")9HOAWS+^&"]\SPSXP\:Z[J^FQ:??:B]GX>34[>:QT_2=6^T@']+=%%%
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MCZ/I-E<ZCJNK:KJ-S'9Z?IFF:?9QS7=_J%_=S0VMG9VL,MS=7,L<$$;RNJD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=233]%\9:=H6KWD<%M?QW-M926MUIFJ6DT^GW/\ #M0 4444 %%%% ']+?\
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M^RI(MG9?:_L6G6]II]O:VD/T_0 4444 %%%% !1110 4444 %?D%_P %J?\
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M'"S^!?%NM7U\U_IL&G_V-X9\2:MJEKJ5Y=KIVG7EI;WNIPW>GP7-I/\ ,%%
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MHH **** "OXAOVL/^3IOVE?^R_\ QD_]6+XCK^WFOXAOVL/^3IOVE?\ LO\
M\9/_ %8OB.@#P"BBB@ HHHH _7W_ ((K?\G3>/O^R >*?_5B_"JOZ>Z_F$_X
M(K?\G3>/O^R >*?_ %8OPJK^GN@ HHHH **** "BBB@ HHHH **** "BBB@
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M$3^Q_A=X>_XEG]I_VQ_PEM\O_"8Z%^]T_4++3_[0^&6G^.O^)G>_8OLGD_\
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M/&D6HZ?%K>BZQH\EY9M-;)JNDZGI[2"[L+J&( _/&BBB@ HHHH ]_P#V3_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI\16FM727][;2>(-#\;>+?%/AW4H+5-/_LS^QX=(OK!-6T_4;BY /SAHHHH
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MKQ5ID%F+O339:A>?5] !1110 4444 %%%% '\@O_  5%_P"3Z_CE_P!TS_\
M5/?#ZO@&OO[_ (*B_P#)]?QR_P"Z9_\ JGOA]7P#0 4444 %??W_  2Z_P"3
MZ_@;_P!U,_\ 5/?$&O@&OO[_ ()=?\GU_ W_ +J9_P"J>^(- ']?5%%% !11
M10!\ _\ !47_ ),4^.7_ '3/_P!7#\/J_D%K^OK_ (*B_P#)BGQR_P"Z9_\
MJX?A]7\@M !1110 4444 ?U]?\$NO^3%/@;_ -U,_P#5P_$&OOZO@'_@EU_R
M8I\#?^ZF?^KA^(-??U !1110 4444 %%%% 'X!_\%S/^;7?^ZV?^\CK\ Z_?
MS_@N9_S:[_W6S_WD=?@'0 4444 %%%% ']_%%%% !7P#_P %1?\ DQ3XY?\
M=,__ %</P^K[^KX1_P""F>DZKK7[#OQWL]'TS4-6NX=/\$ZM-:Z997-_<Q:5
MH'Q,\%Z[KNIR06L<LJ:?HNB:=J&L:M>,HMM.TJPO-0O)(;2UGF0 _CUHHHH
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M3IO'W_9 /%/_ *L7X55_3W7\PG_!%;_DZ;Q]_P!D \4_^K%^%5?T]T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW--=7EY=32W-U<RR3SR/*[,0#/HHHH **** /?\ ]D__ ).F_9J_[+_\&_\
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M +R.OP#H **** "BBB@#^_BBBB@ KP#]K#_DUG]I7_L@'QD_]5UXCKW^N?\
M%GA;0O'/A;Q+X*\4V/\ :GAGQAX?UGPMXCTS[3>67]HZ%X@TZYTG5['[;IUQ
M::A:?:]/N[BW^U6-W:WEOYGFVMQ#.B2* ?P3T444 %%%% !7[N?\$._%.A6G
MBG]HGP5<7WE^)O$'A_X<>*=(TS[+>/\ :]"\'ZCXPTGQ'??;$MVT^#^SM0\<
M>%K?[+=7<-Y=_P!J>;8V]U!9:C):?A'7Z/?\$I_B7_PKO]LCP5IUQ=^']/TG
MXH>'_%/PTU>^U^?[)Y/]H6,?BGP[::+=/?V5M'X@USQMX2\+>'=-@NDU#^T_
M[8FTBQL'U;4-.N+8 _K:HHHH **** "BBB@ K^83_@M3_P G3> ?^R >%O\
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M1110 4444 %%%% !7Y!?\%J?^36? /\ V7_PM_ZKKXJU^OM?D%_P6I_Y-9\
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M\%J?^3IO /\ V0#PM_ZL7XJU^[G[5O[5WPX_9+^'$OC7QK+_ &KX@U7[78^
M/ %C=Q6VN^.-=MHHGDM[>1XKG^RO#^E?:;2X\4^*;BTN;/0;.YM8HK75?$&J
M^'O#VM_QZ_&?XO>,OCU\3_%_Q;\?S:?-XK\9ZA!>:@NDV":;I5E;6&GV>CZ/
MI.F6:M+*FGZ+HFG:=I%G)>W-_JMS;64=UK&IZIJLUYJ%R >84444 %%%% !7
M]_%?P#U_?Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YH_\
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MOVWSD_M/^S_[2^R:?]K^P6P!]?4444 <?\0O!6E?$KP#XX^'6NW&H6FB>/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK7B+R["&"]\SPSXP\%:%I&I2ZA?:B]GX>?3+B&QT_2=)^U 'XQ4444 %%%%
M!1110!]_?\$QOA=_PM#]LCX8?:]"_MSP_P##O^V/BCXA_P")G_9G]C_\(E8M
M_P (=KO[K4-/O=0_L_XFZAX%_P")98_;?M?G?\333[GP_'K&S^OJOPC_ ."(
MGPT^S>%OCA\8KNT\/S_VQX@\/?#3P]?>1YOBG2O^$:TY_%/C&T^U2V"_8?#^
MO_\ "5^!9O(L=4E_M74?#7F:I80?V/H]Q<_NY0 4444 %%%% !7'_$+P5I7Q
M*\ ^./AUKMQJ%IHGC_P?XE\%:Q=:3+;P:K;:5XJT6]T+4+C3)[RTO[2'4(;2
M_FDLY;JQO+:.Y6-Y[2XB#0OV%% '\(_Q5^&GBKX-_$?QI\+O&MI]D\3>!_$%
M_H&I[(-1@L[[[)*?L>M:1_:UAI>H77A_Q!I[VFN^'=2N-/M/[5T+4=.U.*%8
M+N//G]?T6?\ !7;]CRY\5:5'^U/\.M'U"_\ $7AS3['1?BWH6B:/I31W?@W2
M[;4Y[;XH7TUK]DUN\U#PK$+'P[XDGDA\0R#P:FAZB[>'/#O@'5[J\_G3H **
M** "BBB@#[N_8_\ V_?BY^R=JHT]7U#XE?">;3[NSG^%.N^);ZPTK2;F2YU'
M5+75O VHS6>N1>"=0_MO4[R\UN/3]'N=*\3VU_?KK&F3:PFA:]H/]#GPA_X*
M3?L?_%ZV@$'Q3T_X<:VVGW^IWGASXO+!X!N=-MK'55TM8Y_$NH74WP^O]0OU
MFM=3L-)T+QGJ^JRZ5<-<S6<$NG:Q;Z;_ !ZT4 ?WT:3JVE:_I6F:[H6IZ?K6
MB:UI]GJVCZQI-Y;ZCI6K:5J-M'>:?J>F:A9R36E_I]_:30W5G>6LTMM=6TL<
M\$CQ.K'G_&OQ"\ _#72K?7?B+XX\'^ -$N]0BTFUUCQKXET7PKI5SJL]M=WD
M&F6^H:[>V%I-J$UI87UU%9QS-<R6UG=SI&8K>9D_@WHH _J+_:*_X*[? ;X;
M6WBSPS\'(]0^+WQ!L-/NK30M<L[$0_".V\31:K=Z1-%JWB&?4],UOQ#I^E16
MIU^.X\%Z7J7A[Q;8S:98:-XUL%U*ZUG1?YT_CI\=/B/^T7\1]9^*'Q0UG^U?
M$&J[;6SL[59;;0O#&A6TL\FF>%O"VF23W/\ 97A_2OM,[6]NT]S>7MY<WVM:
MU?:KX@U75M6OO(** "BBB@ HHHH *_3[_@E)^SI_PNC]HZU\?:U;^;X)^ G]
MD>.K_P#?;/MOCN>ZN?\ A6FE_P"B:YI6K6WV;5M*U+QK]MAL]8T>;_A"/^$<
MU^T%MXE@\S\X?"?A;7?'/BGPUX*\+6/]J>)O&'B#1O"WAW3/M-G9?VCKOB#4
M;;2=(L?MNHW%II]I]KU"[M[?[5?7=K9V_F>;=7$,"/(O]E/[%O[-%O\ LI?
M;P_\,)K[3]7\5W6H:CXM^(.NZ2=5&E:OXRUL6T%PVF0ZK<RRII^BZ)IVA>%K
M.Y@L]$CUFVT"/Q#=:#I.J:OJ-JH!]7T444 %%%% '\PG_!:G_DZ;P#_V0#PM
M_P"K%^*M?D%7Z^_\%J?^3IO /_9 /"W_ *L7XJU^05 !1110 5[_ /LG_P#)
MTW[-7_9?_@W_ .K%\.5X!7O_ .R?_P G3?LU?]E_^#?_ *L7PY0!_;S1110
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M7K_A%M"\-_#3]J'3_$'B"#3?*TFS^-FDR_VSKHTY[S2;/3#\0_#LB1:AK?\
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M4HU6\TS5M'UBSU'1-:T]Y8K:]CL]7TZ]MK;5;#3-8M8X=5TO3[RV_H<_9_\
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M=\1:E;Z?:?VKKNHZCJ<L*SW<F>_HHH **** /@'_ (*B_P#)BGQR_P"Z9_\
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MI87MS)X?T/P3XM\4^(]2GM7T_P#LS^QX=7OK]-)T_4;>Y /Y):*** "BBB@
MKH/"?A;7?'/BGPUX*\+6/]J>)O&'B#1O"WAW3/M-G9?VCKOB#4;;2=(L?MNH
MW%II]I]KU"[M[?[5?7=K9V_F>;=7$,"/(O/U]_?\$QOA=_PM#]LCX8?:]"_M
MSP_\._[8^*/B'_B9_P!F?V/_ ,(E8M_PAVN_NM0T^]U#^S_B;J'@7_B66/VW
M[7YW_$TT^Y\/QZQL /ZVO"?A;0O WA;PUX*\+6/]E^&?!_A_1O"WAS3/M-Y>
M_P!G:%X?TZVTG2+'[;J-Q=ZA=_9-/M+>W^U7UW=7EQY?FW5Q-.[R-T%%% !1
M110 5^47_!8CX:?\)A^RI;^.K2T\/C4/A)\0/#>OWFJ:C!C78_"WBEI_ NIZ
M+X=O8["ZG3^U/$WB#P5JFKZ;+=Z;IU[9^'$OKB:XU#2-)M)OU=K@/BQX&_X6
MA\+/B7\-/[4_L/\ X6)X \9>!?[:^P_VG_8__"6^'=2T#^U/[-^UZ?\ VA_9
M_P#:'VO[%]OLOM?D^1]KMO,\Y #^$:BBB@ HHHH ***]?_9^^&G_  N3XX?"
M;X726GB"[T_QQ\0/"^@:]_PBT'GZ[8^%KO5K;_A+=:L=UAJD%K_PC_AE-6UV
MZU*\T^[T[2K/3KC4]3A;3[2YP ?UE_\ !/CX8:5\*OV/_@CIFGG3[F[\7>#]
M/^*&NZK9Z+;Z+<ZIJOQ*@C\70KJP@GNI=5U#P]HFIZ/X,CUJ\N7N;_2O#.F%
M8-.M([72K'[.HHH **** "BBB@ HHHH *_D5_P""A?[%NJ_LL_$^\UWPCX?U
M!/@#XWU!'^'^L-J-SKT?A[59=/6\U;P!KVH7%M#=V&H6%W#JMUX2CU6;4;G7
M/!L%M./$/B'7]%\8MIG]=5<?X_\  '@WXI>#?$/P^^(/A[3_ !5X-\5:>^F:
M[H6II(;:\MC)'/#)'-!)#=V&H6%W#;ZCI.K:=<6FJZ-JMI9ZKI5Y9ZE9VMU"
M ?P;T5]W?MQ_L.>,OV0_&275J^H>*O@OXJU":+P'X\EA0W-I<F.:[_X0KQK]
MDAAM+#QA86D,\UI=PP6FE>,M*M+C7="M[.XL_$GAOPK\(T %%%% !1110 44
M44 %%%% !1110 445^YG_!/3_@F1JOB'5;/XT?M1>#M0T7PWHNH.W@SX-^+M
M)N=.U7Q5JNG7+1'7OB'H&IP0W=AX/L+N%AI?A+4[:*Y\;7,7V[7+9/ B6UEX
M^ /</^"2W[%__"%Z%IO[5OC]=WB;QKX?U*Q^%_A:^T/R9?"WA;4;S[+/XZN+
MC6M-CU"'Q!XPT^RDB\+7?AZ6#3O^%<:Y=7;ZIKT'CAK'P[^WE%% !1110 44
M44 ?S"?\%J?^3IO /_9 /"W_ *L7XJU^05?K[_P6I_Y.F\ _]D \+?\ JQ?B
MK7Y!4 %%%% !7O\ ^R?_ ,G3?LU?]E_^#?\ ZL7PY7@%>_\ [)__ "=-^S5_
MV7_X-_\ JQ?#E ']O-%%% !1110 4444 %%%% !1110 5^07_!:G_DUGP#_V
M7_PM_P"JZ^*M?K[7Y!?\%J?^36? /_9?_"W_ *KKXJT ?S"4444 %%%% !7]
MO/[)_P#R:S^S5_V0#X-_^JZ\.5_$-7]O/[)__)K/[-7_ &0#X-_^JZ\.4 >_
MT444 %%%% !7\BO_  4W_9_U7X(_M1>,==5-0NO!OQJU#5?BIX8UB[6YGC;5
M?$.ISWGCOP[+J T72=*.H:!XKNKRZM](T^;5;G2_!NN^"I]8U&?4M3E9OZZJ
M_.'_ (*E? NS^,'[*GBWQ)9Z-_:'C;X,X^)'AJ\MVT*SO+?0M/:&/XCV=UJ>
MKP?:?^$?_P"$)_M/Q/?:)I.H:?>:WKOA'PL8UU.YT^TTF] /Y):*** "BBB@
M K^IO_@D+\=+SXG_ +..H?#GQ#K/]J>)O@?X@B\.6D<RZ[<:C#\./$%J^I^!
M7U+5M4GN]/N_LFH6GC'PKHNG://;1:#X6\)Z!ILND64"65YJG\LE?7_["_[1
M?_#,?[1W@WQ]J5QY'@G6/,\"_$O]SYNSP)XENK'[?JG[C0]?U9O^$4U:QT7Q
MK]AT"SBUC7?^$:_X1R&[@MM8N]X!_9S1110 4444 ?R"_P#!47_D^OXY?]TS
M_P#5/?#ZO@&OO[_@J+_R?7\<O^Z9_P#JGOA]7P#0 4444 %??W_!+K_D^OX&
M_P#=3/\ U3WQ!KX!K[^_X)=?\GU_ W_NIG_JGOB#0!_7U1110 4444 ? /\
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MM?#?3)9KG^RO$&E?:98%^'FC+;:%J^A6UG8>!])TKQ!I5OH/C3^>.@ HHHH
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M4$>I^*?%.IQP6W]J^(-5^S0+<7"P6UG96=M8Z+HMCI7A_2M)TFQ]?H ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD0!_)+17W]_PZY_;K_Z(;_YDSX/?_/!H_P"'7/[=?_1#?_,F?![_ .>#0!\
MT5]_?\.N?VZ_^B&_^9,^#W_SP:/^'7/[=?\ T0W_ ,R9\'O_ )X- 'P#7]O/
M[)__ ":S^S5_V0#X-_\ JNO#E?S"?\.N?VZ_^B&_^9,^#W_SP:_J;_9[\+:[
MX&^ ?P/\%>*;'^R_$W@_X0?#3PMXBTS[39WO]G:[X?\ !>BZ3J]C]MTZXN]/
MN_LFH6EQ;_:K&[NK.X\OS;6XF@=)& /7Z*** "BBB@ HHHH _BV_;;^ ]O\
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M _H[HHHH **** /@'_@J+_R8I\<O^Z9_^KA^'U?R"U_9U^WI\+O'?QH_9/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>0Q6\*IV%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGVO[)Y']J?\ "R[KXB>3_9GV:;[#_8O]C^9_:%W_ &E_:&RP^Q?&'C_]I?\
M:%^*5MXAT_X@_&OXG^*M$\5:@^IZ[X7U/QKKY\&WER=5CUN&./P7!?0^%+#3
M[#58;>\TG2=.T>TTK1I+2S72K.SBL[5(?$** "BBB@ HHHH **** "OZ:_\
M@DQ^Q_JOPA\&WG[0_CL:>/%?QB\'Z)'X#TNSN[FYN?#OPPU:2V\2_;-6GM-1
M;1+C4/'TL'AC6H],-A=:AX8TK0],CEU:UU77_$GAS2/SQ_X)?_L4_P#"_P#Q
MW'\9_B%IGA_5?@G\-/$%SIMUX<UI?[2_X3_QW;:/;ZC8Z!-I%O>P>5X?\-?V
MQH7B;7YM>CN='\09TWPD-%\0Z9JOBE_#_P#4W0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282715044960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001119774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Compugen Ltd<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Azrieli Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">26 Harokmim Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Building D<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Holon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5885849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par value NIS 0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CGEN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of Exchange on which Security is Registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">89,541,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KOST FORER GABBAY & KASIERER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">1281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">David Silberman<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Azrieli Center<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">26 Harokmim Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Building D<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Holon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5885849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-765-8585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">972-3-765-8555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282714212016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 18,229<span></span>
</td>
<td class="nump">$ 13,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term bank deposits</a></td>
<td class="nump">61,397<span></span>
</td>
<td class="nump">25,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="nump">23,629<span></span>
</td>
<td class="nump">11,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses</a></td>
<td class="nump">2,742<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">105,997<span></span>
</td>
<td class="nump">114,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Restricted long-term bank deposits</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="nump">1,888<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SeverancePayFundNoncurrent', window );">Severance pay fund</a></td>
<td class="nump">3,072<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">2,843<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">852<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">8,998<span></span>
</td>
<td class="nump">6,755<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">114,995<span></span>
</td>
<td class="nump">121,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="nump">1,838<span></span>
</td>
<td class="nump">3,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
<td class="nump">9,632<span></span>
</td>
<td class="nump">11,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturity of operating lease liability</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,168<span></span>
</td>
<td class="nump">7,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and related accruals</a></td>
<td class="nump">3,074<span></span>
</td>
<td class="nump">3,125<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,160<span></span>
</td>
<td class="nump">26,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON- CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
<td class="nump">34,045<span></span>
</td>
<td class="nump">25,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">2,464<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent', window );">Accrued severance pay</a></td>
<td class="nump">3,412<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">39,921<span></span>
</td>
<td class="nump">29,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2024 and 2023; 89,541,246 and 89,237,465 shares issued and outstanding at December 31, 2024 and 2023, respectively.</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">543,413<span></span>
</td>
<td class="nump">539,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(488,758)<span></span>
</td>
<td class="num">(474,527)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">54,914<span></span>
</td>
<td class="nump">65,559<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 114,995<span></span>
</td>
<td class="nump">$ 121,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayFundNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayFundNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481179/712-10-25-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481179/712-10-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799527504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">89,541,246<span></span>
</td>
<td class="nump">89,237,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">89,541,246<span></span>
</td>
<td class="nump">89,237,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282714279552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 27,864<span></span>
</td>
<td class="nump">$ 33,459<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">7,930<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">19,934<span></span>
</td>
<td class="nump">31,455<span></span>
</td>
<td class="nump">6,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="nump">24,810<span></span>
</td>
<td class="nump">34,472<span></span>
</td>
<td class="nump">30,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDevelopment', window );">Marketing and business development expenses</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">9,439<span></span>
</td>
<td class="nump">9,731<span></span>
</td>
<td class="nump">10,319<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">34,825<span></span>
</td>
<td class="nump">44,447<span></span>
</td>
<td class="nump">41,899<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(14,891)<span></span>
</td>
<td class="num">(12,992)<span></span>
</td>
<td class="num">(35,374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">5,182<span></span>
</td>
<td class="nump">3,208<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="num">(9,709)<span></span>
</td>
<td class="num">(9,784)<span></span>
</td>
<td class="num">(33,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses (tax benefits)</a></td>
<td class="nump">4,522<span></span>
</td>
<td class="nump">8,970<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,231)<span></span>
</td>
<td class="num">$ (18,754)<span></span>
</td>
<td class="num">$ (33,694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain arising during the period from marketable securities</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (14,222)<span></span>
</td>
<td class="num">$ (18,752)<span></span>
</td>
<td class="num">$ (33,694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share</a></td>
<td class="nump">89,528,031<span></span>
</td>
<td class="nump">87,633,298<span></span>
</td>
<td class="nump">86,555,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">89,528,031<span></span>
</td>
<td class="nump">87,633,298<span></span>
</td>
<td class="nump">86,555,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Income (Expense), Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282715043728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated other comprehensive income [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 528,533<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (422,079)<span></span>
</td>
<td class="nump">$ 106,693<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">86,433,432<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Exercise of options and ESPP shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">352<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Exercise of options and ESPP shares, shares</a></td>
<td class="nump">191,211<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees', window );">Share-based compensation issued to employees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,328<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(33,694)<span></span>
</td>
<td class="num">(33,694)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">533,213<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(455,773)<span></span>
</td>
<td class="nump">77,680<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">86,624,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IssuanceOfSharesAndWarrantsNetValue', window );">Issuance of shares, net</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,074<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IssuanceOfSharesAndWarrantsNetShares', window );">Issuance of shares, net, shares</a></td>
<td class="nump">2,612,822<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees', window );">Share-based compensation issued to employees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,550<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Other comprehensive income from marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,754)<span></span>
</td>
<td class="num">(18,754)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">539,837<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(474,527)<span></span>
</td>
<td class="nump">$ 65,559<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">89,237,465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,237,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options,shares</a></td>
<td class="nump">11,053<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IssuanceOfSharesAndWarrantsNetValue', window );">Issuance of shares, net</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IssuanceOfSharesAndWarrantsNetShares', window );">Issuance of shares, net, shares</a></td>
<td class="nump">292,728<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees', window );">Share-based compensation issued to employees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,023<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Other comprehensive income from marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,231)<span></span>
</td>
<td class="num">(14,231)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 248<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 543,413<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="num">$ (488,758)<span></span>
</td>
<td class="nump">$ 54,914<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">89,541,246<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,541,246<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Representing amount lower than $ 1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IssuanceOfSharesAndWarrantsNetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants, net, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IssuanceOfSharesAndWarrantsNetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IssuanceOfSharesAndWarrantsNetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IssuanceOfSharesAndWarrantsNetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation relating to options issued to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282714167728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,231)<span></span>
</td>
<td class="num">$ (18,754)<span></span>
</td>
<td class="num">$ (33,694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,023<span></span>
</td>
<td class="nump">3,550<span></span>
</td>
<td class="nump">4,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SeverancePayNet', window );">Decrease in severance pay, net</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss from property and equipment sales and disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances', window );">Exchange rate differences loss (gain) on cash balances</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement', window );">Decrease (increase) in interest receivables from short-term bank deposits and long-term restricted deposit</a></td>
<td class="num">(855)<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="num">(584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities', window );">Amortization of discount and accrued interest on marketable securities</a></td>
<td class="num">(1,575)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Decrease (increase) in trade receivables</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="num">(61,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in other accounts receivable and prepaid expenses</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="nump">3,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (increase) in long-term prepaid expenses</a></td>
<td class="num">(655)<span></span>
</td>
<td class="nump">666<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Decrease in operating lease right of use asset</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in trade payables and employees and related accruals and accrued expenses</a></td>
<td class="num">(4,410)<span></span>
</td>
<td class="nump">3,509<span></span>
</td>
<td class="num">(1,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses', window );">Decrease in deferred participation in R&amp;D expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(325)<span></span>
</td>
<td class="num">(6,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInDeferredRevenues', window );">Increase in deferred revenues</a></td>
<td class="nump">7,136<span></span>
</td>
<td class="nump">36,541<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in operating lease liability</a></td>
<td class="num">(503)<span></span>
</td>
<td class="num">(645)<span></span>
</td>
<td class="num">(1,062)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">49,604<span></span>
</td>
<td class="num">(35,886)<span></span>
</td>
<td class="num">(34,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Proceeds from maturity of short-term bank deposits</a></td>
<td class="nump">60,717<span></span>
</td>
<td class="nump">79,242<span></span>
</td>
<td class="nump">114,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Investment in short-term bank deposits</a></td>
<td class="num">(96,219)<span></span>
</td>
<td class="num">(32,100)<span></span>
</td>
<td class="num">(76,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturity of marketable securities</a></td>
<td class="nump">53,230<span></span>
</td>
<td class="nump">10,145<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="num">(63,533)<span></span>
</td>
<td class="num">(21,605)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Investment in long term restricted deposit</a></td>
<td class="num">(330)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(118)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Costs of disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(46,252)<span></span>
</td>
<td class="nump">35,510<span></span>
</td>
<td class="nump">37,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">3,081<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share-based awards</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">3,081<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="num">(393)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">3,974<span></span>
</td>
<td class="nump">2,834<span></span>
</td>
<td class="nump">2,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="nump">14,255<span></span>
</td>
<td class="nump">11,421<span></span>
</td>
<td class="nump">8,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the year</a></td>
<td class="nump">18,229<span></span>
</td>
<td class="nump">14,255<span></span>
</td>
<td class="nump">11,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction', window );">Purchase of property and equipment</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">2,064<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">18,229<span></span>
</td>
<td class="nump">13,890<span></span>
</td>
<td class="nump">11,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 18,229<span></span>
</td>
<td class="nump">$ 14,255<span></span>
</td>
<td class="nump">$ 11,421<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment for Exchange rate differences loss (gain) on cash balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Cash Consideration Of Research And Development Funding Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of Amortization of discount and accrued interest on marketable securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred participation in R and D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInDeferredRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of deferred revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInDeferredRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments for Proceeds from Sales of equipment Investing Activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchase property and equipment as non cash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance pay, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In right of use asset and operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712124608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text">
      <div>
        <div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 1:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">GENERAL</span></span></span></td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.5pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compugen Ltd. (the &#8220;Company&#8221;) is a clinical-stage therapeutic discovery and development company utilizing its AI/ML powered predictive computational discovery platform, recently branded as Unigen<sup style="vertical-align:text-top;line-height:1;font-size:smaller">TM</sup>, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapy. The Company&#8217;s innovative immuno-oncology pipeline consists of four clinical stage programs, COM701, COM902, rilvegostomig and GS-0321 (previously COM503). Two programs that the Company is pursuing internally, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. <span>The Company&#8217;s two ongoing clinical trials (that completed enrollment) were initiated in 2023 and are evaluating the triple combination treatment of COM701, COM902 and pembrolizumab, one in platinum resistant ovarian cancer and the other in microsatellite stable colorectal cancer, </span> In addition, the Company is planning to start enrolling patients to our adaptive platform trial in platinum sensitive ovarian cancer, evaluating COM701 as a monotherapy randomized to placebo in sub-trial 1, in the second quarter of 2025. Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from the Company&#8217;s COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between the Company and AstraZeneca and is being evaluated in multiple Phase 3 clinical trials and in multiple Phase 2 and Phase 1 trials. GS-0321 (previously COM503), the Company&#8217;s potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being developed by the Company in a recently initiated Phase 1 trial. In addition, the Company has an early-stage immuno-oncology therapeutic pipeline that consists of programs aiming to address various mechanisms of immune resistance.</span></span></div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is headquartered in Holon, Israel. Its clinical development activities operate from the Company&#8217;s headquarters in Israel and from its United States subsidiary, Compugen USA, Inc., located in San Francisco, CA.</span></span></div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred losses in the amount of $ 14,231 during the year ended December 31, 2024, has an accumulated deficit of $ 488,758 as of December 31, 2024 and has positive cash flows from operating activities in the amount of $ 49,604 for the year ended December 31, 2024. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures for a period at least twelve months from the reporting date.</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#8220;Bayer Agreement&#8221;) with Bayer Pharma AG (&#8220;Bayer&#8221;) for the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators.</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the Bayer Agreement, the Company received an upfront payment of $ 10,000, and additional aggregate milestone payments of $ 23,200.&#160;</span></span></div>
        </div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>
        <div></div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 29, 2022, Bayer notified the Company that it has resolved to terminate the Bayer Agreement, effective as of February 27, 2023.</span></span></div>
        <div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and is solely responsible for all research, development, and commercial activities under the agreement. In connection with such license agreement, AstraZeneca developed rilvegostomig, a novel PD-/TIGIT bi-specific antibody with a TIGIT component that is derived from COM902.&#160; Rilvegostomig entered the clinic in September 2021, initiated first patient dosing in the first indication in Phase 3 study in December 2023, and first patient dosing in the second indication in Phase 3 study in May 2024. Compugen received a $ 10,000&#160;upfront payment, and $ 30,500 milestone payments out of up to $ 200,000 </span></span>it is eligible to receive in development, regulatory and commercial milestones for the first product in addition to royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.</span></span></div>
                    <div style="line-height:1.25">&#160;</div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:54pt">&#160;</td>
                <td style="width:31.5pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Agreement&#8221;) with Bristol-Myers Squibb Company (&#8220;Bristol&#160;Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol&#160;Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.</span></span></div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the Master Clinical Agreement, as amended from time to time, Compugen sponsored the trials, which included the evaluation of the combination of COM701 and Opdivo&#174; &#177; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Bristol Myers Squibb and Compugen each <span>supplied their</span> own compounds for the studies.</span></span></div>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the Agreement in October 2018, Bristol-Myers Squibb made a $ 12,000 investment in Compugen, see Note 9b.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;text-indent:-1.2pt;margin-left:85.5pt;line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Among several amendments to the Master Clinical Agreement, on November 10, 2021, the <span>Agreement</span> was further amended and in conjunction with the signing of the amendment to the Agreement, Bristol Myers Squibb made a $20,000 investment in Compugen, see Note 9b.</span></span></div>
          </div>
          <div style="text-align:justify;text-indent:-1.2pt;margin-left:85.5pt;line-height:1.25">&#160;</div>
          <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 3, 2022, the Company and Bristol Myers Squibb entered into a letter agreement pursuant to which the Agreement, as amended from time to time, was terminated as of such date.</span></span></div>
          </div>
        </div>
        <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25">
          <p style="margin:0pt">&#160;</p>
        </div>
        <div></div>
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 18, 2023, the Company entered into an exclusive license agreement (the &#8220;License Agreement&#8221;) with Gilead Sciences, Inc. (&#8220;Gilead&#8221;), pursuant to which the Company granted Gilead an exclusive license under the <span>Company&#8217;s</span> pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including the Company&#8217;s COM503 product candidate<span>, now named GS-0321 (&#8220;GS-0321</span> License&#8221;), and additional products that may be so developed by Gilead (together with <span>GS-0321</span>, the &#8220;Licensed Products&#8221;).</span></span></div>
                  </div>
                  <div>&#160;<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the License Agreement, Gilead paid the Company a one-time, upfront payment of $60,000 in January 2024. The Company has continued to develop <span>GS-0321</span> during the initial development term, which included conducting activities defined within the agreement to advance <span>GS-0321</span> through the clearance of an investigational new drug application (&#8220;IND&#8221;). The Company received from Gilead $30,000 in the form of a milestone payment upon clearance of the IND for <span>GS-0321</span>, see also Note 2k. The Company is also eligible to receive up to approximately $758,000 in additional milestone payments upon the achievement of certain development, regulatory and commercial milestones. The Company is further eligible to receive royalties on worldwide net sales of Licensed Products.</span></span></div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;</span></span>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company <span>is</span> responsible for conducting a Phase 1 clinical trial for <span>GS-0321</span>, including handling the regulatory matters in connection therewith, and will bear the costs of such trial (including the <span>GS-0321</span> drug supply), with Gilead providing at no cost <span>its zimberelimab</span> antibody for such trial. In certain circumstances, Gilead may assume the role of conducting the Phase 1 clinical trial.</span></span></div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Upon completion of the Phase 1 clinical trial for GS-0321, the Company will initiate the transfer of development activities related to GS-0321 to Gilead, following which, Gilead will have sole responsibility to develop and commercialize the Licensed Products.</span></span></span></span></div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="text-align:justify;line-height:1.25">&#160;<table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56pt">&#160;</td>
                  <td style="font-size:10pt;vertical-align:top;width:28pt">&#160;</td>
                  <td style="font-size:10pt;vertical-align:top;width:auto">
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>During the term of the License Agreement, the Company is prohibited from researching, developing, making, and commercializing any compounds, molecules, products or treatment methods that are directed to IL-18 or any companion diagnostics for an IL-18 product.</span></span></span></p>
                  </td>
                </tr>
                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56pt">&#160;</td>
                  <td style="font-size:10pt;vertical-align:top;width:28pt">&#160;</td>
                  <td style="font-size:10pt;vertical-align:top;width:auto">&#160;</td>
                </tr>
                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56pt">&#160;</td>
                  <td style="font-size:10pt;vertical-align:top;width:28pt">&#160;</td>
                  <td colspan="1" rowspan="2" style="font-size:10pt;vertical-align:top;width:auto">
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Unless terminated early by a party pursuant to its terms, the License Agreement will continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term in such country.</span></span></span></p>
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="text-align:justify"><span style="text-align:justify"><span><span>Gilead withheld at source 15% from the upfront payment and IND clearance milestone amounts paid to the Company in January 2024 and in September 2024, respectively, and is expected to continue and withhold at source all taxes required by law from all payments payable to the Company under the License Agreement.</span></span></span></span></span></span></span></span></p>
                  </td>
                </tr>
                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56pt">&#160;</td>
                  <td style="font-size:10pt;vertical-align:top;width:28pt">&#160;</td>
                </tr>
                <tr>
                  <td style="width:56pt">&#160;</td>
                  <td style="width:28pt">&#160;</td>
                  <td style="width:auto">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:56pt">&#160;</td>
                  <td style="vertical-align:top;width:28pt">&#160;</td>
                  <td style="vertical-align:top;width:auto">
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The License Agreement contains customary representations, warranties, covenants, and terms governing the prosecution and enforcement of certain intellectual property and issues related to technology transfer, manufacturing transfer, provisions with respect to establishment of joint steering committee and its governance covenants with respect change of control and others.</span></p>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282711533600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
      <div>
        <div style="text-align:justify;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;text-align:left;color:rgb(0, 0, 0)">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span>NOTE 2:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span>SIGNIFICANT ACCOUNTING POLICIES</span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <div>&#160;</div>
          <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</span></span></div>

            <div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Use of estimates:</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company&#8217;s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></span></div>
            </div>


            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>b.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Financial statements in U.S. dollars:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The reporting and functional currency of the Company is the U.S. dollar, as the Company&#8217;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No.&#160;830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.</span></span></div>
            </div>


            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>c.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Basis of consolidation:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.</span></span></div>
            </div>


            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>d.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Cash, Cash equivalents and Restricted cash:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents consist of cash in banks and cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. The Company&#8217;s restricted cash primarily consists of bank deposits collateralizing the Company&#8217;s operating leases and credit cards.</span></span></div>
            </div>

          <div style="line-height:1.25">&#160;</div>
          <div></div>

            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div>
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits and restricted long-term bank deposits:</span></span></div>
                      </div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-family:Times New Roman, Times, serif;font-size:10pt">Short-term bank deposits include deposits with maturities of more than three months but less than one year. Long-term bank deposits include deposits with maturities of more than one year. Bank deposits are stated at cost which approximates market values.</span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank deposits as of December 31, 2024 and 2023 are in U.S. dollars and bear an annual weighted average interest rate of 5.51% and 6.20%, respectively.</span></span></div>
              </div>
            </div>


            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>f.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Investments in marketable securities:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#8220;Investments - Debt Securities&#8221;.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#8220;AFS&#8221;). The Company classifies its marketable securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#8217; equity. Realized gains and losses on sale of investments are included in financial income, net.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#8217;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#8217;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in shareholders&#8217; equity. No credit loss impairment was identified in the year ended December 31, 2024.</span></span></div>
            </div>

          <div style="line-height:1.25">&#160;</div>
          <div></div>

            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>g.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Property and equipment, net:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:90pt">

                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;width:68%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:30%;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                        </td>
                        <td style="width:30%;vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:68%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:68%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                        </td>
                        <td style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:68%;vertical-align:bottom">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6 - 20 (mainly 20)</span></span></div>
                        </td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr style="background-color:rgb(204, 238, 255)">
                        <td style="width:68%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                        <td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Shorter of the term of the lease or useful life</span></span></div>
                        </td>
                        <td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                      </tr>

                  </table>

              </div>
            </div>


            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>h.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Impairment of long-lived assets:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The long-lived assets of the Company. are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant, and Equipment&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset (assets group) with the future undiscounted cash flows expected to be generated by the asset (assets group). If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets group exceeds the fair value of the assets group. During the years 2024, 2023 and 2022, no impairment losses have been recorded.</span></span></div>
            </div>


            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>i.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Leases:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for its leases according to ASC 842 - Leases (&#8220;ASC 842&#8221;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of twelve months or less. The Company elected the practical expedient to combine its lease and non-lease components for its leases.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.</span></span></div>
            </div>

          <div style="line-height:1.25">&#160;</div>

            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>j.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Revenue recognition:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes revenue in accordance with ASC 606 &#8211; &#8220;Revenue from Contracts with Customers&#8221;.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As such, the Company analyzes its contracts to assess whether they are within the scope of ASC&#160;606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Identification of the contract, or contracts, with a customer</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Identification of the performance obligations in the contract</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Determination of the transaction price</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Allocation of the transaction price to the performance obligations in the contract</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recognition of revenue when, or as, the Company satisfies a performance obligation</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (&#8220;IP&#8221;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $ 10,000 upfront payment and is eligible to receive up to $ 200,000 for development, regulatory and commercial milestones for the first product, of which $&#160;30,500 was received as well as tiered royalties on future product sales.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#8220;probable&#8221; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 18, 2020, the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 2,000 in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 29, 2021, the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 6,000 in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 7,500 in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 27, 2023, the fourth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 10,000 in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 30, 2024, the fifth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 5,000 in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 18, 2023, the Company entered into an exclusive License Agreement with Gilead. Under the terms of the agreement, the Company granted Gilead an exclusive license under the Company&#8217;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products derived from a Compugen pipeline program. Compugen received an upfront payment of $&#160;60,000 and an IND clearance milestone payment of $&#160;30,000 and is also eligible to receive up to approximately $ 758,000 additional milestone payments subject to and upon the achievement of certain development, regulatory and commercial milestones and as detailed in the agreement.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gilead may terminate the Gilead Collaboration Agreement for convenience by giving a certain prior written notice to the Company at any time after the effective date of the agreement.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services, all of which are outputs of the Company&#8217;s ongoing activities, in exchange for consideration.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company assessed the promises under the License Agreement and concluded that (i) the delivery of the GS-0321 License; (ii) the preclinical research and development activities towards IND approval of GS-0321 (the &#8220;IND research and development activities&#8221;) and (iii) the contingent promise to additional research and development activities in connection with Phase 1 clinical trial (the &#8220;Phase 1 research and development activities&#8221;), are capable of being distinct and are distinct within the context of the License Agreement. The Company considered that the license has standalone functionality, considered to be functional intellectual property, and is capable of being distinct. The Company also determined that the IND research and development activities and Phase 1 research and development activities could be provided by resources otherwise available to Gilead and thus are capable of being distinct. Also, the Company concluded that the Company&#8217;s contingent promise to additional research and development activities in connection with Phase 1 clinical trial represents a material right.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As a result, the Company concluded that its promise to deliver the GS-0321 License, the promise to perform IND research and development activities and Phase 1 research and development activities represented separate performance obligations in the License Agreement.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company also evaluated all milestones and royalties as a possible variable consideration. With respect to clinical development and regulatory milestones, based upon the high degree of uncertainty and risk associated with these potential payments, the Company concluded that all such amounts should be fully constrained and are not included in the initial transaction price as the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Accordingly, the Company did not include any potential clinical development, regulatory and sales milestones and royalties in the initial transaction price.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company allocated the transaction price to each performance obligation on a relative estimated standalone selling price basis. The Company developed the estimated standalone selling price for the GS-0321 License based on the present value of expected future cash flows associated with the license and related clinical development and regulatory milestones. In developing such estimate, the Company applied judgement in determining the timing needed to develop the Licensed Product, the probability of success, and the discount rate. The Company developed the estimated standalone selling price for the IND research and development activities using a &#8220;cost plus&#8221; reasonable margin approach. To determine the estimated standalone selling price of the material right for the Phase 1 research and development activities obligation, the Company estimated the standalone selling price of the underlying performance obligations included in the material right and estimated the probability of the Company&#8217;s performance of such obligations.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company determined that the GS-0321 License was a functional license since the underlying intellectual property (the &#8220;IP&#8221;) has significant standalone functionality. In addition, the Company determined that December 18, 2023, represents (i) the date at which the Company made available the IP to Gilead and (ii) the beginning of the period during which Gilead is able to use and benefit from its right to use the IP. Based upon these considerations, the Company recognized the entirety of the initial transaction price allocated to the GS-0321 License performance obligation during the year ended December 31, 2023.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Further, the IND research and development activities and Phase 1 research and development activities performance obligations are recognized over time. The Company using the input method in order to measure the progress of the services, based on the actual internal and external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs were estimated reflected the Company&#8217;s best estimate of the period over which it would perform the activities to achieve clearance of an IND application for GS-0321 and the phase 1 clinical trial. The Company determined that the input method is the best measure of progress towards satisfying the performance obligation as incurred labor effort represents work performed that corresponds with, and thereby best depicts the transfer of goods and services.</span></span></div>
              </div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="margin-top:0pt;margin-bottom:0pt"></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the year ended December 31, 2024, the Company recognized $ 22,864 of license, IND services and Phase 1 services revenues, and during the year ended December 31, 2023, the Company recognized $ 23,459 of license revenues.</span></span></div>
              </div>
              <div style="text-align:justify;line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.3pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Of the $36,541 of deferred revenue recorded as of December 31, 2023, and additional deferred revenues incurred during the year ended December 31, 2024, the Company recognized $22,864 as revenue during the year ended December 31, 2024. The Company had no deferred revenues as of December 31, 2022. The milestone payment was accounted for as an available consideration and was allocated to the separate performance obligations.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, the Company included deferred revenues of $ 9,632 in current liabilities and $ 34,045 in non-current liabilities.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s remaining performance obligations represent contracted revenue that has not yet been recognized. As of December 31, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations that the Company expects to recognize as revenue was $43,677. As of December 31, 2024, the Company expects to recognize 22% of its remaining performance obligations as revenue over the next 12 months, and the remainder through 2029.</span></span></div>
                <div style="line-height:1.25">&#160;</div>
              </div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For additional information regarding revenues, please refer to Note 11 below.</span></span></div>
            </div>


            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>k.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Cost of revenues:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenues consist of certain royalties and milestones paid or accrued in addition to research and development services allocated in relation to Gilead license agreement.</span></span></div>
            </div>

          <div style="line-height:1.25">&#160;</div>

            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>l.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research and development expenses, net:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The portion of the Bristol&#160;Myers Squibb $ 12,000 investment in 2018 over the fair market value of the shares issued in the amount of $ 4,121 and the portion of the $ 20,000 investment in 2021 over the fair market value of the shares issued in the amount of $ 5,000 were considered as deferred participation of Bristol&#160;Myers Squibb in R&amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;D, see Note 1f and Note 9b.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of participation in R&amp;D expenses for the years ended December 31, 2024, 2023 and 2022 were $ 0, $&#160;325 and $ 6,019, respectively.</span></span></div>
            </div>

          <div style="line-height:1.25">&#160;</div>

            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>m.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Severance pay:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset on the Company&#8217;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#8217;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#8217;s monthly salary for each year of service, no additional payments are required to be made by the Company to the employee to cover severance obligation.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Severance expenses for the years ended December 31, 2024, 2023 and 2022 amounted to approximately $&#160;481, $&#160;432 and $&#160;468, respectively.</span></span></div>
            </div>


            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>n.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25">Share-based compensation<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for share-based compensation to employees and non-employees in accordance with ASC 718, &#8220;Compensation - Share Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company selected the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Share Purchase Plan (&#8220;ESPP&#8221;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:</span></span></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>

                <div>
                  <div style="margin-left:90pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee options</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90.45%-95.88%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">75.93%-80.95%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">69.44%-74.61%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.47%-4.54%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.37%-4.81%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.54%-4.39%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.02-4.97</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.02-5.06</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.05-5.4</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="margin-left:90pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ESPP</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">69.74%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.63%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.50</span></span></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                </div>

            </div>


            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>o.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Concentration of credit risks:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits, restricted long-term bank deposit and investment in marketable securities.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents, restricted cash, short-term bank deposits and restricted long-term bank deposit are invested in major banks in Israel and in the United States. Generally, these deposits may be redeemed upon demand and bear minimal risk. The Company's marketable securities consist of investments, which are highly rated by credit agencies, in government debentures.</span></span></div>
              </div>
            </div>

          <div style="line-height:1.25">&#160;</div>
          <div></div>

            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>p.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Basic and diluted loss per share:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic loss per share is calculated by dividing net loss for each reporting period by the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated by dividing net loss for each reporting period by the weighted average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during the period in accordance with ASC 260, &#8220;Earnings per Share&#8221;.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All outstanding share options and warrants for the years ended December 31, 2024, 2023 and 2022 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2024, 2023 and 2022 the average number of shares related to outstanding options, RSUs and warrants excluded from the calculations of diluted net loss per share were 8,496,655, 7,921,020 and 8,405,615, respectively.</span></span></div>
            </div>


            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>q.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Income taxes:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2024 and 2023, a full valuation allowance was provided by the Company.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.</span></span></div>
            </div>


            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>r.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Fair value of financial instruments:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</span></span></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The hierarchy is broken down into three levels based on the inputs as follows:</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:56.7pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1 -</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:56.7pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2 -</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:56.7pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3 -</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, marketable securities, restricted long-term bank deposit, other accounts receivable and prepaid expenses, trade payable and employees and related accruals and accrued expenses approximate their fair values due to the short-term maturities of such instruments.</span></span></div>
            </div>

          <div style="line-height:1.25">&#160;</div>
          <div></div>

            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">s.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently adopted accounting pronouncement :</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:28.1pt">&#160;</td>
                    <td style="width:56.7pt;vertical-align:top">&#160;</td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280),&#160;Improvements to Reportable Segment Disclosures&#160;requiring public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for the fiscal years beginning after December 15, 2024. The Company adopted the ASU 2023-07 during the year ended December 31, 2024, on a retrospective basis which resulted in updated segment disclosures. See Note 11 in the accompanying notes to the consolidated financial statements for further detail.</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>

          <div>

              <div>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:56.7pt">&#160;</td>
                      <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">t.</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently issued accounting pronouncements not yet adopted</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) -&#160;<span style="font-style:italic">Improvements to Income Tax Disclosures</span>. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. The Company is currently evaluating the effect of adopting the ASU on its financial statements disclosures.</span></span></div>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40) -&#160;<span style="font-style:italic">Disaggregation of Income Statement Expenses</span>. The ASU requires, among other items, additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the consolidated Statements of Operations. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the effect of adopting the ASU on its financial statements disclosures.</span></span></div>
              </div>

          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282809696064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">MARKETABLE SECURITIES</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:59.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following is a summary of available-for-sale marketable securities as of December 31, 2024 and 2023:</span></span></div>
        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortized cost</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross unrealized gains</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross unrealized losses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">&#160;</div>
                      <div style="line-height:1.25">&#160;</div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Available-for-sale &#8211; matures within one year:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">U.S. Treasury</p>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,618</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,629</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Available-for-sale &#8211; matures within one year:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">U.S. Treasury</p>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,740</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730211801692_20250224141027740_2">*</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,742</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:58.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Represents an amount lower than $1</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:58.5pt;line-height:1.25">The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2024 and December 31, 2023, and the length of time that those investments have been in a continuous loss position:</div>
        <div style="text-align:justify;margin-left:58.5pt;line-height:1.25">&#160;</div>

          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less than 12 months</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12 months or greater</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross unrealized loss</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Gross unrealized loss</strong></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">992</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730224938615_20250224141027741_9">*</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:58.5pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents an amount lower than $1.</span></span></div>
                  </td>
                </tr>

            </table>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:58.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, the Company had no significant unrealized losses related to marketable securities and determined the unrealized losses are not due to credit related losses. Therefore, the Company did not record an allowance for credit losses for its available-for-sale marketable securities.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:58.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, all of the Company&#8217;s available-for-sale marketable securities were due within one year.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:58.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company had no sales of marketable securities during the years ended December 31, 2024 and 2023, and accordingly no realized gains or losses were recorded.&#160;Proceeds from maturities of available-for-sale marketable securities during the year ended December 31, 2024, and 2023 were $&#160;53,230&#160;and $&#160;10,145, respectively.</span></span></div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799612976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">
      <div>
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 4:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">FAIR VALUE MEASUREMENTS</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:54pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The company evaluates assets and liabilities subject to fair value measurements on recurring basis to determine the appropriate level to classify them for each reporting period. There have been no transfers between fair value measurements levels during the years ended December 31, 2024 and 2023. The carrying amounts of cash and cash equivalents marketable securities, trade receivables, short term deposits and trade payables approximate their fair value due to the short-term maturity of such instruments.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:54pt;line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the Company&#8217;s assets that were measured at fair values of December 31, 2024 and <span>2023 by</span> level within the fair value hierarchy:</span></span></div>
          </div>
        </div>
        <div style="text-align:justify;margin-left:54pt;line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair&#160;value&#160;measurements&#160;as&#160;of</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;margin-left:4.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair Value</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Hierarchy</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cash equivalents:</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Money market funds</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,919</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,966</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketable securities:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25">U.S. Treasury</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,629</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,742</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799500000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock', window );">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</a></td>
<td class="text">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold">NOTE 5:-</td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">December 31,</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25">Prepaid expenses</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">$</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,473</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">$</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,211</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25">Government authorities</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">127</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">92</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25">Other</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">142</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">226</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">$</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,742</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">$</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,529</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713009776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 6:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LEASES</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company leases all its real estate, storage area and cars under various operating lease agreements that expire on various dates.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s operating leases have original lease periods expiring between 2021 and 2027. The offices in Israel lease include two options to renew, one of which was exercised in 2020. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain. The Company has an option to extend the lease of its offices in Israel until 2031, which is reasonably certain to be assured.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments and payments for optional renewal periods where it is reasonably certain the renewal period will be exercised.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
        <div></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under ASC 842, all leases, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled Operating lease right of use asset. The corresponding lease liabilities are split between current maturity of operating lease liability within current liabilities and long-term operating lease liability within long-term liabilities. The Company&#8217;s leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate based on information available on the commencement date to determine the present value of lease payments.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table represents the weighted-average remaining lease term and discount rate:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%">

                <tr>
                  <td style="vertical-align:bottom;width:90%">&#160;</td>
                  <td style="vertical-align:bottom;width:10%">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="padding-bottom:2px;vertical-align:bottom;width:90%">&#160;</td>
                  <td style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:10%">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:90%">&#160;</td>
                  <td style="vertical-align:bottom;width:10%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:90%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining lease term</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%">
                    <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.05</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:90%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average discount (annual) rate</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:10%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.96%</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease expenses were approximately $&#160;775, $ 800 and $&#160;884 in the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Variable payments as CPI, included in the lease expenses, were approximately $&#160;79, $&#160;61 and $&#160;37 in the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash paid for amounts included in the measurement of lease liabilities was approximately $&#160;761, $&#160;852 and $&#160;959 in the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Maturities of operating lease liabilities were as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></div>
                    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2024</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">650</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">584</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">565</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:2px;vertical-align:bottom;width:88%">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2028 and on</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,809</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating lease payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,608</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: imputed interest</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(696</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,912</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td rowspan="1" style="vertical-align:bottom;width:88%">&#160;</td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, current</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">448</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:2px;vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, non- current</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,464</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:4px;vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,912</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above annual minimum future rental commitments include both of the period covered by the first exercised option with respect to the leased facility of Compugen Ltd. through March 2026 and the second option to extend the lease of the Company facility for additional five-year period following expiration of the current lease period.</span></span></div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799577328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 7:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PROPERTY AND EQUIPMENT, NET</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">719</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">739</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,567</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,519</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,314</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,314</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,600</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,572</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation:</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">622</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">609</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,059</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,909</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,067</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,838</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,748</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,356</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciated cost</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">852</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,216</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2024 and 2023 total cost of $&#160;92 and $&#160;1,357, respectively and total accumulated depreciation of $&#160;92 and $&#160;1,350, respectively were disposed from the consolidated balance sheets.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2024 and 2023 the Company sold equipment with cost of $&#160;3 and $&#160;0, respectively and accumulated depreciation of $&#160;2 and $&#160;0, respectively. Gains from the sale during 2024 were $ 0.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2024, 2023 and 2022, depreciation expenses were approximately $&#160;486, $&#160;476 and $&#160;482, respectively.</span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712673072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 8:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS AND CONTINGENCIES</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company provided bank guarantees in the amount of $ 342 related to its offices in Israel, leased cars fueling in Israel and credit card security for its U.S. subsidiary.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the Office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (the &#8220;IIA&#8221;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from the results of the funded research programs. If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue arising from such research programs, and up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is 100% plus interest at LIBOR until December 31, 2023, and from January 1, 2024, the 12 months Term SOFR interest). For the years ended December 31, 2024, 2023 and 2022, the Company had an aggregate of paid or accrued royalties costs (income) to the IIA, recorded as cost of revenue in the consolidated statements of comprehensive loss in the amount of $&#160;(554), $&#160;1,004 and $&#160;225, respectively.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December&#160;31, 2024, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $ 9,872.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Following IIA approval that sales related to IL-18BP are excluded from sales subject to IIA royalties payment, the Company decreased previous year royalties accrual related to revenues under the Gilead Agreement in the amount of $ 704 and reduced the cost of revenues for the year ended December 31, 2024, by this amount.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as &#8220;Contingent Fees&#8221;). For the years ended December 31, 2024, 2023 and 2022, the Company incurred such Contingent Fees in the amounts of $ 0, $ 1,000 and $ 750.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 9, 2012, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the agreement the Advisor was entitled to 4% of the cash considerations that may be received under such transactions. In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Bayer Agreement was terminated effective February 27, 2023 and no further payments are expected under the May 2012 Agreement.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div></div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the years ended December 31, 2024, 2023 and 2022, the Company has not paid and did not accrue payments under this agreement.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (CLA) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the years ended December 31, 2024, 2023 and 2022, the Company did not incur any amount in the research and development expenses in connection with such milestone payment.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the years ended December 31, 2024, 2023 and 2022, the Company incurred in the research and development expenses such milestone payment in the amounts of $&#160;225, $ 500 and $ 0.</span></span></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799453808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text">
      <div>
        <div style="text-align:justify;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;text-align:left;color:rgb(0, 0, 0)">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>NOTE 9:-</span></span></span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>SHAREHOLDERS</span>&#8217;<span> EQUITY</span></span></span></span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>a.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Ordinary shares:</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends, and to participate in the distribution of the assets of the Company upon its winding-up,&#160;in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div></div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>b.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Issuance of shares:</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol-Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol Myers Squibb made a $ 12,000 equity investment in the Company.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Under the terms of the securities purchase agreement, Bristol Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $ 4.95 per share. The share price represented a 33% premium over the average closing price of Compugen&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The premium over the fair market value in the amount of $ 4,121 represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D) and $ 7,788 (net of $ 91 issuance expenses) were considered equity investment.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $&#160;20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $&#160;8.57333 per share. The share price represented a 33% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.</span></span></span></span></div>
            <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
            <div style="margin-top:0pt;margin-bottom:0pt"></div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>b.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Issuance of shares: (Cont.)</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The premium over the fair market value in the amount of $&#160;5,000 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D) and $&#160;14,958 (net of $&#160;42 issuance expenses) were considered equity investment.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#8220;Leerink Partners&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#8220;at the market offering&#8221; (ATM). The offer and sale of the Company&#8217;s ordinary shares, if any, are made pursuant to the Company&#8217;s shelf registration statement on Form F-3, as supplemented by a prospectus supplement filed on January 31, 2023. Pursuant to the applicable prospectus supplement, the Company may offer and sell up to $50,000 of its ordinary shares. From the date the Company started selling ordinary shares in 2023 through its ATM and through December 31, 2024, 2,905,550 ordinary shares were issued and sold through the ATM, with proceeds of approximately $ 3,625 (net of $ 548 issuance expenses).</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>c.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Share option plan:</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Under the Company&#8217;s 2010 Share Option Plan, as amended (the &#8220;Plan&#8221;), options and RSUs may be granted to employees, directors and non-employees of the Company and Compugen USA, Inc.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">Under the 2010 Share Option Plan the Company reserved for issuance up to an aggregate of 14,195,152 options and RSUs.&#160;The Company&#8217;s board of directors last amended the Plan in July 2024, to increase the number of shares available under the 2010 Plan. As of December 31, 2024, an aggregate of 891,922 options and RSUs under the 2010 Share Option Plan of the Company were still available for future grants.</div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In general, options granted under the Plan vest over a four-year period and expire 10 years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company&#8217;s ordinary shares on the date of grant, unless otherwise determined by the Company&#8217;s board of directors. The exercise price of the options granted under the Plan may not be less than the nominal value of the shares into which such options are exercisable, and the expiration date may not be later than 10 years from the date of grant. RSUs vest over a four-year period as well. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div></div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>c.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Share option plan (Cont.):</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Any options that are cancelled, forfeited or expired become available for future grants.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2024, were as follows:</span></span></span></span></div>
          </div>
        </div>
        <div style="font-family:'Times New Roman',Times,serif">
          <div style="line-height:1.25;margin-left:85.05pt">&#160;</div>
        </div>
        <div style="margin-left:90pt">

            <div>
              <div>
                <div>
                  <div>
                    <div style="margin-left:0pt">
                      <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Number of options</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Weighted average exercise</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">price</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Weighted average remaining contractual life</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Aggregate intrinsic</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">value</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Years</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options outstanding at beginning of year</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">8,373,745</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4.65</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">6.61</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1,912</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options granted</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1,027,200</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1.88</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options exercised</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(11,053</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.94</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options forfeited</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(495,781</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">3.33</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options expired</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(238,390</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">7.67</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options outstanding at end of year</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">8,655,721</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4.31</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">6.05</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">802</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Exercisable at end of year</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5,920,552</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.36</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4.93</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">286</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>

                      </table>
                    </div>
                  </div>
                </div>
              </div>
            </div>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div>
          <div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Weighted average fair value of options granted to employees, directors and non-employees during the years 2024, 2023 and 2022 was $&#160;1.20, $&#160;0.70 and $&#160;1.51 per share, respectively.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Aggregate intrinsic value of exercised options by employees, directors and non-employees during the years 2024, 2023 and 2022 was $&#160;9, $ 0 and $&#160;19, respectively. The aggregate intrinsic value of the exercised options represents the total intrinsic value (the difference between the sale price of the Company&#8217;s share at the date of exercise, and the exercise price) multiplied by the number of options exercised.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#8217;s closing share price on the last trading day of calendar 2024 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2024. This amount is impacted by the changes in the fair market value of the Company&#8217;s shares.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>As of December 31, 2024, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $ 3,602 which is expected to be recognized over a weighted average period of approximately 2.56 years.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div></div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="vertical-align:top;width:56pt">&#160;</td>
                  <td style="vertical-align:top;width:28pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>d.</span></span></span></span></td>
                  <td style="vertical-align:top;text-align:justify;width:auto">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="text-align:justify;text-indent:0pt;margin-left:85pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0pt;margin-left:85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>A summary of RSUs activity for the year ended December 31, 2024 is as follows:</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:90pt">

                <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%">

                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Number of RSUs</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Weighted average grant date per value</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs outstanding at beginning of year</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>-</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:76%">
                        <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs granted</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>319,150</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.70</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    </tr>
                    <tr>
                      <td style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                        <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs forfeited</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(1,800</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.69</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:76%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    </tr>
                    <tr>
                      <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                        <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs outstanding at end of year</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>317,350</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                      <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.70</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    </tr>

                </table>

            </div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>e.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Employee Share Purchase Plan:</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The Company adopted an ESPP in November 2020, with the first offering period starting on January 1, 2021. In connection with its adoption, a total of 600,000 ordinary shares were reserved for issuance under this plan.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.5pt;margin-left:85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The ESPP is implemented through six-month offering periods (except for the first offering period that was five months). According to the ESPP, eligible employees and non-employees may use up to 15% of their base salaries to purchase ordinary shares up to an aggregate limit of $&#160;40 per participant for every calendar year. The price of an ordinary share purchased under the ESPP is equal to 85% of the lower of the fair market value of the ordinary share on the first day of each offering period or on the last day of such period.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.5pt;margin-left:85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In the years ended December 31, 2024, 2023 and 2022, 0, 0 and 158,025 ordinary shares, respectively, had been purchased under the ESPP and as of December 31, 2024, no ordinary shares were available for issuance under the ESPP.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>f.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The share-based compensation expenses related to options, RSUs and ESPP are included as follows in the expense categories:</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:90pt">

                <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Year ended December 31,</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2024</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2023</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2022</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Research and development expenses</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,460</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,933</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2,158</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Marketing and business development expenses</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>115</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(41</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>269</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>General and administrative expenses</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,448</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,658</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,901</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3,023</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3,550</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>4,328</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>

            </div>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799605456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME, NET</a></td>
<td class="text">
      <div>
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 10:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">TAXES ON INCOME, NET</span></span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israeli taxation:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax rates applicable to the income of the Company.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxable income of the Company is subject to a corporate tax rate of 23% in 2024, 2023 and 2022.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Measurement of taxable income in U.S. dollars:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has elected to measure its taxable income and file its tax return under the Israeli Income Tax Regulations (Principles Regarding the Management of Books of Account of Foreign Invested Companies and Certain Partnerships and the Determination of Their Taxable Income), 1986. Accordingly, results for tax purposes are measured in terms of earnings in dollars.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (the &#8220;Investment Law&#8221;):</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 1, 2005, an amendment to the Investment Law came into effect (the &#8220;Amendment 60&#8221;) that significantly changed the provisions of the Investment Law. The Amendment 60 limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as a &#8220;Beneficiary Enterprise&#8221; including a provision generally requiring that at least 25% of the Beneficiary Enterprise&#8217;s income will be derived from export.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Another condition for receiving the benefits under the alternative track in respect of expansion programs pursuant to Amendment 60 is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2012 as its &#8220;year of election&#8221;.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additionally, Amendment 60 enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits. However, the Investment Law provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the Investment Law as they were on the date of such approval.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, there was no taxable income attributable to the Beneficiary Enterprise.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January 2011, another amendment to the Investment Law came into effect (the &#8220;2011 Amendment&#8221;). According to the 2011 Amendment, the benefit tracks in the Investment Law were modified and a flat tax rate applies to the Company&#8217;s entire income subject to this amendment (the &#8220;Preferred Income&#8221;).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Once an election is made, the Company&#8217;s income will be subject to the amended tax rate of 16% from 2015 and thereafter (or 9% for a preferred enterprise located in development area A).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commencing 2011 tax year, the Company can elect (without possibility of reversal) to apply the Amendment in a certain tax year and from that year and thereafter, it will be subject to the amended tax rates.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company adopted the 2011 Amendment in 2024. Accordingly, the Company did not adjust its deferred tax balances as of December 31, 2024.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2016 and 2017 Budget Years), 2016, which includes Amendment 73 to the Law (the &#8220;Amendment 73&#8221;) was published. According to Amendment 73, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2016 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amendment 73 also prescribes special tax tracks for technological enterprises, which are subject to rules that were issued by the Minister of Finance in May 2017. The new tax tracks under the Amendment are as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred Technological Enterprise (&#8220;PTE&#8221;) - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion in a tax year. A PTE, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above changes in the tax rates relating to PTE tax track were not taken into account in the computation of deferred taxes as of December 31, 2024 and 2023, since the Company estimates that it will not implement the PTE tax track.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax benefits under the law for the Encouragement of Industry (Taxes), 1969 (the &#8220;Encouragement Law&#8221;):</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Encouragement Law provides several tax benefits for industrial companies. An industrial company is defined as a company resident in Israel, at least 90% of the income of which in a given tax year exclusive of income from specified Government loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose major activity in a given tax year is industrial production activity.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management believes that the Company is currently qualified as an &#8220;industrial company&#8220; under the Encouragement Law and, as such, is entitled to tax benefits, including: (1) deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period; (2) the right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial companies and an industrial holding company; (3) accelerated depreciation rates on equipment and buildings; and (4) expenses related to a public offering on the Tel-Aviv Stock exchange and on recognized stock markets outside of Israel, are deductible in equal amounts over three years.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Eligibility for benefits under the Encouragement Law is not subject to receipt of prior approval from any Governmental authority. No assurance can be given that the Israeli tax authorities will agree that the Company qualifies, or, that the Company will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating losses carryforward and capital loss:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December&#160;31, 2024, </span></span>Compugen Ltd.&#8217;s<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"> net operating losses carryforward for tax purposes in Israel amounted to approximately $&#160;413,900. These net operating losses may be carried forward indefinitely and may be offset against future taxable income.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-Israeli subsidiary, Compugen USA, Inc.:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221; or &#8220;TCJA&#8221;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include several key tax provisions that might impact the Company, among others: (i) a permanent reduction to the statutory federal corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017; (ii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain new rules designed to prevent erosion of the U.S. income tax base - &#8220;BEAT&#8221;); (iii) establishing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits; and (iv) providing a permanent deduction to corporations generating revenues from non-US markets (known as a deduction for foreign derived intangible income - &#8220;FDII&#8221;) .</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, Compugen USA, Inc. has net operating loss carryforwards for federal income tax purposes of approximately $&#160;1,400. Approximately $300 of these losses are available to offset any future U.S. taxable income of our U.S. subsidiary and will expire in the years 2027 to 2032. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Neither Israeli income taxes, foreign withholding taxes nor deferred income taxes were provided in relation to undistributed earnings of the Company&#8217;s foreign subsidiary. This is because the Company has the intent and ability to reinvest these earnings indefinitely in the foreign subsidiary and therefore those earnings are continually redeployed in those jurisdictions.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss (income) before taxes is comprised as follows:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:90pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Domestic (Israel)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,129</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,164</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">34,096</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(420</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(380</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(460</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,709</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,784</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,636</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes on income for the years ended December 31, 2024 and 2023, represent withholding taxes on the upfront payment and the IND milestone pursuant to the Gilead license agreement, write-off of tax assets and state income taxes in the United States.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred taxes:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#8217;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:90pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;loss carryforward</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">95,485</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">92,885</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,779</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,109</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued social benefits and other</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,535</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,072</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">670</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">312</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset before valuation allowance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">110,469</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">108,380</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(109,814</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(108,073</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset after valuation allowance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">655</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">307</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right of use assets</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(655</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(307</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(655</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(307</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and<span style="font-weight:bold">&#160;</span>Compugen USA, Inc. due to the uncertainty of the realization of such tax benefits and withholding taxes on the upfront payment and the IND milestone pursuant to the Gilead license agreement.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax assessments:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has tax assessments through 2019 that are deemed to be final.</span></span></div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799610032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;color:rgb(0, 0, 0)">

                    <tr>
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span>NOTE 11:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div style="font-weight:bold"><span style="font-size:10pt"><span>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASC 280, &#8220;Segment Reporting,&#8221; establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company&#8217;s business is comprised of one operating segment<span>.</span></span></span></div>
                </div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company's CODM is its Chief Executive Officer (&#8220;CEO&#8221;), who reviews financial information presented on a consolidated basis.</span></span></div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">
                  <div style="line-height:1.25">The CODM uses consolidated net loss to assess financial performance and allocate resources. These financial metrics are used by the CODM to make key operating decisions, such as the allocation of budget between Research and development, Sales and Marketing, and General and Administrative expenses. Segment assets that are reviewed by the CODM is reported within the Consolidated Balance Sheet as consolidated total assets.</div>
                </div>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-indent:0.5pt;margin-left:56.2pt;line-height:1.25">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table presents selected financial information with respect to the Company&#8217;s single operating segment <span>and includes information about segment revenues and significant segment expenses, </span>for the years ended December&#160;31, 2024, 2023 and 2022:</span></span></div>
                  <div style="text-align:justify;line-height:1.25">&#160;</div>
                </div>

                  <div>
                    <div style="margin-left:63pt">
                      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total Revenues</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27,864</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,459</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,500</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less:</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160; &#160; &#160; &#160; R&amp;D expenses</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Preclinical</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,374</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,948</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">17,477</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; Clinical</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,267</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,627</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,357</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SG&amp;A</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,485</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,320</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,690</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income, net</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,182</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,215</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,738</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Taxes on income</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,522</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,970</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">58</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other segment expenses*</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,629</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,563</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,350</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(14,231</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(18,754</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(33,694</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                          </tr>

                      </table>
                    </div>
                  </div>

                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>*Other </span></span>segment expense (income) during the years ended December 31, 2024, 2023 and 2022 includes property and equipment depreciation, participation in R&amp;D expenses, share-based compensation and other adjustments.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25">
                    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operations in Israel and the United States include research and development, clinical operations, general and administrative, marketing and business development.&#160;Total revenues are attributed to geographic areas based on the location of the end customer.</span></span></p>
                  </div>
                </div>
                <div style="line-height:1.25">&#160;</div>
              </div>
              <div></div>
              <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following represents the total revenue for the years ended December 31, 2024, 2023 and 2022 and long-lived assets as of December 31, 2024 and 2023:</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>

                <div>
                  <div style="margin-left:63pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended December 31,</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Revenue from sales to customers:</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Europe</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5,000</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>10,000</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7,500</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>United States</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>22,864</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>23,459</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total revenue</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>27,864</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>33,459</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7,500</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                  <div style="line-height:1.25">&#160;</div>
                  <div>
                    <div style="margin-left:63pt">
                      <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>December 31,</span></strong></span></span></p>
                            </td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Long-lived assets:</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Israel</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,677</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,468</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>United States</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>18</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>77</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total long-lived assets</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,695</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,545</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>

                      </table>
                    </div>
                  </div>
                </div>

              <div>
                <div style="line-height:1.25">&#160;</div>
                <div style="margin-left:63pt">

                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended December 31,</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Sales to a single customer exceeding 10%:</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Customer A</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>18</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>30</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>100</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Customer B</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>82</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>70</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>

                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713147840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">FINANCIAL AND OTHER INCOME, NET</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

        <tr>
          <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 12:-</span></td>
          <td style="width:auto;vertical-align:top;text-align:justify">
            <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">FINANCIAL AND OTHER INCOME, NET</span></div>
          </td>
        </tr>

    </table>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <div>
      <div>
        <div style="margin-left:63pt">

            <div>
              <div>
                <div>
                  <div>
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,489</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,960</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,437</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of discount on marketable securities, net</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,747</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">281</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank fees and other finance expenses</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(34</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(31</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(27</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency transaction adjustments</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(20</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">340</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gain (loss) from sales and disposals of fixed assets</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(7</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,182</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,208</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,738</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                </div>
              </div>
            </div>

        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/720/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 610<br> -Publisher FASB<br> -URI https://asc.fasb.org/610/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799598416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY BALANCES AND TRANSACTIONS</a></td>
<td class="text">
    <div>
      <div>
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 13:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">RELATED PARTY BALANCES AND TRANSACTIONS</span></span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif">December 31,</span></strong></p>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables and accrued expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">58</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">53</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts charged to:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">141</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">147</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">194</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2024, 2023 and 2022 the Company received research and development services related with cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies. The transaction was at arm&#8217;s length.</span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799546080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSSES PER SHARE</a></td>
<td class="text">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 14:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LOSSES PER SHARE</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin:0px 0px 0px 85.5pt;line-height:1.25;text-align:justify;text-indent:-28.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the computation of basic and diluted losses per share:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">

            <div>
              <div>
                <div>
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for basic and diluted loss per share</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(14,231</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(18,754</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(33,694</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">89,528,031</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87,633,298</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">86,555,628</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.16</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.21</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.39</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>

        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712964240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 15:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SUBSEQUENT EVENTS</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January and February 2025, the Company sold through the ATM <span>3,961,641</span> ordinary shares, with proceeds of approximately <span>$ 8,870</span> (net of <span>$ 274</span> issuance expenses).</span></span></div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713107136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (14,231)<span></span>
</td>
<td class="num">$ (18,754)<span></span>
</td>
<td class="num">$ (33,694)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712987344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712953536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">
            <div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">
                <span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, certain third party hosted services, our communications systems, our hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and employees&#8217; information, or the Information Systems and Data.</span></span></span>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our Senior Vice President/Senior Advisor, Data and Informatics Solutions helps in identifying, assessing and managing the Company&#8217;s cybersecurity threats and risks by monitoring and evaluating our threat environment using various methods including, for example, by engaging third parties to conduct penetration tests on our behalf.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depending on the environment and system, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example, incident response policy, business continuity plan, cybersecurity insurance, firewalls and access controls for certain environments and systems, physical security measures, and employee cybersecurity trainings.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our overall risk assessment and management processes covers material risks from cybersecurity threats.&#160; For example, cybersecurity risk is a component in our internal auditor&#8217;s risk assessment report. Our Senior Vice President/Senior Advisor, Data and Informatic Solutions works with relevant management members to prioritize and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including, for example, professional services firms, including legal counsel, cybersecurity and cloud consultants, and a penetration testing firm.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We use third-party service providers to perform a variety of functions throughout our business, including in connection with our clinical data management, antibody development, financial information management, payments and others. We review and require certain security measures of certain of these third parties, such as encryption at rest and in transit and access controls, and in certain cases, we seek to confirm their compliance with different industry standards and certifications, such as SOC1, SOC2, SOC3, ISO 27001, and ISO 27017.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">
                <span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 3D. Risk Factors in this Annual Report on Form 20-F, including the applicable risk factors under &#8220;Risk Factors - Risks Related to our Operations.&#8221;</span></span></span>
              </div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, certain third party hosted services, our communications systems, our hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and employees&#8217; information, or the Information Systems and Data.</span></span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 3D. Risk Factors in this Annual Report on Form 20-F, including the applicable risk factors under &#8220;Risk Factors - Risks Related to our Operations.&#8221;</span></span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">
            <div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Governance</span></span></div>
              <div style="line-height:1.25">&#160;</div>

                <div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">
                    <span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function through its audit committee.</span></span></span>
                  </div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt;font-family:Times New Roman">Our cybersecurity risk assessment and management processes are under the responsibility of our Senior Vice President/Senior Advisor</span>, <span style="font-size:10pt;font-family:Times New Roman">Data and Informatics Solutions, who has over 15 years of experience in the data science, technology, and machine learning spaces.</span></span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">
                    <span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our Senior Vice President/Senior Advisor, Data and Informatics Solutions, is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, communicating key priorities to relevant personnel (such as the Chief Executive Officer), helping to prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></span></span>
                  </div>
                </div>

              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our cybersecurity incident response policy is designed to escalate certain cybersecurity incidents to certain members of management, including our Senior Vice President/Senior Advisor, Data and Informatics Solutions, our Chief Financial Officer and our General Counsel. Under our cybersecurity incident response policy, those members of management will work with the Company&#8217;s incident response team member(s) to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#8217;s cybersecurity incident response policy includes reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></span></div>
              <div>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">
                  <span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The audit committee receives periodic reports at least twice a year from our Senior Vice President/Senior Advisor, Data and Informatics Solutions concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also receives various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></span></span>
                </div>
              </div>
            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function through its audit committee.</span></span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman">Our cybersecurity risk assessment and management processes are under the responsibility of our Senior Vice President/Senior Advisor</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">
                <div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">
                    <span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function through its audit committee.</span></span></span>
                  </div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt;font-family:Times New Roman">Our cybersecurity risk assessment and management processes are under the responsibility of our Senior Vice President/Senior Advisor</span>, <span style="font-size:10pt;font-family:Times New Roman">Data and Informatics Solutions, who has over 15 years of experience in the data science, technology, and machine learning spaces.</span></span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">
                    <span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our Senior Vice President/Senior Advisor, Data and Informatics Solutions, is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, communicating key priorities to relevant personnel (such as the Chief Executive Officer), helping to prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></span></span>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our Senior Vice President/Senior Advisor, Data and Informatics Solutions, is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, communicating key priorities to relevant personnel (such as the Chief Executive Officer), helping to prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman">Data and Informatics Solutions, who has over 15 years of experience in the data science, technology, and machine learning spaces.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The audit committee receives periodic reports at least twice a year from our Senior Vice President/Senior Advisor, Data and Informatics Solutions concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also receives various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712310368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates:</a></td>
<td class="text">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Use of estimates:</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company&#8217;s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Financial statements in U.S. dollars:</a></td>
<td class="text">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>b.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Financial statements in U.S. dollars:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The reporting and functional currency of the Company is the U.S. dollar, as the Company&#8217;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No.&#160;830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of consolidation:</a></td>
<td class="text">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>c.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Basis of consolidation:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash equivalents and Restricted cash</a></td>
<td class="text">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>d.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Cash, Cash equivalents and Restricted cash:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents consist of cash in banks and cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. The Company&#8217;s restricted cash primarily consists of bank deposits collateralizing the Company&#8217;s operating leases and credit cards.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock', window );">Short-term bank deposits and restricted long-term bank deposits</a></td>
<td class="text">
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div>
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits and restricted long-term bank deposits:</span></span></div>
                      </div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-family:Times New Roman, Times, serif;font-size:10pt">Short-term bank deposits include deposits with maturities of more than three months but less than one year. Long-term bank deposits include deposits with maturities of more than one year. Bank deposits are stated at cost which approximates market values.</span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank deposits as of December 31, 2024 and 2023 are in U.S. dollars and bear an annual weighted average interest rate of 5.51% and 6.20%, respectively.</span></span></div>
              </div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in marketable securities</a></td>
<td class="text">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>f.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Investments in marketable securities:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#8220;Investments - Debt Securities&#8221;.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#8220;AFS&#8221;). The Company classifies its marketable securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#8217; equity. Realized gains and losses on sale of investments are included in financial income, net.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#8217;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#8217;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in shareholders&#8217; equity. No credit loss impairment was identified in the year ended December 31, 2024.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net:</a></td>
<td class="text">
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>g.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Property and equipment, net:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:90pt">

                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;width:68%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:30%;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                        </td>
                        <td style="width:30%;vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:68%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:68%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                        </td>
                        <td style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:68%;vertical-align:bottom">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6 - 20 (mainly 20)</span></span></div>
                        </td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr style="background-color:rgb(204, 238, 255)">
                        <td style="width:68%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                        <td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Shorter of the term of the lease or useful life</span></span></div>
                        </td>
                        <td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                      </tr>

                  </table>

              </div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Impairment of long-lived assets:</a></td>
<td class="text">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>h.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Impairment of long-lived assets:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The long-lived assets of the Company. are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant, and Equipment&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset (assets group) with the future undiscounted cash flows expected to be generated by the asset (assets group). If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets group exceeds the fair value of the assets group. During the years 2024, 2023 and 2022, no impairment losses have been recorded.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases:</a></td>
<td class="text">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>i.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Leases:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for its leases according to ASC 842 - Leases (&#8220;ASC 842&#8221;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of twelve months or less. The Company elected the practical expedient to combine its lease and non-lease components for its leases.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition:</a></td>
<td class="text">
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>j.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Revenue recognition:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes revenue in accordance with ASC 606 &#8211; &#8220;Revenue from Contracts with Customers&#8221;.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As such, the Company analyzes its contracts to assess whether they are within the scope of ASC&#160;606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Identification of the contract, or contracts, with a customer</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Identification of the performance obligations in the contract</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Determination of the transaction price</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Allocation of the transaction price to the performance obligations in the contract</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recognition of revenue when, or as, the Company satisfies a performance obligation</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (&#8220;IP&#8221;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $ 10,000 upfront payment and is eligible to receive up to $ 200,000 for development, regulatory and commercial milestones for the first product, of which $&#160;30,500 was received as well as tiered royalties on future product sales.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#8220;probable&#8221; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 18, 2020, the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 2,000 in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 29, 2021, the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 6,000 in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 7,500 in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 27, 2023, the fourth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 10,000 in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 30, 2024, the fifth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 5,000 in accordance with the criteria prescribed under ASC 606.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 18, 2023, the Company entered into an exclusive License Agreement with Gilead. Under the terms of the agreement, the Company granted Gilead an exclusive license under the Company&#8217;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products derived from a Compugen pipeline program. Compugen received an upfront payment of $&#160;60,000 and an IND clearance milestone payment of $&#160;30,000 and is also eligible to receive up to approximately $ 758,000 additional milestone payments subject to and upon the achievement of certain development, regulatory and commercial milestones and as detailed in the agreement.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gilead may terminate the Gilead Collaboration Agreement for convenience by giving a certain prior written notice to the Company at any time after the effective date of the agreement.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services, all of which are outputs of the Company&#8217;s ongoing activities, in exchange for consideration.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company assessed the promises under the License Agreement and concluded that (i) the delivery of the GS-0321 License; (ii) the preclinical research and development activities towards IND approval of GS-0321 (the &#8220;IND research and development activities&#8221;) and (iii) the contingent promise to additional research and development activities in connection with Phase 1 clinical trial (the &#8220;Phase 1 research and development activities&#8221;), are capable of being distinct and are distinct within the context of the License Agreement. The Company considered that the license has standalone functionality, considered to be functional intellectual property, and is capable of being distinct. The Company also determined that the IND research and development activities and Phase 1 research and development activities could be provided by resources otherwise available to Gilead and thus are capable of being distinct. Also, the Company concluded that the Company&#8217;s contingent promise to additional research and development activities in connection with Phase 1 clinical trial represents a material right.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As a result, the Company concluded that its promise to deliver the GS-0321 License, the promise to perform IND research and development activities and Phase 1 research and development activities represented separate performance obligations in the License Agreement.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company also evaluated all milestones and royalties as a possible variable consideration. With respect to clinical development and regulatory milestones, based upon the high degree of uncertainty and risk associated with these potential payments, the Company concluded that all such amounts should be fully constrained and are not included in the initial transaction price as the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Accordingly, the Company did not include any potential clinical development, regulatory and sales milestones and royalties in the initial transaction price.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company allocated the transaction price to each performance obligation on a relative estimated standalone selling price basis. The Company developed the estimated standalone selling price for the GS-0321 License based on the present value of expected future cash flows associated with the license and related clinical development and regulatory milestones. In developing such estimate, the Company applied judgement in determining the timing needed to develop the Licensed Product, the probability of success, and the discount rate. The Company developed the estimated standalone selling price for the IND research and development activities using a &#8220;cost plus&#8221; reasonable margin approach. To determine the estimated standalone selling price of the material right for the Phase 1 research and development activities obligation, the Company estimated the standalone selling price of the underlying performance obligations included in the material right and estimated the probability of the Company&#8217;s performance of such obligations.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company determined that the GS-0321 License was a functional license since the underlying intellectual property (the &#8220;IP&#8221;) has significant standalone functionality. In addition, the Company determined that December 18, 2023, represents (i) the date at which the Company made available the IP to Gilead and (ii) the beginning of the period during which Gilead is able to use and benefit from its right to use the IP. Based upon these considerations, the Company recognized the entirety of the initial transaction price allocated to the GS-0321 License performance obligation during the year ended December 31, 2023.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Further, the IND research and development activities and Phase 1 research and development activities performance obligations are recognized over time. The Company using the input method in order to measure the progress of the services, based on the actual internal and external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs were estimated reflected the Company&#8217;s best estimate of the period over which it would perform the activities to achieve clearance of an IND application for GS-0321 and the phase 1 clinical trial. The Company determined that the input method is the best measure of progress towards satisfying the performance obligation as incurred labor effort represents work performed that corresponds with, and thereby best depicts the transfer of goods and services.</span></span></div>
              </div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="margin-top:0pt;margin-bottom:0pt"></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the year ended December 31, 2024, the Company recognized $ 22,864 of license, IND services and Phase 1 services revenues, and during the year ended December 31, 2023, the Company recognized $ 23,459 of license revenues.</span></span></div>
              </div>
              <div style="text-align:justify;line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.3pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Of the $36,541 of deferred revenue recorded as of December 31, 2023, and additional deferred revenues incurred during the year ended December 31, 2024, the Company recognized $22,864 as revenue during the year ended December 31, 2024. The Company had no deferred revenues as of December 31, 2022. The milestone payment was accounted for as an available consideration and was allocated to the separate performance obligations.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:84.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, the Company included deferred revenues of $ 9,632 in current liabilities and $ 34,045 in non-current liabilities.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s remaining performance obligations represent contracted revenue that has not yet been recognized. As of December 31, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations that the Company expects to recognize as revenue was $43,677. As of December 31, 2024, the Company expects to recognize 22% of its remaining performance obligations as revenue over the next 12 months, and the remainder through 2029.</span></span></div>
                <div style="line-height:1.25">&#160;</div>
              </div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For additional information regarding revenues, please refer to Note 11 below.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_CostOfSalesContractWithCustomerPolicyTextBlock', window );">Cost of revenues:</a></td>
<td class="text">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>k.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Cost of revenues:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenues consist of certain royalties and milestones paid or accrued in addition to research and development services allocated in relation to Gilead license agreement.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses, net:</a></td>
<td class="text">
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>l.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research and development expenses, net:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The portion of the Bristol&#160;Myers Squibb $ 12,000 investment in 2018 over the fair market value of the shares issued in the amount of $ 4,121 and the portion of the $ 20,000 investment in 2021 over the fair market value of the shares issued in the amount of $ 5,000 were considered as deferred participation of Bristol&#160;Myers Squibb in R&amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;D, see Note 1f and Note 9b.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of participation in R&amp;D expenses for the years ended December 31, 2024, 2023 and 2022 were $ 0, $&#160;325 and $ 6,019, respectively.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ServerancePayPolicyTextBlock', window );">Severance pay:</a></td>
<td class="text">
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>m.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Severance pay:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset on the Company&#8217;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#8217;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#8217;s monthly salary for each year of service, no additional payments are required to be made by the Company to the employee to cover severance obligation.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Severance expenses for the years ended December 31, 2024, 2023 and 2022 amounted to approximately $&#160;481, $&#160;432 and $&#160;468, respectively.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation:</a></td>
<td class="text">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>n.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25">Share-based compensation<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for share-based compensation to employees and non-employees in accordance with ASC 718, &#8220;Compensation - Share Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company selected the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Share Purchase Plan (&#8220;ESPP&#8221;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:</span></span></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>

                <div>
                  <div style="margin-left:90pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee options</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90.45%-95.88%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">75.93%-80.95%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">69.44%-74.61%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.47%-4.54%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.37%-4.81%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.54%-4.39%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.02-4.97</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.02-5.06</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.05-5.4</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="margin-left:90pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ESPP</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">69.74%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.63%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.50</span></span></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                </div>

            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks:</a></td>
<td class="text">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>o.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Concentration of credit risks:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits, restricted long-term bank deposit and investment in marketable securities.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents, restricted cash, short-term bank deposits and restricted long-term bank deposit are invested in major banks in Israel and in the United States. Generally, these deposits may be redeemed upon demand and bear minimal risk. The Company's marketable securities consist of investments, which are highly rated by credit agencies, in government debentures.</span></span></div>
              </div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted loss per share:</a></td>
<td class="text">
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>p.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Basic and diluted loss per share:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic loss per share is calculated by dividing net loss for each reporting period by the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated by dividing net loss for each reporting period by the weighted average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during the period in accordance with ASC 260, &#8220;Earnings per Share&#8221;.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All outstanding share options and warrants for the years ended December 31, 2024, 2023 and 2022 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2024, 2023 and 2022 the average number of shares related to outstanding options, RSUs and warrants excluded from the calculations of diluted net loss per share were 8,496,655, 7,921,020 and 8,405,615, respectively.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes:</a></td>
<td class="text">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>q.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Income taxes:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2024 and 2023, a full valuation allowance was provided by the Company.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments:</a></td>
<td class="text">
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:56.7pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.35pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>r.</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Fair value of financial instruments:</span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</span></span></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The hierarchy is broken down into three levels based on the inputs as follows:</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:56.7pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1 -</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:56.7pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2 -</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:85.05pt">&#160;</td>
                    <td style="width:56.7pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3 -</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, marketable securities, restricted long-term bank deposit, other accounts receivable and prepaid expenses, trade payable and employees and related accruals and accrued expenses approximate their fair values due to the short-term maturities of such instruments.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncement</a></td>
<td class="text">
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">s.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently adopted accounting pronouncement :</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:28.1pt">&#160;</td>
                    <td style="width:56.7pt;vertical-align:top">&#160;</td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280),&#160;Improvements to Reportable Segment Disclosures&#160;requiring public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for the fiscal years beginning after December 15, 2024. The Company adopted the ASU 2023-07 during the year ended December 31, 2024, on a retrospective basis which resulted in updated segment disclosures. See Note 11 in the accompanying notes to the consolidated financial statements for further detail.</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently issued accounting pronouncements not yet adopted</a></td>
<td class="text">
              <div>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:56.7pt">&#160;</td>
                      <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">t.</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently issued accounting pronouncements not yet adopted</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) -&#160;<span style="font-style:italic">Improvements to Income Tax Disclosures</span>. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. The Company is currently evaluating the effect of adopting the ASU on its financial statements disclosures.</span></span></div>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40) -&#160;<span style="font-style:italic">Disaggregation of Income Statement Expenses</span>. The ASU requires, among other items, additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the consolidated Statements of Operations. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the effect of adopting the ASU on its financial statements disclosures.</span></span></div>
              </div>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_CostOfSalesContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_CostOfSalesContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policy for Recently issued accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ServerancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Serverance Pay [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ServerancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short Term Bank Deposits And Restricted Long Term Bank Deposits [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712104768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock', window );">Schedule of depreciation rates for property and equipment</a></td>
<td class="text">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;width:68%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:30%;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                        </td>
                        <td style="width:30%;vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:68%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:68%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                        </td>
                        <td style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:68%;vertical-align:bottom">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6 - 20 (mainly 20)</span></span></div>
                        </td>
                        <td style="vertical-align:bottom;width:30%;vertical-align:bottom">&#160;</td>
                      </tr>
                      <tr style="background-color:rgb(204, 238, 255)">
                        <td style="width:68%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                        <td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Shorter of the term of the lease or useful life</span></span></div>
                        </td>
                        <td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                      </tr>

                  </table>
                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions', window );">Schedule of weighted average assumptions for granted options</a></td>
<td class="text">
                <div>
                  <div style="margin-left:90pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee options</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90.45%-95.88%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">75.93%-80.95%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">69.44%-74.61%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.47%-4.54%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.37%-4.81%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.54%-4.39%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.02-4.97</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.02-5.06</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.05-5.4</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="margin-left:90pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ESPP</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                          <td style="vertical-align:middle;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">69.74%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.63%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0%</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:65.95%;vertical-align:bottom">
                            <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom">
                            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.50</span></span></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the annual rates used to calculate depreciation for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of granted stock options, including, but not limited to: (a) expected term of granted share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713036944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of available-for-sale marketable securities</a></td>
<td class="text">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortized cost</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross unrealized gains</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross unrealized losses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">&#160;</div>
                      <div style="line-height:1.25">&#160;</div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Available-for-sale &#8211; matures within one year:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">U.S. Treasury</p>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,618</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,629</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Available-for-sale &#8211; matures within one year:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">U.S. Treasury</p>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,740</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730211801692_20250224141027740_2">*</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,742</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:58.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Represents an amount lower than $1</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of unrealized loss on investments</a></td>
<td class="text">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less than 12 months</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12 months or greater</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross unrealized loss</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Gross unrealized loss</strong></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">992</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730224938615_20250224141027741_9">*</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:58.5pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents an amount lower than $1.</span></span></div>
                  </td>
                </tr>

            </table>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799574368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value measurements</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair&#160;value&#160;measurements&#160;as&#160;of</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;margin-left:4.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair Value</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Hierarchy</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cash equivalents:</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Money market funds</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,919</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,966</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketable securities:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;margin-left:4.5pt;line-height:1.25">U.S. Treasury</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,629</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,742</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712114496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of other accounts receivable and prepaid expenses</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">December 31,</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25">Prepaid expenses</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">$</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,473</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">$</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,211</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25">Government authorities</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">127</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">92</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25">Other</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">142</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">226</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">$</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,742</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">$</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,529</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799594816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate', window );">Schedule of weighted-average remaining lease term and discount rate</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%">

                <tr>
                  <td style="vertical-align:bottom;width:90%">&#160;</td>
                  <td style="vertical-align:bottom;width:10%">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="padding-bottom:2px;vertical-align:bottom;width:90%">&#160;</td>
                  <td style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:10%">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:90%">&#160;</td>
                  <td style="vertical-align:bottom;width:10%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:90%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining lease term</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%">
                    <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.05</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:90%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average discount (annual) rate</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:10%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.96%</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of operating leases</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></div>
                    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2024</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">650</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">584</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">565</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:2px;vertical-align:bottom;width:88%">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2028 and on</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,809</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating lease payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,608</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: imputed interest</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(696</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,912</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td rowspan="1" style="vertical-align:bottom;width:88%">&#160;</td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, current</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">448</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:2px;vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, non- current</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,464</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-bottom:4px;vertical-align:bottom;width:88%">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%">&#160;</td>
                  <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:9%">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,912</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted-average remaining lease term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713922176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">719</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">739</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,567</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,519</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,314</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,314</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,600</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,572</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation:</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">622</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">609</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,059</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,909</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,067</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,838</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,748</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,356</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciated cost</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">852</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,216</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712425312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of share option plan</a></td>
<td class="text">
            <div>
              <div>
                <div>
                  <div>
                    <div style="margin-left:0pt">
                      <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Number of options</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Weighted average exercise</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">price</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Weighted average remaining contractual life</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Aggregate intrinsic</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">value</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Years</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options outstanding at beginning of year</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">8,373,745</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4.65</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">6.61</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1,912</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options granted</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1,027,200</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1.88</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options exercised</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(11,053</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.94</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options forfeited</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(495,781</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">3.33</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options expired</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(238,390</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">7.67</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options outstanding at end of year</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">8,655,721</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4.31</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">6.05</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">802</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Exercisable at end of year</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5,920,552</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.36</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4.93</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">286</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>

                      </table>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule Of RSUs activity</a></td>
<td class="text">
                <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%">

                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Number of RSUs</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Weighted average grant date per value</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs outstanding at beginning of year</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>-</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:76%">
                        <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs granted</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>319,150</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.70</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    </tr>
                    <tr>
                      <td style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                        <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs forfeited</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(1,800</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.69</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:76%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    </tr>
                    <tr>
                      <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                        <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>RSUs outstanding at end of year</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>317,350</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                      <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                      <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.70</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    </tr>

                </table>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expenses</a></td>
<td class="text">
                <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Year ended December 31,</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2024</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2023</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2022</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Research and development expenses</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,460</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,933</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2,158</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Marketing and business development expenses</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>115</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(41</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>269</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>General and administrative expenses</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,448</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,658</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,901</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3,023</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3,550</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>4,328</span></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713569520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of loss (income) before taxes</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Domestic (Israel)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,129</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,164</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">34,096</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(420</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(380</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(460</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,709</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,784</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,636</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;loss carryforward</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">95,485</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">92,885</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,779</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,109</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued social benefits and other</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,535</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,072</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">670</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">312</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset before valuation allowance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">110,469</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">108,380</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(109,814</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(108,073</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset after valuation allowance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">655</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">307</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right of use assets</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(655</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(307</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(655</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(307</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282716693456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of financial information with respect to single operating segment</a></td>
<td class="text">
                  <div>
                    <div style="margin-left:63pt">
                      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total Revenues</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27,864</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,459</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,500</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less:</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160; &#160; &#160; &#160; R&amp;D expenses</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Preclinical</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,374</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,948</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">17,477</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; Clinical</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,267</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,627</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,357</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SG&amp;A</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,485</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,320</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,690</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income, net</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,182</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,215</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,738</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Taxes on income</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,522</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,970</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">58</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other segment expenses*</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,629</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,563</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,350</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(14,231</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(18,754</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(33,694</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                            </td>
                          </tr>

                      </table>
                    </div>
                  </div>
                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of total revenues and long-lived assets by geographic area</a></td>
<td class="text">
                <div>
                  <div style="margin-left:63pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended December 31,</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Revenue from sales to customers:</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Europe</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5,000</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>10,000</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7,500</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>United States</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>22,864</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>23,459</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total revenue</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>27,864</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>33,459</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7,500</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                  <div style="line-height:1.25">&#160;</div>
                  <div>
                    <div style="margin-left:63pt">
                      <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>December 31,</span></strong></span></span></p>
                            </td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Long-lived assets:</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Israel</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,677</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,468</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>United States</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>18</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>77</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total long-lived assets</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,695</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,545</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>

                      </table>
                    </div>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of sales to single customer exceeding 10%</a></td>
<td class="text">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended December 31,</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Sales to a single customer exceeding 10%:</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Customer A</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>18</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>30</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>100</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                            <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Customer B</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>82</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>70</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713106480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of financial and other income, net</a></td>
<td class="text">
            <div>
              <div>
                <div>
                  <div>
                    <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,489</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,960</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,437</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of discount on marketable securities, net</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,747</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">281</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank fees and other finance expenses</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(34</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(31</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(27</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency transaction adjustments</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(20</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">340</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gain (loss) from sales and disposals of fixed assets</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(7</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,182</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,208</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,738</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                </div>
              </div>
            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799464176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party balances and transactions</a></td>
<td class="text">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif">December 31,</span></strong></p>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables and accrued expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">58</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">53</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts charged to:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">141</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">147</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">194</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712513392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted losses per share</a></td>
<td class="text">
            <div>
              <div>
                <div>
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for basic and diluted loss per share</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(14,231</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(18,754</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(33,694</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">89,528,031</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87,633,298</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">86,555,628</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.16</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.21</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.39</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282714264544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 05, 2013</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,231)<span></span>
</td>
<td class="num">$ (18,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33,694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(488,758)<span></span>
</td>
<td class="num">(474,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,604<span></span>
</td>
<td class="num">$ (35,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (34,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NonRefundableUpfrontPayment', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MilestonePaymentReceivable', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram', window );">Potential milestone compensation company is now eligible for</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 758,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable', window );">Preclinical milestone compensation</a></td>
<td class="nump">$ 23,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue', window );">Amount of investment in Compugen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payment received</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AccruedMilestonePayment', window );">Accrued milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Potential milestone compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfExpectedFromPaymentAmountPaid', window );">Percentage of expected from payment amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AccruedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AccruedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-refundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfExpectedFromPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of expected from payment amount paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfExpectedFromPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone compensation company is now eligible for.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount on the investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 10<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480679/815-10-10-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 10<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480769/815-20-10-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282714412560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Nov. 11, 2022</div></th>
<th class="th"><div>Aug. 05, 2013</div></th>
<th class="th"><div>May 30, 2024</div></th>
<th class="th"><div>Dec. 27, 2023</div></th>
<th class="th"><div>Sep. 29, 2021</div></th>
<th class="th"><div>Dec. 18, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShortTermBankDepositsWeightedAverageRateForeign', window );">Average interest rate, short-term bank deposits in U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.51%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognition under milestone method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,864<span></span>
</td>
<td class="nump">36,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_TotalRemainingPerformanceObligations', window );">Total transaction price allocated to remaining performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RemainingPerformanceObligationsRecognizedPercentage', window );">Percentage of total remaining performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Potential milestone compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AccruedMilestonePayments', window );">Accrued milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_LicenseRevenue', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,864<span></span>
</td>
<td class="nump">$ 23,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredRevenuesIncludedInCurrentLiabilities', window );">Deferred revenues included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities', window );">Deferred revenues included in non current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MilestonePaymentReceivable', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,496,655<span></span>
</td>
<td class="nump">7,921,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,405,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember', window );">Master Clinical Agreement One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredParticipationOfBMSInRAndDExpenses', window );">Deferred participation of BMS in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember', window );">Master Clinical Agreement Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredParticipationOfBMSInRAndDExpenses', window );">Deferred participation of BMS in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_LicenseAgreementWithGileadMember', window );">License Agreement With Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payment received</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Potential milestone compensation</a></td>
<td class="nump">758,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 758,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MilestonePaymentReceivable', window );">Milestone payment</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AccruedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AccruedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredParticipationOfBMSInRAndDExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred participation of BMS in R and D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredParticipationOfBMSInRAndDExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredRevenuesIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenues included in current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredRevenuesIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenues included in non current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredRevenuesIncludedInNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_LicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_LicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RemainingPerformanceObligationsRecognizedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the total remaining performance obligations expected to be recognized as revenue within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RemainingPerformanceObligationsRecognizedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermBankDepositsWeightedAverageRateForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average interest rate for short-term bank deposits outside of the domestic currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermBankDepositsWeightedAverageRateForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_TotalRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total transaction price allocated to remaining performance obligations yet to be recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_TotalRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_LicenseAgreementWithGileadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_LicenseAgreementWithGileadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282715103648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers, software and related equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRateDescription', window );">Annual depreciation rate</a></td>
<td class="text">Shorter of the term of the lease or useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AnnualDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Depreciation Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AnnualDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AnnualDepreciationRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Depreciation Rates, Description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AnnualDepreciationRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713297392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">90.45%<span></span>
</td>
<td class="nump">75.93%<span></span>
</td>
<td class="nump">69.44%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.47%<span></span>
</td>
<td class="nump">3.37%<span></span>
</td>
<td class="nump">1.54%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">4 years 7 days<span></span>
</td>
<td class="text">4 years 7 days<span></span>
</td>
<td class="text">5 years 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">95.88%<span></span>
</td>
<td class="nump">80.95%<span></span>
</td>
<td class="nump">74.61%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.54%<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
<td class="nump">4.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">4 years 11 months 19 days<span></span>
</td>
<td class="text">5 years 21 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">69.74%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713911376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of available-for-sale marketable securities</a></td>
<td class="nump">$ 53,230<span></span>
</td>
<td class="nump">$ 10,145<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713093664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Schedule of available-for-sale marketable securities) (Details) - U.S. Treasury [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 23,618<span></span>
</td>
<td class="nump">$ 11,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 23,629<span></span>
</td>
<td class="nump">$ 11,742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount lower than $1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282716717056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Schedule of gross unrealized losses and fair values on investments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue', window );">Available-for-Sale Securities, fair value, less than 12 months</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 992<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses', window );">Available-for-Sale Securities, gross unrealized losses, less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue', window );">Available-for-Sale Securities, fair value, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses', window );">Available-for-Sale Securities, gross unrealized losses, less than 12 months</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount lower than $1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of available for sale securities, continuous unrealized loss position, greater than 12 Months, fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of available for sale securities, continuous unrealized loss position, greater than 12 Months, gross unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of available for sale securities, continuous unrealized loss position, less than 12 Months, fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of available for sale securities, continuous unrealized loss position, less than 12 Months, gross unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282714159200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in marketable securities</a></td>
<td class="nump">$ 13,919<span></span>
</td>
<td class="nump">$ 3,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | U.S. Treasury [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in marketable securities</a></td>
<td class="nump">$ 23,629<span></span>
</td>
<td class="nump">$ 11,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799503600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Schedule Of Other Accounts Receivable And Prepaid Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 2,473<span></span>
</td>
<td class="nump">$ 2,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses</a></td>
<td class="nump">$ 2,742<span></span>
</td>
<td class="nump">$ 2,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Authorities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282718761360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expenses</a></td>
<td class="nump">$ 775<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeasePayment', window );">Variable payments as CPI</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="nump">$ 761<span></span>
</td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">$ 959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for variable lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799459552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">6 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount (annual) rate</a></td>
<td class="nump">7.96%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282715498704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Schedule of Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028 and on</a></td>
<td class="nump">1,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">3,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(696)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">2,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">$ 632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, non- current</a></td>
<td class="nump">2,464<span></span>
</td>
<td class="nump">$ 719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712608400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="nump">$ 6,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">5,748<span></span>
</td>
<td class="nump">5,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="nump">$ 482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Sale of equipment,cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gains from the sale of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Sale of equipment,cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Accumulated depreciation equipment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gains from the sale of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember', window );">Obsolete property and equipment and certain nonfunctional Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">1,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713293456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="nump">$ 6,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">5,748<span></span>
</td>
<td class="nump">5,356<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Depreciated cost</a></td>
<td class="nump">852<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers, software and related equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">3,567<span></span>
</td>
<td class="nump">3,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">3,059<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">2,314<span></span>
</td>
<td class="nump">2,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 2,067<span></span>
</td>
<td class="nump">$ 1,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712817440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</a></td>
<td class="nump">$ 342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentExpensesMilestonePayment', window );">Research and development expenses milestone payment</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember', window );">IIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived', window );">Maximum royalty repaid as percentage of grant received</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 554<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyContingentObligations', window );">Contingent royalty obligations</a></td>
<td class="nump">$ 9,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember', window );">IIA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember', window );">IIA [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember', window );">May 2012 Agreement Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AgreementStartDate', window );">Agreement, start date</a></td>
<td class="text">May  09,  2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AgreementTerminationDescription', window );">Agreement termination description</a></td>
<td class="text">In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember', window );">May 2012 Agreement Member | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ParticipationRights', window );">Participation Rights</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_AntibodiesDiscoveryCollaborationAgreementMember', window );">Antibodies Discovery Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ContingentFees', window );">Contingent fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_GileadAgreementMember', window );">Gilead Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Royalties accrual</a></td>
<td class="nump">$ 704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement start date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ContingentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ContingentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Royalty Repaid As Percentage Of Grant Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ParticipationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ParticipationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentExpensesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentExpensesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyContingentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyContingentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyPercentageBasedOnFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Percentage Based On Future Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyPercentageBasedOnFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_AntibodiesDiscoveryCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_AntibodiesDiscoveryCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_GileadAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_GileadAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282716748128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY  (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 10, 2018</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cgen_EmployeesDirectorsAndNonEmployeesMember', window );">Employees Directors And Non Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value of exercised options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Ordinary shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InitialOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">five months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares', window );">Percentage of use of base salary to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering', window );">Percentage of fair market value of ordinary shares at time of offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">158,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgen_TwoThousandTenShareOptionsPlanMember', window );">2010 Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Ordinary shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,195,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">891,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementMember', window );">Master Clinical Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.57333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares</a></td>
<td class="nump">2,424,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,332,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity investment</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfClosingPrice', window );">Percentage of closing price</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsMember', window );">Collaborative Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Maximum Authorized Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredParticipationOfBMSInRAndDExpenses', window );">Deferred Participation Of B M S In R And D Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsTwoMember', window );">Collaborative Arrangements Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Maximum Authorized Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredParticipationOfBMSInRAndDExpenses', window );">Deferred Participation Of B M S In R And D Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_LeerinkPartnersLlcMember', window );">Leerink Partners LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,905,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from ordinary shares in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredParticipationOfBMSInRAndDExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred participation of BMS in R and D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredParticipationOfBMSInRAndDExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Authorized Proceeds From Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of closing price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair market value of ordinary shares at time of offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of use of base salary to purchase ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the time period when the company made its initial offering of a class of securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cgen_EmployeesDirectorsAndNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cgen_EmployeesDirectorsAndNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgen_TwoThousandTenShareOptionsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgen_TwoThousandTenShareOptionsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_MasterClinicalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_CollaborativeArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_CollaborativeArrangementsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_LeerinkPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_LeerinkPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713718960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule Of Share Option Plan) (Details) - Employees Directors And Non Employees [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of year</a></td>
<td class="nump">8,373,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">1,027,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(11,053)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options forfeited</a></td>
<td class="num">(495,781)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options expired</a></td>
<td class="num">(238,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of year</a></td>
<td class="nump">8,655,721<span></span>
</td>
<td class="nump">8,373,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
<td class="nump">5,920,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of year</a></td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="nump">0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited</a></td>
<td class="nump">3.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options expired</a></td>
<td class="nump">7.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at end of year</a></td>
<td class="nump">4.31<span></span>
</td>
<td class="nump">$ 4.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
<td class="nump">$ 5.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options outstanding</a></td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">6 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable at end of year</a></td>
<td class="text">4 years 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at end of year</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="nump">$ 1,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of year</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cgen_EmployeesDirectorsAndNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cgen_EmployeesDirectorsAndNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713999904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule Of RSUs Activity) (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at beginning of year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted</a></td>
<td class="nump">319,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited</a></td>
<td class="num">(1,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at end of year</a></td>
<td class="nump">317,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date per value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted | &#8362; / shares</a></td>
<td class="nump">&#8362; 1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs forfeited | &#8362; / shares</a></td>
<td class="nump">1.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs outstanding at end of year | &#8362; / shares</a></td>
<td class="nump">&#8362; 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713907568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule Of Stock-Based Compensation Expenses) (Details) - Employee Stock Purchase Plan [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 3,023<span></span>
</td>
<td class="nump">$ 3,550<span></span>
</td>
<td class="nump">$ 4,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
<td class="nump">2,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Marketing and business development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">115<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 1,448<span></span>
</td>
<td class="nump">$ 1,658<span></span>
</td>
<td class="nump">$ 1,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713034080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME, NET (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Israeli corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ReducedTaxRate', window );">Reduced tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NetOperatingLossCarryforwardExpired', window );">Net operating loss carryforward, Expired</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">United States [Member] | Subsidiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NetOperatingLossCarryforwardExpired', window );">Net operating loss carryforward, Expired</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 413,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NetOperatingLossCarryforwardExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforward, Expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NetOperatingLossCarryforwardExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ReducedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduced tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ReducedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282799470016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME, NET (Schedule of Loss (Income) Before Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic (Israel)</a></td>
<td class="nump">$ 10,129<span></span>
</td>
<td class="nump">$ 10,164<span></span>
</td>
<td class="nump">$ 34,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(420)<span></span>
</td>
<td class="num">(380)<span></span>
</td>
<td class="num">(460)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="nump">$ 9,709<span></span>
</td>
<td class="nump">$ 9,784<span></span>
</td>
<td class="nump">$ 33,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713685856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>TAXES ON INCOME, NET (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">$ 95,485<span></span>
</td>
<td class="nump">$ 92,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development</a></td>
<td class="nump">11,779<span></span>
</td>
<td class="nump">12,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued social benefits and other</a></td>
<td class="nump">2,535<span></span>
</td>
<td class="nump">3,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredIncomeTaxLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">670<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset before valuation allowance</a></td>
<td class="nump">110,469<span></span>
</td>
<td class="nump">108,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(109,814)<span></span>
</td>
<td class="num">(108,073)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset after valuation allowance</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredIncomeTaxRightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(655)<span></span>
</td>
<td class="num">(307)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(655)<span></span>
</td>
<td class="num">(307)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredIncomeTaxLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax lease liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredIncomeTaxLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredIncomeTaxRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax Right of use assets attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredIncomeTaxRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset (liabilities) for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282715487744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282718507648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Financial Information With Respect To Single Operating Segment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 27,864<span></span>
</td>
<td class="nump">$ 33,459<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial income, net</a></td>
<td class="num">(5,182)<span></span>
</td>
<td class="num">(3,208)<span></span>
</td>
<td class="num">(1,738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="nump">4,522<span></span>
</td>
<td class="nump">8,970<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,231)<span></span>
</td>
<td class="num">(18,754)<span></span>
</td>
<td class="num">(33,694)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cgen_SingleOperatingSegmentMember', window );">Single Operating Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">27,864<span></span>
</td>
<td class="nump">33,459<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment', window );">Preclinical R&amp;D expenses</a></td>
<td class="nump">15,374<span></span>
</td>
<td class="nump">20,948<span></span>
</td>
<td class="nump">17,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment', window );">Clinical R&amp;D expenses</a></td>
<td class="nump">15,267<span></span>
</td>
<td class="nump">10,627<span></span>
</td>
<td class="nump">11,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SG&amp;A</a></td>
<td class="nump">9,485<span></span>
</td>
<td class="nump">9,320<span></span>
</td>
<td class="nump">9,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial income, net</a></td>
<td class="num">(5,182)<span></span>
</td>
<td class="num">(3,215)<span></span>
</td>
<td class="num">(1,738)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="nump">4,522<span></span>
</td>
<td class="nump">8,970<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_OtherSegmentExpenses', window );">Other segment expenses</a></td>
<td class="nump">2,629<span></span>
</td>
<td class="nump">5,563<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,231)<span></span>
</td>
<td class="num">$ (18,754)<span></span>
</td>
<td class="num">$ (33,694)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ClinicalAmountOfExpenseForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ClinicalAmountOfExpenseForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Income (Expense), Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_OtherSegmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other segment expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_OtherSegmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cgen_SingleOperatingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cgen_SingleOperatingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712501616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Total Revenues And Long-Lived Assets By Geographic Area) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from sales to customers</a></td>
<td class="nump">$ 27,864<span></span>
</td>
<td class="nump">$ 33,459<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">3,695<span></span>
</td>
<td class="nump">2,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeographicAreaAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from sales to customers</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeographicAreaAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">3,677<span></span>
</td>
<td class="nump">2,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeographicAreaAxis=country_US', window );">Unites States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from sales to customers</a></td>
<td class="nump">22,864<span></span>
</td>
<td class="nump">23,459<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeographicAreaAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeographicAreaAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeographicAreaAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeographicAreaAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeographicAreaAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeographicAreaAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282716693456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Sales To Single Customer Exceeding 10%) (Details) - Revenue [Member] - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Sales to a single customer exceeding 10%</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Sales to a single customer exceeding 10%</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cgen_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cgen_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cgen_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cgen_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282715490800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 3,489<span></span>
</td>
<td class="nump">$ 2,960<span></span>
</td>
<td class="nump">$ 1,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfDiscount', window );">Amortization of discount on marketable securities, net</a></td>
<td class="nump">1,747<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Bank fees and other finance expenses</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction adjustments</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain (loss) from sales and disposals of fixed assets</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">$ 5,182<span></span>
</td>
<td class="nump">$ 3,208<span></span>
</td>
<td class="nump">$ 1,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Income (Expense), Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of purchase discount on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282713090848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Schedule of Related Party Transactions) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Trade payables and accrued expenses</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Amounts charged to research and development expenses</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712748752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for basic and diluted loss per share</a></td>
<td class="num">$ (14,231)<span></span>
</td>
<td class="num">$ (18,754)<span></span>
</td>
<td class="num">$ (33,694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share</a></td>
<td class="nump">89,528,031<span></span>
</td>
<td class="nump">87,633,298<span></span>
</td>
<td class="nump">86,555,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">89,528,031<span></span>
</td>
<td class="nump">87,633,298<span></span>
</td>
<td class="nump">86,555,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per ordinary share</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45282712424784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Narrative) (Details) - ATM [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold in transaction | shares</a></td>
<td class="nump">3,961,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 8,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="nump">$ 274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Authorized Proceeds From Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgen_OrdinarySharesIssuedAndSoldThroughAtmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgen_OrdinarySharesIssuedAndSoldThroughAtmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIQ+MU,]4#?>/=^K3XN7A9>YIQB8\_AZ%<G7>&79(R!YH'LM;OOW$JA?J*[V
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MUQTUYYD$2_TK6A_\:@V*_>&P/_1.,3IM$PX>V^\B"2&8/Q#;^?W^#[)@02X
MMY$*5[H1,+N@=*UJD".RAA1X0^,<(OQL0:QCRR9K)LJ?,79M(@X>_R$5*";T
MXCFYYW$CLJ&:^'AYC9%H[W#PD*^<0G7BY5.PHND2CE.R747!JNY0$F65M3#Q
MNNZK6 V/\!<7_I\8K?83IY6?@$\EA9'PX/$($A@U:N0FES ]4]6OC9"ELE<H
MJS6-S6AXVO=LQQN<]39-5-I$G%8F\AWRJ.YC"E$$^HYF/&4AF659WIPA&#2O
M.=9AVCF<5L[QC<<02]045WF+:*RB#$HXD#8(IY5![*KA,MTL/@7("IK+.X/B
M#WS50-N"V\H69LJURS4EE772'6KC\@&N:"#3ON"V\H5BZ,@$DJ<E;[8%@XX?
M! PD0" LQ3 Z[1)N*Y>X3)A8JH'\" IRM2LH&C%_K9)P]U:"\,#NYV$DP=E]
M*1G$AB+[/%0Y&Z0,Y:"K0[^+1VY=H :!,OAJ[J<A%8W!U2#W]7AQ3#[Z_AR#
MTV[@MJHD7I2$C5"XC'$$=<!W\8"_&\%#!8VA^>>;Q1V9WMQ>WD(?C<?^#_*.
M)NL/Y+._F%W"58Q1AW_7D/!7C%<\.+BV:I"X8W'7WT2;(S ,05F,<>G8[QI6
MBRJN:202,FN>7+B"[0RQ)4971WVWY8+1%!*M-(@@BZQ7B\BE$$ YX1!FRQ7]
MG^H;_;N1]]>6D3QM!AX>NL=Y!E>*)!Q\,Y#DYQ>F:OU&*EQ+[;^\S]8T8.>=
M-20J3&Q89_3N-WM@?<!8M3UX>%C?(<[!V'F:LOC@UV(0NJ";*"2+*(8732A6
MTWC:';RWU1!M"FR#9.L"V]-&X;7:,WA3@6V0?%.![>WM(K1:?GIC@6T0;55@
M>]I%O%8NTKK -LB9"FQ/NXG7JGQH46 ;A- "V]/.X;UM]:E%@6U0-!?8GO8/
M#X_^Q;#Y@M'#,+C Z0FVONEI]_#PL*Z,-2;S%514R)*K0<3MG@SZ7>B=/K9I
MI@VBCQO$_X/NE#XA= 8YZ*KNCK#?2-C;VPM6J7:QXYV1(H<LMX7KJ_6NNE_N
M)>O;RRWY+U1EZAF)V0,TM8Y/X/L3Y2YW>2+YNMA9ON=2\J0X7#$:,J%N@-\?
M.)>[$_6 ^O\:C/X#4$L#!!0    ( - [9%J1T#:Y^@8  -4=   8    >&PO
M=V]R:W-H965T<R]S:&5E=#(N>&ULK5EM<^(V$/XK&N[FVLXDP9+\FDN8X0AM
MF$D@#:2=?E2,")XS%B?+Y-)?7\D0;"Q9(9U\N(N-5^MG)>WS[%H7SXQ_SY>4
M"O!SE6;Y96<IQ/J\V\WC)5V1_(RM:2:?+!A?$2%O^5,W7W-*YN6@5=I%CN-W
M5R3).KV+\K<[WKM@A4B3C-YQD!>K%>$OWVC*GB\[L//ZPWWRM!3JAV[O8DV>
MZ)2*A_4=EW?=O9=YLJ)9GK ,<+JX[/3A^0 ':D!I\5="G_/:-5"A/#+V7=V,
MYI<=1R&B*8V%<D'DGPT=T#15GB2.'SNGG?T[U<#Z]:OWW\O@93"/)*<#EOZ=
MS,7RLA-VP)PN2)&*>_9\37<!><I?S-*\_!\\[VR=#HB+7+#5;K!$L$JR[5_R
M<S<1M0'0;1F =@/0L0/P;@ N ]TB*\.Z(H+T+CA[!EQ92V_JHIR;<K2,)LG4
M,DX%ET\3.4[T!I/Q='(SNNK/AE?@6_^F/QX,P?1Z.)Q-P2EXF%Z!7S__!CZ#
M) .S)2MRDLWSBZZ0;U;CN_'N+=^V;T$M;[FB\1G \ 0@![F&X8/CA^/#X5T9
M[SYHM \:E?Z\MJ ?[N^'XQGH3Z<RSG-3/%L'V.Q Y=9YOB8QO>S(Y,DIW]!.
M[\LGZ#M?3=%]D+.#6/$^5FSSWAN0? GDJH%87= ?1;(A*<V$<16WKOS2E2*
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M&@#O5YRKYQO]@>94>?(?4$L#!!0    ( - [9%H;<5"&FP8  $HF   8
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M=,-/.A$6EE[ \Z5!SY4N:(/NX^3Y?P%02P,$%     @ T#MD6NY#K<K@)@
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M<L3W(\T' !VG#!9E79<;^G.M0)-5. !^7Y9 4O(!%\ ;5@3>J_\%4$L#!!0
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M%Y_$Z^#-\GBI?B7=DA*4J06V#GK'XXYP\:(Z/@1;\.7PW(9@<_ZYPAE*.5J
M[PMK0_U "IK_+3C_-U!+ P04    " #0.V1:Z6BT/"L.   X*   &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6S-6EESV\@1?L>OF%*<C50%00!(2J1\
M5,G'9C>UMA3+3BJ5RL,0&)*S!C!<'**57Y^O>P8'+]F5S4,>1)' 3$^?7Q_
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MOU9GQ AS!'_Z2P,+6C?!T;I CTJ9C9NXAOVH[_3E@]09AT>S+2L1"\0-:^J
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M?GK@1K3A1U5N^!O?15E59<Z7:R1Z9>@%/%^6915^T ;-1]_O_@]02P,$%
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M\,6S^$W[W9FDNX>DN^?0_V=>YX&G=\L)Q)W>Z^ ?0P0T#Q0KU&XF@9N)$YV
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M.P,Z7RME'Q47X/"C&OX&4$L#!!0    ( - [9%H<'A-QZ@(  %@&   9
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MS9Z?;A F+4*T!R&,X$)PG2N8\@RSEP ^T=EQBK:<)M%!Q#-,.Q"''D1!U#V
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M4[71)"[CYE(66M)J1G$Z6CQ.%M/OC].[!Y@^4;L(74U8L^C&.\2D1@1'$'X
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M.[3]# U?PG-IGZAN8H=#!R655+QHP;J"@K+F39[;.>P W-$!@-<"O+> X #
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M/]4RVZCB*TVCT?=$K"F3*(>5IAQ<7>O+)AK=:PS%2ZL$2ZZTKMAEIG\5($R
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M"HT"T"39?H@8+RPQ7@S2QK7'SP Q+YN,":UBP6L7Q0V/NIJ,'C/P2Y^YG2X
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MA@<S&?F(EK";23M3M$U[\N=0]$D(W]^>H_2Y1'>P9*FTSO7/M^/I8CXS@_P
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M^'U5  O(!YP #\X2>*__%U!+ P04    " #0.V1:G'AN"Y8#  #3!P  &0
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MI((T#GB?"J&/&Q.@&=+1'U!+ P04    " #0.V1:APY>$Z\"  "5!0  &0
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MGL+)EPC"NQG$\R@.;V80?8NCNT6T@/</=)FC_##RE"8W$%ZR(YHT1.05(I_
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M[9X-]8\EFB'0;!2O;.,MN=)M;,U,STT4QD'?KSA7^XTA:"=Q\ =02P,$%
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M@- !^#[E7!T<?4#W3XG^ 5!+ P04    " #0.V1:\4[($0T$  !]"0  &0
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M/ZC9:-I8,F4QJ9\$:18'[VFN0:=2QAQ!J54-AE>M8V*^5B2:IA8/E"!N#!+
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MI#F56XS58N L40B5:6XI,GC!P5+AF-"G-$$WL/;.V$]=<N["O9.N*0'AS6Q
M*L/8-%"[VXZ?N.FZ?^'-['I$=04^%P8;3/5O[O"IR68>-(X6E>W!1&CL:+O,
M<82"- %XOA%"'QU#T [EZ"]02P,$%     @ T#MD6C#2TS+5 @  '08  !D
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MGF3Q.Y$]T;;5:-MZC3V:")X@IA*6@A>ZE=1.3+X$LM%?.EGD>*$-]4*2''6
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M#/'^ ](8X/>Y$'HS,0'R&Y7_!U!+ P04    " #0.V1:]2TJZ+\"  #K"
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M8S;R0U2T  NM^MZTU 7$K0MVL7@!2E.I(:*Z5AW\!XX-;O#Z%Y"'>.TK6"?
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M7?IL=Z9_-E"8#7I]PKE:#PQ!^?L2_0%02P,$%     @ T#MD6K2;ZAOM P
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MM]M"/S<HC(.^7W.N#H8)T#Q@T5]02P,$%     @ T#MD6E?O$(*8!   ;Q(
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M$2>KN?7@WJ=3%:\#_J[(3AR,D6+RRM@W-?FCF%N..A"I22X5 H:_+7DD=:V
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M-[!O>K"12IZ49;G0L4T$\SDIA^\ FQX(9)Q7 KNN,8P&!9&2BNQ*=?1@;7P
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M^1.5/)XF>1H(TFRZ[WE,JUE>WQ[S?":/^<6J3++3A[6GCX(O_P902P,$%
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M?GR6G6WZMWPV_B-N\0)02P$"% ,4    " #0.V1:!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( - [
M9%H/O!:.[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( - [9%J97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ T#MD6C+=[O;G
M!@  =R   !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( - [9%J1T#:Y^@8  -4=   8              "
M@2H/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #0.V1:
M%^/=99@"   ]!P  &               @(%:%@  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ T#MD6M 6XTFA!0  818  !@
M     ("!*!D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M - [9%H;<5"&FP8  $HF   8              " @?\>  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " #0.V1:0&5'6%@)  "?+@  &
M            @('0)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ T#MD6A32:]]F"P  J!P  !@              ("!7B\  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( - [9%KN0ZW*X"8  ..!
M   8              " @?HZ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " #0.V1:P' ++54$  !C"P  &               @($08@
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ T#MD6MLB[GZ^
M P  -@@  !D              ("!FV8  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " #0.V1:'9:XV)D"  "X!0  &0
M@(&0:@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( - [
M9%JG:IOX2@8  *0/   9              " @6!M  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ T#MD6HE+X$./ P  50@  !D
M         ("!X7,  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " #0.V1:<2=K3F()   Y&   &0              @(&G=P  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( - [9%KI:+0\*PX  #@H
M   9              " @4"!  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ T#MD6M]*.E]1$0   "X  !D              ("!HH\
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #0.V1:88!1
MXE<&  "D#@  &0              @($JH0  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( - [9%J+J$>N#0,  &@&   9
M  " @;BG  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MT#MD6@K$RLL/ P  M 8  !D              ("!_*H  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " #0.V1:'!X3<>H"  !8!@  &0
M            @(%"K@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( - [9%JH/\+=3@(  /\$   9              " @6.Q  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ T#MD6@)_0<MC @
MB 8  !D              ("!Z+,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " #0.V1: K!<GA$"  #=!   &0              @(&"
MM@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( - [9%J7
MUZQ1C H  -4O   9              " @<JX  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ T#MD6D*C7%@%*   0(P  !D
M     ("!C<,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M" #0.V1:G'AN"Y8#  #3!P  &0              @(')ZP  >&PO=V]R:W-H
M965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( - [9%H3G2<0(P,  +('   9
M              " @9;O  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!
M A0#%     @ T#MD6F0D!Z"G @  L 4  !D              ("!\/(  'AL
M+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #0.V1:APY>$Z\"
M  "5!0  &0              @('.]0  >&PO=V]R:W-H965T<R]S:&5E=#(Y
M+GAM;%!+ 0(4 Q0    ( - [9%J"8-#N[0(  /4&   9              "
M@;3X  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ T#MD
M6L:)?M;C @  7P8  !D              ("!V/L  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " #0.V1:\4[($0T$  !]"0  &0
M        @('R_@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( - [9%K!<@EHB0,   X(   9              " @38# 0!X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ T#MD6GR\OIL@!   E D
M !D              ("!]@8! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " #0.V1:"52>G0\#  !3!@  &0              @(%-"P$
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( - [9%IMB30;
MG@(  * %   9              " @9,. 0!X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ T#MD6C#2TS+5 @  '08  !D
M ("!:!$! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #0
M.V1:*;M+_7P%  !?)   &0              @(%T% $ >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( - [9%JV!UY9>@D  %ED   9
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M970T,RYX;6Q02P$"% ,4    " #0.V1:6TJ>CA4#  !="0  &0
M    @(&N,@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M - [9%KU+2KHOP(  .L(   9              " @?HU 0!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ T#MD6DVT5)OD @  ; <  !D
M             ("!\#@! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " #0.V1:'(IG->L"   Y"   &0              @($+/ $ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( - [9%H9)&Y!1P(
M /H$   9              " @2T_ 0!X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ T#MD6@L3H"(Y P  _PL  !D              ("!
MJT$! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #0.V1:
M8W1SOR($  !)%   &0              @($;10$ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( - [9%K6F%ZQR0,  %P0   9
M      " @71) 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ T#MD6H$TA1-(!@  XB8  !D              ("!=$T! 'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #0.V1:*%XXD+$)  !C6P
M&0              @('S4P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+
M 0(4 Q0    ( - [9%H@]'C+V00  .P6   9              " @=M= 0!X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ T#MD6@9Q\>P&
M P  R@@  !D              ("!ZV(! 'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"% ,4    " #0.V1:M)OJ&^T#   6$@  &0
M@($H9@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( - [
M9%J3Q^,$4P,  +X-   9              " @4QJ 0!X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L! A0#%     @ T#MD6H9BU8#K @  .0@  !D
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M=#8R+GAM;%!+ 0(4 Q0    ( - [9%I^'E3S.P,  /,+   9
M  " @6^  0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @
MT#MD6B$[0?.K P  _@H  !D              ("!X8,! 'AL+W=O<FMS:&5E
M=',O<VAE970V-"YX;6Q02P$"% ,4    " #0.V1:TREX;=D"  #@!P  &0
M            @('#AP$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4
M Q0    ( - [9%JX(5]A=@,  .(+   9              " @=.* 0!X;"]W
M;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ T#MD6@>5>S>E @
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M2P$"% ,4    " #0.V1:R%S!4B "  #0)P  &@              @ %ZFP$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #0.V1:XB$R
M0O$!   9)P  $P              @ '2G0$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     2P!+ (04  #TGP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>156</ContextCount>
  <ElementCount>348</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-daei1</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cbsp</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-csocl</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/StatementsOfChangesInShareholdersEquity</Role>
      <ShortName>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-g</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sap</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/MARKETABLESECURITIES</Role>
      <ShortName>MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oarape</Role>
      <ShortName>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-paen</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cac1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-se12</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - TAXES ON INCOME, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-it</Role>
      <ShortName>TAXES ON INCOME, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-giamc</Role>
      <ShortName>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - FINANCIAL AND OTHER INCOME, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-faoin</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-rpbat</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - LOSSES PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-lps</Role>
      <ShortName>LOSSES PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9960701 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapp</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9960702 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapt</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sap</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9960703 - Disclosure - MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/MARKETABLESECURITIESTables</Role>
      <ShortName>MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/MARKETABLESECURITIES</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9960704 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9960705 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oarapet</Role>
      <ShortName>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oarape</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9960706 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9960707 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-paent</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-paen</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9960708 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-set1</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-se12</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9960709 - Disclosure - TAXES ON INCOME, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-itt</Role>
      <ShortName>TAXES ON INCOME, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-it</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9960710 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-giamct</Role>
      <ShortName>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-giamc</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9960711 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-faoint</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-faoin</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9960712 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-rpbat</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9960713 - Disclosure - LOSSES PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-lpst</Role>
      <ShortName>LOSSES PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-lps</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9960714 - Disclosure - GENERAL (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-gd</Role>
      <ShortName>GENERAL (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-g</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9960715 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapnd</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sapt</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9960716 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapsodrfpaed</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sapt</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9960717 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sapt</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9960718 - Disclosure - MARKETABLE SECURITIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/MARKETABLESECURITIESNarrativeDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/MARKETABLESECURITIESTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9960719 - Disclosure - MARKETABLE SECURITIES (Schedule of available-for-sale marketable securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/MARKETABLESECURITIESDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Schedule of available-for-sale marketable securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/MARKETABLESECURITIESTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9960720 - Disclosure - MARKETABLE SECURITIES (Schedule of gross unrealized losses and fair values on investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Schedule of gross unrealized losses and fair values on investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/MARKETABLESECURITIESTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9960721 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9960722 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Schedule Of Other Accounts Receivable And Prepaid Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oaraped</Role>
      <ShortName>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Schedule Of Other Accounts Receivable And Prepaid Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oarapet</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9960723 - Disclosure - LEASES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LEASESNarrative</Role>
      <ShortName>LEASES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/LeasesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9960724 - Disclosure - LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails</Role>
      <ShortName>LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/LeasesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9960725 - Disclosure - LEASES (Schedule of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails</Role>
      <ShortName>LEASES (Schedule of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/LeasesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9960726 - Disclosure - PROPERTY AND EQUIPMENT, NET (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-paent</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9960727 - Disclosure - PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-paend</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-paent</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9960728 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-cac1</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9960729 - Disclosure - SHAREHOLDERS' EQUITY  (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sesopnd</Role>
      <ShortName>SHAREHOLDERS' EQUITY  (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9960730 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Share Option Plan) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule Of Share Option Plan) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9960731 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of RSUs Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule Of RSUs Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9960732 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock-Based Compensation Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sesosced</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule Of Stock-Based Compensation Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9960733 - Disclosure - TAXES ON INCOME, NET (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>TAXES ON INCOME, NET (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9960734 - Disclosure - TAXES ON INCOME, NET (Schedule of Loss (Income) Before Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails</Role>
      <ShortName>TAXES ON INCOME, NET (Schedule of Loss (Income) Before Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9960735 - Disclosure - TAXES ON INCOME, NET (Schedule of Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>TAXES ON INCOME, NET (Schedule of Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9960736 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails</Role>
      <ShortName>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-giamct</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9960737 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Financial Information With Respect To Single Operating Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails</Role>
      <ShortName>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Financial Information With Respect To Single Operating Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-giamct</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9960738 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Total Revenues And Long-Lived Assets By Geographic Area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/GeographicInformationAndMajorCustomersDetails</Role>
      <ShortName>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Total Revenues And Long-Lived Assets By Geographic Area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-giamct</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9960739 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Sales To Single Customer Exceeding 10%) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details</Role>
      <ShortName>SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Sales To Single Customer Exceeding 10%) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-giamct</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9960740 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-faoint</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9960741 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Schedule of Related Party Transactions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Schedule of Related Party Transactions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9960742 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails</Role>
      <ShortName>LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-lpst</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="zk2532769.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9960743 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SubsequentEventsNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cgen-20241231.xsd</File>
    <File>cgen-20241231_cal.xml</File>
    <File>cgen-20241231_def.xml</File>
    <File>cgen-20241231_lab.xml</File>
    <File>cgen-20241231_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="zk2532769.htm">zk2532769.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="606">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="47">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zk2532769.htm": {
   "nsprefix": "cgen",
   "nsuri": "http://cgen.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "cgen-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/ebp/elts/us-gaap-ebp-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cgen-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cgen-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cgen-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cgen-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2532769.htm"
     ]
    }
   },
   "keyStandard": 280,
   "keyCustom": 68,
   "axisStandard": 19,
   "axisCustom": 2,
   "memberStandard": 29,
   "memberCustom": 20,
   "hidden": {
    "total": 6,
    "http://cgen.com/20241231": 1,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://fasb.org/us-gaap/2024": 2
   },
   "contextCount": 156,
   "entityCount": 1,
   "segmentCount": 49,
   "elementCount": 664,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 606,
    "http://xbrl.sec.gov/dei/2024": 47,
    "http://xbrl.sec.gov/cyd/2024": 16,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://cgen.com/role/cgen-daei1",
     "longName": "0001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "dei:CurrentFiscalYearEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "dei:DocumentPeriodEndDate",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "dei:CurrentFiscalYearEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "dei:DocumentPeriodEndDate",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cgen.com/role/ConsolidatedBalanceSheets",
     "longName": "0002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cgen.com/role/cgen-cbsp",
     "longName": "0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "NIS_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "NIS_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://cgen.com/role/cgen-csocl",
     "longName": "0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
     "longName": "0005 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "shortName": "STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://cgen.com/role/cgen-g",
     "longName": "0007 - Disclosure - GENERAL",
     "shortName": "GENERAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cgen.com/role/cgen-sap",
     "longName": "0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cgen.com/role/MARKETABLESECURITIES",
     "longName": "0009 - Disclosure - MARKETABLE SECURITIES",
     "shortName": "MARKETABLE SECURITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cgen.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "0010 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cgen.com/role/cgen-oarape",
     "longName": "0011 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES",
     "shortName": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cgen.com/role/Leases",
     "longName": "0012 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cgen.com/role/cgen-paen",
     "longName": "0013 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cgen.com/role/cgen-cac1",
     "longName": "0014 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cgen.com/role/cgen-se12",
     "longName": "0015 - Disclosure - SHAREHOLDERS' EQUITY",
     "shortName": "SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cgen.com/role/cgen-it",
     "longName": "0016 - Disclosure - TAXES ON INCOME, NET",
     "shortName": "TAXES ON INCOME, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cgen.com/role/cgen-giamc",
     "longName": "0017 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA",
     "shortName": "SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cgen.com/role/cgen-faoin",
     "longName": "0018 - Disclosure - FINANCIAL AND OTHER INCOME, NET",
     "shortName": "FINANCIAL AND OTHER INCOME, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cgen.com/role/cgen-rpbat",
     "longName": "0019 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cgen.com/role/cgen-lps",
     "longName": "0020 - Disclosure - LOSSES PER SHARE",
     "shortName": "LOSSES PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cgen.com/role/SUBSEQUENTEVENTS",
     "longName": "0021 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cgen.com/role/cgen-sapp",
     "longName": "9960701 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cgen.com/role/cgen-sapt",
     "longName": "9960702 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cgen.com/role/MARKETABLESECURITIESTables",
     "longName": "9960703 - Disclosure - MARKETABLE SECURITIES (Tables)",
     "shortName": "MARKETABLE SECURITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cgen.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "9960704 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cgen.com/role/cgen-oarapet",
     "longName": "9960705 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)",
     "shortName": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cgen.com/role/LeasesTables",
     "longName": "9960706 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cgen.com/role/cgen-paent",
     "longName": "9960707 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cgen.com/role/cgen-set1",
     "longName": "9960708 - Disclosure - SHAREHOLDERS' EQUITY (Tables)",
     "shortName": "SHAREHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cgen.com/role/cgen-itt",
     "longName": "9960709 - Disclosure - TAXES ON INCOME, NET (Tables)",
     "shortName": "TAXES ON INCOME, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cgen.com/role/cgen-giamct",
     "longName": "9960710 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)",
     "shortName": "SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://cgen.com/role/cgen-faoint",
     "longName": "9960711 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)",
     "shortName": "FINANCIAL AND OTHER INCOME, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables",
     "longName": "9960712 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://cgen.com/role/cgen-lpst",
     "longName": "9960713 - Disclosure - LOSSES PER SHARE (Tables)",
     "shortName": "LOSSES PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://cgen.com/role/cgen-gd",
     "longName": "9960714 - Disclosure - GENERAL (Narrative) (Details)",
     "shortName": "GENERAL (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231218",
      "name": "cgen:NonRefundableUpfrontPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://cgen.com/role/cgen-sapnd",
     "longName": "9960715 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cgen:ShortTermBankDepositsWeightedAverageRateForeign",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "cgen:ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cgen:ShortTermBankDepositsWeightedAverageRateForeign",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "cgen:ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://cgen.com/role/cgen-sapsodrfpaed",
     "longName": "9960716 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "name": "cgen:AnnualDepreciationRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "name": "cgen:AnnualDepreciationRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
     "longName": "9960717 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://cgen.com/role/MARKETABLESECURITIESNarrativeDetails",
     "longName": "9960718 - Disclosure - MARKETABLE SECURITIES (Narrative) (Details)",
     "shortName": "MARKETABLE SECURITIES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://cgen.com/role/MARKETABLESECURITIESDetails",
     "longName": "9960719 - Disclosure - MARKETABLE SECURITIES (Schedule of available-for-sale marketable securities) (Details)",
     "shortName": "MARKETABLE SECURITIES (Schedule of available-for-sale marketable securities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_20241231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails",
     "longName": "9960720 - Disclosure - MARKETABLE SECURITIES (Schedule of gross unrealized losses and fair values on investments) (Details)",
     "shortName": "MARKETABLE SECURITIES (Schedule of gross unrealized losses and fair values on investments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails",
     "longName": "9960721 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_20241231_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://cgen.com/role/cgen-oaraped",
     "longName": "9960722 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Schedule Of Other Accounts Receivable And Prepaid Expenses) (Details)",
     "shortName": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Schedule Of Other Accounts Receivable And Prepaid Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "div",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "div",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://cgen.com/role/LEASESNarrative",
     "longName": "9960723 - Disclosure - LEASES (Narrative) (Details)",
     "shortName": "LEASES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails",
     "longName": "9960724 - Disclosure - LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)",
     "shortName": "LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails",
     "longName": "9960725 - Disclosure - LEASES (Schedule of Operating Leases) (Details)",
     "shortName": "LEASES (Schedule of Operating Leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
     "longName": "9960726 - Disclosure - PROPERTY AND EQUIPMENT, NET (Narrative) (Details)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://cgen.com/role/cgen-paend",
     "longName": "9960727 - Disclosure - PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment, Net) (Details)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment, Net) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://cgen.com/role/CommitmentsAndContingenciesDetails",
     "longName": "9960728 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://cgen.com/role/cgen-sesopnd",
     "longName": "9960729 - Disclosure - SHAREHOLDERS' EQUITY  (Narrative) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY  (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USD_per_share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USD_per_share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
     "longName": "9960730 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Share Option Plan) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Share Option Plan) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails",
     "longName": "9960731 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of RSUs Activity) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule Of RSUs Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://cgen.com/role/cgen-sesosced",
     "longName": "9960732 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock-Based Compensation Expenses) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Stock-Based Compensation Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://cgen.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9960733 - Disclosure - TAXES ON INCOME, NET (Narrative) (Details)",
     "shortName": "TAXES ON INCOME, NET (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails",
     "longName": "9960734 - Disclosure - TAXES ON INCOME, NET (Schedule of Loss (Income) Before Taxes) (Details)",
     "shortName": "TAXES ON INCOME, NET (Schedule of Loss (Income) Before Taxes) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "9960735 - Disclosure - TAXES ON INCOME, NET (Schedule of Deferred Tax Assets and Liabilities) (Details)",
     "shortName": "TAXES ON INCOME, NET (Schedule of Deferred Tax Assets and Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://cgen.com/role/GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails",
     "longName": "9960736 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Narrative) (Details)",
     "shortName": "SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails",
     "longName": "9960737 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Financial Information With Respect To Single Operating Segment) (Details)",
     "shortName": "SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Financial Information With Respect To Single Operating Segment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails",
     "longName": "9960738 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Total Revenues And Long-Lived Assets By Geographic Area) (Details)",
     "shortName": "SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Total Revenues And Long-Lived Assets By Geographic Area) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details",
     "longName": "9960739 - Disclosure - SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Sales To Single Customer Exceeding 10%) (Details)",
     "shortName": "SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Schedule Of Sales To Single Customer Exceeding 10%) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails",
     "longName": "9960740 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)",
     "shortName": "FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails",
     "longName": "9960741 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Schedule of Related Party Transactions) (Details)",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Schedule of Related Party Transactions) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:OtherLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:OtherLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
     "longName": "9960742 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)",
     "shortName": "LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://cgen.com/role/SubsequentEventsNarrativeDetails",
     "longName": "9960743 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)",
     "shortName": "SUBSEQUENT EVENTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_20240101to20240131_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240131_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532769.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r700"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "cgen_AccruedMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AccruedMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Accrued milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AccruedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AccruedMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Milestone Payments",
        "documentation": "Amount of accrued milestone payments.",
        "terseLabel": "Accrued milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-paend": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r135",
      "r546"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment",
        "verboseLabel": "Accumulated depreciation equipment",
        "documentation": "Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r73",
      "r137",
      "r541",
      "r575",
      "r576"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated other comprehensive income [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r12",
      "r18",
      "r419",
      "r422",
      "r483",
      "r571",
      "r572",
      "r849",
      "r850",
      "r851",
      "r860",
      "r861",
      "r862",
      "r864"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r860",
      "r861",
      "r862",
      "r864",
      "r936",
      "r994"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization in R&amp;D expenses",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AdjustmentForExchangeRateDifferencesLossGainOnCashBalances",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment For Exchange Rate Differences Loss (Gain) On Cash Balances",
        "documentation": "Adjustment for Exchange rate differences loss (gain) on cash balances.",
        "totalLabel": "Gain (Loss), Foreign Currency Transaction, before Tax, Total",
        "terseLabel": "Foreign currency transaction adjustments",
        "verboseLabel": "Exchange rate differences loss (gain) on cash balances",
        "negatedLabel": "Exchange rate differences loss (gain) on cash balances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AggregateLimitOfOrdinarySharesPerCalendarYear": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AggregateLimitOfOrdinarySharesPerCalendarYear",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate limit of ordinary shares per calendar year.",
        "label": "Aggregate limit of ordinary shares per calendar year"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r759",
      "r792"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r752",
      "r762",
      "r795"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "cgen_AgreementStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AgreementStartDate",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement start date.",
        "label": "Agreement Start Date",
        "verboseLabel": "Agreement, start date"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AgreementTerminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AgreementTerminationDescription",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of termination of agreement.",
        "label": "Agreement Termination Description",
        "verboseLabel": "Agreement termination description"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r753",
      "r763",
      "r787",
      "r796",
      "r800",
      "r808"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expenses",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r372"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Cash Consideration Of Research And Development Funding Arrangement",
        "negatedLabel": "Decrease (increase) in interest receivables from short-term bank deposits and long-term restricted deposit",
        "label": "Amortization Of Cash Consideration Of Research And Development Funding Arrangement",
        "terseLabel": "Amortization research and development component"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Of Discount And Accrued Interest On Marketable Securities",
        "documentation": "Represent the amount of Amortization of discount and accrued interest on marketable securities",
        "negatedLabel": "Amortization of discount and accrued interest on marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AnnualDepreciationRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AnnualDepreciationRate",
     "presentation": [
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Depreciation Rate",
        "label": "Annual depreciation rate"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AnnualDepreciationRateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AnnualDepreciationRateDescription",
     "presentation": [
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Depreciation Rates, Description.",
        "label": "Annual Depreciation Rate, Description",
        "verboseLabel": "Annual depreciation rate"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AntibodiesDiscoveryCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AntibodiesDiscoveryCollaborationAgreementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antibodies Discovery Collaboration Agreement [Member]",
        "documentation": "Information about the Antibodies Discovery Collaboration Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r114",
      "r136",
      "r159",
      "r191",
      "r197",
      "r215",
      "r219",
      "r262",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r414",
      "r416",
      "r454",
      "r535",
      "r612",
      "r670",
      "r671",
      "r700",
      "r716",
      "r893",
      "r894",
      "r950"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r140",
      "r159",
      "r262",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r414",
      "r416",
      "r454",
      "r700",
      "r893",
      "r894",
      "r950"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r262",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r414",
      "r416",
      "r454",
      "r893",
      "r894",
      "r950"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm Id",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722",
      "r745"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722",
      "r745"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722",
      "r745"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r270",
      "r534"
     ]
    },
    "cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Greater Than 12 Months Fair Value",
        "documentation": "Represents the amount of available for sale securities, continuous unrealized loss position, greater than 12 Months, fair value.",
        "terseLabel": "Available-for-Sale Securities, fair value, greater than 12 months"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Greater Than 12 Months Gross Unrealized Losses",
        "terseLabel": "Available-for-Sale Securities, gross unrealized losses, less than 12 months",
        "documentation": "Represents the amount of available for sale securities, continuous unrealized loss position, greater than 12 Months, gross unrealized losses."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-Sale Securities, fair value, less than 12 months",
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Fair Value",
        "documentation": "Represents the amount of available for sale securities, continuous unrealized loss position, less than 12 Months, fair value."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-Sale Securities, gross unrealized losses, less than 12 months",
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Gross Unrealized Losses",
        "documentation": "Represents the amount of available for sale securities, continuous unrealized loss position, less than 12 Months, gross unrealized losses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r270",
      "r429",
      "r527",
      "r689",
      "r692",
      "r872",
      "r940",
      "r941",
      "r942"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r745"
     ]
    },
    "us-gaap_BusinessDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing and business development expenses",
        "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r133",
      "r660"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents:",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash:",
        "verboseLabel": "Cash, Cash equivalents and Restricted cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r101"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the year",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "verboseLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r84",
      "r157"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r84"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash paid for amounts included in measurement of lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase to ordinary shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase to ordinary shares remain outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration period of warrants.",
        "label": "Class Of Warrant Or Rights Period From Which Warrants Or Rights Exercisable",
        "terseLabel": "Expiration period of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ClinicalAmountOfExpenseForResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ClinicalAmountOfExpenseForResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Amount Of Expense For Research And Development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.",
        "verboseLabel": "Clinical R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "cgen_CollaborativeArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "CollaborativeArrangementsMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements [Member]",
        "label": "Collaborative Arrangements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CollaborativeArrangementsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "CollaborativeArrangementsTwoMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements Two [Member]",
        "label": "Collaborative Arrangements Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r105",
      "r538",
      "r599"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-cac1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r293",
      "r294",
      "r654",
      "r890",
      "r892"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r707",
      "r708",
      "r710",
      "r711",
      "r712",
      "r713",
      "r860",
      "r861",
      "r864",
      "r936",
      "r992",
      "r994"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Ordinary shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r600"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "label": "Ordinary shares, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r67",
      "r600",
      "r618",
      "r994",
      "r995"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital: Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2021 and 2020; 86,433,432 and 83,675,856 shares issued and outstanding at December 31, 2021 and 2020, respectively",
        "terseLabel": "Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2024 and 2023; 89,541,246 and 89,237,465 shares issued and outstanding at December 31, 2024 and 2023, respectively.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r540",
      "r700"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r145",
      "r147",
      "r153",
      "r528",
      "r552",
      "r553"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income (loss):",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers, software and related equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r226",
      "r653"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r226",
      "r578",
      "r653"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r226",
      "r653",
      "r834"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of credit risks:",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r119"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales to a single customer exceeding 10%",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r226"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r226",
      "r653"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of consolidation:",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r662"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ContingentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ContingentFees",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent fees.",
        "label": "Contingent Fees",
        "verboseLabel": "Contingent fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r159",
      "r262",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r454",
      "r670",
      "r893"
     ]
    },
    "cgen_CostOfSalesContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "CostOfSalesContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.",
        "label": "Cost Of Sales Contract With Customer Policy Text Block",
        "terseLabel": "Cost of revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts charged to research and development expenses",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r226"
     ]
    },
    "cgen_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One [Member]",
        "label": "Customer One Member",
        "terseLabel": "Customer A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Two [Member]",
        "documentation": "This member stands for Customer two",
        "verboseLabel": "Customer B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r819"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r819"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r821"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r821"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r823"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r821"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r814"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r815"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r815"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r813"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r813"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r813"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r816"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r818"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r818"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r819"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r822"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r820"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r817"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of available-for-sale marketable securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_DeferredIncomeTaxLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "DeferredIncomeTaxLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax lease liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Deferred tax liabilities",
        "negatedTotalLabel": "Deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r103",
      "r391"
     ]
    },
    "cgen_DeferredIncomeTaxRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "DeferredIncomeTaxRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax Right of use assets attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Right Of Use Assets",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_DeferredParticipationOfBMSInRAndDExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "DeferredParticipationOfBMSInRAndDExpenses",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred participation of BMS in R and D expenses.",
        "label": "Deferred Participation Of B M S In R And D Expenses",
        "terseLabel": "Deferred participation of BMS in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenues",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenues",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Long-term deferred revenues",
        "verboseLabel": "Deferred revenues",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "cgen_DeferredRevenuesIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "DeferredRevenuesIncludedInCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenues Included In Current Liabilities",
        "documentation": "Amount of deferred revenues included in current liabilities.",
        "terseLabel": "Deferred revenues included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_DeferredRevenuesIncludedInNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "DeferredRevenuesIncludedInNonCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenues Included In Non Current Liabilities",
        "documentation": "Amount of deferred revenues included in non current liabilities.",
        "terseLabel": "Deferred revenues included in non current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax asset before valuation allowance",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset (liabilities) for property, plant and equipment.",
        "label": "Deferred Tax Assets Liabilities Property Plant And Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax asset after valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued social benefits and other",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "verboseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Restricted long-term bank deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r37"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of outstanding forward contracts",
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net gain on derivative transactions",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net gain on derivative recorded as financial and other income, net for the ineffective portion",
        "documentation": "The portion of gains on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r100"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, notional amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934"
     ]
    },
    "cgen_DerivativeRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "DerivativeRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the derivative related expenses incurred during the reporting period.",
        "label": "Derivative Related Expense",
        "terseLabel": "Derivative related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative instruments:",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r44",
      "r45",
      "r46",
      "r47",
      "r162",
      "r176"
     ]
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-set1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of share option plan",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r40"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722",
      "r745"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722",
      "r745",
      "r788"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic net loss per share",
        "terseLabel": "Basic loss per ordinary share",
        "verboseLabel": "Basic net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r179",
      "r181",
      "r183",
      "r184",
      "r185",
      "r190",
      "r410",
      "r413",
      "r426",
      "r427",
      "r529",
      "r554",
      "r664"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r181",
      "r183",
      "r184",
      "r185",
      "r190",
      "r410",
      "r413",
      "r426",
      "r427",
      "r529",
      "r554",
      "r664"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per share:",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r187"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-lps"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSSES PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r186",
      "r188",
      "r189"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israeli corporate tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r382",
      "r401",
      "r688"
     ]
    },
    "cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss) for next fiscal year.",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate For Next Fiscal Year",
        "terseLabel": "Israeli corporate tax rate for next fiscal year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. income state and local taxes rate (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r688",
      "r859",
      "r927"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employees and related accruals",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized share-based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost, recognition period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd",
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Employee Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan Member",
        "verboseLabel": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_EmployeesDirectorsAndNonEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "EmployeesDirectorsAndNonEmployeesMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees Directors And Non Employees [Member]",
        "documentation": "Information about the employees, directors and non-employees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses Address Type [Axis]",
        "verboseLabel": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r128",
      "r149",
      "r150",
      "r151",
      "r163",
      "r164",
      "r165",
      "r167",
      "r172",
      "r174",
      "r176",
      "r192",
      "r263",
      "r264",
      "r286",
      "r313",
      "r399",
      "r400",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r468",
      "r470",
      "r472",
      "r483",
      "r550",
      "r571",
      "r572",
      "r573",
      "r589",
      "r641"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment amount",
        "verboseLabel": "Equity investment",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r759",
      "r792"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r746",
      "r756",
      "r789"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EuropeMember",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998",
      "r999"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "cgen_ExtendLease": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ExtendLease",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extend Lease",
        "label": "Extend Lease",
        "verboseLabel": "Extend lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r443",
      "r689"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r443",
      "r689"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of fair value measurements",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r938",
      "r939",
      "r944"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r444",
      "r690"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r444",
      "r690"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r442",
      "r443",
      "r445",
      "r496",
      "r497",
      "r498",
      "r678",
      "r679",
      "r682",
      "r683",
      "r684",
      "r689",
      "r692"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r440",
      "r441",
      "r442",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r526",
      "r689",
      "r693"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r325",
      "r330",
      "r430",
      "r443",
      "r496",
      "r682",
      "r683",
      "r684",
      "r689"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r325",
      "r330",
      "r430",
      "r431",
      "r443",
      "r497",
      "r678",
      "r679",
      "r682",
      "r683",
      "r684",
      "r689"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r442",
      "r443",
      "r445",
      "r496",
      "r497",
      "r498",
      "r678",
      "r679",
      "r682",
      "r683",
      "r684",
      "r689",
      "r692"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of financial instruments:",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "cgen_FinancialIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "FinancialIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      },
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails",
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Income (Expense), Net.",
        "label": "Financial Income Expense Net",
        "terseLabel": "Financial and other income, net",
        "totalLabel": "Financial and other income, net",
        "verboseLabel": "Financial income, net",
        "negatedLabel": "Financial income, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r310",
      "r311",
      "r424",
      "r450",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r551",
      "r676",
      "r689",
      "r690",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r701",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r885",
      "r886",
      "r887",
      "r888",
      "r937",
      "r940",
      "r941",
      "r942",
      "r943",
      "r945"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "terseLabel": "Foreign currency transaction adjustments",
        "verboseLabel": "Exchange rate differences loss (gain) on cash balances",
        "negatedLabel": "Exchange rate differences loss (gain) on cash balances",
        "totalLabel": "Gain (Loss), Foreign Currency Transaction, before Tax, Total",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r460",
      "r638"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial statements in U.S. dollars:",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r753",
      "r763",
      "r796"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r753",
      "r763",
      "r796"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r753",
      "r763",
      "r796"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r753",
      "r763",
      "r796"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r753",
      "r763",
      "r796"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) from sales and disposals of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of other assets."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss from property and equipment sales and disposals",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "verboseLabel": "Gains from the sale of equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r622"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "cgen_GileadAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "GileadAgreementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gilead Agreement [Member]",
        "documentation": "Represent the member of Gilead Agreement",
        "terseLabel": "Gilead Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "GovernmentAndOtherGrantsAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Other Grants [Axis]",
        "label": "Government and Other Grants [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "GovernmentAndOtherGrantsDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "auth_ref": []
    },
    "cgen_GovernmentAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "GovernmentAuthorities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-oaraped": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-oaraped"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Authorities",
        "label": "Government authorities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76",
      "r113",
      "r159",
      "r262",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r454",
      "r665",
      "r670",
      "r866",
      "r868",
      "r869",
      "r870",
      "r871",
      "r893"
     ]
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuaranteeObligationsMaximumExposure",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security",
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IL",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722",
      "r745"
     ]
    },
    "us-gaap_ImpairmentOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfInvestments",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities impairment losses",
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Domestic (Israel)",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "Domestic (Israel)",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r381"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before taxes on income",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes on income",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r108",
      "r113",
      "r530",
      "r548",
      "r665",
      "r670",
      "r866",
      "r868",
      "r869",
      "r870",
      "r871"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r381"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r289",
      "r290",
      "r435",
      "r439",
      "r444",
      "r568",
      "r570",
      "r625",
      "r657",
      "r691",
      "r963"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r435",
      "r439",
      "r444",
      "r568",
      "r570",
      "r625",
      "r657",
      "r691",
      "r963"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r382",
      "r383",
      "r388",
      "r396",
      "r688",
      "r931"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r382",
      "r383",
      "r388",
      "r396",
      "r688",
      "r931"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-it"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME, NET",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r377",
      "r382",
      "r385",
      "r386",
      "r387",
      "r389",
      "r395",
      "r402",
      "r404",
      "r405",
      "r406",
      "r585",
      "r688"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expenses (tax benefits)",
        "verboseLabel": "Taxes on income",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r125",
      "r175",
      "r176",
      "r191",
      "r205",
      "r219",
      "r380",
      "r382",
      "r403",
      "r555",
      "r688"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes:",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r378",
      "r379",
      "r389",
      "r390",
      "r394",
      "r398",
      "r582"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax payment withheld",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r86",
      "r856",
      "r929",
      "r930"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 150.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in trade receivables",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 100.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in trade payables and other accounts payable and accrued expenses",
        "verboseLabel": "Increase (decrease) in trade payables and employees and related accruals and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 80.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in other accounts receivable and prepaid expenses",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 110.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deferred participation in R and D expenses.",
        "label": "Increase Decrease In Deferred Participation In Research And Development Expenses",
        "terseLabel": "Decrease in deferred participation in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "verboseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "cgen_IncreaseDecreaseInDeferredRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "IncreaseDecreaseInDeferredRevenues",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 130.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Deferred Revenues",
        "documentation": "Represent the amount of deferred revenues",
        "negatedLabel": "Increase in deferred revenues"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 120.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right of use asset.",
        "negatedLabel": "Decrease in operating lease right of use asset",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 140.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in operating lease liability",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 90.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in long-term prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInRoyaltiesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInRoyaltiesPayable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Royalties Payable",
        "terseLabel": "Royalties accrual",
        "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "cgen_IncreaseOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "IncreaseOperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right of use asset increased.",
        "label": "Increase Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right of use asset increased"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r753",
      "r763",
      "r787",
      "r796",
      "r800",
      "r808"
     ]
    },
    "us-gaap_InitialOfferingPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InitialOfferingPeriod",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering period",
        "documentation": "A description of the time period when the company made its initial offering of a class of securities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r812"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r812"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r812"
     ]
    },
    "us-gaap_InterestAndDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndDebtExpense",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Bank fees and other finance expenses",
        "label": "Interest and Debt Expense",
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "cgen_InterestPaidReceivedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "InterestPaidReceivedNet",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest payments paid (received) from bank short-term deposits and cash equivalents",
        "label": "Interest Paid Received Net",
        "terseLabel": "Interest payments received from short-term bank deposits and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeAmortizationOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeAmortizationOfDiscount",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Amortization of Discount",
        "verboseLabel": "Amortization of discount on marketable securities, net",
        "documentation": "Amount of accretion of purchase discount on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r200",
      "r219",
      "r670",
      "r852"
     ]
    },
    "us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedUnderlyingFaceAmountAtMarketValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of investment in Compugen",
        "documentation": "Nominal or face amount on the investment owned."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r48"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investment in marketable securities",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r939",
      "r943"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "MARKETABLE SECURITIES",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r127",
      "r228",
      "r230",
      "r451",
      "r452",
      "r959"
     ]
    },
    "cgen_IssuanceOfSharesAndWarrantsNetShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "IssuanceOfSharesAndWarrantsNetShares",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares and warrants, net, shares.",
        "label": "Issuance of shares and warrants, net, shares",
        "terseLabel": "Issuance of shares, net, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_IssuanceOfSharesAndWarrantsNetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "IssuanceOfSharesAndWarrantsNetValue",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares and warrants, net.",
        "label": "Issuance Of Shares And Warrants Net Value",
        "terseLabel": "Issuance of shares, net"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_JmpSecuritiesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "JmpSecuritiesLlcMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jmp Securities Llc [Member]",
        "documentation": "This member stands for JMP Securities LLC.",
        "verboseLabel": "JMP Securities LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_LaboratoryEquipmentAndOfficeFurnitureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "LaboratoryEquipmentAndOfficeFurnitureMember",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment And Office Furniture [Member]",
        "label": "Laboratory equipment and office furniture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r482"
     ]
    },
    "cgen_LeerinkPartnersLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "LeerinkPartnersLlcMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leerink Partners Llc [Member]",
        "documentation": "This member stands for Leerink Partners LLC.",
        "verboseLabel": "Leerink Partners LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]",
        "verboseLabel": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases:",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cgen.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Leases",
        "terseLabel": "Schedule of operating leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028 and on",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: imputed interest",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period of options to extend leases",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://cgen.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r106",
      "r543",
      "r700",
      "r857",
      "r889",
      "r946"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r132",
      "r159",
      "r262",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r415",
      "r416",
      "r417",
      "r454",
      "r700",
      "r893",
      "r950",
      "r951"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r60",
      "r61",
      "r62",
      "r65",
      "r159",
      "r262",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r415",
      "r416",
      "r417",
      "r454",
      "r893",
      "r950",
      "r951"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON- CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_LicenseAgreementWithGileadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "LicenseAgreementWithGileadMember",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement With Gilead [Member]",
        "documentation": "This member represents about license agreement with Gilead."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_LicenseRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "LicenseRevenue",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Revenue",
        "documentation": "Amount of license revenue.",
        "terseLabel": "License revenue"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r681",
      "r702",
      "r705",
      "r896",
      "r962",
      "r964",
      "r965",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "terseLabel": "Investment in marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in marketable securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "cgen_MasterClinicalAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "MasterClinicalAgreementMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement [Member]",
        "label": "Master Clinical Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MasterClinicalAgreementOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "MasterClinicalAgreementOneMember",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement One [Member]",
        "label": "Master Clinical Agreement One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MasterClinicalAgreementTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "MasterClinicalAgreementTwoMember",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement Two [Member]",
        "label": "Master Clinical Agreement Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "MaximumAuthorizedProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Authorized Proceeds From Issuance Of Common Stock",
        "label": "Maximum Authorized Proceeds From Issuance Of Common Stock",
        "terseLabel": "Aggregate offering price",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r332",
      "r373",
      "r433",
      "r524",
      "r567",
      "r569",
      "r577",
      "r591",
      "r592",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r655",
      "r656",
      "r675",
      "r680",
      "r685",
      "r692",
      "r693",
      "r697",
      "r698",
      "r703",
      "r895",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "MaximumRoyaltyRepaidAsPercentageOfGrantReceived",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Royalty Repaid As Percentage Of Grant Received",
        "label": "Maximum Royalty Repaid As Percentage Of Grant Received",
        "verboseLabel": "Maximum royalty repaid as percentage of grant received"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_May2012AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "May2012AgreementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2012 Agreement Member",
        "label": "May 2012 Agreement Member",
        "terseLabel": "May 2012 Agreement With Advisor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "cgen_MilestonePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "MilestonePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payment Receivable",
        "documentation": "Amount of milestone payment receivables.",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r332",
      "r373",
      "r433",
      "r524",
      "r567",
      "r569",
      "r577",
      "r591",
      "r592",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r655",
      "r656",
      "r675",
      "r680",
      "r685",
      "r692",
      "r693",
      "r697",
      "r703",
      "r895",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r681",
      "r702",
      "r705",
      "r896",
      "r962",
      "r964",
      "r965",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "terseLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-csocl",
      "http://cgen.com/role/cgen-gd",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss",
        "disclosureGuidance": "Net loss for basic and diluted loss per share",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r87",
      "r109",
      "r130",
      "r144",
      "r146",
      "r151",
      "r159",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r175",
      "r176",
      "r182",
      "r262",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r410",
      "r413",
      "r427",
      "r454",
      "r549",
      "r620",
      "r639",
      "r640",
      "r714",
      "r893"
     ]
    },
    "cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss After Adjustment Of Change In Fair Value Of Research And Development Funding Arrangement Abstract",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_NetOperatingLossCarryforwardExpired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "NetOperatingLossCarryforwardExpired",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforward, Expired.",
        "label": "Net operating loss carryforward, Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently issued and recently adopted Accounting Standards:",
        "verboseLabel": "Recently adopted accounting pronouncement",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r753",
      "r763",
      "r787",
      "r796"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "cgen_NonRefundableUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "NonRefundableUpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Refundable Upfront Payment",
        "documentation": "Amount of non-refundable upfront payment.",
        "verboseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-lived assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of licensed programs to achieve substantive milestones revenues.",
        "label": "Number of licensed programs to achieve substantive milestones revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://cgen.com/role/GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r867"
     ]
    },
    "cgen_NumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "NumberOfWarrantsExercised",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Number Of Warrants Exercised",
        "terseLabel": "Warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to obsolete property and equipment and certain nonfunctional Lab equipment.",
        "label": "Obsolete property and equipment and nonfunctional Lab equipment [Member]",
        "terseLabel": "Obsolete property and equipment and certain nonfunctional Lab equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r665",
      "r866",
      "r868",
      "r869",
      "r870",
      "r871"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "verboseLabel": "Operating lease expenses",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability",
        "terseLabel": "Present value of lease liabilities",
        "verboseLabel": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current maturity of operating lease liability",
        "verboseLabel": "Lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term operating lease liability",
        "verboseLabel": "Lease liabilities, non- current",
        "terseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount (annual) rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r699"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r699"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforward",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year of expiration of operating loss carryforward",
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "cgen_OrdinarySharesIssuedAndSoldThroughAtmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "OrdinarySharesIssuedAndSoldThroughAtmMember",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares Issued And Sold Through Atm [Member]",
        "documentation": "This member stands for ordinary shares issued and sold through ATM.",
        "verboseLabel": "ATM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-g"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r99",
      "r579",
      "r580"
     ]
    },
    "cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "OtherAccountsReceivableAndPrepaidExpensesTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-oarape"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other accounts receivable and prepaid expenses.",
        "label": "Other Accounts Receivable And Prepaid Expenses Text Block",
        "terseLabel": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-oaraped": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-oaraped"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r700"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation income",
        "verboseLabel": "Exchange rate income (loss) on lease liabilities",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r4",
      "r459",
      "r467"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "verboseLabel": "Other comprehensive income from marketable securities",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r73",
      "r143",
      "r261"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net gain on derivative classified to operating expenses as effective portion",
        "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r50",
      "r73"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain arising during the period from marketable securities",
        "verboseLabel": "Changes in other comprehensive income from marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r261"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-faoin"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL AND OTHER INCOME, NET",
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r926"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables and accrued expenses",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r536",
      "r595",
      "r596",
      "r716",
      "r961",
      "r993"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "cgen_OtherSegmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "OtherSegmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Segment Expenses",
        "documentation": "Other segment expenses.",
        "verboseLabel": "Other segment expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term bank deposits",
        "verboseLabel": "Short-term bank deposits",
        "documentation": "Amount of short-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r532",
      "r533",
      "r847"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r751",
      "r761",
      "r794"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r764",
      "r797"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r764",
      "r797"
     ]
    },
    "cgen_ParticipationRights": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ParticipationRights",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.",
        "label": "Participation Rights",
        "verboseLabel": "Participation Rights"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payments for Proceeds from Sales of equipment Investing Activities.",
        "negatedLabel": "Proceeds from sale of property and equipment",
        "label": "Payments For Proceeds From Sales Of Property And Equipment Investing Activities",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total",
        "verboseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/SubsequentEventsNarrativeDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Issuance expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Held-to-Maturity Securities",
        "terseLabel": "Proceeds from maturity of marketable securities",
        "positiveTerseLabel": "Investment in short-term bank deposits",
        "negatedLabel": "Investment in short-term bank deposits",
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r229"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Investment in marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Restricted Investments",
        "negatedLabel": "Investment in long term restricted deposit",
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "cgen_PercentageOfClosingPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "PercentageOfClosingPrice",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of closing price.",
        "label": "Percentage of closing price"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PercentageOfConsolidatedRevenuesOfCollaborator": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "PercentageOfConsolidatedRevenuesOfCollaborator",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of consolidated revenues of collaborator.",
        "label": "Percentage of consolidated revenues of collaborator"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PercentageOfExpectedFromPaymentAmountPaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "PercentageOfExpectedFromPaymentAmountPaid",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Expected From Payment Amount Paid",
        "documentation": "Percentage of expected from payment amount paid.",
        "terseLabel": "Percentage of expected from payment amount paid"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair market value of ordinary shares at time of offering.",
        "label": "Percentage of fair market value of ordinary shares at time of offering"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of use of base salary to purchase ordinary shares.",
        "label": "Percentage of use of base salary to purchase ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_PostemploymentBenefitsLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PostemploymentBenefitsLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued severance pay",
        "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898"
     ]
    },
    "cgen_PreclinicalAmountOfExpenseForResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "PreclinicalAmountOfExpenseForResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preclinical Amount Of Expense For Research And Development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.",
        "verboseLabel": "Preclinical R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 50.0
      },
      "http://cgen.com/role/cgen-oaraped": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-oaraped"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts receivable and prepaid expenses",
        "totalLabel": "Other accounts receivable and prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-oaraped": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-oaraped"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r274",
      "r275",
      "r661"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term prepaid expenses",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIncomeTaxRefunds",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax receivables refunded",
        "documentation": "Amount of income tax refund received from tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r85",
      "r856",
      "r929",
      "r930"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from ordinary shares in offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of ordinary shares, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/MARKETABLESECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturity of marketable securities",
        "positiveTerseLabel": "Investment in short-term bank deposits",
        "positiveLabel": "Proceeds from maturities of available-for-sale marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Held-to-Maturity Securities",
        "terseLabel": "Proceeds from maturity of marketable securities",
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total",
        "positiveLabel": "Proceeds from maturity of short-term bank deposits",
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r229"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of stock-based awards",
        "verboseLabel": "Proceeds from exercise of share-based awards",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r15"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "verboseLabel": "Proceeds from warrant exercised",
        "terseLabel": "Proceeds from exercise of stock-based awards",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "verboseLabel": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r482"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-paen"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT, NET",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r120",
      "r123",
      "r124"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisposals",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Costs of disposal of property and equipment",
        "label": "Property, Plant and Equipment, Disposals",
        "verboseLabel": "Costs of disposal of property and equipment",
        "terseLabel": "Sale of equipment,cost",
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-paend": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r134",
      "r547"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentImpairment",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets:",
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 30.0
      },
      "http://cgen.com/role/cgen-paend": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-paend"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Depreciated cost",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r482",
      "r531",
      "r547",
      "r700"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net:",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r120",
      "r123",
      "r545"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-paent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property And Equipment, Net",
        "terseLabel": "Schedule of property and equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r482"
     ]
    },
    "cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "PurchaseOfPropertyAndEquipmentAsNonCashTransaction",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Of Property And Equipment As Non Cash Transaction",
        "documentation": "The amount of purchase property and equipment as non cash transaction.",
        "negatedLabel": "Purchase of property and equipment",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "verboseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r324",
      "r332",
      "r362",
      "r363",
      "r364",
      "r373",
      "r433",
      "r499",
      "r508",
      "r524",
      "r567",
      "r569",
      "r577",
      "r591",
      "r592",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r655",
      "r656",
      "r675",
      "r680",
      "r685",
      "r692",
      "r693",
      "r697",
      "r698",
      "r703",
      "r708",
      "r891",
      "r895",
      "r941",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r324",
      "r332",
      "r362",
      "r363",
      "r364",
      "r373",
      "r433",
      "r499",
      "r508",
      "r524",
      "r567",
      "r569",
      "r577",
      "r591",
      "r592",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r655",
      "r656",
      "r675",
      "r680",
      "r685",
      "r692",
      "r693",
      "r697",
      "r698",
      "r703",
      "r708",
      "r891",
      "r895",
      "r941",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "cgen_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]",
        "documentation": "Accounting policy for Recently issued accounting pronouncements not yet adopted.",
        "terseLabel": "Recently issued accounting pronouncements not yet adopted"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r746",
      "r756",
      "r789"
     ]
    },
    "cgen_ReducedCorporateIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ReducedCorporateIncomeTaxRate",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduced Corporate income tax rate",
        "label": "Reduced Corporate income tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ReducedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ReducedTaxRate",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduced tax rate.",
        "label": "Reduced tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered direct offering [Member]",
        "label": "Registered direct offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r331",
      "r487",
      "r488",
      "r537",
      "r544",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r617",
      "r619",
      "r646"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r331",
      "r487",
      "r488",
      "r537",
      "r544",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r617",
      "r619",
      "r646",
      "r949"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-rpbat"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY BALANCES AND TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r586",
      "r587",
      "r588",
      "r623",
      "r624",
      "r625",
      "r644",
      "r645"
     ]
    },
    "cgen_RemainingPerformanceObligationsRecognizedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "RemainingPerformanceObligationsRecognizedPercentage",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Performance Obligations Recognized Percentage",
        "documentation": "The percentage of the total remaining performance obligations expected to be recognized as revenue within the next 12 months.",
        "verboseLabel": "Percentage of total remaining performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-gd",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Upfront payment received",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Research And Development Arrangement Payments Receivable",
        "terseLabel": "Potential milestone compensation"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone compensation company is now eligible for.",
        "label": "Research And Development Arrangement Payments Receivable On Remaining Program",
        "terseLabel": "Potential milestone compensation company is now eligible for"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Preclinical Payments Receivable",
        "terseLabel": "Preclinical milestone compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "verboseLabel": "Research and Development expenses",
        "terseLabel": "Research and development expenses, net",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r657",
      "r670",
      "r958"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses, net:",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "cgen_ResearchAndDevelopmentExpensesMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ResearchAndDevelopmentExpensesMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses milestone payment.",
        "label": "Research And Development Expenses Milestone Payment",
        "verboseLabel": "Research and development expenses milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ResearchAndDevelopmentExpensesMilestonePaymentWithConnection",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses milestone payment with connection.",
        "label": "Research And Development Expenses Milestone Payment With Connection",
        "verboseLabel": "Research and development expenses milestone payment with connection"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentGrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ResearchAndDevelopmentGrantOneMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Grant One [Member]",
        "label": "Research And Development Grant One Member",
        "terseLabel": "IIA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r747",
      "r757",
      "r790"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r748",
      "r758",
      "r791"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r755",
      "r765",
      "r798"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r101",
      "r133",
      "r157",
      "r539"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r133",
      "r157"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r95",
      "r542",
      "r574",
      "r576",
      "r584",
      "r601",
      "r700"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r163",
      "r164",
      "r165",
      "r167",
      "r172",
      "r174",
      "r176",
      "r263",
      "r264",
      "r286",
      "r399",
      "r400",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r418",
      "r420",
      "r421",
      "r423",
      "r425",
      "r470",
      "r472",
      "r571",
      "r573",
      "r589",
      "r994"
     ]
    },
    "cgen_RetainerFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "RetainerFee",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the retainer fee per month.",
        "label": "Retainer Fee",
        "verboseLabel": "Retainer fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition under milestone method",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r191",
      "r198",
      "r199",
      "r213",
      "r219",
      "r222",
      "r224",
      "r226",
      "r322",
      "r323",
      "r525"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition:",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r659"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails",
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total revenues",
        "verboseLabel": "Revenue from sales to customers",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r152",
      "r159",
      "r191",
      "r198",
      "r199",
      "r213",
      "r219",
      "r222",
      "r224",
      "r226",
      "r262",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r454",
      "r530",
      "r670",
      "r893"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails",
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails",
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RoyaltyContingentObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "RoyaltyContingentObligations",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.",
        "label": "Royalty Contingent Obligations",
        "verboseLabel": "Contingent royalty obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense",
        "negatedLabel": "Royalty expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "cgen_RoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "RoyaltyPercentage",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage.",
        "label": "Royalty Percentage",
        "verboseLabel": "Royalty percentage"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RoyaltyPercentageBasedOnFutureRevenues": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "RoyaltyPercentageBasedOnFutureRevenues",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Percentage Based On Future Revenues",
        "label": "Royalty Percentage Based On Future Revenues",
        "verboseLabel": "Royalty percentage based on future revenues"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails",
      "http://cgen.com/role/cgen-sesopnd",
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Number of shares issued and sold in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r833"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "auth_ref": [
      "r177",
      "r333",
      "r831",
      "r863"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-itt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Deferred Tax Assets And Liabilities",
        "terseLabel": "Schedule of deferred tax assets and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-lpst"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of computation of basic and diluted losses per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-set1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expenses",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-itt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Loss Before Taxes",
        "terseLabel": "Schedule of loss (income) before taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-oarapet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Accounts Receivable And Prepaid Expenses",
        "terseLabel": "Schedule of other accounts receivable and prepaid expenses",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-faoint"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial and Other Income, Net",
        "terseLabel": "Schedule of financial and other income, net",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the annual rates used to calculate depreciation for property, plant and equipment.",
        "label": "Schedule Of Property Plant And Equipment Depreciation Rates Table Text Block",
        "verboseLabel": "Schedule of depreciation rates for property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r482"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Balances and Transactions",
        "terseLabel": "Schedule of related party balances and transactions",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-giamct"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales To A Single Customer Exceeding 10%:",
        "terseLabel": "Schedule of sales to single customer exceeding 10%",
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-giamct"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Revenues And Long-Lived Assets By Geographic Area",
        "terseLabel": "Schedule of total revenues and long-lived assets by geographic area",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r74"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails",
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails",
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATAScheduleOfSalesToSingleCustomerExceeding10Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r74"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-giamct"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Schedule of financial information with respect to single operating segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-set1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "verboseLabel": "Schedule Of RSUs activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ScheduleOfWeightedAverageAssumptionsForGrantedOptions",
     "presentation": [
      "http://cgen.com/role/cgen-sapt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of granted stock options, including, but not limited to: (a) expected term of granted share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Weighted Average Assumptions For Granted Options",
        "verboseLabel": "Schedule of weighted average assumptions for granted options"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
     "presentation": [
      "http://cgen.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of weighted-average remaining lease term and discount rate.",
        "label": "Schedule Of Weighted Average Remaining Lease Term And Discount Rate",
        "terseLabel": "Schedule of weighted-average remaining lease term and discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Exchange on which Security is Registered",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r191",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r226",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r291",
      "r292",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r667",
      "r670",
      "r671",
      "r677",
      "r704",
      "r962",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-giamc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS",
        "terseLabel": "SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r209",
      "r211",
      "r212",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r226",
      "r666",
      "r668",
      "r669",
      "r670",
      "r672",
      "r673",
      "r674"
     ]
    },
    "cgen_SegmentReportingGeographicAreaAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "SegmentReportingGeographicAreaAxis",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Reporting Geographic Area [Axis]",
        "label": "Segment Reporting Geographic Area [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SegmentReportingGeographicAreaDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "SegmentReportingGeographicAreaDomain",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Geographic Area [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing and business development expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "SG&amp;A",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "cgen_ServerancePayPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ServerancePayPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Serverance Pay [Policy Text Block]",
        "label": "Serverance Pay Policy Text Block",
        "terseLabel": "Severance pay:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance expenses",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "cgen_SeverancePayFundNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "SeverancePayFundNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.",
        "label": "Severance Pay Fund Noncurrent",
        "verboseLabel": "Severance pay fund"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SeverancePayNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "SeverancePayNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance pay, net.",
        "label": "Severance Pay Net",
        "terseLabel": "Decrease in severance pay, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "verboseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period",
        "verboseLabel": "Award expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "RSUs forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "RSUs granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "RSUs outstanding at beginning of year",
        "periodEndLabel": "RSUs outstanding at end of year",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "verboseLabel": "Number of RSUs",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "RSUs outstanding at end of year",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date per value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares reserved for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares available for issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable at end of year",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total intrinsic value of options exercised during the period",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options expired",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value of stock options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding at end of year",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options outstanding at end of year",
        "periodStartLabel": "Options outstanding at beginning of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options outstanding at end of year",
        "periodStartLabel": "Options outstanding at beginning of year",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Remaining Contractual Term Abstract",
        "verboseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of year",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested and expected to vest at end of year",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options vested and expected to vest at end of year",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum percentage of total shares of common stock outstanding",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cgen.com/role/SHAREHOLDERSEQUITYScheduleOfRSUsActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation:",
        "terseLabel": "Share-based compensation:",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r340",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value of exercised options",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable at end of year",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable at end of year",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-se12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r96"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Bank Deposits And Restricted Long Term Bank Deposits [Policy Text Block]",
        "documentation": "Short Term Bank Deposits And Restricted Long Term Bank Deposits [Policy Text Block]",
        "verboseLabel": "Short-term bank deposits and restricted long-term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ShortTermBankDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ShortTermBankDepositsPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for short-term bank deposits.",
        "label": "Short Term Bank Deposits Policy Text Block",
        "verboseLabel": "Short-term bank deposits:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ShortTermBankDepositsWeightedAverageRateForeign": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "ShortTermBankDepositsWeightedAverageRateForeign",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average interest rate for short-term bank deposits outside of the domestic currency.",
        "label": "Short Term Bank Deposits Weighted Average Rate Foreign",
        "terseLabel": "Average interest rate, short-term bank deposits in U.S. dollars"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsAbstract",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sap"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r158"
     ]
    },
    "cgen_SingleOperatingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "SingleOperatingSegmentMember",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Single Operating Segment [Member]",
        "documentation": "Single operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://cgen.com/role/SEGMENTSGEOGRAPHICINFORMATIONANDMAJORCUSTOMERDATADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r129",
      "r191",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r226",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r291",
      "r292",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r667",
      "r670",
      "r671",
      "r677",
      "r704",
      "r962",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r67",
      "r70",
      "r71",
      "r128",
      "r149",
      "r150",
      "r151",
      "r163",
      "r164",
      "r165",
      "r167",
      "r172",
      "r174",
      "r176",
      "r192",
      "r263",
      "r264",
      "r286",
      "r313",
      "r399",
      "r400",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r468",
      "r470",
      "r472",
      "r483",
      "r550",
      "r571",
      "r572",
      "r573",
      "r589",
      "r641"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-daei1",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r192",
      "r472",
      "r525",
      "r581",
      "r590",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r621",
      "r622",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r641",
      "r709"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r333",
      "r831",
      "r832",
      "r863"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-daei1",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r192",
      "r227",
      "r472",
      "r525",
      "r581",
      "r590",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r621",
      "r622",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r641",
      "r709"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r750",
      "r760",
      "r793"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation relating to options issued to employees and directors.",
        "label": "Stock Based Compensation Relating To Options Issued To Employees, Directors And Non Employees",
        "terseLabel": "Share-based compensation issued to employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options and ESPP shares, shares",
        "verboseLabel": "Exercise of options and ESPP shares, shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r66",
      "r67",
      "r95"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares, net, shares",
        "verboseLabel": "Issuance of shares, net, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r66",
      "r67",
      "r95",
      "r583",
      "r641",
      "r652"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Options exercised",
        "terseLabel": "Exercise of options,shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r66",
      "r67",
      "r95",
      "r346"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options and ESPP shares",
        "verboseLabel": "Exercise of options and ESPP shares",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r66",
      "r67",
      "r95"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r66",
      "r67",
      "r95",
      "r589",
      "r641",
      "r652",
      "r715"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercised",
        "terseLabel": "Exercise of options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r67",
      "r70",
      "r71",
      "r95"
     ]
    },
    "cgen_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r70",
      "r71",
      "r90",
      "r602",
      "r618",
      "r642",
      "r643",
      "r700",
      "r716",
      "r857",
      "r889",
      "r946",
      "r994"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r699"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r492"
     ]
    },
    "us-gaap_SubsidiaryOfCommonParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfCommonParentMember",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary of Common Parent [Member]",
        "terseLabel": "Subsidiary [Member]",
        "documentation": "Refers to an entity under the control of the same parent as another entity (that is, a sister company)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails",
      "http://cgen.com/role/cgen-sesopnd",
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid (received) during the year for:",
        "terseLabel": "Cash received during the year for:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "SupplementalRightOfUseAssetAndOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In right of use asset and operating lease liability.",
        "label": "Supplemental Right Of Use Asset And Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "SvbLeerinkLlcAndStifelNicolausAndCompanyMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SVB Leerink LLC and Stifel, Nicolaus &amp;amp; Company [Member]",
        "label": "Svb Leerink Llc And Stifel Nicolaus And Company Member",
        "terseLabel": "SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "cgen_TotalRemainingPerformanceObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "TotalRemainingPerformanceObligations",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Remaining Performance Obligations",
        "documentation": "Total transaction price allocated to remaining performance obligations yet to be recognized as revenue.",
        "terseLabel": "Total transaction price allocated to remaining performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r310",
      "r311",
      "r424",
      "r450",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r551",
      "r689",
      "r690",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r701",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r885",
      "r886",
      "r887",
      "r888",
      "r937",
      "r940",
      "r941",
      "r942",
      "r943",
      "r945"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "cgen_TwoThousandTenShareOptionsPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "TwoThousandTenShareOptionsPlanMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Ten Share Options Plan [Member]",
        "documentation": "Information about the share option plan 2010.",
        "verboseLabel": "2010 Share Option Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unites States [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "verboseLabel": "U.S. Treasury [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r682",
      "r684",
      "r689",
      "r960"
     ]
    },
    "cgen_UnderwritersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20241231",
     "localname": "UnderwritersMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters [Member]",
        "label": "Underwriters [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Schedule of unrealized loss on investments",
        "terseLabel": "Schedule of gross unrealized losses and fair values on investments",
        "documentation": "Tabular disclosure of unrealized gains and losses on investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of estimates:",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r117",
      "r118",
      "r121",
      "r122"
     ]
    },
    "us-gaap_VariableLeasePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeasePayment",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Payment",
        "verboseLabel": "Variable payments as CPI",
        "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r707",
      "r710",
      "r711",
      "r712",
      "r713"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r185"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of ordinary shares used in computing basic net loss per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r185"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "10",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480679/815-10-10-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "20",
   "Section": "10",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480769/815-20-10-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480901/815-30-45-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-8A"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "610",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/610/tableOfContent"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-4"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-5"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/720/tableOfContent"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001178913-25-000679-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-25-000679-xbrl.zip
M4$L#!!0    ( - [9%K/>[)L*1@  !?Y   1    8V=E;BTR,#(T,3(S,2YX
M<V3M/6MSVSB2W_=7\%QU=3-5J_B1F=E-*C-;M"T[VI,EGR0GF4]3$ E)W%"@
M!B =>W[]=8,OD.!3<B;4+K\DIM  ^@$TNAL-X-T_GK:N\4BY<#SV\\GYJ[,3
M@S++LQVV_ODD\%>#OY_\XY>_O!/6AFZ) <!,O+76%& WOK][>WJ*'Z\L;WMZ
M<7;QP_G%Z_.3$"H!^/+ERZLOKU]Y? T@9^>GG^[&<]E:!/C6==CG#/33DKLQ
M_.M3+%X206-P++7]I((*_.-I6)B NA7M?AI#PVJC3@6PPX1/F)4BH2$=D7C^
MYLV;4UD:@S*Z)CZU2QM_<\H]EYY&8'$M3E>E-7XZA=(8T*8[3JV:'@BW9"<K
M8OD#^K1S"2.^QY]OX#MIR.<#_WE'17$[4'R*Q2CGB\'9ZT$B:4#!R8I#4.O5
MVGL\A0(Y+&) RPN8SY^+@:/";(6 <QB.936BTDP5^F1MBL&Q) /*B&.)8EA9
ME $6CE4,"@590'_'2R"A) ,:B!S'5T0L);?CDFS+W-<AX<<\4%FC25&682S8
M7A1-IXLS8)E/F7"6+AT@&.7$!STA!A>H)Z+JEEW";LO.$[LF9%=(*Q84 0_H
MLKP"%F8IL>R!"):EZ&!A=G@]VP.R*J^3EA=4JZJ2!R^%C0!]PM?4GY M%3MB
MT2KE2EVZI<R_\?CVFJY(X,*8^#T@KK-R0'O\\A?#>/=?@X$QFBR&MZ-/QO+9
M&/XQ^'0Y&QN#@2QUMCN/^P;3.JO2>J'^'WN6'  55?!K$-<;X$^#\PO0%:^>
MA'URVA:!5/>W0R"NUQ*!XK6D8==Q!>SSQWW(S2\$3?IU.<_4PL[?(,'G/QV$
M0D.RE>[]@[NN7J2:HJ.V,DP;:8E=R3)6A(0H \<_!OA'ZPZS2V&C3M4J\<>>
MG6=7U6:]JW62K_WZ5Y;I1GTG\/*O_?I4E_M&G:85PC_WZS8U'1IU&H/C'WMV
MF%H@S7J,X>5?C?LL,V,J^RRT!TZIZXNDF?8(I-91L[YC^+!?-)CVZ7(/HO6.
MVU%<8GHUFT$1N+21]I&Q8KX=(&)IT^W;O6(,[H,"5,Z@ 3^T8WTSD[D,M=QB
M6-U,Z]6UT'5KA$I!3?DM]AF2BAW=?EA"W3V7L[P-WVQ!BTQSI?HAW1_2];[=
M[MUGKD/"F.?+ROB)/^QV#EMYX1=\H[']%FVN!8P, _]XF(UT%T9:9?@UL EU
M8 0ZX!8IWW%[<8LV73G,D?V>G9V=&P/CVK,"]'W4/PFSC2'S'?_9& %2?"LQ
M?7>:;R+7>""H/66_R+]WG IH2E;$F%!4.0*IJ)@VWZJ:15PK<*N[BWZ,N;H7
MKZ] 7WBN8Z-?<$E<=,CF&TI]$;*^O+A:$A? _CEPBT:BN)I.YM/QZ-I<#*^-
M2W-L3JZ&QOS]<+B8]V*(A[RU%#MEQ,O/:C:_;LYFX[M[ @:WOZ&^ U1]W[,]
M8;OP+%?EN_RN9OP/58R?+^"_N^$$F#Z]@:*[^]GP_7 R'WT8&N/IO!_QR/J$
M>V*ZNMH0MJ9BQ.8;&*,;S[4I%\/? U#8H5R: E<+[<><T')R>F].;H=S8S2!
M&6."Q*;CZ^%L_C_&\/\>1HM?>Z'E5HN,3(C8W+C>EX)5HQBL6E _M9A=YOR]
M<3.>?NQG5:+0UHHR6]>P^F]H)SG"<CT1< H?M\/)<&:.>V[&W!1$793QJYJC
M?\]S=#ZZG8QN1E?F9&&85U?3A\EB-+DU[F%$7XV&_;A%3M^9L_\=+LS+\7 ^
MO *P!3 FY'IA2;4$WN0ED+9AI(WT? >^WYBCV0=S_  *U9P_S$*]&C*^N*B2
M\^=G><YC(X9LQ5";Z7D?:Q>/<+*CBH*)?JCF\WF>S]/%^^$LUBYS8S:\&HX^
MR %O3JX-L#_OS=&U,?QT#V9H/_0E^\>4"!H9+-'?U4R_R#-]#".Z9V8ZEG>$
M,F4DR\]JEK[.L_1^-KT?SA:_RF&+AO<]ZHN_&I/AHN=SXK 22XV,R<]J/O^0
MYS,XI7>C16A%(ZO!PD:C9#CI+9*,[4?/+U3C#S^K.?VC9OWUOF0%@QU?82]\
M5#/WISQS%^8G\-BG$W#:840/>SV1]0,=LK547U!^5[-8\P?GPUNI)OX*GN'T
M=F;>OQ]= ;MOIK,[<S$"UJ/ZN#/_.9T95P_S!4AA9H"C;O9BB,6P(IZCKHOA
M=[48-"?R9C0Q03F;8\GOT-SK!WT!M_EN252E$GY7<UMS&&?#L8PUW9MHBT2!
M]'"E7,S,R=R\PJ'?+Y0)U]V=4'B.7Y4<O] <18R+ X?!^ M7S)ZU&"-_N)R#
MQ0#J=_@A=<RU7ZM9K?F*:7TC;*#GM1+KRP7[*J-];][\=/:W,YW!U0$_X[M[
MSW4LAXI^$T[EO)_E?*72#CFO>>2UG%^0I=OSO3SF&O*G//(:E==*1G/L"T.P
MO3QJ8[&J0*H :B6BA0!*0K.]3$IBM+X6I&V@H;1P0+M ;2\,/6*KSHC,+[7"
MT,('80"W9W)A)-?/A7(;C'8M>% 1SNVY7A!M],\ST4:_,JX;\ES?;BX(./;,
M+H@\9D./#8:W%B8H"C_VK"Z.0_KY0&0]P_7MY'V#D;U0BJ.2?CXLV4 HFKM;
M$YKL>:_R?D9=S(J[)]Q_CA*JA<GL!2=,$ N[SQ@XS<%KY:8YRPV#G+W\BJ*=
M?C;<V6#>:"YQ/N39,UI?.6QUU;#KF:QYN5$ZH_'=A' \'O5(OS>^NZ8^<=R>
MT9GP&[.S\3?6@-WZ;G== *X70XT8A&?S%?A;.6FD/]<*17-S:X6"5^W8@4L-
M;V5<RZMB'$FP,8/%1Q@KCQOWW-M16(3"LU2_!\X.<[-[(>8V;)PU<U:.19AO
M6O* O</6<;0_YO)T]9$ZZPU>Q$ >*2=K:@H1;'=R-;_Q^"TL[E X#7^(^!MM
M_7R]]FN'E9X9T&98)2B9(4J&@I,<8!%61H16/[+J@_6)+LV,D4:0M=+6P@HE
M ?Q>G[<06*V<&HNG68I[=@J21V@;+<P!S#=84^#7+>&?H4OXS1#4"CAT0?NI
MUT"2J:Z]Y9X0#XQ3XCI_4'L,7])%NR$._T#<@(HI&[%'*GQY"*IV"!S<<MW8
MT7,O&HR=->)B! DRABNQD=; "O Q'B5"!M@,3HI2/Y(:[/!E1D0E1*UD]=!,
MV1Y?+Y;B33Y;V^2K-[@OM,A*VTV^9*9-5\;4WU!N1-:=,&;4HLZCU- P]<$,
MISOB@ 7^M*-,]+I:VR*4.WJ)41+M$N9^K!6H'JJ)-@I[:Z=R:[;< YG1+0'\
MV5H"+BC?PFA&%N,H1R\SHP5?K+5:26OQHEC2E;Y+TK\A$3 0 [D4QCA(Q[D?
M(]5C9+J3%Q9%4A25(Z $ME:^6H"J2+Y)XZ$X>Z6:$UR\BP^+5[*'/QDNBMW/
MIL"UHM/"6)7)!+UFKLOGL'/Y' T,FW;Y'.J4*@X7 B#M8X;:G1K;K1/Z2["*
M77DRID<91O0R$ZL!7*U M:A.Y3G ?E;5Y>L(+[=M$OU2*P@M?E.8M=,+H#S2
MKEW^HQH+V+UI =_@]VP O76U.E&^UI-4"A.P5!]/8A%%NHU[E[!>NCGI*BP,
M&9B*:39_$,6R;5FI5K+ZP8Y:R6(_1MQ1+]42I2DLFM>:\J=:B>@'/NKGFN]9
MGP>78-?;!BRA&#8)]S;[$$JQE$8,_J0+\D1%L85?!5 K02VT4IQ#V:][]=))
MM1MN#5S2E<?#@C)IU5:HE9X6+BF6GNH)8%?&=R$6WQMAIX;LM1=M ]%>TQ7E
MG-KPLRD$E;;_V"%+QY5[=?6B;MA K>BU2$J]Z..N4=Q&V+GT!Y7N^S&0'0-I
M6K.2U0R.F<QICE.:2S;^]ZQ;*WD]GVCO+.Q>K9<9O!%+&\D0>9FU?/>M72O[
M%[L.)&N4W3B,,,LAKGH?M_'1\3?&C(H=M7QCX1ESAZT1/@G/SNFZSSHK4!K4
M6W.RVSB6PDU0\W?D7QZ_"H0/JP+/+A7MJM0.$_T0THL,DX7GPQ"9T4?*,+D
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M9=/^)2DO/ +\M=A<TMF_,\O'5(BO-Y0K6O]/8NK7&\0->^H^L]%RO">.#1P
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MU#T6H(X#-AK'X?DFW @K(;FF3I?%C"Y2>$E"Y"AE%UG37SA;_!6ODH&!6\*
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MR!J?>^WIR'I4,9O5FT(:&0Z8<\Z!%\40Z*!8Q6P&UJ3D(/%KZC46$!]1+'H
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M\)U<:B0EWP0@0(+Z\&F^)0&"(:U@7]VA9'TH*$C<*,) =AS]#@K Q\,M[D&
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M+ 02^>78]M*/0<8T#V#BG@I.SR-8"X6G L&HA /^M(4??[ >[7^'<'M_51^
MZH:RII5:\!''^/%\9W(J99GM%1F"\D'' 6 ;C@\:*@9@]BT4 Z!HJ,CRI&W!
M#+D:G@$D7]@+<"YSFDO=.LIG?C($]=<0)""%&VL+$H%=%.L#>=U,"Y$(X)0C
M19'PS348M;B\O4AKJ_'(EUX7YB;8YL MB.S.0Z0GAWP79@JBW+=*KTYZLY7]
MD.>;^G@R+T,U'=1#E%@/+;/.+Q?:*I-NQ>OM>+#:>1(:6.=#S3[\<$XIO#<H
MAQ"'-K:_G9%Y7FT$_O[_ 5!+ P04    " #0.V1:D7'R^3C)   F30H %0
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M,!C2MP=A,*0@BY;!_%_"T.-YQ"G) AJM\,=.0/)JLW>&=-U Z RIK8'0&=)
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MR8^AU2_MV/JT,OO9D,YP@MV0OG""W9"N$,U/$]*Q=&P7G/UL2!\<@,#0FG\
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M-_.4/OL47P%&M%V]:%0%F&8TXN PS6B^ZS2Y)7,8-?S2/Z_F-$WRCJ36BBH
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M C)9K6CZY,>_^QESL&D_65=6 FC&-*UY:,;T:-'+&3[17=$H(\=DX5>O[#4
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M64NO@:HARTR&YA F.T -Q3^R -24O34X4%.VD:2S[5-4/\>8$/#+]N.A?LT
M?%/6C2/XIFP/1_!-60:B7Z.Y5P]K%<@9UNKC(F=8CX^+G"'-#39?3,I02.*L
MM<-_0U$'@!G2L\:!&8J.Q!(][IC:MR1F?=ZGPJ+F013NT[/E*DXWA&3\%7=*
M,YY H?Q]*QG#_8  #.GKURL 0W; ZQ6 (4L"@?%N3]>4/S&/TI"%7]3.:M.K
M$8!NR(IP =V0!>$"NB'[8+U:Q>P<PH]9_'D6'W*2900=K*KT<.AY<!GY#U$<
MY9M6"OLT!E0,60-CH&)(]X^!BB%KX>GADF!XE"^7<8 99_)H3N+K*$AC?XWK
M(*Z@?K+IL!]ZM3+[8"BBDR/PAJP!-^#-:/)[_P46N^4J5U]7;!6#[LWHT;V[
M-Z,+11"F:7(:X4G:PUKILB@O#6#,:#=#8,SHJ_L45S%U )U6:!IU :@9;60!
MJ!E=8P&H&4UR_YS>/Z;KS$\P<UGM7_<D$08W.H:KE[->C<P^&(JZY 2Z&2WB
M!+HA'=+HA]VR[8.XM2X -:1MA@=J2"\-#]2,SOJ<A(0^TR@GM"/\R&Y) &%&
M5QT(HJ<>>LSS5?:7[[]_>:#Q=QD)OEND3]\S%W&Z^1[!%?]@2#E*_HO9Q:4,
M6/E'P-)3U1R Y?.= LOG.\#24YM(L80DXCC@APH#_&,V@8U2R-\490&-5BT!
M(=J*SC[T#:FS+[[SV)>%UM\I XAZ:H*^B-9A!&V<1W1Y(;.4=\H HIX+_'Z(
M+K$IQ? U2P&JGJOY?JBN_:7,H7JK!*#IN63W1'.\SJ*$9!FZE?A!^_%]:UE
MV'.M[HGP),HWZ$=^DH9M JL7 3P]E^V^>#A[L'(S#.L2GX'9&T_"D()DVO I
MJ@!>$RN\/MYS_X7G*]<$6Y8'I";6?WVDBD]$5A3P#:L33M(G0A6.7CME9A_Z
MAGSIBXC[=)]'6>#'?R<^/4O"4_G;,E5QP#FL;CA-@S7S:"M#EM_E8 #ZM$U1
MM%< K,-JC;+K)%GCKA8?M72AK!4%?,/JCZ+3\RBYRY?Y&:4I/4DIY0&F%.9
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MSQ@*E]E'2KC2&H#6AOXZ>ZF,H]9+?U5QP&E#>YU',5$>XVP7 UPV]!5V2$_
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M30FJXTE<5U5@8U]+[T!2! ;7J 4<[.OH+30GE(11CC_UX5#5FOUX4+13(QS
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ML!G.STGZD('=A7 ODM4Z;QZ1'&]8=19+KO,!\E!=@O1L6VPEE3J:CM?\K74
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M1-)],:2N"$R<:5'C3)SIUR8@K9O?SKK QYF^'8B/,UT\$!^W>KIPZM0F450
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M8O4$A?>PSKTH\Y(TYQZ*L/[E*6K0C+N@XUW\&K>V63K/8680;T73<,T?YSR
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MOQ@+PF4&81Y-B#=JWU83!,6AK7*(1!G78U% 5;^T*\0LSI8=O:';@BS]AIM
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MP6&LZCO8;<2DC-XO[L94[M>L@E?6*)/&NO?855&13EA.I4P_4.1C'>1KU*.
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MK:,VU[ 7I_O73) Q2$(*^U1!(N]RJUNM2+#K(U0ZY_TVM8!PONXJG>L'-K6
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M#)&=EV(&%8Q=$=WL/]=BR?%2&*V=?G$!QQ"\$@BT4S NX!B"UP*!=OK%!5Q
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M!2O./NRU4,X&;;#B?,1>"^%]E598<:IBKX4PFU(KK#B)L=?RQF6L91KPMWA
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MUT;<>70X9;$0I^Q5>^:5>'"FHA5PIGWVNA5.1C 94ASE'H[:P5YX/^9L!?'
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M31\G_U@L;YY7Z\7C=+E2A;[FJDV1>9PL_SE=3ZX?IJOI#8)N/9L*#PAU3AN
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M%A57H#18/8054%=@-G 51!1]5^ Y<&V$$Z]W])0/&T5*I%^!VF UDJD@.+#
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M2%P?BB^??>P&=%)>O <VI7HU]=I'9XPA'TWHU\+I:NU:'#2%ZYS+05N'I!^
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MM;4'C]&15T+!9E<@_A0"5')R;0-M-8P_!FOJLE2T%3O^)+N4^:2M7O+HZ=W
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M\RT[U3@N)&,WK3C(Y&/FV Z@S80YT@C #/W(8[GSP9I>JJA]D4Y+/Z&]LZQ
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M=>C <!]+G,R"%*]9 #8;X) &/OB.)?Z@U&%35JFG^2 D1J,U+E80;*78J$T
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M8+C+@Q,7&QP?$09$,K"?&E57LJY,:_4WOAU%BTWFU5Y $K1;V![%V]2-[?O
MO3YDXZ)L(,^>;KBR=66Z/@L58#E9*)IJ79E6QJD0Y5* G)OBCP7)>9I*K?6L
MJPZ*TQ<G+ .G$'V\-P#.-.M*43UEO;O3*!AEBAK>]]5S7D])F$'!"';1LJYU
M95PKS,.\@7N;P,)<3R7[''PC?^*ZZJ06L+Z:UM3:* KTU;2FDZIGCP!=6NZ,
M6!Y$F<AU,@P5SZ(1S[:^Z@ED*2OK-WX883[ @HAU4%CCK:]Z%(?;+&RQD@2S
MV%P_KF;!$H=&Y@&1+ "E%["^&G]-I6@N,VQ6VOY3\N)[3OYZ+REDN6M87\V7
M9B-@Y  P_73<\=9730782GSZ'*'_PTK]RO9M>%B'3PET7M&_%Q#I%?A=E<@\
M&9:77,KZJJ> 6W'D'[R=%R-SNK(+ @PI?B!P;8@;V++@5UK$^JKGHBX3#?OX
M'FWX&XA3$_0$@DF\]O!S,(?[FRYI?1V,TX;J/37FIK7^U'E3=F&<=0X(LX50
M\V#EOM8&T(ICE8R\J.B^D8,+*P4M3@AU+U'CP5M%3RH:>PPXBL.Z>U>H12N:
MY>CPWE5KJ8.I<F YN]#$@+!FQJJ/JDY$'<IP N>U%87H VT,7.6LT'YMY7]Z
M4:KE##N&6MA.R+^N\I2](&5;-*(<<V'"0M^4%;,T8B9(]$Z[Z8!WZ&D;O=.&
M#$KXT^R0WM+B#% ^/L<TDKZ* PJD%(Z534+1=9M\, 6'FQG3.WM!#FH&IE*Y
M,WT]+)+0TU%G)-WT%M?VV5XM>4>;9=D+5541=S$!CTE#HU+I&2A2[BB%1*51
M4<C$_:0E&XKM_NB:@GK0TTP[7J94;R^-(5"2ECTU7+.T$XHRTJMZ:[:U0L66
M\K2T%:+NE1'52S:NG^'%5D;'3.A6L[X^IGI@/NF+77][S'1N.PN,7<![]%3M
M,.VKM]7 ^\G+BOE?[%KDHZ<N*Z>,4W5\C#1ID+G&J40^1DII3'3CE"K_<)0[
M29OCE!__<*21R;?CE"0?,[U$&7QM%AP?&4FU9146-&_<]Z<_+9':U4.D\QH+
MTHZJ>U"[$D*095F0]-RR^"0IPY,AE^Q94'94'8[:D[V\1-6CO_U#7._J>;$%
M@3Z6$:*47%O0Z&.9&\RLW8(>'\/&:)(:7)#J8Y@7];*0"R)]C(<-'2G.!<D^
MWRB:I4 7A&0\2[3<'8M 6TF!/@8KI3!/G-A[0[^_Q>U0_>BSA=9G"ZVAUYGO
M$K\Z9>;U=+DR5&5^,)4>'\P4F1],W>_LBBKY\Y>A[]^%$/^Q#1IQ-QPRW=+'
M)#,D2_<:'+6JBM ]#*-6CB%[-]6F;>U6T2-_/'G[YYXYY<6,=X5K'@*1!UZ:
MJ$U$V<TRWO*H(0Y(<FZ %R<0F* 893?+=&'X8<OLH14*^SD-< QP3#32 (&[
M#O&O3!)1%@3E1G^=$[?T%MLZ%<_V,M^34.-I.HD&KP1=8(5R8U*#E03&NAA,
M+R4U'+NG<@])RW2WR&0W:".O/B@Z:&;9%+FS@-JNJ*P$B'5AW$IICM^9(MT=
MJ95 L2YZ9R*),*3HX%T16Q&4#AK*?IP+<&AFF%BK[XCBS0"S+D9BX97LA7Y]
M"$G =/7I;8K%$N#G',0U-V% WB$3VU\#N..\9QK9U[KLI)-4G:RTN@>310)A
M:]-> -F7#Y3%@Q1I1J1,7LG=C$N-156;%].J=$PSTD@B?JG\=8Q#.*"NR'G>
MINMZ:83)K1<Y?AAAG4TFI*+-?95;_W9.QM(Q-M86D+EG1^1K(!Q+)ZZ*2IL2
MF;UIN?WR9S>*_E4MZE6I.PZ=AEB>3 US,?7$'2^&3B5N>7GY0*E1T6<81>[&
M74>,6>VXM1BMWEX8K2'<.H&+B"Y=XF&?Q@;%2'(-.Q.OHV]#CQ[3UN)B%$F2
M=3]-G3@V=@U#6<K_F%(^(%E"[L>D?"L!<\TK(WY^FI8B\YH7Y_[\-*T$ 6KK
M.97>\]/@\].T'5HXO@*-G=TBE$C$,1=J-"%9%&(0QV<,-R-'I]^F_$$^;;XN
MOZ?>4,E/2['W'U0Y*K.Y#?KY35O_ILKAG_UMY#6J+U,C5G1\U?P'K:CP>@%\
M6JU]^9S-PU?9AN[G-=?K;ZP0&<LVMS_B-^:8ZL9B<4>E7)JC&N> ]2:*MV_O
MY?W\.IU$\7Z:Z89=EL* X-&:8V+,6]?OS^.'^R::>D'LUH*-6Y0V+9>,),E1
M$8C"R$'C/\M!-BH'*=5<;N(3,#Q<1?NT?1RIAR]?&E+C?L8K_<T"Q(-@A3B8
M'+^'#$9!74C.K+Y@(*P)R9W703G+"" 1_HI+N8,WX(=[#%16U)U91%)AMOD:
MDL!'RVT12&D99/2S+#JBJ9;IS+U[$"!=UT< 3=P=4G:QB(N]-R"+D-1\RWC2
M6_(2>:Z':U+;),8<"W3!R6?.,5\+[[C_W,:EM$MI%L+#+YYL')_B%B$M-D4<
M11G='<2-[KT'B9*QFG<R7B4N PVX=,@S,< A@-P");P&FV^G5YGJK?W5%KYT
M\O+UM;X220"U$JKB_+E^(LO*BE/3_$:&M(1^V-L@O)HHRVJ0[&>.CR7Q>'IJ
M;WF#"S0#3QE%MJ_'7PYX.N)T!;BWF)KE?OWZ<F_E2@NHTFDJK8+S>;!E1W)Z
MO:SM=Q#-<6=:?$=TTF6H .3X0"#A4^;,,N]0SN]HH2>X,K C!RBB6?:V*^SJ
M0Y_0 [@E?;;G4SJ /080G>DETKF#)!<^L^5*Z+@1S#2."2(@B&+/N0F3((8'
M(?S4\<8=LJ:[6YFN!-6TNY7QRE6%YKK8H%MQ%P9/Y/86N_JY$SMH*)/;93*-
MK,X&&V_6,=UL .XE" K)N$0P814G<#S?2Y6?^ ZXV'C$\"8(AD-E,,_MVGQU
M58JP^JPUA^0NA'.D2-TAQ<+V<9=2"N*M[67<XUS2 Y]LC]>HX62D^2X?E;;-
M!17!)@E<WNGC33/?>T.&:8B\F 0N]OGX);(W/(&L9:T+T[?R8@^PQ1%L'\(H
MND'FQR&+U>:AR)ZDW'6"(3SF(&9N0A*:J&W!9*>:;]S IM@Q/>N6+]EEEU!N
MEL#X!$O@)@XVF.$^1*L#T0TDGJ3<68 /F1PHQ=Y_Z=KMP3>46<["4T.UM^ZR
M,T!YCST42[:OB+$!ED5P( ]9=)!92(I,XO'@RC*?^_LF(7D4E8QI;8&ZO:C2
MJ8:ZF'R%#3^J6J9T#$6O=PRO@"[*(,'3EZ02R7-&=3KT]G6&#BWCT4J+MV%4
M9T:&?&WZ++3)Z1Z>,PF.I+A&1G'21*Z3_N:(:18G/-=)?ZMC*!"![US15F]B
M6,)2TJG3WX*$6AC@W-'3WQJ!LE]6Z#'*4?SKT%$L>:)RG'[L.N#D&.2$F>T:
M($Y+__ 9@-(  TQ+?%'C]'HO2-!1SLXTMC )C4N?('<O"#&LM6I'(2)*L"(U
M%GA;<1!)G46-ASG4 '7ZCI@5200O0-8S$21SI/#@T@PA"9HFSC;T-?422';7
M4HY;URX[%<=YLS/3V"3M89%P4V0\GKSFMN@')J/"^=3="6(=QK9OKI("51^Y
MS>#&GOHH C'N'O7@V2_(#HR]3_VD;NC@*561826! F^:^?#'4V!JQ3 HK-(]
MANB'&_1O+Z[ E2>2J6#)7\FXMD2#+_]=%IY?20H(W&L0@(T7*WU:Z455\_D9
M 0KY9L7)?P!V!$K2BQ6S()QH*0:N"  L*%3:X@F&Z"3$!UQ<+,;UWOZ=>"1#
M402TTF+&PT3/H"0-K%2X*.UX93IC_PP,7#NIR)#Y9@?<AO,2LZV_=(T1NDP4
M[Q[C0;LE($K<K7QYTN<JQV_*BITEKOJWV#Q'(*6<M-@YG6@^PO1<$G*EI\PT
M\Q&F/,FHR/35F>4PRR&900(]<GPA B*$)<G$U4W[&FFE"7>AQMK;."Q]!)#6
M7GO[UJU&"VEEN'FCQ8&+C$8:>/->B .GGE#7U_;<'I^XU 9/(:HAT;Q/0@\=
MOIH(EIHMVKH,](>AFFJ";*-HE*7(Y3"7N0]I5MJH56AI>LF:@[H?J$X?3H9[
M*%E6I[:>'*?RJ^4WIGL0;J&]?_6<68!LB%VN.S_:_PKA31+%B%JPFU>E%=AB
M?6P)]B'$-IY,'6_&E XK>&>90.1]<_J>9@<5="7QFLAZ]=Z FQLULJ6ZZRRL
M^F+#<*B=DOG(1!,(;$:I"LF91D!DUJ&0GJOG[2N"<8F;T+^.G(3^84T3;*0P
M"T^<#FD$4P2</VS#MR].FLV5@I7]XPA5]@MK]D C7O''1N]E:I \KSB0/*^,
M5Z)6/)8/$L4YZBYI_$TF!U0"%^.PX2"1!&(5@>GS9PVU.D^1YMQK#)6E\3W1
M5^]I<\0H)H34M32*="P%=)7I),[G'AFE6!G2E(NY;\>I 7:5:[YWCPP:$"-:
M0V]?#'0+0 U:1N^80 =.?"KQ"O0.V FGGV 494K +BU[/.Z\P X<CQ0@7\2O
M *8NH3F(CR>+/:833T@)A*S1:! =>]1Q-%G^Q ZR@-Y %&/)G,(DE<!!G])!
M_DX5D,D.7RV_9Y68L3<1WQX*F- 7Z" O)R4HZ;KP$HO[M] G&+>SLVR*&R);
MG'*QDGMTN5>R]CC(**RB&F+:&,,<@D60%I<GAUEHO')FJ<:6,EQKA7!,^3AC
M 'K<%G]"R0G0T7TG%)",6XTCEOJFZ>M&E2FW1ODJ69]J#"FI.R=IT%12$[\C
M#&JJ2SB^E.]MO0]5=(771VMQ2"T;(>4*8M>VC\.$L'E5+KG6B:7!JO\F86N(
MIAJW-@BSR87'GPXU;EV0SBVE(U$F)@=NWK22)=&#,GD,CF"(-\KWZ*M:51])
MP<?KUDN"+Q<0/0%(6@0=/2,XQ#J),^7OVHX\!VLXGI]@5:0RIQ/Y-;5AX 7;
M @@)N<6:HBJOV!6[CTGNDPU2/2;NOY)4H4;D?+6#+;(>[FP/XLA1XM6EM4&\
M2P(7/_Q!B"?@WW!0,[.Q<2%9P8CW?EL>9QS*7P ./P3N!)DQ]A;,$_P"M-@0
MWHH621S%=DI1,6NJ+F7<"2,+(!$4&A EZ_0%RTSJG0&ICB=K)>,NIU-9*/IN
MU/'&4YA/H<C(J0!W-J-[?Q3G,J*91B9D_'@BI\V1C/$4=G(OZ:*L6X0RWR>>
M2S+?!\/&#:ZZWKXZU\&E&57R>W$\9]48+3EW[PA+1NLC)^OJUY<(\0&(=M0[
M6O-MM^PG6#U?KZ;_\SR=KZ<_H_];&4X125XB\.\$(3)]0_\GXZ9D33&?(G("
MR!I1_1IM]9L"\,6<DI7;8<-W!ET9AX&'3%L76=NGX02E;OM6C^AT"-.B*,.-
M>WY.@4!;"=KV,F;T 7)AJU[FG*ZAEVK4>S:^$ZC3QD#I$^XJ1J)/@E^H<XQ[
MBDK[S^T=^K'T]B%F'>%D3?7\%EF9V%15FT51@K2XP%V%OKM^A6&R?9W$.R:_
MJ"YA_B-4&?E!IM$S8XKQ:G=E'J@HU"F)9T&))R192;2,*HX,IGJTW[U=LLOZ
MY/T.W$H/&K0M]L#DS;X(9"S>4E_)>(&_)_N G5M11N,<*/)VR?DLO&FE!M)#
MU56%27)#2G02X2A'D:/J,FJBE-"4ILNX\N*D$)6BC3@Y;@QT$1\CED8WKM:B
M7$P9Q)'1$\?%/%(84UX"U=34,::N-;J^RGJP-@]V/SB*@ZCXU$FHU!^ ESA$
MJZ_'CS)=0IW;!):"ML-X3J6V(RBGD]5T57B S;I^'T 4 :#4CH4UQ7S<=E'4
M&=>U%2<D4L<;=^>EY*O"LB"\N@ZGA&N$M.=-5LT+9?@N9H$#T\7+6YT43&2Y
M*Z0F&X_.(['B."P9@E?TY8LNN:2I%"6_R$]E8A'TPT\0U;"Z<;?@SS;TL/9#
M/D\F7SDHTH8;C^%#%X>/]T^IRW=@E@:JEI%B'(L;.WK%;;'1%YWL<#ICA);W
M$Q=K.X]H-R0.T_@PV88UM1?LOM84YQY@7.$L 3Q&S5"=.E*RO;>Q;/+X*ET1
M(XP2JG%NM-PMVB*'AGW,&+>8ME+^PZ;.V:W)3IP=#&Z-+UIV57X3]N'3<O$T
M7:Y_G<QOI__S/'MZG,[7\^FZVY A9E<,"0-2.+?#*LQ,V.3K+?.7,&YO,L&Y
M/D@$'DG,[@]&4N%($K.-8U3 ( Q).AFIJ0CVXB5"DB8&.6TJAS)PYV&P20(G
ME7GH8A.#JV%5XP6NF(SQ(!$N(YYLW%)F@B1JW,F?:!R/B>,DNX2DO-\"=*DZ
M'KE2T<^(N3S2A*!<:DBE_:KN+3IH;GJ$EH-?>9CQ "XFM9#NM@\CVZ_%B\5D
MXY%.BLR2OI(Q\;C0QY:BG4KQ5&8H=5I\J *:S+F46Z#<7+4C8T1&I6597/**
M8U]+FZB@P'C<DU(S^XJ_)/2*J,M%A/45=9DPKW-E=E0Q.K5HHT=S'F%&:HM"
MIJRC]];!+@>](N:Y1C\X\2*!M$:E?I1,<6(4]+:/02N,7S8?1E@NU."YD; Z
M1OFVTH3$\G:-MKJEQL/:[J>+^^7DZ:?9S6Q^MU@^3M:SQ7PROWV<_&.QO'E>
MK1>/T^6JX\3G 7>.S$-NBQ?T##)NP3O6G!Z4!5#N7,9#9J!E 1XGRW].UY/K
MA^EJ>O.\G*UG4\.%,HY%W"-<CCR3:_%A!9P$DO=0B3,BOTB'G46B69 !]VC#
MWY#T0;;#&9B!>X/D,I+6:VB3RBVD<O;QT5FF%D=;6W9_9I6^,^,4MTB=$0D!
M8MD:OAS'+@HP/"4PWI#Z@:E\%T*LE!&*RQQOE66,/RP_!Q#8/LXT.:J<I4\B
MC:32.MT7%-<AF!2_Z_@JZND@HBK?M)CKU('4[L2F^13;O# MB=G&A72I;PFB
M:4*<_/RH+,8,XY"3:.--VO%Q!>";YR"5K-05\0A>A-\\(OJ?A"%;.K<Q?P6O
MUI#$EY8.CS#,BSW)?/FIXMWE]+0<07N0*2BDLH[Q5*A3F$[D1.KO!"[.-L4%
M3'F(JB[5-UR/[E_R.E2]PF5Z)6I9WWR864VH93M(:EG?>( 9^ZQ6X5= G+5$
M]QEMALR&L<4Y2*),IQ=;E1D5C3AHTNFB6><9%3%UTX9AN_)TL#&FK#8ZQZKJ
MW<AJ5JEBSWAZ5U<=Q^=W,D-+:2UTU*%TG5#X5*,=88YW2Q3FJ,Y#[0M!\YL>
MJ4?A'/((6+1=JOJ3/QVNTBE_;-:Z"8/8"Y(P.2'\4QAYY&N#*%J_VL'%Y2,:
M^1H5WX*"7EM;:<I[U <9E5';)PAU6TTEH.I#>8]^B<2((2;A[:9:9,H$*0RQ
MBNS.)??C -TN+0J8\6G6/2(T2W"-4-OND.H"T3A"Q;M?Q&8)W*$JZW>3V?+G
MR</S]'$Z63TOI[@433=1#@4;'T/_9-1LWC3CD0P%,&D0(^+54MFAK":1NPB6
MF ,ACG4DF7\P_R?Q (GB';3M83XJ(H?\^E#\^),'()('KX<'W&!7%"0AM4!W
M>)6J3D7G  J#(I36Z0[+6;!/XHB0^T(8]L"9U0L,+FMA<-E109O2 2"G_\:W
MHTC^T%3G&'^//Y%<%%E%A--S$+Y$ +YA&45HCOX<!@Z2<.2V*Z,A?Z0T;VF<
M=DC[ (<TBA[W'Q?'&]$GF/_FVB+A3!>%&6(DG&D:Z8Z$,PV_#EWJ02)23NL^
MUH7IBS.%FJ)I2^CGPKGFT5F]AC!> [@KF98R>:*<:>:1* %!(:[<NP1E8AF1
MK@)K^!8=*^I(HUDTJM :K801T%YDEXV3L$*L!523-/?&23Q9Y 4TI)J7GQ23
MH]BE_BI3_2*9$=%W9EV/E)@T3*7N9)W6]SB/=@MTHG\9IG=@S'1MY?PSO17C
MZB7)P9-.&,U^C5'QI6[:T+\ U\\RQFAWD]>]+D>.MG?C7C"V?O+0/X.44VE\
MT3YR:--))O)>C8]:0HSIA!+[QP9:A8@:ZM%%&:+/2(_272-3JT?_9MU7&NO8
MRSN"JF+4\_QYDG7@H'0H:?,&?[X82 WTJ*Q^FBRG/RT>;J?+%>ZXM_[UF)"T
M7#U'$R?VWKSXT$W)VAC1]C7T$6&C-+1U'L8R3ZO\B1VVW%N](A9%LA;GM>YP
M2^",^9'9NTW]UM>'XYBL8^?DFPU=^9Y\#?<P'GR6;BUNSU<99[XT4&VJ'N$.
M7%ST>F[OQ)W[VMC..,V6R%R GA,#EQS(Y\"+(R14A'$PW'G]^_*L+R$3_])\
M<>,EE6J#G$KBDI^.]'K&.01IZ^\(*:38P@3N,O3]NQ#B26W0KA8@8Z1S6E:\
M6Q*G,(R(NO=H"5S@^0E +^R&?ZL@& ]M;0\Q=!8WP(MQ(^L.R7L&A?%291]+
M-ICNXFD LU^ MWU%_YV\ 6AO 3FPMW8,"C.S-U>@"J3&NVZ:$J%"(O1 S MA
M'-'7R20P=L+T\].H %CNZ3KT#R,O-GHNU7H0[BWT8K$>-#6Z@D857:*5,(SW
M]Q,GU:CH=X8<ZT&]%=_5J$C9%HWH7T3D4!L7:=L_Y5J\=N,*@M9#$LWDKNOH
M&V,,H'DB=O8Q"Y>BKN^X)P;6*K9A_/DMN_%@CK!8UOB_(LU1VCSZ_\?T0P9@
MBPON?G[*CGRRV@*T4^DZ#0;^*?NAR"BZ:S_%J@DB=WM[RCB&/S7>43*"JAOZ
M4QR,D0O4O-[:TC-I]WK;X:S3>Q+L?3]=W"\G3S_-;F;SN\7R<;*>+>:3^>WC
MY!^+Y<WS:KUXG"YO)^M)-W&M8(N_TQ+L<9.38"L3T<J8TF$LZQ*\@2 !T1TZ
M<E/TB2!BD9LDBL-=FK_Y$ ;;!^\-<1O)2) /8*VSL/FH0,2LZ:E,(J3X15'V
MA41%![GSS&.1;BX.1RV/T]208(78&'UN)"5LS-'9%LS@4.&<#L);E?A4)ART
M[I+&P^=R0"5P486-P2Y/$#AHE.?8_F07)D&\V$S?\36)JU<OT?6!B[P@$MWB
MNBWA'O,%BXMJ+*4:0\= XD83!JKKF ]0 SY:;GL/ G14?03,Q-TAD/&E%2/^
MS>#E2AR9!51#PQB?I51$ *D2^>)SP*0_<X+Q0HTI &O[/8/A&A%LX_';[U!G
MJ$8',4A)=,],+F<;,!M^T,::#X9!7RTE"2Y9SZ%;95P?PD/8*J$P,*2FBC72
M=^*ZU&!06:#AC8N((F09-#K1)\=%DU/DJC20463'18^6#EH#97E<L1=-",$G
M+>\-?31(-[ )M/%1G_SFFBE;PU;1YH(<)UF5;21M3[7CI*?0I,OI]W5,,0OZ
M^9%M6>8$_-,G S(9D&4-Y[3[\R?M>,QW9I[G=/N+?KIUT"=Z;L-4JG_V?6X!
MOR<8.@"XA!UQ)T0$VZ,=8Z@.BTU:#1C;(D=(.6@JK]5]2:0FG22;H*TM/I>T
MI7PS63=)]:&YE)6 B!.MP]0#D,N\Z3LF'OK5Q1\_GZ0_GZ1KT>$F#!ST02!A
M[J47_79]0!J8\[I#AT_P*BV:V@-<<G"$;]6BJ>8?V?&!SS@(:2G"\D?4\3WX
M @>)(EV<6<;?J,]@P9"HL\]QEGD,,A%S!I.0AP0S]6 2P;B$!?K7$0/T#^O1
M_E<(CU*2SCCT@7I*?@C@PYF36#4I;<[D#NYX3:_0^:*+ /"C8,X&:@9@_2V4
M Z 8:/S9NT^Q-\8[W)T=ZB< \2_L+;A0D6RE:9_OV7UZVVCKQ4Q"S>LK261
MET7Z3!\<U7.K#+Z,\\10//O*$P:/24F)9;_Y]>[#5\"6Q+6B[H[[8%119=!'
MJ$A_E-/!U-39K[4=48 -Z3E&/*5^%-PO1)+V9$\Q,,;3!J<)1<H6SRB#/WH7
MK,5M!3;45TQVDR61D<:_;6BO'O_Y!6_T8D?@O_X_4$L#!!0    ( - [9%I[
M *IB?C$   0% 0 0    97AH:6)I=%\Q,2UB+FAT;>U]:W/;1I?F]ZW:_X#5
M.YF1IBB%!$"0M!-7.8Z<T99C:RUGWLK'!M 0$8, @XMDSJ_?<^EN-$#H9ENB
M[%>NQ)9(7/IR^MS/<WY:UJOLQ?_^7X[STU**F'Z"G^NTSN2+GW[D?]6'_^?P
MT'F31C*O9.S4Q3,G*E9KD6_X:_KS:Q$U*YG73E1*4<-E397FY\XO92'B,HW/
MI7/Z_EV29M)QIT?NT>1HZLYGUOVOBO6F3,^7M3-9+*;.H>..W:E]^^$A#_9'
M-=J?PB+>..%Y5&1%^?/>/Q+ZL^=4]2:3/^\E15X?)F*59IMGSG]\2%>R<M[*
M2^=]L1+Y?XP<^F3D5+),D^<.75VE_R.?.9/QNG[NU/)3?2BR]#Q_YF0R@4_H
M/<^<?XSIS_,]'@VLC)K7J3B7;YM5*,OWLI+U#_#S#Y,?\%/GAQ_TX./T0J_I
MLG3H^3_OP;K6LC0C#XLREO"FO,CE<X=_.PR+NBY6,+KU)Z<JLC1VPDQ$'\WW
M=;%^YOC]+Y<25Y3F]*F= :\4W K7G)=%D\>'_:_LZ?/PGCLK49ZG^2&NQC-'
M-'5A/BKY+?39GIY?.U7^14_/?C3=^-S)TEP>FK$>N5.U(5=O'^^>O7D7HDQ%
M#O=7*Y%EAY%85^J;2_7@L,AB&-Y/S8N?\/,.H72NZ3TP+TIX)-SI'']:IF$*
M%#K9#P]^^A$O@Y,"SPO+=JH_WF;B>DVOFOFM9^/L\-VO@ DTYS)WWM3QT=7O
MWG[/'J[8=5_O:$(G>97"87(^E")&YG4*9RG:/.*9T2W/G+2&ZR-X^GMYD2*+
M#C=.O93.+X4H8Z=(G%_34D9U459.D3O_5^2-*#>.ZXZ(R=YA?GLO_OT?DV#\
M_':C_ZNIZC39]-D$,/_UX*'?>_%AF5;.\"XX^S5^^>__F+LN#.#Z$[SW0F\=
MG5&Z:?+\P%F7Q04\NW+.&_@'1U"!. ,^G#EK659%GLMLY*1YE#7TZEBOVPA6
M,0$!B#_)U3HK-A)N%7D,3#6OFJP&^JJ<_=N.[A6+3S,\6M,;IZ1'V)\5;'#G
M*-*X4AA/U82PE"EN]IV&AD_JOJ05U$5)I/6Y,^4ACX!\X3FER"L1U2DLX4]5
ML];/N9!EG48BTW1$- 4"KD\S';%-9QO.RMZ+__SI1WC8"]A&&JD: ;YZ,GL.
MBR*CIDSK5'[5=^J7XM+C6Y?P0X8D!)L#))( N>5U*C(858+R!"?MB+!H:KR\
M75XU6GI. =_ D;U,ZZ5SN4RC)6RJ$Q= >"$J5[*J=LEU[WJZ!SGN2SAY>LJ&
MOIUJ6319[( BB8L)IUZQ -BDC1.)4B9-EFV.G-<BS9I2XA$N0E &+F1W,>&X
MD\!& J,5A0\B&<,M2 8U$B$L;2BSXA(VB5^)AQE)!W6+HJE ^3N'79.X:Y$D
M!5=1[ CF '='Z46:,2<HTU6:BXR)>U,T_,JBJM(PV]BTZ(#*!0R.[O\C3U%;
M/JM!:>9!GE2E -[DO!&71\ ,'1''- 5X;CM?5,#AH40;]A*MA*64P_G_"_@7
MC07N46\_3%<P*'AG)7(]%9OE5:NTJG :)4R]C#.@,Z3BRZ5$>D0&D!=PYAN@
MQUL,B%>TPB45SD5:9$SZ\, ,YO? ]/LEI'KZ[LW)JS_O2_*]A+UWUDT(:X:T
M J)/QMK*&L':PX;!RL,.(3.OE@))&/Z"9U5(/K"B1$T?@,C>BBH6?P-%%=%'
MYW=1?@1*OS7[YYO[$D9SM0]P.%]>P)SYX<>?(N!S8.#<^O$?7IX=]V5!E_F1
M%$LK0[M(6L";!= /2>^*#C.03_?@)!).%!S4EKLC??&! CINF.R T@4P5 E<
M!_[5!^V&>XZ<TZ:L&I#P.!A8!MB*X6>K54B5 E.S J,F.M(\O**E;'!#$R 0
M4/! +K2+,"@@#.>HEZ+&1^ 1_)@7E[D:$]QV(8'HX 0S%8UP>'"P$Q0:EQ)(
MI7.YONB2V%Z6?I09LE8<E7 J(.(4U!V<LMIA)4S7)2A!..X.GW6N$;+./G$*
M>U8P?&#ALBS)F<"/;AF&N+V2IQ</3>5#GI'](D5H([4!K!95SJJ Q2 )XLA/
MZPPH2\;V\CMGDMBBXZF).K^UVB(+B_V[J$#MW3W*/[#X+@L-^4D %Y7\"VND
M,+M0YC*!783/$J5^F8\2K27@%X4>4YVNMQ4WI4TL"V=%?I:5^ B;G2O*(=$6
MRX@.&/(3>HVH4CIL_3T<X4*F&0G'(^=/D"] +# J9RF)G$282>9(2A:"W$#B
MLS0^VHZ^&NC()('59Q-&.#"/M83EP*6YD+GY!(>D?P8UH"EQ;KBO(Z1V'!J(
MN!*5\G;^=')P4@+N$O!.)N3>8671;X@79B0N"K@ M.J36I_=-5.JH@YS-+M"
M$(T*>!5<28O1?\\@I_FJIMB7"+OWQV>G[]Z>G?QR\N;DP[T)O6W-#]07Y4 <
M,8<L09,&M4Y$$:HAL,0WG/DCYU@0J<(@T[B!ZY8"U]DZX)HT'-!G4.6G76 U
MKX#'G3.3HE>E.0D>W&5;B4_KS?"A0*X,-\K\7##/)+JPZ?M&HP2E!)$+:8XP
M::4MW3!OFH1ZO;)RM\8'J]DN QS78IWFZK#C.-48MNCZ,P>$=C7<S5R,V [-
M%O@P'2'^&!DC:/5X(+9&B_*J8@I @2&0&>))8I<E$0-PXQ08@WGR); DYFM*
MO.*K!I:!+FS7HJG3# PZNEHO"G'@ID1-N5+LIMU'_0AG+8 JD0^K^1*3/1HP
M:>"&]S(CQ_BI*%DPPK1BX.(Y<CL4*P=(_L#[RV(%O&U%:C7^.^(S +_!H.1Y
M@9IB6; .;P_J9MHB)@HJP9).5M6QE3*1YRR0:0'Q2?;#0XDO[Q!&.[L,&"K>
MK%;\-K1*0ZG!T#M?ML.A\U\U( -*)% )AZY8P<U9455*_-'\X11&Z9I6$U8"
M!2&(BTN1HOYS9!Q'758.OW7,#U+DVOF7\N\F+<G"HU?Q(2(+WC+#;YK9?L]*
M0LL+N'Z*+ Q63(MMVF*B2\T7D*!021.7J-6K=03V@U(YW/"U?&:(\,E  /V!
MUZMCY56PLO"(;;L4[H>_<2U0[[ X@;(O\6:P_F!A,S8S],YW;5?1T:#0C$8=
MU5*;)OZVWJ2E)ZX);NRG" \HB61:HI29EU)?X#NML_$R6+IC3DH*;4QOK3N,
MMT>^#VUH7G?7UW68\L: QH7ZS#MV4N)*H\KU&Y ;&D6O@&%6$A2UJR\'>W(-
MM)4B@]5*IHB!;L"^+/69L35^2V7O+>[7G%\GO-%?\+LL.0?<\@),YQ@N5C_L
M71&"TX]Q[;"9"OP-A<WT5Y\?-G,Z43^@P"YIW9,"]O6]KJR4:C.D/8!;Y@AR
M+I%5A3*!6++(3[($"X088+%FSKA?@;ZO><MLF[6P=T*@[KU*V8Q!1E;T=2_-
M%2R1T%5T1H:A6 H*R$)D-?@L=37+()(O%;%(%!$Y^=O1Q GE4F0)\B1M0ZD/
M$EOW(IFBWT''K21)"+P1&%A.MAYJ'+"C8.%\"]O_GPX3 'ITZ\V:5U?10;OD
MQA1'"56@H%+!*EA+MJIL7V3/X34"=:NL@:55RW1M6^QPSL""A>^3IF[H0I"B
M)89DT(D)#"PEDY*>XC1YBI\K\AJ!. GKCK]"'IT?H7,7=$S2Z"5?!+N"SSYH
M7?/67:.^, +-A584^2D9]NQ'4:8@.JR[<[NW/;YE@#A"%>X9F>SFX913P.D0
MZA.3A8 ?[CE1!NKOSWN_O#]]C7D.OX"2_O$E_'4;6:?8X]9#.(6"GW*U:T7%
MY#M14!VG'W[BW@M*Q9B8L/W5DF0-%QZ&.)E#D=3(E$5V*3;5%3.^C9CII'8<
M7J9QO7SF<%+&]L)S(@=]JZZ<C,<_M-D<=Y1*#R5,3A+2Y=A>!W[Y=X,.2?+T
MD!NS6H/BEO049M:TMVR9BGP^HM+N2NU(2=GV+GNG?UW*VE+L6V>BTF3P%64J
MV;;%L<6R2I'W\-M&'*T!YB#S"!0GV-F8W3E@_T>M [:K-ATYOQ:L>);D_(%3
M7&07R&"4PYIE3&[<7]]2M YS"582#PY8G\4EVA0C]EN#!8%64*LQ\IZ@TLCN
M+U+-^V$@DM'H22/!N<(-D5W7GVV* 3/G1\#240R,'L7Q*,O%)U$SO;#L"#0J
M:+5#> 3,.3Y'?>#(>8D'-UUQU"GZB/]2"*ZJ85PJ2CMD.I-(HETL\9)SE%@Y
M>>_(742WPY JX\.N)*P(C0FH2;"/ $E$&3Q(>F@Y1H:8OJ4(V&]_G/QZ_.;D
M[?'98R!D^C#-T24'$YD?>5-+4-U,WI,CK:I^SM\W)VNTH6<E<8B.S]DB&UT3
M]AV(1OU(;*P]3#JN/>")0<_"LR]W(]>DJ$0RRZJUB(#B?]X;[]'O:W07J-_3
M^.>]_Q&1G(W#L8RGD>M+?RX2.9[- G\:32=)Y 5&:/YZ=OKZ#9B3'_#97RM/
MLR,@;YFTR7\Z0KLN.T(</XGU"-4KO !UGA==@Y3IMHYOO'LRQ]%N*=F@7^^]
M$ >W>@3;B4./<(8.R%[O@2HE,VPV%&ZJ8"]9QV9E]A+-+AV<V&]U\(&(DS)?
M#KZN,WL?7G3;D!H'4_I1:DNO>-[7[P8W"CXH!R@"/D82_:S3,)MZR73NAF,1
M2#](QN$\$)-)[ MO',UGH?]T&FXZ#>%#G@9T&H!!& DRX^]"@AA\A'OZ-+@5
M;" %-BUCLEW14NR/P[$,7MYYAQ4OM&=!:24SM"HB/"XB^KNAH!1H#BPUX-P5
MN:3P"D922!,A#6A9@,*QQ+'NZBA,W=ET$<S#Q=B-_?'<7<RF<3)93,+Q)(Z$
M.WLZ"C<=A>@ACT(I\3!(UH>O\)W=AM-S@'R0VW?.!>KL&-E#]3B4,F^SGS (
MD156'K-6<_9):=\^0%IU GUI1"ZTJ,;(+P5)=-1!Q7?B@YV=ATD\GB3A//87
M<N+'B^D\FB83;S$._<DX\;WYTWFXZ3S$#WD>8"M23JA2/):#2[$.ZRN3480%
MY2> T4<'@=*,=D5BD5P$;IP$KC<5?NQ-YOY$+")O',)';A@_D=B-)"8?E,3R
MZI*3'UI?62?T?&,@?2L_4*?^BR01:5E9:;\8IJ44I,II<DKJU4XO[9@3&-"%
MF2V+$G8UYC#*-K>MT'FMG#!"I2^5I-[@F2#E _B_2ED&!I]P>I83RUJ C(A5
M]K,]ZE^9XV,J\14AQ2\Z03?X)SZKIJ7C?B!ZO&.9BY6<SH$P\G'*3I+3Z-J-
M'YF\W%8.6_E^R4B%*3B-F&(;VVIMOX2(HA]*J\4CF\&K5 !81U]&3@2K4*Q4
MVF'5T,!+]MFV+U-U"\6JS>NE7"Q3O0"THQ+?ENGZ0/EC7MMID$BA&"@,*;\5
MO:O,?J_*?\%+B&/C!4C6Y(H;?)_3S3Q4.7NYO6*;(^<D&3QOPLXKM!Z"Q4!U
M6C?HT['/[L .LET-.E#GC:TG6I,'S)&R14CZJ*R67D:9GO50=+/_ IV(T6;!
MU>3$5DY49?WHL:?U1D?LX)XXQ<0<C$[BX,UO[5*8O4=?5T_54VJ8617EV-<<
M0.VR_75_,^Z_3NW+SC2E[\#_>8'N7JG"UVS_M0$)%6 6E/Q428Q$1&4:,F'W
MP]SMTMJI-)TCDG+416G<-TF,SZ*OVV:5D>W;3?'%7";C7<HE)G%BS!,FP(O.
MB<)(3KCL:TEKKY+]=.JXL)B:R8E.TAR,8)QH&_>O=+@GERR]2H&O78'RQO$)
MT=XO@7L!1XHH!QR-'@SN'CR*",V74*%[OU[M#_;F@G'VFOT5O[._XKESG-=,
M$J_@YA*$!]MP?V(41\F4#TO9K<L"CII1#F2_#D#+1 JND5K!JJFM 1A/B4K2
MR](+1<-=)XCVE3A2CY"5$ [-E?;CU3,-H4<\%?,$/L%M@C%1G7DL5^KT#Y!U
M6/#\P8',&B ^.+Y<8<J"D]^S?U5-@ !]DW(0.O%/Q\[?3QI5\W'C6^K>3E)F
M"]Q]</M:GEX^:\\3-I0$2Q'63VM.\*?T77L>0REH;:",',]9MI5%V^6OCUQ(
M>/=[/'_7S/\M,/]39OXG=F[\8/+#3BN^;U9(?]^JD'(ZD])SNFEQ]#SHZI-N
M.5)/[=$ZCZ9".P\<?^\&[X;*QVQ&E@Z6SUCI8,;Q115:O9HL004QCDQ-9MJ*
M2_KL4JQKI#,SD5#6-2<GX6^715EQ58V6B.9&4P&$Q[/9<)R(DO"1BU[_*CCR
MG/B0;8@)]7-W,:^<&>"E+J9##QT%]&G.UI*412BP:I8SWU&Q%2NIJH,PIX+Y
M/2GH@^K//M=#:!WH8%L)0HV3LS?(2YAS"F%W:IB:!8PW1E0%XP;**JDR#-D2
M;F,(<FO*7 1A;FM 3&3T=MSJMB3)OF5IZSM;CM%*8BYWC?5(?Y $Z_@^.P6(
M]E.-%L_)EM6V*Y9L(^:G,2AT6;$V*I5AV9TONGKA2!4*5CWA9.[57U^A3H)<
M4EGH2)66F&V'R=8;VCE%]\VFKG*K*%(IP/=="=F?3;L MCE6;MW:SR+D,FN<
MS T:MU"5&*3$<,:- -*H'UI__5?)&G2?L@9WIP"\-5S\JZH ;X<]:^C4!/9S
M?:BJC5"Q1$HO))LI0Y781[9[,]S80DXYI<#<E19_Z!_\4J*OIE)^%-#RTTR[
MU_#RL^-7G$!T]I*8H+&R[5(N>SYZ6*^+LB^L0BIT)#<QUE8IU@CO7,'&TOP+
MD.YX6;L$6CR-0&$@<89^$#3>%(Q'**FD"Q/I4.IC85MB"XFA-2/!&59%&:IB
M,9$U0_)55:51Z9.6XS<I*2\S57968UW4.2D"%[A>[(# CYJU2MZ/TC)J5I45
M</\+GE/%J<H;%<YY4<1.V61*%@#7X"IAW*HN65D+FP^0-.L&J"I@995)Q8G%
MAF@/*PTQ8159BUZDV- 5*4+]Q5&4%?/+T8C\-%)59U7/1;H2?Z%NR$X5*RO(
MMA.9#MA/UR$R,,M F=%E9.B\4WL\I YA135M++D&KJ<"2IFC 7?V@?4WRJW$
MH13H1^H&BWOU39PXRH[AJDDYH*;*!5$!3HO8U#>VM8-4D((F-\'ND+>S4L69
M0Q2F<D%5&<-#&Z+CH^G=\A^/V:#@2,T%L9]<GG,^;5=I[SAFC\"V!*T(B4EK
MFR'#-N)+3-4>IM_*3VE56[H0:9;P%#ATF+""/L/N ='O>$[*3%4I!;1-(, \
M8Q4'@)U<PFN!%R5 G8=6;CF&^3D.IBF$RA4+.#@Y.UZ1C9F1D-]I"<M8T2Q"
M.C#J],,T!9L;9(%0^8@F$%+BF(>JY&3T63)I*L;'7A>[[&<[*5Z7C5RQ%+:N
MV\\^-WPL-=YU!39$]@DBPY#'Q%3C#.5AC%1-$QYA.B#(O)U$7FJ_4\4@"=O>
M?,IGBC#V1V6@)N\YCUO&;T=)&!54M'-[V#15.9N/A9O _\'4GP:+^7R>R#"9
M3]W%8I(DWTTVTF1V]&7!\=G1?'IU?)Q.>/#\ 8/D=/1J43>5L]]RJ\1PJX,.
M:1/304+NA"ZKG27]!'+JQ6$\DY.%]+U)M(B\R32>>6/?'8=RL7@BNT=*=NNB
M5HA].:RWH:]'0E8QD-5,BH472=>?B$BX\WCNSY+%3,ID$2=/9/5(R:KC4 (Q
M1P T1:E1@ HR0UHOV\X(#&2C.YW-@YDKIS[\(\9C5TI_*A+A>E'@/1'8-T!@
MR+G RHN;""N>U4\V?3F4QU%1)3;F+NY,2D9>"-S,E;&8^<G$$_Y< L6-HTD4
M3]TP>J*V1TIMJ)PIA$^$)[T P:@JWL$<0=!D='(9/E?53:Q<X>:S&L7J#BEO
MYLZ%G,E@'$_]\5PLYFZR<.,X!$8WG4^?*._;I3RCLW&Q+F'_2MS]#MYM!@;%
MN3*%5_!UBU ERC!5V#<[(T\Y#F>!-_47(?P5S.4BG+ISX)#!.(PFPHN?R/,1
MD^<Y8@<"03)Z&4+(669$#J05U6TJ[0@HD1JL<$C9LC)V5[ R$T)Z6-"X&/O^
M;"'BQ<2?1"+VO$C,YD_$]UB)3UB>?,N!OS-"&@O7G<6)[RTBX;OCJ9A&8BK=
MT)VX,HJ])]_;8R6DOQM1UIAAP%D9.5;5(=0C"E$M?7=&55&\2)))$B:AG/G1
M?+'PO&GB+<+%))Q[X\5W SSPW5$5:&)_28U[F2C0+M,H "M*1+9#8W06>C*8
MR?DB=$,_6/CS4 1^++VY\"=A.'URV3Y6NC*<2>E<.Z2AV(W&,S?T@$5%?A@D
M"S^:^.-@X7J^G'KA](F&'BD-84*L@H2RD,FH6 14=,1?2'5IHU'F_RK2O-;)
M^2-X&R5F%H1B;!(IJA1V4Y3M782K*L\QU^41J&BS,(ZFX\1+)G/?%VXD/)"D
M\\#UO$GL!<F3KO]8"=;*JZ6*%)G'!K8,\Y,JZM12K3-N($$0YTB9"O7,RMII
M<Z1V9W'"]DZFR23P ]]?A'[H!FZ2@+TIPL2=?S\0"=\S%58R3POD<[DX)SCU
MG2(B>-%\,@<=SA.SL;^(X_D\B#SAB<@/IA.P&YXHZI%2%,([LB .1?ZQ;-8U
MPWFVA9]9"L(XQIPPK!;)Y*H/HON%5+;+LJ@/;88A]IM<"J2J2A>,I!5G=V&B
MF"PQ]3C-LH:!VB^D*8K90F)5@*HZYZS-X&I7XZH\-/*KZZ353I9;6T-SZUH8
M3%W&Y+=UB9Q"K!'P OL<797 >>3<'QBI-?4A5-(^&.FW7B#LWV\%HDH)_<#@
M:$<J'[33YW2H+I1*?0>*TCN85 0U<7ZN,H1[E5468F&_0K1;D*0@U0ZN+G#K
MUN/@2 TX0_L2+M[?!I!'$"SX:$/3N1X-ZPIHCU[W'6- &' % E7!W.X+@=BV
M)SFEP(ZN[J,))]1> ;.HND5/!XQ>UZ1M!E;G&NA\P@"@I%[D!W=M%C1R0LDE
M5YR>WHY1*%P-54@ 9[11Q<-]U!MSS2JM,JFRN+GTTI[]]BKIMB2Z\PKFS.KE
M[;:6:CN #0(%;U3S)<9FQ<O:!'W*6+Q%HZ21E1%,17RX_PS<TUUPA>%CM2J
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MWR?!\M;$M0;I[2EO:V1C-XQ5PN0NG-&"N5TX@)WK2S0.A4UF2 +&E1BH7)7
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M_G^"PBML/?%Z=.L&M'D]NG5WNI?KT:995L^+I\$!WU.[A_K"_7]02P,$%
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M%NS0J-]Z37/;M2^;:_O?4$L#!!0    ( - [9%KNH<F:DP0  )80   0
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M\HZ\UW,U&G?<([X>+'^-^!M02P,$%     @ T#MD6ALIK.]M(P  ?I@   \
M  !E>&AI8FET7S(M,2YH=&WM76USW#:2_GY5]Q]X3NVN5#529"7>7&PG58J3
M[+HJL5V6]Z[N(X;$:!!SR E!:CS[ZZ_? #1(CBS'7D>^2ZKN5N:0(-#HUZ<;
MS<?K?E-_^^__5A2/U]94]!?\W;N^MM\^_IS_5R[^Q\E)\9,K;>-M5?3MPZ)L
M-UO3[/EG^N_[MAPVMNF+LK.FA]L&[YJKXKNN-57GJBM;O'CY?.5J6YP_.#T_
MO7_ZX/P_OU+//VFW^\Y=K?OB_M=?/RA.BO.S\P?Z\9,3GNSG,MO'R[;:%\NK
MLJW;[IM[GZWHOWN%[_>U_>;>JFWZDY79N'K_L/C+*[>QOGAF=\7+=F.:ORP*
MNK(HO.W<ZE%!=WOW3_NPN'^V[1\5O7W3GYC:734/B]JNX J]YV'QV1G]]^@>
MSZ9RUX%(ZZZ@![ZY!X3J;1>GLFR[RL*C3=O81P7_ZV39]GV[@==MWQ2^K5U5
M+&M3OHZ_]^WV8?'E^,>U11+1)-^D*?'2X5&XYZIKAZ8Z&?^DU\/3>U1L3'?E
MFA-<WL/"#'T;+W7\%KIV+ZP/EAI6I$>C>Q\5M6OL29S>Z?D#(>KA+> =T!NP
MD\>7;5W!>Q\/W_[P9NV6KB^ 81Y_/@!;*GJK^4Q>?N_;/W]V_Z]GCPX],$>.
M0RL8S>K['RZ?O'SZXM73Y\^*YS\6ES\\^<?+IZ^>_G#Y+YG<+X/OW6H_-[M[
MW[Y:VZ*RONS<MG=MXXMV5?1PS=MRZ%SO@-XEK,# HQ6P3F==4_AA YL,G$YW
M;D!4.V=JX(]NXPO35,6V:Z^=U\,!0[K&=/O"KTUGZ?(3D/_ARC;%3WUU&J3X
M"&_^\V?_>7Y^]N@)*PCZU_U'QXNBLU?.PUM0,S3 X,6E+7'2Q?WS\)[+-.T?
MWI1KTX#47Y0]_GS_ZR^^/+T+N__\Y?=/GUV\_)_B\N\7+W^//7\^="B7ZQ;W
ML.(M*4JS=3WLH@,!>WI9G"] 0^'_%? &5\%MKNE;T*AG\8?1GBY .6W@0ET<
M;4UW7%R;>K TUMGIV?UB"_M%-YX6E\/R%]BYL.<P;(LS M6/[T$&@N%ZL@"F
MZUU9,\,8[]O2&=SQ!;R<'KJ0WQ?%:JCK?;$UH.AFF UY0_@)^7D%DP&^P:MK
MV!3;>?R[LW GZ2*/DS)]#S.B^<"_KMO>PJ4".-9VL,B-M3U8IR0P^"X9+"X1
M'\0?95"X-;RN787ERR1WKE_#;FT<+AM6M^TLS!)Y71[>K5VY!FD#@V5AE_Q
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M"8V $<_IF/C'\4R7+1H!33=X70E&AEB@A>FX)N&8Y"J 789["0U-:P?"$5U
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M#%/2,M% 5=>$&A)3P'U4O(82C2X2G2+$\J[H9G4JJ(Z64L^7U]!'(",RN>O
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M]Z7_!R)\*BW_<A+-SI)BH?9>.RM,X;P==^;2)_?NG=\9NE!G)21R*$GO>D8
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M7%^N,!MH!"_ KFLP/SASRBG_TK!$E\!2<8><OUBY3Q"RT9K]5CVT,]8:S-]
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M@?9R H;&5AQ*P-R2[53\9 )U,P=@\N X%3<DWK'QYDM[H662L*A/;SA0<25
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M/=[HDQQWE8^HQJ,V8H[_FT=4#+QM4Z9'5(+Z5T+&CJB4CJB&XP6VX2*YS4^
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M:C#$1LFJX7PT@20T8%0ZY&*B?43E9A7]^K; U!M=PF5X$EJ0O?HM3VYM;>@
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M>2WBI$XSL_:A99>02[^X75SCMM\6MBCO+6)=(?[GS51=5NQ% CEH\>[.XKM
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M_[2OF+3 [C:(C8ZX-0S3+PBN0U#4<6E!;YS]93BF_44Z (UC0+[Y"A/<@T)
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MY85 ]3DU6HHQ1^/MDJ7=1S',IC\-@!JG-<V$,B:UY)M2/86&/.UEQ0I!7NZ
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MTVFBGS:6U<A]%R6 '\0-9DP8A([H2NAM_B&[^[LPGK<R<X@\-4%1O[MW:5]
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M>&=+M_0&D*ED5]O<MKSI[V3<H<4$L&+#O9H_KG[,,V?9X*1=1"$@Z<V<SU-
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M+\S(0%FX6NQJ)4-QWL.<*V,]6EP$CD9O"N<0X$&!J&';Q@A3]&S9Y=T2/J6
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M4Y;.=5L21Z?M#DE[>P8'7R^8A6.:*G\ATV%YV.%(=BY?K$7B<EV*)FV#=%N
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M)4T[&D5R-K?P><(%4C-!@5D)L=X7#1^-KT\K;/ 9:=X=Y<_%97HB1]T$>X"
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ML=XG-6H"O?O56*5GZ>>]K/"@J$,*A+VNM!N1:R/9!^"Y;MH-:3<?QSZ%;^Z
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M_]J(OZ!"T55-91T]+>&&WW/2C-*R$NRST[)K@*(-<V-\]>Y?4JXS?['XJX3
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MK@"H7\FRE"<;ZVR_9E&V9B\#"-!F'6G-+ES5OJ["4_YY_A:IQ+@ H'4KJ$-
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M_J/1)+$X\XS _:!RK,3SQAV(_*#""I_OI3.B;&RTF?<"1%-WC(L\/XV*GG[
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MG%K64W@<4,BLVT6Z3VI!)YC8#[T(#W_+4W/U?BM/1SBW%_\TIG_6%BSME>4
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MC?!DY/WR52I)5@CE[2"5R-[)G>CFXL0!]G%7X="L'.ZC''W7_Z^C*L>W3_$
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M8%=K\YAX<\[:!Z)4N@4::FC:GO1<>[@^=B@Z?_0S7'6AA:3WV(YHG*S%A:J
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M_YB8#<?H["P^FO)D5I=,X__=CF,1DDE%>.^4E[8$K+N_.3EVQV BO[XV<GY
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MGK+W]:9N^'R_X2"[,0L8[%[S";+:KU-K&S[0ZS_D_]NJ6I>/Z9\RWWML:G\
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M(&L/?+&Y-[6^$!OBKU=LV!U0<&+1)8M(.#U+'V"F!3?7IO?'X>+[&^KKD+R
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M\*U#V8_#JU1=(<Z0=&,ELH@S),?"$0OP]QF2K?=]9;LG33<I?ANY#[<34Q9
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M'6([IP#6"J;]0;_BSJ\@S22J8D9$[SIKYRY->8+Z 2+6:JV']Q!S!J)B2+"
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M=;_HCP1&OCF31]PW=;XDQ^6WV7R[!NXOQCTD7@/')'*R.+]? RD8%Z_!2-=
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M__1MQA\N(26:J_'],7$/>><-].(&8E+[V";+CF?, E\-?L1Z6>VX8TN]4**
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ML]*M=<H6!UH9R1=7U?34JN"G99*&I7IZ^S?/3O^3)0>4!N*HFLUF!>%G*H2
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M7/:;+^T9:TD2^5(K_=I'FSK_ Y;0_R;^ZU-V7W#=^E4*Q7 B.?\:-] WVO(
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M&,,;J=O\V(.)'%$H/-(*\XK92?[X+-RAU%E6-MY.IMI63@VQ2.=HB,42'LJ
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M*C9'@#%@B@CS*1=KOFAD:&N89!OH-_'"5I-; M\^70U37#X]G+A$0WB$4Z)
M>BKB#Y,;H* 5RZAU24,#NV45%>"<D0HYP:0M(G 51,NROA64'AA,GVO/]/>X
M)[.3?[^R_4J6G#YOOR:4;NWIL&33W)L/PNW-87TI?AUM%7)!*>/ \$PP "OU
MHK?Z">6AD'%&G\5@<N8^\CZ(P^BAKH%H<]-064N37%G+ORB4^D0]CKXE$=@7
M&J2)* L#KY(QAXF,NMLU77:>E5>.]SE=H1VXMHD!4%2_M1&[X0\PV^9MQ+][
M7L_K*[N*=3W;#LU4"TC;LST_3"N*XR\UN>#BT!5@Q?<^WTU9_7RO-(=].$<B
M'__!+/R$^7'<<, 3-\NGW@4MX>O\[<_-;"]./[+19.B#\_ !M&@4S794O8L&
M-$0,TM#M^L]I$ 4SH.%MFTT>F"A7EGZ@!H9YUTPD@_K5^M7ZU6_G:LXAL#.5
MPS:D<?#(,[ -%"<SWR:EQC%[. M'<V?Z"2!;3 MK8+67[4XIXPS[R=JUR_CD
M36+G I[54&5X8^V:\$9_!Y;WV2OG5GO9=R+"_Z583D17FCG* YO8: ,)EFW^
MK;T7JK8R\#V>_9"Q<G]AWIF.IN>5J,4M7]YI*$:(*7X1[),3%.^0E_3"P1JW
M9A>WVY) 6ZZ9&M@555$Z\UX,?VQ=WFBHC59C7#>.9$)C?'(<R2N-\5?C2#Z=
MT!C/T(TCT6J,?WF&U&%S>!GB08GI"#@0I$#W<O*0-71+\JIB+YWL^5QFI]>A
M7?X3LN=Q':1#>YR^+5Q[>D+VG(58V!$\_HU.]EQFG<AXN,;OZY"7Y6^<U\W^
M,">JG&K&)Q\7TR=$M"<DQ^T)1J3P'0JO5Y+CKT2T_28DQP=T(MKX($)W1('/
MO >T#TY18T&=B+:M/!8:GA#1IG*D19V:Y1,BVF9C I^S2J_LY%]%M ^$;Z [
MM,=,B&CGDD[NRI<>U8EHMZ ^/'<8OI>ED_L'FSA'L%JY_SU'DLB%'2F,>/^:
MR.K4_"'$63*%^4ZQ#)7A\"XK8/J0-W?@V*,>U'O%+?9/6ZY)C\6)2I"[+OF&
M=3:_1NY?C_](@O=[PF=D3 V\XZT&$GQE8UKZN$@3U!5">[$_KP0QH'0+X:4#
M'0&V@C(,G)4;_<6T<<6_FI*<>C'0IRT<SGG8 ^S,P-Z[3._GRLI=">6[([!S
M2M>I@?)-72:S6U=F1&?X0OX!4=X+2)P'?ENOWO TO"Q2 \;@T1['#LO++%>K
MQVU:]4Q145 +DNQPNY>_#/'#FV;(IHK[FI<2KOIKKH/QB2YYGNQHX-:$-+#<
MHU,-1#L=KLHH"HK(Q!=X?X5#6<L&F,^3&1*GV-@1E<TN?K'1H06,L_VCQB>&
MJZR?V=OYET62DV*?FC] 1A7J:D!$0V5#<^LF:D!B=_[(4Q9]J@;NC-ANLVDN
MWB-&WA6&)-E;)"J74Q=S1RDG%>\[.'O6'5(X*Y [3VAVP$.@=K;7%!QE?3<7
M?M/9HK<8;YMTI&Y@V'GA"SP*I<M)BNDJ'^SLK)??YDJ&X'>9:L ZKVM(@817
MJ8%FHO3V*30V^%_-LW>;"-2 _&@#)X1V&EX!!=VBYY'.M-7),!7QOJ.>=:OK
M/X-HZ3@G=F),+CO";@T;RX*HSQ7>8UMEIME)J"RDW"PK\Q?)!GG'LOPF!V<3
M1L\UDTZL=Q,Q8,9>G58!SSZ L(6'G- JR D;\/%H#NN[^DJK(&:P8M>=HAB=
M5,'!^^S[Y[?9Q*_<NIN.97.D^PBM)[=+#2\4KU=L@1"?<4? N<H=O+5D1YD9
M?\>9CNI6JLW+R)BB0^*(990 K3XE>'U3%BK;'C1IU>E3%O-'!S9K]2DOX6E5
MJ]_@*<+$:%OMZ)'KVM&V<SN"DZ*?EP_-[C5#K8 *LMUG_M24K5P?? QI5_QQ
M1*9?[[AQ>VJ:S&!H)V$V+M:=1SM[-#1GE&"*&Z<\HT433^0#*J8N;5B'EF;#
MQKV(I<H]-U7)U4(+EUS(G2H\\+37"5E>MSH<_ND%FA6VQ!BK803?#GG[TQ8%
MJ&)]FLG.8M#(EVS?,D N2@[*Y0O>O/V^S=#O3?_JWJ1%)VJUTGY"QW1"T6I"
MQU2G:(7C=NQ3Y2R?5+1JME=@YY' 79Z3BE;AJLLY$L$)QB([UYLD>"5UO?)]
M6>(#[#D8";EW0?80V:>S;K.1ZR96\@B/E=6&5Z'J]S6.AJZ3>:_":H>5N.]L
M[N\JR;_3',K,/<1NL:]#[HT9QN3#O7A9'#Q[5+$JD+Q-:DU7;(.<D,Z5PG>+
MT6N_[V):+_$*W\TCNTG%7@>0=@Z6&YQ7$<(4",C'+X8IM@3](L*2/\QQL<O&
MCS^^*_YPF92:F($%0/N_OJG(2Q5/?2#41I,,*1K3Z/!)L?!<J3/\LRRVRJ@M
MSFL6P;[]!,6ZY1.7F?A;/?>$:@!' A\DYZXY>CAA?\N:(6*;)J*%$CPH&VHK
MLVZV4E>!9=;HPWCP M8<B;*'ZKUXB ?T=]C&"_=(N>ZHK/0V/-W\@]+\%I=/
M+0(W,99X'<)(]Z9_+T.<#4L./;FS-+^9: *L903=A@A^FM>9V[OVS7_N;SG^
MO?W,OR=LQT]JO*(M^# ;4FC+M<Z#HP'DU;G="S@,#O1!@3*IGL;IYT ,-;"7
M7WX;4%&N_X9C^FS5;QQMM#-ZT32E_]0),BG3L'R^5O8'IP9BXB=D?VP4;F*"
MMJ,,4FAU?]:@^-DA]%:Y3O?G3#:UZEI?ZK(236A04"&K4R6*ZLP5:,7)FDCT
M:9"5NZ 60P:7L?[]_'R3"&V$+_U4J]ED*L(C!C +2165%H[1Q<[:XMM:A7N
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MNQL;39;]EC#W?P/MR+ID81Y&:4\8L+RF!@@2M  QI]1<E5PCG(?B'Y"7(+Z
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MZ%A,WVF6A*)W^7LVBM$F.$<G^0W*\=L2&!VPKGZ[M",N72*_AKCTQ>_N&JS
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MDA,2MQUK'1[J%)UK1":L4IA0L<'FB$X!(:6[\P:4,T5 =S)>IJ:&0\5GXA;
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MF2Y6+/)Z#E'.]C>>CKE*&E3NO'<_S1]ZQ#$F6YYV56\:1&:YS SGT MMI]X
M:1$SG<_&XPCR/XQ1XB"L#H6F8SRD06F';[@&3QE$YC@>V_L<?.QIE4<A=)>V
M<YY$@UI7.$W'< HNTJ_E98?ZHV=Z-_A*9\HZGY95H]B9J%'Q^]KS!?!1N,6H
M_H\\';IV".($6_(UJE]7$X@__&9=S2__//8!"JP-8/ML$Z;C/C4^ZO=*$ ^
M_]LOROZ/#OZW8+BD[;KN@/%[I"$'UE=3V^S7'G]HPB31.D-X;+]NP0AXN]>$
M.9V=V)8?R9FVOS%*[Q57@\RFT*74MA)/XD'60?VN'NQ=H!.G1FW99++QNM@U
M]OI&R%IN6$YXIQ:5FZLLV^ 23DUT*7 ;U4\53>LRI CF,70,\A91>@TR@^=>
M;G\H)9_29[\$5;%+3V*>HS 2UP 6^PQUZS\V7O?7CI^5%'DR+%--F+FR!W=(
M<%H-K<>$V5EOPLSVPQ:']./GM-\8U!TVIA@<2N0G)<61K((>J%=7]3-N#_@
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MGNP\QYSQHZ==>L\/25WUTV'+S4(1QOCSO_ (?_?18,LWO_&5]? BCJ'=UM@
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M8_16/2.C.B-&MX#J>_]U */]27MLI@H0;&_?0:H53[VQR6@/HX1A,LUX"_D
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MYKR^_;U2%V\E;?<7=N)IGI,>+OPQV(ZWCF?'XP>$U.]4S[Y<2''$;_O5;P*
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MIBD.Q29I=YW$FAFM2/BC]C:R-9\PJ#51%J>XXOZF_6!3+?9%$%D@-H;GQ:R
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MIS775]0Z03NT3]0:CI /QK6R6Q>>^;72C]'XA28;W 67K&T]I2.C)PGIA%E
ME8T!<]34C.)G&5>!E9C&"?\\M*BC/IO17B=5# E/-'>2=J<+1(KY?!PV.)'3
M9%<C.^X>7N0?<JVO>I0C_9 ?;55X7P(OY6J]@0=Z5"Q]'CM!K!M"4![BE2^2
M$]%5U#E3:<>?^MYFMA1>.Y":SHQ]TE<(QGNS:_T^.: 8XN:M3S$Z&VY"V J=
M*0PQ+Z+1QQX_$'UX@^(;Y:-2>%U/* H_E1\SLY#B7'SJQE"4>45^R&]$.V5^
MKYL24Z/BKEP?1,?POE6R$YZR?8R5"S5K("<M*?A+9/D<S@>^CMDAC2%$7(-L
M51>^*TV*D.!ICTF9N<X7V&:CJ>Q>4U-)@;NC?B;Y&>M>4"&4""]D>E;+[PN/
M%]?-T'W='"A62WO(-4"'5(4O!<6JN"0]JBU$:\L<+?0,S6:P76^G,IXW+8'\
MO2\9T]%N0/&13-I32V-J@VT#==2"5-(BVI87(O=*_NY5UN6AGVZQ5'/]MOXZ
M/'/_L(UM:YB6EV@SJQ5;#2S*Y@M;^+=Q3[=2>290M9TQL?78DU*ISN?:^S+5
M!%]OM/...C6IUY\P?T!&PJ?0WP7JN:PTH&HMR\5?MU1?P$]^;UA8?A:_!.K@
MU(/W5>]/F/C8%](_0(BS']E4D-%HO/MFZ]<R@9%,E5%E>;BQ]<1"B-597U[&
MPY<<SI/<J(J:H3\\W<]3#52% (\'13/1U%&U8JJ$M;;]L1GB',MXNL4 ;&6D
MRCJEQL$6.)VM>(2 H03.@FL-F-@(=+\"S<9L5W$!K;?6$U[,?N^%#:!;H?A&
M:_%PU3A<VZ\O)O)?.!HPRP#)MP;,T( 8'2H /4);@VTGG\%+@PP8O^T&S%^)
M!DS=$X;1J#LJ;H18/A4RZV4GD5%](\0BSN+@A6PH7XP*'&W2YZ'*1M_&$)2$
M%^\A3[VVG56O(8PJA ;,3VN'1[&'M;BG+@8,OWK&BUF_IJ:FM-KU0-4:L3(/
M/XMAU>NGP[&G)9/0_YX!K^%!/@KPXK2V9O6F7NP"!A%V(X E82^%W48-F/%Y
M BU!7MF@-6"6CVY (.A>-*/62Y@JQR'W#W9"1Y!_@/"D9J!OL0&COHWJ-/N-
M]>LV-L'%B"O[A&W )/U,4-8!$V%DU&7JCKW*N&%KG-"$WFJOZ80>@";T"BUJ
MPGO,]#8Q^Q#7Z@A4/X X:IR*K+.G:["Z=<0$F\_4[1J<;JWI*&$$@#QCME^G
MHA^5DT$^<CFCIB/HEUM,X8@YF8K*(=[RC\S:&8D<\W<G@XXR$@._.R6_GP@O
M'_G[6N615X]\'7&T*<'2[Q10 BB1>%2]$M7-G@\5DN%6&/'99_MKN@'DQLUI
MZL#7:N;$-)6],&"HR2/=7G>-^DQ^G2\_.E8-0,N#=':FL6P3/ +#)#L,&.2Z
MJVM HS,QX2BKGW=&2]1BX46*^8/E!HR&K$G3V9F\')G@-L*F:6>ER75LPDAJ
M=]"ED]B$K_[1W>VQGIXV.W\#<D.O&3"_(,ZZ]R_)T'&V/L "X;$&C-7W,Y!5
M\;:.IS]CY^I,IH<2!DF(<6PYNY,-%NMF]"C>,6!HS'CM!NTA>"$..4TC#4=#
MET^\O./(%X$^<712_,TS4;+@T0M6Z"3:[O$O3PC'$%:(>XH 0;]N+2X>"S9U
MS[LS7KD\A@SJZW4KDX]?U9<WN4-.W%J5Z?QAPN%6^N%D8GR-S2>MZXIUA$.:
M:+MCS,VN K77<R0V#G\&$?S8+\[RR)!6G1B@OXK_+,85DJ@^9MTK8/36+ YQ
MG JZ$G1<'Y]-VC8[14F?K[]5[]E\M14Q%"OP/CLWF" ?RR<%4K$="GGZ><?L
MB/#E+V:]WHX3@SC4><IQ*GP2*%:RDJ:;EL/;GHQ*/6G9C$.N9:ES)@A+(([W
M!>-7)2BGCJTW-\YHZ&S(L+;87H(6H PZ>X%&?Z4X[R[D#94?B<VFI,<)N,.D
MV*R4G($IK\OW<VX,R8MS0JVSV/F4=.8/H0&*(8O)4#=J4!#U/:&3WV?U[RX4
M%=]@P9 ;XDENZV_B[?RW72?VT A*WW,1'$7W_B&QA6"3SC9T2V/<C7)OR@;(
MG2B=,& 2G'=GAU4/P=5>$=66@9<C\_8+GCM?.:]UMV0_WZ3%L:J!&>+#7;:?
MB\"QN# #QBQF;ZFT)WD?)%1Y+HQ041N_Z@S1E,?VQ]GQUCM8$>/ES"?Y=ZX'
M]^\"<T@'% P&90HX+Z";D?>7\4(UX1C@$S;XA"[/@./'3F*AKW2("^SWF1XI
ME R4&<6&%3+=7).5\36%MP5SBI#@:=9+&7'P]Z38%?<S22IZ0KG%R; =TI[4
M;JM-AP2R]>'>H4#P TH*:>5$&WO";SL&F T[0-&]8W'EW,I8M<5=^!-PMC""
M4UM(&H =P/L"98!O_\ZLOJ?W378KB.U'B];W2?LJ;E8*SH]O),D],S;_N,C-
M3O3S#TP@@K (-HO9"-U34L6S8O:"Y'C=<66&>(L!4^J@Q]N*;W8?H+1/$365
MB=%G6UT(*N, PE>M=L\5"P?\HDY4Y#&+*6&-.UI./#,:'S1@9B'F<YKU"/ZI
MW=GB@HMI\9#-6@BGXKHV24Y$9*VH:$G^5K2A=WE>8(C)-2J5TS%HGM[-YLHI
MEF4EV</I^!2*]0\GTN3S[QP*"@W*&;:QP^B:7^>KII! <'H3J\W)22/GC>3U
M;G$G?L$/(.Q5!U6E7E+LE!8?*4OS$<M<@)Y)$6V';(S<.JN[*"9(.6Q+L]C;
M=K#EFEI_GU.4?^[:0!0S?NPP,$\Q"_]QB'@6:WW,)HB74YSMH#@9<S ;ND C
M[)(5QVP)+1[TM6AVK%"><TC<M_YEU+9VDZ274&VUE.?<+]&*63$_/7J3 ?,C
M>R[$<577QXH<>LG&9""$$51G@VT6>2L;B2/"5++<V2+!?ICF_T6EUB:'3BD@
M,7G$"N&/6KN)/.YCFZ#+X?3W!M0%1MNFX<1W9)#$?N' QJ#^'A3"A;SS@BGM
MV][F(V']][245:PS1NZ2*]RL6#SRG+Y MP-Y8"!!XIP_F,M7+_$+7 8ES\\\
MGKWM!L7Y$L-B5[077CH:%?O($I]S#2JLPR]6[SYC5\Q;GW=UA<;W!.FJT1,S
M,[T=Y _/R0#G2UU+A&I>+9 (+U/; R&PM$UGM_JT#IL=,";Z,9IP$XKP!847
M'$PVCTQ%DTA=S)Q:9XY\[,,?*Q-']@2X<TAA6,0>.H(0>T!GUW^%3DKJ]]F*
M_66EF?8V$H?FG%,5T@5=.FM(J=0?:E*_B\0.<+)&;!J"MX1_!OEB>FK[*.M3
ML!3B:8$:\\UA%1_HV.] U-UM,9WZ+Y$H^9'"_;;N&M2F70<_()>*'ZZ :D%Q
MC8VI=()X*^_"G3Y*UC*0/YDFEG.IN4"UOY*JITL^99S>9^_UY3-XX3U!\$2K
ME"OF/Y:F$-.[^_:88GB#='A.(2B%%QHPIPR8Q:R/N^2,TPU[H(OJ=]JWEL+-
M9T:FS*\KZ?$DHL[3@3?_1>J"IN@^1D:=C<,# 7.GG:MV=W23Z:HK=),+V;E#
MBA"88JO=KT]D60+5U_27\>]"YI[$!11Y+.>D/1<(;-%Y&W4X=&%K\1LING!5
ME_G4O2+[>VBE#GTQ(\6W932LLV%[:]CP9L]HZ]W4.Z[=?4__;,KYWQQ3^N\<
M)\HK1(!7<J=G;]-(7BC35&*Z@#(9N*1M8F8A56PJ\N<X"GNZR#Z6/O<OS\^7
M@0<&Y=V)!2N^[&@*C532(K;>EGW3;&]%7G"O$*'HQ3^(/T8PU4._$2[B;XPA
M$ZWWH\'N)<UC#NA,BG)I?T6&DI>X_)T^V NW4RHP.4$V@BZU[3ZGXN+O^]_9
M=I0K][*J\ROW/54$G7]61=J=?'A+#1#A!^+^50D5.)'0DX$.7800J'L3".+)
M+0(-F,13<%*.SAY**SJ H%<#9O)/-\&(;^G]]!<?8__2*>G^\'8*;&O =%%(
M16+P)OY>1"]HVOGS_ZOB^&]5<9CV$V%CFMK-IUP]6=5T&BS.IEP+9IF*H>P"
M^ZBV)HVO^ 942&K5K<GA]L?[SAF=G:VT(AI1.;MDG-NBVX[=CFU%M#])/[*X
M%**("]=$Z)8XU97[)8MIV.2II\GT G_2/D9U>Y6W^_5:NDE#B-@D9M.U&.?V
M8\L]_2M^NL".0#N,RUL.4R[U,==2-XW9K5O_.*M.T?MZ4F*YZ5S(/T#==#[&
MH8=GC"#^$-1)+&L6H2H*HXXGD  QEN!@15O]18GV6,[Q5YVS0J'69Z*+FRF^
MTM=UP.T=E_,SM,B#?/>2/C&,&R+'RGFJM/CG>E*+]=;5=Z.-N3ODL-S.;VM;
M. U7DT5H"YLSFG?.P<3"7WJM131W55Y!8N9FGYMJHW-6D@==<FAQS3W];#\L
M.%E%\I.0,1!6*8L]7A PD(4!@3B164Y72$MGTXU'@X%FS4?Y=OA>[ZS[+2^'
M4\SY1I0JJ[LO]TR]V,,7)A2M>?AKU]%W,6&0!=BK282.O\J0H6J^TQFR9G]J
MY?OMM&MO,F3]6K0@41Z$9LCZ[FON]Z$9LG"$;Y>7I3!U(7 S>8;NL-8IYH Z
MJ)KW04?(W/6)!0&>2NZ)9[N]G#OKNDU2IYZ:SF>T>\1U(PN#;\D24T(.7VKI
M]&W]IMEAGX!@,A0QESM0GL<53R[^9Y>P:.9T5>Q^M"KV9 Q:%1NN<I[\.WK
M4-P;D_D/C!!6(/X3US%<2Q88U1&-=<M!09/&72/L=, M9.1/JW&/&4'^'B>[
M0J;@/#H'(=F!4_A$DXF^%$Y(Y9HVOLGL85(+(+@TA1U=?=<& ]*K%;.A:.6D
M9,R4 IN!]-BPYU)[.^-='K,$F3<O>?1=\N"\VNJF)KG[M@FL$N_X[6\[-N80
MX#O^[$M1>7F&N@F-CE3M8F5]C>)">EGFDR$;9_4LWJF8E<<+H$,CPHL,_RHU
MLR*PS66S*B-MPU @5DT\)V \IP4V[#IM[6P7H4RW>]*=4[#?KOB<-O(WQ3 (
M<O;C=7!@,W:=%Z&7'<MGES)6][JC<L<6#]>Y9&[>#G'RMK+E,* Y<>9@[J 8
MS!RTI:L2B<*0*5Z"B*C*P)V+ZFI/HQV]K-_2_@NV+$U"A/S%MSCU]'?J*2H3
M]ST5X.Q"WH S.?:J-K"BB,&Y.VIT0;3RVL,.NS@./EM?JJ*;##H'R#*"@N47
M<H(BCA_*]Z(4'/ /N#M#Y_UF!V#" C''$+6^Z1Q"&Z*KTI,3PO2N8TI>C1[8
MU:PC6 WN':JT!NGGPAJM:IUCTE)3C]=>Q[.YC(:]"!2]4DA]1^79D$'SWW5+
M%.TU]RC?@'G2(J8#/0E9SG 3Q%%+E!P-&1T/03_ILJ67-\HK>P&@):/%NL^G
MC!#J3._ CJ(;&GQ\NV9,V(EJ,QU\@?WF#BQ]Q@=-!YZ^E*!Z8MJ9@_BRD\ A
M T:^/$!F-V&<X6G Q-E\!'[UZ>!%_\:_E/-J"BQ0\_\H(*"CQE[K1:\E,67<
MM;],?D+9TTT,H@ 12\V=,-B?<'7B\Y:\.EXB>V&E[;!Q@5M$[]C[U*SE\<36
MB4+V@D<#)!_]<VXVX^LM7P\9>]#M$78]<(8(]EWR_;E:;F+K65I6BHI#GKYO
M^LGK.'459,<*%$LACB1P'BA(GM844)E,ZZ[@I4&']3G%T)F]92UAB=BR(2?S
M5U.[H@$!.4#>T?DBB]96\\GRGT3ZZ4ZWI94+'D'MFM0VUIH#VPK6GP/]JJ:2
M'CO)(J:^,E> 5QAH*J/:TCRE<%_ .CD79@-*C\IE0WOOY=;2K5,+LRE)!4-_
MWNYB>>SF#&W&OZW"D\G\347XB\,H8$$B<Q2%S"^['*GV5@9DL:_I6,UAS_?W
M!)5)^;Q$DF_FT9OR >>)UD:3O/AOU]E]>*&I.M!.=,F60KM6!G+./_7>ZF4<
M +J/7T=;3!<H_JB@\\#HY.LC3BN)^Z*%_NI)_7>F2Q 45POYD*5=J(UMI[]P
MIF.!#HR:B'PLUD>_Y9^8QO4W+W(C1V=>H8R[K!Q+9,]EV0[V$\LJH"L]^@A)
MU%-VT+7.AX^ZD'A)YZ?&UTR5E;P+'[M=$!*U.HD/S-^!6W>I?U>+R"K??WUV
M)&4E-^NR?N7?G<4]$UDJY\,5,]&EX@ *)C7D<R(LLE1007JX(2A:GUD, 7O+
MVOB)8R5#CI-13$6'@[%G=/(M!2E@?].3%WZ^S[:.60'1OZVS>]OKOSF?31N-
MW& D )VF ]5WX2I]-A <8 3;&3!3CB6@5)E?0C-@EB,?S)+4X3^]F0D\WHJ
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M*WT^')ER7Y97R887T1-L/AAWV-&N&PX@[&O3V<W.4.TG*%>U/C=@;(8U;)Y
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M&9E+Y08@\+*%X5DG[T]87G8K>O\$;B&#LP^6P@_$E6W*5H<@82M-O#'XJNG
MLYXFG7FALDZHS\S5A4&'5:;O#"T"JC=P#C"$=X5[&9+JENX >IF:F"#PFJW5
M+J_I-@?AC(UGO$M:["GX5=1;@]* CL+N(<OP0BJP$:@BLQQT*Z"V/%;#5'UU
M<D*WJ7HBUQFHM7LYGR,)+LSV9\1U*@-DR=ASSU=^3V69M>(^XM_9FPLE$ULF
M]JT_ZF"\.6/CL1'<LC/JG7]/!O*M0I'_0I!\'<EZL-":INHQB(0M$=<@MAU,
M[LQ:!D7HD]7N$H5Z _P+7(] V)TO .6G[4!T 45#BD<>B9U;/5F][HZ6+M>-
M09<')_'+DMT[=*?;)R^JC:M(?C4\#-2KE%4<+R %9Q% X%R,65$ Y;/.JAN=
ME,"US?0P.]?>75GC+7"+M:N5YXO<TM2ANG'YYLM)_?P?$^QQ.JM?H?58D&[A
MS'J-.D2,Q9LK&/%[G"*F@-,Z0)D\[XNI(OF7_A0GY_;XF B5U<8:^C6*_.RM
M8?)\?I=7MW^ 'ZDLWF-?KYC_8"5M\]1[O+[%;^\<Q=@^QG:.U9/!8K1'5KZ8
MC+"3A_ #<%;_*=8]C0()D:MA\]B)> EQE$@82:L,TF!U*\6=Y(/CWEJBEJ!U
M&HT"Y+""-C'!VC9=KBY#\?%A Z9:,55<N79:@.$U_D2+[C=XM(61'T;T;,\J
MR0^Q]'HD!Y($P;3PS;89QE?"N( J* G-EUXP+E!=?JZG?MX:IC_D(?)QE%^X
M# 05[+_GD->ZF* >#E3DPE(R_\*I/%0'1KM-1V\.\[(@EK:$,;$>$*^W\=6(
MN\U;"+ND]MHM+"M/$WQUR_NTHR.C!\_+9?*/>T[;GS/;:C2Y>#NP0 '*L (G
M_5(>\K1U+NR%P(N<'-A2HLDW8'(N0P8,0AQ35 B7M0^;H1<UDVN<= [QHUX&
MC+NM&OVEZ>H:,AP\8,#$W=1?%P\\8:'-CX^A1 .FT1H#T.W]U CC-3FH]0::
M?]8!!HSDGMK"@$EW)BB+""'TJ4UDM+0N$O^1 ?/,?2NVLQ&P9X/^.&-J&1N+
M7\) <&4#V)2 7^"NI"WWUGI-AU\@R<6[D'&^?L3CS_)8L>8$NY=M?(!Y8ZC%
M:K-XE+BV3C44;;=C,_$^%J*:RC/@"WZ]"/VV(2:(=<WM,WIYB=@E\,=H>W9U
M Y2FGJE:K<%VBDL I;,Z+4'DKT_6<S3$4=R(>%3ON0>5^X";;FHC.ES8 OUY
M:=,S?./\NZ:$US:D01#.N5[>"(J]EN(M@<,O%& J-%/2[0S+M?0T/=N F3=6
M0[R*'NZ(_B+<KB\Q8(S=1H%C6J90 VBP%S6>BE'"9B)\8?B%&1)'?8?DQ9G:
MXS'+2Z436URKI60IO(+B/,K-?-+(+1/DN8%-M?(1YR/<=Q>M(%U@FPNO#4S5
MG(A(=+@54K[[2L&ZKY]6RX+%Q3=>.@G$PM?B='_EU..T^<#4CRRLGZ(--$6U
MCG9YO]0Z.D P+9CY8M8;1S$\#,\-1XNW0"=X* @NQB8X(+8],8&@E_)ITF>%
M^)L-*.FKL415L/]V^MK_-+G&&^W7$*=!>CJ"%F*L4)"N_!G^L% ;^1:]MI-;
MX-\=]2R0:.-LP,1FJXDJ<HUX1#Q"@/:Q%[@<1IX,N0P!1=-CEZK]57:>J(6W
M:%>Q]=EZY*4A"IFG&T991+;&D[[A'G&D_RU4 6$*;WSF9"D\AYX[Z!TBYA=7
M.%[A-' 'Y4 U;351MN*6D.DKV2DK9BT/I%H>SKK:G%$10/"M>&!OR]U]?^XE
M.=R_O26H_,+^L&''>,0E*;%WQ>;X-3H<C)"&6(H:IS*2B$>;D,/3@&KC7B2$
M>6H/:3>, AUB.?NA9>JK,T:6C."%XALM37'QB3Z?ID=L]FWF.%,;>0T!;G\T
M@.:W&B,&[@[FJ:S>;O: 9!^K5?'\+V*L 0..QR LJ>_"28(PW1:*>ZO58__H
M4-#0"\\;ZZ%#GL A)A7MTFA")W>I9][-<M:N?LAJU]_69S/#0:D6UZ0-$&J"
M4M#]0"UUM')W=A]:"((8#X&/5QS67?/C01S-64C;FS0/[36&E&J@SN:#Z6&V
M2L42G:>:DV!OYS[BE_JR7].?]"K53"*3]->ZB:7=I,ZN[;<8A\+'7[&480/F
MX>*7,>!H<L?8JQ@ G0KJ(=]B"K4$5-4L^Q" G)MWDW;EV!5TKW(N7=/^,.9[
M!&,TP8W:0+9&+.R,.46RW,V],6!9?*5X@)25?6TX:GUV4&'P5%U*9"@'L<]"
MSH'Z2,Y0U)'LH!5.)RQC8Q]]TK6_F]1HULC]96_3N^?6VF),QZ[]:W:$%@!G
M*&GSI#W86L"R\^$+UBJU4>T+%[O"(8 B @0#@:8@.59 G[]/?^ZI%5$(WV]U
M"55E) M(<K=(A+T\(1\(V':8XT[1M?C]TV;_O_CZMXX54!@PZ Z8,[VC$*4X
M56*$XBR]:CK:]S:!"$(]C'RT%C<;BE=.UF!-*?!:D'Z>/SF]I>EA(GA2<FF3
M\M*FJY>L*DQ<JY]:,=T]VOC#B5Y^.]IHZR8"UHXW?5DJ*(^'ZO1%"-_7^VD.
M0\]Z>;%.YPH\$;!RJDTTMRC$^"_CC/B[SLW13>^%!.U)V_[ SH'F*GM0=D85
MW8C=[65N^D%PY8J6YR]6)NZV(W=ZL3Y$3CJDT@2@Z39"A]52#ZFHT>UNY;)R
M$)=XS'[L/>:-<;(QHQHG#';F)(B\CZJ83A+87.UX<552[OZ0/WMQ/(MUN\)+
M*Z0"8YE =I?PPZ^3,"\9,#WG"4L<R MTRR$!F+,GP+5/JF1_:X];.$"*[1.$
M,FG4O)B=)6VI]/<HSBY@),F&G4]ES96YN']8>B>:1O11IW+^(F=F/HKP2^<]
MHY#S%* 'T7*HTDS/C\%F4S13,3+V(A&Z_36+>BMP>^C*QOS+!Y4-[(2;CRBX
M65VB/2$F7,C(77#)_R?ZZ(7+H=?OEIV+<.!._-5HXO(T?GK+CFHES#LY7?#]
M-?M5P;<28F[%_F3WIB[O#SNJO,?F8AX/6MF.A,6["NUU-A(6ESTP4K3^1L3/
M##)"SO(7 R8CP( I[S!@1!?$P!\1-X8UXPV_GU23[VX!@-\D96:^^=WO4TFZ
MF;^OO?Q^AO;%:\2+MB'.NH[6/H&F^N],C8&A6JB0_)T/6A/UEO??;"N^'(&&
M\3O)DF''J00^#_FC;]E3Q2+W0 ,F<(9V'W"O"&X1:[;B/P.&RM4(+EO0^J8<
MZ _B\&+,\!\R8A@6_&_)R;[E9*+U;Q4/"YNA<]O['[^%O\NKG7ZYXJ;@5RMN
M"[+B9O#$XC^V&+PD+61@.L,]!;_.<&]1SW[Y@30R\H&7">XL-,'=WO8_*-S2
MBV#DUB#/M]0/N8(S /)\-Y%K'  ZX1:@2V\::4,;97L4<"%O_AXC<?-O'Y?:
M!+WM4A9RV\DP<MMKU=8 W4'GAJZ7, 6R7M(,&&3!E,2X;[5YP[^&QW0+_1$W
M6J_0;'7Q1M/=2A^ &(XVYIJ)'P^*F.CQ:@E3)2PSO^>3_T5]6C!RF>Z$8YO9
M'9Y5Y>YG\=A5[$AUC@K/ON&9'=#EE4?VC]D,3N1>W._5&^ G>=;X,KW@4)M\
MRL[!VAX*VML6EKR /"2T3!+''A/9J; \ R:8EVQCHL^H7 B5JGC?CH4]3]PN
M?7H-E,5&%GAP#D"==5\^[&I2-LVB;-AVL# @R8U<(?C4(X*6._3I0/I7)/8Y
MA\UAS?8!7PXIH#*H4(VK)7^ 7PY)5<E)Q^!V%7TI WGVY%8-L>#1_H?Z8F_-
M%HLO8)FXS<&8; H!1$\O8TDYK0X5(\^FR$]<6=(X*Y>!:4( &"KHZED7^"%T
M1FU4XQQ_7G18Q=TV@0[<[3)I?'+OPL8/+VS\TX67?,R*N=FC)6PXVLMV1PMW
MW7/NVOM-7J4"07SR/VAR^8]D!S O#P'/^(W\DA,\9[(WP+9:7/9NE'DVO< K
M0FVKC$\2F65[!)F)4F7IW+-3%C7[BQV"LIYV[[/7-+O,+"+5V_W@-+G:Y[9T
M&?5S?OK05--4(0^)Z2C+6-W^DF5<'TMPT#,1^XD#0'\#QG*HS 9Q(."0%7,+
MGVC&D-1E.;2NSSW_>.CF4.6,YK  8W=A:>:QEI8M^#ZIRK=B%6>)QLEBPP$Y
M!4>-"%IB\9T"[OO[5_M?O-!A8TA@8)-?!@9.Y3*$^2"$=X0]W0GM '0 D!-J
M!Y++>M$KD__/1:5I'X#NXTZ[L?V(&T.,%O%CY8@?XPG>_@NT5^W-4=_B)Q#'
M0.YL0J\/\;[(]6'0Z[LQ+/E^QMCSWQPVYHR6"0W#9HH1NM9UNB2O$RNWP8A
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MFRQN%BEIFS2^C)66J*Y@A) G^MO38ULL77)J<[:[.J2>J  O^@G#\_H6"+2
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M'HIZTG#5^0G54Y.HL$QR.U>&B:9W94]>>H0)Q2"D6\;JK=M!+ZI]<2,##!$
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M8!<5!71U/Y:$G((=X:I?M/Q\\:Z+*XF37E&':4,E1YB5\Q XI>60<Q7C>/%
M\+;.\:/AE0EW<A_.#5=]+O.!Z>I,#XGKH4T!-7VRKGHY(A6Y&7PX83)>0RH=
MS4,#<K_.C6A/XYZR3WMJ7*GVSW2RL.(\Z7#6U1]9FA,I]2VR32[Q+ <SC]3Z
M+/'L=& :OP!-'G%VABRD^0#FIUQT,P#7!VK8MH@@G( V'R27U2:?T>^*CHA&
MYI]@!%,F/*K%U"5RUN;G<QVA9ST>(@E_,&]#Q[!^Q_5CO:&YIV_JA;1./B<*
M0B$BA1O/67.=/]U7+3G1!X<%]MP/*Z0@=M_)WOAM;Z]72K>I'9O5Q71P.Z+(
M2_4F/HAY*15_P R'D$FPK5J;-.,98AEM/5C9O[$9L*(>TC!E4KU/?\9"W-!D
MP;UQZ]0=",Z/M+9K@PBI9+*TD&C:I8.#^$)*E,_M:75'MOT.7]&:*U?9&;;
M;XYLB5"6IRWLUF,,-]S,D26SZ5'7J)M%XZA4*3/_9V/E\3#W]O@0T9C)7;.X
MYKO"*H[Y1L4"OMP\TMM,5^F^^=5^X?C'Y-S)-4YQ!V9.IAKH/"N@*<^D;B\/
MSRY L#O<X'UPLP&K"?V:1]%6RR922$YY9- [HM)&;'5L J?^AG)EG!0Y=)@K
M4CG;^+\Z=+MC_.. @_5WVEF/WT;+#7RU'_F\=@HV!T6PQS5+EV47PN.1V_$O
MJ0=J<WUV^/EL[FX-F,Q7L9IMK-J#.LCCRSG,7>.W"S4\!HFX_FL:HD8SDEF\
M"^(>7PP>Z36&3D\"S5IMR 7D14"(3:QNYC[C(S!/S5<AD2"@]89SAJP8VKA*
MH"F@KQ)Q,]3U19(C(+=7Z\. 4V"8I['=V*OIS>C#J>R:;XEDB-]-LP%^@!J-
M!C\(SM)YX_V!><;-P?A)QS:5)3KR0D1ZMZ^09X_'1%3[1+!"M]^XOCW;]L,;
M[ 3O=@MP_\./F24U*2]::$MK?&8X]Y@U(LHY>K-!UYK*JX2ZT_6%A)B$5.9
M77P!LVC(RN?GA_D5@ZY5^6$VS^GE@[GQ__BFYPG!PO(+041(--$I8'OM1UYN
MB]>574>% *=&I_/KS)+0@CF&:UPHOQY0CV0P&DLQ>D]UCRF_BJ4_=@=0UFG<
MT^O+=EVC3,$.WL[BHHK2CHX#LY4W\%I,0@.KER)I#LC<]\4,P_K'N ^I3@8V
M_Q0ZE7\RXR[?ACHCJHR 7'6Q21I\D:5D]@%+AZQ4LB<6/[9YJG/2KZIER1RZ
M:NZXG;?[]B%OX=GA<1O/4M&6LQL[[!U45R=-)SVL[Y'KC5+<+4:3(Z>MGY7.
M@[$[G$87HN6D([L>.?MKVE+"XR)%JJ'8$TR*]]T;E,QFJ8N6.DGJ*2B)J,!O
MSXZ)O'9C,$>RD& 9F2TZ'X>"4/ENHX@_>_I(V@Q+82A>)$/+'^#P.<?5M8GA
MW9^,DY>"@D/"\$%GZS27G4+[1$/TDP=,HJ45.I[-]/)_3(I0 ?N,XIO1_)7\
M4#AH[_RPJ 29J'.B(CN<S.H-[D5UFM$6[[C-I #/.W4U8N9&] )PX^Y.#G-Q
MD(=OUIA-R%X-/(GJ48E'ARTH*B;TPOCL#V7>8&+_% P!WE?D7.)Z:.8HX$D1
M\&64^RV8B\J8D?KR.NN\^YDKO_!8^47CRC?GV-LG(S.+!\7:7/^T$LS108Q?
M?D%>")'X_ASEZ 5^WTV^-8GG]I3";\OUIP-J1&#'^FJZW#:1$1KBIXY*+-W^
MC539:ZWY6DJ[P@036ZT^\^>?Y64TUWV'7*%Q?S!2>QQ?2MEL9I@WT81[+(/0
M:Y\L)=C\+7H5Z?WZ9,OP@]/H]:4U\?Z)==_XK/RF?>4;(1,7JTAFL7*[-K<J
MK4(:C,<P\PM*0B*(<#49%T43T&L1E_@G42O<F4+"6W?-%=3HOH]+/<+P7YY(
M$!F7X&;%5862MK@=/XZ?O[!'ZN->FM5OOUDHVRTYNV5DB]Y%@9YW'CC^60"B
M#XX I]73W35SY!-)X6_5TV,()L=NMVGU]'5+O-9M:WNKGMZ:7XEW36N85D_/
MR?6O# DI/]J#$3SY'8'[@-9C.T_(!70(XV,KBYOG3-YIU \UEFG',P]D]UIG
M=]*L[O(7A=M%VRJ%+]<R>H9HRT2JB-#LI7?H^W-?FNVH-[NSBE<[R>->U'X]
MK2%]'ECIMDQ.1*C02R@"^9QFOADEZH#.)_]M6_P0YG^O(KUT)GCZU[,/J0Q<
M:]F6"LS3HS7\NS:1$P<MZ,N<0"JZ+_1DA_/1L4KT"HH=NF.$NXO1-7 P,&BP
M)B8QA6MUNF,<M3@(%ZK)(R=:^29_TGEV-#QPRQ1L:>5?8DH# V*7!BARIID)
M%3Q>17'Q5;]0><654>P4"Y(9[383S>;;FB836'TR:Z]3&_+)QZ,W9,K-W-%8
M]<0EY\"JJA%GTE:1 *=.>)WK^;R\5"E=,V1%OLAN%XZ"1'A7B#$]H&^.T1:=
MB-,_?C2'#X48"D,K-GSKABC$45+]#47(A4&#DU%=M,=D.7EE:,''DI.ZH)\;
M+N&@[7RABKM+03IR<N)0@T1[^G*4UL[Y=@?9+0TI'%$BSM-<@<;3-',0TWY4
MB)P)'FE&+*7ZV':3-K8@U]RB-T[!%LSI=MHT4B0^W*M1:$9J#<E5]X\S"$BK
M!C6TQ3B*Q( X5$OV0<]2'&$GHIH=H*G42+1"0]D4C-C@+VE"KM;,OAJ.7JBT
M.IM9I+<&<0Q"3$A"1+[_RQ<"#7[R1*A%E$F:):(L&$S=(XH(LFAOB6&E5(6W
M+^SQ=;.SS5HF[7+4^OT[?>_'@<8@DQ/T7/(PF4F<@DGI)I.M2N,JRI(VW$D=
M7&HZ.&([5O%,>F30C=48?WH)R#\'2'&U]SK<VH>!8=FMC=K$[N'SJ.]^<X?(
MA8!E.HX].ZO?\0*&===\UYC.<9G>IL/9!KN;D\94545,P6!@^S&^Y'2'<.YX
M'M/;K\/-O=\>'2C2>T2'%.%S'3)+B 4P-MZ!$[1?B4==V0^E:.C.M(E@H6X;
MY35RC7Y39[AA!S8''00/Y'2RXU 8(==#GB-F!T4=5/<R9CW;,")!=U:-F;ON
MN*^:K?/4S+>XMP8?TYN_A>D, \XY!;R W^6#FP.&RS47VO=4:S:FHN0'P.Z#
M/>1H.2MY!MLPK_=E^^Z+ 1TCUXUKV^#ZU2AUAH&A\]CWV)&++@>]@L0LI_%+
M(!9]IV,LSUO&F(+)KZ-.T2<_P9U'@-%(&^"5UT[;*9@G]6(_JWM4ZP)&F>IE
MNMT0QS0^T45UH>2SN#RP\)E)SR>S_8UPUW&%;!BU377#D*@CZE Z]"F9E@Q]
M =6CQ@>OBS2Q1C-2R7JV%C4#N8!@&1"&UR[&4NB*<0,GOB:_(LTOG1&"^LIM
M13EAZQ F=N#RFD#".;WG(X?/.\E2[[0-1)]UGDP837L(]Z/C\$5-@ *EPNEB
MC>T2.GMCFMLNS4;=QF;;=1K?9(;2Y>6@JV7BN&P.=4>G&[I01HD2%%B[.B;J
MW3,64JR;ZFI8Q&N#V1:T]5SA8?3B;J6,P+/$=7;"EH$ET![.!^%A"E:"[?N@
MH? H'EHR8$"9CSQCY0/;_))=%3V@2VM=PA6BW+#[55"!401!,[U=_^H%5THI
M9\5M@=\<TWMU<F[/SL*?8J*C==AC<UIP"046X#UU?RO=C$O$:_GSP7[!Q.1L
MQBUSUUB3Y#BMC8E'2,56ORB.XZO J,.W12-O%,=].Q3Q#'8&#-'DO&P 0KA6
ME,H^F0GA.FB8C"XWGSY@(6[ JN 'Y^5;1GGW-NEL.<4 ,1#_BQ!Z:;V\9W\_
M^HT0^HXC*<LNC+B]-KQ5NS&92M09ZIU8%W*9[7?I:;8;.K88+2F5!SF9$#Q.
MXA"'3LCI\;P-]7=XF7[5'5*%3!6#NJ@G1L62PJ++TPY08IN"5[,SL3SAF6&J
M7S]BV2"0_H88 VOX-Z=@^J5ABA?#A27PF=LO,_1HT#?"K,$7BOEU^=K,"O#L
M\Y'N0[%E>G-%TO$.A5I+KQB*\H\1UQ8K;1$:BZQS840 F1%RE6B[1A)1+Y.U
M?XU2'R8_F8(IQME_@Z?$ ((T$EMG\'TEH%MFPV%/!VO$KA6#Q)7&]1T.I6 <
M4(:[+J[+3\@LI+0'=)X25ED])WZ\7L1)C7.:.:*T0^WK9#.!_=/Z5:)QYA*,
M:/B-)8_]N(V=OY!C'?J+)4^N< IF<HJ>]N0IJ:FKR?ZD[[(BXD3ASEG+GMLZ
M@SUJG+RJDEQ(]03KU8*[5CV]= LFL0B4M/4N55=5AI6@PZ)"9C/(C*$ZSIM.
M"TOQS6 O,^R^L)"HO^T]57OER*LYB@F]152?R]<.(2+>(G!M*V)YE8IC]GYW
M(/=[JK.:I,T**W'^^>?GF65$J].<_DT1YCL.QY)L?;8%J&<GD\+6$*)JZMC9
MV76Q1!B"R=ND"8GGPJ'DP&CEK5=/P2[JMY48<G3HYN!-XO!1^  FJIML/S:$
MJB5,<AZ4TO':AMTCPE:)RG*1X=I+9:_8_M4#*Y=7]W3[("[].7)MC][+*F08
M2BZ&C?*<>.JNDJ=>"O12\&R05Q!8:)%I/]#))+,-OA24?(5Z3C)7%ZHZ<^;,
M&#UI,(2!5;:U("T:.EEN'Q490XV/$!QZ&UT:XA?;GM+K"@73Q?:[..:(N[G[
M2)9WD;:7'2+*PU^54CY_T%(B+BR6$B?3,T(4<=$<U@KT-6X,K5SAON>#[R0/
ME\XP7#?^B.-$"3*D(GDSE+H_@WCC*B'OW@F3H0PNJ"6L"D0$W4D)2.]5?&HB
MCH))5E?5B)N](B_6F^@>\U"JW$0*9RW$!Z]6:Y/'#,!\V=^,KE0O0SYR[8!L
M*=)R"&7ZO%I37\V66E?+Y#&[*W_//**N30G_X46-L5-MK-2&6BEZ0FJXM[@U
M-\5L+,1VK/PS*P.G8#C<K1Q5D+I?RP;/6:91ESEJ Y*<6+<"P2G874O)N6-#
MO#F2LY]G]=?>OKSF[4<1ZS/,**6]0FE[<'5-70HVR.2LFD1UOP:+0_T*S/YS
MON+OGNX"%G:^2S]I.MS_UQJ2_ 7F)/_N*V!L!137R@U?FP[C$!S'5MQ\)9S)
M*[2!EK.C&26A56J_6;(_1?KCJ"_8L/Z[G"5!,J7E1-@QK[Y9G=>=AD@;NGW1
M"/P7Q,-#P7,UL\_/&)_0+Q[2!G<"(1GG)<@U&EYR62AB*>U#I05OG0:94;DK
M[$0%&"9P_9!7K=Z8X.SNIIS0?J-<*,4IC7;<K?@Z>%*XCKYBGQRW!#\4)Z=D
M.PJ5O^N9:4> F_C#4[ 2ZEE##O5$505>R]L*VC&4_&5N'UT/8G(7.V3)55MC
MVVW R*"=H74U%4X&H"F[-L=_<@]]>Q:I@G)_M_JSR=:BV7FE^^_K4R03&ER;
MH^J5;E,P[4=@I;/YD@.I#\!3_7P5:CG5L:&6+?%O]WG$Z*PJHM\-P!1P["%,
MDI/D-K?N8>MDX/B#SU].[.:K:Y.=0T1DZGZISS=SFIU^5YP-Q?^+I-L=U8)B
M;VR3K0P-Z+70L-K@J<8/U0_+M3@5:@'(4."@3%Y(0'W.K>TX8^PI)D@[>^E1
M6I_=0N&D1&7Q,J[@I;A7:9\IL&9]\XZO'@#^R1X2<=?]U\')?[*O9MUU_</1
M\4X$_Y<!7U,'-K2Q7,FFC06#-M9U7 KG]2P<B_^NMW_[#V4MO]Z,+5]]$+HJ
MT\^0!X3B%EVWD%+ .(W708EQM=Z5ODL]WI[(=2\:Q-3P ><)P1#QL]J@Q;*#
MZO>JI8,J1FA CO]C\+2N"=,LKEM+U$!!6[L,M] H0]W*HJN.JE$''SO]P&4E
M\]XSBC2)3;KN6)^Y+&?[2/,-RD_TLR+*APX_ 4Z#0%OLF6%R2<:QQ\/#G&ZX
M&273/V[_?8%/<:]IVOC?41A:9M 'J.$X6<N;/_4A.(GZW'93+_O)F?T;H4BS
M2,*7_%%ESS1E^-_VT']YYP='DP0.FO5& N>(#%[99Z73O:,[[<W/-F':XM#E
M;P9RC\@6$J<O_R<Q'J<9AKA?S@M?):I"=*A!'%MREVQ#W<3U0=J3#XD>,OM\
M3AS$AF<(>I&//7HI)XZX?EWGP(\J'IP(.,Y&+.D-G0P;.@*Z8#0;<ACWEM8E
M$XR;.*2-?H^<@Z8;BST\Q6-!N]\V%K_P[0S/#_"]\TMC\<=O:M*GIQN+[?*P
MWQ=?H @_.X60>0*N@#I0UA7K)W([54+K"%[XV-E,M@"DHT5<%TVD\J%97CT9
M3LG;DR[8K0:2Q_'/.T=^KA;I_:[9N#1]E&H#]U9KLRK (P>PAMW (HKR1^NK
M<('K!^]6]/BU'P(']*7(7H;W(DW]$@JZ(9 _KW(R]L_5Q?^L9=Y(A;A6C>S]
MLT?\P$\T(ZWFNXG>3.A#Y?#DD75\84(6X]B38TK:-O4ZBYCC@9S:#N<R#B+I
M%B%J8&+R,W_I[$SRFD&7L$\C6(VN1N@R_6HUN0U"[XZ@5S_H/)>[J=\=:>:^
MBYWWVJG'_\?G@H/5T,/%'N#Z9:\S63'ZBCBQ'X^26&.5>7D?J"+2MGTF+.6*
M1H!D<@K?W,U/35:@TI"6%+%HN&"#&I7D.&:./FEUR2)*=O([0P9&B.)<=VK8
M/20PKA+UBH+4(R7G&%* ,(!)SR]OF=<89;O3[=<&3+X7;P&4@3[C$X&O,4M[
M;>YH$(E&^\'^^\:?;H,MQYD@(^CQJ^@*7' T<I.0ZB7G+R&BI$N4A&^!)FPE
MF*%S;?<1CJGFZ-:B:[\5 P^M3/K+$$*[\(QP8Q!STG5TN).A='V*B?M'3&MA
ML?[HG<?AE08_^R)H.1UX/(I<.301XTN/B-Q0T'Z@3A)1F6<6DBZ.PQ[*WL#-
MZW"#UOFL>O HXPVW9H,(S<P67E0WOX8O=]7 $VE0Z@QY#9PT/C#>-][-4"1J
MVZ03,D.]"GABLK0^S7Z)8AN[7;3 JT1/&.VAWANZK4[J%YHY4A72DKI5/4<0
MAYP0O!J4G9&,<,A)O$W"\>Z,VC:(M%NDED_!6A#R[XTM[TFI=6<O5X%VS=OQ
M94\>G"OG,1DRX*34&*@_"$HT8?W^%75M+4!2[X>:\:>N"9SR0368>8S'%[+M
MZ N?-D9<]Y*GS2VQVA@?KKM'VO+=('*E:*QALQG1'/E0^M#:V^SC5:_F_5,_
M^#NU_O[-%?]&"R-"]_K/G>C_](RJG ^NHP]W5>DM0<1UZ@$-7N>2A$1!CWFM
M(M]N7VWGEG'K'8Z)$'J,C>WS'BI3G<D91JZ20.O?3L+)&_(3.P<6/JKBVI/"
MR-<H%[J;K4X"2;@;+L,ET3I_ZA>B,1]?1SMYSE>H:K?CFMU:A2B(Z.Z]^Z(_
M)QT^ Z.,V5*#Z.*MTO1VW[=><5+B%'O??IZ@!;E.B#O<H!8.NO"?=/YNB,G4
M O$IZB0*/(6Z=-&XB.A835T)9FH-(?*H_*HI&(G@2M9^9H72K^]=TL'K7&K%
MQJG3"-('?*W]@PDMJYMJ7SZ (&@<[BB\R8L-J9.3K(6&:[R9H(OV,NBE:(\/
MWG9KNJ.O+D> 43W/WU 4UD=?X7DB:DZB&[%8,,OXIJ-OX/[ZDAHFPXLY>%A)
ML^X807PJYGACS\/ETI2Q*=BE*=C[U%-J2P60:EP$&LV1B&7@MH,7V@^2-AB<
M[3=KI1!7^V6#IP28B-VA-QO\NC.62'QBVN#>G<>Y(A6WZ4\C&W+$D(@ZBUI!
M^X&V-19;W %% 5P+YNNMX*N[YPXD/!<^:S-GZ#?PYNF./9(&4IJ:A,M7U[-S
M8WWL6C%^);SXJJ='GQX%R<T%RXPUW!D0(9FM/ZPF)_)6Z9&:!70%:S98B?8Q
M1?NV;[J#L2O670A]ED"1U]_HV.(@ORV"LL&A6G9G.,E?^&I_YYGA<;L=E8'
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M""A2WHVR\O^JQ#,," NSY5> ,YMS2YF,T%R'@F_O,Y2'P"5^*8+](F9B$E9
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M."?R&;.9&C28[I(&O6; :0A.8H:")^I=W8!4#AS>KY:>"47=)$?72E])]4W
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MN;P*VJ\#*)H%8FJI%DK/A*DN +X>KGR2_JX+0%B%S,%U$ZK>=0&(I_6K)[L
M&M4ICQ@I-Z.;G2\^0-2[UHZT8]07P59=@BL?=1:QV,,W'X1R9XUE/?#4,L3U
MM"-0RF,OVVN I9QFI=K5;.H^<D_ &NT>O4^%N^\[J[& NP9?6_D)$E4-Q;4:
M<^KJ0:!=6M&(NE"-4#K0;+6KW5(;SU69XAU_\ BTSQ)K:,O!Z*\D+-X=#R<9
M<3'N]CSG1];8'6GR(PD.>2Z=\H)A&CVDI$)GW6KT?$]HDYYOHXZV5PD_"Y13
M""991L_7N#<$3&_$O33 CFTUP)960J[O:;_G\L[\P?&,.>/:CT(<$WD5463F
M1RJ$NOXQ @^PBGZC;W")[C;R:\=S-,[%'TESTU @7O6-]3;!:WBRU#*QF#@6
M&B)U)[C[<@64$_3M,3F/>@E(S;+=966M:]I<4@AHON4F"[.\@>_Z1DKZW,;?
MO%(Q]/.O:S!:2\V<1NTJK++<&4JO[_!U+&60"\]:EQ+ U8N H0X(TP('<6&;
MRC4NY5?5#"9>OR1<R49*0X+2U)I(":V]U0##?C5U)!!CXP+&]2 NA 15)Z@L
M'^CA*OT%7)$7(Z1/[Z)\DB)G?MH1=$8Z_,3,OQLE.<I2?-3V$9M7S4E^_:?@
ME^[X1W>7;C6O^T5_\/V.;[(@Z3>VROKU"XQ?G,@-:DA0#D)?K)Q[(;K(EQ$:
MH5\ ?;$L]--70=E2P9-X_UY42W&Q_;JV=>S;I9QKKW>&O/3%N^^TV6Y>]>DI
M1&-%#>VINYH!]NNRXGH@N\Y>):AR*H)2'J>H;!=5&[Z':+HI07[_=7_7)X)A
M[8ZC'+B1?=[35<0J\9A32"YY;;^9N2:Y01Z/WEG!T_D9L?QL'\%EJ>E(&O#!
MF"GC'EL##E,V*A-KI;4=_J(=M_)V5YUMI#H)75:0F%M&=V:-C#[TM(ZPW!A9
M,6A=S70IO'Q8S(M;?P/^&;A=>4B6]  [MZ8'?HZZ6*A=(=M),M7M9VLVCYEJ
M,CO1>R^%O D4<5*_>1,@'F-NE2=+?W%OP@;<OU<N*'9NLA'OC&(ZHLK*1R?^
MH9SZ9T?I&_W\S<I>^4@'!:]! K5(Y5FY,^]I\(@,65:?2UDIWC!$Z;#?,:A9
MR<]&W&^#(N9\]ML-)9Z=,HTOTS2 ]N5K5I6]19G<#]NPF+I"2]9=0.*([0W2
M\7W@)67''ALS=IN+J0L$CQ(="!Y!/9+R,M%1Y[@MF#UM43'''+2V=/#,2)#0
MDG\<'$$I2QB,A^0-,N'< ES1?FB><=.G321/%W"U$BL/9A!+M%Z@EY+?.-%9
M2+.X@B\F2Q[8+%<%,P@%6T]$Q\R]3BS"<_UTS]PHKM'CDH#]C9]W>)^(B7;;
ML?;N=5K:;\1;44X^A.%YM_HS+!(*(ZW$%<Q(BUC_M+S^36BWBPQ&)#?U\<E8
MZO5"G/IX4S10A.UL,F-F915__JSSP*,/%^]XS;VIEP*_/L<*ZX9N&WRZ &>\
M+6["X4)NOWKJML$3)Z_F]X>0V.]NR\<=I#\-V3YYVXV8D XOZ+:7/BZ"Z;VH
M"R!GY83$ ZD(XEUH49KJS3VO'%07 1R]R[J*'E3YP"9>.TJ7>5#6/&2/;I @
M<>4BJ@C/!&HW9%MD:ER#2O7=H2'-&C>4N/L<4KD#<:IK\;VS >"]7N #RC>5
MY6V.ST-MGBQ12FHJI$%/?BP_>3*VG)8W$"OYH:#-6>$S3#H_MF5UXX0UY_&%
MPOVAN,]#0@9,BZD-K5]\")SRF-'3G5!MIASGCR1UV0BU=CW="_K["R-"+'ZZ
M;(IW/[CF2M.:*Z@U4YA(8G61R8ATM8PM*;O5V17)9;YX61!#(KD>_(=:HC=)
MBAF:=92YND(VO0QD]H0B \1R80>J51N=?SH7U/!;"\HY%MG.S<O:;U1RA:.9
M]X$ \0;M1I8#IZ=]C)ZV1^2QN>C1TF3MF<E@["/:^S)NY!3M@U$-PX=C.D]1
MM5$56_NR]I6_(/%'?F 5K9&Z4.@R15M[:<CY9[UUA$4K#JVP;F"Z=%U>*^;=
M^ 6*;>5@CL:,*J:91!5(*#%*]P8+[L?]$V)F7#'Y:+\-4L#>8L<7MX3AK6@7
MQN"P2*HM6UE(P^&0TH17%]8)F"4$YMA\Q9IL>Z< //9'.PTXC5ICWK<@$;_>
MD3$V7E3"YU"VJ,;KF,&]VT!2#_ !V0##L(4O1"5L8 XY/&3:!G#AGO3C]+Y@
M])0@]%/IHY@U=@3KIA?Y\%77Y.; L.WO=8(Z/CI#RZ48Q1 W4P5=+O?.],JO
M,2"_>8;[\8"E.KJE*W)3-E+UY_*SNS ,,XQ/2]5'@&N"XZA&%QS!OKFZK7I5
M7PCSQY,3V;G2;U5;"VN*J72**?1I?^ICGLE8Y\KZZC5&]:)>U_/.!AB\/"NF
M@+*S0MF0HY3WAE:5G9$$JLQIIU<K#3#=.<LO!1XH%IG;[)6R!W-Y(NF\<Y-M
MG066SOX'3<!YD"EMXQV!(ZAB[!SM1N6@3,SJT5EB6JFV?=4N7*Z*J>?0<7MQ
M(=$)'O@<%)'HF0"E]DLZJV^,4U>77EZ?7YK<SLRMC*[TV?M!N(;[/W%BD-M\
MQG.!B&JEM82\X&#H7>'P& ]&^4P)/\-)8:[#7!]E9*%KJY<+HNRW]>[.?BVH
M'29XXBOGYY==&VAX\M+W2.HK=L6/[$_Z1__;B+C^&/]IC^QSA+6G&^5/NBS/
M#_'(Y9[K\4@C27FY<0.I&.TV<F&LXR?ZE=W*B@3V0]OI<F6<M*N37EYVIZR\
M6LQA*.SX$\%,QKY3E!P#;(ZK[H8SZPSRSL@/46OC/0<;L%9L'5J&372.*Z_(
MWB&HVEZ("N_E+?&EIX;[B/QI-\A[!UZ+N]%"F8C YJW 5R\XNT](%Y(V!_$N
MA4Q L$BL8W"ZI<V]Z^B]CJYU5D1^UK*3EY25-2&BSK_PE#_T;3-=SS';@??[
M?/TH2-G::[;MD0;  N[H*O:;J&[(G&N]F'U=%BTEJ__*"U#"EXT8C[K"/)5(
M/G-!+XHMU@*]<#.RG3=75'#O[*YR$26(N3\B)+Z!/JG\;0SERH<Q]LS4%X]/
M/EI=@SN^?M^!61,0:#N#(\]\)1L?"E5&2O8JU;0;>.JGPK%FQ #S2$; /0FS
MZK!\"WJ?,NT\"=_TJ<\U VP/#XQW/?=1ZLBK*T%"-L//:5OUQ2>A:W!J6C0:
M"2'ZB+"YRHK$*B.C\!!O(8CD3[@F5&TNC"]\/:YQWZ;49Q'R^RV0A+9C#F.F
MO#LX]34UY"*K*[E5=U]K.Q@7Z-&7N M^DXKHC_''^-\S[L*3*Q!+AO0?D@4:
MF1DK:0Q^@0LDC8PAYN \/RE-W]/"Z8Q&G>\*(9^<^%-58 _O#F3+WL\W)>$9
MS7(_S^9M56WV8Y6C;1O8FM3/E;-XN<:&N7B4,9)M@T.1;&VU,9*U%>LP>E-W
M#7K +9A.;P>Q/8FGHP%ZUW[I(!=UCG)P$R/W62?&9[95N;'NT#2D=6V;<W\H
M<4.OD61G5]Q/AT*W[^:QG4)^F:'SDB#E- LRYL&$N?'P3(Z%0^;IAC562WO)
ML\+]E?H$>GSYZV[_,LU)%N. %+)I?)N#8@.!VGH<(75T8"J^Z?9HS0-657\"
M.8X_4SO"/FMA5;DS*'&J.86T(EVZPM+& LHF3FOA)8UJWT=Q?=5\.6T.&<O7
MKQ.,-^.M0H$CD6H:H0R?ZO:F63@\K#CRUJ3><X,*?=&E8V0Y**FK7J5*NL!!
M02\*!Z;4NSW)DYM%!VC,LZJSPM4*;/"]WZX"R=5[ #5&BH*$<@D7X,=PX!>[
M/N>TN9AM9(\LC&?QN\S*[@E<,*9V#UW@B$&KW5-\(=*L5XECQ)D1>C<!Y[KS
MC;(N7,8Q.GUP&> &L!T5[JHKZALJOXIDJ@.9IL%H;#7!"%-RM%_961]EQ=E1
M!2;@2L!=8939QVV ).L'J;CT.(-,AYQBEH4D3#)&',JT3'KPMT131*#GA^XR
MNG9-M;L*J[!G=0P+J!_J*A[PX 98?!JR,59_D::\.D#K"WENN1&H=>G).F)M
M.Q0B/AN?-XA0WJ9V%W;R&>0 +:O1$4:>U8!=7G58-I+4#:_:4D1F-(1]VK9L
M=PO;?N/B9UT'?GJ>C5N3$?/1U%G W382 1-PERU@$SX5O D2$3>,=K@SB@ V
MK3U%':NL&.(IB;50ZJJU/Z%CZ:ZHFWSKPC[)W 7]$N\&FT]$=->0:MY-3'^K
M 2:I3LOEQ\<P(MW0">RL65NY8@YQZ,?JGV9U]_V/F^,?XX_Q7QOZK4!//K(,
MI75*5UBS('QF)"U:6+T^GM[8#=<_/*CV0_CJ6[A$<)?6_)#:WF2[4I>N_3AL
MU67B$&]1!$^*>.HY6^QAJBL@CW//ONJQTI<88#T, #)MA[3VAL%&J3TOLY=X
MBB;5N]W6J9O+P:5Q&"*X/Q8[$7:O +>I^X@@BNG:P"-D-.\3KX,0VFK]DJ:9
M+0? :X#3VR__H;MOR&-&#WP%9:\J/:D:0?%4JG/DK!5DQAXH\6IAUVT_$?/]
MH<LQ^9=QSZ=:RQ-[ T0<P@ZY<%<KF^';A ZJ*A,>'2[)T4.IVT$DN Y[ECJO
M/VP%6*!J]A)J]ZODUML:ZR8\KZ\=2M>O /U.$ G?.>N,A'Q]?=F?JA+^4H&_
M&4E=4YT2)& C%S_%V?>L7JA'8%> /\[:KI\/:)9#(>V4<@VP0O\1+GN5H'H3
MQ5>I>Y))DC7A@#) !E.N?5)*+'K:MPQG,5[V%G+OCFK/!#F!2HAU)QSB@T+*
M&F<L/#(6G8RM0S#8_Q7RX#_&'\,XT$\0;!-%N'*E^H@@^XV\XB)[4JN!L-U;
MN>[R#D[OR.(&M;2-&R/TV'CDY;10@[=WF<JS2NIX]FOQY2W(KU0V61MN1<SJ
MFWC+5Y_2%>MG41]+ [LHP2HQC8[_OE]1%*&?+=@IKHJ7?]#5$9*.<@M/W/"L
M4]H_P>DZ7=2GIMI*,KV41ZT$WO2![-7"@JM^U/EZ0;<2S?J!M@S)J;)7.J$,
ML 3'GDQ:Q5.@UNMES2UMH)C=SZM@CR UV$,XS]EZ@8 XFC)RAQS6-5[O^8'*
MXJJ:N4P>VL3.M'OM&RSBA )!;6.=T8%M+DQB2)NC"^'0/A'+@62-#A:15EYW
M=#%#!;8YKLD8-L*RR@P\X]&CFP7WN/>N^;RZ].+D-S,F.J844C^G['ZGD+J<
M=^88=5HA=2Y#A0H1%KY32$W-!Y=I?'UXTPJIW<O!0W4A:*-":O0FP5%6GY/Z
ML/&)U,=T-)=WSP1^I,P+%KNDAKQ^%2 B$= !2IO3,461L=DY,=-[EL+0L+!0
M/V,=QQV41YI=&4(F?6\OU?I_GD)H9:!1^@H)FFC<M?M4V)IN*]!;KK\I)YI
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M$X1"\M&L;3X.%( 1>7(U"A._9V"5L:EYPCK? *NQ X[9>P<)G37-YV*IIW%
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MGLR2SXRN0<ZV=T8A**BIZGA;/M7C;%"YH"I(?M]V6YN#\\,1S[58Z?:B[3C
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M/+GUH5K)DOWDE'UB$A2<:N9>+^B&49^T[H< CE%L=A+@3(G-3@.<=V*SWN\
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M#C!2 "#OO[@=T]'VQI2B7E^C!C][#3DX)?L'"9;.7.1+SNQ%U,A%?G;]/5$
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M">>%V?L;=U,B6UO=R/,&E+9?QZRQ<W]YY$FG=U34[<&,"&(AXEJ#R678&JO
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M;$=$3K ;5L"U!L9Y-UJNP(@\<^4;JOVAAK).R9)\VB2@<Y5=/)SU\TLWLGM
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MQL8__>HU4&F@Q81%O6<&*M[OZ&X5_HK@%',-\@*/75,>6-V(&IQ&"1ER 7I
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M"B&X?U^;Z/R9M<\:Q/R"H-!M!9?$).#E +E4!NXF7P' -.-74!98/C(JUY.
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M!IN55,,8B>&K\+]T]/IVK7";#C=)0#/B5$2!.[KSJA,^$UQ?5[E!8YGMS!V
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M5,JT/?TK;)^;ZE?)[LO4L:P.LS:$#68B)OWW+=_42#IP-5K",'Y89\Z+9G?
MC' $9H0J&+AWDJBC85,H6]U1G<-P$HS3=4\POYLAX6H2T-H@S&%QO)8+KNC-
MVZS'<\A:]M(Y)](..QML=?>GA^:<2,?:[>#%0WL;3)ZQ(A6(^4,-[H@5:04.
M?<T-^AKFL<*X%YB$;OM6EIG>%"S3F+J4(%:L*/U'FHF$L#-^1.NK8]QTG^K*
ME:V"+IS,Z_SCD>H1*HY2]M;1\KBVR<?/W8]?6EU6\E/^0^8R32$,U'N$,PD5
M-KD U,ECSOZE/*'.F4NHA$]\.Z#NDC4B"15)ZL>=F\C.7;69.<#W0$\A0F:^
M=]<ZM/$Q,)?!@$3L4J=%/22!H628W0YT3$A(RZ=0 J>D.X>G4.27,F06X6U6
M31\9@FFV-E4JT^&'3:]C?YO+\EH8?:^W*03[ZG!F:I^H?$#@Y-&+61K4;:(>
MN:J]MLU6:1%>:Y90G'SCH*%D_UV^6(F3Y/IU=AIN3HZT/9;]_B*D\/USEKN@
M09PE:+T'I/1@Y^L=GQ3:HRM6W+?$J"7G^6<*B+X1X[[IUM6E-BE1G*?!H1W2
M@T2/7 _RD;=3+TO;.SK=OA,YF:1H5D7A?R*!5DW5YD \J=CH'*?ENGADC!!%
M9'$T9PX4E0M;3VP.O*?.GV2QY>^.I8A^LF_+O*'?+M&_7_CH"$ /S/8G$_TY
MQB](.[](RIM"^7TU_23U8 4Q^K0F9.+LL?F]ZR$N;YE$8_S?2\@PW4W@&J.S
M-L]:63CFEY5J[?7-P_!:60#.K[&TOF1_,(Q3W%I(YRUCJ&K:OENT8F<+_:WL
M9I9%,#'-R8=8&$_=>KGYT1$R[[?2I+%W23^2U+MH+^W96* #T!#@[X\Z,*G[
M)U=S$UF)*[Q]HUCM6/X74?F'R1,.X3"]U._J/7A,;'4OK2.,%^O%J_5;W.U:
MRB_Z*=@D;7T<7^='M(I27F\]4@XO.TCTJ6TAGI\&[0)Z;A+W<3FLIR136WOC
M+9ZW^)*Q*53T9'$4/2(@E$(M('OJMZ@3H[9R;C0YD4VR.'4%_:4/DJR>7?,X
MD5:8G#>@7%UVJS1Z-:;);!8(.$^AICTR<Q"/3*$>\<B,E_\&=5- 5Y PD]=;
MB0SUF\OK:>9753I"=3K:G") 3$>BM-+V3O K2< Q77B[+2()@/_WWJ@^%1J9
M-7!\7?Z)]W#C-*9XS>NS2HPR3$SEXE:6%4,'XZ@E?.L$G-@71J@_.-GW%%@.
M>:<\-][8>4#C+0C()$^8_:(]E3KS@-58_5%<[( \8$D+LFLSCWR+4:UYG>7/
MOVTO^L]P80C)T6KCX?MQ%.:AYKW*/;T/U?MN/V>8*D@CS*Z,-S4VK4F=XX2G
M0:>A?)DZ+KC-T3:!57/]4%T^1:A. *H_,WYJ(JWKAJ_G<\2 L%38<Q7+7WA%
M4Z;U4Y_ZOHDC!1MZ"MG93&L-+BFH3;V[U">&_W"3?I'B0_Z+_$%IKAC>,!<3
M.Z1/@R>_=SQ0G-=K@WYP*V@RS"SDZO)<HW[Z/YNJ/[1%GA,";^8Y\9)AN#UF
M.AVT&/X)ZR6:!FB #>6I8EK5QC-@8V)"OWP(?GL/S=#2!+]]*67Z[8OHR-O5
M#M!@(/SVBW;S#)%_&BCT+P\B;VAH^AO6;9CYAD)L3*O^_*LBA]'X^&R98N5<
MF<('4VNFFZR<-U.FB&/.EBFX,0KC5T-]9W_164!]N.FE0*8K8.L>#LUPB7OL
M%Q3AA"]^XM)<:F6ZXQ28&4 ;HXSADHFVPYFZW=T4LPSV#:F'>H?B5+)Q&R>"
M=H2ZF<L#\3Y/^#:??#9R8W:8@7@L<EWCP:>#C@6&C&GMN:?+%,I5\J\MIM<Q
M?YB\6F693>#[LBA!)P'-:L;9W[T]JM^BP"QE?JHNOI1GR&F$)(4@?I\FND!A
MC;UM51-L C,<*9#(M#FIY7)WGQA!PC[7/#YO6/".$I_A.#UL)4X&KT[<].I4
ML.'5N3AW_K@V[O^U1/!G4R@3AJ^+IBFJW+V'MQ)&&,&,P >6V#:FC<)YB](A
M!<9%IA?MAM+7^]S6A:2?).<2(WF$LKLEN@,)707/A%>?2Y_N</P@7K\6+*J6
MJLZ5>RE("Q@Y];,HMDA.6T9FD^=0[-,!QXJDSK"A^%D46R>4YH>,Y(\X";>V
M*8(L/J"IOA%>)LTDE'V 8M?IA#)F8))0A\& <_EDPGJ=RX-7^63K(/WV0D9G
MM?],/GD0"X/"I8,3$A4WV"RAXI91G_'<NFJ!89%LVF3\3G;]N9 1_>RX[9G$
M)3@S;OM5XG)NW/9LVG)FW/9P@1P9MTT<H;5*H9/XGHOP36P".9H:.4>+#"%:
M1#OKY-S+0UQ" 3B&J@OU.R>-M"0MK0.K1+ JXIZO*NE$:B='7F*/54#B%_PI
M5/_(M!'T="IMSQ0J2#632Y/=T*]7+TC5IL0;KFI)PQ@+<&1@W$"!UGF1M1)'
MGI9WGEIIY@<IIE!?-@^?BC!A'VV]1HH2KN;*D')K''[::^@'& ++)?A9LR$2
MC$R\B(BV S$;.I-UG8F?0L52!B9GS8:"3-B:3VXA9D,OQGD.WBE:LM,;T\MD
MV]\3OH%6&;B)4Z6TOH\UQ6% 28T9YH)^BYQ@ROR(M.!0/_2.2#GF>Z65M5*V
MZ[C$+)K-&4@Y'216.IDK>&\PCM9\5T</#5UX17[IUVL>V_8T\^EW7]9 BQ)@
M=F<2H[R$S!8WU?;%0-.SQ?=K,/J]")^8'BY^FP;N$,BZ@LTB1S(-;(T#,ES<
M?1-K=KAX9%-,;]O6Z8G;W^#,@.HCNHV^X*!(7-/K";IIYM><-CS/RZU*.(5'
M,[(YZLV<7\%3VFWH/+'.J[9[M=H[CSMPIVN@E*YDQRR?5% 2=NP64=>AH$-S
M=!MZ(.SY10B#OAG[L04"\W@AII'+<*]YP;1K'0Y;I&\:!D"?< G.1*W,$01/
M3$8]9BN,=U0Y E'EN_*VAVEE%.AIC,_M6W=$=&?'+ESWM >_40(=C@8H/1.D
MVU=FE*Z/8A[I$9H-3.RO^\[^D("$#2IMB\KW[=XGH9'7L:EDM<0E>6\<VOS,
MSR$AXX&E9>5Q9SX]@0^%=W1[1+4'2@YH?)19O<9HSQ*QG \#1<2FQMKE\F/K
MGT="QKCP;?=E[DKK]8X8&5G#]O2CU4OK\K_KJ#ERPHY+_60A_\S=$!X/;T=Y
M@MO$&(+O1QT^%E@^'=9NP3_\&^;GFM1$X6U6IX&#-)<MHET4V  Z6YW[<-KT
ML!9M3 >N2XNV%;S$ 1TVY4U63M!L%$M#)E*1W@IAOJ\VAZ^>J?T[]FB*\ ?_
MCZ*;7 _9PNA^HZY*:/P%)VM@4I">GE:9S0E>#C80-="EO/K\PS=2MTHMD^D!
M.43I[M+HV_K??"96Z+8RWR\!T6ISN4_UIU^+Y67JP MCG?BE6Y.!FX/$ ZH?
M>#5#EI^U\AL:R=_,]C@.E5;\$MIYT)5*/6-14'@U6[IC(?O$/.5T241_E"5C
M(06,6-TQUA/X=.$''J\%:M%-;QB2E4*I9;A^H\X< Q.Z#*!C4SE2WM@I+*ZL
M^4,(PZ\8+4TZCKD36=FG^XRG,-?>FH9QV0 ,XXXA,$[AB%*_2A,G&7YTFC=3
M6D7W/&0ZSY56H^SQ2QF M\=<:?53IE?OS^/;/()WSI56E8W/DS]%2JOOVC7X
M;M.5W=U4B"^>QJ)72O=Q<Z&GI+=4=H8MGD+^$QA'QYH5E]$# T+IU%\'O)A;
M-*>BEG"XA#=I)NF<AH(A(B[)XEGOCA.3A04YY*'WRX2":-+0S7^R)5P!KRD9
M^,9S/^L>;)TU%D-6B&H\-9RS3@3%7?&>F -GTHF=NS2FYYR<(]Z_9%_A2HBS
M,55LSLY9LXN>'52R);CQ@Q33TWKW7$CK\T>JWB3<K96.[=A1/9'&NII+D@9A
MS?5KN902[U,^#M[2S5<<+D#O!WD.GN:KO]"0I<S2;D%6OZ;;WVYKT\U!Z?&,
M.^9ENH,!*,CO'SXHCG]3C@+_P 8@D1 CBX\),T86W^JW7\<(<^%O 8U> Y(D
M"#9ZG10CZ!\"IC,SZ;E\4(?D]>* <3_F1IY$.CUUQ!FT/J#F#0.69;F'R2^(
MS#T@NY=FUK^_HR'4JC'GRI&%4>I!2N2A]?R2../M B&*8KJ_+M#><%M4&/9(
MJMS\O/1VD<'C]9Z9_TX/P[3_Y'.@$2:Q72>F4-VNR. 5)/5\TLEK.O5\2GV@
M8F(F]:S Q]$CMPR7S*:>+XRQEY B;RLE!+;.U5.-CZ-"#91P^V?P5GHMDD99
M,))NU6XDM_B3V.F6\#R?AV+5P[>@,BKK:;#IUM0IU-M.VWH/W6AY5I+VC$Z*
M]72H]3O5[2#@%UU$BFUQ K3?NG51(U^+,HNF586?J0KQ\?^5W<V?R<#K'T:$
M4T4;\O%_# C)))WM%.I=_/@W8.)9IU<7\?\4X]'IV&P/]%R'[X ]*8I4;/1
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MH4\P_4WTS9UH_.^VTT(5/LZ$.2U406I$5IKYM;@%4)T.<W4Z([FB)H\'7R.
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M[\'S@/4.\5@CK<H1'[/6-(5 S1NL_$1LD^I95);8UG3 4,#[&4^UC6:K2X
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M0RK^8@;?!@'53]1&B7JT5EAL2-9A=+@'$@5)R[FD=6<K\=N@53*M;3M3B6^
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M-/6U?J=D!'Z;/K(7LQR4'!2(OH'?6MS*/%#@/U0:57EUP;,NPU-'ID/X"]?
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M =C2*+@;'>9F"KIJ J,$LOD,3FWE8HU'TNR\W<#J[C5BG'ANWNX]$?T,MGA
M8CH[;S<>$!SLZCKT-()%+:A]XKC[_GN&.;J--#T(38!'M:")JE8XML_ID%QE
M='@(K_TT"/I8LSE!/A "#.\2Z=WSVZ7 $\[1FX>G4 \M-QKTO#]\H$6AFM,R
MN:WR7$^0_0:^SF.%HI"=IW^_E6:[R=Y7]_-FY@$<&\9PQE9A.3:4W&#9TC#,
M6T%?DF32;K+W:>^\O$9F\<?S\LELR5\M)U;I?5E=EO:MS$C=UZQFLY';-,0Q
M!EZNIN<SD_;&S3C&/!;.KOI9OYCI57\,\8M!5CW:;?7M$J@2?L8]196+]6O!
M! WIH!^.0D"!^,.:]QQ9G )?\'2G7^N)30%4=,VR(5-/O[K 7 ;7UQ&(L;M<
M[#.Q9; T.UV0P0;"[4Q@6/6V]#_$F4O?GNN6^B^5C@B\.[^380XMEW6NW86T
MAB.NV7(?<'X]RU&WOITE,=PS9!ZEJ,4ZVR:=7XDV,!DI'.@HRLI]F<\15Y[C
MADMX/DX68/";V>U?+)JU7\A18PP_8M P2 "YI!\/3.I>^_I7,\!""#V:0L$0
MHL@'@1 7 !A"?.8_#[&B68](M5B-)!APP%ALL$[]# 70[/[)#>(_=81 ],(Q
M9YWF]=K&^7^BGJA1Q71;MC@=Z+5=%;P(:?;[^6((;?/>[PAVESV<?I0>)&M-
M?GP:[%A<D/N42"9NO4*.N#E8DG*:FM[:@N\@#&?K-C _-5R&WMO5PUNPRX!8
MJ VG=N,UAO$;WE)5HGUG4/;ND<UKW4* Z5QFSH@,WDQ*RNX5/3DQ$I*=,G1
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MPD!V<3PC Q:R#RF%YY?2*$?B0_,?#DYYGL&5G@EO_T'>M*)L#_=J4,;F-J=
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M =02$#R/)-+^Q#B*NAY-I-.8*G@MZ%48GGW_52:M;!89)VP^>=]M-I,^N?3
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MHX3;X8<SQ[75B>>)JZ8QY[BHNYU^M9?--.:M$^4ZP0YR91NI"+8:M)B'_-^
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M[KY[1<4V5Z&,,1=ITL[H>@KAG&TET?5K:?Q>HP>_P0+=;=W[0)6_1&G:7.$
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M5E,_/SZ![IZX-Z[6XD/I<'9\M8QCD6RR%5Y>?SO\Q%1NI=$%7$.-I/3'/^P
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M,9G&_'H%/#F-R3#!@T/<;B%\E@%_TQ2MT(-!<_MPKW=^LE9,8_Z2_61"N D
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M*OU4<X'//VC@>;4?M2&U;%SWG#V-(0(;Y.MSOY\[M?45 WWM@;HNF7H +&\
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MT T^%7/6UJ>'9C\<D YPYK@'V]!KX 7-I*N_?# 7,OO'QYAE6CN=%WQ'@4"
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MSIW58+Y4_,4O_UU4-H1DLN391=1M6$[Q8CH9:P8"5PD/1,9BVDH6BD-/_H*
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MSXVS+)Z^M68_C32>A+[A3ICW7=W-XME;9^G6F(<7X^RM9<Y^OO/B29R\_8^
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MO;*B%W%<-@17A<WR5C+YG<!U#^(\K,7>2+_80)R_TUKN21.P[&_V1NK)!IK
MG=9S5R4"UK%>H[F)$G&G5=Q1_X!%K->$;JA_W&D==U9=8"7K-:F-59>[K*'6
M>G*M!T7*IG'.)WR&C+YI'.U-63@Q6.2_B1/@NUX:3@O'*UXW-$U)AO,8<G\-
MP69K)>E^E*0;J43>A+,$F'DV5AGWF.)/46OR;U40@#:A,CA''V_&+OB>"Q+K
M]ST6 #S>LLDE6Z1K8Z%6BA'LB9@J*B:P/#<J/8!WM( ZN7"[*#X@8NDJB@_(
M(+N5J@%R)FNWZW9 N':K-L7=!X\,X]X\";,0GDC(U\03[J-Y.8L-E^O79O,D
MG:.#$^[ 6V2&%KF-<*@Q]&7@99NZ>N^*P]<$=0IDRN,Y7T!\9^NO=XE!W!5D
M/ ^S"1>PCP/QDS-O+'[S)BQ-[RW:\!EO8L)(\ATMIO"-UQN;'U_RGJ%(LP[O
M^$]OS*(+=3\2/R_'H7J@H)&/$ N[<Y1A:V: UC>[Y,Z0G&QAV2[1D4U\*J<)
M'!66+ Q15:MIS%AB_&"3.3=.AB/#W#<M#.,4MV\IW%\/[9<&MI+!6I(K0:TV
M"C7[>'12@^):+@ "V8;@Z%:=HB-)]38, %R-WH#WE6Y\PE*?_<\RS RJ7VQ\
M9LEWGAF?/AW<"(@[L<DJ9@OV6JS1D.5VY:KNC_4^3G+$8TKJ3]I,?6>MZ>(V
M6M,3<8X^C(061_PYFHA>DZQ"=C'4;^I KKN=1F!#!HGF>+82;H2IP62>%.I$
ML0OK$A%TE0>3\MYVZF!N,EQ]W+9YW&Y[N/XU3[,P6#R.I#*,?)!?,TZ8+>WR
ML GQ/,,6'60O$"H0I1Z"[JM.09BF<Y[\+37(_"+N>U+(@;/F42<*F Z*<BQ5
M;WF3..7J#YD'Y\4_B".Z"[K*J)B2/)N;)F<=)TR<U'6R;$5ZEM8L0Y2*/BT6
M7279"GD6BQK315E>VO"Y%T[9)/W[J^')<3G'&/9SSX^S/?G(J_>]?K/M6$W;
MZ2BA5TU<89I$F:L7G6NG(UGSN8RK+P5E 6&\,0?\FH)0?1VBA,'Z)R*$&8 '
MT2\I$G:(1USRR63O>Q1?PIN<I4#^?(G[3<1KGP=A)/)YSN9 0!RSK=!;XSY5
M+./N#*1J"<])M)-9^<:?/!7+NNU_J:K:1EJO\\VN""'Y!^# [X@"(XD!0T*
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M2]$%6G78-6ATYT-52>B*AB8MT\'^UX[E5*5YR@J89\JD@IF>FU64_!,UF*H
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MN<:=D%^XKW7C4I61[K4(-Z1J)$+S2G\A[-,M:R@W<Y9XX^;&<JUN1KX"2U4
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M"9R3G"O6W9#+$+(NRBURQ))NHM4"D^\O862.@M0+?LF,BS13=+'7G&J:B 3
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M545WWK-2MZH30[/&9D<^@SG&1A:"P$'+K8D0T28]&PI?CL#RH_W0R9:[#+:
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M!YQY0DAVKU4S*QN-]K [<,TU4INDKOA #6$)=NU'>_M(;9TY31Q"3X$;I)]
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M3U?9*%Y,4J!_MW,]7B7C>#R9S\ZS^\7I@/*VY!)*C<T\:_#ER7HGFN]0HVA
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M5"KU2D-$:@15!PQS.J3XM$CB46(FZ2J-LUEB0_UQFDZ+Z6BQ6B2K/WH+R1_
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M]; &9#=;<Q>%?P056:%MZK$YS(1X-3%TE#3WDJ8 &SAUQ+O'AVOYG?M?#$Y
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M'RUL6!\%7)-MB>F./GJ8,TEL?-! 79Z*;/U74<_8TFF7)X4)B'Q;MF:0PY3
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M;Y361,E.87.0-^S,I+80K%[W&8='3MBGV>U9+MY=BYI@RBL$'@[=C$*-;E_
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M-@6W&B,\5C6\N97HZ2"/.M(?[B.'U#/?K_H9/>1:7=:;#JV/& 8: ^CS"_'
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M>2V>9^QLV@[>()O89#1>(@HDZ "SAF4^9>L]2$P[I&7KA=Z8_#4H IG!+_:
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M176$MO%]:[M@0*:^J>S6C355+G!CHJ "U9HUIQX)%X!L7M=VXF V#Z4]I)E
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M_#-&U_LZ7[.5.;4ZSD9C1 Y/0#3&_11=>25]PK@BA%?TWGU3_Q:Z+UR74 0
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M!4VFK7X_Z-MT=PP=#+A>]^3]S *4F$%Y+8"]>IQ\J7#R0Y]Z:ARFV8'C[?O
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MJ&G<$'NIN4I(CMKN&=*'CJZ"A([7H"AD=TZ(H)RWG%X.?O6[PPQWAW@(QCL
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MRF73VJAT\=9)1%@'6>]OZ$6KEOZ<ZNA'L*?+,Y7;6Z"MO/*=KH0,;7Z,X$Q
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MI0>+],"X:!5'*-N0*-;T0H6O83K&OCX6,T^(0+G2<.37TOT3P;:.L'T/&6M
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MN G5=Y59"DYJOB]N^;B=G!W/7LPNSF?^!I_RW_1\]^I!-KOU92&625MBXF:
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M;=$;2FPD;LDEKFCN SJF(PGM=(J^XX@I;J25<!2 H\[N(#$@!&>.5Z)$'0%
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M;;\A)K5%I/)9R;$5P ;N-L9*:%RV5<W<.RX'Z$DF^[S>?%3CYY4M,O@OYH-
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MKY@)G]"IQF%@_+T4:$#R6[:8='&-HL*5AI4I_JF$?>FCFFE($T,EI,5W4@H
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ML4<[CJ0,\G;T\N#?Z(_([HGX'DVU!PI2D=- EI]=#;N.T2?6-VR+&MR.)VZ
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M%>F?IS8B69ADU7-SA;@RQ$Z>4/1BZ M3(EG>U<_4$GA[U3U_^445\I<B<76
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MQ]_JK$1<XZF]P@2 7);5VBO%8P+=;9CY\L0U<>F8WQ*\@QT;Z_9"Q^ OG"!
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M> LG*I=EM77\9R[0LC%W8/DF9CSM#8=YK]\=]M-1,AYE_5DWFP_2-!U/'O3
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M)\_P(M"X5W6)(*\O2E=[Z;#M&H<IE\6^D71I@" 9J/4EP8]*6M7A)():0:T
MR!KP\4</[R58P;U"L<XH5[!$=CHFI.)I=\B?PTKC N^_E%FK@!/@H&^U2CFW
M33J34#45@<A:*@[T7^=<6ZRHN2OLW%)Z=5^>%0ASN9%,E*/-VE T .-Q5D:;
MO 2K4>V1V+:@;K?*UUJL/!N&\4BR(-;NE:,M#@"J?1ZJV*.4G-X@QI;*PZL
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M!--=V@"VWMB2SR-GI:^[65\D^W^+[LFO9YR5:>U:C"N%BUOO<ZSK@*AV6+D
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M<<WEBA^]?-6;_OCVL60X['?AF.%G\)/''"L$8WF1+)=)52[-D<#_(WC*D7Y
MR0K-MG=X=ZB,0*#IB+^AC-P"17\5%LI0%;99G1>;<L6>)@>,BFW-XXO!^MXQ
MF%'2,T$^QB8\2"BXL!O'CW[Y+_[[,5Q?O )G9F&J2L8:$S[8AK<VZ ([\(!:
M(N[UM.XL?"E_E",A#&QK%*0=7:()\TR+!?R WO;CV^/XLA.!(9+<5'#0>-IS
MT.[Z<AFO5@==OI)1BA47"Y-4Y#YOV8:2,7C+C"D=/8$4.CN8X^H$>5/TI3.,
M#;+GM"B6Q=;A,3AKQ)F;**@:MDM[^3K DHL-0LOP4[' @"@=UJK-_..(=7)
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M%%;NPV3)5L20:EZ ;*;#FR R\^8([T^<U L,R"SV?$ 8CN1 O@OA4ON=Z%_
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MM^,N*JP%87Y%T^FA$@T4/_IVU+-?6IEMQ B4;V?VC\0)C<MZ9A:DT%G=4M=
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M;8RUCAP,[%YOJ!^8K4IT4HD":!*_9=]>F&RW6HNMF]L,L)/]#;/E2C*7GK=
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MF!+E'##C-J5),+OO"9%3"8+I8A3@T2(+X9%CQ89)/2'HM/42J0^30""D Z>
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M_89Q)U(DP8QZ<N\IPF,[YQIOPW+GM^_97(YTR;0WR9"AW/+28&JK)L)8F9I
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MU[]T]/IE(?+O8!LYU[O2)%C#0U"1\,I2Z_DP"SI-,4>350JW/A;N2+C0?*,
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MFX1J<L!8'7)+-[]G 992P@X_;DB!)<92(X3TKQA6!A]B:/PWD23 X4$PTZ$
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M'9^0-=&6Q$N^9,'G*TT&8R//Q8)S27OZZMU6M":$K 17_R=X(VI=:D!(/G'
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M_<:+[3V/*\I_D0\<N_)59  UR0>I3994L;864?<0$J)QP31SDQ6MLFM4=L4
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M9/Y@C>^N\;NE=JM-X3=*U.L"U2IX6PVB>.%R :,S1^16M;RLX77?@$V#\)D
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MCSKNAQUZ7'==#-8,(<3$'8R_,RQ (/-B;@&/'9T$0?P(A"_! PE9!ZP:+J3
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MZ[S$/_ OP]HI5NU57O<WMN((__<2CVI$6M>^;'>K\WH/7@<V"N$@ZBM!'?[
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MD.IEUB8.#UW,?R([1O0^O8%??;OPQ1\N(]_$OEZ;C%QREOCOV,=BHU]Q=*7
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M=I:$YFAE/[B93FR42$,#6I)'QHU/#%T,.(2"L)=.3TDA U%5>")G2$T^TH
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M<>&&<:,BR:^1N6%A(*'3FL.S8G#2LR);YML:&P;0/Y=WH[8N:FSM,0ZF[BB
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M_+,*[=VT7QFAE&_#99QL=^MF#!!?IQ.IWY%04Y)'IT,CF,YZ5PB"=N3&)O&
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MCI%JK6#GKV,PM#,&]M,C'O=(Z<G :>O>%CD%H5F(PY^XD!=6,K)[=Z/06H%
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M=GG8/68E47DCSM$B@\.P%$YTUTL6:UH/QSI<<:)*-/?DAH@)=LN4AXSUT7J
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M8 *TNK%VD(P^M<FAM<F6AZL5=D5#],X\L-=(QZEMDU*ML9(0?&)9YU;&OM[
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M)$EFE$.%Z\-PXL_:!OU&+9S1)SB]M];2[=4T 6B:9T 3:@",*V0+1Z_0J7"
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M&IY<TRW#1Z3*)& !SU,#=29W:L.EZ\/ C[ 2_72*],24T#/[3+;-#0M,S?C
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M5Z9^R--=F: ^$S CR /'LC8\J%RV[5>-G @C=619#;H@%:L<D;R% DS+O$Y
MJ_QK)S>D9L3)U]Z80(1LCVSGUFSQJ*(+5@1D$:9YK7[D$=IV%#K\RG:20.V-
MWBB[3GH#*H%XMEN#9%?\*KNI16GA/5T;JL5<65K=B5?FUFSZ$.0.F()?F'W.
MD7.\&976:[!:M.RPEJHFDN*:28[Q,G6"[FQFTWI2 1)]*>A0N$U"#:&L[1P
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MT872X(;N5 &FT290<<[]/16^J,&+JU!P6.E>0OK0&+*:\XV)#+NRB;8 8*U
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M$"/QAH)$52%C40.5YL@I#&R'Q8+O5H'$M,PX>Z- 2]B4W2W8!-:1B];S,7!
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M:5<;:9HF_#U^18R[<QK>5\A(+ 9G59V10=BJQ(B6Y,S*^=(G) 4094FABI#
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MR7E\ A8_C(G)\"; B\&:K&#)1RCZ19<D#4-.WE'U5]4G0<O<#,2*IT+ECIB
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MXY&0$O0*-1_0;;.W[ HGM'EG:B_;GU,8GZ6$@[=4<DF=F"7&LQ2@ K!$!B8
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MDW&B5BKP AAU0O.&6<\Z($FH4"\O4:3/0IGPX]3Z_.?>=F5[>]M,-#8Q356
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M7)J"29"/RJ.IM)6,9<%W8R0 >".G?:SHI[5D620.W$8*[FA69..;6W.,_S_
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MIM*M\!*(-$YX-O@L(D17C.$$.* FHZHDC& _N:+2\2WK;5T9YH-?/H:5YU2
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MKA!W-[F^2-46Z=Y828LD-D3F3O6]:I7DSU!OI%P4=D9R]Z/JB\RU19JN2(=
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MW6'-IESML.^O9<*SG&QC. PIL;*L2&B#,4_!K5WQG%<G$(HC (\2"/7MNWT
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M/N+$#5%H#Y*(2-D/4S0)(Q!/@M0N[SCB=VSA+RYY ,))$HS#FSCYZD=I.C?
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MA*/W:H\^Y5"V/=D.N_?'5G@-/+IDK98)<,FX=LDR+4KJ"]3(DBX.JZ_% %P
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MA6:T#H5F^ C'[*!H0^&8>E9T#$D:] +K)TK:P\+W%Z;NDHRBYLK%^FLM^G.
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MNN]VY+X; 4"NJ<T_;SG#^4RL;JV<]U@W;YTKIID)^*_40-,UTL=1;1[]05E
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M^MEN#4R_1L[T>JU=-TRYZFH,I8D#N?YZ6U 44)2MBI*IT#M442K)K])$K:^
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MZ?.J*BHR[/BMT#FN%G-> )"=/C\8:OG#/DH'@3/*;P,4:-EB.HL"!7,J!K5
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M.@=] T]2?QZDJOY);@!1 %&Y$'6JA0((TS&$X;BVI9O'I%PMII(S6XY(!;D
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ME%Y/SM2L%8>&4G;5GB[J^K!-^MS*ML,<'15T=3%PQ-,95G*U&)"KSK"2J\6
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MIM#U:/VIU'_J@S:!-O&M3;JDZYFDY*.UJ5(_089CHC,_)KKY:;X8SC,2/"-
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MBU)5G!OBYP&, HP"C&H/1IT$44JU$%6"%\Y9J04<'W)X?!AXQA0ESP[YB,I
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M=V=D<LT"/]!*,)RI@+!8+H@4\N&E0^R)KRSKS&27#*+=A])T;QM.,'*F-Y%
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M)^%"&&Z2,/UC\6$+#>,EOGC1NR$EB6:PF,1?F(V0#59$;V2NETH[,I:!&[U
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MUBWK(+4!@ : ABL:YC?1S"#-L'RDJ:(;1!T LS6/_W* +:;B8,(#]X_O?@F
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M3E(UV.8"[58XY>YH.KRFBD"S-H"TFB4004Q,8"&Z%Y^QC0L6]N5^Q/$80V$
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M2"IPR[D-.8^!V>6+J!)+,D1G)1YAH//H BP2#/R>L@)A#=$2.!;2DK#H\(Q
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M_J^@M9"&8@'];-.+&$F@C0!'M"?&'$V(+Z8V]-PQ#2014?A"\".S%',;,,K
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M3V9X&H.KSURIJN6R,7'5XWF7.*7E [SW\BAEH3,.G[;>D(!*G>OZY^6%K7:
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M?6L23:*0B]ZA6BNMD],Y91G?NIUV"U?%7S(/;+F<JFH#2I/NL WHF6H#JMJ
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MXY.M"9"A!]#7\ ZCM!!$,RUP \,F>5)SA]IO8C]5<+R72[[:2I.5FR??M5G
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MTL]6XFN?^PZR&&'HS3,<PJ- K QV+H*_D6=(G2524%)^8QSNBS$%,"7&&ED
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M\^#OL4N&I ATOIO(7(;O!<29>:P])&X 2D(&J)ELPJ@O6;QON8!@.N$F*KJ
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M#\O$9OPC:X4U:C-N&MYXZ0]!ZY"JC.5I0F;@>@4NCBK6! %SN/;WXF+1*%E
MRM;&C&&"250LRD\('L?:?9S^&PU(C\II4%'D2R'=#C.^A!XVB=*WQ%L\&%)$
MEEJ^'\8*$*_'PY6D[!9EP2VA.V5VG-ROQS"2^T]*+^934G8QA;""^HYU"AU3
M**^D,\M@WZC.B8GEP82B%Y6K\7T6Y)9!\V.-OE?+H=Z,X:3!L0L#1#UW@JU0
M<(EN,G&9'%/AA-1:LIGRJBO1QPYZJF2*,[[GN!CX:&LOAAVRU!'YVHAAFAUJ
MJFR<;ZZ#>7E"T8;79" J_(@ 0:;;)\8+$O#B N*!!!! 8^:/C T3#@@/&6VK
M6 W!(RCR(I!L;(5C/HSE4,RL[Q?NH8&%S-#"L25OFPJ\7$/@94L%7JK 2Q5X
MJ0(O5>"E"KRL=>#E8N:KI>[Y XGM+(SN7$=\Y_8C/-=#J=6WO>#CRQOM2L"Y
MC5C0#42#UOR8\E,OMN$YYL@51DX;,LM"5BN96NA@RZ.."X-8BXQWQ8&L:PEE
M+63M<^-;E0&T/@;0?.WYPS6 ]GT_-&3$A+*!;MS>[$01/GJS0GCK=\.'O[4+
M6"ABD?;@8:1KE1)?V3=+*E)\\2P_<&WM^Q2-D/=_AM;3$T6VH+4++8N\*?"0
M!5-A=[299SQ9=J(]0;;:*&C@)TV=1P".GV3&>'*ZH^1TT7NWET?PUGB,!= &
M(S;X.7$M"A(964]6X'K:S02.V 4$..E\TMX[\+L=CHVG#PV-LMH#BX+C>?23
M^8)HC:7%; N6'8Y=M ?W*2KQ7Z&3"$ODN=0ET&H40VA,+1>JU47J--N=D[-F
MKM0O=XM_9Z#SF'WGA?G4F.Q<EFJ]</V"V ;]5&_J3:RT<"_+6-^#\FEXEINH
M'(";D7O92*FH5G&M*$9;@M.0NY&&:1D7MCVK:=TY01P@A]4!8O<%[Z%#%4I#
M;S R_$0$70DRR@=+HL2SV-AKGIWD&_;>!^[@9Y^\&I?4_OL6-N3RD T?-DM?
M%503083D81KK1$T^;1(G^]=?YX5:-3JM3J/5R3>=F.>3H2X?$;@GGNB34I&Z
M>_K923O7\8GO@ /T%D<$>-)GFZ7I'_>7CQ.LR\*G6@1^G>.S?*Q:;'7AX8C<
M ,-!Y&&/9Q]O+!/@5PU6K9-F+UU$,-DVXL)V,2J3X+4M5%NEO4E1?Q/I3,)8
M6^X[@U]@=]J ;R[&+T2_$%8:78!9-*6HVE=8]%1[WVI^T*X-WS3^Q HV5$33
M-*9^.L> _0+VD73^S60G_$03S!I7R"M^1T)*BPLIBG&GW-BY,QX:E@="@?>3
M!<+7N5S%YT[SI-ENGZ8IY%(XHE/5G6Z&7[[?]YT[#)*4H9$52@_-))F$7/G"
MSCT/"SM1F-X:18=.0V_E\X-B7B(\_UB>#-W>!-C(>VQ*EWRZ CU\4W@QPAG<
M_:<QGGRZC".1WW-7,AF5Q^CDQM2BZ!PG=.E%Y:6D.!B@V)THB"^BKH&0XG8A
M8J8/U0MFPF'KG6ZS4]1;1_0 ^S=>'NZ ,=/_ZKECJ:T!IW3'8]>A2WL?3OVD
M<7)ZFC_U]Z)-0%5PM7NG>NZFE;&D-\-(AD$8H?R\%Q1Q5D .EE3+)=Z"NL8\
M%M4ZPTI265E;\>C8JE&BYOFP4KPYHTY.S#''HN'23#40B?P:N 3E2 #JZ'/T
MPNI9#-W6>A3#%L9A[UPQ;#6+%<-2C; AY1(\EFKPZJQ+=4&0-5O$"M8(O.54
MEW:[U0#>MC;591$$7$5W62?D5M!=3H^[)^T"<7Q%]24'JMZ2JLMF4&WCJDNA
MRI(T]>6PDQ.W#1LHT%;0N,=,BW?Z645Q6>--5\%_5>DJK."@4V%\JX7QM548
MGPKC4V%\*HQ/A?&I,#X5QJ?"^%08GPKC.[1C4F%\*HQ/A?&I,+Z5P_A6(E 5
MSK=97_ ,\ZQT>K6Q>HW>:G4Z9\V37LT<P@^O[AJ]!MUBI\&:?,)'=?$)+W+H
MW=Y)IH-:C1S#ZSU]O=,XZ\YR#B\ MVZST^TT:^$A7B^0.OG&\'OL)*:/+"IC
M]_&H>=Q)6%8D0]]5>+8L/BP*X;5GAF??4U7 \W3AQ6\,6_']U) [.\AYOGV[
MT-[+AO+V5/OIN*\.UDVX_\<7[3YV=,!S'Z*F?]E1XB[*\"*O1F@\4TSH)/00
M#\B)S1E9MB:M.\22$U3S$"31ANCWA15JT?U"_XX\-WS.K[U!-2*R7A[Y- !5
MK-;@U1W%K4?S@; KUJR]/W_X_H$[X!)+@3V419!G)I1%%QK$HLG'GMQTT0C^
MB-G8-_X9BT'P&\&7-(S<^BL0F_;UJ,W!&4XF-GW%J"*%@8R<:D^$R2^UH65S
M7I]%DF/M-K,> UZ":P*U@<*Q\H6#TX>$Y31@J-^JQ,7H/;W3:^8B>HONASYP
M(KBV;L,G6-V-.*;950*;^CP6*)!&XLPW>[!.V: DH@ PIP UC[6OLI>=*;,7
M))!][#S*.'@I""2#U9;#:UY*[,;A 7%YVH/XK*!.9K43:F$#[;4%+BQT0U4X
MGN5B%LZ:W4:WH#]R#K)T*XF*.83@O%(J!RGUP'SXSFNS(+$0TE*-[ G\!4(/
M]Q=7BQ'3>^U.YR0?([8"+:P;V,O30KO1*R@GNF 4G7ZB=T[B0(9MR$B;91"=
M MDQ+QJI]AA%"CM?\J%:@ 9OR )$+)R*1P/=3VS#47F<6\G>R@J>6'M8XX=Q
MPP_CUD8O&XB9%&X*5V R31._C$5[?GP^79)W]S]\66WN&5L#\TKI;#RQW2E#
MOF!:'HB5KN>+SK'.4?1E+DP0'I#I)MJ/^_.&UG?F44>M H9C@!<#.+5;M!IY
MV/89$VBBJX!+U-BK14;2(I3F7)GM9KO5[&!:1D\O#).D<L8X,5PSI&<D; !?
MIKF*Q^>OAF=>AWC[P4U+XE%LT2FZ9^EV#7V<$/=Y#2N([M6'5_=!>-H?F$.C
M<9#X^.A:I#R]T]#/N@V]6V!_R&+K,4>!AP*J>'*QW!Y:ZR*<I1A!21)X>G2,
M((3_3VA/A6P-YV4Y X]A]!^5XB/ )8HV&B^&9=.-&Z81! <[ULZ)$ J$]N6P
M0.]T3_)"_)JP0.X$-%/J!%Y#9#@]TQMGK0J8D#V-/+EF^!-I", /0/&-CQ2I
MEU?6Y S0/ZX94]I\%H.H<AK?#/(FB %,X$3S'K=8&S.+M@L=H'/:.3EMYW.
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ME._\A(U5C0$KA:N]NL-W)& ==JSG-K!S JQ8 G,*K[*+3CUMQJNG%7B%M7H
MHDRL1 /002<C"R^MAK''("_F9ID6,Z+V2U:=GTCQX K ;65MFTZ]HR:KVTC
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MLVF>:P47&._P*]$=3:/9;]G$T<YBI%,G@EPW?Z\/ZV1B&0:Z$IFZSX6U0RY
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M\:SL"\:('+Y/[LRFE''Q^23_W+&3[#SS"L5'AC:09BW=85&N:$0>3^S/F7X
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MTHZXU"@:EX2UA%6EUFE(7#KL6,]M8!*7\N%2#LN\ &P2URQ7:\VVQ*;D7&1
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M5;\B79_Q3SGV7"0M96G*"9J?4B3S5J["2>21R".*6RF51KX=[)1@_BVQ1]"
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MN 6NK5Z>59B6 5NK\&S[[H]97]VU'7(6]%8M8NY-\B_-]##JA#&I3_3)9G\
M*K5KL4;)#E '7 !!^\Q;<?9'7\GO? /7Z6YMT%=Z")B-]E6OD0),#=M<#EV
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M 5!+ 0(4 Q0    ( - [9%K/>[)L*1@  !?Y   1              "  0
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M+3(P,C0Q,C,Q7W!R92YX;6Q02P$"% ,4    " #0.V1:>P"J8GXQ   $!0$
M$               @ &M;P$ 97AH:6)I=%\Q,2UB+FAT;5!+ 0(4 Q0    (
M - [9%HNLI$>C0<   DC   0              "  5FA 0!E>&AI8FET7S$R
M+3$N:'1M4$L! A0#%     @ T#MD6BSV3+I0!P  >1\  !
M ( !%*D! &5X:&EB:71?,3(M,BYH=&U02P$"% ,4    " #0.V1:*%& $GH$
M  "_#P  $               @ &2L $ 97AH:6)I=%\Q,RTQ+FAT;5!+ 0(4
M Q0    ( - [9%KNH<F:DP0  )80   0              "  3JU 0!E>&AI
M8FET7S$U+3$N:'1M4$L! A0#%     @ T#MD6ALIK.]M(P  ?I@   \
M         ( !^[D! &5X:&EB:71?,BTQ+FAT;5!+ 0(4 Q0    ( - [9%J.
M5?NV?@(  "D(   /              "  97= 0!E>&AI8FET7S@M,2YH=&U0
M2P$"% ,4    " #0.V1:VB=RXNB! P!V<08 "@              @ % X $
M:6UA9V4P+FIP9U!+ 0(4 Q0    ( - [9%KZS0KJ/%8$ '?6)@ -
M      "  5!B!0!Z:S(U,S(W-CDN:'1M4$L%!@     .  X ;@,  +>X"0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>zk2532769_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cgen="http://cgen.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cgen-20241231.xsd" xlink:type="simple"/>
    <context id="C_20240101to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandTenShareOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandTenShareOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-10</instant>
        </period>
    </context>
    <context id="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-10</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230131_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LeerinkPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LeerinkPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20130801to20130805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2013-08-01</startDate>
            <endDate>2013-08-05</endDate>
        </period>
    </context>
    <context id="C_20130805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2013-08-05</instant>
        </period>
    </context>
    <context id="C_20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_20230101to20231218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="C_20231218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="C_20240101to20240131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenGileadAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:GileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:AntibodiesDiscoveryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:AntibodiesDiscoveryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:AntibodiesDiscoveryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240131_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgen:OrdinarySharesIssuedAndSoldThroughAtmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221101to20221111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-11</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210901to20210929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-29</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20231201to20231227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-27</endDate>
        </period>
    </context>
    <context id="C_20231210to20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LicenseAgreementWithGileadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-10</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="C_20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LicenseAgreementWithGileadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="C_20201201to20201218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-18</endDate>
        </period>
    </context>
    <context id="C_20240501to20240530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="C_20241231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapSubsidiaryOfCommonParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:SubsidiaryOfCommonParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_cgenSegmentReportingGeographicAreaAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cgen:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cgen:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cgen:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="NIS_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>cgen:Segment</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD_per_share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_20240101to20241231" id="FFact_0000000000684">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_20240101to20241231" id="FFact_0000000000685">0001119774</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus contextRef="C_20240101to20241231" id="FFact_0000000000686">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      id="Fxbrl_20240730211801692_20250224141027740_2"
      unitRef="usd"
      xsi:nil="true"/>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses
      contextRef="C_20231231"
      id="Fxbrl_20240730224938615_20250224141027741_9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20250224182302928"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_20240101to20241231" id="F20241016070140805_0">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="C_20240101to20241231" id="F20241016070140806_1">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="C_20240101to20241231" id="F20241016070140806_2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_20240101to20241231" id="F20241016070140807_3">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="C_20240101to20241231" id="F20241016070140807_4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_20240101to20241231" id="F20241016070140807_5">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_20240101to20241231" id="F20241016070140808_6">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="C_20240101to20241231" id="F20241016070140808_7">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="C_20240101to20241231" id="F20241016070140808_8">000-30902</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_20240101to20241231" id="F20241016070140808_9">Compugen Ltd</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_20240101to20241231"
      id="F20241016070140817_36">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="C_20240101to20241231"
      id="F20241016070140809_10">Azrieli Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_20240101to20241231"
      id="F20241016070140809_11">26 Harokmim Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="C_20240101to20241231"
      id="F20241016070140809_12">Building D</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="C_20240101to20241231"
      id="F20241016070140810_13">Holon</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20240101to20241231"
      id="F20241016070140810_14">5885849</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20240101to20241231"
      id="F20241016070140810_15">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20241016070140810_16">David Silberman</dei:ContactPersonnelName>
    <dei:CityAreaCode
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20241016070140811_17">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20241016070140818_39">3-765-8585</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20241016070140811_18">972-3-765-8555</dei:ContactPersonnelFaxNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20241016070140811_19">Azrieli Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20241016070140811_20">26 Harokmim Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20241016070140812_21">Building D</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20241016070140812_22">Holon</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20241016070140812_23">5885849</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20241016070140812_24">IL</dei:EntityAddressCountry>
    <dei:Security12bTitle
      contextRef="C_20240101to20241231"
      id="F20241016070140813_25">Ordinary shares, par value NIS 0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20240101to20241231"
      id="F20241016070140813_26">CGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20240101to20241231"
      id="F20241016070140813_27">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20241231"
      decimals="INF"
      id="F20241016070140813_28"
      unitRef="Shares">89541246</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_20240101to20241231"
      id="F20241016070140814_29">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_20240101to20241231"
      id="F20241016070140814_30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250304022141436">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250304022146953">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_20240101to20241231"
      id="F20241016070140818_40">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228181502329">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_20240101to20241231"
      id="F20241016070140815_33">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_20240101to20241231"
      id="F20241016070140818_38">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard
      contextRef="C_20240101to20241231"
      id="F20241016070140815_34">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="C_20240101to20241231"
      id="F20241016070140815_35">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228163143155">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228163309020">
            &lt;div&gt;
              &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;
                &lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, certain third party hosted services, our communications systems, our hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and employees&#x2019; information, or the Information Systems and Data.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Our Senior Vice President/Senior Advisor, Data and Informatics Solutions helps in identifying, assessing and managing the Company&#x2019;s cybersecurity threats and risks by monitoring and evaluating our threat environment using various methods including, for example, by engaging third parties to conduct penetration tests on our behalf.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Depending on the environment and system, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example, incident response policy, business continuity plan, cybersecurity insurance, firewalls and access controls for certain environments and systems, physical security measures, and employee cybersecurity trainings.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Our overall risk assessment and management processes covers material risks from cybersecurity threats.&#160; For example, cybersecurity risk is a component in our internal auditor&#x2019;s risk assessment report. Our Senior Vice President/Senior Advisor, Data and Informatic Solutions works with relevant management members to prioritize and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including, for example, professional services firms, including legal counsel, cybersecurity and cloud consultants, and a penetration testing firm.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;We use third-party service providers to perform a variety of functions throughout our business, including in connection with our clinical data management, antibody development, financial information management, payments and others. We review and require certain security measures of certain of these third parties, such as encryption at rest and in transit and access controls, and in certain cases, we seek to confirm their compliance with different industry standards and certifications, such as SOC1, SOC2, SOC3, ISO 27001, and ISO 27017.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;
                &lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 3D. Risk Factors in this Annual Report on Form 20-F, including the applicable risk factors under &#x201c;Risk Factors - Risks Related to our Operations.&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228172033563">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, certain third party hosted services, our communications systems, our hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and employees&#x2019; information, or the Information Systems and Data.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228172141502">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228172202943">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228174643711">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 3D. Risk Factors in this Annual Report on Form 20-F, including the applicable risk factors under &#x201c;Risk Factors - Risks Related to our Operations.&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228174708096">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228163335599">
            &lt;div&gt;
              &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Governance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;
                    &lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function through its audit committee.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;Our cybersecurity risk assessment and management processes are under the responsibility of our Senior Vice President/Senior Advisor&lt;/span&gt;, &lt;span style="font-size:10pt;font-family:Times New Roman"&gt;Data and Informatics Solutions, who has over 15 years of experience in the data science, technology, and machine learning spaces.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;
                    &lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Our Senior Vice President/Senior Advisor, Data and Informatics Solutions, is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, communicating key priorities to relevant personnel (such as the Chief Executive Officer), helping to prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Our cybersecurity incident response policy is designed to escalate certain cybersecurity incidents to certain members of management, including our Senior Vice President/Senior Advisor, Data and Informatics Solutions, our Chief Financial Officer and our General Counsel. Under our cybersecurity incident response policy, those members of management will work with the Company&#x2019;s incident response team member(s) to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#x2019;s cybersecurity incident response policy includes reporting to the audit committee of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;
                  &lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The audit committee receives periodic reports at least twice a year from our Senior Vice President/Senior Advisor, Data and Informatics Solutions concerning the Company&#x2019;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also receives various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228174931968">
                &lt;div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;
                    &lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function through its audit committee.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;Our cybersecurity risk assessment and management processes are under the responsibility of our Senior Vice President/Senior Advisor&lt;/span&gt;, &lt;span style="font-size:10pt;font-family:Times New Roman"&gt;Data and Informatics Solutions, who has over 15 years of experience in the data science, technology, and machine learning spaces.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"&gt;
                    &lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Our Senior Vice President/Senior Advisor, Data and Informatics Solutions, is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, communicating key priorities to relevant personnel (such as the Chief Executive Officer), helping to prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228172524272">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function through its audit committee.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228174839002">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;Our cybersecurity risk assessment and management processes are under the responsibility of our Senior Vice President/Senior Advisor&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228174907959">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;Data and Informatics Solutions, who has over 15 years of experience in the data science, technology, and machine learning spaces.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228175111815">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Our Senior Vice President/Senior Advisor, Data and Informatics Solutions, is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, communicating key priorities to relevant personnel (such as the Chief Executive Officer), helping to prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228175151355">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228174432444">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228175213514">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The audit committee receives periodic reports at least twice a year from our Senior Vice President/Senior Advisor, Data and Informatics Solutions concerning the Company&#x2019;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also receives various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228175249251">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorFirmId contextRef="C_20240101to20241231" id="FFact_0000000000042">1281</dei:AuditorFirmId>
    <dei:AuditorName contextRef="C_20240101to20241231" id="FFact_0000000000043">KOST FORER GABBAY &amp; KASIERER</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_20240101to20241231" id="FFact_0000000000044">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000045"
      unitRef="usd">18229000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000046"
      unitRef="usd">13890000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000047"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000048"
      unitRef="usd">365000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000049"
      unitRef="usd">61397000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000050"
      unitRef="usd">25053000</us-gaap:OtherShortTermInvestments>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240227231100990_Fact_0000000000049"
      unitRef="usd">23629000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240227231100990_Fact_0000000000050"
      unitRef="usd">11742000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240227231059015_Fact_0000000000049"
      unitRef="usd">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240227231059015_Fact_0000000000050"
      unitRef="usd">61000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000053"
      unitRef="usd">2742000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000054"
      unitRef="usd">2529000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000055"
      unitRef="usd">105997000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000056"
      unitRef="usd">114579000</us-gaap:AssetsCurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250224184103804"
      unitRef="usd">343000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20250224184107099"
      unitRef="usd">0</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000057"
      unitRef="usd">1888000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000058"
      unitRef="usd">1233000</us-gaap:PrepaidExpenseNoncurrent>
    <cgen:SeverancePayFundNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000059"
      unitRef="usd">3072000</cgen:SeverancePayFundNoncurrent>
    <cgen:SeverancePayFundNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000060"
      unitRef="usd">2977000</cgen:SeverancePayFundNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000061"
      unitRef="usd">2843000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000062"
      unitRef="usd">1329000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000063"
      unitRef="usd">852000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000064"
      unitRef="usd">1216000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000065"
      unitRef="usd">8998000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000066"
      unitRef="usd">6755000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000067"
      unitRef="usd">114995000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000068"
      unitRef="usd">121334000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000069"
      unitRef="usd">1838000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000070"
      unitRef="usd">3502000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250224184239781"
      unitRef="usd">9632000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20250224184245908"
      unitRef="usd">11149000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000073"
      unitRef="usd">448000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000074"
      unitRef="usd">632000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250224185219347"
      unitRef="usd">5168000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20250224185226324"
      unitRef="usd">7858000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250224185300088"
      unitRef="usd">3074000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20250224185306141"
      unitRef="usd">3125000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000077"
      unitRef="usd">20160000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000078"
      unitRef="usd">26266000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250224185857857"
      unitRef="usd">34045000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20250224185904182"
      unitRef="usd">25392000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250224190059221_xbrl_20250224185857857"
      unitRef="usd">2464000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20250224190059221_xbrl_20250224185904182"
      unitRef="usd">719000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000083"
      unitRef="usd">3412000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000084"
      unitRef="usd">3398000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000085"
      unitRef="usd">39921000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000086"
      unitRef="usd">29509000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20241231"
      id="Fxbrl_20250225101052443"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20231231"
      id="Fxbrl_20250225101058499"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20230214011115128"
      unitRef="NIS_Per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20241231"
      decimals="INF"
      id="Fxbrl_20230214011053357"
      unitRef="NIS_Per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_s_20230214011030882"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20241231"
      decimals="INF"
      id="Fxbrl_20230214011030883"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20241231"
      decimals="INF"
      id="Fxbrl_20230214101530012"
      unitRef="Shares">89541246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20241231"
      decimals="INF"
      id="FFact_0000000000092"
      unitRef="Shares">89541246</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20230214011437479"
      unitRef="Shares">89237465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20231231"
      decimals="INF"
      id="FFact_0000000000094"
      unitRef="Shares">89237465</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000095"
      unitRef="usd">248000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000096"
      unitRef="usd">247000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000097"
      unitRef="usd">543413000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000098"
      unitRef="usd">539837000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240227232850023_Fact_0000000000097"
      unitRef="usd">11000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240227232850023_Fact_0000000000098"
      unitRef="usd">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000099"
      unitRef="usd">-488758000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000100"
      unitRef="usd">-474527000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000101"
      unitRef="usd">54914000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000102"
      unitRef="usd">65559000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000103"
      unitRef="usd">114995000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000104"
      unitRef="usd">121334000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000105"
      unitRef="usd">27864000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000106"
      unitRef="usd">33459000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214012425376"
      unitRef="usd">7500000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000108"
      unitRef="usd">7930000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000109"
      unitRef="usd">2004000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214012430928"
      unitRef="usd">975000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000111"
      unitRef="usd">19934000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000112"
      unitRef="usd">31455000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214012436309"
      unitRef="usd">6525000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230222115443735_Fact_0000000000117"
      unitRef="usd">24810000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230222115443735_Fact_0000000000118"
      unitRef="usd">34472000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230222115443735_Fact_0000000000119"
      unitRef="usd">30648000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessDevelopment
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000117"
      unitRef="usd">576000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000118"
      unitRef="usd">244000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000119"
      unitRef="usd">932000</us-gaap:BusinessDevelopment>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230222115622478_Fact_0000000000117"
      unitRef="usd">9439000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230222115622478_Fact_0000000000118"
      unitRef="usd">9731000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230222115622478_Fact_0000000000119"
      unitRef="usd">10319000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230222115529913"
      unitRef="usd">34825000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000124"
      unitRef="usd">44447000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000125"
      unitRef="usd">41899000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000126"
      unitRef="usd">-14891000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000127"
      unitRef="usd">-12992000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000128"
      unitRef="usd">-35374000</us-gaap:OperatingIncomeLoss>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000129"
      unitRef="usd">5182000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000130"
      unitRef="usd">3208000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000131"
      unitRef="usd">1738000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000132"
      unitRef="usd">-9709000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000133"
      unitRef="usd">-9784000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000134"
      unitRef="usd">-33636000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230214012403897"
      unitRef="usd">4522000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230214012406780"
      unitRef="usd">8970000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000137"
      unitRef="usd">58000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000138"
      unitRef="usd">-14231000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000139"
      unitRef="usd">-18754000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000140"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20250224174645707"
      unitRef="USD_per_share">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="FFact_0000000000141"
      unitRef="USD_per_share">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20250224174709901"
      unitRef="USD_per_share">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000142"
      unitRef="USD_per_share">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20250224174800107"
      unitRef="USD_per_share">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000143"
      unitRef="USD_per_share">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240228001617126_Fact_0000000000129"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228001617126_Fact_0000000000130"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240228001617126_Fact_0000000000131"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000147"
      unitRef="usd">-14222000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000148"
      unitRef="usd">-18752000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000149"
      unitRef="usd">-33694000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20240228001903510"
      unitRef="Shares">89528031</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="FFact_0000000000153"
      unitRef="Shares">89528031</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20240228001918048"
      unitRef="Shares">87633298</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000154"
      unitRef="Shares">87633298</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20240228001929235"
      unitRef="Shares">86555628</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000155"
      unitRef="Shares">86555628</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000173"
      unitRef="Shares">86433432</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000174"
      unitRef="usd">239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000175"
      unitRef="usd">528533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240228010711681"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000176"
      unitRef="usd">-422079000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000177"
      unitRef="usd">106693000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000199"
      unitRef="Shares">191211</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000200"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000201"
      unitRef="usd">352000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230214013718917"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230214013728837"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20250224175055453"
      unitRef="usd">353000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20250224180339449"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000211"
      unitRef="usd">4328000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250224180414715"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250224180434405"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000212"
      unitRef="usd">4328000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20250224180533427"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20250224180546817"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250224180550362"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000213"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000214"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000215"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000216"
      unitRef="usd">240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000217"
      unitRef="usd">533213000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240228010718949"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000218"
      unitRef="usd">-455773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000219"
      unitRef="usd">77680000</us-gaap:StockholdersEquity>
    <cgen:IssuanceOfSharesAndWarrantsNetShares
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240228004702895_Fact_0000000000165"
      unitRef="Shares">2612822</cgen:IssuanceOfSharesAndWarrantsNetShares>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240228004702895_Fact_0000000000166"
      unitRef="usd">7000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240228004702895_Fact_0000000000167"
      unitRef="usd">3074000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="FFact_0000000000166"
      unitRef="usd">0</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000167"
      unitRef="usd">0</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228004702895_Fact_0000000000168"
      unitRef="usd">3081000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20250224182621810"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240228004651156_Fact_0000000000211"
      unitRef="usd">3550000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250224182627052"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20250224182644309"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228004651156_Fact_0000000000212"
      unitRef="usd">3550000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20250224182709791"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20250224182713378"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240228005606782"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20250224182721113"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250224181409213"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20250224182736559"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20250224182740340"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250224182743304"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240228004710783_Fact_0000000000213"
      unitRef="usd">-18754000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228004710783_Fact_0000000000214"
      unitRef="usd">-18754000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240228003430903_Fact_0000000000215"
      unitRef="Shares">89237465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240228003430903_Fact_0000000000216"
      unitRef="usd">247000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240228003430903_Fact_0000000000217"
      unitRef="usd">539837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240228010218091"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240228003430903_Fact_0000000000218"
      unitRef="usd">-474527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240228005626619"
      unitRef="usd">65559000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20250224181658809"
      unitRef="Shares">11053</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20250224181849098"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250224183710836"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20250224183717971"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250224181857069"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cgen:IssuanceOfSharesAndWarrantsNetShares
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20250224181915623"
      unitRef="Shares">292728</cgen:IssuanceOfSharesAndWarrantsNetShares>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20250224181927559"
      unitRef="usd">1000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20250224181950893"
      unitRef="usd">543000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250224183658456"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20250224183701490"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250224182103901"
      unitRef="usd">544000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20250224183640629"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20250224182159337"
      unitRef="usd">3023000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250224183643810"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20250224183646763"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250224182204714"
      unitRef="usd">3023000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20250224183732283"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20250224183728638"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250224182213962"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20250224183738392"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250224182230211"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20250224183746510"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20250224183749235"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250224183752462"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20250224182239490"
      unitRef="usd">-14231000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250224182244882"
      unitRef="usd">-14231000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20250224175231100_xbrl_20240228003430903_Fact_0000000000215"
      unitRef="Shares">89541246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20250224175231100_xbrl_20240228003430903_Fact_0000000000216"
      unitRef="usd">248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20250224175231100_xbrl_20240228003430903_Fact_0000000000217"
      unitRef="usd">543413000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250224175231100_xbrl_20240228010218091"
      unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20250224175231100_xbrl_20240228003430903_Fact_0000000000218"
      unitRef="usd">-488758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250224175231100_xbrl_20240228005626619"
      unitRef="usd">54914000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000220"
      unitRef="usd">-14231000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000221"
      unitRef="usd">-18754000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20250224185520749"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000223"
      unitRef="usd">3023000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000224"
      unitRef="usd">3550000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000225"
      unitRef="usd">4328000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000226"
      unitRef="usd">486000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000227"
      unitRef="usd">476000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000228"
      unitRef="usd">482000</us-gaap:Depreciation>
    <cgen:SeverancePayNet
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000229"
      unitRef="usd">-81000</cgen:SeverancePayNet>
    <cgen:SeverancePayNet
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230214015430934"
      unitRef="usd">-50000</cgen:SeverancePayNet>
    <cgen:SeverancePayNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000231"
      unitRef="usd">-81000</cgen:SeverancePayNet>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250224185641065"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250224185646941"
      unitRef="usd">-7000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20250224185650553"
      unitRef="usd">-12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240301111210380"
      unitRef="usd">68000</cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances>
    <cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240301111218731"
      unitRef="usd">129000</cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances>
    <cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240301111232004"
      unitRef="usd">-393000</cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250224191156710"
      unitRef="usd">855000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250224191201240"
      unitRef="usd">-92000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20250224191203268"
      unitRef="usd">584000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240228013916179_xbrl_20230214015610319"
      unitRef="usd">1575000</cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities>
    <cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228013916179_Fact_0000000000251"
      unitRef="usd">280000</cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities>
    <cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240228013916179_Fact_0000000000252"
      unitRef="usd">0</cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000238"
      unitRef="usd">-61000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000239"
      unitRef="usd">61000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214015520285"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000241"
      unitRef="usd">213000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000242"
      unitRef="usd">112000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000243"
      unitRef="usd">-3043000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000244"
      unitRef="usd">655000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000245"
      unitRef="usd">-666000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214015551570"
      unitRef="usd">-12000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000247"
      unitRef="usd">-550000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000248"
      unitRef="usd">-568000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000249"
      unitRef="usd">-658000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250224190735907"
      unitRef="usd">-4410000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250224190741453"
      unitRef="usd">3509000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20250224190744120"
      unitRef="usd">-1601000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250224190823689"
      unitRef="usd">0</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250224190806504"
      unitRef="usd">-325000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20250224190828721"
      unitRef="usd">-6019000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredRevenues
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240228013913681_xbrl_20230214015610319"
      unitRef="usd">-7136000</cgen:IncreaseDecreaseInDeferredRevenues>
    <cgen:IncreaseDecreaseInDeferredRevenues
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228013913681_Fact_0000000000251"
      unitRef="usd">-36541000</cgen:IncreaseDecreaseInDeferredRevenues>
    <cgen:IncreaseDecreaseInDeferredRevenues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240228013913681_Fact_0000000000252"
      unitRef="usd">0</cgen:IncreaseDecreaseInDeferredRevenues>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000256"
      unitRef="usd">-503000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000257"
      unitRef="usd">-645000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000258"
      unitRef="usd">-1062000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250224185433978"
      unitRef="usd">49604000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250224185439147"
      unitRef="usd">-35886000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20250224185444630"
      unitRef="usd">-34113000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000262"
      unitRef="usd">60717000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000263"
      unitRef="usd">79242000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000264"
      unitRef="usd">114445000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000265"
      unitRef="usd">96219000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000266"
      unitRef="usd">32100000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000267"
      unitRef="usd">76900000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240228013918979_xbrl_20230214015610319"
      unitRef="usd">53230000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228013918979_Fact_0000000000251"
      unitRef="usd">10145000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240228013918979_Fact_0000000000252"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240228013920658_xbrl_20230214015610319"
      unitRef="usd">63533000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228013920658_Fact_0000000000251"
      unitRef="usd">21605000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240228013920658_Fact_0000000000252"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250224194420319"
      unitRef="usd">330000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250224194432849"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20250224194443396"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000268"
      unitRef="usd">118000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000269"
      unitRef="usd">172000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000270"
      unitRef="usd">477000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230222115924752_Fact_0000000000268"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230222115924752_Fact_0000000000269"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230222115924752_Fact_0000000000270"
      unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230222112447073"
      unitRef="usd">-1000</cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities>
    <cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000272"
      unitRef="usd">0</cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities>
    <cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000273"
      unitRef="usd">-2000</cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000274"
      unitRef="usd">-46252000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000275"
      unitRef="usd">35510000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214015724492"
      unitRef="usd">37060000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000277"
      unitRef="usd">544000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000278"
      unitRef="usd">3081000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000279"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000283"
      unitRef="usd">10000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000284"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000285"
      unitRef="usd">353000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000286"
      unitRef="usd">554000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000287"
      unitRef="usd">3081000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000288"
      unitRef="usd">353000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240301111348803"
      unitRef="usd">68000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240301111408147"
      unitRef="usd">129000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240301111411299"
      unitRef="usd">-393000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000289"
      unitRef="usd">3974000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000290"
      unitRef="usd">2834000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214015801453"
      unitRef="usd">2907000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20250224201122601"
      unitRef="usd">14255000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20250224201149235"
      unitRef="usd">11421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20250224201210319"
      unitRef="usd">8514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250224194820349"
      unitRef="usd">18229000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20250224194822717"
      unitRef="usd">14255000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20250224194825126"
      unitRef="usd">11421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000298"
      unitRef="usd">-5000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000299"
      unitRef="usd">5000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20250228010101761"
      unitRef="usd">117000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230214015821971"
      unitRef="usd">2064000</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000305"
      unitRef="usd">71000</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214015838501"
      unitRef="usd">237000</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000310"
      unitRef="usd">18229000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000311"
      unitRef="usd">13890000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000312"
      unitRef="usd">11059000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000313"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000314"
      unitRef="usd">365000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000315"
      unitRef="usd">362000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000316"
      unitRef="usd">18229000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000317"
      unitRef="usd">14255000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000318"
      unitRef="usd">11421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240228025141975">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 1:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;GENERAL&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:28.5pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Compugen Ltd. (the &#x201c;Company&#x201d;) is a clinical-stage therapeutic discovery and development company utilizing its AI/ML powered predictive computational discovery platform, recently branded as Unigen&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;TM&lt;/sup&gt;, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapy. The Company&#x2019;s innovative immuno-oncology pipeline consists of four clinical stage programs, COM701, COM902, rilvegostomig and GS-0321 (previously COM503). Two programs that the Company is pursuing internally, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. &lt;span&gt;The Company&#x2019;s two ongoing clinical trials (that completed enrollment) were initiated in 2023 and are evaluating the triple combination treatment of COM701, COM902 and pembrolizumab, one in platinum resistant ovarian cancer and the other in microsatellite stable colorectal cancer, &lt;/span&gt; In addition, the Company is planning to start enrolling patients to our adaptive platform trial in platinum sensitive ovarian cancer, evaluating COM701 as a monotherapy randomized to placebo in sub-trial 1, in the second quarter of 2025. Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from the Company&#x2019;s COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between the Company and AstraZeneca and is being evaluated in multiple Phase 3 clinical trials and in multiple Phase 2 and Phase 1 trials. GS-0321 (previously COM503), the Company&#x2019;s potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being developed by the Company in a recently initiated Phase 1 trial. In addition, the Company has an early-stage immuno-oncology therapeutic pipeline that consists of programs aiming to address various mechanisms of immune resistance.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company is headquartered in Holon, Israel. Its clinical development activities operate from the Company&#x2019;s headquarters in Israel and from its United States subsidiary, Compugen USA, Inc., located in San Francisco, CA.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has incurred losses in the amount of $ 14,231 during the year ended December 31, 2024, has an accumulated deficit of $ 488,758 as of December 31, 2024 and has positive cash flows from operating activities in the amount of $ 49,604 for the year ended December 31, 2024. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures for a period at least twelve months from the reporting date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#x201c;Bayer Agreement&#x201d;) with Bayer Pharma AG (&#x201c;Bayer&#x201d;) for the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the terms of the Bayer Agreement, the Company received an upfront payment of $ 10,000, and additional aggregate milestone payments of $ 23,200.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On November 29, 2022, Bayer notified the Company that it has resolved to terminate the Bayer Agreement, effective as of February 27, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#x201c;AstraZeneca&#x201d;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and is solely responsible for all research, development, and commercial activities under the agreement. In connection with such license agreement, AstraZeneca developed rilvegostomig, a novel PD-/TIGIT bi-specific antibody with a TIGIT component that is derived from COM902.&#160; Rilvegostomig entered the clinic in September 2021, initiated first patient dosing in the first indication in Phase 3 study in December 2023, and first patient dosing in the second indication in Phase 3 study in May 2024. Compugen received a $ 10,000&#160;upfront payment, and $ 30,500 milestone payments out of up to $ 200,000 &lt;/span&gt;&lt;/span&gt;it is eligible to receive in development, regulatory and commercial milestones for the first product in addition to royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:54pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:31.5pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201c;Agreement&#x201d;) with Bristol-Myers Squibb Company (&#x201c;Bristol&#160;Myers Squibb&#x201d;) to evaluate the safety and tolerability of Compugen&#x2019;s COM701 in combination with Bristol&#160;Myers Squibb&#x2019;s PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25"&gt;
            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to the Master Clinical Agreement, as amended from time to time, Compugen sponsored the trials, which included the evaluation of the combination of COM701 and Opdivo&#xae; &#xb1; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Bristol Myers Squibb and Compugen each &lt;span&gt;supplied their&lt;/span&gt; own compounds for the studies.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In conjunction with the signing of the Agreement in October 2018, Bristol-Myers Squibb made a $ 12,000 investment in Compugen, see Note 9b.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;text-indent:-1.2pt;margin-left:85.5pt;line-height:1.25"&gt;
            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Among several amendments to the Master Clinical Agreement, on November 10, 2021, the &lt;span&gt;Agreement&lt;/span&gt; was further amended and in conjunction with the signing of the amendment to the Agreement, Bristol Myers Squibb made a $20,000 investment in Compugen, see Note 9b.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
          &lt;div style="text-align:justify;text-indent:-1.2pt;margin-left:85.5pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"&gt;
            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On August 3, 2022, the Company and Bristol Myers Squibb entered into a letter agreement pursuant to which the Agreement, as amended from time to time, was terminated as of such date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"&gt;
          &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;g.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 18, 2023, the Company entered into an exclusive license agreement (the &#x201c;License Agreement&#x201d;) with Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;), pursuant to which the Company granted Gilead an exclusive license under the &lt;span&gt;Company&#x2019;s&lt;/span&gt; pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including the Company&#x2019;s COM503 product candidate&lt;span&gt;, now named GS-0321 (&#x201c;GS-0321&lt;/span&gt; License&#x201d;), and additional products that may be so developed by Gilead (together with &lt;span&gt;GS-0321&lt;/span&gt;, the &#x201c;Licensed Products&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                  &lt;div&gt;&#160;&lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to the License Agreement, Gilead paid the Company a one-time, upfront payment of $60,000 in January 2024. The Company has continued to develop &lt;span&gt;GS-0321&lt;/span&gt; during the initial development term, which included conducting activities defined within the agreement to advance &lt;span&gt;GS-0321&lt;/span&gt; through the clearance of an investigational new drug application (&#x201c;IND&#x201d;). The Company received from Gilead $30,000 in the form of a milestone payment upon clearance of the IND for &lt;span&gt;GS-0321&lt;/span&gt;, see also Note 2k. The Company is also eligible to receive up to approximately $758,000 in additional milestone payments upon the achievement of certain development, regulatory and commercial milestones. The Company is further eligible to receive royalties on worldwide net sales of Licensed Products.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company &lt;span&gt;is&lt;/span&gt; responsible for conducting a Phase 1 clinical trial for &lt;span&gt;GS-0321&lt;/span&gt;, including handling the regulatory matters in connection therewith, and will bear the costs of such trial (including the &lt;span&gt;GS-0321&lt;/span&gt; drug supply), with Gilead providing at no cost &lt;span&gt;its zimberelimab&lt;/span&gt; antibody for such trial. In certain circumstances, Gilead may assume the role of conducting the Phase 1 clinical trial.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Upon completion of the Phase 1 clinical trial for GS-0321, the Company will initiate the transfer of development activities related to GS-0321 to Gilead, following which, Gilead will have sole responsibility to develop and commercialize the Licensed Products.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%"&gt;

                &lt;tr&gt;
                  &lt;td style="font-size:10pt;vertical-align:top;width:56pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-size:10pt;vertical-align:top;width:28pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-size:10pt;vertical-align:top;width:auto"&gt;
                    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;During the term of the License Agreement, the Company is prohibited from researching, developing, making, and commercializing any compounds, molecules, products or treatment methods that are directed to IL-18 or any companion diagnostics for an IL-18 product.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="font-size:10pt;vertical-align:top;width:56pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-size:10pt;vertical-align:top;width:28pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-size:10pt;vertical-align:top;width:auto"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="font-size:10pt;vertical-align:top;width:56pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-size:10pt;vertical-align:top;width:28pt"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="2" style="font-size:10pt;vertical-align:top;width:auto"&gt;
                    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Unless terminated early by a party pursuant to its terms, the License Agreement will continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term in such country.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&#160;&lt;/p&gt;
                    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="text-align:justify"&gt;&lt;span style="text-align:justify"&gt;&lt;span&gt;&lt;span&gt;Gilead withheld at source 15% from the upfront payment and IND clearance milestone amounts paid to the Company in January 2024 and in September 2024, respectively, and is expected to continue and withhold at source all taxes required by law from all payments payable to the Company under the License Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="font-size:10pt;vertical-align:top;width:56pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-size:10pt;vertical-align:top;width:28pt"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="width:56pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:auto"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:56pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:top;width:28pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:top;width:auto"&gt;
                    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The License Agreement contains customary representations, warranties, covenants, and terms governing the prosecution and enforcement of certain intellectual property and issues related to technology transfer, manufacturing transfer, provisions with respect to establishment of joint steering committee and its governance covenants with respect change of control and others.&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000319"
      unitRef="usd">-14231000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000320"
      unitRef="usd">-488758000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000321"
      unitRef="usd">49604000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20130801to20130805"
      decimals="-3"
      id="FFact_0000000000323"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable
      contextRef="C_20130805"
      decimals="-3"
      id="FFact_0000000000325"
      unitRef="usd">23200000</cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000326"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:AccruedMilestonePayment
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000327"
      unitRef="usd">30500000</cgen:AccruedMilestonePayment>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240228095106065"
      unitRef="usd">200000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000329"
      unitRef="usd">12000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="C_20211130"
      decimals="-3"
      id="FFact_0000000000330"
      unitRef="usd">20000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <cgen:NonRefundableUpfrontPayment
      contextRef="C_20230101to20231218"
      decimals="-6"
      id="Fxbrl_20240228025953345"
      unitRef="usd">60000000000</cgen:NonRefundableUpfrontPayment>
    <cgen:MilestonePaymentReceivable
      contextRef="C_20230101to20231218"
      decimals="-6"
      id="Fxbrl_20240228031257594"
      unitRef="usd">30000000000</cgen:MilestonePaymentReceivable>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram
      contextRef="C_20231218"
      decimals="-6"
      id="Fxbrl_20240228030428945"
      unitRef="usd">758000000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram>
    <cgen:PercentageOfExpectedFromPaymentAmountPaid
      contextRef="C_20240101to20240131"
      decimals="2"
      id="Fxbrl_20240228030716817"
      unitRef="Pure">0.15</cgen:PercentageOfExpectedFromPaymentAmountPaid>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240228140455566">
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;NOTE 2:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div&gt;
          &lt;div&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Use of estimates:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company&#x2019;s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;


            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Financial statements in U.S. dollars:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The reporting and functional currency of the Company is the U.S. dollar, as the Company&#x2019;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No.&#160;830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;


            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Basis of consolidation:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;


            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:left;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Cash, Cash equivalents and Restricted cash:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents consist of cash in banks and cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. The Company&#x2019;s restricted cash primarily consists of bank deposits collateralizing the Company&#x2019;s operating leases and credit cards.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;

          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div&gt;&lt;/div&gt;

            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;
                        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Short-term bank deposits and restricted long-term bank deposits:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman, Times, serif;font-size:10pt"&gt;Short-term bank deposits include deposits with maturities of more than three months but less than one year. Long-term bank deposits include deposits with maturities of more than one year. Bank deposits are stated at cost which approximates market values.&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Bank deposits as of December 31, 2024 and 2023 are in U.S. dollars and bear an annual weighted average interest rate of 5.51% and 6.20%, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;


            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Investments in marketable securities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#x201c;Investments - Debt Securities&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#x201c;AFS&#x201d;). The Company classifies its marketable securities as either short-term or long-term based on each instrument&#x2019;s underlying contractual maturity date. Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#x2019; equity. Realized gains and losses on sale of investments are included in financial income, net.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;At each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#x2019;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#x2019;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in shareholders&#x2019; equity. No credit loss impairment was identified in the year ended December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;

          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div&gt;&lt;/div&gt;

            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;g.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Property and equipment, net:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="margin-left:90pt"&gt;

                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;width:68%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:30%;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="width:30%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:68%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:bottom;width:30%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:bottom;width:30%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:68%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:68%;vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:bottom;width:30%;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6 - 20 (mainly 20)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="vertical-align:bottom;width:30%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                        &lt;td style="width:68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                        &lt;td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                          &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Shorter of the term of the lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;

              &lt;/div&gt;
            &lt;/div&gt;


            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;h.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Impairment of long-lived assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The long-lived assets of the Company. are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant, and Equipment&#x201d; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset (assets group) with the future undiscounted cash flows expected to be generated by the asset (assets group). If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets group exceeds the fair value of the assets group. During the years 2024, 2023 and 2022, no impairment losses have been recorded.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;


            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;i.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Leases:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for its leases according to ASC 842 - Leases (&#x201c;ASC 842&#x201d;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset for leases with a term of twelve months or less. The Company elected the practical expedient to combine its lease and non-lease components for its leases.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#x201c;IBR&#x201d;) based on the information available at commencement date in determining the present value of lease payments. The Company&#x2019;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;

          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;j.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Revenue recognition:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company recognizes revenue in accordance with ASC 606 &#x2013; &#x201c;Revenue from Contracts with Customers&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As such, the Company analyzes its contracts to assess whether they are within the scope of ASC&#160;606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:27pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Identification of the contract, or contracts, with a customer&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Identification of the performance obligations in the contract&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Determination of the transaction price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Allocation of the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Recognition of revenue when, or as, the Company satisfies a performance obligation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (&#x201c;IP&#x201d;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $ 10,000 upfront payment and is eligible to receive up to $ 200,000 for development, regulatory and commercial milestones for the first product, of which $&#160;30,500 was received as well as tiered royalties on future product sales.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#x201c;probable&#x201d; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sales or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 18, 2020, the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 2,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On September 29, 2021, the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 6,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 7,500 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 27, 2023, the fourth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 10,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 30, 2024, the fifth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 5,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 18, 2023, the Company entered into an exclusive License Agreement with Gilead. Under the terms of the agreement, the Company granted Gilead an exclusive license under the Company&#x2019;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products derived from a Compugen pipeline program. Compugen received an upfront payment of $&#160;60,000 and an IND clearance milestone payment of $&#160;30,000 and is also eligible to receive up to approximately $ 758,000 additional milestone payments subject to and upon the achievement of certain development, regulatory and commercial milestones and as detailed in the agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gilead may terminate the Gilead Collaboration Agreement for convenience by giving a certain prior written notice to the Company at any time after the effective date of the agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company assessed the promises under the License Agreement and concluded that (i) the delivery of the GS-0321 License; (ii) the preclinical research and development activities towards IND approval of GS-0321 (the &#x201c;IND research and development activities&#x201d;) and (iii) the contingent promise to additional research and development activities in connection with Phase 1 clinical trial (the &#x201c;Phase 1 research and development activities&#x201d;), are capable of being distinct and are distinct within the context of the License Agreement. The Company considered that the license has standalone functionality, considered to be functional intellectual property, and is capable of being distinct. The Company also determined that the IND research and development activities and Phase 1 research and development activities could be provided by resources otherwise available to Gilead and thus are capable of being distinct. Also, the Company concluded that the Company&#x2019;s contingent promise to additional research and development activities in connection with Phase 1 clinical trial represents a material right.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As a result, the Company concluded that its promise to deliver the GS-0321 License, the promise to perform IND research and development activities and Phase 1 research and development activities represented separate performance obligations in the License Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company also evaluated all milestones and royalties as a possible variable consideration. With respect to clinical development and regulatory milestones, based upon the high degree of uncertainty and risk associated with these potential payments, the Company concluded that all such amounts should be fully constrained and are not included in the initial transaction price as the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Accordingly, the Company did not include any potential clinical development, regulatory and sales milestones and royalties in the initial transaction price.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company allocated the transaction price to each performance obligation on a relative estimated standalone selling price basis. The Company developed the estimated standalone selling price for the GS-0321 License based on the present value of expected future cash flows associated with the license and related clinical development and regulatory milestones. In developing such estimate, the Company applied judgement in determining the timing needed to develop the Licensed Product, the probability of success, and the discount rate. The Company developed the estimated standalone selling price for the IND research and development activities using a &#x201c;cost plus&#x201d; reasonable margin approach. To determine the estimated standalone selling price of the material right for the Phase 1 research and development activities obligation, the Company estimated the standalone selling price of the underlying performance obligations included in the material right and estimated the probability of the Company&#x2019;s performance of such obligations.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company determined that the GS-0321 License was a functional license since the underlying intellectual property (the &#x201c;IP&#x201d;) has significant standalone functionality. In addition, the Company determined that December 18, 2023, represents (i) the date at which the Company made available the IP to Gilead and (ii) the beginning of the period during which Gilead is able to use and benefit from its right to use the IP. Based upon these considerations, the Company recognized the entirety of the initial transaction price allocated to the GS-0321 License performance obligation during the year ended December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Further, the IND research and development activities and Phase 1 research and development activities performance obligations are recognized over time. The Company using the input method in order to measure the progress of the services, based on the actual internal and external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs were estimated reflected the Company&#x2019;s best estimate of the period over which it would perform the activities to achieve clearance of an IND application for GS-0321 and the phase 1 clinical trial. The Company determined that the input method is the best measure of progress towards satisfying the performance obligation as incurred labor effort represents work performed that corresponds with, and thereby best depicts the transfer of goods and services.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the year ended December 31, 2024, the Company recognized $ 22,864 of license, IND services and Phase 1 services revenues, and during the year ended December 31, 2023, the Company recognized $ 23,459 of license revenues.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.3pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Of the $36,541 of deferred revenue recorded as of December 31, 2023, and additional deferred revenues incurred during the year ended December 31, 2024, the Company recognized $22,864 as revenue during the year ended December 31, 2024. The Company had no deferred revenues as of December 31, 2022. The milestone payment was accounted for as an available consideration and was allocated to the separate performance obligations.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024, the Company included deferred revenues of $ 9,632 in current liabilities and $ 34,045 in non-current liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s remaining performance obligations represent contracted revenue that has not yet been recognized. As of December 31, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations that the Company expects to recognize as revenue was $43,677. As of December 31, 2024, the Company expects to recognize 22% of its remaining performance obligations as revenue over the next 12 months, and the remainder through 2029.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For additional information regarding revenues, please refer to Note 11 below.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;


            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;k.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Cost of revenues:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost of revenues consist of certain royalties and milestones paid or accrued in addition to research and development services allocated in relation to Gilead license agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;

          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;l.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Research and development expenses, net:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The portion of the Bristol&#160;Myers Squibb $ 12,000 investment in 2018 over the fair market value of the shares issued in the amount of $ 4,121 and the portion of the $ 20,000 investment in 2021 over the fair market value of the shares issued in the amount of $ 5,000 were considered as deferred participation of Bristol&#160;Myers Squibb in R&amp;amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;amp;D, see Note 1f and Note 9b.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of participation in R&amp;amp;D expenses for the years ended December 31, 2024, 2023 and 2022 were $ 0, $&#160;325 and $ 6,019, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;

          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;m.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Severance pay:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset on the Company&#x2019;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#x2019;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#x2019;s monthly salary for each year of service, no additional payments are required to be made by the Company to the employee to cover severance obligation.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Severance expenses for the years ended December 31, 2024, 2023 and 2022 amounted to approximately $&#160;481, $&#160;432 and $&#160;468, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;


            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;n.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;Share-based compensation&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for share-based compensation to employees and non-employees in accordance with ASC 718, &#x201c;Compensation - Share Compensation&#x201d; (&#x201c;ASC 718&#x201d;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company selected the Black-Scholes-Merton (&#x201c;Black-Scholes&#x201d;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Share Purchase Plan (&#x201c;ESPP&#x201d;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="margin-left:90pt"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Employee options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;90.45%-95.88%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;75.93%-80.95%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;69.44%-74.61%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.47%-4.54%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.37%-4.81%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.54%-4.39%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.02-4.97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.02-5.06&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.05-5.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="margin-left:90pt"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ESPP&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;69.74%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.63%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;


            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:left;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;o.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Concentration of credit risks:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits, restricted long-term bank deposit and investment in marketable securities.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash, cash equivalents, restricted cash, short-term bank deposits and restricted long-term bank deposit are invested in major banks in Israel and in the United States. Generally, these deposits may be redeemed upon demand and bear minimal risk. The Company's marketable securities consist of investments, which are highly rated by credit agencies, in government debentures.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;

          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div&gt;&lt;/div&gt;

            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;p.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Basic and diluted loss per share:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic loss per share is calculated by dividing net loss for each reporting period by the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated by dividing net loss for each reporting period by the weighted average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during the period in accordance with ASC 260, &#x201c;Earnings per Share&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;All outstanding share options and warrants for the years ended December 31, 2024, 2023 and 2022 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2024, 2023 and 2022 the average number of shares related to outstanding options, RSUs and warrants excluded from the calculations of diluted net loss per share were 8,496,655, 7,921,020 and 8,405,615, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;


            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;q.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Income taxes:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for income taxes in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2024 and 2023, a full valuation allowance was provided by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;


            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;r.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Fair value of financial instruments:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market participants at the measurement date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The hierarchy is broken down into three levels based on the inputs as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:56.7pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1 -&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:56.7pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2 -&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:56.7pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 3 -&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, marketable securities, restricted long-term bank deposit, other accounts receivable and prepaid expenses, trade payable and employees and related accruals and accrued expenses approximate their fair values due to the short-term maturities of such instruments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;

          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div&gt;&lt;/div&gt;

            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;s.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Recently adopted accounting pronouncement :&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:28.1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:56.7pt;vertical-align:top"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280),&#160;Improvements to Reportable Segment Disclosures&#160;requiring public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for the fiscal years beginning after December 15, 2024. The Company adopted the ASU 2023-07 during the year ended December 31, 2024, on a retrospective basis which resulted in updated segment disclosures. See Note 11 in the accompanying notes to the consolidated financial statements for further detail.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;

          &lt;div&gt;

              &lt;div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                    &lt;tr&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;t.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Recently issued accounting pronouncements not yet adopted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) -&#160;&lt;span style="font-style:italic"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. The Company is currently evaluating the effect of adopting the ASU on its financial statements disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40) -&#160;&lt;span style="font-style:italic"&gt;Disaggregation of Income Statement Expenses&lt;/span&gt;. The ASU requires, among other items, additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the consolidated Statements of Operations. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the effect of adopting the ASU on its financial statements disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;

          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_20240101to20241231" id="F20240228054857421_1">
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Use of estimates:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company&#x2019;s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_20240101to20241231" id="F20240228054857421_2">
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Financial statements in U.S. dollars:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The reporting and functional currency of the Company is the U.S. dollar, as the Company&#x2019;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No.&#160;830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_20240101to20241231" id="F20240228054857422_3">
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Basis of consolidation:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_20240101to20241231" id="F20240228054857423_5">
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:left;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Cash, Cash equivalents and Restricted cash:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents consist of cash in banks and cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. The Company&#x2019;s restricted cash primarily consists of bank deposits collateralizing the Company&#x2019;s operating leases and credit cards.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <cgen:ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250224191009709">
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;
                        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Short-term bank deposits and restricted long-term bank deposits:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman, Times, serif;font-size:10pt"&gt;Short-term bank deposits include deposits with maturities of more than three months but less than one year. Long-term bank deposits include deposits with maturities of more than one year. Bank deposits are stated at cost which approximates market values.&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Bank deposits as of December 31, 2024 and 2023 are in U.S. dollars and bear an annual weighted average interest rate of 5.51% and 6.20%, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </cgen:ShortTermBankDepositsAndRestrictedLongTermBankDepositsPolicyTextBlock>
    <cgen:ShortTermBankDepositsWeightedAverageRateForeign
      contextRef="C_20240101to20241231"
      decimals="4"
      id="Fxbrl_20250228020158248"
      unitRef="Pure">0.0551</cgen:ShortTermBankDepositsWeightedAverageRateForeign>
    <cgen:ShortTermBankDepositsWeightedAverageRateForeign
      contextRef="C_20230101to20231231"
      decimals="4"
      id="Fxbrl_20250228020206464"
      unitRef="Pure">0.062</cgen:ShortTermBankDepositsWeightedAverageRateForeign>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_20240101to20241231"
      id="F20240228054857466_78">
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Investments in marketable securities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#x201c;Investments - Debt Securities&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#x201c;AFS&#x201d;). The Company classifies its marketable securities as either short-term or long-term based on each instrument&#x2019;s underlying contractual maturity date. Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#x2019; equity. Realized gains and losses on sale of investments are included in financial income, net.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;At each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#x2019;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#x2019;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in shareholders&#x2019; equity. No credit loss impairment was identified in the year ended December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_20240101to20241231" id="F20240228054857425_9">
            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;g.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Property and equipment, net:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="margin-left:90pt"&gt;

                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;width:68%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:30%;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="width:30%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:68%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:bottom;width:30%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:bottom;width:30%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:68%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:68%;vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:bottom;width:30%;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6 - 20 (mainly 20)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="vertical-align:bottom;width:30%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                        &lt;td style="width:68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                        &lt;td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                          &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Shorter of the term of the lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;

              &lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock
      contextRef="C_20240101to20241231"
      id="F20240228054857451_53">
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;width:68%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:30%;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="width:30%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:68%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:bottom;width:30%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:bottom;width:30%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:68%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="vertical-align:bottom;text-align:right;width:30%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:68%;vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:bottom;width:30%;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6 - 20 (mainly 20)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="vertical-align:bottom;width:30%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                        &lt;td style="width:68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                        &lt;td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                          &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Shorter of the term of the lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="width:30%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                </cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock>
    <cgen:AnnualDepreciationRate
      contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="2"
      id="F20240228054857425_10"
      unitRef="Pure">0.33</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRate
      contextRef="C_20240101to20241231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="2"
      id="F20240228054857426_11"
      unitRef="Pure">0.06</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRate
      contextRef="C_20240101to20241231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="2"
      id="F20240228054857426_12"
      unitRef="Pure">0.20</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRate
      contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="2"
      id="F20240228054857431_13"
      unitRef="Pure">0.20</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRateDescription
      contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      id="Fxbrl_20240228113754899">Shorter of the term of the lease or useful life</cgen:AnnualDepreciationRateDescription>
    <us-gaap:PropertyPlantAndEquipmentImpairment
      contextRef="C_20240101to20241231"
      id="F20240228054857432_15">
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;h.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Impairment of long-lived assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The long-lived assets of the Company. are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant, and Equipment&#x201d; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset (assets group) with the future undiscounted cash flows expected to be generated by the asset (assets group). If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets group exceeds the fair value of the assets group. During the years 2024, 2023 and 2022, no impairment losses have been recorded.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="F20240228054857465_76">
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;i.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Leases:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for its leases according to ASC 842 - Leases (&#x201c;ASC 842&#x201d;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset for leases with a term of twelve months or less. The Company elected the practical expedient to combine its lease and non-lease components for its leases.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#x201c;IBR&#x201d;) based on the information available at commencement date in determining the present value of lease payments. The Company&#x2019;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="F20240228054857465_77">
            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;j.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Revenue recognition:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company recognizes revenue in accordance with ASC 606 &#x2013; &#x201c;Revenue from Contracts with Customers&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As such, the Company analyzes its contracts to assess whether they are within the scope of ASC&#160;606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:27pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Identification of the contract, or contracts, with a customer&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Identification of the performance obligations in the contract&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Determination of the transaction price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Allocation of the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Recognition of revenue when, or as, the Company satisfies a performance obligation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (&#x201c;IP&#x201d;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $ 10,000 upfront payment and is eligible to receive up to $ 200,000 for development, regulatory and commercial milestones for the first product, of which $&#160;30,500 was received as well as tiered royalties on future product sales.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#x201c;probable&#x201d; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sales or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 18, 2020, the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 2,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On September 29, 2021, the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 6,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 7,500 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 27, 2023, the fourth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 10,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 30, 2024, the fifth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 5,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 18, 2023, the Company entered into an exclusive License Agreement with Gilead. Under the terms of the agreement, the Company granted Gilead an exclusive license under the Company&#x2019;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products derived from a Compugen pipeline program. Compugen received an upfront payment of $&#160;60,000 and an IND clearance milestone payment of $&#160;30,000 and is also eligible to receive up to approximately $ 758,000 additional milestone payments subject to and upon the achievement of certain development, regulatory and commercial milestones and as detailed in the agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gilead may terminate the Gilead Collaboration Agreement for convenience by giving a certain prior written notice to the Company at any time after the effective date of the agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company assessed the promises under the License Agreement and concluded that (i) the delivery of the GS-0321 License; (ii) the preclinical research and development activities towards IND approval of GS-0321 (the &#x201c;IND research and development activities&#x201d;) and (iii) the contingent promise to additional research and development activities in connection with Phase 1 clinical trial (the &#x201c;Phase 1 research and development activities&#x201d;), are capable of being distinct and are distinct within the context of the License Agreement. The Company considered that the license has standalone functionality, considered to be functional intellectual property, and is capable of being distinct. The Company also determined that the IND research and development activities and Phase 1 research and development activities could be provided by resources otherwise available to Gilead and thus are capable of being distinct. Also, the Company concluded that the Company&#x2019;s contingent promise to additional research and development activities in connection with Phase 1 clinical trial represents a material right.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As a result, the Company concluded that its promise to deliver the GS-0321 License, the promise to perform IND research and development activities and Phase 1 research and development activities represented separate performance obligations in the License Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company also evaluated all milestones and royalties as a possible variable consideration. With respect to clinical development and regulatory milestones, based upon the high degree of uncertainty and risk associated with these potential payments, the Company concluded that all such amounts should be fully constrained and are not included in the initial transaction price as the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Accordingly, the Company did not include any potential clinical development, regulatory and sales milestones and royalties in the initial transaction price.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company allocated the transaction price to each performance obligation on a relative estimated standalone selling price basis. The Company developed the estimated standalone selling price for the GS-0321 License based on the present value of expected future cash flows associated with the license and related clinical development and regulatory milestones. In developing such estimate, the Company applied judgement in determining the timing needed to develop the Licensed Product, the probability of success, and the discount rate. The Company developed the estimated standalone selling price for the IND research and development activities using a &#x201c;cost plus&#x201d; reasonable margin approach. To determine the estimated standalone selling price of the material right for the Phase 1 research and development activities obligation, the Company estimated the standalone selling price of the underlying performance obligations included in the material right and estimated the probability of the Company&#x2019;s performance of such obligations.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company determined that the GS-0321 License was a functional license since the underlying intellectual property (the &#x201c;IP&#x201d;) has significant standalone functionality. In addition, the Company determined that December 18, 2023, represents (i) the date at which the Company made available the IP to Gilead and (ii) the beginning of the period during which Gilead is able to use and benefit from its right to use the IP. Based upon these considerations, the Company recognized the entirety of the initial transaction price allocated to the GS-0321 License performance obligation during the year ended December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Further, the IND research and development activities and Phase 1 research and development activities performance obligations are recognized over time. The Company using the input method in order to measure the progress of the services, based on the actual internal and external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs were estimated reflected the Company&#x2019;s best estimate of the period over which it would perform the activities to achieve clearance of an IND application for GS-0321 and the phase 1 clinical trial. The Company determined that the input method is the best measure of progress towards satisfying the performance obligation as incurred labor effort represents work performed that corresponds with, and thereby best depicts the transfer of goods and services.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the year ended December 31, 2024, the Company recognized $ 22,864 of license, IND services and Phase 1 services revenues, and during the year ended December 31, 2023, the Company recognized $ 23,459 of license revenues.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.3pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Of the $36,541 of deferred revenue recorded as of December 31, 2023, and additional deferred revenues incurred during the year ended December 31, 2024, the Company recognized $22,864 as revenue during the year ended December 31, 2024. The Company had no deferred revenues as of December 31, 2022. The milestone payment was accounted for as an available consideration and was allocated to the separate performance obligations.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:84.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024, the Company included deferred revenues of $ 9,632 in current liabilities and $ 34,045 in non-current liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s remaining performance obligations represent contracted revenue that has not yet been recognized. As of December 31, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations that the Company expects to recognize as revenue was $43,677. As of December 31, 2024, the Company expects to recognize 22% of its remaining performance obligations as revenue over the next 12 months, and the remainder through 2029.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For additional information regarding revenues, please refer to Note 11 below.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20240228054857433_16"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20241231"
      decimals="-3"
      id="F20240228054857433_17"
      unitRef="usd">200000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <cgen:AccruedMilestonePayments
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20240228054857434_18"
      unitRef="usd">30500000</cgen:AccruedMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_20201201to20201218"
      decimals="-3"
      id="Fxbrl_20240301103700585"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_20210901to20210929"
      decimals="-3"
      id="F20240228054857467_79"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_20221101to20221111"
      decimals="-3"
      id="F20240228054857446_43"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_20231201to20231227"
      decimals="-3"
      id="Fxbrl_20240228115609016"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_20240501to20240530"
      decimals="-3"
      id="Fxbrl_20250225134915853"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20231210to20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember"
      decimals="-3"
      id="Fxbrl_20240228120200198"
      unitRef="usd">60000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:MilestonePaymentReceivable
      contextRef="C_20231210to20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember"
      decimals="-3"
      id="Fxbrl_20250225135355836"
      unitRef="usd">30000000</cgen:MilestonePaymentReceivable>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember"
      decimals="-3"
      id="Fxbrl_20240228120212438"
      unitRef="usd">758000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <cgen:LicenseRevenue
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240228121336624"
      unitRef="usd">22864000</cgen:LicenseRevenue>
    <cgen:LicenseRevenue
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250224191115062"
      unitRef="usd">23459000</cgen:LicenseRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250224191436866"
      unitRef="usd">36541000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250224191538634"
      unitRef="usd">22864000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <cgen:DeferredRevenuesIncludedInCurrentLiabilities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240228121352406"
      unitRef="usd">9632000</cgen:DeferredRevenuesIncludedInCurrentLiabilities>
    <cgen:DeferredRevenuesIncludedInNonCurrentLiabilities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240228121407737"
      unitRef="usd">34045000</cgen:DeferredRevenuesIncludedInNonCurrentLiabilities>
    <cgen:TotalRemainingPerformanceObligations
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250224192453825"
      unitRef="usd">43677000</cgen:TotalRemainingPerformanceObligations>
    <cgen:RemainingPerformanceObligationsRecognizedPercentage
      contextRef="C_20240101to20241231"
      decimals="2"
      id="Fxbrl_20250224192519729"
      unitRef="Pure">0.22</cgen:RemainingPerformanceObligationsRecognizedPercentage>
    <cgen:CostOfSalesContractWithCustomerPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="F20240228054857434_19">
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;k.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Cost of revenues:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost of revenues consist of certain royalties and milestones paid or accrued in addition to research and development services allocated in relation to Gilead license agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </cgen:CostOfSalesContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_20240101to20241231"
      id="F20240228054857434_20">
            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;l.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Research and development expenses, net:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The portion of the Bristol&#160;Myers Squibb $ 12,000 investment in 2018 over the fair market value of the shares issued in the amount of $ 4,121 and the portion of the $ 20,000 investment in 2021 over the fair market value of the shares issued in the amount of $ 5,000 were considered as deferred participation of Bristol&#160;Myers Squibb in R&amp;amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;amp;D, see Note 1f and Note 9b.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of participation in R&amp;amp;D expenses for the years ended December 31, 2024, 2023 and 2022 were $ 0, $&#160;325 and $ 6,019, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember"
      decimals="-3"
      id="F20240228054857451_54"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:DeferredParticipationOfBMSInRAndDExpenses
      contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember"
      decimals="-3"
      id="F20240228054857452_55"
      unitRef="usd">4121000</cgen:DeferredParticipationOfBMSInRAndDExpenses>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember"
      decimals="-3"
      id="F20240228054857453_56"
      unitRef="usd">20000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:DeferredParticipationOfBMSInRAndDExpenses
      contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember"
      decimals="-3"
      id="F20240228054857453_57"
      unitRef="usd">5000000</cgen:DeferredParticipationOfBMSInRAndDExpenses>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20240228054857435_21"
      unitRef="usd">0</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240228054857435_22"
      unitRef="usd">325000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240228054857436_23"
      unitRef="usd">6019000</us-gaap:AdjustmentForAmortization>
    <cgen:ServerancePayPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="F20240228054857436_24">
            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;m.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Severance pay:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset on the Company&#x2019;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#x2019;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#x2019;s monthly salary for each year of service, no additional payments are required to be made by the Company to the employee to cover severance obligation.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Severance expenses for the years ended December 31, 2024, 2023 and 2022 amounted to approximately $&#160;481, $&#160;432 and $&#160;468, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </cgen:ServerancePayPolicyTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20240228054857437_25"
      unitRef="usd">481000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240228054857437_26"
      unitRef="usd">432000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240228054857438_27"
      unitRef="usd">468000</us-gaap:SeveranceCosts1>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_20240101to20241231"
      id="F20240228054857438_28">
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;n.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;Share-based compensation&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for share-based compensation to employees and non-employees in accordance with ASC 718, &#x201c;Compensation - Share Compensation&#x201d; (&#x201c;ASC 718&#x201d;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company selected the Black-Scholes-Merton (&#x201c;Black-Scholes&#x201d;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Share Purchase Plan (&#x201c;ESPP&#x201d;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="margin-left:90pt"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Employee options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;90.45%-95.88%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;75.93%-80.95%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;69.44%-74.61%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.47%-4.54%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.37%-4.81%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.54%-4.39%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.02-4.97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.02-5.06&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.05-5.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="margin-left:90pt"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ESPP&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;69.74%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.63%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228015358695">
                &lt;div&gt;
                  &lt;div style="margin-left:90pt"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Employee options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;90.45%-95.88%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;75.93%-80.95%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;69.44%-74.61%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.47%-4.54%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.37%-4.81%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.54%-4.39%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.02-4.97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.02-5.06&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.05-5.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="margin-left:90pt"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="7" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ESPP&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td style="vertical-align:middle;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;69.74%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.63%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:65.95%;vertical-align:bottom"&gt;
                            &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="text-align:center;vertical-align:bottom;width:1.04%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1.04%;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9.27%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20240101to20241231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857454_58"
      unitRef="Pure">0.9045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20240101to20241231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857454_59"
      unitRef="Pure">0.9588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857455_60"
      unitRef="Pure">0.7593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857455_61"
      unitRef="Pure">0.8095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857456_62"
      unitRef="Pure">0.6944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857456_63"
      unitRef="Pure">0.7461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20240101to20241231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857457_64"
      unitRef="Pure">0.0347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20240101to20241231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857458_65"
      unitRef="Pure">0.0454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857459_66"
      unitRef="Pure">0.0337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857460_67"
      unitRef="Pure">0.0481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857460_68"
      unitRef="Pure">0.0154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857461_69"
      unitRef="Pure">0.0439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20240101to20241231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="2"
      id="F20240228054857439_29"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="2"
      id="F20240228054857439_30"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="2"
      id="Fxbrl_20240228114441654"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20240101to20241231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="F20240228054857461_70">P4Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20240101to20241231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="F20240228054857462_71">P4Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="F20240228054857463_72">P4Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="F20240228054857463_73">P5Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="F20240228054857464_74">P5Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="F20240228054857464_75">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20240101to20241231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="F20240228054857440_31"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="F20240228054857447_44"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="F20240228054857467_80"
      unitRef="Pure">0.6974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20240101to20241231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="F20240228054857440_32"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="F20240228054857448_46"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="F20240228054857468_81"
      unitRef="Pure">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20240101to20241231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="F20240228054857440_33"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="F20240228054857449_48"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="F20240228054857450_51"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      id="F20240228054857468_82">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_20240101to20241231"
      id="F20240228054857441_35">
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:left;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;o.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Concentration of credit risks:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits, restricted long-term bank deposit and investment in marketable securities.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash, cash equivalents, restricted cash, short-term bank deposits and restricted long-term bank deposit are invested in major banks in Israel and in the United States. Generally, these deposits may be redeemed upon demand and bear minimal risk. The Company's marketable securities consist of investments, which are highly rated by credit agencies, in government debentures.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_20240101to20241231"
      id="F20240228054857442_36">
            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;p.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Basic and diluted loss per share:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic loss per share is calculated by dividing net loss for each reporting period by the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated by dividing net loss for each reporting period by the weighted average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during the period in accordance with ASC 260, &#x201c;Earnings per Share&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;All outstanding share options and warrants for the years ended December 31, 2024, 2023 and 2022 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2024, 2023 and 2022 the average number of shares related to outstanding options, RSUs and warrants excluded from the calculations of diluted net loss per share were 8,496,655, 7,921,020 and 8,405,615, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20240101to20241231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"
      decimals="INF"
      id="F20240228054857442_37"
      unitRef="Shares">8496655</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"
      decimals="INF"
      id="F20240228054857443_38"
      unitRef="Shares">7921020</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"
      decimals="INF"
      id="F20240228054857445_39"
      unitRef="Shares">8405615</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="F20240228054857445_40">
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;q.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Income taxes:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for income taxes in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2024 and 2023, a full valuation allowance was provided by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_20240101to20241231"
      id="F20240228054857446_41">
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.35pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;r.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Fair value of financial instruments:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market participants at the measurement date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The hierarchy is broken down into three levels based on the inputs as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:56.7pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1 -&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:56.7pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2 -&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:56.7pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 3 -&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, marketable securities, restricted long-term bank deposit, other accounts receivable and prepaid expenses, trade payable and employees and related accruals and accrued expenses approximate their fair values due to the short-term maturities of such instruments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250225133021418">
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;s.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Recently adopted accounting pronouncement :&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:28.1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:56.7pt;vertical-align:top"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280),&#160;Improvements to Reportable Segment Disclosures&#160;requiring public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for the fiscal years beginning after December 15, 2024. The Company adopted the ASU 2023-07 during the year ended December 31, 2024, on a retrospective basis which resulted in updated segment disclosures. See Note 11 in the accompanying notes to the consolidated financial statements for further detail.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cgen:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228015334197">
              &lt;div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                    &lt;tr&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;t.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Recently issued accounting pronouncements not yet adopted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) -&#160;&lt;span style="font-style:italic"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. The Company is currently evaluating the effect of adopting the ASU on its financial statements disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40) -&#160;&lt;span style="font-style:italic"&gt;Disaggregation of Income Statement Expenses&lt;/span&gt;. The ASU requires, among other items, additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the consolidated Statements of Operations. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the effect of adopting the ASU on its financial statements disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
            </cgen:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_20240101to20241231"
      id="F20250224141027742_18">
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 3:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;MARKETABLE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:0pt;margin-left:59.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following is a summary of available-for-sale marketable securities as of December 31, 2024 and 2023:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortized cost&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross unrealized gains&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross unrealized losses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;U.S. Treasury&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,618&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;U.S. Treasury&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20240730211801692_20250224141027740_2"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:58.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;* Represents an amount lower than $1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:58.5pt;line-height:1.25"&gt;The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2024 and December 31, 2023, and the length of time that those investments have been in a continuous loss position:&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:58.5pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less than 12 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12 months or greater&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross unrealized loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Gross unrealized loss&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20240730224938615_20250224141027741_9"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:58.5pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Represents an amount lower than $1.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:58.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024, the Company had no significant unrealized losses related to marketable securities and determined the unrealized losses are not due to credit related losses. Therefore, the Company did not record an allowance for credit losses for its available-for-sale marketable securities.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:58.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024, all of the Company&#x2019;s available-for-sale marketable securities were due within one year.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:58.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company had no sales of marketable securities during the years ended December 31, 2024 and 2023, and accordingly no realized gains or losses were recorded.&#160;Proceeds from maturities of available-for-sale marketable securities during the year ended December 31, 2024, and 2023 were $&#160;53,230&#160;and $&#160;10,145, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_20240101to20241231"
      id="F20250224141027742_16">
          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortized cost&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross unrealized gains&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross unrealized losses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;U.S. Treasury&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,618&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;U.S. Treasury&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20240730211801692_20250224141027740_2"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:58.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;* Represents an amount lower than $1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_20241231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="F20250224141027740_0"
      unitRef="usd">23618000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_20241231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="F20250224141027740_1"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_20241231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="F20250224141027740_2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_20241231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="F20250224141027741_3"
      unitRef="usd">23629000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20240730211801692_20250224141027740_0"
      unitRef="usd">11740000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20240730211801692_20250224141027740_1"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20240730211801692_20250224141027741_3"
      unitRef="usd">11742000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="C_20240101to20241231"
      id="F20250224141027742_17">
          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less than 12 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12 months or greater&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross unrealized loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Gross unrealized loss&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20240730224938615_20250224141027741_9"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:58.5pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Represents an amount lower than $1.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        </us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue
      contextRef="C_20241231"
      decimals="-3"
      id="F20250224141027741_8"
      unitRef="usd">0</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses
      contextRef="C_20241231"
      decimals="-3"
      id="F20250224141027741_9"
      unitRef="usd">0</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue
      contextRef="C_20241231"
      decimals="-3"
      id="F20250224141027742_10"
      unitRef="usd">0</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses
      contextRef="C_20241231"
      decimals="-3"
      id="F20250224141027742_11"
      unitRef="usd">0</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240730224938615_20250224141027741_8"
      unitRef="usd">992000</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240730224938615_20250224141027742_10"
      unitRef="usd">0</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240730224938615_20250224141027742_11"
      unitRef="usd">0</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250225054513616"
      unitRef="usd">53230000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250225054519696"
      unitRef="usd">10145000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_20240101to20241231" id="F20250224141027750_3">
      &lt;div&gt;
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 4:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:54pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The company evaluates assets and liabilities subject to fair value measurements on recurring basis to determine the appropriate level to classify them for each reporting period. There have been no transfers between fair value measurements levels during the years ended December 31, 2024 and 2023. The carrying amounts of cash and cash equivalents marketable securities, trade receivables, short term deposits and trade payables approximate their fair value due to the short-term maturity of such instruments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:54pt;line-height:1.25"&gt;
            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table sets forth the Company&#x2019;s assets that were measured at fair values of December 31, 2024 and &lt;span&gt;2023 by&lt;/span&gt; level within the fair value hierarchy:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:54pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:63pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair&#160;value&#160;measurements&#160;as&#160;of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;margin-left:4.5pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Description&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair Value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Hierarchy&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;margin-left:4.5pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;margin-left:4.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Cash equivalents:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;margin-left:4.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Money market funds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;13,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;margin-left:4.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketable securities:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;margin-left:4.5pt;line-height:1.25"&gt;U.S. Treasury&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="C_20240101to20241231" id="F20250224141027750_2">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair&#160;value&#160;measurements&#160;as&#160;of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;margin-left:4.5pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Description&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair Value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Hierarchy&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;margin-left:4.5pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;margin-left:4.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Cash equivalents:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;margin-left:4.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Money market funds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;13,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;margin-left:4.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketable securities:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;margin-left:4.5pt;line-height:1.25"&gt;U.S. Treasury&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20241231_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member"
      decimals="-3"
      id="Fxbrl_20250224200043634_20250224141027750_0"
      unitRef="usd">13919000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20231231_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member"
      decimals="-3"
      id="Fxbrl_20250224200043634_20250224141027750_1"
      unitRef="usd">3966000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20241231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="F20250224141027750_0"
      unitRef="usd">23629000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="F20250224141027750_1"
      unitRef="usd">11742000</us-gaap:InvestmentsFairValueDisclosure>
    <cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20230222132226340">
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;NOTE 5:-&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div style="font-weight:bold"&gt;OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:63pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;December 31,&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2024&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2023&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;Prepaid expenses&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,473&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,211&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;Government authorities&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;127&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;92&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25"&gt;Other&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;142&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;226&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,742&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,529&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    </cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240228020440395">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;December 31,&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2024&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2023&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;Prepaid expenses&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,473&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,211&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;Government authorities&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;127&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;92&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25"&gt;Other&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;142&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;226&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,742&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,529&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000406"
      unitRef="usd">2473000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000407"
      unitRef="usd">2211000</us-gaap:PrepaidExpenseCurrent>
    <cgen:GovernmentAuthorities
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000408"
      unitRef="usd">127000</cgen:GovernmentAuthorities>
    <cgen:GovernmentAuthorities
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000409"
      unitRef="usd">92000</cgen:GovernmentAuthorities>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000410"
      unitRef="usd">142000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000411"
      unitRef="usd">226000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000412"
      unitRef="usd">2742000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000413"
      unitRef="usd">2529000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_20240101to20241231" id="FFact_0000000000441">
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 6:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;LEASES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company leases all its real estate, storage area and cars under various operating lease agreements that expire on various dates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s operating leases have original lease periods expiring between 2021 and 2027. The offices in Israel lease include two options to renew, one of which was exercised in 2020. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain. The Company has an option to extend the lease of its offices in Israel until 2031, which is reasonably certain to be assured.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments and payments for optional renewal periods where it is reasonably certain the renewal period will be exercised.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under ASC 842, all leases, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled Operating lease right of use asset. The corresponding lease liabilities are split between current maturity of operating lease liability within current liabilities and long-term operating lease liability within long-term liabilities. The Company&#x2019;s leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate based on information available on the commencement date to determine the present value of lease payments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table represents the weighted-average remaining lease term and discount rate:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:63pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:90%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-bottom:2px;vertical-align:bottom;width:90%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:10%"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:90%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:90%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"&gt;
                    &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:90%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average discount (annual) rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:10%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.96%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating lease expenses were approximately $&#160;775, $ 800 and $&#160;884 in the years ended December&#160;31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Variable payments as CPI, included in the lease expenses, were approximately $&#160;79, $&#160;61 and $&#160;37 in the years ended December&#160;31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash paid for amounts included in the measurement of lease liabilities was approximately $&#160;761, $&#160;852 and $&#160;959 in the years ended December&#160;31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Maturities of operating lease liabilities were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:63pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-bottom:2px;vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2028 and on&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:2px;vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:2px;vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total operating lease payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td rowspan="1" style="vertical-align:bottom;width:88%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities, current&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-bottom:2px;vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities, non- current&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:2px;vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:2px;vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-bottom:4px;vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The above annual minimum future rental commitments include both of the period covered by the first exercised option with respect to the leased facility of Compugen Ltd. through March 2026 and the second option to extend the lease of the Company facility for additional five-year period following expiration of the current lease period.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:LesseeOperatingLeasesTextBlock>
    <cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate
      contextRef="C_20240101to20241231"
      id="Fxbrl_20230222013426728">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:90%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-bottom:2px;vertical-align:bottom;width:90%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:10%"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:90%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:90%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"&gt;
                    &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:90%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average discount (annual) rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:10%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.96%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_20241231" id="FFact_0000000000421">P6Y18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20241231"
      decimals="4"
      id="FFact_0000000000422"
      unitRef="Pure">0.0796</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000424"
      unitRef="usd">775000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000425"
      unitRef="usd">800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000426"
      unitRef="usd">884000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeasePayment
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240301102821130"
      unitRef="usd">79000</us-gaap:VariableLeasePayment>
    <us-gaap:VariableLeasePayment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240301102854023"
      unitRef="usd">61000</us-gaap:VariableLeasePayment>
    <us-gaap:VariableLeasePayment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240301102901175"
      unitRef="usd">37000</us-gaap:VariableLeasePayment>
    <cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000427"
      unitRef="usd">761000</cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000428"
      unitRef="usd">852000</cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000429"
      unitRef="usd">959000</cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20230222013609784">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-bottom:2px;vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2028 and on&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:2px;vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:2px;vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total operating lease payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td rowspan="1" style="vertical-align:bottom;width:88%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities, current&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-bottom:2px;vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities, non- current&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:2px;vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:2px;vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:88%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-bottom:4px;vertical-align:bottom;width:88%"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:9%"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000431"
      unitRef="usd">650000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000432"
      unitRef="usd">584000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000433"
      unitRef="usd">565000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250224211559627"
      unitRef="usd">1809000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000435"
      unitRef="usd">3608000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000436"
      unitRef="usd">696000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000437"
      unitRef="usd">2912000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000438"
      unitRef="usd">448000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000439"
      unitRef="usd">2464000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20230214024012785"
      unitRef="usd">2912000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_20240101to20241231" id="FFact_0000000000468">
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 7:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:63pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;739&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,567&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accumulated depreciation:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;622&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,059&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,067&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Depreciated cost&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During 2024 and 2023 total cost of $&#160;92 and $&#160;1,357, respectively and total accumulated depreciation of $&#160;92 and $&#160;1,350, respectively were disposed from the consolidated balance sheets.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During 2024 and 2023 the Company sold equipment with cost of $&#160;3 and $&#160;0, respectively and accumulated depreciation of $&#160;2 and $&#160;0, respectively. Gains from the sale during 2024 were $ 0.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the years ended December 31, 2024, 2023 and 2022, depreciation expenses were approximately $&#160;486, $&#160;476 and $&#160;482, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_20240101to20241231" id="FFact_0000000000460">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;739&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,567&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accumulated depreciation:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;622&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,059&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,067&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Depreciated cost&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000442"
      unitRef="usd">719000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000443"
      unitRef="usd">739000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="FFact_0000000000444"
      unitRef="usd">3567000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="FFact_0000000000445"
      unitRef="usd">3519000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000446"
      unitRef="usd">2314000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000447"
      unitRef="usd">2314000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000448"
      unitRef="usd">6600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000449"
      unitRef="usd">6572000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000450"
      unitRef="usd">622000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000451"
      unitRef="usd">609000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="FFact_0000000000452"
      unitRef="usd">3059000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="FFact_0000000000453"
      unitRef="usd">2909000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000454"
      unitRef="usd">2067000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000455"
      unitRef="usd">1838000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000456"
      unitRef="usd">5748000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000457"
      unitRef="usd">5356000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000458"
      unitRef="usd">852000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000459"
      unitRef="usd">1216000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="FFact_0000000000461"
      unitRef="usd">92000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="FFact_0000000000462"
      unitRef="usd">1357000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="FFact_0000000000463"
      unitRef="usd">92000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="FFact_0000000000464"
      unitRef="usd">1350000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember"
      decimals="-3"
      id="Fxbrl_20250225030006205"
      unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember"
      decimals="-3"
      id="Fxbrl_20250225030011327"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember"
      decimals="-3"
      id="Fxbrl_20250225030033500"
      unitRef="usd">2000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember"
      decimals="-3"
      id="Fxbrl_20250225030045690"
      unitRef="usd">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapEquipmentMember"
      decimals="-3"
      id="Fxbrl_20250225030100373"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:Depreciation
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000465"
      unitRef="usd">486000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000466"
      unitRef="usd">476000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000467"
      unitRef="usd">482000</us-gaap:Depreciation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_20240101to20241231" id="FFact_0000000000498">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 8:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company provided bank guarantees in the amount of $ 342 related to its offices in Israel, leased cars fueling in Israel and credit card security for its U.S. subsidiary.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the Office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (the &#x201c;IIA&#x201d;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from the results of the funded research programs. If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue arising from such research programs, and up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is 100% plus interest at LIBOR until December 31, 2023, and from January 1, 2024, the 12 months Term SOFR interest). For the years ended December 31, 2024, 2023 and 2022, the Company had an aggregate of paid or accrued royalties costs (income) to the IIA, recorded as cost of revenue in the consolidated statements of comprehensive loss in the amount of $&#160;(554), $&#160;1,004 and $&#160;225, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December&#160;31, 2024, the Company&#x2019;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $ 9,872.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Following IIA approval that sales related to IL-18BP are excluded from sales subject to IIA royalties payment, the Company decreased previous year royalties accrual related to revenues under the Gilead Agreement in the amount of $ 704 and reduced the cost of revenues for the year ended December 31, 2024, by this amount.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#x201c;Antibodies Discovery Agreement&#x201d;) with a U.S. antibody technology company (&#x201c;mAb Technology Company&#x201d;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as &#x201c;Contingent Fees&#x201d;). For the years ended December 31, 2024, 2023 and 2022, the Company incurred such Contingent Fees in the amounts of $ 0, $ 1,000 and $ 750.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 9, 2012, the Company entered into agreement (the &#x201c;May 2012 Agreement&#x201d;) with a U.S. Business Development Strategic Advisor (&#x201c;Advisor&#x201d;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the agreement the Advisor was entitled to 4% of the cash considerations that may be received under such transactions. In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Bayer Agreement was terminated effective February 27, 2023 and no further payments are expected under the May 2012 Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;For the years ended December 31, 2024, 2023 and 2022, the Company has not paid and did not accrue payments under this agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (CLA) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#x2019;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the years ended December 31, 2024, 2023 and 2022, the Company did not incur any amount in the research and development expenses in connection with such milestone payment.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the years ended December 31, 2024, 2023 and 2022, the Company incurred in the research and development expenses such milestone payment in the amounts of $&#160;225, $ 500 and $ 0.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250228031216265"
      unitRef="usd">342000</us-gaap:GuaranteeObligationsMaximumExposure>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="FFact_0000000000478"
      unitRef="Pure">0.03</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMaximumMember"
      decimals="2"
      id="FFact_0000000000479"
      unitRef="Pure">0.05</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived
      contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="2"
      id="FFact_0000000000480"
      unitRef="Pure">1</cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived>
    <us-gaap:RoyaltyExpense
      contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="FFact_0000000000481"
      unitRef="usd">554000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="FFact_0000000000482"
      unitRef="usd">1004000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="FFact_0000000000483"
      unitRef="usd">225000</us-gaap:RoyaltyExpense>
    <cgen:RoyaltyContingentObligations
      contextRef="C_20241231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="FFact_0000000000484"
      unitRef="usd">9872000</cgen:RoyaltyContingentObligations>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenGileadAgreementMember"
      decimals="-3"
      id="Fxbrl_20250228034607242"
      unitRef="usd">704000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <cgen:ContingentFees
      contextRef="C_20241231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember"
      decimals="-3"
      id="Fxbrl_20250228035035553"
      unitRef="usd">0</cgen:ContingentFees>
    <cgen:ContingentFees
      contextRef="C_20231231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember"
      decimals="-3"
      id="Fxbrl_20250228035049625"
      unitRef="usd">1000000</cgen:ContingentFees>
    <cgen:ContingentFees
      contextRef="C_20221231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember"
      decimals="-3"
      id="Fxbrl_20250228035058377"
      unitRef="usd">750000</cgen:ContingentFees>
    <cgen:AgreementStartDate
      contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      id="FFact_0000000000488">2012-05-09</cgen:AgreementStartDate>
    <cgen:ParticipationRights
      contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="FFact_0000000000489"
      unitRef="Pure">0.04</cgen:ParticipationRights>
    <cgen:AgreementTerminationDescription
      contextRef="C_20240101to20241231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      id="FFact_0000000000490">In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</cgen:AgreementTerminationDescription>
    <cgen:RoyaltyPercentage
      contextRef="C_20240101to20241231"
      decimals="2"
      id="FFact_0000000000491"
      unitRef="Pure">0.01</cgen:RoyaltyPercentage>
    <cgen:ResearchAndDevelopmentExpensesMilestonePayment
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000495"
      unitRef="usd">225000</cgen:ResearchAndDevelopmentExpensesMilestonePayment>
    <cgen:ResearchAndDevelopmentExpensesMilestonePayment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250228130721702"
      unitRef="usd">500000</cgen:ResearchAndDevelopmentExpensesMilestonePayment>
    <cgen:ResearchAndDevelopmentExpensesMilestonePayment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000497"
      unitRef="usd">0</cgen:ResearchAndDevelopmentExpensesMilestonePayment>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240228135111319">
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;NOTE 9:-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;SHAREHOLDERS&lt;/span&gt;&#x2019;&lt;span&gt; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Ordinary shares:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends, and to participate in the distribution of the assets of the Company upon its winding-up,&#160;in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Issuance of shares:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201c;Master Clinical Agreement&#x201d;) with Bristol Myers Squibb to evaluate the safety and tolerability of the Company&#x2019;s COM701 in combination with Bristol-Myers Squibb&#x2019;s PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol Myers Squibb made a $ 12,000 equity investment in the Company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Under the terms of the securities purchase agreement, Bristol Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $ 4.95 per share. The share price represented a 33% premium over the average closing price of Compugen&#x2019;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The premium over the fair market value in the amount of $ 4,121 represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;amp;D) and $ 7,788 (net of $ 91 issuance expenses) were considered equity investment.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $&#160;20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $&#160;8.57333 per share. The share price represented a 33% premium over the closing price of Company&#x2019;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Issuance of shares: (Cont.)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The premium over the fair market value in the amount of $&#160;5,000 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;amp;D) and $&#160;14,958 (net of $&#160;42 issuance expenses) were considered equity investment.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#x201c;Leerink Partners&#x201d;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#x201c;at the market offering&#x201d; (ATM). The offer and sale of the Company&#x2019;s ordinary shares, if any, are made pursuant to the Company&#x2019;s shelf registration statement on Form F-3, as supplemented by a prospectus supplement filed on January 31, 2023. Pursuant to the applicable prospectus supplement, the Company may offer and sell up to $50,000 of its ordinary shares. From the date the Company started selling ordinary shares in 2023 through its ATM and through December 31, 2024, 2,905,550 ordinary shares were issued and sold through the ATM, with proceeds of approximately $ 3,625 (net of $ 548 issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Share option plan:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Under the Company&#x2019;s 2010 Share Option Plan, as amended (the &#x201c;Plan&#x201d;), options and RSUs may be granted to employees, directors and non-employees of the Company and Compugen USA, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;Under the 2010 Share Option Plan the Company reserved for issuance up to an aggregate of 14,195,152 options and RSUs.&#160;The Company&#x2019;s board of directors last amended the Plan in July 2024, to increase the number of shares available under the 2010 Plan. As of December 31, 2024, an aggregate of 891,922 options and RSUs under the 2010 Share Option Plan of the Company were still available for future grants.&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In general, options granted under the Plan vest over a four-year period and expire 10 years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company&#x2019;s ordinary shares on the date of grant, unless otherwise determined by the Company&#x2019;s board of directors. The exercise price of the options granted under the Plan may not be less than the nominal value of the shares into which such options are exercisable, and the expiration date may not be later than 10 years from the date of grant. RSUs vest over a four-year period as well. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Share option plan (Cont.):&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Any options that are cancelled, forfeited or expired become available for future grants.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2024, were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="font-family:'Times New Roman',Times,serif"&gt;
          &lt;div style="line-height:1.25;margin-left:85.05pt"&gt;&#160;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="margin-left:90pt"&gt;

            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;div style="margin-left:0pt"&gt;
                      &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Number of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Weighted average exercise&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Aggregate intrinsic&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25;font-weight:bold;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25;font-weight:bold;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options outstanding at beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;8,373,745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;4.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;6.61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options granted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1,027,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1.88&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options exercised&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(11,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options forfeited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(495,781&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;3.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options expired&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(238,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;7.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options outstanding at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;8,655,721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;4.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Exercisable at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5,920,552&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;4.93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Weighted average fair value of options granted to employees, directors and non-employees during the years 2024, 2023 and 2022 was $&#160;1.20, $&#160;0.70 and $&#160;1.51 per share, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Aggregate intrinsic value of exercised options by employees, directors and non-employees during the years 2024, 2023 and 2022 was $&#160;9, $ 0 and $&#160;19, respectively. The aggregate intrinsic value of the exercised options represents the total intrinsic value (the difference between the sale price of the Company&#x2019;s share at the date of exercise, and the exercise price) multiplied by the number of options exercised.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#x2019;s closing share price on the last trading day of calendar 2024 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2024. This amount is impacted by the changes in the fair market value of the Company&#x2019;s shares.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2024, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $ 3,602 which is expected to be recognized over a weighted average period of approximately 2.56 years.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:56pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:top;width:28pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
                    &lt;div&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;RSUs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="text-align:justify;text-indent:0pt;margin-left:85pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0pt;margin-left:85pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;A summary of RSUs activity for the year ended December 31, 2024 is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:90pt"&gt;

                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Number of RSUs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Weighted average grant date per value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;RSUs outstanding at beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:76%"&gt;
                        &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;RSUs granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;319,150&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                        &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;RSUs forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(1,800&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.69&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                        &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;RSUs outstanding at end of year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;317,350&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;

            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Employee Share Purchase Plan:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The Company adopted an ESPP in November 2020, with the first offering period starting on January 1, 2021. In connection with its adoption, a total of 600,000 ordinary shares were reserved for issuance under this plan.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.5pt;margin-left:85pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The ESPP is implemented through six-month offering periods (except for the first offering period that was five months). According to the ESPP, eligible employees and non-employees may use up to 15% of their base salaries to purchase ordinary shares up to an aggregate limit of $&#160;40 per participant for every calendar year. The price of an ordinary share purchased under the ESPP is equal to 85% of the lower of the fair market value of the ordinary share on the first day of each offering period or on the last day of such period.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.5pt;margin-left:85pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In the years ended December 31, 2024, 2023 and 2022, 0, 0 and 158,025 ordinary shares, respectively, had been purchased under the ESPP and as of December 31, 2024, no ordinary shares were available for issuance under the ESPP.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The share-based compensation expenses related to options, RSUs and ESPP are included as follows in the expense categories:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:90pt"&gt;

                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,460&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,933&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2,158&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Marketing and business development expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;269&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;General and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,448&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,658&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,901&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;3,023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;3,550&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;4,328&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="Fxbrl_20250228040347903"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="Fxbrl_20250228040609767"
      unitRef="Shares">2424243</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="Fxbrl_20250228040619735"
      unitRef="USD_per_share">4.95</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="2"
      id="Fxbrl_20250228040627063"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:DeferredParticipationOfBMSInRAndDExpenses
      contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="Fxbrl_20250228040703383"
      unitRef="usd">4121000</cgen:DeferredParticipationOfBMSInRAndDExpenses>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="Fxbrl_20250228040714504"
      unitRef="usd">7788000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="Fxbrl_20250228040736815"
      unitRef="usd">91000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_0000000000523"
      unitRef="usd">20000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="FFact_0000000000524"
      unitRef="Shares">2332815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="FFact_0000000000525"
      unitRef="USD_per_share">8.57333</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="2"
      id="FFact_0000000000526"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:DeferredParticipationOfBMSInRAndDExpenses
      contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20230221122449076"
      unitRef="usd">5000000</cgen:DeferredParticipationOfBMSInRAndDExpenses>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20230221122456788"
      unitRef="usd">14958000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20230221122504540"
      unitRef="usd">42000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20230101to20230131_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember"
      decimals="-3"
      id="Fxbrl_20250228041614607"
      unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember"
      decimals="INF"
      id="Fxbrl_20250228041623503"
      unitRef="Shares">2905550</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember"
      decimals="-3"
      id="Fxbrl_20250228041634475"
      unitRef="usd">3625000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20240101to20241231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember"
      decimals="-3"
      id="Fxbrl_20250228041714726"
      unitRef="usd">548000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"
      decimals="INF"
      id="Fxbrl_20250303204407061"
      unitRef="Shares">14195152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"
      decimals="INF"
      id="Fxbrl_20250303204414573"
      unitRef="Shares">891922</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"
      id="Fxbrl_20250228044847837">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"
      id="Fxbrl_20250228044900553">P10Y</cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240228135136508">
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;div style="margin-left:0pt"&gt;
                      &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Number of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Weighted average exercise&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Aggregate intrinsic&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25;font-weight:bold;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25;font-weight:bold;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options outstanding at beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;8,373,745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;4.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;6.61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options granted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1,027,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1.88&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options exercised&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(11,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options forfeited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(495,781&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;3.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options expired&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(238,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;7.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options outstanding at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;8,655,721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;4.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Exercisable at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5,920,552&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;4.93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000541"
      unitRef="Shares">8373745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000542"
      unitRef="USD_per_share">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      id="FFact_0000000000543">P6Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="Fxbrl_20250225035705811"
      unitRef="usd">1912000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000545"
      unitRef="Shares">1027200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000546"
      unitRef="USD_per_share">1.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20250225040326886_Fact_0000000000545"
      unitRef="Shares">11053</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20250225040326886_Fact_0000000000546"
      unitRef="USD_per_share">0.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000549"
      unitRef="Shares">495781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000550"
      unitRef="USD_per_share">3.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000551"
      unitRef="Shares">238390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000552"
      unitRef="USD_per_share">7.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000553"
      unitRef="Shares">8655721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000554"
      unitRef="USD_per_share">4.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      id="FFact_0000000000555">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="FFact_0000000000556"
      unitRef="usd">802000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000557"
      unitRef="Shares">5920552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000558"
      unitRef="USD_per_share">5.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      id="FFact_0000000000559">P4Y11M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="FFact_0000000000560"
      unitRef="usd">286000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000562"
      unitRef="USD_per_share">1.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000563"
      unitRef="USD_per_share">0.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000564"
      unitRef="USD_per_share">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="FFact_0000000000565"
      unitRef="usd">9000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="FFact_0000000000566"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="FFact_0000000000567"
      unitRef="usd">19000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"
      decimals="-3"
      id="FFact_0000000000568"
      unitRef="usd">3602000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"
      id="FFact_0000000000569">P2Y6M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250225120800994">
                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Number of RSUs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Weighted average grant date per value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;RSUs outstanding at beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:76%"&gt;
                        &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;RSUs granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;319,150&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                        &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;RSUs forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(1,800&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.69&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                        &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;RSUs outstanding at end of year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;317,350&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              </us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20250225051213220_33"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_20240101to20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20250225051213220_43"
      unitRef="Shares">319150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20240101to20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20250225051213220_47"
      unitRef="NIS_Per_Share">1.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_20240101to20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20250225051213220_53"
      unitRef="Shares">1800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_20240101to20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20250225051213220_57"
      unitRef="NIS_Per_Share">1.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20250225051213220_73"
      unitRef="Shares">317350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_20241231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20250225051213220_77"
      unitRef="NIS_Per_Share">1.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="Fxbrl_20240228002524767"
      unitRef="Shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:InitialOfferingPeriod
      contextRef="C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      id="FFact_0000000000571">five months</us-gaap:InitialOfferingPeriod>
    <cgen:PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares
      contextRef="C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="FFact_0000000000572"
      unitRef="Pure">0.15</cgen:PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares>
    <cgen:PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering
      contextRef="C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="FFact_0000000000574"
      unitRef="Pure">0.85</cgen:PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="Fxbrl_20240301101934967"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="Fxbrl_20240301101942293"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="Fxbrl_20240301101953685"
      unitRef="Shares">158025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240228135148323">
                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,460&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,933&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2,158&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Marketing and business development expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;269&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;General and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,448&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,658&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,901&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;3,023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;3,550&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;4,328&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000577"
      unitRef="usd">1460000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000578"
      unitRef="usd">1933000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000579"
      unitRef="usd">2158000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000580"
      unitRef="usd">115000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000581"
      unitRef="usd">-41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000582"
      unitRef="usd">269000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20250225040210122"
      unitRef="usd">1448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000584"
      unitRef="usd">1658000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000585"
      unitRef="usd">1901000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20240101to20241231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000586"
      unitRef="usd">3023000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000587"
      unitRef="usd">3550000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000588"
      unitRef="usd">4328000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250225051833820">
      &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 10:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;TAXES ON INCOME, NET&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Israeli taxation:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax rates applicable to the income of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Taxable income of the Company is subject to a corporate tax rate of 23% in 2024, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Measurement of taxable income in U.S. dollars:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has elected to measure its taxable income and file its tax return under the Israeli Income Tax Regulations (Principles Regarding the Management of Books of Account of Foreign Invested Companies and Certain Partnerships and the Determination of Their Taxable Income), 1986. Accordingly, results for tax purposes are measured in terms of earnings in dollars.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (the &#x201c;Investment Law&#x201d;):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 1, 2005, an amendment to the Investment Law came into effect (the &#x201c;Amendment 60&#x201d;) that significantly changed the provisions of the Investment Law. The Amendment 60 limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as a &#x201c;Beneficiary Enterprise&#x201d; including a provision generally requiring that at least 25% of the Beneficiary Enterprise&#x2019;s income will be derived from export.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Another condition for receiving the benefits under the alternative track in respect of expansion programs pursuant to Amendment 60 is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2012 as its &#x201c;year of election&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additionally, Amendment 60 enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits. However, the Investment Law provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the Investment Law as they were on the date of such approval.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024, there was no taxable income attributable to the Beneficiary Enterprise.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In January 2011, another amendment to the Investment Law came into effect (the &#x201c;2011 Amendment&#x201d;). According to the 2011 Amendment, the benefit tracks in the Investment Law were modified and a flat tax rate applies to the Company&#x2019;s entire income subject to this amendment (the &#x201c;Preferred Income&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Once an election is made, the Company&#x2019;s income will be subject to the amended tax rate of 16% from 2015 and thereafter (or 9% for a preferred enterprise located in development area A).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Commencing 2011 tax year, the Company can elect (without possibility of reversal) to apply the Amendment in a certain tax year and from that year and thereafter, it will be subject to the amended tax rates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company adopted the 2011 Amendment in 2024. Accordingly, the Company did not adjust its deferred tax balances as of December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2016 and 2017 Budget Years), 2016, which includes Amendment 73 to the Law (the &#x201c;Amendment 73&#x201d;) was published. According to Amendment 73, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2016 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amendment 73 also prescribes special tax tracks for technological enterprises, which are subject to rules that were issued by the Minister of Finance in May 2017. The new tax tracks under the Amendment are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Preferred Technological Enterprise (&#x201c;PTE&#x201d;) - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion in a tax year. A PTE, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The above changes in the tax rates relating to PTE tax track were not taken into account in the computation of deferred taxes as of December 31, 2024 and 2023, since the Company estimates that it will not implement the PTE tax track.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax benefits under the law for the Encouragement of Industry (Taxes), 1969 (the &#x201c;Encouragement Law&#x201d;):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Encouragement Law provides several tax benefits for industrial companies. An industrial company is defined as a company resident in Israel, at least 90% of the income of which in a given tax year exclusive of income from specified Government loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose major activity in a given tax year is industrial production activity.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Management believes that the Company is currently qualified as an &#x201c;industrial company&#x201c; under the Encouragement Law and, as such, is entitled to tax benefits, including: (1) deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period; (2) the right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial companies and an industrial holding company; (3) accelerated depreciation rates on equipment and buildings; and (4) expenses related to a public offering on the Tel-Aviv Stock exchange and on recognized stock markets outside of Israel, are deductible in equal amounts over three years.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Eligibility for benefits under the Encouragement Law is not subject to receipt of prior approval from any Governmental authority. No assurance can be given that the Israeli tax authorities will agree that the Company qualifies, or, that the Company will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net operating losses carryforward and capital loss:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December&#160;31, 2024, &lt;/span&gt;&lt;/span&gt;Compugen Ltd.&#x2019;s&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt; net operating losses carryforward for tax purposes in Israel amounted to approximately $&#160;413,900. These net operating losses may be carried forward indefinitely and may be offset against future taxable income.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-Israeli subsidiary, Compugen USA, Inc.:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#x201c;U.S. Tax Reform&#x201d; or &#x201c;TCJA&#x201d;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include several key tax provisions that might impact the Company, among others: (i) a permanent reduction to the statutory federal corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017; (ii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain new rules designed to prevent erosion of the U.S. income tax base - &#x201c;BEAT&#x201d;); (iii) establishing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits; and (iv) providing a permanent deduction to corporations generating revenues from non-US markets (known as a deduction for foreign derived intangible income - &#x201c;FDII&#x201d;) .&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024, Compugen USA, Inc. has net operating loss carryforwards for federal income tax purposes of approximately $&#160;1,400. Approximately $300 of these losses are available to offset any future U.S. taxable income of our U.S. subsidiary and will expire in the years 2027 to 2032. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the &#x201c;change in ownership&#x201d; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Neither Israeli income taxes, foreign withholding taxes nor deferred income taxes were provided in relation to undistributed earnings of the Company&#x2019;s foreign subsidiary. This is because the Company has the intent and ability to reinvest these earnings indefinitely in the foreign subsidiary and therefore those earnings are continually redeployed in those jurisdictions.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss (income) before taxes is comprised as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:90pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Domestic (Israel)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;34,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Foreign&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,784&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Taxes on income for the years ended December 31, 2024 and 2023, represent withholding taxes on the upfront payment and the IND milestone pursuant to the Gilead license agreement, write-off of tax assets and state income taxes in the United States.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred taxes:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#x2019;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:90pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;loss carryforward&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;95,485&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;92,885&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,779&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued social benefits and other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,072&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;670&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax asset before valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;110,469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;108,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(109,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(108,073&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax asset after valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and&lt;span style="font-weight:bold"&gt;&#160;&lt;/span&gt;Compugen USA, Inc. due to the uncertainty of the realization of such tax benefits and withholding taxes on the upfront payment and the IND milestone pursuant to the Gilead license agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;g.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax assessments:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has tax assessments through 2019 that are deemed to be final.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20230214114856319"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20230214114847978"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20240101to20241231"
      decimals="2"
      id="Fxbrl_20230214114839776"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <cgen:ReducedTaxRate
      contextRef="C_20240101to20241231"
      decimals="2"
      id="FFact_0000000000594"
      unitRef="Pure">0.25</cgen:ReducedTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_20241231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"
      decimals="-3"
      id="FFact_0000000000595"
      unitRef="usd">413900000</us-gaap:OperatingLossCarryforwards>
    <cgen:NetOperatingLossCarryforwardExpired
      contextRef="C_20241231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember"
      decimals="-3"
      id="FFact_0000000000597"
      unitRef="usd">1400000</cgen:NetOperatingLossCarryforwardExpired>
    <cgen:NetOperatingLossCarryforwardExpired
      contextRef="C_20241231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapSubsidiaryOfCommonParentMember"
      decimals="-3"
      id="Fxbrl_20240228003646758"
      unitRef="usd">300000</cgen:NetOperatingLossCarryforwardExpired>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20230214044607742">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Domestic (Israel)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;34,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Foreign&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,784&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000600"
      unitRef="usd">-10129000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000601"
      unitRef="usd">-10164000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000602"
      unitRef="usd">-34096000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000603"
      unitRef="usd">420000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000604"
      unitRef="usd">380000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000605"
      unitRef="usd">460000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000606"
      unitRef="usd">-9709000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000607"
      unitRef="usd">-9784000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000608"
      unitRef="usd">-33636000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20230214044633836">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;loss carryforward&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;95,485&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;92,885&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,779&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued social benefits and other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,072&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;670&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax asset before valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;110,469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;108,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(109,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(108,073&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax asset after valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000610"
      unitRef="usd">95485000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000611"
      unitRef="usd">92885000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000612"
      unitRef="usd">11779000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000613"
      unitRef="usd">12109000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000614"
      unitRef="usd">2535000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000615"
      unitRef="usd">3072000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <cgen:DeferredIncomeTaxLeaseLiabilities
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000618"
      unitRef="usd">670000</cgen:DeferredIncomeTaxLeaseLiabilities>
    <cgen:DeferredIncomeTaxLeaseLiabilities
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000619"
      unitRef="usd">312000</cgen:DeferredIncomeTaxLeaseLiabilities>
    <cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000620"
      unitRef="usd">0</cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
    <cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000621"
      unitRef="usd">2000</cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000622"
      unitRef="usd">110469000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000623"
      unitRef="usd">108380000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000624"
      unitRef="usd">109814000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000625"
      unitRef="usd">108073000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240228010347732_Fact_0000000000622"
      unitRef="usd">655000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240228010347732_Fact_0000000000623"
      unitRef="usd">307000</us-gaap:DeferredTaxAssetsNet>
    <cgen:DeferredIncomeTaxRightOfUseAssets
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000616"
      unitRef="usd">-655000</cgen:DeferredIncomeTaxRightOfUseAssets>
    <cgen:DeferredIncomeTaxRightOfUseAssets
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000617"
      unitRef="usd">-307000</cgen:DeferredIncomeTaxRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240228010350775_Fact_0000000000622"
      unitRef="usd">655000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240228010350775_Fact_0000000000623"
      unitRef="usd">307000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240228010353797_Fact_0000000000622"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240228010353797_Fact_0000000000623"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20230222123726446">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;color:rgb(0, 0, 0)"&gt;

                    &lt;tr&gt;
                      &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;NOTE 11:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                        &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ASC 280, &#x201c;Segment Reporting,&#x201d; establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company&#x2019;s business is comprised of one operating segment&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company's CODM is its Chief Executive Officer (&#x201c;CEO&#x201d;), who reviews financial information presented on a consolidated basis.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;
                  &lt;div style="line-height:1.25"&gt;The CODM uses consolidated net loss to assess financial performance and allocate resources. These financial metrics are used by the CODM to make key operating decisions, such as the allocation of budget between Research and development, Sales and Marketing, and General and Administrative expenses. Segment assets that are reviewed by the CODM is reported within the Consolidated Balance Sheet as consolidated total assets.&lt;/div&gt;
                &lt;/div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-indent:0.5pt;margin-left:56.2pt;line-height:1.25"&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table presents selected financial information with respect to the Company&#x2019;s single operating segment &lt;span&gt;and includes information about segment revenues and significant segment expenses, &lt;/span&gt;for the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;/div&gt;

                  &lt;div&gt;
                    &lt;div style="margin-left:63pt"&gt;
                      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total Revenues&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;27,864&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160; &#160; &#160; &#160; &#160; R&amp;amp;D expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Preclinical&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20,948&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;17,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; Clinical&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15,267&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,357&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SG&amp;amp;A&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,485&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(5,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(3,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Taxes on income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,522&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other segment expenses*&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,563&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(14,231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(18,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(33,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;

                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;*Other &lt;/span&gt;&lt;/span&gt;segment expense (income) during the years ended December 31, 2024, 2023 and 2022 includes property and equipment depreciation, participation in R&amp;amp;D expenses, share-based compensation and other adjustments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operations in Israel and the United States include research and development, clinical operations, general and administrative, marketing and business development.&#160;Total revenues are attributed to geographic areas based on the location of the end customer.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The following represents the total revenue for the years ended December 31, 2024, 2023 and 2022 and long-lived assets as of December 31, 2024 and 2023:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="margin-left:63pt"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Revenue from sales to customers:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Europe&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;10,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;22,864&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;23,459&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Total revenue&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;27,864&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;33,459&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div&gt;
                    &lt;div style="margin-left:63pt"&gt;
                      &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;December 31,&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Long-lived assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Israel&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,677&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,468&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;77&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Total long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,695&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,545&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

              &lt;div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-left:63pt"&gt;

                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Sales to a single customer exceeding 10%:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Customer A&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Customer B&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;

                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_20240101to20241231"
      decimals="0"
      id="Fxbrl_20250228050756758"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250228093519033">
                  &lt;div&gt;
                    &lt;div style="margin-left:63pt"&gt;
                      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total Revenues&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;27,864&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160; &#160; &#160; &#160; &#160; R&amp;amp;D expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Preclinical&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20,948&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;17,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; Clinical&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15,267&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,357&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SG&amp;amp;A&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,485&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(5,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(3,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Taxes on income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,522&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other segment expenses*&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,563&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(14,231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(18,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(33,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                </us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110108919_Fact_0000000000631"
      unitRef="usd">27864000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110108919_Fact_0000000000632"
      unitRef="usd">33459000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110108919_xbrl_20230214023238881"
      unitRef="usd">7500000</us-gaap:Revenues>
    <cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment
      contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110138411_xbrl_20250228110108919_Fact_0000000000631"
      unitRef="usd">15374000</cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment>
    <cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment
      contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110138411_xbrl_20250228110108919_Fact_0000000000632"
      unitRef="usd">20948000</cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment>
    <cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment
      contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110138411_xbrl_20250228110108919_xbrl_20230214023238881"
      unitRef="usd">17477000</cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment>
    <cgen:ClinicalAmountOfExpenseForResearchAndDevelopment
      contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110140733_xbrl_20250228110108919_Fact_0000000000631"
      unitRef="usd">15267000</cgen:ClinicalAmountOfExpenseForResearchAndDevelopment>
    <cgen:ClinicalAmountOfExpenseForResearchAndDevelopment
      contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110140733_xbrl_20250228110108919_Fact_0000000000632"
      unitRef="usd">10627000</cgen:ClinicalAmountOfExpenseForResearchAndDevelopment>
    <cgen:ClinicalAmountOfExpenseForResearchAndDevelopment
      contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110140733_xbrl_20250228110108919_xbrl_20230214023238881"
      unitRef="usd">11357000</cgen:ClinicalAmountOfExpenseForResearchAndDevelopment>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110144645_xbrl_20250228110108919_Fact_0000000000631"
      unitRef="usd">9485000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110144645_xbrl_20250228110108919_Fact_0000000000632"
      unitRef="usd">9320000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110144645_xbrl_20250228110108919_xbrl_20230214023238881"
      unitRef="usd">9690000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110146997_xbrl_20250228110108919_Fact_0000000000631"
      unitRef="usd">5182000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110146997_xbrl_20250228110108919_Fact_0000000000632"
      unitRef="usd">3215000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110146997_xbrl_20250228110108919_xbrl_20230214023238881"
      unitRef="usd">1738000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110149186_xbrl_20250228110108919_Fact_0000000000631"
      unitRef="usd">4522000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110149186_xbrl_20250228110108919_Fact_0000000000632"
      unitRef="usd">8970000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110149186_xbrl_20250228110108919_xbrl_20230214023238881"
      unitRef="usd">58000</us-gaap:IncomeTaxExpenseBenefit>
    <cgen:OtherSegmentExpenses
      contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110151261_xbrl_20250228110108919_Fact_0000000000631"
      unitRef="usd">2629000</cgen:OtherSegmentExpenses>
    <cgen:OtherSegmentExpenses
      contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110151261_xbrl_20250228110108919_Fact_0000000000632"
      unitRef="usd">5563000</cgen:OtherSegmentExpenses>
    <cgen:OtherSegmentExpenses
      contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110151261_xbrl_20250228110108919_xbrl_20230214023238881"
      unitRef="usd">4350000</cgen:OtherSegmentExpenses>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110153451_xbrl_20250228110108919_Fact_0000000000631"
      unitRef="usd">-14231000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110153451_xbrl_20250228110108919_Fact_0000000000632"
      unitRef="usd">-18754000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250228110153451_xbrl_20250228110108919_xbrl_20230214023238881"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250225144752809">
                &lt;div&gt;
                  &lt;div style="margin-left:63pt"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Revenue from sales to customers:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Europe&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;10,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;22,864&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;23,459&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Total revenue&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;27,864&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;33,459&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div&gt;
                    &lt;div style="margin-left:63pt"&gt;
                      &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;December 31,&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Long-lived assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Israel&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,677&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,468&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;77&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                              &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Total long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,695&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,545&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_20240101to20241231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"
      decimals="-3"
      id="FFact_0000000000631"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"
      decimals="-3"
      id="FFact_0000000000632"
      unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"
      decimals="-3"
      id="Fxbrl_20230214023238881"
      unitRef="usd">7500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20241231_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20240228002914108_Fact_0000000000631"
      unitRef="usd">22864000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20240228002914108_Fact_0000000000632"
      unitRef="usd">23459000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20240228002914108_xbrl_20230214023238881"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000634"
      unitRef="usd">27864000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000635"
      unitRef="usd">33459000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214023305010"
      unitRef="usd">7500000</us-gaap:Revenues>
    <us-gaap:NoncurrentAssets
      contextRef="C_20241231_cgenSegmentReportingGeographicAreaAxis_countryIL"
      decimals="-3"
      id="FFact_0000000000637"
      unitRef="usd">3677000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryIL"
      decimals="-3"
      id="FFact_0000000000638"
      unitRef="usd">2468000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20241231_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="FFact_0000000000639"
      unitRef="usd">18000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="FFact_0000000000640"
      unitRef="usd">77000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000641"
      unitRef="usd">3695000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000642"
      unitRef="usd">2545000</us-gaap:NoncurrentAssets>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250225144739098">
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Sales to a single customer exceeding 10%:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Customer A&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Customer B&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  </us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20240101to20241231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="FFact_0000000000644"
      unitRef="Pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="FFact_0000000000645"
      unitRef="Pure">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="Fxbrl_20230214023433284"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20240101to20241231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="Fxbrl_20240228002946105_Fact_0000000000644"
      unitRef="Pure">0.82</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="Fxbrl_20240228002946105_Fact_0000000000645"
      unitRef="Pure">0.70</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="Fxbrl_20240228002946105_xbrl_20230214023433284"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="C_20240101to20241231" id="FFact_0000000000665">
    &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

        &lt;tr&gt;
          &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;NOTE 12:-&lt;/span&gt;&lt;/td&gt;
          &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
            &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;FINANCIAL AND OTHER INCOME, NET&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;

    &lt;/table&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="margin-left:63pt"&gt;

            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,489&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of discount on marketable securities, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,747&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Bank fees and other finance expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Foreign currency transaction adjustments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gain (loss) from sales and disposals of fixed assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="C_20240101to20241231" id="FFact_0000000000664">
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,489&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of discount on marketable securities, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,747&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Bank fees and other finance expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Foreign currency transaction adjustments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gain (loss) from sales and disposals of fixed assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000649"
      unitRef="usd">3489000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000650"
      unitRef="usd">2960000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000651"
      unitRef="usd">1437000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240228002028020_Fact_0000000000649"
      unitRef="usd">1747000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228002028020_Fact_0000000000650"
      unitRef="usd">281000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240228002028020_Fact_0000000000651"
      unitRef="usd">0</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000652"
      unitRef="usd">34000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000653"
      unitRef="usd">31000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000654"
      unitRef="usd">27000</us-gaap:InterestAndDebtExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000655"
      unitRef="usd">-20000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230214022140608"
      unitRef="usd">5000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000657"
      unitRef="usd">340000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230214022153855"
      unitRef="usd">-0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000659"
      unitRef="usd">-7000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000660"
      unitRef="usd">-12000</us-gaap:GainLossOnSaleOfOtherAssets>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000661"
      unitRef="usd">5182000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000662"
      unitRef="usd">3208000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000663"
      unitRef="usd">1738000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_20240101to20241231" id="FFact_0000000000672">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 13:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;RELATED PARTY BALANCES AND TRANSACTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;strong&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;December 31,&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade payables and accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the years ended December 31, 2024, 2023 and 2022 the Company received research and development services related with cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies. The transaction was at arm&#x2019;s length.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250225051438914">
          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;strong&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;December 31,&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade payables and accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OtherLiabilities
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000666"
      unitRef="usd">58000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000667"
      unitRef="usd">53000</us-gaap:OtherLiabilities>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000668"
      unitRef="usd">141000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000669"
      unitRef="usd">147000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000670"
      unitRef="usd">194000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20230222124735774">
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 14:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;LOSSES PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin:0px 0px 0px 85.5pt;line-height:1.25;text-align:justify;text-indent:-28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table sets forth the computation of basic and diluted losses per share:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:63pt"&gt;

            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss for basic and diluted loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(14,231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(18,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(33,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average number of ordinary shares used in computing basic and diluted net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;89,528,031&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;87,633,298&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;86,555,628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20230222124750140">
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss for basic and diluted loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(14,231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(18,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(33,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average number of ordinary shares used in computing basic and diluted net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;89,528,031&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;87,633,298&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;86,555,628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000673"
      unitRef="usd">-14231000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000674"
      unitRef="usd">-18754000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000675"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="FFact_0000000000676"
      unitRef="Shares">89528031</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000677"
      unitRef="Shares">87633298</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000678"
      unitRef="Shares">86555628</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20230214135651704"
      unitRef="USD_per_share">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="FFact_0000000000679"
      unitRef="USD_per_share">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20230214135713278"
      unitRef="USD_per_share">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000680"
      unitRef="USD_per_share">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230214135731057"
      unitRef="USD_per_share">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000681"
      unitRef="USD_per_share">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20230214053733944">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                    &lt;tr&gt;
                      &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 15:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                        &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In January and February 2025, the Company sold through the ATM &lt;span&gt;3,961,641&lt;/span&gt; ordinary shares, with proceeds of approximately &lt;span&gt;$ 8,870&lt;/span&gt; (net of &lt;span&gt;$ 274&lt;/span&gt; issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_20240101to20240131_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember"
      decimals="INF"
      id="Fxbrl_20250228053725982"
      unitRef="Shares">3961641</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20240101to20240131_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember"
      decimals="-3"
      id="Fxbrl_20250228053737270"
      unitRef="usd">8870000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20240101to20240131_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember"
      decimals="-3"
      id="Fxbrl_20250228053744926"
      unitRef="usd">274000</us-gaap:PaymentsOfStockIssuanceCosts>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fxbrl_20240730211801692_20250224141027740_2"
          xlink:label="Fxbrl_20240730211801692_20250224141027740_2"
          xlink:type="locator"/>
        <link:footnote id="FN20250224141027743_19" xlink:label="FN20250224141027743_19" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount lower than $1</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20240730211801692_20250224141027740_2"
          xlink:to="FN20250224141027743_19"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20240730224938615_20250224141027741_9"
          xlink:label="Fxbrl_20240730224938615_20250224141027741_9"
          xlink:type="locator"/>
        <link:footnote id="FN20250224141027743_20" xlink:label="FN20250224141027743_20" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount lower than $1.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20240730224938615_20250224141027741_9"
          xlink:to="FN20250224141027743_20"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250224182302928"
          xlink:label="Fxbrl_20250224182302928"
          xlink:type="locator"/>
        <link:footnote id="FN20250225105352845" xlink:label="FN20250225105352845" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Representing amount lower than $ 1</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250224182302928"
          xlink:to="FN20250225105352845"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
